<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vaccines for measles, mumps, rubella, and varicella in children - Di Pietrantonj, C - 2021 | Cochrane Library</title> <meta content="Vaccines for measles, mumps, rubella, and varicella in children - Di Pietrantonj, C - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004407.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vaccines for measles, mumps, rubella, and varicella in children - Di Pietrantonj, C - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004407.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004407.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Vaccines for measles, mumps, rubella, and varicella in children" name="citation_title"/> <meta content="Carlo Di Pietrantonj" name="citation_author"/> <meta content="Azienda Sanitaria Locale ASL AL" name="citation_author_institution"/> <meta content="cdipietrantonj@aslal.it" name="citation_author_email"/> <meta content="Alessandro Rivetti" name="citation_author"/> <meta content="ASL CN2 Alba Bra" name="citation_author_institution"/> <meta content="Pasquale Marchione" name="citation_author"/> <meta content="Italian Medicine Agency - AIFA" name="citation_author_institution"/> <meta content="Maria Grazia Debalini" name="citation_author"/> <meta content="SC Farmacia Ospedaliera ASL" name="citation_author_institution"/> <meta content="Vittorio Demicheli" name="citation_author"/> <meta content="Azienda Sanitaria Locale ASL AL" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD004407.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004407.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004407.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004407.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Chickenpox [prevention &amp; control]; *Measles [prevention &amp; control]; Measles-Mumps-Rubella Vaccine [adverse effects]; *Mumps [prevention &amp; control]; *Rubella [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004407.pub5&amp;doi=10.1002/14651858.CD004407.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004407\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004407\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","th","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004407.pub5",title:"Vaccines for measles, mumps, rubella, and varicella in children",firstPublishedDate:"Nov 22, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004407.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004407.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004407.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004407.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004407.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004407.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004407.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004407.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004407.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004407.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16223 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004407.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-sec-0115"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/appendices#CD004407-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/table_n/CD004407StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/table_n/CD004407StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vaccines for measles, mumps, rubella, and varicella in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#CD004407-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Carlo Di Pietrantonj</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#CD004407-cr-0005">Alessandro Rivetti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#CD004407-cr-0006">Pasquale Marchione</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#CD004407-cr-0007">Maria Grazia Debalini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information#CD004407-cr-0008">Vittorio Demicheli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information/en#CD004407-sec-0159">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004407.pub5">https://doi.org/10.1002/14651858.CD004407.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004407-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004407-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004407-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004407-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004407-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD004407-abs-0005">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004407-abs-0001" lang="en"> <section id="CD004407-sec-0001"> <h3 class="title" id="CD004407-sec-0001">Background</h3> <p>Measles, mumps, rubella, and varicella (chickenpox) are serious diseases that can lead to serious complications, disability, and death. However, public debate over the safety of the trivalent MMR vaccine and the resultant drop in vaccination coverage in several countries persists, despite its almost universal use and accepted effectiveness. This is an update of a review published in 2005 and updated in 2012. </p> </section> <section id="CD004407-sec-0002"> <h3 class="title" id="CD004407-sec-0002">Objectives</h3> <p>To assess the effectiveness, safety, and long‐ and short‐term adverse effects associated with the trivalent vaccine, containing measles, rubella, mumps strains (MMR), or concurrent administration of MMR vaccine and varicella vaccine (MMR+V), or tetravalent vaccine containing measles, rubella, mumps, and varicella strains (MMRV), given to children aged up to 15 years. </p> </section> <section id="CD004407-sec-0003"> <h3 class="title" id="CD004407-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2019, Issue 5), which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to 2 May 2019), Embase (1974 to 2 May 2019), the WHO International Clinical Trials Registry Platform (2 May 2019), and ClinicalTrials.gov (2 May 2019). </p> </section> <section id="CD004407-sec-0004"> <h3 class="title" id="CD004407-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective cohort studies (PCS/RCS), case‐control studies (CCS), interrupted time‐series (ITS) studies, case cross‐over (CCO) studies, case‐only ecological method (COEM) studies, self‐controlled case series (SCCS) studies, person‐time cohort (PTC) studies, and case‐coverage design/screening methods (CCD/SM) studies, assessing any combined MMR or MMRV / MMR+V vaccine given in any dose, preparation or time schedule compared with no intervention or placebo, on healthy children up to 15 years of age. </p> </section> <section id="CD004407-sec-0005"> <h3 class="title" id="CD004407-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed the methodological quality of the included studies. We grouped studies for quantitative analysis according to study design, vaccine type (MMR, MMRV, MMR+V), virus strain, and study settings. Outcomes of interest were cases of measles, mumps, rubella, and varicella, and harms. Certainty of evidence of was rated using GRADE. </p> </section> <section id="CD004407-sec-0006"> <h3 class="title" id="CD004407-sec-0006">Main results</h3> <p>We included 138 studies (23,480,668 participants). Fifty‐one studies (10,248,159 children) assessed vaccine effectiveness and 87 studies (13,232,509 children) assessed the association between vaccines and a variety of harms. We included 74 new studies to this 2019 version of the review.<br/><b>Effectiveness</b> <br/>Vaccine effectiveness in preventing measles was 95% after one dose (relative risk (RR) 0.05, 95% CI 0.02 to 0.13; 7 cohort studies; 12,039 children; moderate certainty evidence) and 96% after two doses (RR 0.04, 95% CI 0.01 to 0.28; 5 cohort studies; 21,604 children; moderate certainty evidence). The effectiveness in preventing cases among household contacts or preventing transmission to others the children were in contact with after one dose was 81% (RR 0.19, 95% CI 0.04 to 0.89; 3 cohort studies; 151 children; low certainty evidence), after two doses 85% (RR 0.15, 95% CI 0.03 to 0.75; 3 cohort studies; 378 children; low certainty evidence), and after three doses was 96% (RR 0.04, 95% CI 0.01 to 0.23; 2 cohort studies; 151 children; low certainty evidence). The effectiveness (at least one dose) in preventing measles after exposure (post‐exposure prophylaxis) was 74% (RR 0.26, 95% CI 0.14 to 0.50; 2 cohort studies; 283 children; low certainty evidence).<br/>The effectiveness of Jeryl Lynn containing MMR vaccine in preventing mumps was 72% after one dose (RR 0.24, 95% CI 0.08 to 0.76; 6 cohort studies; 9915 children; moderate certainty evidence), 86% after two doses (RR 0.12, 95% CI 0.04 to 0.35; 5 cohort studies; 7792 children; moderate certainty evidence). Effectiveness in preventing cases among household contacts was 74% (RR 0.26, 95% CI 0.13 to 0.49; 3 cohort studies; 1036 children; moderate certainty evidence). <br/>Vaccine effectiveness against rubella, using a vaccine with the BRD2 strain which is only used in China, is 89% (RR 0.11, 95% CI 0.03 to 0.42; 1 cohort study; 1621 children; moderate certainty evidence). <br/>Vaccine effectiveness against varicella (any severity) after two doses in children aged 11 to 22 months is 95% in a 10 years follow‐up (rate ratio (rr) 0.05, 95% CI 0.03 to 0.08; 1 RCT; 2279 children; high certainty evidence).<br/><b>Safety</b><br/>There is evidence supporting an association between aseptic meningitis and MMR vaccines containing Urabe and Leningrad‐Zagreb mumps strains, but no evidence supporting this association for MMR vaccines containing Jeryl Lynn mumps strains (rr 1.30, 95% CI 0.66 to 2.56; low certainty evidence). The analyses provide evidence supporting an association between MMR/MMR+V/MMRV vaccines (Jeryl Lynn strain) and febrile seizures. Febrile seizures normally occur in 2% to 4% of healthy children at least once before the age of 5. The attributable risk febrile seizures vaccine‐induced is estimated to be from 1 per 1700 to 1 per 1150 administered doses.<br/>The analyses provide evidence supporting an association between MMR vaccination and idiopathic thrombocytopaenic purpura (ITP). However, the risk of ITP after vaccination is smaller than after natural infection with these viruses. Natural infection of ITP occur in 5 cases per 100,000 (1 case per 20,000) per year. The attributable risk is estimated about 1 case of ITP per 40,000 administered MMR doses.<br/>There is no evidence of an association between MMR immunisation and encephalitis or encephalopathy (rate ratio 0.90, 95% CI 0.50 to 1.61; 2 observational studies; 1,071,088 children; low certainty evidence), and autistic spectrum disorders (rate ratio 0.93, 95% CI 0.85 to 1.01; 2 observational studies; 1,194,764 children; moderate certainty). There is insufficient evidence to determine the association between MMR immunisation and inflammatory bowel disease (odds ratio 1.42, 95% CI 0.93 to 2.16; 3 observational studies; 409 cases and 1416 controls; moderate certainty evidence).<br/>Additionally, there is no evidence supporting an association between MMR immunisation and cognitive delay, type 1 diabetes, asthma, dermatitis/eczema, hay fever, leukaemia, multiple sclerosis, gait disturbance, and bacterial or viral infections.  </p> </section> <section id="CD004407-sec-0007"> <h3 class="title" id="CD004407-sec-0007">Authors' conclusions</h3> <p>Existing evidence on the safety and effectiveness of MMR/MMRV vaccines support their use for mass immunisation. Campaigns aimed at global eradication should assess epidemiological and socioeconomic situations of the countries as well as the capacity to achieve high vaccination coverage. More evidence is needed to assess whether the protective effect of MMR/MMRV could wane with time since immunisation. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004407-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004407-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004407-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004407-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004407-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004407-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004407-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004407-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD004407-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD004407-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004407-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004407-abs-0002" lang="en"> <h3>Does the measles, mumps, rubella and varicella (MMRV) vaccine protect children, and does it cause harmful effects? </h3> <p><b>Background</b> </p> <p>Measles, mumps, rubella (German measles) and varicella (chickenpox) are infectious diseases caused by viruses. They are most common in children and young adults. They are not always serious, but can cause disability (such as deafness), complications and death. If pregnant women catch rubella, it may cause loss (miscarriage) of, or harm to, their unborn babies.<br/><br/>A vaccine is a medicine that prevents infection by a specific disease. The MMR (measles, mumps, rubella) vaccine protects people against all three of these infections (a combined vaccine). Doctors can vaccinate against chickenpox at the same time by mixing the chickenpox (varicella) vaccine with the MMR vaccine (MMRV) or giving it separately at the same time (MMR+V).<br/><br/>The MMR vaccine has reduced measles, mumps and rubella infections. However, some people think the MMR vaccine causes unwanted effects such as autism, swelling of the brain (encephalitis), meningitis, learning difficulties, type 1 diabetes, and other conditions. As a result, the number of children being vaccinated has fallen.<br/><br/>This is the 2019 update of a review first published in 2005 and previously updated in 2012.<br/><br/><b>Review question</b> </p> <p>We wanted to find out how effectively MMR, MMR+V and MMRV vaccines stop children (up to 15 years old) from catching measles, mumps, rubella and chickenpox. We also wanted to know if the vaccines cause unwanted effects. </p> <p><b>Study characteristics</b> </p> <p>We looked for studies that assessed MMR, MMRV or MMR+V vaccines, given in any dose or time schedule, compared with not giving the vaccine, or giving a placebo vaccine (a sham treatment), to healthy children up to 15 years old. Studies needed to measure the number of cases of measles, mumps, rubella and chickenpox, and report whether children suffered any unwanted effects attributable to vaccination. We checked each study to make sure it used robust methods so that we could judge how reliable its results were. </p> <p><b>Results</b> <br/>We found 138 studies with more than 23 million children. Fifty‐one studies (10 million children) assessed how effective the vaccines were at preventing the diseases, and 87 studies (13 million children) assessed unwanted effects. In this 2020 update we have included 74 new studies published since 2012.<br/><br/><b>Measles:</b> results from seven studies (12,000 children) showed that one dose of vaccine was 95% effective in preventing measles. Seven per cent of unvaccinated children would catch measles and this number would fall to less than 0.5% of children who receive one dose of vaccine.<br/><br/><b>Mumps:</b> results from six studies (9915 children) showed that one dose of vaccine was 72% effective in preventing mumps. This rose to 86% after two doses, (3 studies, 7792 children). In unvaccinated children, 7.4% would catch mumps and this would fall to 1% if children were vaccinated with two doses.<br/><br/>The results for <b>rubella</b> (1 study, 1621 children) and <b>chickenpox</b> (one study, 2279 children) also showed that vaccines are effective. After one dose, vaccination was 89% effective in preventing rubella, using a vaccine with the BRD2 strain which is only used in China, and after 10 years the MMRV vaccine was 95% effective at preventing chickenpox infection.<br/><br/><b>Unwanted effects</b><br/>Overall, the studies found that MMR, MMRV and MMR+V vaccines did not cause autism (2 studies 1,194,764 children), encephalitis (2 studies 1,071,088 children) or any other suspected unwanted effect.<br/>Our analyses showed very small risks of fits due to high temperature or fever (febrile seizures) around two weeks after vaccination, and of a condition where blood does not clot normally (idiopathic thrombocytopenic purpura) in vaccinated children.<br/>  </p> <p><b>Certainty of the evidence</b> </p> <p>Our certainty (confidence) in the evidence is slightly limited by the design of most of the studies. Nonetheless, we judged the certainty of the evidence for the effectiveness of the MMR vaccine to be moderate, and that for the varicella vaccine to be high. Our certainty in the evidence for autism and febrile seizures was also moderate. </p> <p><b>Conclusions</b> </p> <p>Our review shows that MMR, MMRV and MMR+V vaccines are effective in preventing the infection of children by measles, mumps, rubella and chickenpox, with no evidence of an increased risk of autism or encephalitis and a small risk of febrile seizure. </p> <p><b>Search date</b> </p> <p>This review includes evidence published up to 2 May 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004407-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004407-sec-0121"></div> <h3 class="title" id="CD004407-sec-0122">Implications for practice</h3> <section id="CD004407-sec-0122"> <p>Existing evidence on the safety and effectiveness of MMR and MMRV vaccine supports current policies of mass immunisation aimed at global measles eradication in order to reduce morbidity and mortality associated with measles mumps rubella and varicella. Campaigns aimed at global eradication should assess epidemiological and socioeconomic situations of the countries as well as the capacity to achieve high vaccination coverage. </p> </section> <h3 class="title" id="CD004407-sec-0123">Implications for research</h3> <section id="CD004407-sec-0123"> <p>We have observed an improvement in the quality of the design and reporting of safety outcomes in MMR and MMRV in recent years both pre‐ and post‐marketing. More evidence is needed to assess whether the protective effect of MMR/MMRV could wane with time since immunisation. More evidence is needed to assess efficacy of a third dose against MMRV. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004407-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004407-sec-0008"></div> <div class="table" id="CD004407-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Effectiveness against measles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against measles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population or school or day‐care centre or general practitioner or households<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of measles<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of measles<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.05<br/>(0.02 to 0.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12,039<br/>(7 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 9) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.04<br/>(0.01 to 0.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,604<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies household contacts ‐ 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/>(0.04 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/>(20 to 452) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies household contacts ‐ 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.15<br/>(0.03 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>378<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(15 to 381) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies household contacts ‐ 3 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.04<br/>(0.01 to 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(4 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies postexposure prophylaxis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/>(0.14 to 0.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>283<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(44 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Effectiveness against mumps</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against mumps</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population or school or day‐care centre or general practitioner or households<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of mumps<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of mumps<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/>(0.08 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9915<br/>(6 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(7 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.12<br/>(0.04 to 0.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7792<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(3 to 26) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ unspecified number of doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/>(0.14 to 0.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ household contacts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/>(0.13 to 0.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1036<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>408 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(53 to 200) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Urabe strain ‐ unspecified numbers or at least 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/>(0.12 to 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2721<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(24 to 89) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Rubini strain ‐ unspecified numbers or at least 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.55 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4219<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000<br/>(111 to 334) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ mumps strain not reported or any strain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/>(0.29 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>769<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000<br/>(65 to 212) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ third dose versus 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.33 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5417<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(2 to 8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies).<br/><sup>2</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Effectiveness against rubella</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against rubella</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> school<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of rubella<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of rubella<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies secondary cases ‐ any strain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.11<br/>(0.03 to 0.42)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1621 (1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Cohort study in China using the BRD2 strain.<br/><sup>2</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Effectiveness against varicella</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against varicella</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMRV or MMR+V vaccine<br/><b>Comparison:</b> MMR vaccine (RCTs), unvaccinated (cohort studies) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of varicella<br/>amongst<br/>unvaccinated<br/>with MMR vaccine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of varicella<br/>amongst<br/>vaccinated<br/>with MMRV vaccine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.05<br/>(0.03 to 0.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3022<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(8 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.05<br/>(0.04 to 0.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>437 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(17 to 26) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 10 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.05<br/>(0.04 to 0.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>473 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(19 to 28) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.00<br/>(0.00 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3022<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.01<br/>(0.00 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.01<br/>(0.00 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.35<br/>(0.28 to 0.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3006<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/>(76 to 116) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.33<br/>(0.29 to 0.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>437 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/>(127 to 166) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 10 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.33<br/>(0.29 to 0.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>473 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/>(137 to 180) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.09<br/>(0.06 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3006<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(9 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.10<br/>(0.07 to 0.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(17 to 31) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.10<br/>(0.08 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(19 to 33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>MMRV:</b> measles, mumps, rubella, and varicella vaccine; <b>MMR+V:</b> concurrent administration of MMR vaccine and varicella vaccine; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: short‐term side effects (local or systemic reactions)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term side effects<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term side effects<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ RCT/CCT axillary</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.04<br/>(1.09 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(74 to 261) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ RCT/CCT rectal</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/>(0.67 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>170<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>786 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>660 per 1000<br/>(526 to 833) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ RCT/CCT measurement site not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/>(0.83 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>520<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/>(151 to 405) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ cohort studies orally</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/>(1.04 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>334<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>377 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>517 per 1000<br/>(392 to 683) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ cohort studies measurement site not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.84 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>457,123<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/>(26 to 46) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rash ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.49<br/>(0.73 to 3.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>457,261<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(3 to 13) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lymphadenopathy ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(0.52 to 3.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1156<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(11 to 70) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lymphadenopathy ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.98<br/>(0.19 to 20.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>454,085<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coryza ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/>(0.12 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>831<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(4 to 60) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coryza ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(1.05 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3176<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>502 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>567 per 1000<br/>(527 to 602) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>URTI (rhinitis pharyngitis) ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.31<br/>(0.06 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>831<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(16 to 414) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>URTI (rhinitis pharyngitis) ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.44<br/>(1.26 to 1.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>966<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>697 per 1000<br/>(610 to 794) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cough ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.99<br/>(0.45 to 8.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>831<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(4 to 72) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rash ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.05<br/>(1.21 to 3.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1156<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000<br/>(63 to 182) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CCT:</b> controlled clinical trial; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>URTI:</b> upper respiratory tract infection </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to selective reporting (reporting bias).<br/><sup>2</sup>Downgraded one level due to low comparability amongst groups. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: encephalitis or encephalopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of encephalitis or encephalopathy<br/>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of encephalitis or encephalopathy<br/>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control: MMR (risk interval from 0 to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.98<br/>(0.64 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>452 cases, 1280 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(22 to 51) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time cohort</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.90<br/>(0.50 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,071,088<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100,000<br/>(11 to 36) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Safety: aseptic meningitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: aseptic meningitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>aseptic meningitis</b><br/>amongst unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>aseptic meningitis</b><br/>amongst vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ Jeryl Lynn ‐ risk interval 0 to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.85<br/>(0.21 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59 cases, 118 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(13 to 177) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case cross‐over ‐ Urabe or Hoshino</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 4.00<br/>(2.23 to 7.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(2 observational studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case cross‐over ‐ Jeryl Lynn or Rubini</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.60<br/>(0.18 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ any strain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 12.40<br/>(3.12 to 49.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ Urabe</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 30.71<br/>(13.45 to 70.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>564,635<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 100,000<br/>(214 to 1.117) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self controlled case series ‐ Leningrad‐Zagreb</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 6.40<br/>(0.78 to 52.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Person‐time cohort ‐ Jeryl Lynn</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.30<br/>(0.66 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,071,088<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 100,000<br/>(20 to 77) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐only ecological method ‐ Urabe</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 9.12<br/>(5.73 to 14.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,054,305<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 100,000<br/>(51 to 128) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐only ecological method ‐ Leningrad‐Zagreb</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 18.56<br/>(12.09 to 28.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,164,964<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 100,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Safety: seizures (febrile/afebrile)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: seizures (febrile/afebrile)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>seizures </b> <br/><b>(febrile/afebrile)</b><br/>amongst unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>seizures </b> <br/><b>(febrile/afebrile)</b><br/>amongst vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ within 1 week after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 2.45<br/>(2.21 to 2.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,451,990<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000<br/>(238 to 292) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ between 1 and 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.16<br/>(2.89 to 3.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2,147,638<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/>(38 to 46) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ &gt; 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.97<br/>(0.49 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,018,998<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ between 1 and 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.36<br/>(2.65 to 4.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>505,493<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ &gt; 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.18<br/>(0.93 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>102,099<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ between 1 and 2 weeks after vaccination; MMRV </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 6.08<br/>(4.95 to 7.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180,480<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ between 1 and 2 weeks after MMR+V vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.13<br/>(2.38 to 4.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>181,088<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.95<br/>(0.85 to 4.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>115,022<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.69<br/>(0.93 to 3.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>114,922<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/>(1.17 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,381,609<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.01<br/>(1.70 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,381,609<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(3 to 4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/>(1.00 to 1.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>292,535<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.49<br/>(1.66 to 3.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>292,535<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(2 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60<br/>(1.42 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,049,831<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 100,000<br/>(61 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/>(1.32 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,989,157<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 100,000<br/>(28 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>MMRV:</b> measles, mumps, rubella, and varicella vaccine; <b>MMR+V:</b> concurrent administration of MMR vaccine and varicella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to large effect size </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Safety: autistic spectrum disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Safety: autistic spectrum disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>ASD</b> amongst unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>ASD</b> amongst vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ all children, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.93<br/>(0.85 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,194,764<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>451 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>419 per 100,000<br/>(383 to 455) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ autism risk (low), MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.00<br/>(0.89 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93,071<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 100,000<br/>(76 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ autism risk (moderate/high), MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.80<br/>(0.64 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1914<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The apparent protective effect is due to indication bias.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(7 to 11) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ASD:</b> autism spectrum disorders; <b>CI:</b> confidence interval; <b>MMR</b>: measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to residual confounding ‐ confounding expected to increase the effect but no effect was observed. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Safety: inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>IBD</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>IBD</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ all IBD, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.42<br/>(0.93 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>409 cases, 1416 controls<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ ulcerative colitis, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.35<br/>(0.81 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>292 cases, 582 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ Crohn's disease, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.64<br/>(0.42 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>514 cases, 804 controls<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IBD:</b> inflammatory bowel disease; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to residual confounding ‐ confounding expected to increase the effect but no effect was observed. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Safety: cognitive delay ‐ developmental delay</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: cognitive delay ‐ developmental delay</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>cognitive delay ‐ </b> <br/><b>developmental delay</b> amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>cognitive delay ‐ </b> <br/><b>developmental delay</b> amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ MDI‐BSID II 24th month, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.35<br/>(0.15 to 12.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ MDI‐BSID II 36th month, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.37<br/>(0.03 to 4.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ Raven 5th year, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.22<br/>(0.23 to 6.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ WISC‐R verbal 6th year, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.23<br/>(0.09 to 16.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MDI‐BSID II:</b> Mental Development Index of Bayley Scales of Infant Development, second edition; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio; <b>WISC‐R:</b> Wechsler Intelligence Scale for Children, Revised Form </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: idiopathic thrombocytopenic purpura</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of ITP </b> <br/><b>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of ITP </b> <br/><b>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ case cross‐over ‐ case controls MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.80<br/>(1.50 to 5.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410 cases, 2040 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ MMR vaccine ‐ age from 9 to 23 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 4.21<br/>(2.28 to 7.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3,723,677<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 100,000<br/>(39 to 132) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ITP:</b> idiopathic thrombocytopenic purpura; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to large effect size </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: Henoch‐Schönlein purpura</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>HSP </b> <br/><b>amongst</b> <br/><b>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>HSP</b> <br/><b>amongst </b> <br/><b>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ MMR vaccine</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.40<br/>(1.18 to 9.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288 cases, 617 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HSP:</b> Henoch‐Schönlein purpura; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0014"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Safety: type 1 diabetes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: type 1 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>type 1 diabetes</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>type 1 diabetes</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study MMR ‐ all children</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.09<br/>(0.98 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,666,829<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study MMR ‐ children with at least 1 sibling with type 1 diabetes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.86<br/>(0.34 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3848<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(2 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0015"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Safety: asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>asthma </b> <br/><b>amongst </b> <br/><b>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>asthma </b> <br/><b>amongst </b> <br/><b>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study (rate ratio) ‐ all ages</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.05<br/>(0.80 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,067,712<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/>(25 to 44) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies (risk ratio) ‐ all ages</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.24 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>886<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000<br/>(99 to 674) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to non‐critical risk of bias in the study and large number of participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0016"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Safety: eczema ‐ dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: eczema ‐ dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> vaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>eczema ‐ dermatitis</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>eczema ‐ dermatitis</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study (rate ratio)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.50<br/>(2.38 to 5.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,353<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study (risk ratio)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.29 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>555<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to ascertainment bias which seriously weakens confidence in the results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0017"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>hay fever, rhinoconjunctivitis, hypersensitivity/allergy</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>hay fever, rhinoconjunctivitis, hypersensitivity/allergy</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ rhinoconjunctivitis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.64<br/>(0.19 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>489<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000<br/>(48 to 360) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ hypersensitivity/allergy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.63<br/>(0.14 to 2.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>544<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000<br/>(95 to 675) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ hay fever</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.16<br/>(0.92 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0 cases, 0 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to non‐critical risk of bias in the study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004407-tbl-0018"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Safety: acute leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: acute leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>acute leukaemia </b> <br/><b>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>acute leukaemia </b> <br/><b>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ acute leukaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.97<br/>(0.76 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>941 cases, 1667 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ acute lymphoblastic leukaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.91<br/>(0.72 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1375 cases, 2316 controls<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ acute myeloblastic leukaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.56<br/>(0.29 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>62 cases, 1258 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0019"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 19.</span> <span class="table-title">Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of demyelinating diseases ‐ multiple sclerosis ‐ ADEM<br/>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of demyelinating diseases ‐ multiple sclerosis ‐ ADEM<br/>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ multiple sclerosis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.13<br/>(0.62 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206 cases, 888 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ ADEM</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.03<br/>(0.44 to 2.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272 cases, 1096 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ADEM:</b> acute disseminated encephalomyelitis; <b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0020"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 20.</span> <span class="table-title">Safety: gait disturbances</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: gait disturbances</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of gait disturbances<br/>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of gait disturbances<br/>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series (hospitalisations) ‐ hospitalisations ‐ risk period: 0 to 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.46<br/>(0.16 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 0 to 5 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.88<br/>(1.30 to 2.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1398<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 6 to 60 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.93<br/>(0.78 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1398<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>GP:</b> general practitioner; <b>MMR:</b> measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004407-tbl-0021"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 21.</span> <span class="table-title">Safety: bacterial or viral infections, immune overload</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: bacterial or viral infections, immune overload</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bacterial or viral infections, immune overload amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bacterial or viral infections, immune overload amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ lobar pneumonia ‐ lobar pneumonia risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.75<br/>(0.64 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2412<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ invasive bacterial infections ‐ invasive bacterial infections risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.90<br/>(0.71 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2412<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ encephalitis meningitis ‐ encephalitis meningitis risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.84<br/>(0.20 to 3.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.17<br/>(0.56 to 2.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0 to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.72<br/>(0.32 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ varicella zoster ‐ varicella zoster risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.93<br/>(0.68 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ miscellaneous viral infections ‐ miscellaneous viral infections risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.68<br/>(0.43 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004407-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004407-sec-0009"></div> <section id="CD004407-sec-0010"> <h3 class="title" id="CD004407-sec-0010">Description of the condition</h3> <p>Measles, mumps, and rubella (MMR) are serious diseases that can lead to potentially fatal illnesses, disabilities, and death. MMR is particularly prevalent in low‐income countries where vaccination programmes are inconsistent and mortality rates from disease are high. Large‐scale vaccination programmes have reduced MMR incidence, prevalence, and rates of complications in high‐income countries (<a href="./references#CD004407-bbs2-0350" title="HambroskyJ , KrogerA , WolfeS . Epidemiology and prevention of vaccine-preventable diseases. In: HamborskyJ , KrogerA , WolfeS , editors(s). Centers for Disease Control and Prevention. 13th edition. Vol. 1. Washington D.C.: Public Health Foundation, 2015:1.">Hambrosky 2015</a>). </p> <p>Measles is highly contagious with a case‐fatality rate ranging from 0.01% to 0.1% in high‐income countries to 3% to 30% in low‐income areas (<a href="./references#CD004407-bbs2-0406" title="WolfsonLJ , GraisRF , LuqueroFJ , BirminghamME , StrebelPM . Estimates of measles case fatality ratios: a comprehensive review of community-based studies. International Journal of Epidemiology2009;38(1):192-205. [PMID: 19188207]">Wolfson 2009</a>). Otitis media (7% to 9%), pneumonia (8%), and diarrhoea (1% to 6%) are the most frequently reported complications of measles. These complications are responsible for the large proportion of measles‐related morbidity and mortality (<a href="./references#CD004407-bbs2-0377" title="PerryRT , HalseyNA . The clinical significance of measles: a review. Journal of Infectious Diseases2004;189(Suppl 1):S4-16. [PMID: 15106083]">Perry 2004</a>). Pneumonia is the most common fatal complication of measles, occurring in 56% to 86% of measles‐related deaths (<a href="./references#CD004407-bbs2-0329" title="BesterJC . Measles and measles vaccination: a review. JAMA Pediatrics2016;170(12):1209-15. [PMID: 27695849]">Bester 2016</a>). </p> <p>Rubella is an acute viral disease mostly affecting school‐aged children and young adults with high incidence and prevalence worldwide in the pre‐vaccine era (<a href="./references#CD004407-bbs2-0361" title="LambertN , StrebelP , OrensteinW , IcenogleJ , PolandGA . Rubella. Lancet2015;385(9984):2297-307. [PMID: 25576992]">Lambert 2015</a>). Women of childbearing age are susceptible to rubella infection before conception or during early pregnancy which can result in miscarriage, fetal death, or congenital rubella syndrome. These conditions are the most serious complications of rubella with incidence varying from fewer than 2 per 100,000 live births in the Americas and Europe to 121 per 100,000 live births in Africa and South East Asia (<a href="./references#CD004407-bbs2-0393" title="VynnyckyE , AdamsEJ , CuttsFT , ReefSE , NavarAM , SimonsE , et al. Using seroprevalence and immunisation coverage data to estimate the global burden of congenital rubella syndrome, 1996-2010: a systematic review. PLoS ONE2016;11(3):e0149160. [PMID: 26962867]">Vynnycky 2016</a>). </p> <p>Mumps is a viral infection that mostly affects children. Peak incidence occurs among those aged five to nine years (<a href="./references#CD004407-bbs2-0358" title="HviidA , RubinS , MuhlemannK . Mumps. Lancet2008;371(9616):932-44. [PMID: 18342688]">Hviid 2008</a>). Annual incidence of 100 to 1000 cases/100,000 population was reported in the pre‐vaccine era with greater than 90% reduction after mumps vaccines were introduced (<a href="./references#CD004407-bbs2-0350" title="HambroskyJ , KrogerA , WolfeS . Epidemiology and prevention of vaccine-preventable diseases. In: HamborskyJ , KrogerA , WolfeS , editors(s). Centers for Disease Control and Prevention. 13th edition. Vol. 1. Washington D.C.: Public Health Foundation, 2015:1.">Hambrosky 2015</a>). Orchitis (inflammation of the testicles) is the most common age‐related complication (12% to 66% of cases) (<a href="./references#CD004407-bbs2-0408" title="YungCF , AndrewsN , BukasaA , BrownKE , RamsayM . Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006. Emerging Infectious Diseases2011;17(4):661-7; quiz 766. [PMID: 21470456]">Yung 2011</a>). The most serious complications are aseptic meningitis (1% to 10%) and deafness (4%) (<a href="./references#CD004407-bbs2-0408" title="YungCF , AndrewsN , BukasaA , BrownKE , RamsayM . Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006. Emerging Infectious Diseases2011;17(4):661-7; quiz 766. [PMID: 21470456]">Yung 2011</a>). </p> <p>Varicella (chickenpox) is a widespread and highly contagious infectious disease with peak incidence in children aged up to 15 years (<a href="./references#CD004407-bbs2-0348" title="GershonAA , BreuerJ , CohenJI , CohrsRJ , GershonMD , GildenD , et al. Varicella zoster virus infection. Nature Reviews. Disease Primers2015;1:15016. [DOI: 10.1038/nrdp.2015.16] [PMID: 27188665]">Gershon 2015</a>). Most epidemiological data are from high‐income countries and account for high pre‐vaccine incidence (from 320 to 1600 cases per 100,000) with case‐fatality rates of approximately 3 per 100,000 cases (<a href="./references#CD004407-bbs2-0326" title="AmjadiO , RafieiA , HaghshenasM , NavaeiRA , ValadanR , Hosseini-KhahZ , et al. A systematic review and meta-analysis of seroprevalence of varicella zoster virus: a nationwide population-based study. Journal of Clinical Virology 2016 Dec 6 [Epub ahead of print];87:49-59. [DOI: 10.1016/j.jcv.2016.12.001] [PMID: 28011413]">Amjadi 2016</a>; <a href="./references#CD004407-bbs2-0353" title="HelmuthIG , PoulsenA , SuppliCH , MolbakK . Varicella in Europe - a review of the epidemiology and experience with vaccination. Vaccine2015;33(21):2406-13. [PMID: 25839105]">Helmuth 2015</a>). Typically, varicella‐zoster virus (VZV) becomes latent in ganglionic neurons after primary infection, and reactivation may occur to cause zoster (shingles); risk increases with age (<a href="./references#CD004407-bbs2-0347" title="GershonAA , GershonMD . Pathogenesis and current approaches to control of varicella-zoster virus infections. Clinical Microbiology Reviews2013;26(4):728-43. [PMID: 24092852]">Gershon 2013</a>). </p> </section> <section id="CD004407-sec-0011"> <h3 class="title" id="CD004407-sec-0011">Description of the intervention</h3> <p>The single‐component live attenuated vaccines of MMR were first licenced in the USA in the early 1960s (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>), and have been shown to be highly effective. Some combination vaccines were available from the early 1970s, including trivalent MMR vaccines; a combination of MMR with varicella (MMRV) was made available from 2005 (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>; <a href="./references#CD004407-bbs2-0402" title="World Health Organization. WHO Position Paper. Epidemiologic Reviews2017;17:205-28.">WHO Position Paper 2017</a>). At least two MMR vaccines are authorised worldwide and marketed widely: </p> <p> <ol id="CD004407-list-0001"> <li> <p>MMR‐II or MMRVaxPro by Merck/MSD is a live‐virus vaccine. It is a sterile lyophilised preparation of 1000 TCID50 (50% tissue culture infectious doses) Enders' attenuated Edmonston measles strain propagated in chick embryo cell culture; mumps 20000 TCID50 Jeryl Lynn strain propagated in chick embryo cell culture; and rubella 1000 TCID50 Wistar RA 27/3 propagated on human diploid lung fibroblasts. The growth medium is medium 199 (5.7 mg) used with neomycin as stabiliser; </p> </li> <li> <p>Priorix vaccine, Glaxo SmithKline Beecham (GSK), is a lyophilised mixed preparation of the attenuated Schwarz measles CCID50 (50% cell culture infective dose) strain; RIT 4385 mumps CCID50 (derived from Jeryl Lynn strain); and CCID50 Wistar RA 27/3 rubella strain of viruses. These are obtained separately by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). The vaccine also contains residual amounts of neomycin (25 µg per dose). </p> </li> </ol> </p> <p>A World Health Organization (WHO) pre qualified MMR vaccine has also been licenced by the Serum Institute of India/Masu Co Ltd for Asian markets. It is a sterile lyophilised preparation containing live attenuated Edmonston‐Zagreb measles virus (not less than 1000 CCID50), Leningrad‐Zagreb mumps virus (not less than 5000 CCID50), and Wistar RA 27/3 rubella virus (not less than 1000 CCID50). </p> <p>Other commercial formulations of MMR vaccines have been used over the past 30 years, and to date are authorised in few countries, or have been withdrawn from marketing for commercial, safety, or both commercial and safety reasons: </p> <p> <ol id="CD004407-list-0002"> <li> <p>Morupar by Chiron contains live attenuated Schwarz measles strain 1000 TCID50, propagated in chick embryo cell culture; Wistar RA 27/3 rubella strain 1000 TCID50, propagated on human diploid lung fibroblasts; and Urabe AM9 mumps 5000 TCID50, propagated in chick embryo cell culture, with neomycin as stabiliser (withdrawn globally because of increased allergic reactions due to the manufacturing process); </p> </li> <li> <p>Trimovax by Pasteur‐Merieux Serums and Vaccines contains live attenuated Schwarz measles strain, 1000 CCID50; Urabe AM9 mumps strain, 5000 TCID50; and Wistar RA 27/3 rubella strain, 1000 TCID50; </p> </li> <li> <p>Triviraten Berna contains live attenuated Edmonston‐Zagreb (EZ 19) measles strain, 1000 TCID50; Rubini mumps strain, 5000 TCID50; and Wistar RA 27/3 rubella strain, 1000 TCID50 propagated on human diploid cells. The product contains lactose (14 mg), human albumin (8.8 mg), sodium bicarbonate (0.3 mg), medium 199 (5.7 mg), and distilled water as solvent. </p> </li> </ol> </p> <p>Two main MMRV combined vaccines are authorised for worldwide use and contain live attenuated Oka/Merck strain VZV: </p> <p> <ol id="CD004407-list-0003"> <li> <p>ProQuad by Merck/MSD is a live‐virus vaccine with the same composition as MMR‐II/MMRVaxPro, including live attenuated Oka/Merck VZV strain, 3.99 log10 PFU (plaque forming units) propagated on MRC‐5 human diploid cells; and </p> </li> <li> <p>Priorix Tetra by GSK is a live‐virus vaccine with the same composition as Priorix, including live attenuated Oka/Merck VZV strain, 103.3 PFU propagated on MRC‐5 human diploid cells. </p> </li> </ol> </p> <p>The components of monovalent and subsequently combined MMR vaccine are described below (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>). Most attenuated measles vaccines currently produced worldwide are derived from the Edmonston strain. Vaccines containing non‐Edmonston‐derived strains are also in use, including Leningrad‐16, Shanghai‐191, CAM‐70, and TD97. In most cases the virus is cultured in chick embryo cells. However, a few vaccines are attenuated in human diploid cells. Most vaccines contain traces of antibiotics (e.g. 25 µg neomycin per dose), but some do not. Sorbitol and gelatine are used as stabilisers (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>; <a href="./references#CD004407-bbs2-0402" title="World Health Organization. WHO Position Paper. Epidemiologic Reviews2017;17:205-28.">WHO Position Paper 2017</a>). </p> <p>More than 10 mumps vaccine strains (Jeryl Lynn, Urabe, Hoshino, Rubini, Leningrad‐3, L‐Zagreb, Miyahara, Torii, NK M‐46, S‐12, and RIT 4385) have been used throughout the world, but the Jeryl Lynn strain is the most widely used to date (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>). Although some manufacturers produce live mumps vaccines containing the Urabe AM9 virus strain, some countries have promptly stopped Urabe strain‐containing MMR vaccines because of concerns about vaccine‐associated meningitis. Viruses are often cultured in chick embryo fibroblasts (as with the Jeryl Lynn and Urabe strain‐containing vaccines), but quail and human embryo fibroblasts are also used. Most vaccines also contain neomycin (25 µg per dose) (<a href="./references#CD004407-bbs2-0402" title="World Health Organization. WHO Position Paper. Epidemiologic Reviews2017;17:205-28.">WHO Position Paper 2017</a>). </p> <p>Most rubella vaccines used throughout the world contain the RA 27/3 virus strain. Exceptions are vaccines produced in Japan, which use different virus strains: Matsuba, DCRB 19, Takahashi, TO‐336 (cultured in rabbit kidney cells), and Matsuura (produced using quail embryo fibroblasts) (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>). The RA 27/3 strain is used most often because of consistent immunogenicity, induction of resistance to re‐infection, and low rate of adverse effects (<a href="./references#CD004407-bbs2-0402" title="World Health Organization. WHO Position Paper. Epidemiologic Reviews2017;17:205-28.">WHO Position Paper 2017</a>). The live virus produces viraemia and pharyngeal excretion, but both are of low magnitude and are non‐communicable (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>). </p> <p>All available monovalent VZV vaccines consist of the Oka virus strain, which was subsequently attenuated by sequential passage in cultures of human embryonic lung cells, embryonic guinea pig cells, and the human diploid cell line WI‐38 or MCR‐5 (<a href="./references#CD004407-bbs2-0380" title="PlotkinSA , OresteinWA , OffitPA . Plotkin's Vaccines. 7th edition. Vol. 1. Philadelphia: Elsevier Health Sciences Division, 2018.">Plotkin 2017</a>). The titre of VZV is around 14 times higher in the MMRV vaccines described than in the monovalent VZV vaccine (<a href="./references#CD004407-bbs2-0401" title="World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. www.who.int/wer/2014/wer8925.pdf (accessed prior to 2 October 2019).">WHO Position Paper 2014</a>). </p> </section> <section id="CD004407-sec-0012"> <h3 class="title" id="CD004407-sec-0012">How the intervention might work</h3> <p>Combined MMR (trivalent vaccine, containing measles, rubella, mumps strains), MMR+V (concurrent administration of MMR vaccine and varicella (chickenpox) vaccine), and MMRV (tetravalent vaccine containing measles, rubella, mumps, varicella strains) vaccines are widely recommended by health authorities and offer advantages over individual vaccines in the facilitation of current immunisation implementation strategies. Moreover, trivalent vaccines are included in the WHO Expanded Programme on Immunization, and are used in almost all European countries, the USA, Canada, Australia, New Zealand, and 100 other countries around the world (<a href="./references#CD004407-bbs2-0373" title="OrensteinWA , HinmanA , NkowaneB , OliveJM , ReingoldA . Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine2018;36(Suppl 1):A1-34. [PMID: 29307367]">Orenstein 2018</a>; <a href="./references#CD004407-bbs2-0399" title="WHOGVAP . Global vaccine action plan 2011-2020. www.who.int/immunization/global_vaccine_action_plan/ GVAP_doc_2011_2020/en/ (accessed prior to 2 October 2019).">WHO GVAP 2013</a>). Quadrivalent MMRV vaccines are also recommended, but have to date been implemented in a limited number of countries where varicella vaccination is routinely recommended (<a href="./references#CD004407-bbs2-0400" title="WHO Immunization Monitoring. WHO. Varicella vaccine. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. apps.who.int/immunization_monitoring/globalsummary/schedules (accessed prior to 2 October 2019).">WHO Immunization Monitoring 2019</a>). According to accepted recommendations, the first dose of both MMR and MMRV should be administered on or after the child's first birthday (from 9 to 15 months of age), and the second dose at least 28 days later, or from 4 to 10 years of age (<a href="./references#CD004407-bbs2-0400" title="WHO Immunization Monitoring. WHO. Varicella vaccine. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. apps.who.int/immunization_monitoring/globalsummary/schedules (accessed prior to 2 October 2019).">WHO Immunization Monitoring 2019</a>; <a href="./references#CD004407-bbs2-0402" title="World Health Organization. WHO Position Paper. Epidemiologic Reviews2017;17:205-28.">WHO Position Paper 2017</a>). Combined vaccines provide a significant improvement in the efficiency of childhood immunisation, and a meaningful reduction in costs through increasing immunisation coverage against specific diseases with a single injection (<a href="./references#CD004407-bbs2-0392" title="VesikariT , Sadzot-DelvauxC , RentierB , GershonA . Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatric Infectious Disease Journal2007;26(7):632-8. [PMID: 17596807]">Vesikari 2007</a>). </p> <p>Until 2011, single‐component measles vaccine was largely used in nearly all African and several Asian, and Western European WHO member states with different implementation strategies (single‐dose or second‐dose administration) (<a href="./references#CD004407-bbs2-0399" title="WHOGVAP . Global vaccine action plan 2011-2020. www.who.int/immunization/global_vaccine_action_plan/ GVAP_doc_2011_2020/en/ (accessed prior to 2 October 2019).">WHO GVAP 2013</a>). A first dose of measles‐containing vaccine at nine months of age has been recommended in all countries with ongoing transmission and high risk of measles mortality among infants to ensure adequate protection. The introduction of a second measles‐containing vaccine dose at 15 to 18 months of age has been recommended when coverage of at least 80% for the first dose of measles‐containing vaccine has been reached for three consecutive years. By 2011, all 194 WHO member states had introduced or begun the process of introducing a two‐dose measles vaccination strategy through routine immunisation services, supplementary immunisation activity, or both (<a href="./references#CD004407-bbs2-0404" title="World Health Organization. Global measles and rubella strategic plan 2012-2020. apps.who.int/iris/bitstream/handle/10665/44855/9789241503396_eng.pdf?sequence=1 (accessed prior to 2 October 2019).">WHO Strategic Plan 2012</a>). However, this policy was revised in April 2017, and recommended including the second measles vaccine dose in national vaccination schedules regardless of the coverage level (<a href="./references#CD004407-bbs2-0402" title="World Health Organization. WHO Position Paper. Epidemiologic Reviews2017;17:205-28.">WHO Position Paper 2017</a>). As of December 2010, 131 of the 194 WHO member states included MR or MMR combined vaccines in routine immunisation programmes (<a href="./references#CD004407-bbs2-0404" title="World Health Organization. Global measles and rubella strategic plan 2012-2020. apps.who.int/iris/bitstream/handle/10665/44855/9789241503396_eng.pdf?sequence=1 (accessed prior to 2 October 2019).">WHO Strategic Plan 2012</a>). Relevant progress has been made toward the ambitious goals of the Global Measles and Rubella Strategic Plan 2012 to 2020 (<a href="./references#CD004407-bbs2-0404" title="World Health Organization. Global measles and rubella strategic plan 2012-2020. apps.who.int/iris/bitstream/handle/10665/44855/9789241503396_eng.pdf?sequence=1 (accessed prior to 2 October 2019).">WHO Strategic Plan 2012</a>), with a further 23 of 194 WHO member states introducing a second dose of measles‐containing vaccine, and 17 countries introducing the rubella‐containing vaccine (<a href="./references#CD004407-bbs2-0373" title="OrensteinWA , HinmanA , NkowaneB , OliveJM , ReingoldA . Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine2018;36(Suppl 1):A1-34. [PMID: 29307367]">Orenstein 2018</a>). </p> <p>Between 2000 and 2017, estimated measles vaccine coverage increased globally from 72% to 85%, with a reported 83% reduction of annual measles incidence and 80% reduction in estimated measles mortality (<a href="./references#CD004407-bbs2-0336" title="DabbaghA , LawsRL , SteuletC , DumolardL , MuldersMN , KretsingerK , et al. Progress toward regional measles elimination - worldwide, 2000-2017. MMWR. Morbidity and Mortality Weekly Report2018;67(47):1323-9. [PMID: 30496160]">Dabbagh 2018</a>). Estimated global rubella vaccine coverage increased from 39% to 46%, with high regional variability ranging from 12% in South East Asia to 94% in Europe (<a href="./references#CD004407-bbs2-0373" title="OrensteinWA , HinmanA , NkowaneB , OliveJM , ReingoldA . Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine2018;36(Suppl 1):A1-34. [PMID: 29307367]">Orenstein 2018</a>). According to Regional Verification Commissions in the American, European and Western Pacific Regions, the goal of measles elimination (end of endemic transmission for at least three years) had been reached by the end of 2015 in 61 member states (34/35, 21/53, and 6/27 member states respectively in the Americas, Europe, and western Pacific) and elimination of rubella in 55 member states (35/35 and 20/53 member states in the Americas and Europe, respectively) (<a href="./references#CD004407-bbs2-0373" title="OrensteinWA , HinmanA , NkowaneB , OliveJM , ReingoldA . Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine2018;36(Suppl 1):A1-34. [PMID: 29307367]">Orenstein 2018</a>; <a href="./references#CD004407-bbs2-0378" title="PerryRT , MurrayJS , Gacic-DoboM , DabbaghA , MuldersMN , StrebelPM , et al. Progress toward regional measles elimination – worldwide. 2000-2014. MMWR. Morbidity and Mortality Weekly Report2015;64(44):1246-51.">Perry 2015</a>). However, measles elimination milestones have not been met in several countries in all WHO regions, and measles resurgence has been reported from 2017 to 2019 because of large outbreaks (<a href="./references#CD004407-bbs2-0336" title="DabbaghA , LawsRL , SteuletC , DumolardL , MuldersMN , KretsingerK , et al. Progress toward regional measles elimination - worldwide, 2000-2017. MMWR. Morbidity and Mortality Weekly Report2018;67(47):1323-9. [PMID: 30496160]">Dabbagh 2018</a>; <a href="./references#CD004407-bbs2-0409" title="ZimmermanLA , MuscatM , SinghS , Ben MamouM , JankovicD , DattaS , et al. Progress toward measles elimination - European region, 2009-2018. MMWR. Morbidity and Mortality Weekly Report2019;68(17):396-401. [PMID: 31048675]">Zimmerman 2019</a>). </p> <p>A global technical consultation requested by the WHO assessed the feasibility of measles elimination through mass immunisation and convened that eradication is biologically, technically, and operationally feasible (<a href="./references#CD004407-bbs2-0397" title="World Health Organization. Proceedings of the global technical consultation to assess the feasibility of measles eradication, 28-30 July 2010. Journal of Infectious Diseases2011;204(Suppl 1):S4-13. [PMID: 21666191]">WHO 2011</a>). MMR capability to eliminate the targeted diseases has been demonstrated in a number of countries and different scenarios. </p> <p>The largest country to have ended endemic measles transmission is the USA, where the elimination of endemic measles had been previously verified in 2000 (<a href="./references#CD004407-bbs2-0332" title="Centers for Disease Control and Prevention. Achievements in public health: elimination of rubella and congenital rubella syndrome - United States, 1969-2004. MMWR Weekly2005;54(11):279-82.">CDC 2005</a>; <a href="./references#CD004407-bbs2-0333" title="National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention. Documentation and verification of measles, rubella and congenital rubella syndrome elimination in the region of the Americas: United States national report, March 28, 2012. www.cdc.gov/measles/downloads/Report-elimination-measles-rubella-crs.pdf [accessed prior to 2 October 2019].">CDC 2012</a>; <a href="./references#CD004407-bbs2-0372" title="OrensteinWA , PapaniaMJ , WhartonME . Measles elimination in the United States. Journal of Infectious Diseases2004;189(Suppl 1):S1-3. [PMID: 15106120]">Orenstein 2004</a>). The interruption of indigenous transmission was first observed in 1993 after refining the elimination strategy to face the large resurgence of measles that occurred from 1989 to 1991 (<a href="./references#CD004407-bbs2-0331" title="Centers for Disease Control and Prevention. Public sector vaccination efforts in response to the resurgence of measles among preschool-aged children - United States, 1989–1991. MMWR Weekly1992;41(29):522-5.">CDC 1992</a>; <a href="./references#CD004407-bbs2-0395" title="WatsonJC , ReddSC , RhodesPH , HadlerSC . The interruption of transmission of indigenous measles in the United States during 1993. Pediatric Infectious Disease Journal1998;17(5):363-6; discussion 366-7.">Watson 1998</a>). Incidence has remained at less than 1 case per 1 million population continuously since 1997, with most measles cases from 2001 representing importations or import‐associated infections (<a href="./references#CD004407-bbs2-0333" title="National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention. Documentation and verification of measles, rubella and congenital rubella syndrome elimination in the region of the Americas: United States national report, March 28, 2012. www.cdc.gov/measles/downloads/Report-elimination-measles-rubella-crs.pdf [accessed prior to 2 October 2019].">CDC 2012</a>; <a href="./references#CD004407-bbs2-0343" title="FiebelkornAP , ReddSB , GastanaduyPA , ClemmonsN , RotaPA , RotaJS , et al. A comparison of postelimination measles epidemiology in the United States, 2009-2014 versus 2001-2008. Journal of the Pediatric Infectious Diseases Society2017;6(1):40-8. [PMID: 26666559]">Fiebelkorn 2017</a>). The elimination of rubella and congenital rubella syndrome was verified in 2004 by an external expert panel (<a href="./references#CD004407-bbs2-0332" title="Centers for Disease Control and Prevention. Achievements in public health: elimination of rubella and congenital rubella syndrome - United States, 1969-2004. MMWR Weekly2005;54(11):279-82.">CDC 2005</a>). The incidence remained below 1 case per 10 million population with an annual median number of 10 cases (range 4 to 18 cases) (<a href="./references#CD004407-bbs2-0333" title="National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention. Documentation and verification of measles, rubella and congenital rubella syndrome elimination in the region of the Americas: United States national report, March 28, 2012. www.cdc.gov/measles/downloads/Report-elimination-measles-rubella-crs.pdf [accessed prior to 2 October 2019].">CDC 2012</a>; <a href="./references#CD004407-bbs2-0357" title="HinmanAR , HahnC , MaldonadoY , ShultPA , TemteJL . Verification and documentation of elimination of measles and rubella as endemic diseases from the United States: summary and conclusions of an external expert panel. www.cdc.gov/measles/downloads/expert-panel-elimination-measles.pdf (accessed prior to 2 October 2019).">Hinman 2011</a>). Recent studies and reviews of USA measles and rubella outbreaks showed that most imported cases were unvaccinated people in areas with suboptima vaccination coverage and in regions where herd immunity threshold for first or second dose had not been reached, or both (<a href="./references#CD004407-bbs2-0343" title="FiebelkornAP , ReddSB , GastanaduyPA , ClemmonsN , RotaPA , RotaJS , et al. A comparison of postelimination measles epidemiology in the United States, 2009-2014 versus 2001-2008. Journal of the Pediatric Infectious Diseases Society2017;6(1):40-8. [PMID: 26666559]">Fiebelkorn 2017</a>; <a href="./references#CD004407-bbs2-0363" title="LeeAD , ClemmonsNS , PatelM , GastanaduyPA . International importations of measles virus into the United States during the postelimination era, 2001-2016. Journal of Infectious Diseases2019;219(10):1616-23. [PMID: 30535027]">Lee 2019</a>; <a href="./references#CD004407-bbs2-0374" title="PapaniaMJ , WallaceGS , RotaPA , IcenogleJP , FiebelkornAP , ArmstrongGL , et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatrics2014;168(2):148-55. [PMID: 24311021]">Papania 2014</a>). </p> <p>In Europe, measles and rubella outbreaks and endemic transmission persisted at regional levels due to suboptima vaccination coverage (<a href="./references#CD004407-bbs2-0409" title="ZimmermanLA , MuscatM , SinghS , Ben MamouM , JankovicD , DattaS , et al. Progress toward measles elimination - European region, 2009-2018. MMWR. Morbidity and Mortality Weekly Report2019;68(17):396-401. [PMID: 31048675]">Zimmerman 2019</a>). Despite the substantial reduction of measles and rubella incidence, 21 of 53 countries in the European Union had interrupted the endemic transmission of measles, and 20 member states had interrupted endemic transmission of rubella (<a href="./references#CD004407-bbs2-0368" title="MuscatM , SheferA , Ben MamouM , SpataruR , JankovicD , DeshevoyS , et al. The state of measles and rubella in the WHO European Region, 2013. Clinical Microbiology and Infection2014;20(Suppl 5):S12-8. [PMID: 24520948]">Muscat 2014</a>; <a href="./references#CD004407-bbs2-0373" title="OrensteinWA , HinmanA , NkowaneB , OliveJM , ReingoldA . Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine2018;36(Suppl 1):A1-34. [PMID: 29307367]">Orenstein 2018</a>; <a href="./references#CD004407-bbs2-0403" title="WHO Regional Office for Europe. 4th meeting of the European regional verification commission for measles and rubella elimination (RVC). www.euro.who.int/__data/assets/pdf_file/0011/304958/4th-RVC-meeting-report.pdf?ua=1 (accessed prior to 2 October 2019).">WHO Regional Office for Europe 2016</a>). </p> <p>Finland was the first European country to end endemic measles transmission through a national vaccination programme as a two‐dose schedule launched in 1982, with an unremitting 95% coverage for both doses until 2017 (<a href="./references#CD004407-bbs2-0369" title="National Institute for Welfare and Health (TFL). Vaccination coverage good among young children in Finland, but measles epidemics possible. www.thl.fi/fi/web/thlfi-en/-/while-vaccination-coverage-among-children-in-finland-is-good-measles-epidemics-are-possible (accessed prior to 2 October 2019).">National Institute for Welfare and Health 2017</a>; <a href="./references#CD004407-bbs2-0376" title="PeltolaH , JokinenS , PaunioM , HoviT , DavidkinI . Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infectious Diseases2008;8(12):796-803. [PMID: 19022194]">Peltola 2008</a>). Incidence declined to 1 case per 1 million population for all MMR diseases in 1995, and in 1999 the country was documented as being free of indigenous measles, mumps, and rubella (<a href="./references#CD004407-bbs2-0337" title="DavidkinI , KontioM , PaunioM , PeltolaH . MMR vaccination and disease elimination: the Finnish experience. Expert Review of Vaccines2010;9(9):1045-53. [PMID: 20822347]">Davidkin 2010</a>). Since then, a few clusters of MMR imported cases have been observed annually without any outbreaks (<a href="./references#CD004407-bbs2-0398" title="World Health Organization. Joint external evaluation of IHR core capacities of the Republic of Finland. extranet.who.int/spp/sites/default/files/jeeta/WHO-WHE-CPI-2017.24-Report-eng.pdf (accessed prior to 2 October 2019).">WHO 2017</a>). </p> <p>After the introduction of MMR vaccine in 1988 for children aged 13 to 15 months with a catch‐up campaign for preschool‐aged children, the annual incidence of measles declined sharply in England and Wales, from 160/100,000 in 1989 to 17/100,000 in 1995 (<a href="./references#CD004407-bbs2-0346" title="GayN , RamsayM , CohenB , HeskethL , Morgan-CapnerP , BrownD , et al. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Communicable Disease Report. CDR Review1997;7(2):R17-21. [PMID: 9046124]">Gay 1997</a>; <a href="./references#CD004407-bbs2-0384" title="RamsayME , JinL , WhiteJ , LittonP , CohenB , BrownD . The elimination of indigenous measles transmission in England and Wales. Journal of Infectious Diseases2003;187(Suppl 1):S198-207. [PMID: 12721914]">Ramsay 2003</a>). The interruption of indigenous transmission was first observed in 1996 after a widespread vaccination campaign in 1994 and the introduction of the second MMR dose in 1995 (<a href="./references#CD004407-bbs2-0394" title="VyseAJ , GayNJ , WhiteJM , RamsayME , BrownDW , CohenBJ , et al. Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiologic Reviews2002;24(2):125-36. [PMID: 12762088]">Vyse 2002</a>). Nevertheless, endemic transmission in the UK re‐established in 2006 because of intense media coverage of the fraudulent Wakefield claim of a suspected link among MMR vaccines and autism (<a href="./references#CD004407-bbs2-0381" title="Public Health England. UK measles and rubella elimination strategy 2019. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/769970/UK_measles_and_rubella_elimination_strategy.pdf (accessed prior to 2 October 2019).">Public Health England 2019a</a>). Moreover, an increased number of mumps‐confirmed cases were reported in England and Wales (<a href="./references#CD004407-bbs2-0382" title="Public Health England. Measles notifications, by age group, region and sex. www.gov.uk/government/publications/measles-notifications-by-age-group-region-and-sex (accessed prior to 2 October 2019).">Public Health England 2019b</a>). However, after different nationwide vaccination campaigns, the UK had interrupted endemic transmission of measles and rubella by 2014, and elimination was certified in 2017 from the Regional Verification Commission for Measles and Rubella Elimination. Furthermore, a significant reduction of mumps cases in school‐aged children has been observed with persisting outbreaks in young adults (<a href="./references#CD004407-bbs2-0383" title="Public Health England. Confirmed cases of measles, mumps and rubella in England and Wales: 1996 to 2018. www.gov.uk/government/publications/measles-confirmed-cases/confirmed-cases-of-measles-mumps-and-rubella-in-england-and-wales-2012-to-2013 (accessed prior to 2 October 2019).">Public Health England 2019c</a>). </p> <p>Although varicella vaccines are licenced worldwide, a limited number of countries routinely recommend varicella vaccination with a one‐ or two‐dose programme (<a href="./references#CD004407-bbs2-0400" title="WHO Immunization Monitoring. WHO. Varicella vaccine. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. apps.who.int/immunization_monitoring/globalsummary/schedules (accessed prior to 2 October 2019).">WHO Immunization Monitoring 2019</a>). The USA was the first country to recommend a routine one‐dose programme in 1996, and an updated routine two‐dose programme in 2006 (<a href="./references#CD004407-bbs2-0365" title="MarinM , GürisD , ChavesSS , SchmidS , SewardJF . Prevention of varicella recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morbidity and Mortality Weekly Report2007;56:1-40.">Marin 2007</a>). A progressive reduction of overall varicella incidence has been observed in target age groups, with more than 90% decrease in cases when maintaining coverage with two doses over 80%. Moreover, a significant reduction of zoster incidence has been observed in children and adolescents, but it is too early to observe the impact of childhood varicella vaccination in adults and the elderly (<a href="./references#CD004407-bbs2-0351" title="HarpazR . Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. Expert Review of Vaccines2019;18(8):793-811. [PMID: 31318605]">Harpaz 2019</a>). Similar data have been reported in some European countries: Italy and Spain reported 75% and 89% reductions, respectively, despite lower rates of immunisation coverage (<a href="./references#CD004407-bbs2-0328" title="BechiniA , BoccaliniS , BaldoV , CocchioS , CastigliaP , GalloT , et al. Impact of universal vaccination against varicella in Italy. Human Vaccines and Immunotherapeutics2015;11(1):63-71. [PMID: 25483517]">Bechini 2015</a>; <a href="./references#CD004407-bbs2-0345" title="Garcia CenozM , CastillaJ , ChamorroJ , Martinez-BazI , Martinez-ArtolaV , IrisarriF , et al. Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012. Euro Surveillance2013;18(32):20552. [PMID: 23968827]">Garcia Cenoz 2013</a>). No evidence suggested a shift of varicella disease burden to older age groups after the introduction of varicella vaccination, but significant reductions in hospitalisations, complications, and deaths have been reported globally (<a href="./references#CD004407-bbs2-0407" title="WutzlerP , BonanniP , BurgessM , GershonA , SafadiMA , CasabonaG . Varicella vaccination - the global experience. Expert Review of Vaccines2017;16(8):833-43. [PMID: 28644696]">Wutzler 2017</a>). </p> </section> <section id="CD004407-sec-0013"> <h3 class="title" id="CD004407-sec-0013">Why it is important to do this review</h3> <p>Despite its worldwide use, no systematic reviews studying the effectiveness and safety of MMR or MMRV vaccines are available. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004407-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004407-sec-0014"></div> <p>To assess the effectiveness, safety, and long‐ and short‐term adverse effects associated with the MMR (trivalent vaccine, containing measles, rubella, mumps strains), or MMR+V (concurrent administration of MMR vaccine and varicella vaccine), or MMRV (tetravalent vaccine containing measles, rubella, mumps, varicella strains), given to children aged up to 15 years. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004407-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004407-sec-0015"></div> <section id="CD004407-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004407-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective cohort studies (PCS/RCS), case‐control studies (CCS), interrupted time‐series (ITS) studies, case cross‐over (CCO) studies, case‐only ecological method (COEM) studies, self‐controlled case series (SCCS) studies, person‐time cohort (PTC) studies, and case‐coverage design/screening methods (CCD/SM) studies. See <a href="./appendices#CD004407-sec-0127">Appendix 1</a> for study design definitions (based on <a href="./references#CD004407-bbs2-0342" title="FarringtonCP . Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine2004;22(15-16):2064-70.">Farrington 2004</a>; <a href="./references#CD004407-bbs2-0352" title="HarrisAD , McGregorJC , PerencevichEN , FurunoJP , ZhuJ , PetersonDE , et al. The use and interpretation of quasi-experimental studies in medical informatics. Journal of the American Medical Informatics Association2006;13(1):16-23. [DOI: 10.1197/jamia.M1749]">Harris 2006</a>; <a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>; <a href="./references#CD004407-bbs2-0359" title="JeffersonT , DemicheliV . Relation between experimental and non-experimental study designs. HB vaccines: a case study. Journal of Epidemiology and Community Health1999;53(1):51-4.">Jefferson 1999</a>; <a href="./references#CD004407-bbs2-0362" title="LastJ . A Dictionary of Epidemiology. 4th edition. Oxford (UK): Oxford University Press, 2001.">Last 2001</a>; <a href="./references#CD004407-bbs2-0364" title="MaclureM . The case-crossover design: a method for studying transient effects on the risk of acute events. American Journal of Epidemiology1991;133(2):144-53.">Maclure 1991</a>; <a href="./references#CD004407-bbs2-0366" title="MorgensternH . Ecologic studies in epidemiology: concepts, principles, and methods. Annual Review of Public Health1995;16:61-81.">Morgenstern 1995</a>). A study taxonomy is shown in <a href="./appendices#CD004407-sec-0128">Appendix 2</a>. </p> <p>Observational study design was crucial in this review because the main concern about MMR/V vaccination is in regard to safety. The cohort, case‐control, and case‐only studies are valid study designs to investigate the possible association between vaccination and rare adverse events (<a href="./references#CD004407-bbs2-0342" title="FarringtonCP . Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine2004;22(15-16):2064-70.">Farrington 2004</a>). </p> </section> <section id="CD004407-sec-0018"> <h4 class="title">Types of participants</h4> <p>Healthy children aged up to 15 years, or adults who received MMR or MMRV/MMR+V vaccination between 0 and 15 years of age. We included studies (or data sets) where participants received vaccination before 16 years of age. For studies conducted in the general population, only data regarding participants vaccinated under 15 years were included in analyses. Studies where most participants received vaccination when aged 16 years or older were excluded. </p> </section> <section id="CD004407-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Vaccination with any combined MMR or MMRV/MMR+V vaccine given in any dose, preparation, or time schedule compared with no intervention or placebo. </p> <p>MMR (trivalent vaccine containing measles, rubella, mumps strains). MMR+V (concurrent administration of MMR vaccine and varicella vaccine). MMRV (tetravalent vaccine containing measles, rubella, mumps, varicella strains). </p> </section> <section id="CD004407-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD004407-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004407-list-0004"> <li> <p>Effectiveness: clinical and/or laboratory‐confirmed cases of measles, mumps, rubella, or varicella. </p> </li> <li> <p>Safety: encephalitis or encephalopathy, aseptic meningitis, seizure (febrile/afebrile), autism spectrum disorders, inflammatory bowel disease, cognitive delay, developmental delay, idiopathic thrombocytopenic purpura, Henoch‐Schönlein purpura, type 1 diabetes, asthma, dermatitis or eczema, hay fever, rhinoconjunctivitis, hypersensitivity/allergy, acute leukaemia, demyelinating diseases, multiple sclerosis, encephalomyelitis, acute disseminated encephalomyelitis (ADEM), gait disturbances, bacterial or viral infections. </p> </li> </ol> </p> </section> <section id="CD004407-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004407-list-0005"> <li> <p>Short‐term side effects: local reactions (e.g. soreness and redness at the site of inoculation) and systemic reactions (e.g. fever, rash, vomiting, and diarrhoea) following MMR or MMRV vaccination. </p> </li> </ol> </p> </section> </section> </section> <section id="CD004407-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004407-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 2 May 2019:</p> <p> <ol id="CD004407-list-0006"> <li> <p>the Cochrane Central Register of Controlled Trials, which contains the Cochrane Acute Respiratory Infections Group's Specialised Register (CENTRAL; 2019, Issue 5) in the Cochrane Library using the strategy in <a href="./appendices#CD004407-sec-0129">Appendix 3</a>; </p> </li> <li> <p>MEDLINE via PubMed (from 1966 to 2 May 2019) using the strategy in <a href="./appendices#CD004407-sec-0129">Appendix 3</a>; and </p> </li> <li> <p>Embase via Elsevier (from 1974 to 2 May 2019) using the strategy in <a href="./appendices#CD004407-sec-0129">Appendix 3</a>. </p> </li> </ol> </p> <p>We searched the following trial registers on 2 May 2019:</p> <p> <ol id="CD004407-list-0007"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>); and </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ol> </p> <p>We used the strategies in <a href="./appendices#CD004407-sec-0129">Appendix 3</a> and did not restrict the results by language or publication status (published, unpublished, in press, or in progress). </p> </section> <section id="CD004407-sec-0025"> <h4 class="title">Searching other resources</h4> <p>For effectiveness trials, we searched bibliographies of all relevant articles obtained and any published reviews for additional studies. We also searched trial registers (WHO ICTRP and ClinicalTrials.gov) for unpublished, prospectively registered trials. For safety trials, we assessed bibliographies of all relevant articles and any published reviews for additional studies. We imposed no language restrictions on all searches. </p> </section> </section> <section id="CD004407-sec-0026"> <h3 class="title" id="CD004407-sec-0026">Data collection and analysis</h3> <section id="CD004407-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CDP, AR) independently applied the inclusion criteria to all identified and retrieved articles. A third review author (VD) arbitrated in case of disagreements about the eligibility of a study. </p> </section> <section id="CD004407-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CDP, AR) independently performed data extraction using a data extraction form (<a href="./appendices#CD004407-sec-0133">Appendix 4</a>). A third review author (VD) checked data extraction and arbitrated in case of disagreement. For each study, relevant information was summarised and reported by main outcomes in Additional tables and <a href="./references#CD004407-sec-0165" title="">Characteristics of included studies</a>. </p> <p>We used a two‐letter prefix to distinguish types of study designs and whether these related to effectiveness/efficacy or safety (only). The first letter signifies the study design (a = RCT, b = case control, c = cohort, d = self‐controlled case series, e = case cross‐over, f = case‐coverage design, g = case‐only ecological method, h = interrupted time series), and the second letter signifies the endpoint (a = effectiveness/efficacy, b = safety only). See <a href="./appendices#CD004407-sec-0128">Appendix 2</a>. </p> <p>We classified the funding sources of included studies as follows.</p> <p> <ol id="CD004407-list-0008"> <li> <p>Government or not‐for‐profit organisation: explicitly stated that funding sources were public institutions, not‐for‐profit organisations, health department, or other government institutions. All authors were affiliated with public institutions, and none were affiliated with the pharmaceutical industry. All critical aspects of the research (participant selection, outcome assessment, statistical analysis, vaccine supplies) were conducted without pharmaceutical industry support. </p> </li> <li> <p>Pharmaceutical industry: explicitly declared that funding was provided by the pharmaceutical industry. All authors were affiliated with the pharmaceutical industry. All critical aspects of the research (participant selection, outcome assessment, statistical analysis, vaccine supplies) were conducted with pharmaceutical industry support. </p> </li> <li> <p>Mixed (government and pharmaceutical industry): at least one author was affiliated with the pharmaceutical industry. Statistical analysis was conducted with pharmaceutical industry support. Study vaccines were supplied by the pharmaceutical industry. </p> </li> <li> <p>Not stated or unclear: funding source was not declared, therefore it was not possible to apply the funding classification criteria. </p> </li> </ol> </p> </section> <section id="CD004407-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CDP, AR) independently assessed the methodological quality of the included studies (<a href="./appendices#CD004407-sec-0134">Appendix 5</a>). We assessed the quality of RCTs and quasi‐RCTs using criteria adapted from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We assessed the quality of non‐RCTs in relation to the presence of potential confounders that could make interpretation of the results difficult. We evaluated the quality of case‐control (prospective and retrospective) and cohort studies using the appropriate Newcastle‐Ottawa Scales (<a href="./references#CD004407-bbs2-0388" title="StangA . Critical evaluation of Newcastle-Ottawa Scale for the assessment of the quality of non-randomised studies in meta-analyses. European Journal of Epidemiology2010;25:603-5.">Stang 2010</a>; <a href="./references#CD004407-bbs2-0396" title="WellsGA , SheaB , O'ConnellD , PetersonJ , WelchV , LososM , et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. www.Iri.ca/programs/ceu/oxford.htm (accessed 2 October 2019).">Wells 2000</a>). We applied quality control assessment grids based on those developed by the University of York, NHS Centre for Reviews and Dissemination (<a href="./appendices#CD004407-sec-0134">Appendix 5</a>) to historical controlled trials (HCTs), interrupted time‐series (<a href="./references#CD004407-bbs2-0360" title="KhanSK , ter RietG , PopayJ , NixonJ , KleijnenJ . Stage II conducting the review: phase 5: study quality assessment. In: KhanSK , ter RietG , GlanvilleG , SowdenAJ , KleijnenJ , editors(s). Undertaking Systematic Reviews of Research on Effectiveness. CDR's guidance for those carrying out or commissioning reviews. CDR Report No. 4. 2nd edition. York (UK): NHS Centre for Reviews and Dissemination, University of York, 2001.">Khan 2001</a>). </p> <section id="CD004407-sec-0030"> <h5 class="title">Experimental and quasi‐experimental studies</h5> <p>See <a href="./appendices#CD004407-sec-0134">Appendix 5</a>. </p> <section id="CD004407-sec-0031"> <h6 class="title">Random sequence generation</h6> <p> <ol id="CD004407-list-0009"> <li> <p>Low risk of bias: e.g. a table of random numbers or computer‐generated random numbers.</p> </li> <li> <p>High risk of bias: e.g. alternation, date of birth, day of the week, or case record number. </p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ol> </p> </section> <section id="CD004407-sec-0032"> <h6 class="title">Allocation concealment</h6> <p> <ol id="CD004407-list-0010"> <li> <p>Low risk of bias: e.g. numbered or coded identical containers were administered sequentially; an on‐site computer system that could only be accessed after entering the characteristics of an enrolled participant; or serially numbered, opaque, sealed envelopes, or sealed envelopes that were not sequentially numbered. </p> </li> <li> <p>High risk of bias: e.g. an open table of random numbers.</p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ol> </p> </section> <section id="CD004407-sec-0033"> <h6 class="title">Blinding</h6> <p> <ol id="CD004407-list-0011"> <li> <p>Low risk of bias: if adequate double‐blinding (e.g. placebo vaccine) or single‐blinding (i.e. blinded outcome assessment) was used. </p> </li> <li> <p>High risk of bias: if there was no blinding.</p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ol> </p> </section> <section id="CD004407-sec-0034"> <h6 class="title">Incomplete outcome data</h6> <p> <ol id="CD004407-list-0012"> <li> <p>Low risk of bias: no missing data, or the proportion of missing data compared with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate. </p> </li> <li> <p>High risk of bias: when the proportion of missing data compared with observed event risk was large enough to induce clinically relevant bias in the intervention effect estimate. </p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ol> </p> </section> </section> <section id="CD004407-sec-0035"> <h5 class="title">Non‐experimental studies</h5> <p>See <a href="./appendices#CD004407-sec-0134">Appendix 5</a>. </p> <p>We used different methodological quality checklists (unpublished) for the different case‐only design studies for: </p> <p> <ol id="CD004407-list-0013"> <li> <p>self‐controlled case series (SCCS) and person‐time cohort (PTC) checklist based on <a href="./references#CD004407-bbs2-0342" title="FarringtonCP . Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine2004;22(15-16):2064-70.">Farrington 2004</a> and <a href="./references#CD004407-bbs2-0379" title="PetersenI , DouglasI , WhitakerH . Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ2016;354:1-4. [DOI: 10:1136/bmj.i4515]">Petersen 2016</a>; </p> </li> <li> <p>case cross‐over studies (CCO) checklist was based on <a href="./references#CD004407-bbs2-0342" title="FarringtonCP . Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine2004;22(15-16):2064-70.">Farrington 2004</a> and <a href="./references#CD004407-bbs2-0364" title="MaclureM . The case-crossover design: a method for studying transient effects on the risk of acute events. American Journal of Epidemiology1991;133(2):144-53.">Maclure 1991</a>; and </p> </li> <li> <p>case‐coverage methods/screening method (CCM/SM); and for case‐only ecological method (COEM) studies checklist was based on <a href="./references#CD004407-bbs2-0342" title="FarringtonCP . Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine2004;22(15-16):2064-70.">Farrington 2004</a>. </p> </li> </ol> </p> <p>We assessed evidence quality as a component of interpreting the overall results. We assigned the following 'Risk of bias' categories (<a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>): </p> <p> <ol id="CD004407-list-0014"> <li> <p>low risk of bias: plausible bias unlikely to seriously alter the results;</p> </li> <li> <p>unclear risk of bias: plausible bias that raises some doubt about the results; and</p> </li> <li> <p>high risk of bias: plausible bias that seriously weakens confidence in the result.</p> </li> </ol> </p> </section> </section> <section id="CD004407-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratio (RR) and its confidence interval (CI) as measures of effect for RCT and cohort studies. We used the odds ratio (OR) and its CI for case‐control studies. The usual effect measure for case‐only studies is the rate ratio (rr). We calculated vaccine efficacy (or effectiveness) as VE = (1 − effect estimate) x 100, expressed as a percentage. For cohort and RCT/CCT studies VE = (1 − RR) x 100. For case‐control studies VE = (1 − OR) x 100. For study designs adopting the rr as effect measure (rate = events/person‐time), the vaccine effectiveness is VE = (1 − rr) x 100. </p> <p>The inclusion of different studies involved different estimation methods and statistical models, so we are dealing with different measures of effect. Cohort studies may use the RR to compare two groups, or more sophisticated statistical models such as the logistic regression model or the proportional hazard regression model, where the effect measures reported are OR or hazard ratio (HR), respectively. Case‐control studies adopt the logistic regression model, so the effect measure is the OR. Case‐only studies design (SCCS, person‐time cohort, case cross‐over studies) use the Poisson regression model. In this case the effect measure is rr. Consequently, in order to perform meta‐analysis in some cases we had to convert one measure of the effect into another using the formulae described in <a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>. </p> <p>We converted temperatures to degrees celsius (°C) using the formula °C = (Fahrenheit − 32)/1.8. </p> </section> <section id="CD004407-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>We considered analytical studies that provided data at the person‐level for this review. The only ecological design considered was case‐only ecological study (COES). The differences between ecological study design and case‐only ecological study are described in <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=972203011715033678&amp;versionPK1=z2001220013455021601946740356428&amp;versionPK2=z2001230158237975302901048660418#APP-01" target="_blank">Appendix 1</a>. </p> <p>Where several vaccine arms from the same study design were included in the same analysis, we split the placebo group equally between the different arms, so that the total number of participants in a single analysis did not exceed the actual number in the study. </p> </section> <section id="CD004407-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>For this update we wrote to study authors to request missing data or for clarification. The response was disappointing, and we desisted from further attempts. Our analysis relies on existing data. Whenever possible we used the intention‐to‐treat (ITT) population. When necessary and possible we used strategies described in <a href="./references#CD004407-bbs2-0339" title="Di PietrantonjC . Four-fold table cell frequencies imputation in meta analysis. Statistics in Medicine2006;25(13):2299-322. [PMID: 16025540]">Di Pietrantonj 2006</a> to impute missing outcome data. </p> </section> <section id="CD004407-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We calculated the I² statistic for each pooled estimate to assess the impact of statistical heterogeneity. The I² statistic can be interpreted as the proportion of total variation amongst effect estimates due to heterogeneity rather than sampling error, and is intrinsically independent from the number of studies. When the I² statistic is less than 30%, there is little concern about statistical heterogeneity (<a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We used random‐effects models throughout to take account of the between‐study variance in our findings (<a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Not all studies reported detail sufficient to enable a full analysis of the sources of heterogeneity. </p> </section> <section id="CD004407-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>A detailed description of the study quality is provided in the <a href="#CD004407-sec-0052">Risk of bias in included studies</a> section. We assessed publication bias by inspecting the funnel plots and heterogeneity (I²) (see <a href="#CD004407-sec-0039">Assessment of heterogeneity</a>). Due to the limited number of studies in each comparison, the assessment of publication bias was not applicable. Since the evidence presented in this review originated mainly from published data, we cannot be sure that our results are not affected by publication bias. We were unable to retrieve unpublished papers, thus our results could be affected by publication bias. </p> </section> <section id="CD004407-sec-0041"> <h4 class="title">Data synthesis</h4> <p>We carried out quantitative and qualitative data syntheses separately for efficacy/effectiveness and safety. We grouped studies for quantitative analysis according to study design (see <a href="#CD004407-sec-0017">Types of studies</a>), vaccine type (MMR, MMRV, MMR+V), virus strain, and study settings. We incorporated heterogeneity into the pooled estimates by using the DerSimonian Laird random‐effects model. </p> <p>Most of the studies included in this review were observational studies, therefore quantitative synthesis is performed on adjusted estimates by multivariate models. The estimates are adjusted for age and gender. The multicentre studies also take into account the geographical area, address, school, paediatric practice, and health organisation/insurance. Some studies adjusted estimates for the health history and health status of the older siblings. </p> <p>As explained in the <a href="#CD004407-sec-0036">Measures of treatment effect</a> section, the different studies involved different statistical models and estimation methods, so we are dealing with different measures of effect. Consequently, in some cases, in order to perform the meta‐analysis, we converted one measure of effect into another using the formulae described in <a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>. </p> <p>The cohort studies on MMR vaccine effectiveness against measles and mumps present estimates not adjusted by multivariate models but report binary data (fourfold frequency table) stratified by doses. In this case, the quantitative synthesis is performed on binary data. If some studies reported adjusted estimates, we used the method described in <a href="./references#CD004407-bbs2-0339" title="Di PietrantonjC . Four-fold table cell frequencies imputation in meta analysis. Statistics in Medicine2006;25(13):2299-322. [PMID: 16025540]">Di Pietrantonj 2006</a> to convert adjusted effect estimates into adjusted binary data. </p> <p>We used RR for comparisons between vaccine and placebo/control groups for RCTs and cohort studies. We used rr for cohort studies using Poisson regression or the proportional hazard regression model. We OR for case‐control studies and rr for case‐only study designs. </p> <p>We classified and discussed included studies according to the type of outcomes for which they provided evidence, effectiveness, and possible association with harms or local and systemic adverse effects. We illustrated study characteristics, design, population, and outcomes definitions in Additional tables. </p> </section> <section id="CD004407-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out subgroup analyses where data were available, as follows.</p> <p> <ol id="CD004407-list-0015"> <li> <p>Age group</p> <ol id="CD004407-list-0016"> <li> <p>aged &lt; 5 years, aged 5 to 10 years;</p> </li> <li> <p>aged &lt; 6 years, aged 11 to 16 years; and</p> </li> <li> <p>aged &lt; 1 year, aged 1 to 4 years, aged 5 to 14 years.</p> </li> </ol> </li> <li> <p>Number of doses administered</p> <ol id="CD004407-list-0017"> <li> <p>all doses, 1 dose, 2 doses, at least 1 dose (or any dose).</p> </li> </ol> </li> <li> <p>Length of follow‐up</p> <ol id="CD004407-list-0018"> <li> <p>&lt; 5 years, 5 to 10 years.</p> </li> </ol> </li> <li> <p>Risk period (self‐controlled case series)</p> <ol id="CD004407-list-0019"> <li> <p>0 to 30 days, 31 to 60 days, 61 to 90 days.</p> </li> </ol> </li> <li> <p>Disease severity</p> <ol id="CD004407-list-0020"> <li> <p>moderate, severe.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD004407-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to perform a sensitivity analysis on results by applying fixed‐effect and random‐effects models to assess the impact of heterogeneity on our results. We performed a sensitivity analysis by excluding studies at high risk of bias to assess the robustness of our conclusions. </p> </section> <section id="CD004407-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created 21 'Summary of findings' tables using the outcomes listed in <a href="./appendices#CD004407-sec-0135">Appendix 6</a>. </p> <p> <ol id="CD004407-list-0021"> <li> <p>Effectiveness against measles</p> </li> <li> <p>Effectiveness against mumps</p> </li> <li> <p>Effectiveness against rubella</p> </li> <li> <p>Effectiveness against varicella</p> </li> <li> <p>Safety ‐ short‐term side effects</p> </li> <li> <p>Safety ‐ encephalitis or encephalopathy</p> </li> <li> <p>Safety ‐ aseptic meningitis</p> </li> <li> <p>Safety ‐ seizures (febrile/afebrile)</p> </li> <li> <p>Safety ‐ autism spectrum disorders</p> </li> <li> <p>Safety ‐ inflammatory bowel disease</p> </li> <li> <p>Safety ‐ cognitive/developmental delay</p> </li> <li> <p>Safety ‐ idiopathic thrombocytopenic purpura</p> </li> <li> <p>Safety ‐ Henoch‐Schönlein purpura</p> </li> <li> <p>Safety ‐ type 1 diabetes</p> </li> <li> <p>Safety ‐ asthma</p> </li> <li> <p>Safety ‐ eczema/dermatitis</p> </li> <li> <p>Safety ‐ hay fever, rhinoconjunctivitis, hypersensitivity/allergy</p> </li> <li> <p>Safety ‐ acute leukaemia</p> </li> <li> <p>Safety ‐ demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis (ADEM) </p> </li> <li> <p>Safety ‐ gait disturbances</p> </li> <li> <p>Safety ‐ bacterial or viral infections, immune overload</p> </li> </ol> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contributed data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD004407-bbs2-0327" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>). We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004407-bbs2-0355" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), employing GRADEpro GDT software (<a href="./references#CD004407-bbs2-0349" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed prior to 2 October 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We justified all decisions to down‐ or upgrade the quality of studies using footnotes, and made comments to aid readers’ understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004407-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004407-sec-0045"></div> <section id="CD004407-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD004407-sec-0047"> <h4 class="title">Results of the search</h4> <p>We updated searches on 2 May 2019 and identified 13,196 records for screening. We retrieved 101 papers after reviewing titles and abstracts, 74 of which we considered for this 2019 update. We also evaluated 16 studies identified as awaiting classification in our previous update (<a href="./references#CD004407-bbs2-0412" title="DemicheliV , RivettiA , DebaliniMG , Di PietrantojC . Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD004407. [DOI: 10.1002/14651858.CD004407.pub3]">Demicheli 2012</a>), of which we considered 12 studies. We included a total of 74 new studies, plus 12 studies from our previous update, for a total of 86 new included studies for this 2019 update. This review includes a total of 138 studies (see <a href="#CD004407-fig-0001">Figure 1</a>; <a href="#CD004407-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD004407-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram (simplified version)." data-id="CD004407-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram (simplified version).</p> </div> </div> </div> <div class="figure" id="CD004407-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Flow diagram (complete)." data-id="CD004407-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram (complete).</p> </div> </div> </div> </section> <section id="CD004407-sec-0048"> <h4 class="title">Included studies</h4> <p>We included nine randomised controlled trials (RCTs) (<a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a>; <a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a>; <a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a>; <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>; <a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>); one controlled clinical trial (CCT) (<a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>); 63 cohort studies (PCS/RCS) (<a href="./references#CD004407-bbs2-0046" title="ArciuoloRJ , JablonskiRR , ZuckerJR , RosenJB . Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting - New York City, 2013. Clinical Infectious Diseases2017;65(11):1843-7. ">ca‐Arciuolo 2017</a>; <a href="./references#CD004407-bbs2-0047" title="ArenzS , SchmittHJ , TischerA , vonKriesR . Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal2005;24(8):697-9. ">ca‐Arenz 2005</a>; <a href="./references#CD004407-bbs2-0048" title="BarrabeigI , RoviraA , RiusC , MunozP , SoldevilaN , BatallaJ , et al. Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal2011;30(1):78-80. ">ca‐Barrabeig 2011a</a>; <a href="./references#CD004407-bbs2-0049" title="BarrabeigI , RoviraA , MunozP , BatallaJ , RuisC , SanchezJA , et al. MMR vaccine effectiveness in an outbreak that involved day-care and primary schools. Vaccine2011;29(45):8024-31. [DOI: 10.1016/j.vaccine.2011.08.056]">ca‐Barrabeig 2011b</a>; <a href="./references#CD004407-bbs2-0050" title="BhuniyaS , MajiD , MandalD , MondalN . Measles outbreak among Dukpa tribe of Buxa Hills in West Bengal, India: epidemiology and vaccine efficacy. Indian Journal of Public Health2013;57(4):272-5. [DOI: 10.4103/0019-557X.123273]">ca‐Bhuniya 2013</a>; <a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0052" title="ChangC , MoX , HuP , LiangW , MaH , AnZ , et al. Effectiveness of rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014. Vaccine2015;33(28):3223-7. [DOI: 10.1016/j.vaccine.2015.04.083]">ca‐Chang 2015</a>; <a href="./references#CD004407-bbs2-0053" title="ChoeYJ , ParkYJ , KimJW , EomHE , ParkO , OhMD , et al. An outbreak of measles in a university in Korea, 2014. Journal of Korean Medical Science2017;32(11):1876-8. ">ca‐Choe 2017</a>; <a href="./references#CD004407-bbs2-0054" title="Compés-DeaC , Guimbao-BescòsJ , Gaspar-EscayolaJI , Lazaro-BelancheMA , Aznar-BriebaA . An outbreak of mumps in a high school: estimation of vaccine effectiveness. Zaragoza 2011 [Broteescolar de parotiditis: estimacion de la efectividad vacunal Zaragoza 2011]. Enfermedades Infeccionas y Microbiologia Clinical2015;33(6):385-90. [DOI: 10.1016/j.eimc.2014.09.011]">ca‐Compés‐Dea 2014</a>; <a href="./references#CD004407-bbs2-0055" title="GiaquintoC , GabuttiG , BaldoV , VillaM , TramontanL , RaccanelloN , et al. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. BMC Infectious Diseases2018;18(1):103. ">ca‐Giaquinto 2018</a>; <a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a>; <a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a>; <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a>; <a href="./references#CD004407-bbs2-0060" title="Lopez HernandezB , Martin VelezRM , Roman GarciaC , Penalver SanchezI , Lopez RosiqueJA . An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion Primaria/Sociedad Española de Medicina de Familia y Comunitaria2000;25(3):148-52. ">ca‐Lopez Hernandez 2000</a>; <a href="./references#CD004407-bbs2-0061" title="MaC , LiuY , TangJ , JiaH , QinW , SuY , et al. Assessment of mumps-containing vaccine effectiveness during an outbreak: importance to introduce the 2-dose schedule for China. Human Vaccines and Immunotherapy2018;14(6):1392-7. ">ca‐Ma 2018</a>; <a href="./references#CD004407-bbs2-0062" title="MarinM , NguyenHQ , LangidrikJR , EdwardsR , BriandK , PapaniaMJ , et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases2006;42(3):315-9. ">ca‐Marin 2006</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0064" title="MusaS , TopalovićB , ĆatićS , SmajlagićZ . Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. Central European Journal of Public Health2018;26(2):79-82. ">ca‐Musa 2018</a>; <a href="./references#CD004407-bbs2-0065" title="NelsonGE , AguonA , ValenciaE , OlivaR , GuerreroML , ReyesR , et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010. Pediatric Infectious Disease Journal2013;32(4):374-80. [PMID: 23099425]">ca‐Nelson 2013</a>; <a href="./references#CD004407-bbs2-0066" title="OgbuanuIU , KuttyPK , HudsonJM , BlogD , AbediGR , GoodellS , et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics2012;130(6):e1567-74. [PMID: 23129075]">ca‐Ogbuanu 2012</a>; <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a>; <a href="./references#CD004407-bbs2-0068" title="OngG , RasidahN , WanS , CutterJ . Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal2007;48(7):656-61. ">ca‐Ong 2007</a>; <a href="./references#CD004407-bbs2-0069" title="RieckT , FeigM , An der HeidenM , SiedlerA , WichmannO . Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveillance2017;22(17):30521. ">ca‐Rieck 2017</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>; <a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a>; <a href="./references#CD004407-bbs2-0072" title="SpackovaM , Wiese-PosseltM , DehnertM , Matysiak-KloseD , HeiningerU , SiedlerA . Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine2010;28(3):686-91. ">ca‐Spackova 2010</a>; <a href="./references#CD004407-bbs2-0073" title="TafuriS , MartinelliD , PratoR , GerminarioC . Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in region which adopted UMV. Human Vaccines and Immunotherapeutics2013;9(1):184-8. ">ca‐Tafuri 2013</a>; <a href="./references#CD004407-bbs2-0074" title="TaklaA , BohmerMM , KlincC , KurzN , SchafferA , StichH , et al. Outberak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics2014;10(1):140-5. ">ca‐Takla 2014</a>; <a href="./references#CD004407-bbs2-0075" title="WichmannO , HellenbrandW , SagebielD , SantibanezS , AhlemeyerG , VogtG , et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal2007;26(9):782-6. ">ca‐Wichmann 2007</a>; <a href="./references#CD004407-bbs2-0076" title="WoudenbergT , van derMaasNAT , KnolMJ , deMelkerH , vanBinnendijkRS , HahneSJM . Effectiveness of early measles, mumps, and rubella vaccination among 6-14-month-old infants during an epidemic in the Netherlands: an observational cohort study. Journal of Infectious Diseases2017;215(8):1181-7. ">ca‐Woudenberg 2017</a>; <a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a>; <a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a>; <a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a>; <a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>; <a href="./references#CD004407-bbs2-0081" title="BenkeG , AbramsonM , RavenJ , ThienFC , WaltersEH . Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health2004;28(4):336-8. ">cb‐Benke 2004</a>; <a href="./references#CD004407-bbs2-0082" title="BeyerleinA , StroblAN , WinklerC , CarpusM , KnopffA , DonnachieE , et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine2017;35(14):1735-41. ">cb‐Beyerlein 2017</a>; <a href="./references#CD004407-bbs2-0083" title="DeStefanoF , GuD , KramarzP , TrumanBI , IademarcoMF , MulloolyJP , et al. Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal2002;21(6):498-504. ">cb‐DeStefano 2002</a>; <a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a>; <a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a>; <a href="./references#CD004407-bbs2-0086" title="HiividAD , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health2004;8(5):286-7. [CRSREF: 2955568]HviidA , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination and type 1 diabetes. New England Journal of Medicine2004;350(14):1398-404. ">cb‐Hviid 2004</a>; <a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a>; <a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a>; <a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>; <a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a>; <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0093" title="KleinNP , LewisE , McDonaldJ , FiremanB , NalewayA , GlanzJ , et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. Vaccine2017;35(12):1615-21. ">cb‐Klein 2017</a>; <a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a>; <a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>; <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>; <a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a>; <a href="./references#CD004407-bbs2-0098" title="Mrozek-BudzynD , KiełtykaA , MajewskaR , AugustyniakM . Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - the results of the Polish prospective cohort study. Vaccine2013;31(22):2551-7. [DOI: 10.1016/j.vaccine.2013.03.057]">cb‐Mrozek‐Budzyn 2013</a>; <a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a>; <a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a>; <a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a>; <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>; <a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>; <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>; <a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a>; <a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a>; <a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>); 35 case‐control studies (CCS) (<a href="./references#CD004407-bbs2-0011" title="AndradeAL , da Silva VieiraMA , MinamisavaR , ToscanoCM , deLima SouzaMB , FiaccadoriF , et al. Single-dose varicella vaccine effectiveness in Brazil: a case-control study. Vaccine2018;36(4):479-83. [PMID: 29249544]">ba‐Andrade 2018</a>; <a href="./references#CD004407-bbs2-0012" title="CastillaJ , Fernandez AlonsoM , Garcia CenozM , Martinez ArtolaV , Inigo PestanaM , RodrigoI , et al. Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica2009;133(20):777-82. CastillaJ , Garcia CenozM , ArriazuM , Fernandez-AlonsoM , Martinez-ArtolaV , EtxeberriaJ , et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine2009;27(15):2089-93. ">ba‐Castilla 2009</a>; <a href="./references#CD004407-bbs2-0013" title="CenozMG , Martinez-ArtolaV , GuevaraM , EzpeletaC , BarricarteA , CastillaJ . Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Human Vaccines and Immunotherapeutics2013;9(5):1172-6. [DOI: 10.4161/hv.23451]">ba‐Cenoz 2013</a>; <a href="./references#CD004407-bbs2-0014" title="DefayF , De SerresG , SkowronskiDM , BoulianneN , OuakkiM , LandryM , et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics2013;132(5):e1126-33. [DOI: 10.1542/peds.2012-3975]">ba‐Defay 2013</a>; <a href="./references#CD004407-bbs2-0015" title="FuC , XuJ , CaiY , HeQ , ZhangC , ChenJ , et al. Effectiveness of one dose of mumps vaccine against clinically diagnoses mumps in Guangzhou, China, 2006-2012. Human Vaccines and Immunotherapeutics2013;9(12):2524-8. [DOI: 10.4161/hv.26113]">ba‐Fu 2013</a>; <a href="./references#CD004407-bbs2-0016" title="GiovanettiF , LaudaniE , MarinaroL , DoglianiMG , GiachelliV , GiachinoG , et al. Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. Igiene Moderna2002;117(3):201-9. ">ba‐Giovanetti 2002</a>; <a href="./references#CD004407-bbs2-0017" title="GoncalvesG , De AraujoA , Monteiro CardosoML . Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveillance1998;3(12):119-21. ">ba‐Goncalves 1998</a>; <a href="./references#CD004407-bbs2-0018" title="HarlingR , WhiteJM , RamsayME , MacsweenKF , vanden BoschC . The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine2005;23(31):4070-4. ">ba‐Harling 2005</a>; <a href="./references#CD004407-bbs2-0019" title="HungerfordD , ClearlyP , GhebrehewetS , KeenanA , VivancosR . Risk factors for transmission of measles during an outbreak: matched case control study. Journal of Hospital Infections2014;86(2):138-43. [DOI: 10.1016/j.jhin.2013.11.008]">ba‐Hungerford 2014</a>; <a href="./references#CD004407-bbs2-0020" title="JickH , HagbergKW . Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine2010;28(29):4588-92. ">ba‐Jick 2010</a>; <a href="./references#CD004407-bbs2-0021" title="KimHM , ChoHK , ChoiKM , EunBWY , KimKH . Efficacy of mumps in Korea. International Journal of Infectious Diseases2012;16s:e306. [DOI: 10.1016/j.ijid.2012.05.997]">ba‐Kim 2012</a>; <a href="./references#CD004407-bbs2-0022" title="LieseJG , CohenC , RackA , PirzerK , EberS , BlumM , et al. The effectiveness of varicella vaccination in children in Germany. Pediatric Infectious Disease Journal2013;32(9):998-1004. [DOI: 10.1097/INF.0b013e31829ac263]">ba‐Liese 2013</a>; <a href="./references#CD004407-bbs2-0023" title="MackenzieDG , CraigG , HallamNF , MooreJ , StevensonJ . Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice2006;56(528):526-9. ">ba‐Mackenzie 2006</a>; <a href="./references#CD004407-bbs2-0024" title="VazquezM , La RussaPS , GershonAA , StainbergSP , FreudigmanK , ShapiroE . The effectiveness of the varicella vaccine in clinical practice. New England Journal of Medicine2001;344(13):955-60. [DOI: 10.1056/NEJM200103293441302]">ba‐Vazquez 2001</a>; <a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a>; <a href="./references#CD004407-bbs2-0026" title="BaronS , TurckD , LeplatC , MerleV , Gower-RousseauC , MartiR , et al. Enviromental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut2005;54(3):357-63. [DOI: 10.1136/gut.2004.054353]">bb‐Baron 2005</a>; <a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a>; <a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>; <a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a>; <a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a>; <a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a>; <a href="./references#CD004407-bbs2-0032" title="ChenY , MaF , XuY , ChuX , ZhangJ . Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine2018;36(26):3733-9. ">bb‐Chen 2018</a>; <a href="./references#CD004407-bbs2-0033" title="Da DaltL , ZerbinatiC , StrafellaMS , RennaS , RiceputiL , Di PietroP , et al Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics2016;42(1):60. [DOI: 10.1186/s13052-016-0267-2]">bb‐Da Dalt 2016</a>; <a href="./references#CD004407-bbs2-0034" title="DavisRL , KramarzP , BohlkeK , BensonP , ThompsonRS , MulloolyJ , et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine2001;155(3):354-9. ">bb‐Davis 2001</a>; <a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a>; <a href="./references#CD004407-bbs2-0036" title="DockertyJD , SkeggDC , ElwoodJM , HerbisonGP , BecroftDM , LewisME . Infections, vaccinations, and the risk of childhood leukaemia. British Journal of Cancer1999;80(9):1483-9. [DOI: 10.1038/sj.bjc.6690548]">bb‐Dockerty 1999</a>; <a href="./references#CD004407-bbs2-0037" title="GrovesFD , GridleyG , WacholderS , ShuXO , RobisonLL , NegliaJP , et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. British Journal of Cancer1999;81(1):175-8. [DOI: 10.1038/sj.bjc.6690668]">bb‐Groves 1999</a>; <a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a>; <a href="./references#CD004407-bbs2-0039" title="Mallol-MesnardN , MenegauxF , AuvrignonA , AuclercMF , BertrandY , NelkenB , et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology2007;36(1):110-6. ">bb‐Mallol‐Mesnard 2007</a>; <a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a>; <a href="./references#CD004407-bbs2-0041" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768-73. ">bb‐Ray 2006</a>; <a href="./references#CD004407-bbs2-0042" title="ShawSY , BlanchardJF , BernsteinCN . Early childhood measles vaccinations are not associated with paediatric IBD: a population based analysis. Journal of Crohn's and Colitis2015;9(4):334-8. [DOI: 10.1093/ecco-jcc/jjv029]">bb‐Shaw 2015</a>; <a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a>; <a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a>; <a href="./references#CD004407-bbs2-0045" title="VcevA , PezerovicD , JovanovicZ , NakicD , VcevI , MajnaricL . A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. Wiener Klinische Wochenschrift2015;127(9-10):345–54. ">bb‐Vcev 2015</a>); 16 self‐controlled case series/person‐time cohort studies (SCCS/PTC) (<a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a>; <a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a>; <a href="./references#CD004407-bbs2-0113" title="MacartneyK , GiddingHF , TrinhL , WangH , DeyA , HullB , et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatrics2017;171(10):992-8. ">db‐Macartney 2017</a>; <a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a>; <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>; <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a>; <a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a>; <a href="./references#CD004407-bbs2-0118" title="MillerE , AndrewsN , GrantA , StoweJ , TaylorB . No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood2005;90(3):292-6. ">db‐Miller 2005</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>; <a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a>; <a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a>; <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>); 3 case cross‐over studies (CCO) (<a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a>; <a href="./references#CD004407-bbs2-0126" title="LafaurieM , BaricaultB , Lapeyre-MestreM , SaillerL , MoulisG , SommetA , et al. Risk of vaccine-induced immune thrombocytopenia in children. Nationwide case cross-over and self controlled case series studies in France. Fundamental &amp; Clinical Pharmacology2018;32:86. ">eb‐Lafaurie 2018</a>; <a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a>); and 11 case‐only ecological method studies (COEM) (<a href="./references#CD004407-bbs2-0128" title="BoccaliniS , BonanniP , BechiniA . Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004–2012. Euro Surveillance2015;21:1-7. [DOI: 10.2807/1560-7917.ES.2016.21.24.30257]">ga‐Boccalini 2015</a>; <a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a>; <a href="./references#CD004407-bbs2-0130" title="TafuriS , FortunatoF , CappelliMG , CozzaV , BechiniA , BonanniP , et al. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012. Human Vaccines and Immunotherapy2015;11(1):214-9. [DOI: 10.4161/hv.36153]">ga‐Tafuri 2015</a>; <a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a>; <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>; <a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a>; <a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a>; <a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a>; <a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a>; <a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a>; <a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a>). </p> <p>We classified studies reported as field trials or controlled trials as cohort studies when the allocation procedure was not mentioned. </p> <section id="CD004407-sec-0049"> <h5 class="title">Vaccine effectiveness</h5> <p>We included 51 studies on MMR/MMRV effectiveness with the following study designs: 3 RCTs/CCTs, 31 cohorts, 14 case‐control, and 3 COEM. Two studies reported vaccine efficacy data against two diseases (measles and mumps) and were thus included in two different comparisons (<a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>). We presented studies evaluating effectiveness in four main comparisons, as follows. </p> <p> <ol id="CD004407-list-0022"> <li> <p>Measles: 17 studies included effectiveness data: 14 cohort studies, <a href="./references#CD004407-bbs2-0046" title="ArciuoloRJ , JablonskiRR , ZuckerJR , RosenJB . Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting - New York City, 2013. Clinical Infectious Diseases2017;65(11):1843-7. ">ca‐Arciuolo 2017</a>; <a href="./references#CD004407-bbs2-0047" title="ArenzS , SchmittHJ , TischerA , vonKriesR . Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal2005;24(8):697-9. ">ca‐Arenz 2005</a>; <a href="./references#CD004407-bbs2-0048" title="BarrabeigI , RoviraA , RiusC , MunozP , SoldevilaN , BatallaJ , et al. Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal2011;30(1):78-80. ">ca‐Barrabeig 2011a</a>; <a href="./references#CD004407-bbs2-0049" title="BarrabeigI , RoviraA , MunozP , BatallaJ , RuisC , SanchezJA , et al. MMR vaccine effectiveness in an outbreak that involved day-care and primary schools. Vaccine2011;29(45):8024-31. [DOI: 10.1016/j.vaccine.2011.08.056]">ca‐Barrabeig 2011b</a>; <a href="./references#CD004407-bbs2-0050" title="BhuniyaS , MajiD , MandalD , MondalN . Measles outbreak among Dukpa tribe of Buxa Hills in West Bengal, India: epidemiology and vaccine efficacy. Indian Journal of Public Health2013;57(4):272-5. [DOI: 10.4103/0019-557X.123273]">ca‐Bhuniya 2013</a>; <a href="./references#CD004407-bbs2-0053" title="ChoeYJ , ParkYJ , KimJW , EomHE , ParkO , OhMD , et al. An outbreak of measles in a university in Korea, 2014. Journal of Korean Medical Science2017;32(11):1876-8. ">ca‐Choe 2017</a>; <a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a>; <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0062" title="MarinM , NguyenHQ , LangidrikJR , EdwardsR , BriandK , PapaniaMJ , et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases2006;42(3):315-9. ">ca‐Marin 2006</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0064" title="MusaS , TopalovićB , ĆatićS , SmajlagićZ . Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. Central European Journal of Public Health2018;26(2):79-82. ">ca‐Musa 2018</a>; <a href="./references#CD004407-bbs2-0068" title="OngG , RasidahN , WanS , CutterJ . Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal2007;48(7):656-61. ">ca‐Ong 2007</a>; <a href="./references#CD004407-bbs2-0075" title="WichmannO , HellenbrandW , SagebielD , SantibanezS , AhlemeyerG , VogtG , et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal2007;26(9):782-6. ">ca‐Wichmann 2007</a>; <a href="./references#CD004407-bbs2-0076" title="WoudenbergT , van derMaasNAT , KnolMJ , deMelkerH , vanBinnendijkRS , HahneSJM . Effectiveness of early measles, mumps, and rubella vaccination among 6-14-month-old infants during an epidemic in the Netherlands: an observational cohort study. Journal of Infectious Diseases2017;215(8):1181-7. ">ca‐Woudenberg 2017</a>, and 3 CCS (<a href="./references#CD004407-bbs2-0014" title="DefayF , De SerresG , SkowronskiDM , BoulianneN , OuakkiM , LandryM , et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics2013;132(5):e1126-33. [DOI: 10.1542/peds.2012-3975]">ba‐Defay 2013</a>; <a href="./references#CD004407-bbs2-0019" title="HungerfordD , ClearlyP , GhebrehewetS , KeenanA , VivancosR . Risk factors for transmission of measles during an outbreak: matched case control study. Journal of Hospital Infections2014;86(2):138-43. [DOI: 10.1016/j.jhin.2013.11.008]">ba‐Hungerford 2014</a>; <a href="./references#CD004407-bbs2-0020" title="JickH , HagbergKW . Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine2010;28(29):4588-92. ">ba‐Jick 2010</a>). See also <a href="#CD004407-tbl-0022">Table 1</a> and <a href="#CD004407-tbl-0023">Table 2</a>. </p> </li> <li> <p>Mumps: 21 studies included effectiveness data: 14 cohort studies, <a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0054" title="Compés-DeaC , Guimbao-BescòsJ , Gaspar-EscayolaJI , Lazaro-BelancheMA , Aznar-BriebaA . An outbreak of mumps in a high school: estimation of vaccine effectiveness. Zaragoza 2011 [Broteescolar de parotiditis: estimacion de la efectividad vacunal Zaragoza 2011]. Enfermedades Infeccionas y Microbiologia Clinical2015;33(6):385-90. [DOI: 10.1016/j.eimc.2014.09.011]">ca‐Compés‐Dea 2014</a>; <a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a>; <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a>; <a href="./references#CD004407-bbs2-0060" title="Lopez HernandezB , Martin VelezRM , Roman GarciaC , Penalver SanchezI , Lopez RosiqueJA . An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion Primaria/Sociedad Española de Medicina de Familia y Comunitaria2000;25(3):148-52. ">ca‐Lopez Hernandez 2000</a>; <a href="./references#CD004407-bbs2-0061" title="MaC , LiuY , TangJ , JiaH , QinW , SuY , et al. Assessment of mumps-containing vaccine effectiveness during an outbreak: importance to introduce the 2-dose schedule for China. Human Vaccines and Immunotherapy2018;14(6):1392-7. ">ca‐Ma 2018</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0065" title="NelsonGE , AguonA , ValenciaE , OlivaR , GuerreroML , ReyesR , et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010. Pediatric Infectious Disease Journal2013;32(4):374-80. [PMID: 23099425]">ca‐Nelson 2013</a>; <a href="./references#CD004407-bbs2-0066" title="OgbuanuIU , KuttyPK , HudsonJM , BlogD , AbediGR , GoodellS , et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics2012;130(6):e1567-74. [PMID: 23129075]">ca‐Ogbuanu 2012</a>; <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>; <a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a>; <a href="./references#CD004407-bbs2-0074" title="TaklaA , BohmerMM , KlincC , KurzN , SchafferA , StichH , et al. Outberak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics2014;10(1):140-5. ">ca‐Takla 2014</a>, and 7 CCS (<a href="./references#CD004407-bbs2-0012" title="CastillaJ , Fernandez AlonsoM , Garcia CenozM , Martinez ArtolaV , Inigo PestanaM , RodrigoI , et al. Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica2009;133(20):777-82. CastillaJ , Garcia CenozM , ArriazuM , Fernandez-AlonsoM , Martinez-ArtolaV , EtxeberriaJ , et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine2009;27(15):2089-93. ">ba‐Castilla 2009</a>; <a href="./references#CD004407-bbs2-0015" title="FuC , XuJ , CaiY , HeQ , ZhangC , ChenJ , et al. Effectiveness of one dose of mumps vaccine against clinically diagnoses mumps in Guangzhou, China, 2006-2012. Human Vaccines and Immunotherapeutics2013;9(12):2524-8. [DOI: 10.4161/hv.26113]">ba‐Fu 2013</a>; <a href="./references#CD004407-bbs2-0016" title="GiovanettiF , LaudaniE , MarinaroL , DoglianiMG , GiachelliV , GiachinoG , et al. Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. Igiene Moderna2002;117(3):201-9. ">ba‐Giovanetti 2002</a>; <a href="./references#CD004407-bbs2-0017" title="GoncalvesG , De AraujoA , Monteiro CardosoML . Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveillance1998;3(12):119-21. ">ba‐Goncalves 1998</a>; <a href="./references#CD004407-bbs2-0018" title="HarlingR , WhiteJM , RamsayME , MacsweenKF , vanden BoschC . The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine2005;23(31):4070-4. ">ba‐Harling 2005</a>; <a href="./references#CD004407-bbs2-0021" title="KimHM , ChoHK , ChoiKM , EunBWY , KimKH . Efficacy of mumps in Korea. International Journal of Infectious Diseases2012;16s:e306. [DOI: 10.1016/j.ijid.2012.05.997]">ba‐Kim 2012</a>; <a href="./references#CD004407-bbs2-0023" title="MackenzieDG , CraigG , HallamNF , MooreJ , StevensonJ . Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice2006;56(528):526-9. ">ba‐Mackenzie 2006</a>). See also <a href="#CD004407-tbl-0024">Table 3</a> and <a href="#CD004407-tbl-0025">Table 4</a>. </p> </li> <li> <p>Rubella: 1 cohort study included effectiveness data (<a href="./references#CD004407-bbs2-0052" title="ChangC , MoX , HuP , LiangW , MaH , AnZ , et al. Effectiveness of rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014. Vaccine2015;33(28):3223-7. [DOI: 10.1016/j.vaccine.2015.04.083]">ca‐Chang 2015</a>). See also <a href="#CD004407-tbl-0026">Table 5</a>. </p> </li> <li> <p>Varicella: 14 studies included effectiveness data: 3 RCTs (<a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a>; <a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a>; <a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a>), 4 cohort studies (<a href="./references#CD004407-bbs2-0055" title="GiaquintoC , GabuttiG , BaldoV , VillaM , TramontanL , RaccanelloN , et al. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. BMC Infectious Diseases2018;18(1):103. ">ca‐Giaquinto 2018</a>; <a href="./references#CD004407-bbs2-0069" title="RieckT , FeigM , An der HeidenM , SiedlerA , WichmannO . Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveillance2017;22(17):30521. ">ca‐Rieck 2017</a>; <a href="./references#CD004407-bbs2-0072" title="SpackovaM , Wiese-PosseltM , DehnertM , Matysiak-KloseD , HeiningerU , SiedlerA . Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine2010;28(3):686-91. ">ca‐Spackova 2010</a>; <a href="./references#CD004407-bbs2-0073" title="TafuriS , MartinelliD , PratoR , GerminarioC . Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in region which adopted UMV. Human Vaccines and Immunotherapeutics2013;9(1):184-8. ">ca‐Tafuri 2013</a>), 4 CCS (<a href="./references#CD004407-bbs2-0011" title="AndradeAL , da Silva VieiraMA , MinamisavaR , ToscanoCM , deLima SouzaMB , FiaccadoriF , et al. Single-dose varicella vaccine effectiveness in Brazil: a case-control study. Vaccine2018;36(4):479-83. [PMID: 29249544]">ba‐Andrade 2018</a>; <a href="./references#CD004407-bbs2-0013" title="CenozMG , Martinez-ArtolaV , GuevaraM , EzpeletaC , BarricarteA , CastillaJ . Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Human Vaccines and Immunotherapeutics2013;9(5):1172-6. [DOI: 10.4161/hv.23451]">ba‐Cenoz 2013</a>; <a href="./references#CD004407-bbs2-0022" title="LieseJG , CohenC , RackA , PirzerK , EberS , BlumM , et al. The effectiveness of varicella vaccination in children in Germany. Pediatric Infectious Disease Journal2013;32(9):998-1004. [DOI: 10.1097/INF.0b013e31829ac263]">ba‐Liese 2013</a>; <a href="./references#CD004407-bbs2-0024" title="VazquezM , La RussaPS , GershonAA , StainbergSP , FreudigmanK , ShapiroE . The effectiveness of the varicella vaccine in clinical practice. New England Journal of Medicine2001;344(13):955-60. [DOI: 10.1056/NEJM200103293441302]">ba‐Vazquez 2001</a>), and 3 COEM (<a href="./references#CD004407-bbs2-0128" title="BoccaliniS , BonanniP , BechiniA . Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004–2012. Euro Surveillance2015;21:1-7. [DOI: 10.2807/1560-7917.ES.2016.21.24.30257]">ga‐Boccalini 2015</a>; <a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a>; <a href="./references#CD004407-bbs2-0130" title="TafuriS , FortunatoF , CappelliMG , CozzaV , BechiniA , BonanniP , et al. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012. Human Vaccines and Immunotherapy2015;11(1):214-9. [DOI: 10.4161/hv.36153]">ga‐Tafuri 2015</a>). See also <a href="#CD004407-tbl-0027">Table 6</a>, <a href="#CD004407-tbl-0028">Table 7</a>, <a href="#CD004407-tbl-0029">Table 8</a>, and <a href="#CD004407-tbl-0030">Table 9</a>. </p> </li> </ol> </p> <div class="table" id="CD004407-tbl-0022"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Measles: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>N events in exposed/<br/>N total exposed<br/>or person‐time<br/>versus<br/>N events in non‐exposed/<br/>N total non‐exposed<br/>or person‐time</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vaccine effectiveness</b> <br/><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0049" title="BarrabeigI , RoviraA , MunozP , BatallaJ , RuisC , SanchezJA , et al. MMR vaccine effectiveness in an outbreak that involved day-care and primary schools. Vaccine2011;29(45):8024-31. [DOI: 10.1016/j.vaccine.2011.08.056]">ca‐Barrabeig 2011b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children attending day‐care</p> <p>and preschool centres</p> <p>(a) ≥ 15 months (all ages)</p> <p>(b) 15 to 23 months</p> <p>(c) 24 to 35 months</p> <p>(d) ≥ 36 months</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(e) Indirect effectiveness</p> <p>(e1) 12 to 23 months</p> <p>(e2) 24 to 35 months</p> <p>(e3) ≥ 36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed measles</p> <p>was defined as</p> <p>laboratory‐confirmed case or met the WHO clinical case definition</p> <p>and was epidemiologically</p> <p>linked to laboratory‐confirmed case.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Priorix/Schwarz or<br/>MDS/Enders </p> <p>dose 1 at 9 to 12 months</p> <p>dose 2 at 15 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 1027 (any dose)</p> <p>(a1) N = 830 (1 dose)</p> <p>(a2) N = 197 (2 doses)</p> <p>(b) N = 269 (any doses)</p> <p>(c) N = 384 (any doses)</p> <p>(d) N = 374 (any doses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 94</p> <p>(b) n = 57</p> <p>(c) n = 20</p> <p>(d) n = 17</p> <p>unvaccinated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 5/1027 versus 12/94</p> <p>(a1) 5/830 versus 12/94</p> <p>(a2) 0/197 versus 12/94</p> <p>(b) 3/296 versus 6/57</p> <p>(c) 1/384 versus 4/20</p> <p>(d) 1/374 versus 2/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) 96.2% (89.4% to 98.6%)</p> <p>(a1) 95.3% (86.9% to 98.%)</p> <p>(a2) 100% (‐% to ‐%)</p> <p>(b) 89.4% (58.9% to 97.3%)</p> <p>(c) 98.7% (88.9% to 99.8%)</p> <p>(d) 97.7% (76.1% to 99.8%)</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(e1) 71.1% (63.5% to 78.8%)</p> <p>(e2) 80.0% (56.3% to 94.3%)</p> <p>(e3) 88.2% (63.6% to 98.5%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0050" title="BhuniyaS , MajiD , MandalD , MondalN . Measles outbreak among Dukpa tribe of Buxa Hills in West Bengal, India: epidemiology and vaccine efficacy. Indian Journal of Public Health2013;57(4):272-5. [DOI: 10.4103/0019-557X.123273]">ca‐Bhuniya 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 9 to 59 months</p> <p>(at 30 June 2011)</p> <p>(a) 9 to 59 months</p> <p>(b) 9 to 12 months</p> <p>(c) &gt; 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clinical case of measles is</p> <p>defined as fever with maculopapular</p> <p>rash and either conjunctivitis</p> <p>or cough or coryza</p> <p>(catarrhal inflammation of the</p> <p>mucous membrane in the nose).</p> <p>A confirmed case of measles is defined</p> <p>as a clinical case who is positive for</p> <p>anti‐measles virus nucleoprotein</p> <p>immunoglobulin M antibodies</p> <p>in serological tests but has not been</p> <p>vaccinated against measles</p> <p>during last 1 month.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 50 (1 dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 15/50 versus 16/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 66.3% (46.9% to 78.6%)</p> <p>(b) 66.6%(*)</p> <p>(c) 65.4%(*)</p> <p>(*) no statistical evidence</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0053" title="ChoeYJ , ParkYJ , KimJW , EomHE , ParkO , OhMD , et al. An outbreak of measles in a university in Korea, 2014. Journal of Korean Medical Science2017;32(11):1876-8. ">ca‐Choe 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outbreak at a university in 2014</p> <p>Students born between 1984 and 1993.</p> <p>N = 14,465</p> <p>VE &gt; 10 years after vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The definition of suspected measles case was individuals with<br/>following features: fever and rash and at least 1 of cough, coryza,<br/>or conjunctivitis. </p> <p>All suspected cases were quarantined<br/>and were interviewed using standardised questionnaire,<br/>and physical examinations were performed by trained physicians.<br/>Presence of symptoms (fever, rash, cough, coryza, or conjunctivitis),<br/>travel history, and days of illnesses were assessed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/not stated</p> <p>2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 11448</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 3017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/11448 versus 33/3017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60% (38.2% to 74.1%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 11,004</p> <p>children born</p> <p>between 2008 and 2010</p> <p>who underwent vaccination</p> <p>in 2009 to 2011.</p> <p>Follow‐up = 24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for</p> <p>(a) measles</p> <p>(b) mumps (see also <a href="#CD004407-tbl-0024">Table 3</a>) </p> <p>(c) measles and mumps</p> <p>(d) all infectious diseases</p> <p>(e) all respiratory diseases</p> <p>The effectiveness of MMR</p> <p>vaccine in reducing hospitalisations<br/>for any infection was assessed </p> <p>by analysing 2 distinct databases</p> <p>(vaccination record) and</p> <p>(hospital discharge):<br/>Hospital discharge diagnosis which </p> <p>contained the following ICD‐9 codes in primary or secondary diagnosis:</p> <p>001 to 139 for infectious and parasitic diseases;</p> <p>460 to 519 for respiratory diseases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not described</p> <p>the vaccination records of the database of the</p> <p>Roma Local Health Unit from which relevant</p> <p>data were extracted,</p> <p>such as date of birth;</p> <p>MMR vaccination (yes/no);</p> <p>MMR dose (only for vaccinated);</p> <p>personal tax code.</p> <p>The cohort was recomposed</p> <p>through record linkage of the 2<br/>archives, registration and </p> <p>vaccination of hospital discharge<br/>records, using personal </p> <p>tax codes as a common</p> <p>identification<br/>in both archives. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 dose N = 5392</p> <p>(2) 2 doses N = 3310</p> <p>(3) any dose</p> <p>N = 8702</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unvaccinated</p> <p>N = 2302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 3/5392 versus 9/2302</p> <p>(a2) 0/3310 versus 9/2302</p> <p>(a3) 3/8702 versus 9/2302</p> <p>(b1) 1/5392 versus 1/2302</p> <p>(b2) 0/3310 versus 1/2302</p> <p>(b3) 1/8702 versus 1/2302</p> <p>(c1) 4/5392 versus 10/2302</p> <p>(c2) 0/3310 versus 10/2302</p> <p>(c3) 4/8702 versus 10/2302</p> <p>(d1) 82/5392 versus 262/2302</p> <p>(d2) 70/3310 versus 262/2302</p> <p>(d3) 414/8702 versus 262/2302</p> <p>(e1) 202/5392 versus 424/2302</p> <p>(e2) 183/3310 versus 424/2302</p> <p>(e3) 809/8702 versus 424/2302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unadjusted estimates</p> <p>(a1) 85.8% (47.5% to 96.1%)<br/>(a2) 96.3% (37.1% to 99.8%)<br/>(a3) 91.2% (67.5% to 97.6%)<br/>(b1) 57.3% (−582% to 97.3%)*<br/>(b2) 76.8% (−468% to 99.1%)*<br/>(b3) 73.5% (−322% to 98.3%)*<br/>(c1) 82.9% (45.6% to 94.6%)<br/>(c2) 96.7% (43.5% to 99.8%)<br/>(c3) 89.4% (66.3% to 96.7%)<br/>(d1) 86.6% (83% to 89.5%)<br/>(d2) 81.4% (75.9% to 85.6%)<br/>(d3) 84.7% (81.4% to 87.4%)<br/>(e1) 79.7% (76.1% to 82.7%)<br/>(e2) 70% (64.6% to 74.5%)<br/>(e3) 76% (72.6% to 78.9%) </p> <p>(*) no statistical evidence</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Adjusted estimates</p> <p>any doses</p> <p>(a) 91% (68% to 99%)</p> <p>(b) not reported</p> <p>(c) 90% (66% to 97%)</p> <p>(d) 71% (66% to 75%)</p> <p>(e) 82% (52% to 93%)</p> <p>VE = (1 − HR)*100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (19 to 67 months)</p> <p>whose parent required a</p> <p>paediatrician visit during</p> <p>a measles outbreak peak</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis<br/>patient records and<br/>parent interviews </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Pluserix<br/>Schwarz<br/>(b) Morupar<br/>Schwarz </p> <p>(c) Triviraten<br/>Edmonston‐Zagreb </p> <p>vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 329 (1 dose)</p> <p>(b) N = 747 (1 dose)</p> <p>(c) N = 1023 (1dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 646</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0/329 versus 114/646</p> <p>(b) 2/747 versus 114/646</p> <p>(c) 8/1023 versus 114/646</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) 0/ 19,836 PT</p> <p>(b) 2/ 12,906 PT</p> <p>(c) 8/ 31,329 PT</p> <p>(control) 114/22,188 PT = person‐time in months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 100% (‐% to ‐%)</p> <p>(b) 97% (88% to 99%)<br/>(c) 95% (90% to 98%) </p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0064" title="MusaS , TopalovićB , ĆatićS , SmajlagićZ . Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. Central European Journal of Public Health2018;26(2):79-82. ">ca‐Musa 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged up to 14 years.</p> <p>N = 2784</p> <p>(children aged &gt; 14 years, N = 2300).</p> <p>Data were presented by age group.</p> <p>The study included all students in 40</p> <p>classes with 1 or more registered</p> <p>measles cases in the period</p> <p>February 2014 to September 2015.</p> <p>VE</p> <p>≤ 5 years since vaccination</p> <p>6 to 14 years since vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measles diagnosis was confirmed according to WHO guidelines. The clinical criteria<br/>for measles were fever, maculopapular rash (i.e. non‐vesicular<br/>rash), and cough or coryza (i.e. runny nose) or conjunctivitis<br/>(i.e. red eyes). The laboratory criteria for measles surveillance </p> <p>case confirmation were measles IgM antibody detection, or<br/>measles virus isolation, or measles viral RNA detection by<br/>RT‐PCR, or a significant rise in measles IgG antibody in<br/>paired sera.<br/>All suspected cases were investigated and classified based on<br/>clinical, laboratory, and epidemiological data, based on the WHO<br/>case definition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/not stated</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) ≤ 5 years since vaccination</p> <p>(d) 6 to 14 years since vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 100</p> <p>(b) N = 606</p> <p>(c) N = 20</p> <p>(d) N = 76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 3/100 versus 35/95</p> <p>(b) 6/606 versus 35/95</p> <p>(c) 1/20 versus 35/95</p> <p>(d) 2/76 versus 35/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 91.9% (74.4% to 97.4%)<br/>(b) 97.3% (93.8% to 98.8%)<br/>(c) 86.4% (6.6% to 98.0%)<br/>(d) 92.9% (71.2% to 98.2%) </p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0068" title="OngG , RasidahN , WanS , CutterJ . Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal2007;48(7):656-61. ">ca‐Ong 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children from</p> <p>primary school in Singapore</p> <p>(aged 8 to 14 years,</p> <p>&gt; 5 years since vaccination)</p> <p>during</p> <p>a measles outbreak</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical with</p> <p>laboratory confirmation.</p> <p>Active survey and</p> <p>serological confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> <p>Vaccination status was ascertained from health booklet.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 171 (1 dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 13</p> <p>unvaccinated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/171 versus 7 /13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.8% (90.6% to 99.5%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0075" title="WichmannO , HellenbrandW , SagebielD , SantibanezS , AhlemeyerG , VogtG , et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal2007;26(9):782-6. ">ca‐Wichmann 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>School outbreak 2006.</p> <p>Students aged</p> <p>10 to 15 years (N = 875)<br/>16 to 21 years (N = 139) </p> <p>VE</p> <p>&lt; 10 years after vaccination</p> <p>&gt; 10 years after vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or laboratory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/not stated</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) unknown<br/>vaccination status </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>(a) N = 199</p> <p>(b) N = 561</p> <p>(c) N = 218</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years</p> <p>(a) N =196<br/>(b) N = 502<br/>(c) N = 144 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years<br/>(a) N = 3 </p> <p>(b) N = 59</p> <p>(c) N = 74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>N = 36</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years</p> <p>N = 33<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years<br/>N = 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>(a) 2/199 versus 19/36</p> <p>(b) 2/5611 versus 19/36</p> <p>(c) 30/218 versus 19/36</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years</p> <p>(a) 2/196 versus 18/33</p> <p>(b) 2/502 versus 18/33<br/>(c) 25/144 versus 18/33 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years<br/>(a) 0/3 versus 1/3<br/>(b) 0/59 versus 1/3 </p> <p>(c) 5/74 versus 1/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages<br/>(a) 98.1% (92.2% to 99.5%)<br/>(b) 99.3% (97.2% to 99.8%) </p> <p>(c) 73.9% (59.0% to 83.4%)</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years<br/>(a) 98.1% (92.3% to 99.5%)<br/>(b) 99.3% (97.0% to 99.8%)<br/>(c) 68.2% (48.9% to 80.2%) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years </p> <p>(a) 66.7% (*)</p> <p>(b) 97.8% (53.7% to 99.9%)</p> <p>(c) 79.7% (*)<br/>VE = (1 − RR) x 100 </p> <p>(*) no evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0076" title="WoudenbergT , van derMaasNAT , KnolMJ , deMelkerH , vanBinnendijkRS , HahneSJM . Effectiveness of early measles, mumps, and rubella vaccination among 6-14-month-old infants during an epidemic in the Netherlands: an observational cohort study. Journal of Infectious Diseases2017;215(8):1181-7. ">ca‐Woudenberg 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants aged 6 to 14 months</p> <p>living in municipalities where coverage</p> <p>with the first dose of MMR vaccine was &lt; 90%.</p> <p>Infants aged 6 to 11 months were</p> <p>offered an extra vaccination</p> <p>(and would thus still be</p> <p>eligible for their second MMR vaccination</p> <p>at the age of 14 months).</p> <p>Infants aged 12 to 14 months were</p> <p>offered an early MMR vaccination</p> <p>as an alternative to the regular</p> <p>time point at 14 months of age.</p> <p>All infants were eligible for another</p> <p>dose of MMR scheduled at 9 years of age.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory‐confirmed measles</p> <p>N = 1080 infants eligible for analysis laboratory‐confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine:</p> <p>(M‐M‐RVAXPRO; Sanofi</p> <p>Pasteur MSD).</p> <p>This vaccine contains measles</p> <p>virus Enders’ Edmonston strain.</p> <p>Vaccination status was checked</p> <p>in the national vaccination register.</p> <p>Parents were asked whether their</p> <p>infant(s) had had measles in the</p> <p>preceding 3 months.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 919</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/106,631 (PT‐days) versus</p> <p>10/23,769 (PT‐days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR (95% CI)(*)</p> <p>0.29 (0.05 to 1.72)</p> <p>(*) adjusted estimates Cox proportional<br/>hazard model </p> <p>VE = 1 − HR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0047" title="ArenzS , SchmittHJ , TischerA , vonKriesR . Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal2005;24(8):697-9. ">ca‐Arenz 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Household contacts</b> </p> <p>55 families, 43 children</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/strain<br/>not stated </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 13</p> <p>(b) N = 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 1/13 versus 19/26</p> <p>(b) 0/4 versus 19/26</p> <p>(c) 1/20 versus 19/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 96.9% (71.8% to 99.7%)</p> <p>(b) 95.7% (10.6% to 99.8%)</p> <p>(c) 97.7% (79.3% to 99.7%)</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) 90% (35% to 97%)</p> <p>(b) not reported</p> <p>(c) 92% (48% to 98%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Household contacts</b> </p> <p>adolescents and young</p> <p>adults (10 to 29 years)</p> <p>(a) any dose</p> <p>(b) 1 dose</p> <p>(c) 2 doses</p> <p>(d) 3 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or</p> <p>laboratory confirmation, or both</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 302</p> <p>(b) N = 27</p> <p>(c) N = 205</p> <p>(d) N = 70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐campaign</p> <p>MMR doses</p> <p>(a) 16/302 versus 2/16</p> <p>(b) 3/27 versus 2/16</p> <p>(c) 13/205 versus 2/16</p> <p>(d) 0/70 versus 2/16</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐campaign MMR doses</p> <p>(a) (No data)</p> <p>(b) 23.1% (−425.0% to 87.3%)*</p> <p>(c) 63.4% (−103.0% to 90.6%)*</p> <p>(d) 95.9% (45% to 100%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Campaign MMR doses:</p> <p>78.7% (10.1% to 97.7%)</p> <p>for pre‐exposure doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>50.4% (*)</p> <p>for postexposure doses</p> <p>(*) no statistical evidence</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>VE = (1 − OR) x 100</p> <p>from logistic regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0062" title="MarinM , NguyenHQ , LangidrikJR , EdwardsR , BriandK , PapaniaMJ , et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases2006;42(3):315-9. ">ca‐Marin 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Household contacts</b> </p> <p>(6 months to 14 years)</p> <p>of primary measles cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary cases</p> <p>Clinical (WHO definition) or</p> <p>IgM positive antibody of</p> <p>secondary cases</p> <p>Standardised questionnaires</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> <p>Vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) N = 48 (1 dose)</p> <p>(a2) N = 106 (2 doses)</p> <p>(b) N = 44 (&gt; 2 doses)</p> <p>(c) N = 219 any doses</p> <p>contacts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 21</p> <p>unvaccinated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 2/48 versus 11/21</p> <p>(a2) 3/106 versus 11/21</p> <p>(b) 1/44 versus 11/21</p> <p>(c) 17/219 versus 11/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 92.0% (67.2% to 98.1%)</p> <p>(a2) 94.6% (82.3% to 98.4%)</p> <p>(b) 95.7% (68.6% to 99.4%)</p> <p>(c) 85.2% (72.7% to 92.0%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0046" title="ArciuoloRJ , JablonskiRR , ZuckerJR , RosenJB . Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting - New York City, 2013. Clinical Infectious Diseases2017;65(11):1843-7. ">ca‐Arciuolo 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postexposure prophylaxis</b> </p> <p>Childrena aged &lt; 19 years</p> <p>N = 208</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All who subsequently</p> <p>developed measles were</p> <p>considered as contacts.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not described</p> <p>MMR PEP administered within</p> <p>72 hours of initial exposure.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/44 versus 45/164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 83.4% (34.4% to 95.8%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0048" title="BarrabeigI , RoviraA , RiusC , MunozP , SoldevilaN , BatallaJ , et al. Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal2011;30(1):78-80. ">ca‐Barrabeig 2011a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postexposure prophylaxis</b> </p> <p>N = 166 children with</p> <p>median age of 16.5 months</p> <p>(range 6 to 47 months)</p> <p>Candidates for the</p> <p>intervention were</p> <p>susceptible contacts who had</p> <p>not received either measles‐containing vaccine or</p> <p>had not suffered measles.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical and laboratory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not stated</p> <p>(a) at least 1 dose</p> <p>(b) vaccinated ≤ 3 days</p> <p>(c) vaccinated 4 to 5 days</p> <p>(d) vaccinated 6 to 7 days</p> <p>(e) vaccinated 8 to 9 days</p> <p>(f) vaccinated 10 to 12 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 54</p> <p>(b) N = 17</p> <p>(c) N = 14</p> <p>(d) N = 14</p> <p>(e) N = 8</p> <p>(f) N = 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 12/54 versus 13/21</p> <p>(b) 1/17 versus 13/21</p> <p>(c) 4/14 versus 13/21</p> <p>(d) 5/14 versus 13/21</p> <p>(e) 1/8 versus 13/21</p> <p>(f) 1/1 versus 13/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 64.1% (34.5% to 80.3%)</p> <p>(b) 90.5% (34.5% to 98.6%)</p> <p>(c) 53.8% (0.0% to 81.1%)</p> <p>(d) 42.3% (0.0% to 81.1%)</p> <p>(e) 79.8% (0.0% to 73.5%)</p> <p>(f) not reported</p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ARU: attack rate amongst unvaccinated<br/>ARV: attack rate amongst vaccinated<br/>CI: confidence interval<br/>HR: hazard ratio<br/>ICD: International Statistical Classification of Diseases and Related Health Problems<br/>IgG: immunoglobulin G<br/>IgM: immunoglobulin M<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>N: number of participants in intervention and control arm<br/>OR: odds ratio<br/>PEP: postexposure prophylaxis<br/>PT: person‐time in months<br/>rr: rate ratio (relative incidence, incidence rate ratio, hazard ratio)<br/>RR: risk ratio (relative risk)<br/>RNA: ribonucleic acid<br/>RT‐PCR: reverse‐transcription polymerase chain reaction<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </div> <div class="table" id="CD004407-tbl-0023"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Measles: effectiveness ‐ case‐control studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case<br/>definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Controls/<br/>selection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR strain/exposure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N cases vaccinated/N cases<br/>versus<br/>N controls vaccinated/N controls</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OR (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0014" title="DefayF , De SerresG , SkowronskiDM , BoulianneN , OuakkiM , LandryM , et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics2013;132(5):e1126-33. [DOI: 10.1542/peds.2012-3975]">ba‐Defay 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 17 years</p> <p>(a) outside of outbreak school</p> <p>(b) all participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 61</p> <p>(b) N = 102</p> <p>confirmed by laboratory testing</p> <p>or epidemiologic link</p> <p>is notifiables</p> <p>by both physicians and</p> <p>laboratories in Quebec</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 305</p> <p>(b) N = 510</p> <p>Controls were matched</p> <p>for date of birth</p> <p>(± 6 months)</p> <p>and school attended</p> <p>in 2010 to 2011.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR‐II</p> <p>(Merck Canada,</p> <p>Montreal, Quebec)</p> <p>Cases and controls</p> <p>received</p> <p>2 doses of</p> <p>measles‐containing</p> <p>vaccine.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported<br/>amongst unvaccinated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0019" title="HungerfordD , ClearlyP , GhebrehewetS , KeenanA , VivancosR . Risk factors for transmission of measles during an outbreak: matched case control study. Journal of Hospital Infections2014;86(2):138-43. [DOI: 10.1016/j.jhin.2013.11.008]">ba‐Hungerford 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>(median age 16 years,</p> <p>upper quartile age 76 years)</p> <p>living in Merseyside (UK)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 42</p> <p>microbiological confirmation:</p> <p>oral fluid/blood test</p> <p>IgM positive or PCR positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 42</p> <p>Control group participants were</p> <p>selected at random,</p> <p>matched 1:1 by general</p> <p>medical practice and aged</p> <p>within 1 year.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> <p>(a) vaccinated appropriately for age<br/>(b) under age </p> <p>for vaccination (&lt; 14 months)</p> <p>(c) all ‐ vaccinated</p> <p>Unvaccinated: incompletely or partially vaccinated for age (&gt; 13 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 5/27 versus 23/29</p> <p>(b) 15/37 versus 12/18</p> <p>(c) 20/42 versus 35/42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk factors for</p> <p>measles infection</p> <p>(univariate analysis)</p> <p>age &gt; 13 months and incomplete vaccination</p> <p>6.3 (1.9 to 33.4)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(Multivariate analysis)</p> <p>under age for routine</p> <p>vaccination</p> <p>20.4 (2.0 to 300)</p> <p>incomplete/partial vaccination</p> <p>for age &gt; 13 months</p> <p>22.1 (3.8 to 300)</p> <p>(**) adjusted for confounders</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk factors for</p> <p>measles infection</p> <p>(univariate analysis)</p> <p>age &gt; 13 months and incomplete vaccination</p> <p>84.1% (47.4% to 97.0%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(Multivariate analysis)</p> <p>under age for routine</p> <p>vaccination</p> <p>95.1% (50.0% to 100%)</p> <p>incomplete/partial vaccination</p> <p>for age &gt; 13 months</p> <p>95.5% (73.7% to 100%)</p> <p>(**) adjusted for confounders</p> <p>VE = (1 − OR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0020" title="JickH , HagbergKW . Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine2010;28(29):4588-92. ">ba‐Jick 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>aged 1 to 19 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1261</p> <p>clinical definition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 4996</p> <p>randomly selected, matched for year of birth, gender, general practice attended, index date </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR or MR</p> <p>not described</p> <p>(a) 1 dose</p> <p>(b) &gt; 1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 409/1221 versus 2012/4750</p> <p>(b) 40/852 versus 246/2984</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0.49 (0.41 to 0.58)*</p> <p>(b) 0.39 (0.26 to 0.58)*</p> <p>*adjusted estimates, conditional logistic regression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 51.0% (42.0% to 59.0%)<br/>(b) 61.0% (42.0% to 74.0%) </p> <p>VE = (1 − OR) x 100</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>**: multivariate analysis<br/>CCDC: Consultant in Communicable Disease Control<br/>CI: confidence interval<br/>IgM: immunoglobulin M<br/>MR: measles and rubella vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>N: number of participants<br/>OR: odds ratio<br/>PCR: polymerase chain reaction<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </div> <div class="table" id="CD004407-tbl-0024"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Mumps: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N events in exposed/<br/>N total exposed<br/>or PT<br/>versus<br/>N events in non‐exposed/<br/>N total non‐exposed<br/>or PT</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged up to 16 years</p> <p>from Geneva were</p> <p>household contacts<br/>of primary confirmed mumps cases<br/>(clinical or with laboratory confirmation<br/>notified by a paediatrician). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis of</p> <p>secondary cases</p> <p>Phone interview</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) MMR‐II/Jeryl LynnB</p> <p>(b) Pluserix or Trimovax/Urabe AM9</p> <p>(c) Triviraten/Rubini</p> <p>(d) any strain</p> <p>Vaccination records</p> <p>Unspecified</p> <p>number of doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 30</p> <p>(b) N = 75</p> <p>(c) N = 83</p> <p>(d) N = 193</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 72</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 4/30 versus 25/72</p> <p>(b) 7/75 versus 25/72</p> <p>(c) 27/83 versus 25/72</p> <p>(d) 38/193 versus 25/72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 61.6 % (−0.9% to 85.4%)</p> <p>(b) 73.1% (41.8% to 87.6%)</p> <p>(c) 6.3% (−45.9% to 39.8%)</p> <p>(d) 43.0% (12.7% to 62.8%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0054" title="Compés-DeaC , Guimbao-BescòsJ , Gaspar-EscayolaJI , Lazaro-BelancheMA , Aznar-BriebaA . An outbreak of mumps in a high school: estimation of vaccine effectiveness. Zaragoza 2011 [Broteescolar de parotiditis: estimacion de la efectividad vacunal Zaragoza 2011]. Enfermedades Infeccionas y Microbiologia Clinical2015;33(6):385-90. [DOI: 10.1016/j.eimc.2014.09.011]">ca‐Compés‐Dea 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235 students (in Spain)</p> <p>(aged 16 to 17 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine:<br/>Jeryl Lynn RIT4385 or Rubini </p> <p>(a) 1 dose</p> <p>(b) 2 dose</p> <p>(c) 3 dose</p> <p>(d) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 5</p> <p>(b) N = 37</p> <p>(c) N = 2</p> <p>(d) N = 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 2</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/5 versus 1/2</p> <p>(b) 9/37 versus 1/2</p> <p>(b) 2/2 versus 1/2</p> <p>(d) 13/44 versus 1/2</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Incidence</p> <p>(a) 33 versus 50 x 100 person‐day</p> <p>(≥ 2 doses) 16 versus 50 x 100 person‐day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) not reported<br/>(b) not reported<br/>(c) not reported<br/>(d) not reported </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>VE = (1 − rr) x 100</p> <p>(a) 34% (−44% to 70%)*</p> <p>(≥ 2 doses) 67% (28% to 83%)</p> <p>*no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Students from the</p> <p>3 university cities</p> <p>N = 989</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine: Jeryl Lynn</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 29</p> <p>(b) N = 706</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 16</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/29 versus 7/16</p> <p>(b) 92/706 versus 7/16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) not reported</p> <p>(b) 68% (40.6% to 82.2%)</p> <p>adjusted estimate</p> <p>VE = 1 − RR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 11,004</p> <p>children born</p> <p>between 2008 and 2010,</p> <p>who underwent vaccination</p> <p>in 2009 to 2011.</p> <p>Follow‐up = 24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for</p> <p>(a) measles (see also <a href="#CD004407-tbl-0022">Table 1</a>) </p> <p>(b) mumps</p> <p>(c) measles and mumps</p> <p>(d) all infectious diseases</p> <p>(e) all respiratory diseases</p> <p>The effectiveness of MMR vaccine in reducing</p> <p>hospitalisations<br/>for any infection </p> <p>was assessed</p> <p>by analysing 2 distinct</p> <p>databases</p> <p>(vaccination record) and</p> <p>(hospital discharge):<br/>hospital discharge </p> <p>diagnosis contained the</p> <p>following ICD‐9 codes</p> <p>in primary or</p> <p>secondary diagnosis:</p> <p> <ul id="CD004407-list-0023"> <li> <p>001 to 139 for infectious and parasitic diseases;</p> </li> <li> <p>from 460 to 519 for respiratory diseases.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not described (we assume Jeryl Lynn)</p> <p>the vaccination records</p> <p>from the Roma Local Health Unit database</p> <p>from which relevant</p> <p>data were extracted,</p> <p>such as date of birth;</p> <p>MMR vaccination</p> <p>(yes/no);</p> <p>MMR dose (only for vaccinated);</p> <p>personal tax code.</p> <p>The cohort was recomposed</p> <p>through record linkage of the 2<br/>archives, registration and </p> <p>vaccination of hospital discharge<br/>records, using </p> <p>personal tax codes as a common</p> <p>identification<br/>in both archives. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 dose N = 5392</p> <p>(2) 2 doses N = 3310</p> <p>(3) any dose</p> <p>N = 8702</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unvaccinated</p> <p>N = 2302</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 3/5392 versus 9/2302</p> <p>(a2) 0/3310 versus 9/2302</p> <p>(a3) 3/8702 versus 9/2302</p> <p>(b1) 1/5392 versus 1/2302</p> <p>(b2) 0/3310 versus 1/2302</p> <p>(b3) 1/8702 versus 1/2302</p> <p>(c1) 4/5392 versus 10/2302</p> <p>(c2) 0/3310 versus 10/2302</p> <p>(c3) 4/8702 versus 10/2302</p> <p>(d1) 82/5392 versus 262/2302</p> <p>(d2) 70/3310 versus 262/2302</p> <p>(d3) 414/8702 versus 262/2302</p> <p>(e1) 202/5392 versus 424/2302</p> <p>(e2) 183/3310 versus 424/2302</p> <p>(e3) 809/8702 versus 424/2302</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unadjusted estimates</p> <p>(a1) 85.8% (47.5% to 96.1%)<br/>(a2) 96.3% (37.1% to 99.8%)<br/>(a3) 91.2% (67.5% to 97.6%)<br/>(b1) 57.3% (−582% to 97.3%)*<br/>(b2) 76.8% (−468% to 99.1%)*<br/>(b3) 73.5% (−322% to 98.3%)*<br/>(c1) 82.9% (45.6% to 94.6%)<br/>(c2) 96.7% (43.5% to 99.8%)<br/>(c3) 89.4% (66.3% to 96.7%)<br/>(d1) 86.6% (83% to 89.5%)<br/>(d2) 81.4% (75.9% to 85.6%)<br/>(d3) 84.7% (81.4% to 87.4%)<br/>(e1) 79.7% (76.1% to 82.7%)<br/>(e2) 70% (64.6% to 74.5%)<br/>(e3) 76% (72.6% to 78.9%) </p> <p>(*) no statistical evidence</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Adjusted estimates</p> <p>any dose</p> <p>(a) 91% (68% to 99%)</p> <p>(b) not reported</p> <p>(c) 90% (66% to 97%)</p> <p>(d) 71% (66% to 75%)</p> <p>(e) 82% (52% to 93%)</p> <p>VE = 1 − HR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 2176 household residents</p> <p>from 2009 to 2010</p> <p>All ages,</p> <p>(age group 1) age ≤ 17 years</p> <p>(age group 2) age ≥ 18 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or<br/>laboratory confirmed, or both </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine: Jeryl Lynn</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) unknown</p> <p>(d) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age ≤ 17 years</p> <p>(group 1)</p> <p>(1a) 1 dose N = 342</p> <p>(1b) 2 doses N = 361</p> <p>(1c) unknown N = 914</p> <p>(d) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Age ≥ 18 years</p> <p>(2a) 1 dose N = 9</p> <p>(2b) 2 doses N = 97</p> <p>(2c) unknown N = 574</p> <p>(d) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age ≤ 17 years</p> <p>(group 1)</p> <p>N = 126</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Age ≥ 18 years</p> <p>(group 2)</p> <p>N = 6</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages (group 1 + 2)</p> <p>(a) 4/117 versus 4/20</p> <p>(b) 19/691 versus 4/20</p> <p>(c) 17/520 versus 4/20</p> <p>(d) 23/808 versus 4/20</p> <p>Secondary households</p> <p>contacts age ≥ 5 years N = 1348</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>(a) 82.9% (37.1% to 95.4%)</p> <p>(b) 86.3% (63.3% to 94.9%)</p> <p>(c) 83.7% (55.9% to 93.9%)</p> <p>(d) 85.8% (62.7% to 94.6%)</p> <p>VE = (1 − RR) x 100</p> <p>assessed amongst 44</p> <p>secondary cases and</p> <p>1304 non‐sick household contacts</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0060" title="Lopez HernandezB , Martin VelezRM , Roman GarciaC , Penalver SanchezI , Lopez RosiqueJA . An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion Primaria/Sociedad Española de Medicina de Familia y Comunitaria2000;25(3):148-52. ">ca‐Lopez Hernandez 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male children</p> <p>aged between</p> <p>3 and 15 years</p> <p>attending a scholastic</p> <p>institute in Spain</p> <p>during a mumps outbreak</p> <p>(March to November 1997)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis. Cases notified by the Andalusian survey system.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR strain not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 685</p> <p>vaccination record</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 38</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/685 versus 8/38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (3% to 74%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0061" title="MaC , LiuY , TangJ , JiaH , QinW , SuY , et al. Assessment of mumps-containing vaccine effectiveness during an outbreak: importance to introduce the 2-dose schedule for China. Human Vaccines and Immunotherapy2018;14(6):1392-7. ">ca‐Ma 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conducted between</p> <p>1 December 2014 and</p> <p>20 September 2015.</p> <p>N = 2303 students</p> <p>aged 6 to 15 years.</p> <p>Of these, 114 were excluded</p> <p>because they had history of mumps illness; 281 students were excluded</p> <p>because of unknown immunisation history.</p> <p>N = 1378 vaccinated and</p> <p>unvaccinated</p> <p>N = 530 children included</p> <p>in the analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mumps case was defined as</p> <p>a student having unilateral or</p> <p>bilateral parotid or other salivary</p> <p>gland swelling and pain, lasting 2 or more days, with onset between</p> <p>1 December 2014 and 20 September 2015.</p> <p>All cases were diagnosed by</p> <p>clinical criteria without laboratory confirmation, and no mumps</p> <p>virus genotype information was obtained during this outbreak investigation.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR:</p> <p>S79 strain of mumps</p> <p>vaccine virus,</p> <p>derived through further attenuation of the Jeryl Lynn strain.</p> <p>Students’ vaccination</p> <p>certificates were obtained during the field investigation.</p> <p>(a) 1 dose</p> <p>(≤ 5 years since vaccination)</p> <p>(b) 1 dose</p> <p>(&gt; 5 years since vaccination)</p> <p>(c) any time since vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 363</p> <p>(b) N = 301</p> <p>(c) N = 664</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unvaccinated</p> <p>N = 530</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 28/363 versus 93/530</p> <p>(b) 21/301 versus 93/530</p> <p>(c) 49/664 versus 93/530</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 56% (34.4% to 70.6%)<br/>(b) 60.2% (37.5% to 74.7%)<br/>(c) 57.9% (41.7% to 69.7%) </p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (19 to 67 months)<br/>whose parent required a<br/>paediatrician visit during a<br/>measles outbreak peak </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>Patient records and</p> <p>parent interviews</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Pluserix/Urabe</p> <p>(b) Morupar/Urabe</p> <p>(c) Triviraten/Rubini</p> <p>Vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 329 (1 dose)</p> <p>(b) N = 747 (1 dose)</p> <p>(c) N = 1023 (1 dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 646</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 38 cases/19433 (PT)</p> <p>(b) 28 cases/12785 (PT)</p> <p>(c) 185 cases/29974 (PT)</p> <p>Control = 206 cases/25,816</p> <p>PT=person‐ time in months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 75% (65% to 83%)</p> <p>(b) 73% (59% to 82%)</p> <p>(c) 23% (6% to 37%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0065" title="NelsonGE , AguonA , ValenciaE , OlivaR , GuerreroML , ReyesR , et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010. Pediatric Infectious Disease Journal2013;32(4):374-80. [PMID: 23099425]">ca‐Nelson 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>During 2009 to 2010 mumps outbreak</b> </p> <p>Children aged 9 to 14 years with a history of 2 MMR vaccine doses,</p> <p>had not previously received</p> <p>a third MMR vaccine dose, and</p> <p>had no history of mumps</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine</p> <p>not described</p> <p>third dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only 2 doses MMR</b> </p> <p>N = 2171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1068 versus 5/2171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.3% (−247% to 95.2%)</p> <p><b>VE = (1 − RR) x 100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0066" title="OgbuanuIU , KuttyPK , HudsonJM , BlogD , AbediGR , GoodellS , et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics2012;130(6):e1567-74. [PMID: 23129075]">ca‐Ogbuanu 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>During 2009 to 2010 mumps outbreak</b> </p> <p>Schoolchildren</p> <p>(aged 11 to 17 years) from 3 schools. N = 2665.</p> <p>N = 2178 had validated</p> <p>history of</p> <p>receiving 2 previous</p> <p>doses of MMR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine</p> <p>not described</p> <p>third dose</p> <p>(a) all students with validated 2 doses</p> <p>(b1) postvaccination period 1 to 21 days after third dose</p> <p>(b2) postvaccination period 22 to 41 days after third dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Third dose</p> <p>(a) N = 1755</p> <p>(b1) N = 1751</p> <p>(b2) N = 1723</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only 2 doses MMR</b> </p> <p>(a) N = 432</p> <p>(b1) N = 420</p> <p>(b2) N = 413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 35/1755 versus 14/432</p> <p>(b1) 28/1751 versus 7/420</p> <p>(b2) 1/1723 versus 2/413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 39.7% (−11.0% to 67.3%)</p> <p>(b1) 4.1% (−118% to 57.8%)</p> <p>(b2) 88% (−31.9% to 98.9%)</p> <p><b>VE = (1 − RR) x 100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children from childcare centres and<br/>primary schools in Singapore, </p> <p>aged 5 to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis.</p> <p>Standard questionnaire</p> <p>filled by trained public health officer</p> <p>or physician diagnoses.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Jeryl Lynn</p> <p>(b) Urabe</p> <p>(c) Rubini</p> <p>Health booklet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 711</p> <p>(b) N = 190</p> <p>(c) N = 1694</p> <p>1 or 2 MMR doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 614</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 8/711 versus 35/614</p> <p>(b) 5/190 versus 35/614</p> <p>(c) 150/1694 versus 35/614</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 80.3% (57.8% to 90.8%)</p> <p>(b) 53.8%*</p> <p>(c) −55.3% (−121.8% to −8.8%)</p> <p>VE = (1 − RR) x 100</p> <p>*no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 13 years<br/>from a small village in Switzerland </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical confirmation</p> <p>after virus isolation</p> <p>or clinical picture observed</p> <p>in sibling of confirmed cases.</p> <p>Parents interview and</p> <p>evaluation by study investigators</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Jeryl Lynn</p> <p>(b) Urabe</p> <p>(c) Rubini</p> <p>Vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 36</p> <p>(b) N = 40</p> <p>(c) N = 79</p> <p>at least 1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 8</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 5/36 versus 5/8</p> <p>(b) 3/40 versus 5/8</p> <p>(c) 53/79 versus 5/8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 78% (64% to 82%)</p> <p>(b) 87% (76% to 94%)</p> <p>(c) −4%</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (aged &lt; 19 years)</p> <p>attending</p> <p>(a) primary schools</p> <p>and</p> <p>(b) their household contacts.</p> <p>(c) index case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR Jeryl Lynn</p> <p>or RIT 4385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) (1 dose) N = 484</p> <p>(a2) (2 doses) N = 301</p> <p>(b) (unspecified number of doses) N = 19</p> <p>(c) (any dose) N = 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 351</p> <p>(b) N = 87</p> <p>(c) N = 90</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 13/484 versus 183/351</p> <p>(a2) 7/301 versus 183/351</p> <p>(b) 3/19 versus 44/87</p> <p>(c) 3/16 versus 44/90</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>adjusted data</p> <p>(a1) 9/484 versus 65/351</p> <p>(a2) 7/301 versus 86/351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 92% (83% to 96%)</p> <p>(a2) 93% (85% to 97%)</p> <p>(b) 67% (65% to 95%)</p> <p>(c) 11% (−4% to 88%)</p> <p>Adjusted for confounders</p> <p>from Poisson regression</p> <p>VE = 1 − incidence rate</p> <p>In order to include "adjusted data", <a href="./references#CD004407-bbs2-0339" title="Di PietrantonjC . Four-fold table cell frequencies imputation in meta analysis. Statistics in Medicine2006;25(13):2299-322. [PMID: 16025540]">Di Pietrantonj 2006</a> method is used to convert adjusted estimates and its 95% CI in "adjusted data". </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0074" title="TaklaA , BohmerMM , KlincC , KurzN , SchafferA , StichH , et al. Outberak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics2014;10(1):140-5. ">ca‐Takla 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary school: 108 students of 5 classes with at least 1 mumps case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or<br/>laboratory confirmed, or both </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: RIT 4385 or<br/>Jeryl Lynn strain </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) (1 dose) N = 4</p> <p>(b) (2 doses) N = 89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 3/4 versus 5/6</p> <p>(b) 6/89 versus 5/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 10% (−75% to 53%)</p> <p>(b) 91.9% (81.0% to 96.5%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ARU: attack rate amongst unvaccinated<br/>ARV: attack rate amongst vaccinated<br/>CI: confidence interval<br/>HR: hazard ratio<br/>ICD: International Statistical Classification of Diseases and Related Health Problems<br/>IgM: immunoglobulin M<br/>incidence : cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>N: number of participants<br/>OR: odds ratio<br/>PT: person‐time in months<br/>rr: rate ratio (relative incidence, incidence rate ratio, hazard ratio)<br/>RNA: ribonucleic acid<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </div> <div class="table" id="CD004407-tbl-0025"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mumps: effectiveness ‐ case‐control studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Controls/selection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR strain/exposure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N cases vaccinated/<br/>N cases<br/>versus<br/>N controls vaccinated/<br/>N controls</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OR (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0012" title="CastillaJ , Fernandez AlonsoM , Garcia CenozM , Martinez ArtolaV , Inigo PestanaM , RodrigoI , et al. Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica2009;133(20):777-82. CastillaJ , Garcia CenozM , ArriazuM , Fernandez-AlonsoM , Martinez-ArtolaV , EtxeberriaJ , et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine2009;27(15):2089-93. ">ba‐Castilla 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged between 15 months and 10 years from Navarre region</p> <p>(Northern Spain)</p> <p>at the time a mumps outbreak occurred (between August 2006 and June 2008)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 181</p> <p>(b) N = 72</p> <p>(c) N = 241</p> <p>Laboratory or epidemiological<br/>confirmation of clinical cases: </p> <p>swelling of 1 of more salivary glands<br/>for at least 2 days with either laboratory<br/>(PCR or IgM positive) or<br/>epidemiological confirmation<br/>(i.e. epidemiological relation with<br/>other laboratory confirmed or<br/>clinical mumps cases). </p> <p>Obtained from cases notified<br/>to the regional health authority </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 875</p> <p>(b) N = 353</p> <p>(c) N = 1205</p> <p>matched for sex,<br/>municipality,<br/>district of residence, and paediatrician </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) any dose</p> <p>MMR/Jeryl Lynn</p> <p>doses received</p> <p>at least 30 days</p> <p>before symptom</p> <p>disease onset.</p> <p>Blinded review of</p> <p>primary care vaccination</p> <p>registry</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 169/181 versus 852/875</p> <p>(b) 59/72 versus 330/353</p> <p>(c) 228/241 versus 1182/1205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 66% (25% to 85%)</p> <p>(b) 83% (54% to 94%)</p> <p>(c) 72% (39% to 87%)</p> <p>adjusted for confounders</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0015" title="FuC , XuJ , CaiY , HeQ , ZhangC , ChenJ , et al. Effectiveness of one dose of mumps vaccine against clinically diagnoses mumps in Guangzhou, China, 2006-2012. Human Vaccines and Immunotherapeutics2013;9(12):2524-8. [DOI: 10.4161/hv.26113]">ba‐Fu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children in Guangzhou</p> <p>aged 8 months to 12 years</p> <p>during 2006 to 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1983</p> <p>randomly selected clinical definition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1983</p> <p>matched 1:1</p> <p>by birth date,</p> <p>gender,</p> <p>residence</p> <p>not reported</p> <p>breakdown</p> <p>by type of vaccine administrated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) MMR/Jeryl Lynn RIT4385</p> <p>(b) measles‐mumps</p> <p>(c) missing (vaccine type)</p> <p>(d) any vaccine</p> <p>1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 112 versus 145</p> <p>(b) 242 versus 261</p> <p>(c) 620 versus 837</p> <p>(d) 974/1983 versus 1243/1983</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) OR extracted from</p> <p>VE reported</p> <p>0.49 (0.26 to 0.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 51.3% (7.2% to 95.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0016" title="GiovanettiF , LaudaniE , MarinaroL , DoglianiMG , GiachelliV , GiachinoG , et al. Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. Igiene Moderna2002;117(3):201-9. ">ba‐Giovanetti 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents aged 14 months to</p> <p>15 years from urban area of Alba and Bra and 10 rural towns (n = 12,800 residents from 0 to 15 years) </p> <p>during 2000 to 2001 epidemic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>(cases notified by</p> <p>national infectious diseases surveillance system)</p> <p>N = 139</p> <p>notified mumps cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 139 randomly selected from immunisation registry,</p> <p>matched for birth year and address.</p> <p>(controls received<br/>at least 1 MMR dose) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not specified.</p> <p>Vaccination registry and phone interviews, immunisation</p> <p>should have been received</p> <p>at least 30 days before disease onset.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90/139 versus 111/139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46 (0.27 to 0.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.7% (20.4% to 73.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0017" title="GoncalvesG , De AraujoA , Monteiro CardosoML . Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveillance1998;3(12):119-21. ">ba‐Goncalves 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents</p> <p>(15 months to 16 years)</p> <p>from Oporto (Portugal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>Cases reported by GPs or hospital</p> <p>doctors, occurred during the 1995 to 1996 mumps outbreak</p> <p>(a) N = 73</p> <p>(b) N = 133</p> <p>(c) N = 189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 consecutive<br/>vaccination records<br/>of the same sex, month and birth year as the case<br/>were selected. </p> <p>(a) N = 169</p> <p>(b) N = 236</p> <p>(c) N = 378</p> <p>Controls received at least 1 MMR dose.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assuming that before 1 November 1992 MMR mumps <b>Urabe</b> strain </p> <p>was administered,</p> <p>subsequently</p> <p>the <b>Rubini</b> strain </p> <p>(a) Urabe</p> <p>(b) Rubini</p> <p>(c) all</p> <p>at least 1 MMR dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 56/73 versus 142/169</p> <p>(b) 116/133 versus 209/236</p> <p>(c) 172/189 versus 351/378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 70% (25% to 88%)</p> <p>(b) 1% (−108% to 53%)</p> <p>adjusted for confounders</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0018" title="HarlingR , WhiteJM , RamsayME , MacsweenKF , vanden BoschC . The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine2005;23(31):4070-4. ">ba‐Harling 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents<br/>aged between 1 and 18 years<br/>from religious community<br/>in Northeast London.<br/>Mumps outbreak </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>N = 156 (GP notification to the local CCDC, mumps diagnoses from electronic practice list, verbal reports by community members) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Laboratory confirmation</p> <p>of clinical diagnosis</p> <p>N = 43</p> <p>GP notification to the local CCDC</p> <p>of notified cases,</p> <p>IgM and mumps RNA</p> <p>testing was offered</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 175<br/>randomly selected<br/>and stratified for<br/>age and sex<br/>from practice list </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Jeryl Lynn</b> 1 or 2 </p> <p>MMR doses</p> <p>received</p> <p>at least 1 month</p> <p>before index date</p> <p>(a) at least 1 dose</p> <p>(b) 1 dose</p> <p>(c) 2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79/156 versus 134/175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0.31 (0.20 to 0.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 69% (50% to 80%) (crude)</p> <p>(a) 69% (41% to 84%)</p> <p>adjusted for age, sex, practice</p> <p>‐‐‐‐‐‐‐‐‐‐</p> <p>Laboratory‐confirmed cases</p> <p>(a) 65% (25% to 84%)</p> <p>(b) 64% (40% to 78%)</p> <p>(c) 88% (62% to 96%)</p> <p>All adjusted for age, sex, practice. Proportion of vaccinated in cases and controls not provided. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0021" title="KimHM , ChoHK , ChoiKM , EunBWY , KimKH . Efficacy of mumps in Korea. International Journal of Infectious Diseases2012;16s:e306. [DOI: 10.1016/j.ijid.2012.05.997]">ba‐Kim 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> <p>(a) prospective</p> <p>case‐control study</p> <p>from March 2010<br/>to October 2011 </p> <p>(b) retrospective</p> <p>case‐control study</p> <p>2008 to 2009 in western Seoul, Incheon, and Goyang</p> <p>(c) total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 55</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>(a3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b) N = 122</p> <p>(b1) 1 dose</p> <p>(b2) 2 doses</p> <p>(b3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) N = 177</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> <p>(c3) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 165</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>(a3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b) N = 449</p> <p>(b1) 1 dose</p> <p>(b2) 2 doses</p> <p>(b3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) N = 614</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> <p>(c3) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described (assumed to be <b>Jeryl Lynn</b> following <a href="./references#CD004407-bbs2-0375" title="ParkSH . Resurgence of mumps in Korea. Infection &amp; Chemotherapy2015;47(1):1-11. [PMID: 25844258]">Park 2015</a>) </p> <p>For (a) and (b):</p> <p>data about demographic characteristics and MMR vaccination status were collected from cases </p> <p>and controls.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐‐‐‐‐‐‐‐‐(a)‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a1) 0.58 (0.05 to 6.90)</p> <p>(a2) 1.1 (0.09 to 13.3)</p> <p>(a3) 0.67 (0.06 to 7.35)</p> <p>‐‐‐‐‐‐‐‐‐‐(b)‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b1) 0.33 (0.02 to 5.33)</p> <p>(b2) 0.11 (0.01 to 2.12)</p> <p>(b3) 0.33 (0.02 to 5.33)</p> <p>‐‐‐‐‐‐‐‐‐(c)‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c1) 0.58 (0.10 to 3.56)</p> <p>(c2) 0.42 (0.06 to 2.81)</p> <p>(c3) 0.50 (0.08 to 2.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐‐‐‐‐‐‐(a)‐‐‐‐‐‐‐‐‐</p> <p>(a1) 42.0%*<br/>(a2) −10.0%*<br/>(a3) 33.0%*<br/>‐‐‐‐‐‐‐‐‐(b)‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(b1) 67.0%*<br/>(b2) 89.0%*<br/>(b3) 67.0%* </p> <p>‐‐‐‐‐‐‐‐‐(c)‐‐‐‐‐‐‐‐‐‐‐<br/>(c1) 42.0%*<br/>(c2) 58.0%*<br/>(c3) 50.0%* </p> <p>*no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0023" title="MackenzieDG , CraigG , HallamNF , MooreJ , StevensonJ . Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice2006;56(528):526-9. ">ba‐Mackenzie 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>About 600 pupils attending</p> <p>a boarding school in Scotland</p> <p>during a mumps outbreak that</p> <p>peaked between October and</p> <p>November 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virological confirmation<br/>of clinical diagnosis </p> <p>N = 20 (aged 13 to 17 years).</p> <p>Cases notified to consultant<br/>in public health medicine.<br/>Acute cases with virological<br/>positive test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 40<br/>matched for<br/>age, sex,<br/>residential status,<br/>UK or international<br/>students </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) any dose</p> <p>Not specified. Pre‐outbreak<br/>vaccination status obtained by medical notes held in the school, </p> <p>communication</p> <p>with parents, and</p> <p>from Scottish</p> <p>Immunisation</p> <p>Recall System.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 9/18 versus 20/34</p> <p>(b) 2/11 versus 6/20</p> <p>(c) 11/20 versus 26/40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0.7 (0.22 to 2.21)</p> <p>(b) 0.52 (0.09 to 3.16)</p> <p>(c) 0.66 (0.22 to 1.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 30.0%*</p> <p>(b) 48.1%*</p> <p>(c) 32.4%*</p> <p>*no statistical evidence</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CCDC: Consultant in Communicable Disease Control<br/>CI: confidence interval<br/>GP: general practitioner<br/>ICD: International Statistical Classification of Diseases and Related Health Problems<br/>IgM: immunoglobulin M<br/>N: number of participants in intervention and control arm<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PCR: polymerase chain reaction<br/>PT: person‐time<br/>RNA: ribonucleic acid<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy </p> </div> </div> <div class="table" id="CD004407-tbl-0026"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rubella: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N events in exposed/<br/>N exposed<br/>or person‐months<br/>versus<br/>N events in non‐exposed/<br/>N non‐exposed<br/>or person‐months</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0052" title="ChangC , MoX , HuP , LiangW , MaH , AnZ , et al. Effectiveness of rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014. Vaccine2015;33(28):3223-7. [DOI: 10.1016/j.vaccine.2015.04.083]">ca‐Chang 2015</a> </p> <p>Cohort study</p> <p>Secondary attack rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle school with</p> <p>a total of 1621 students</p> <p>enrolled in the 7th,</p> <p>8th, and 9th grades,</p> <p>with a total of 37 classes (ages 11 to 13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable rubella case: defined as a</p> <p>suspected rubella case with fever &gt; 37.5 °C</p> <p>and at least 1 of the following symptoms:</p> <p>arthralgia, arthritis, lymphadenopathy, or conjunctivitis.</p> <p>Laboratory‐confirmed case: required</p> <p>a positive serologic test for rubella IgM antibody.</p> <p>Epidemiologically linked case: confirmed case</p> <p>was defined as a suspected case or</p> <p>a probable case that was not</p> <p>laboratory confirmed, but that was</p> <p>geographically and temporally</p> <p>related to a laboratory‐confirmed case.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR (BRD‐II or RA27/3)</p> <p>A BRD‐II rubella strain vaccine was</p> <p>developed in the 1980s in China,</p> <p>and has been available in the</p> <p>Chinese private market since1993.</p> <p>All monovalent rubella and measles</p> <p>and rubella combined (MR) vaccines</p> <p>in use in China are based on the BRD‐II rubella</p> <p>strain. A domestic measles, mumps, and rubella</p> <p>combined vaccine (MMR) based on</p> <p>BRD‐II strain has been available in China’s</p> <p>private market since 2003. There is also an imported RA27/3 strain‐based</p> <p>vaccine available in China.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary cases = 2</p> <p>Exposed person = 47</p> <p>RR 0.11 (95% CI 0.03 to 0.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89% (56% to 97%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>IgM: immunoglobulin M<br/>MMR: measles, mumps, rubella vaccine<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy </p> </div> </div> <div class="table" id="CD004407-tbl-0027"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Varicella: effectiveness ‐ RCTs/CCTs</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and<br/>design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>enrolled</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arms<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a> </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study is the first phase</p> <p>(1 September 2005 to 29 June 2009)</p> <p>of an RCT.</p> <p>The study was done in 111</p> <p>study centres in Europe:</p> <p>Czech Republic (22), Greece (11),</p> <p>Italy (9), Lithuania (9), Norway (5),</p> <p>Poland (10), Romania (9), Russia (14),</p> <p>Slovakia (17), and Sweden (5).</p> <p>An eligible participant was a healthy</p> <p>child aged 12 to 22 months at the time of the first vaccination; had a<br/>negative history of varicella, mumps, </p> <p>measles, and rubella diseases and vaccinations; and was one of the following:</p> <p>(1) at home with at least 1 sibling</p> <p>(with negative history</p> <p>of varicella disease and vaccination),</p> <p>(2) attending a child minder</p> <p>(where at least 1 child was without</p> <p>a known positive<br/>history of varicella disease and vaccination), </p> <p>(3) playing for more than 5 min weekly with</p> <p>children without a known positive history of</p> <p>varicella disease and vaccination,<br/>(4) registered to attend </p> <p>a day‐care centre from 24 months of age.</p> <p>An eligible participant’s</p> <p>parents or guardians had direct access</p> <p>to a telephone and were deemed by the<br/>investigator of being capable of </p> <p>complying with the requirements of the trial protocol.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The primary efficacy endpoint was</p> <p>the occurrence of confirmed varicella</p> <p>from 42 days after the second vaccine</p> <p>dose to the end of the first phase of the trial.</p> <p>The secondary efficacy</p> <p>endpoint was</p> <p>the occurrence of confirmed varicella graded by severity</p> <p>over the same time period.</p> <p>Varicella cases</p> <p>(a) All</p> <p>(b) Moderate/severe</p> <p>Follow‐up = 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV group:</p> <p>2 doses of MMRV (Priorix‐Tetra, GSK)</p> <p>N = 2279</p> <p>MMR+V group: 1 dose MMR (Priorix, GSK) and</p> <p>monovalent varicella vaccine</p> <p>(Varilrix, GSK) at dose 2</p> <p>N = 2263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR group (control):</p> <p>2 doses of MMR (Priorix, GSK)</p> <p>N = 743</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV</p> <p>(a) 37/2279</p> <p>(b) 2/2279</p> <p>MMR+V</p> <p>(a) 243/2263</p> <p>(b) 37/2263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR</p> <p>(a) 201/743</p> <p>(b) 117/743</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV</p> <p>(a) 94.9% (92.4% to 96.6%)</p> <p>(b) 99.5% (97.5% to 99.9%)</p> <p>MMR+V</p> <p>(a) 65.4% (57.2% to 72.1%)</p> <p>(b) 90.7% (85.9% to 93.9%)</p> <p>VE = (1 − HR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a> </p> <p>RCT</p> <p>linked to</p> <p><a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy children aged</p> <p>12 to 22 months.</p> <p>n = 5803</p> <p>children enrolled and</p> <p>vaccinated (TVC) in phase A,</p> <p>n = 4580</p> <p>in the TVC in phase B,</p> <p>n = 3829</p> <p>completed the study up to Year 6;</p> <p>n = 5289</p> <p>ATP cohort for efficacy in phase A + B,</p> <p>n = 3791</p> <p>in the ATP cohort for efficacy</p> <p>in phase B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases</p> <p>(a) All</p> <p>(b) Moderate/severe</p> <p>(c) Severe</p> <p>Follow‐up = 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ATP<br/>cohort for efficacy </p> <p>phase A + B</p> <p>MMRV n = 2279</p> <p>MMR+V n = 2266</p> <p>Phase B</p> <p>MMRV n = 1802</p> <p>MMR+V n = 1593</p> <p>MMRV group</p> <p>2 doses of MMRV</p> <p>(Priorix‐Tetra, GSK) at Day 0 and Day 42</p> <p>MMR+V group</p> <p>1 dose of MMR</p> <p>(Priorix, GSK)</p> <p>at Day 0 and</p> <p>1 dose of monovalent varicella vaccine</p> <p>(Varilrix, GSK)</p> <p>at Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ATP<br/>cohort for efficacy </p> <p>phase A + B<br/>MMR n = 744 </p> <p>Phase B</p> <p>MMR n = 396</p> <p>MMR group</p> <p>2 doses of the MMR</p> <p>(Priorix, GSK) vaccine at Day 0 and Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase A + B</p> <p>MMRV</p> <p>(a) 71/2279</p> <p>(b) 6/2279</p> <p>(c) 0/2270</p> <p>MMR+V</p> <p>(a) 419/2266</p> <p>(b) 58/2266</p> <p>(c) 1/2266</p> <p>Phase B</p> <p>MMRV</p> <p>(a) 33/1800</p> <p>(b) 4/1800</p> <p>(c) 0/1800</p> <p>MMR+V</p> <p>(a) 176/1592</p> <p>(b) 18/1592</p> <p>(c) 0/1592</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase A + B</p> <p>MMR</p> <p>(a) 325 /744</p> <p>(b) not reported</p> <p>Phase B</p> <p>(a) 125/396</p> <p>(b) not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.0% (93.6% to 96.2%)</p> <p>(b) 99.0% (97.7% to 99.6%)</p> <p>(c) undefined</p> <p><b>MMR+V</b> </p> <p>(a) 67.0% (61.8% to 71.4%)</p> <p>(b) 90.3% (86.9% to 92.8%)</p> <p>(c) 94.6% (55.3% to 99.4%)</p> <p><b>Phase B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.3% (93.1% to 96.8%)</p> <p>(b) 98.4% (95.5% to 99.4%)</p> <p>(c) undefined</p> <p><b>MMR+V</b> </p> <p>(a) 69.5% (61.5% to 75.8%)</p> <p>(b) 91.8% (85.9% to 95.2%)</p> <p>(c) undefined</p> <p>VE = (1 − HR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a> </p> <p>RCT</p> <p>linked to</p> <p><a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 22</p> <p>months were eligible</p> <p>for inclusion if: had not received MMR</p> <p>or varicella vaccines, or both, or had measles‐mumps‐rubella</p> <p>or varicella zoster or</p> <p>herpes zoster diseases,</p> <p>or both, and were at home</p> <p>with at least 1 sibling with</p> <p>negative history of varicella</p> <p>disease and vaccination,</p> <p>at a child‐minders where</p> <p>at least 1 child was without</p> <p>a known positive history of</p> <p>varicella disease and vaccination,</p> <p>playing for more than 5 min/week</p> <p>with children without a known positive</p> <p>history of varicella disease</p> <p>and vaccination, or registered</p> <p>to attend day care from 24 months.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases</p> <p>(a) All</p> <p>(b) Moderate/Severe</p> <p>Follow‐up = 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p>MMRV n = 2279</p> <p>MMR+V n = 2266</p> <p><b>Phase B</b> </p> <p>MMRV n = 1800</p> <p>MMR+V n = 1591</p> <p><b>MMRV group</b> </p> <p>2 doses of MMRV</p> <p>(Priorix‐Tetra, GSK)</p> <p>at Day 0 and Day 42</p> <p><b>MMR+V group</b> </p> <p>1 dose of MMR</p> <p>(Priorix, GSK)</p> <p>at Day 0 and</p> <p>1 dose of monovalent</p> <p>varicella vaccine</p> <p>(Varilrix, GSK)</p> <p>at Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b><br/>MMR n = 744 </p> <p><b>Phase B</b> </p> <p>MMR n = 396</p> <p><b>MMR group</b> </p> <p>2 doses of the MMR</p> <p>(Priorix, GSK) vaccine at Day 0 and Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMRV</b> </p> <p>(a) 71/2279</p> <p>(b) 6/2279</p> <p><b>MMR+V</b> </p> <p>(a) 469/2266</p> <p>(b) 67/2266</p> <p><b>Phase B</b> </p> <p><b>MMRV</b> </p> <p>(a) 33/1800</p> <p>(b) 4/1800</p> <p><b>MMR+V</b> </p> <p>(a) 176/1592</p> <p>(b) 18/1592</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMR</b> </p> <p>(a) 352/744</p> <p>(b) 176/744</p> <p><b>Phase B</b> </p> <p>(a) 149/396</p> <p>(b) 59/396</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.4% (94.0% to 96.4%)</p> <p>(b) 99.1% (97.7% to 99.6%)</p> <p><b>MMR+V</b> </p> <p>(a) 67.2% (62.3% to 71.5%)</p> <p>(b) 89.5% (86.1% to 92.1%)</p> <p><b>Phase B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.9% (94.1% to 97.1%)</p> <p>(b) 98.7% (96.4% to 99.5%)</p> <p><b>MMR+V</b> </p> <p>(a) 69.8% (62.8% to 75.5%)</p> <p>(b) 90.0% (84.2% to 93.7%)</p> <p><b>VE = (1 − HR) x 100</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ATP: according‐to‐protocol<br/>CI: confidence interval<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>RCT: randomised controlled trial<br/>RR: risk ratio (relative risk)<br/>TVC: total vaccinated cohort<br/>VE: vaccine effectiveness/efficacy </p> </div> </div> <div class="table" id="CD004407-tbl-0028"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Varicella: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N events in exposed/<br/>N exposed<br/>or person‐months<br/>versus<br/>N events in non‐exposed/<br/>N non‐exposed<br/>or person‐months</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0055" title="GiaquintoC , GabuttiG , BaldoV , VillaM , TramontanL , RaccanelloN , et al. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. BMC Infectious Diseases2018;18(1):103. ">ca‐Giaquinto 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 0 to 14 registered with</p> <p>35 Pedianet database physicians</p> <p>across Italy between</p> <p>1 October 1997 and 30 September 1998</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases recorded in the</p> <p>Pedianet databases are based</p> <p>on physician confirmation only</p> <p>(no laboratory tests were performed).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV: vaccine ProQuad</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 2357</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 912 unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/2357 versus 287/912</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>unadjusted estimate</p> <p>94% (92% to 96%)</p> <p>adjusted estimate</p> <p>94% (91% to 95%)</p> <p><b>VE = (1 −</b> <b>RR) x 100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0069" title="RieckT , FeigM , An der HeidenM , SiedlerA , WichmannO . Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveillance2017;22(17):30521. ">ca‐Rieck 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between January 2006</p> <p>and October 2013,</p> <p>n = 1,449,411 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐step algorithm to only select confirmed<br/>and incident varicella cases. </p> <p>Step 1: excluded incompatible or</p> <p>implausible coding combinations for</p> <p>varicella diagnosis reliability;</p> <p>step 2: excluded observations with</p> <p>diagnosis reliability other than confirmed</p> <p>(i.e. suspected, excluded, recovered);</p> <p>step 3: excluded observations</p> <p>with diagnosis</p> <p>type other than incident</p> <p>(i.e. previous state, unknown,</p> <p>not provided);<br/>step 4: limited the data selection </p> <p>to the earliest</p> <p>ICD‐10 code per patient whilst also keeping the information</p> <p>about the most severe</p> <p>ICD‐10 code (within up to one‐quarter</p> <p>following the initial diagnosis) using the</p> <p>following ranking</p> <p>(in descending order of severity):</p> <p>varicella with encephalitis, meningitis,</p> <p>pneumonia, other complications,</p> <p>no complications, no further<br/>details, with the last equalling </p> <p>‘no complications’.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since 2004, single‐dose</p> <p>varicella vaccination has<br/>been recommended for </p> <p>all children aged 11 to 14 months.</p> <p>2 single‐compound varicella vaccines (VAR; Varivax,<br/>Sanofi Pasteur MSD; Varilrix, GSK) </p> <p>were initially available. In 2006, a combined</p> <p>(MMR)‐varicella vaccine (MMRV;<br/>Priorix‐Tetra, GlaxoSmithKline) </p> <p>was licenced with a 2‐dose schedule.</p> <p>A 2‐dose schedule has been recommended</p> <p>since 2009 targeting children</p> <p>with the second dose at age 15 to 23 months.</p> <p>Since 2011, the first immunisation has been given preferably as 2 separate injections of </p> <p>VAR and MMR due to higher rates of febrile seizures following immunisation with MMRV.</p> <p>(a) 1 dose MMRV</p> <p>(b) 2 doses MMRV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VE = (1 − HR) x 100</b> </p> <p>adjusted estimate</p> <p>(a) 81.7% (81.0% to 82.4%)</p> <p>(b) 94.4% (94.2% to 94.6%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>VE = (1 −</b> <b>RR) x 100</b><br/>RR obtained from HR and attack rate<br/>of varicella in unvaccinated<br/>children, Risk in unvaccinated children = 9% </p> <p>(a) 61.8% (60.6% to 63.0%)<br/>(b) 86.6% (86.1% to 87.0%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0072" title="SpackovaM , Wiese-PosseltM , DehnertM , Matysiak-KloseD , HeiningerU , SiedlerA . Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine2010;28(3):686-91. ">ca‐Spackova 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1084 children attended day‐care centres in Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella was classified clinically as</p> <p>mild (&lt; 50 skin lesions),</p> <p>moderate (≥ 50 skin lesions),</p> <p>severe (any hospitalised case).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV Priorix‐Tetra</p> <p>(a) All‐brand doses</p> <p>(b1) All‐brand 1 dose</p> <p>(b2) All‐brand 2 dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) Varivax 1 dose</p> <p>(d) Varilrix 1 dose</p> <p>(e1) Priorix‐Tetra 1 dose</p> <p>(e2) Priorix‐Tetra 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(f1) Mild disease</p> <p>(f2) Moderate disease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 244</p> <p>(b1) n = 167</p> <p>(b2) n = 77</p> <p>(c) n = 48</p> <p>(d) n = 77</p> <p>(e1) n = 38</p> <p>(e2) n = 56</p> <p>(f1) n = 233</p> <p>(f2) n = 221</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 108</p> <p>(f1) n = 71</p> <p>(f2) n = 93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 33/244 versus 52/108</p> <p>(b1) 31/167 versus 52/108</p> <p>(b2) 2/77 versus 52/108</p> <p>(c) 4/48 versus 52/108</p> <p>(d) 19/77 versus 52/108</p> <p>(e1) 7/38 versus 52/108</p> <p>(e2) 2/56 versus 52/108</p> <p>(f1) 22/233 versus 15/71</p> <p>(f2) 10/221 versus 37/93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 71% (57% to 81%)</p> <p>(b1) 62% (43% to 75%)</p> <p>(b2) 94% (75% to 98%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) 86% (56% to 96%)</p> <p>(d) 56% (29% to 72%)</p> <p>(e1) 55% (8% to 78%)</p> <p>(e2) 91% (65% to 98%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(f1) 53% (14% to 75%)</p> <p>(f2) 89% (78% to 95%)</p> <p>adjusted for confounders</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0073" title="TafuriS , MartinelliD , PratoR , GerminarioC . Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in region which adopted UMV. Human Vaccines and Immunotherapeutics2013;9(1):184-8. ">ca‐Tafuri 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children at</p> <p>(a) preschool</p> <p>(b) elementary school</p> <p>(c) all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported by<br/>parents </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV</p> <p>(Priorix‐Tetra)</p> <p>Varicella OKA;</p> <p>1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 170</p> <p>(b) n = 71</p> <p>(c) n = 241</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 40</p> <p>(b) n = 287</p> <p>(c) n = 327</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/170 versus 14/40</p> <p>(b) 2/71 versus 223/287</p> <p>(c) 4/241 versus 237/327</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Not reported</p> <p>(b) 69.2% (50.5% to 88.1%)</p> <p>(c) 59.9% (48.3% to 69.8%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ARU: attack rate amongst unvaccinated<br/>ARV: attack rate amongst vaccinated<br/>CI: confidence interval<br/>ICD‐10: International Classification of Diseases, Tenth Revision<br/>HR: hazards ratio<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy </p> </div> </div> <div class="table" id="CD004407-tbl-0029"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Varicella: effectiveness ‐ case‐control studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Controls/selection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR strain/exposure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N cases vaccinated/N cases<br/>versus<br/>N controls vaccinated/N controls</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OR (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0011" title="AndradeAL , da Silva VieiraMA , MinamisavaR , ToscanoCM , deLima SouzaMB , FiaccadoriF , et al. Single-dose varicella vaccine effectiveness in Brazil: a case-control study. Vaccine2018;36(4):479-83. [PMID: 29249544]">ba‐Andrade 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From November 2013 to December 2015,<br/>children aged 15 to 32 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases were defined as</p> <p>children aged 15 to 32 months with rash and either suspected</p> <p>as having varicella by an attending physician or being a contact to a confirmed varicella case. Cases were confirmed by either clinical or laboratory criteria. </p> <p><b>Cases:</b> n = 168 </p> <p>Cases were further classified by</p> <p>severity of disease based on number of skin lesions, being:</p> <p>(1) mild – fewer than 50 lesions;</p> <p>(2) mild/moderate – between 50 and 249 lesions;</p> <p>(3) moderate – between 250 and 499 lesions; or</p> <p>(4) severe – 500 lesions or more, having been hospitalised, or having any complication.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Controls matched 1:2 by:</p> <p>age (15 to 32 months).<br/>Controls were defined as<br/>children residing in the </p> <p>neighbourhood of the case,</p> <p>in which no history of varicella or outpatient clinics visits</p> <p>due to skin lesion was reported. To identify controls,</p> <p>houses nearby the cases</p> <p>were visited following a systematic sampling procedure.</p> <p><b>Controls:</b> n = 301 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b> </p> <p>A combined tetravalent vaccine containing measles, mumps, rubella,</p> <p>and varicella antigens (MMRV), manufactured by GlaxoSmithKline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Any severity<br/>(b) Moderate severe cases &gt; 50 lesions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted‐estimates</p> <p>(a) 0.14 (0.07 to 0.28)</p> <p>(b) 0.07 (0.03 to 0.18)</p> <p>adjusted for confounders:<br/>age in months, day‐care attendance, and pulmonary diseases </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 86% (72% to 92%)</p> <p>(b) 93% (82% to 97%)</p> <p>VE = 1 − OR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0013" title="CenozMG , Martinez-ArtolaV , GuevaraM , EzpeletaC , BarricarteA , CastillaJ . Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Human Vaccines and Immunotherapeutics2013;9(5):1172-6. [DOI: 10.4161/hv.23451]">ba‐Cenoz 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children between 15 months and 10 years of age</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR‐confirmed varicella</p> <p>Cases n = 54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matched 1:8 by paediatric practice, district of residence, and date of birth (± 1 year) </p> <p>Controls n = 432</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR+V</b> (Varivax OKA/Merck) </p> <p>not described</p> <p>(a) any doses and age</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>(b) age &lt; 3 years</p> <p>(b1) 1 dose</p> <p>(c) age ≥ 3 years</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 6/54 versus 175/432</p> <p>(a1) 5/54 versus 112/432</p> <p>(a2) 1/54 versus 63/432</p> <p>(b1) 1/6 versus 36/48</p> <p>(c1) 4/48 versus 76/384</p> <p>(c2) 1/48 versus 63/384</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted estimates</p> <p>(a) 92% (77% to 97%)</p> <p>(a1) 87% (60% to 97%)</p> <p>(a2) 97% (79.5% to 99.6%)</p> <p>(b1) 84% (−58% to 100%)(*)</p> <p>(c1) 80% (37% to 95%)</p> <p>(c2) 97% (79% to 100%)</p> <p>VE = (1 −OR) x 100</p> <p>(*) no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0022" title="LieseJG , CohenC , RackA , PirzerK , EberS , BlumM , et al. The effectiveness of varicella vaccination in children in Germany. Pediatric Infectious Disease Journal2013;32(9):998-1004. [DOI: 10.1097/INF.0b013e31829ac263]">ba‐Liese 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children at least 1 year of age, born on or after 1 July 2003, who resided in Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR‐confirmed varicella</p> <p>n = 432</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children matched by</p> <p>age and paediatric practice,</p> <p>fulfilling the same criteria</p> <p>as cases but without</p> <p>history or present clinical</p> <p>diagnosis of varicella</p> <p>n = 432</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any varicella vaccine</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>OKA/GSK</p> <p>(b1) 1 dose</p> <p>(b2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Other than OKA/GSK*</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Unknown vaccine</p> <p>(d1) 1 dose</p> <p>(d2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Any varicella vaccine</p> <p>(after vaccination)</p> <p>(y1) up to 1 year</p> <p>(y2) 1 to 2 year</p> <p>(y3) 4 to 5 year</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(*) includes OKA/Merck<br/>and MMR‐OKA/GSK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 57/432 versus 195/432</p> <p>(a1) 55/430 versus 153/390</p> <p>(a2) 2/377 versus 42/279</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b1) 35/410 versus 63/300</p> <p>(b2) 0/375 versus 6/243</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c1) 19/394 versus 87/324</p> <p>(c2) 2/377 versus 25/262</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(d1) 1/376 versus 3/240</p> <p>(d2) 0/375 versus 11/248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted estimates</p> <p>(a1) 86.4% (77.3% to 91.8%)</p> <p>(a2) 94.3% (76.4% to 98.6%)</p> <p>(b1) 71.5% (49.1% to 84.0%)</p> <p>(b2) not reported</p> <p>(c1) not reported</p> <p>(c2) not reported</p> <p>(d1) not reported</p> <p>(d2) not reported</p> <p>(y1) 94.5% (76.9% to 98.7%)</p> <p>(y2) 81.5% (56.8% to 92.1%)</p> <p>(y3) 73.2% (9.1% to 92.1%)</p> <p>VE = (1 − OR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0024" title="VazquezM , La RussaPS , GershonAA , StainbergSP , FreudigmanK , ShapiroE . The effectiveness of the varicella vaccine in clinical practice. New England Journal of Medicine2001;344(13):955-60. [DOI: 10.1056/NEJM200103293441302]">ba‐Vazquez 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children between 13 months and 16 years of age.</p> <p>(a) &lt; 5 years old</p> <p>(b) 5 to 10 years old</p> <p>(c) &gt; 10 years old</p> <p>(d) all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR‐confirmed varicella</p> <p>n = 202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matched 1:2 according to date of birth (within 1 month) and paediatric practice</p> <p>n = 389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR+V</b> </p> <p>Vaccine type and<br/>number of doses not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/202 versus 238/389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted estimates</p> <p>(a) 79% (61% to 89%)</p> <p>(b) 89% (80% to 94%)</p> <p>(c) 92% (45% to 99%)</p> <p>(d) 87% (78% to 90%)</p> <p>VE = (1 − OR) x 100</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>IgM: immunoglobulin M<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, and varicella vaccine<br/>n: number of participants in intervention and control arm<br/>OR: odds ratio<br/>PCR: polymerase chain reaction<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </div> <div class="table" id="CD004407-tbl-0030"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Varicella: effectiveness ‐ case‐only ecological method studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0128" title="BoccaliniS , BonanniP , BechiniA . Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004–2012. Euro Surveillance2015;21:1-7. [DOI: 10.2807/1560-7917.ES.2016.21.24.30257]">ga‐Boccalini 2015</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation between 2004 to 2012 in the Tuscan region.</p> <p>Aged 0 to 14 years</p> <p>(a) age &lt; 1 year</p> <p>(b) age 1 to 4 years</p> <p>(c) age 5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised cases for varicella</p> <p>or its complications, as a primary or secondary discharge diagnosis, with the following ICD‐9‐CM </p> <p>codes (2002 and 2007) were examined:<br/>052.0 (post‐varicella encephalitis),<br/>052.1 (varicella (haemorrhagic) pneumonitis),<br/>052.2 (post‐varicella myelitis),<br/>052.7 (varicella with other specified complications),<br/>052.8 (varicella with unspecified complication),<br/>052.9 (varicella without complication). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV vaccine: not described</p> <p>and monovalent varicella vaccine</p> <p>Reference period</p> <p>2004 to 2007</p> <p>Exposed period</p> <p>2009 to 2012</p> <p>Data from 2008, the transition year<br/>between the 2 periods, were excluded from our analysis in this study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reference period</p> <p>(a) 73/122,483</p> <p>(b) 189/478,481</p> <p>(c) 105/1,141,304</p> <p>Exposed period</p> <p>(a) 42/128,440</p> <p>(b) 99/523,810</p> <p>(c) 55/1,222,222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR (95% CI) (*)</p> <p>(a) 0.55 (0.38 to 0.80)</p> <p>(b) 0.48 (0.38 to 0.61)</p> <p>(c) 0.48 (0.35 to 0.67)</p> <p>(*) Relative risk</p> <p>between exposed and reference period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VE = 1 −</b> RR </p> <p>(a) 45.1% (19.8% to 62.5%)<br/>(b) 52.2% (39% to 62.5%)<br/>(c) 51.1% (32.2% to 64.7%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a><br/>Case‐only ecological method </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation between 2000 to 2008 in the Veneto region.</p> <p>Aged 0 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases incidence:</p> <p>(a) from surveillance data retrieved</p> <p>from the RDP</p> <p>(b) sentinel surveillance system</p> <p>based on a sample of paediatricians</p> <p>(SPES).</p> <p>Hospitalised cases for varicella</p> <p>hospital discharges that reported<br/>in the primary and secondary </p> <p>diagnoses codes 052.X.</p> <p>Admissions</p> <p>with coexistent codes</p> <p>for herpes zoster, i.e. 053.X, were excluded.</p> <p>(c) hospitalisations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV vaccine: not described</p> <p>and monovalent varicella vaccine</p> <p>Reference period</p> <p>2000 to 2006</p> <p>Exposed period</p> <p>2007 to 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases/person time</p> <p>(RDP) incidence</p> <p>reference period</p> <p>(a) 81,276/438,3097</p> <p>Exposed period</p> <p>(a) 14,749/1,345,351</p> <p>(SPES) incidence</p> <p>reference period</p> <p>(b) 13,543/196,949</p> <p>Exposed period</p> <p>(b) 1344/26,861</p> <p>Hospitalised</p> <p>reference period</p> <p>(c) 770/4,383,497</p> <p>Exposed period</p> <p>(c) 126/1,348,474</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rr (95% CI)</p> <p>(a) 0.59 (0.58 to 0.6)<br/>(b) 0.73 (0.69 to 0.77)<br/>(c) 0.53 (0.44 to 0.64) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a1) 0.44 (0.43 to 0.45)<br/>(b1) 0.58 (0.53 to 0.64)<br/>(c1) 0.48 (0.37 to 0.63) </p> <p>Sensitivity analysis</p> <p>Data from 2007,<br/>the transition year<br/>between the 2 periods,<br/>were excluded from analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VE = (1 − rr) x 100</p> <p>(a) 40.9% (39.8% to 41.9%)<br/>(b) 27.2% (23% to 31.2%)<br/>(c) 46.8% (35.8% to 55.9%) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a1) 56.2% (54.9% to 57.3%)<br/>(b1) 41.8% (36.2% to 46.8%)<br/>(c1) 52.2% (37.4% to 63.5%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0130" title="TafuriS , FortunatoF , CappelliMG , CozzaV , BechiniA , BonanniP , et al. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012. Human Vaccines and Immunotherapy2015;11(1):214-9. [DOI: 10.4161/hv.36153]">ga‐Tafuri 2015</a><br/>Case‐only ecological method </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation between 2003 to 2012 in the Puglia region.</p> <p>Aged 0 to 14 years</p> <p>(a) age &lt; 1 year</p> <p>(b) age 1 to 4 years</p> <p>(c) age 5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised cases for varicella</p> <p>Hospitalisation rates, overall and specific by<br/>age, were calculated on data extracted </p> <p>from the regional HDR, selecting</p> <p>all hospital admissions with<br/>a main diagnosis of chickenpox </p> <p>or its complications (ICD9‐CM<br/>codes: 052.x) in the same period. </p> <p>Incidence rates, overall and specific by age,</p> <p>between 2003<br/>and 2012 were calculated by using data </p> <p>collected in the Apulian<br/>computerised surveillance system </p> <p>for communicable diseases.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV vaccine: not described</p> <p>and monovalent varicella vaccine</p> <p>Reference period</p> <p>2003 to 2005</p> <p>Exposed period</p> <p>2009 to 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised</p> <p>reference period</p> <p>(a) 245/39,618</p> <p>(b) 2148/163,321</p> <p>(c) 2201/451,858</p> <p>Exposed period</p> <p>(a) 39/37,356</p> <p>(b) 161/152,607</p> <p>(c) 289/420,058</p> <p>Incidence</p> <p>reference period</p> <p>(a) 14/39,548</p> <p>(b) 57/1,623,931</p> <p>(c) 42/446,809</p> <p>Exposed period</p> <p>(a) 5/39,063</p> <p>(b) 9/160,714</p> <p>(c) 10/434,783</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rr (95% CI)(*)</p> <p>Hospitalised</p> <p>(a) 0.17 (0.12 to 0.24)</p> <p>(b) 0.08 (0.07 to 0.09)</p> <p>(c) 0.14 (0.12 to 0.16)</p> <p>Incidence</p> <p>(a) 0.36 (0.13 to 1.03)</p> <p>(b) 0.16 (0.08 to 0.33)</p> <p>(c) 0.25 (0.12 to.050)</p> <p>(*) Relative risk</p> <p>between exposed and reference period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VE = (1 − rr) x 100</p> <p>Hospitalised</p> <p>(a) 63.8% (−0.4% to 87%)<br/>(b) 84% (67.8% to 92.1%)<br/>(c) 75.5% (51.2% to 87.7%) </p> <p>Incidence</p> <p>(a) 83.1% (76.3% to 88%)<br/>(b) 92% (90.6% to 93.2%)<br/>(c) 85.9% (84% to 87.5%) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>HDR: hospital discharge registry<br/>ICD‐9‐CM<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>n: number of participants in intervention and control arm<br/>RDP: Regional Department of Prevention<br/>SPES: Sorveglianza PEdiatric Sentinella<br/>VE: vaccine effectiveness/efficacy </p> </div> </div> </section> <section id="CD004407-sec-0050"> <h5 class="title">Vaccine safety‐harms</h5> <p>We included 87 studies on the safety of MMR/MMRV vaccines, with the following study designs: 7 RCTs/CCTs, 21 case control, 32 cohorts, 16 SCCS/PTC, 3 CCO, and 4 COEM. Seven of 87 studies reported data on several adverse effects and were therefore included in each corresponding comparison group (<a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>; <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>; <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>). The studies evaluating adverse events are presented in 18 main groups. </p> <p> <ol id="CD004407-list-0024"> <li> <p>Short‐term side effects: overall 17 studies: 7 RCTs/CCTs, <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; <a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>; <a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>, and 10 cohort studies (<a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a>; <a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>; <a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a>; <a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>; <a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a>; <a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a>; <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>; <a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>; <a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>). See <a href="#CD004407-tbl-0031">Table 10</a> and <a href="#CD004407-tbl-0032">Table 11</a>. </p> </li> <li> <p>Encephalitis or encephalopathy: overall 3 studies: 1 case control (<a href="./references#CD004407-bbs2-0041" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768-73. ">bb‐Ray 2006</a>), 1 SCCS (<a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>), and 1 PTC (<a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>). See <a href="#CD004407-tbl-0033">Table 12</a>. </p> </li> <li> <p>Aseptic meningitis: overall 10 studies: 1 case control (<a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>), 4 SCCS/PTC (<a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>), 1 PTC (<a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>), 2 CCO (<a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a>; <a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a>), and 2 COEM (<a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a>; <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>). See <a href="#CD004407-tbl-0034">Table 13</a>. </p> </li> <li> <p>Seizure ‐ febrile/afebrile: overall 8 studies: 2 cohort (<a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a>; <a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a>), 4 SCCS (<a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0113" title="MacartneyK , GiddingHF , TrinhL , WangH , DeyA , HullB , et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatrics2017;171(10):992-8. ">db‐Macartney 2017</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>), and 2 PTC (<a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a>; <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a>). See <a href="#CD004407-tbl-0035">Table 14</a>. </p> </li> <li> <p>MMRV versus MMR/MMR+V ‐ febrile seizures: overall 7 cohort (<a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a>; <a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a>; <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0093" title="KleinNP , LewisE , McDonaldJ , FiremanB , NalewayA , GlanzJ , et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. Vaccine2017;35(12):1615-21. ">cb‐Klein 2017</a>; <a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a>; <a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a>). See <a href="#CD004407-tbl-0036">Table 15</a>. </p> </li> <li> <p>Autism spectrum disorders: overall 13 studies: 4 cohort (<a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a>; <a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a>; <a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a>; <a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a>), 4 case control (<a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a>; <a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a>; <a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a>; <a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a>), 1 SCCS (<a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a>), 1 PTC (<a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>), and 3 COEM (<a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a>; <a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a>; <a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a>). See <a href="#CD004407-tbl-0037">Table 16</a>. </p> </li> <li> <p>Inflammatory bowel disease: overall 6 studies: 4 case control, <a href="./references#CD004407-bbs2-0026" title="BaronS , TurckD , LeplatC , MerleV , Gower-RousseauC , MartiR , et al. Enviromental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut2005;54(3):357-63. [DOI: 10.1136/gut.2004.054353]">bb‐Baron 2005</a>; <a href="./references#CD004407-bbs2-0034" title="DavisRL , KramarzP , BohlkeK , BensonP , ThompsonRS , MulloolyJ , et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine2001;155(3):354-9. ">bb‐Davis 2001</a>; <a href="./references#CD004407-bbs2-0042" title="ShawSY , BlanchardJF , BernsteinCN . Early childhood measles vaccinations are not associated with paediatric IBD: a population based analysis. Journal of Crohn's and Colitis2015;9(4):334-8. [DOI: 10.1093/ecco-jcc/jjv029]">bb‐Shaw 2015</a>; <a href="./references#CD004407-bbs2-0045" title="VcevA , PezerovicD , JovanovicZ , NakicD , VcevI , MajnaricL . A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. Wiener Klinische Wochenschrift2015;127(9-10):345–54. ">bb‐Vcev 2015</a>, and 2 COEM (<a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a>; <a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a>). See <a href="#CD004407-tbl-0038">Table 17</a>. </p> </li> <li> <p>Cognitive delay, developmental delay: 1 cohort study reported data on cognitive delay (<a href="./references#CD004407-bbs2-0098" title="Mrozek-BudzynD , KiełtykaA , MajewskaR , AugustyniakM . Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - the results of the Polish prospective cohort study. Vaccine2013;31(22):2551-7. [DOI: 10.1016/j.vaccine.2013.03.057]">cb‐Mrozek‐Budzyn 2013</a>). See <a href="#CD004407-tbl-0039">Table 18</a>. </p> </li> <li> <p>Idiopathic thrombocytopenic purpura: overall 9 studies: 2 case control (<a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a>; <a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a>), 5 SCCS (<a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a>; <a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>), 1 CCO (<a href="./references#CD004407-bbs2-0126" title="LafaurieM , BaricaultB , Lapeyre-MestreM , SaillerL , MoulisG , SommetA , et al. Risk of vaccine-induced immune thrombocytopenia in children. Nationwide case cross-over and self controlled case series studies in France. Fundamental &amp; Clinical Pharmacology2018;32:86. ">eb‐Lafaurie 2018</a>), 1 COEM (<a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a>). See <a href="#CD004407-tbl-0040">Table 19</a>. </p> </li> <li> <p>Henoch‐Schönlein purpura: 1 case control study (<a href="./references#CD004407-bbs2-0033" title="Da DaltL , ZerbinatiC , StrafellaMS , RennaS , RiceputiL , Di PietroP , et al Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics2016;42(1):60. [DOI: 10.1186/s13052-016-0267-2]">bb‐Da Dalt 2016</a>). See <a href="#CD004407-tbl-0041">Table 20</a>. </p> </li> <li> <p>Type 1 diabetes: 2 cohort studies (<a href="./references#CD004407-bbs2-0082" title="BeyerleinA , StroblAN , WinklerC , CarpusM , KnopffA , DonnachieE , et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine2017;35(14):1735-41. ">cb‐Beyerlein 2017</a>; <a href="./references#CD004407-bbs2-0086" title="HiividAD , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health2004;8(5):286-7. [CRSREF: 2955568]HviidA , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination and type 1 diabetes. New England Journal of Medicine2004;350(14):1398-404. ">cb‐Hviid 2004</a>). See <a href="#CD004407-tbl-0042">Table 21</a>. </p> </li> <li> <p>Asthma: 5 cohort studies (<a href="./references#CD004407-bbs2-0081" title="BenkeG , AbramsonM , RavenJ , ThienFC , WaltersEH . Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health2004;28(4):336-8. ">cb‐Benke 2004</a>; <a href="./references#CD004407-bbs2-0083" title="DeStefanoF , GuD , KramarzP , TrumanBI , IademarcoMF , MulloolyJP , et al. Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal2002;21(6):498-504. ">cb‐DeStefano 2002</a>; <a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a>; <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>; <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>). See <a href="#CD004407-tbl-0043">Table 22</a>. </p> </li> <li> <p>Dermatitis or eczema: 2 cohort studies (<a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>; <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>). See also <a href="#CD004407-tbl-0044">Table 23</a>. </p> </li> <li> <p>Hay fever, rhinoconjunctivitis, hypersensitivity/allergy: overall 3 studies: 1 cohort study (<a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>), 2 case control (<a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a>; <a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a>). See <a href="#CD004407-tbl-0045">Table 24</a>. </p> </li> <li> <p>Acute leukaemia: 4 case control studies (<a href="./references#CD004407-bbs2-0036" title="DockertyJD , SkeggDC , ElwoodJM , HerbisonGP , BecroftDM , LewisME . Infections, vaccinations, and the risk of childhood leukaemia. British Journal of Cancer1999;80(9):1483-9. [DOI: 10.1038/sj.bjc.6690548]">bb‐Dockerty 1999</a>; <a href="./references#CD004407-bbs2-0037" title="GrovesFD , GridleyG , WacholderS , ShuXO , RobisonLL , NegliaJP , et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. British Journal of Cancer1999;81(1):175-8. [DOI: 10.1038/sj.bjc.6690668]">bb‐Groves 1999</a>; <a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a>; <a href="./references#CD004407-bbs2-0039" title="Mallol-MesnardN , MenegauxF , AuvrignonA , AuclercMF , BertrandY , NelkenB , et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology2007;36(1):110-6. ">bb‐Mallol‐Mesnard 2007</a>). See <a href="#CD004407-tbl-0046">Table 25</a>. </p> </li> <li> <p>Demyelinating diseases, multiple sclerosis, encephalomyelitis, acute disseminated encephalomyelitis (ADEM): overall 3 studies reported data on demyelinating diseases, multiple sclerosis, and ADEM: 1 cohort study (<a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a>), 2 case control studies (<a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a>; <a href="./references#CD004407-bbs2-0032" title="ChenY , MaF , XuY , ChuX , ZhangJ . Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine2018;36(26):3733-9. ">bb‐Chen 2018</a>). See <a href="#CD004407-tbl-0047">Table 26</a>. </p> </li> <li> <p>Gait disturbances: 1 SCCS (<a href="./references#CD004407-bbs2-0118" title="MillerE , AndrewsN , GrantA , StoweJ , TaylorB . No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood2005;90(3):292-6. ">db‐Miller 2005</a>). See <a href="#CD004407-tbl-0048">Table 27</a>. </p> </li> <li> <p>Bacterial or viral infections: 2 SCCS reported data on bacterial or viral infections (<a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a>; <a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a>). See <a href="#CD004407-tbl-0049">Table 28</a>. </p> </li> </ol> </p> <div class="table" id="CD004407-tbl-0031"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions) ‐ RCTs/CCTs</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>enrolled</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR vaccine arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other vaccine arms<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>events/n</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>11 months to 4 years</p> <p>Observation period</p> <p>21 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine</p> <p>Measles Schwarz</p> <p>Mumps Jeryl Lynn</p> <p>Rubella Cendehill</p> <p>n = 183</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Temperature<br/>above normal </p> <p>sample size</p> <p>n = 160</p> <p>Normal temperature</p> <p>rectal 99.6 °F (37.5 °C)</p> <p>(163 children)</p> <p>Oral 98.6 °F (37 °C)</p> <p>(6 children)</p> <p>Axillary 97.6 °F<br/>(36.4 °C)<br/>(26 children) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> <p>n = 40</p> <p>‐‐‐‐‐‐‐‐‐‐</p> <p>Temperature</p> <p>sample size</p> <p>n = 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Rash</p> <p>(b) Lymphadenopathy<br/>(c) Coryza </p> <p>(d) Rhinitis</p> <p>(e) Cough</p> <p>(f) Other</p> <p>total</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> <br/><b>above normal</b> </p> <p>(a) 1.5 to 2.4 °F</p> <p>(b) 2.5 to 3.4 °F</p> <p>(c) 3.5 to 4.4 °F</p> <p>(d) 4.5 to 4.9 °F</p> <p>(e) ≥ (normal + 1.5) °F</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>(a) 22/183</p> <p>(b) 2/183</p> <p>(c) 4/183</p> <p>(d) 2/183</p> <p>(e) 5/183</p> <p>(f) 35/183</p> <p>total 70/183</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> </p> <p><b>above norma</b>l </p> <p>(a) 17/160</p> <p>(b) 1/160</p> <p>(c) 5/160</p> <p>(d) 2/160</p> <p>(e) 25/160</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>(a) 2/40</p> <p>(b) 1/40</p> <p>(c) 4/40</p> <p>(d) 4/40</p> <p>(e) 1/40</p> <p>(f) 8/40</p> <p>total 20/40</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> </p> <p><b>above norma</b>l </p> <p>(a) 2/35</p> <p>(b) 2/35</p> <p>(c) 0/35</p> <p>(d) 0/35</p> <p>(e) 4/35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; </p> <p>CCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants aged</p> <p>38 to 40 months</p> <p>Observation period</p> <p>28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm A: n = 442</p> <p>(1) MV/Rouvax</p> <p>Measles Schwarz</p> <p>at 9 months;</p> <p>and</p> <p>(2) MMR/Trimovax</p> <p>Measles Schwarz</p> <p>Mumps Urabe AM9</p> <p>Rubella Wistar RA 27/3</p> <p>at 15 months</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Arm B: n = 495</p> <p>(3) MMR/Trimovax</p> <p>Measles Schwarz</p> <p>Mumps Urabe AM9</p> <p>Rubella Wistar RA 27/3</p> <p>at 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No placebo arm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic reactions</b> </p> <p>(a) Fever</p> <p>(b) Runny nose</p> <p>(c) Cough</p> <p>(d) Rash</p> <p>(e) Diarrhoea</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Local</b> </p> <p>(f) Redness</p> <p>(g) Swelling</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Total events</b> </p> <p>(x) Fever</p> <p>(y) Systemic</p> <p>(z) Local</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>(2)15 months; (3)12 months</b> </p> <p>(a) 40/442; 55/495</p> <p>(b) 7/442; 22/495</p> <p>(c) 36/442; 34/495</p> <p>(d) 16/442; 19/495</p> <p>(e) 2/442; 5/495</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Local</b> </p> <p><b>(2)15 months; (3)12 months</b> </p> <p>(f) 14/442; 19/495</p> <p>(g) 2/442; 3/495</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Total events</b> </p> <p><b>(2)15 months; (3)12 months</b> </p> <p>(x) 40/442; 55/495</p> <p>(y) 61/442; 80/495</p> <p>(z) 16/442; 22/495</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MV vaccine</b> </p> <p>(1) 9 months</p> <p>(a) 38/442</p> <p>(b) 19/442</p> <p>(c) 28/442</p> <p>(d) 2/442</p> <p>(e) 5/442</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Local</b> </p> <p>(f) 7/442</p> <p>(g) 2/442</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Total events</b> </p> <p>(x) 38/442</p> <p>(y) 54/442</p> <p>(z) 9/442</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>12 to 18 months.</p> <p>Observation period</p> <p>21 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arm A:</b> n = 196 </p> <p>MV/Rouvax</p> <p>Measles Schwarz</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Arm B:</b> n = 198 </p> <p>MMR/Trimovax</p> <p>Measles Schwarz</p> <p>Mumps Urabe AM9</p> <p>Rubella Wistar RA 27/3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No placebo arm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local symptoms</b> <br/>(a) Erythema<br/>(b) Induration<br/>(c) Pain </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Specific systemic</b> <br/>(a) Rash<br/>(b) Parotitis<br/>(c) Conjuntivitis<br/>(d) Testicular swelling<br/>(e) Arthralgia<br/>(f) Arthritis<br/>(g) Convulsion </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>N<b>on‐specific systemic</b> <br/>(a) Fever<br/>(b) Adenopathy<br/>(c) Nasopharyngeal disorders<br/>(d) Gastrointestinal disorders<br/>(e) Restlessness </p> <p><b>Restlessness:</b> </p> <p>used to describe a non‐specifically</p> <p>unwell child; it covers terms such as irritable</p> <p>miserable tearful clingy not sleeping.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine (Arm B)</b> </p> <p><b>Local</b> </p> <p>(a) 18/198<br/>(b) 1/198<br/>(c) 9/198 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Specific systemic</b><br/>(a) 87/198<br/>(b) 5/198<br/>(c) 17/198<br/>(d) 0/198<br/>(e) 0/198<br/>(f) 0/198<br/>(g) 0/198 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Non‐specific systemic</b> </p> <p>(a) 76/198<br/>(b) 2/198<br/>(c) 113/198<br/>(d) 83/198<br/>(e) 124/198 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MV vaccine (Arm A)</b> </p> <p><b>Local</b> </p> <p>(a) 16/196</p> <p>(b) 0/196</p> <p>(c) 14/196</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Specific systemic</b> </p> <p>(a) 100/196<br/>(b) 0/196<br/>(c) 21/196<br/>(d) 0/196<br/>(e) 0/196<br/>(f) 0/196<br/>(g) 0/196 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Non‐specific systemic</b> </p> <p>(a) 74/196<br/>(b) 3/196<br/>(c) 115/196<br/>(d) 74/196<br/>(e) 147/196 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>15 months to 5 years</p> <p>Observation period</p> <p>42 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm(1): n = 43:<br/>Measles (MSD) </p> <p>Arm(2): n = 41:<br/>Mumps (MSD)<br/>Jeryl Lynn </p> <p>Arm(3): n = 47:<br/>Rubella HPV‐77:CE‐5 </p> <p>Arm(4): n = 142<br/>MMR (MSD)<br/>with Rubella HPV‐77:DE‐5 </p> <p>Arm(5): n = 46:</p> <p>Rubella/Wistar RA27/3</p> <p>Arm(6): n = 141:<br/>MMRII (MSD)<br/>with Rubella Wistar RA27/3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm<br/>n = 42 </p> <p>(vaccine diluent)<br/>1 dose<br/>subcutaneously </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Local reaction</p> <p>(b) Fever<br/>101 to 102.9 °F<br/>(fever 38.3 to 39.4 °C) </p> <p>(c) Fever<br/>103 to 104.9 °F </p> <p>(fever 39.4 to 40.5 °C)</p> <p>(d) Respiratory symptoms</p> <p>(e) Rash</p> <p>(f) Lymphadenopathy</p> <p>(g) Sore eyes</p> <p>(h) Joint symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> <br/><b>Arms: (4); (6)</b><br/>(a) 7/142; 11/141<br/>(b) 31/142; 35/141<br/>(c) 11/142; 16/141<br/>(d) 97/142; 102/141<br/>(e) 24/142; 28/141<br/>(f) 6/142; 11/141<br/>(g) 24/142; 23/141<br/>(h) 1/142; 1/141 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other vaccine arms: (1); (2); (3); (5)</b> </p> <p>(a) 1/43; 6/41; 3/47; 2/46<br/>(b) 12/43; 6/41; 6/47; 11/46<br/>(c) 2/43; 3/41; 3/47; 2/46<br/>(d) 34/43; 26/41; 31/47; 31/46<br/>(e) 5/43; 1/41; 6/47; 5/46<br/>(f) 1/43; 2/41; 2/47; 2/46<br/>(g) 6/43; 8/41; 8/47; 8/46<br/>(h) 0/43; 0/41; 0/47; 0/46 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>(a) 3/42<br/>(b) 10/42<br/>(c) 0/42<br/>(d) 31/42<br/>(e) 4/42<br/>(f) 0/42<br/>(g) 4/42<br/>(h) 0/42 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pairs of twins aged</p> <p>(a) 14 to 18 months (first dose)</p> <p>(b) 6 years (second dose)</p> <p>Observation period</p> <p>21 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>Vivirac (MSD)</p> <p>2 doses</p> <p>n = 581</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm<br/>n = 581 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for quantitative synthesis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>10 months to 8 years</p> <p>Observation period<br/>21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>Measles Schwarz</p> <p>Mumps Jeryl Lynn</p> <p>Rubella Cendehill</p> <p>n = 403</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm</p> <p>n = 205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Temperature</b> <br/><b>(1) Axillary</b> </p> <p><b>(2) Rectal</b> </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) &lt; 37.0 °C</p> <p>(b) 37.0 to 37.4 °C</p> <p>(c) &lt; 37.5 °C</p> <p>(d) 37.5 to 37.9 °C</p> <p>(e) 38.0 to 38.4 °C</p> <p>(f) 38.5 to 38.9 °C</p> <p>(g) 39.0 to 39.4 °C</p> <p>(h) 39.5 to 39.9 °C</p> <p>(i) 40.0 to 40.4 C°</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Reactions</b> </p> <p>(s1) Rash<br/>(s2) Lymphadenopathy<br/>(s3) Conjunctivitis<br/>(s4) Otitis media<br/>(s5) Coryza<br/>(s6) Rhinitis<br/>(s7) Pharyngitis<br/>(s8) Cough<br/>(s9) Headache<br/>(s10) Parotitis<br/>(s11) Orchitis<br/>(s12) Arthralgia<br/>(s13) Paraesthesia </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>(1) Temperature axillary</b> </p> <p>(a) 56/244</p> <p>(b) 154/244</p> <p>(c) 210/244</p> <p>(d) 21/244</p> <p>(e) 6/244</p> <p>(f) 2/244</p> <p>(g) 3/244</p> <p>(h) 2/244</p> <p>(i) 0/244</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(2) Temperature rectal</b> </p> <p>(a) not reported</p> <p>(b) not reported</p> <p>(c) 48/142</p> <p>(d) 51/142</p> <p>(e) 30/142</p> <p>(f) 8/142</p> <p>(g) 1/142</p> <p>(h) 1/142</p> <p>(i) 3/142</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Reactions</b> </p> <p>(s1) 36/403<br/>(s2) 4/403<br/>(s3) 8/403<br/>(s4) 4/403<br/>(s5) 8/403<br/>(s6) 69/403<br/>(s7) 2/403<br/>(s8) 7/403<br/>(s9) 1/403<br/>(s10) 0/403<br/>(s11) 0/403<br/>(s12) 1/403<br/>(s13) 0/403 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p><b>(1) Axillary temperature</b> </p> <p>(a) 32/176</p> <p>(b) 132/176</p> <p>(c) 164/176</p> <p>(d) 9/176</p> <p>(e) 2/176</p> <p>(f) 1/176</p> <p>(g) 0/176</p> <p>(h) 0/176</p> <p>(i) 0/176</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(2) Rectal temperature</b> </p> <p>(a) Not reported</p> <p>(b) Not reported</p> <p>(c) 6/28</p> <p>(d) 13/28</p> <p>(e) 6/28</p> <p>(f) 1/28</p> <p>(g) 2/28</p> <p>(h) 0/28</p> <p>(i) 0/28</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Reactions</b> </p> <p>(s1) 9/205<br/>(s2) 4/205<br/>(s3) 5/205<br/>(s4) 1/205<br/>(s5) 5/205<br/>(s6) 59/205<br/>(s7) 2/205<br/>(s8) 1/205<br/>(s9) 1/205<br/>(s10) 0/205<br/>(s11) 0/205<br/>(s12) 0/205<br/>(s13) 0/205 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>; </p> <p>Cluster‐RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>13 to 15 months</p> <p>Observation period</p> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>MMRII</b> (MSD) </p> <p>n = 253</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No placebo arm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Lymphadenopathy</p> <p>(b) Nasal discharge</p> <p>(c) Rash<br/>(d) Otitis media<br/>(e) Conjunctival abnormality<br/>(f) Abnormal tonsils </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) 57/240</p> <p>(b) 15/240</p> <p>(c) 11/240</p> <p>(d) 8/240</p> <p>(e) 8/240</p> <p>(f) 2/240</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>MR: mumps‐rubella vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>RCT: randomised controlled trial </p> </div> </div> <div class="table" id="CD004407-tbl-0032"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions) ‐ non‐RCT study designs</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and<br/>design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>enrolled</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR vaccine arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other vaccine arms<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>events/n</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>12 to 14 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> n = 103 </p> <p>containing 4.1 TCID50<br/>mumps strain L‐Zagreb </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> n = 93 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Local reactions(*)</p> <p>(b) Fever &gt; 37.5 °C</p> <p>(c) Catarrhal symptoms</p> <p>(d) Swelling of cheeks</p> <p>(*)Local reactions: redness, swelling, tenderness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b> </p> <p>(a) 2/103</p> <p>(b) 2/103</p> <p>(c) 13/103</p> <p>(d) 3/103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>(a) 1/93</p> <p>(b) 1/93</p> <p>(c) 9/93</p> <p>(d) 4/93</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a> </p> <p>Retrospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>1 to 5 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> n = 1588 </p> <p>strain not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> <p>Not immunised n = 1242</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All episodes</b> <br/>(a) Arthralgia<br/>(b) Possible or probable arthritis<br/>(c) All specific joint syndromes<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>First‐ever episodes</b><br/>(a1) Arthralgia(*)<br/>(b1) Possible(§)/probable arthritis<br/>(c1) All specific joint syndromes<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>(d) Sore eyes </p> <p>(e) Convulsion</p> <p>(f) Coryza</p> <p>(g) Swollen glands</p> <p>(h) Fever</p> <p>(i) Skin rash<br/>(j) Hospital admission </p> <p>(k) Doctor consultation</p> <p>(*)Arthralgia was defined<br/>as pain experienced in the </p> <p>joint but not accompanied</p> <p>by swelling.</p> <p>(§)Possible arthritis<br/>was defined as swelling of joint<br/>reported by parent<br/>but not corroborated<br/>by a doctor. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b> </p> <p><b>All episodes</b> <br/>(a) 16/1588<br/>(b) 8/1588<br/>(c) 24/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>First‐ever episodes</b><br/>(a1) 16/1588<br/>(b1) 7/1588<br/>(c1) 23/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>(d) 154/1588 </p> <p>(e) 11/1588</p> <p>(f) 897/1588</p> <p>(g) 184/1588</p> <p>(h) 279/1588</p> <p>(i) 260/1588</p> <p>(j) 76/1588</p> <p>(k) 616/1588</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p><b>All episodes</b> <br/>(a) 3/1588<br/>(b) 1/1588<br/>(c) 4/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>First‐ever episodes</b><br/>(a1) 3/1588<br/>(b1) 1/1588<br/>(c1) 4/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>(d) 150/1588 </p> <p>(e) 5/1588</p> <p>(f) 797/1588</p> <p>(g) 135/1588</p> <p>(h) 262/1588</p> <p>(i) 216/1588</p> <p>(j) 78/1588</p> <p>(k) 554/1588</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>15 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 319 </p> <p>Trimovax Mérieux,</p> <p>measles Schwarz<br/>1000 TCID50, </p> <p>rubella RA 27/3<br/>1000 TCID50,<br/>mumps Urabe AM/9<br/>5000 TCID50 </p> <p><b>(2) MV vaccine</b> n = 16 </p> <p>Mérieux, containing<br/>measles Schwarz,<br/>1000 TCID50 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local symptoms</b> </p> <p>(a) Injury site bruise</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Systemic symptoms</b> </p> <p>(a) Rash</p> <p>(b) Fever</p> <p>(c) Cough</p> <p>(d) Off‐color</p> <p>(e) Diarrhoea</p> <p>(f) Nappy rash</p> <p>(g) Earache</p> <p>(h) Parotitis</p> <p>(i) Lymphadenopathy</p> <p>(j) Hospital admission<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(a) Asymptomatic/unrelated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p><b>Local symptoms</b> </p> <p>(a) 19/319</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Systemic symptoms</b> </p> <p>(a) 93/319</p> <p>(b) 74/319</p> <p>(c) 71/319</p> <p>(d) 55/319</p> <p>(e) 22/319</p> <p>(f) 29/319</p> <p>(g) 16/319</p> <p>(h) 5/319</p> <p>(i) 4/319</p> <p>(j) 1/319<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(a) 138/319</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) MV vaccine</b> </p> <p><b>Local symptoms</b> </p> <p>(a) 0/16</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Systemic symptoms</b> </p> <p>(a) 4/16</p> <p>(b) 3/16</p> <p>(c) 6/16</p> <p>(d) 8/16</p> <p>(e) 0/16</p> <p>(f) 0/16</p> <p>(g) 0/16</p> <p>(h) 0/16</p> <p>(i) 0/16</p> <p>(j) 0/16<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(a) 9/16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>8 months to<br/>18 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 893<br/>Kitasato Institute, Japan<br/>containing<br/>measles AIK‐C<br/>5000 TCID50,<br/>mumps Hoshino<br/>15000 TCID50, </p> <p>rubella Takahashi<br/>32000 TCID50<br/><b>(2) Measles vaccine</b> n = 147<br/>Kitasato Institute, containing<br/>measles AIK‐C 25000 TCID50<br/><b>(3) Mumps vaccine</b> n = 122<br/>Kitasato Institute, containing<br/>mumps Hoshino 10000 TCID50 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical reactions</b> </p> <p>(a) Fever (≥ 37.5 °C)<br/>(b) Fever (≥ 39.0 °C)<br/>(c) Rash<br/>(d) Rash (mild)<br/>(e) Rash (moderate)<br/>(f) Rash (severe)<br/>(g) Lymphadenopathy<br/>(h) Parotitis<br/>(i) Cough<br/>(j) Vomiting<br/>(k) Diarrhoea </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p>(a) 139/893<br/>(b) 12/893<br/>(c) 91/893<br/>(d) 81/893<br/>(e) 6/893<br/>(f) 4/893<br/>(g) 12/893<br/>(h) 8/893<br/>(i) 5/893<br/>(j) 2/893<br/>(k) 10/893 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Measles; (3) Mumps</b> </p> <p>(a) 18/147; 0/122<br/>(b) 1/147; 0/122<br/>(c) 24/147; 0/122<br/>(d) 23/147; 0/122<br/>(e) 1/147; 0/122<br/>(f) 0/147; 0/122<br/>(g) 0/147; 0/122<br/>(h) 0/147; 0/122<br/>(i) 0/147; 0/122<br/>(j) 0/147; 0/122<br/>(k) 0/147; 0/122 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a> </p> <p>Prospective<br/>Cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>1 to 2 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 6149 </p> <p>Immrawa or Pluserix,<br/>both containing<br/>measle Schwarz,<br/>rubella RA 27/3,<br/>mumps Urabe 9)<br/><b>(2) Measles vaccine</b> n = 162 </p> <p>(not described)<br/>single dose </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical reactions</b> </p> <p>(a) Symptoms (1 day only)<br/>(b) Fever (&gt; 1 day)<br/>(c) Rash (&gt; 1 day)<br/>(d) Off food (&gt; 1 day)<br/>(e) Convulsion (in 1 to 21 days)<br/>(f) Convulsion (in 1 to 6 days) </p> <p>observation period<br/>21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b><br/>(a) 2319/6149<br/>(b) 976/6149<br/>(c) 1061/6149<br/>(d) 1627/6149<br/>(e) 18/7247<br/>(f) 7/7247 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Measles vaccine</b><br/>(a) 73/162<br/>(b) 23/162<br/>(c) 18/162<br/>(d) 31/162<br/>(e) not reported<br/>(f) not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>13 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 236<br/>Mérieux, containing<br/>measles Schwarz,<br/>mumps Urabe AM/9,<br/>rubella Wistar RA 27/3<br/><b>(2) Measles vaccine</b> n = 52<br/>Schwarz strain </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical reactions</b> </p> <p>(a) Irritability<br/>(b) Rash<br/>(c) Coryza<br/>(d) Fever<br/>(e) Cough<br/>(f) Lethargy </p> <p>(g) Diarrhoea<br/>(h) Vomiting<br/>(i) Anorexia<br/>(j) Conjunctivitis<br/>(k) Lymphadenopathy<br/>(l) Parotitis<br/>(m) Local reactions<br/>(n) No symptoms </p> <p>(o) Given paracetamol</p> <p>(p) Seen by a doctor</p> <p>observation period<br/>21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b><br/>(a) 175/236<br/>(b) 109/236<br/>(c) 104/236<br/>(d) 88/236<br/>(e) 40/236<br/>(f) 65/236 </p> <p>(g) 55/236<br/>(h) 33/236<br/>(i) 48/236<br/>(j) 23/236<br/>(k) 6/236<br/>(l) 3/236<br/>(m) 14/236<br/>(n) 33/236<br/>(o)156/236<br/>(p) 42/236 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Measles vaccine</b><br/>(a) 40/52<br/>(b) 23/52<br/>(c) 27/52<br/>(d) 16/52<br/>(e) 12/52<br/>(f) 13/52 </p> <p>(g) 10/52<br/>(h) 7/52<br/>(i) 14/52<br/>(j) 5/52<br/>(k) 0/52<br/>(l) 0/52<br/>(m) 4/52<br/>(n) 4/52 </p> <p>(o) 29/52<br/>(p) 11/52 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a><br/>Costa Rica; </p> <p>prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Costa Rica</b> </p> <p>children aged<br/>7 months to<br/>7 years old </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>(MSD) containing<br/>measles Moraten<br/>1000 TCID50,<br/>mumps Jeryl Lynn<br/>5000 TCID50,<br/>rubella HPV ‐ 77<br/>1000 TCID50<br/>1 dose subcutaneous </p> <p>n = 457</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>n = 175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Conjunctivitis<br/>(b) URTI<br/>(c) Lymphadenopathy<br/>(d) Gastroenteritis<br/>(e) Fever<br/>(f) Irritability<br/>(g) Malaise and anorexia<br/>(h) Measles‐like rash<br/>(i) Arthralgia<br/>(j) Unrelated illness* </p> <p>Observation period</p> <p>28 days</p> <p>(*)Otitis, allergy,<br/>fatigue, headache,<br/>viral infection,<br/>chickenpox, flush,<br/>scarlatina,<br/>whooping cough,<br/>abdominal pain,<br/>herniorrhaphy,<br/>heat or diaper rash </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b><br/>(a) 36/457<br/>(b) 312/457<br/>(c) 31/457<br/>(d) 228/457<br/>(e) 217/457<br/>(f) 175/457<br/>(g) 217/457<br/>(h) 10/457<br/>(i) 0/457<br/>(j) 81/457 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b><br/>(a) 0/175<br/>(b) 88/175<br/>(c) 9/175<br/>(d) 77/175<br/>(e) 75/175<br/>(f) 49/175<br/>(g) 64/175<br/>(h) 9/175<br/>(i) 2/175<br/>(j) 29/175 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a> </p> <p>USA;</p> <p>prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>USA</b> </p> <p>children aged<br/>10 months to<br/>6 years old </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>(MSD) containing<br/>measles Moraten<br/>1000 TCID50,<br/>mumps Jeryl Lynn<br/>5000 TCID50,<br/>rubella HPV ‐ 77<br/>1000 TCID50<br/>1 dose subcutaneous </p> <p><b>USA</b> n = 228 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b><br/>n = 106 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Conjunctivitis<br/>(b) URTI<br/>(c) Lymphadenopathy<br/>(d) Fever &gt; 37.2 °C (orally)<br/>(e) Gastroenteritis<br/>(f) Irritability<br/>(g) Malaise and anorexia<br/>(h) Measles‐like rash<br/>(i) Unrelated illness*<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>Temperature</b> </p> <p>(a) &lt; 99 °F,<br/>&lt; 37.2 °C<br/>(b) 99 to 100.9 °F,<br/>37.2 to 38.3 °C<br/>(c) 101 to 102.9 °F,<br/>38.3 to 39.4 °C<br/>(d) 103 to 104.9 °F,<br/>39.4 to 40.5 °C<br/>(e) Not taken </p> <p>Observation period</p> <p>28 days</p> <p><b>(*)Unrelated illness:</b><br/>Otitis, allergy, exanthema,<br/>headache, measles,<br/>whooping cough, heat rash,<br/>boils </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> <br/>5 to 12 days after vaccination </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b><br/>(a) 1/228<br/>(b) 158/228<br/>(c) 3/228<br/>(d) 118/228<br/>(e) 51/228<br/>(f) 43/228<br/>(g) 14/228<br/>(h) 11/228<br/>(i) 89/228 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>Temperature</b><br/>(a) 105/228<br/>(b) 86/228<br/>(c) 26/228<br/>(d) 6/228<br/>(e) 5/228 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> <br/>(a) 0/106<br/>(b) 48/106<br/>(c) 1/106<br/>(d) 40/106<br/>(e) 6/106<br/>(f) 2/106<br/>(g) 1/106<br/>(h) 0/106<br/>(i) 13/106<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>Temperature</b><br/>(a) 57/106<br/>(b) 36/106<br/>(c) 3/106<br/>(d) 1/106<br/>(e) 9/106 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a> </p> <p>cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>(1) 16 to 24 months<br/>(2) 5 to 7 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>Tresivac, </p> <p>Serum Institute of India</p> <p>measles Edmonston‐Zagreb, 1000 CCID50<br/>mumps Leningrad‐Zagreb,<br/>5000 CCID50,<br/>rubella Wistar RA 27/3<br/>1000 CCID50,<br/>in each 0.5 mL dose </p> <p><b>Sample sizes vaccine arms</b> </p> <p>(1) n = 65,423</p> <p>(2) n = 329,211</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm</p> <p>unvaccinated</p> <p><b>Sample sizes placebo arms</b> </p> <p>(1) n = 12,253</p> <p>(2) n = 46,232</p> <p>observation period<br/>42 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local reactions</b><br/>(a) Pain<br/>(b) Redness<br/>(c) Swelling </p> <p><b>Systemic reactions</b><br/>(a) Fever<br/>(b) Rash<br/>(c) Parotitis<br/>(d) Arthralgia<br/>(e) Lymphadenopathy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine arms</b> </p> <p><b>(1) age 16 to 24 months</b> </p> <p><b>Local reactions</b><br/>(a) 1548/65,423<br/>(b) 1157/65,423<br/>(c) 688/65,423 </p> <p><b>Systemic reactions</b><br/>(a) 1640/65,423<br/>(b) 113/65,423<br/>(c) 25/65,423<br/>(d) 11/65,423<br/>(e) 6/65,423<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>(2) age 5 to 7 years</b> </p> <p><b>Local reactions</b><br/>(a) 4350/329,211<br/>(b) 3728/329,211<br/>(c) 2745/329,211 </p> <p><b>Systemic reactions</b><br/>(a) 8184/329,211<br/>(b) 391/329,211<br/>(c) 8208/329,211<br/>(d) 200/329,211<br/>(e) 430/329,211 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arms</b> </p> <p><b>(1) age 16 to 24 months</b> </p> <p><b>Local reactions</b><br/>(a) 10/12,253<br/>(b) 10/12,253<br/>(c) 12/12,253 </p> <p><b>Systemic reactions</b><br/>(a) 197/12,253<br/>(b) 20/12,253<br/>(c) 21/12,253<br/>(d) 0/12,253<br/>(e) 4/12,253<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>(2) age 5 to 7 years</b> </p> <p><b>Local reactions</b><br/>(a) 0/46,232<br/>(b) 0/46,232<br/>(c) 0/46,232 </p> <p><b>Systemic reactions</b><br/>(a) 1344/46,232<br/>(b) 11/46,232<br/>(c) 433/46,232<br/>(d) 0/46,232<br/>(e) 2/46,232 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a> </p> <p>Prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 children aged<br/>1 to 6 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 22<br/>Merck Institute for<br/>Therapeutic Research<br/><b>(2) Mumps‐rubella vaccine</b> n = 15 </p> <p>Merck Institute<br/>for Therapeutic Research<br/><b>(3) Rubella vaccine</b> n = 22<br/>Merck ‐ Meruvax HPV 77‐DE5 </p> <p><b>Temperature</b> </p> <p>(1) 7 to 11 days</p> <p>(2) 7 to 12 days</p> <p>(3) 7 to 15 days<br/>after vaccination </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Swollen glands<br/>(b) Enanthema </p> <p>(c) Conjunctivitis</p> <p>(d) Rash<br/>(e) No reactions<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b> </p> <p>(a) &lt; 37.2 °C<br/>(b) 37.2 to 38.3 °C<br/>(c) 38.3 to 39.3 °C<br/>(d) ≥ 39.4 °C </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p>(a) 12/22</p> <p>(b) 8/22</p> <p>(c) 7/22</p> <p>(d) 1/22</p> <p>(e) 10/22</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b><br/>(a) 15/22 </p> <p>(b) 4/22</p> <p>(c) 3/22</p> <p>(d) 0/22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) MR; (3) Rubella</b> </p> <p>(a) 9/15: 7/22</p> <p>(b) 8/15; 5/22</p> <p>(c) 7/15; 7/22</p> <p>(d) 3/15; 2/22</p> <p>(e) 6/15; 14/22</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> <br/>(a) 9/15; 16/22 </p> <p>(b) 3/15; 3/22</p> <p>(c) 3/15; 3/22</p> <p>(d) 0/15; 0/22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>; </p> <p>Prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 68 </p> <p>(Merck, containing<br/>measles Moraten,<br/>mumps Jeryl Lynn,<br/>rubella RA 27/3)<br/><b>(2) Rubella vaccine</b> n = 67<br/>(strain RA 27/3)<br/>1 dose subcutaneous </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Rash</p> <p>(b) Lymphadenopathy</p> <p>(c) Arthralgia<br/>(d) Myalgia </p> <p>(e) Anorexia<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b> <br/>(a) &lt; 99 °F<br/>&lt; 37.2 °C<br/>(b) 99 to 100.9 °F<br/>37.2 to 38.3 °C<br/>(c) 101 to 102.9 °F<br/>38.3 to 39.4 °C<br/>(d) 103 to 104.9 °F<br/>39.4 to 40.5 °C<br/>(e) &gt; 105 °F, ≥ 40.6 °C </p> <p><b>Temperature</b> <br/>5 to 12 days<br/>after vaccination </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p><b>Reactions</b> </p> <p>(a) 16/68<br/>(b) 8/68<br/>(c ) 3/68<br/>(d) 4/68<br/>(e) 60/68<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b><br/>(a) 39/68<br/>(b) 14/68<br/>(c ) 9/68<br/>(d) 1/68<br/>(e) 0/68 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Rubella vaccine</b> </p> <p><b>Reactions</b> </p> <p>(a) 3/67<br/>(b) 3/67<br/>(c ) 1/67<br/>(d) 3/67<br/>(e) 22/67<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b> </p> <p>(a) 37/67<br/>(b) 14/67<br/>(c ) 4/67<br/>(d) 1/67<br/>(e) 0/67 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>CCID50: cell culture infectious dose 50%<br/>MR: mumps‐rubella vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>RCT: randomised controlled trial<br/>TCID50: Median Tissue Culture Infectious Dose<br/>URTI: upper respiratory tract infection </p> </div> </div> <div class="table" id="CD004407-tbl-0033"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and<br/>design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0041" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768-73. ">bb‐Ray 2006</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases:<br/>(n = 452) children aged<br/>0 to 6 years<br/>with outcome of interest. </p> <p>Controls: (n = 1280) matching for HMO, location, age within 7 days, sex, and length of enrolment in health plan </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Encephalopathy:</b> acute generalised </p> <p>disturbance of brain function requiring</p> <p>hospitalisation and consisting of coma or</p> <p>stupor that cannot be attributed to medication</p> <p>or postictal state. Such cases must have altered</p> <p>consciousness, delirium, obtundation and/or confusion.</p> <p><b>2. Reyes syndrome:</b> clinical symptoms of </p> <p>acute encephalopathy with altered level of consciousness as well as:</p> <p> <ol id="CD004407-list-0025"> <li> <p>absence of inflammatory changes in cerebrospinal fluid as indicated by 5 white blood cells/mm<sup>3</sup> or brain histology showing cerebral oedema without perivascular or meningeal inflammation, plus </p> </li> <li> <p>evidence of hepatitis or liver failure documented by a 3‐fold or greater elevation in serum glutamic oxaloacetic transaminase, serum glutamate pyruvate transaminase or serum ammonia or fatty changes of hepatocytes on liver biopsy or autopsy, plus </p> </li> <li> <p>absence of other aetiologies for cerebral or hepatic abnormalities.</p> </li> </ol> </p> <p><b>3. Encephalitis/encephalomyelitis:</b> evidence of acute neurologic disease presenting with non‐specific signs such as fever, seizures, altered consciousness, headache, vomiting, meningismus, or anorexia. Multifocal involvement of the central nervous system and evidence of cerebrospinal fluid inflammation (7 white blood cells/mm<sup>3</sup>) were required. </p> <p>Diseases with other known aetiologies were excluded.</p> <p>For data analysis, all cases were stratified on the basis of their aetiology: known, unknown, suspected but unconfirmed (this last when a diagnosis was not confirmed by a diagnostic test). </p> <p>Hospitalisation cases for encephalopathy, Reyes syndrome, or encephalitis (primary or secondary diagnosis) in children aged 0 to 6 years, members of the health plan of 4 HMOs in the USA, and occurred between 1 January 1981 and 31 December 1995, were considered as possible cases.<br/>Hospital charts were reviewed by abstracter (not blind to vaccination status of the cases) who included in first instance encephalitis diagnoses by a neurologist with clear aetiology and excluded all cases with a condition other than encephalopathy. All other neurologic cases were reviewed by a neurologist (blind to vaccination status of the cases) and included as cases if they met case definition (see column on the right). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine exposure</b> <br/>t<b>ime interval</b><br/>relative to onset of<br/>encephalopathy </p> <p>(a) 7 to 14 days<br/>(b) 0 to 14 days<br/>(c) 0 to 30 days<br/>(d) 0 to 60 days<br/>(e) 0 to 90 days </p> <p>MMR type</p> <p>not reported.</p> <p>Vaccination status<br/>of both cases and controls<br/>was ascertained from<br/>medical records. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The findings do not support a conclusion that there is an<br/>increased risk of encephalitis or encephalopathy after MMR vaccination. Although this study is large, encephalopathy is rare and thus it is not possible to exclude completely a small increase in the risk of encephalopathy after MMR vaccination. However, if such an increased risk exists, the absolute risk is extremely small and it is much lower after vaccination than after measles. </p> <p>This corresponds roughly to an all‐cause incidence (not an attributable risk) of 1 in 200,000 after MMR, a rate that is not statistically different from background. </p> <p>Consequently, our results support the continued use of DTP and MMR vaccines.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) 1/452 versus 6/1280<br/>(b) 1/452 versus 7/1280<br/>(c) 4/452 versus 13/1280<br/>(d) 8/452 versus 33/1280<br/>(e) 15/452 versus 44/1280 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) 0.40 (0.05 to 3.46)</p> <p>(b) 0.35 (0.04 to 2.95)</p> <p>(c) 0.85 (0.27 to 2.68)</p> <p>(d) 0.64 (0.27 to 1.50)</p> <p>(e) 0.98 (0.47 to 2.01)</p> <p>adjusted estimates</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children immunised aged 1 to 7 years old. Between<br/>November 1982 and September 1986 </p> <p>n = 535,544</p> <p>n = 119</p> <p>children<br/>hospitalised<br/>for encephalitis </p> <p>(MMR vaccine was administered before the disease), and</p> <p>only 97 between 0 and 24 months after MMR vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Encephalitis:</b> acute or subacute onset of neurologic symptoms. Presence of neurologic symptoms or findings (clinical or laboratory, e.g. microbiological, electroencephalographic, computed tomographic) indicative of involvement of the brain parenchyma, such as coma, seizures, focal neurologic findings, or mental function impairment. Absence of evidence of other diagnoses, including non‐inflammatory conditions, and no microbiological or other laboratory findings suggestive of a non‐viral infection. When pleocytosis in CSF is present, the term encephalitis is used, implying an inflammatory response within the brain. The presence of normal CSF findings does not preclude the diagnosis if the other criteria are satisfied. </p> <p><b>Encephalopathy:</b> clinically resembles encephalitis but no inflammatory response is evident. Chronic encephalopathy: persistence of acute findings usually over several months. </p> <p>The National Hospital Discharge Register was consulted by using the following ICD‐8 codes: 065.99, 066.01, 066.02, 072.01, 292.20, 292.38, 292.39, 323.00, 323.01, 323.08, 323.09, 781.70, 999, 999.10. </p> <p>Medical records of hospitalised participants were reviewed (in order to evaluate possible other causes of the event) and their correspondence to diagnostic criteria (see column on the right) examined. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b> </p> <p>(a) 0 to 3 months after vaccination</p> <p><b>Control period:</b> </p> <p>(b) 4 to 24 months</p> <p><b>Observation period:</b> </p> <p>(c) 0 to 24 months</p> <p><b>MMR II vaccine</b> (Merck &amp; Co, West Point, PA) </p> <p>measles: Enders‐Edmonston</p> <p>mumps: Jeryl Lynn</p> <p>rubella: Wistar RA 27/3</p> <p>Vaccination data were assessed through vaccination register.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant excess of hospitalisation within 3 months of vaccination (P = 0.28)</p> <p>Incidence of encephalitis of undefined cause amongst 1‐ to 7‐year‐old children decreased from<br/>19.9 per 100,000 in 1983 to </p> <p>13.0 per 100,000 in 1985.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 9 cases (3 months)</p> <p>(b) 88 cases (21 months)</p> <p>(c) 97 cases (24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)*</b> </p> <p>0.72 (0.36 to 1.42)</p> <p>(*)rate ratio amongst risk period (b) and control period (a)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 35 months (immunised with MMR; NK) with outcome of interest diagnosed between October 1998 and September 2001 (n = 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset of illness: day of hospital admission Fever: temperature of 37.5 °C; the questionnaire asked whether there was a fever and also for the maximum temperature recorded at any site by any method<br/>Encephalopathy: a depressed or altered level of consciousness<br/>Case definition of serious neurologic disease: any child 2 to 35 months old with a severe illness with fever and convulsions (see <a href="#CD004407-tbl-0035">Table 14</a>)<br/>and/or encephalitis was included </p> <p><b>Encephalitis:</b> </p> <p> <ul id="CD004407-list-0026"> <li> <p>encephalopathy for at least 24 hours and at least 2 of the following: fever, convulsions, focal neurologic findings (≥ 24 h), pleocytosis (&gt; 5 leukocytes per μL CSF), characteristic abnormal results of neuroimaging (computerised tomography or MRI), herpes simplex virus nucleic acid (or nucleic acid of any other virus proven to cause encephalitis) in CSF; or </p> </li> <li> <p>postmortem histologic evidence of encephalitis</p> </li> </ul> </p> <p><b>Exclude:</b> </p> <p> <ul id="CD004407-list-0027"> <li> <p>viral (aseptic) meningitis without encephalopathy</p> </li> <li> <p>the following confirmed causes were excluded: hypoxic/ischaemic; vascular; toxic; metabolic, neoplastic, traumatic and pyogenic infections </p> </li> <li> <p>uncomplicated convulsions or a series of convulsions lasting &lt; 30 min</p> </li> <li> <p>immunocompromised children</p> </li> </ul> </p> <p>Cases of suspected encephalitis and/or severe illness with fever and convulsion occurring in children aged between age 2 and 35 months through Britain and Ireland were identified by consultant paediatricians taking part in a survey (October 1998 to September 2001) and notified to the British Paediatric Surveillance Unit. Details about neurologic illnesses were collected by reporting paediatricians by means of a detailed questionnaire. For diagnostic purposes, saliva, blood, and cerebrospinal samples were also collected. Questionnaires were reviewed by study investigators in order to assess whether reported cases corresponded to an analytical case definition taking into account severe illness with fever and convulsion and encephalitis (see column on the right). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b><br/>15 to 35 days after immunisation, because this is the incubation period for postinfectious encephalitis induced by wild‐type measles and for aseptic meningitis induced by the Urabe vaccine strain mumps </p> <p><b>MMR vaccine type</b>, not reported. </p> <p>Immunisation history of cases was obtained by the Immunisation Department of the Health Protection Agency (other than MMR vaccine, the study also considers DTP, Hib, and MenC vaccines). Only cases with known vaccination history were included in the analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regarding MMR vaccine, there was no evidence of a raised relative incidence of serious neurologic disease 15 to 35 days after immunisation. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within 15 to 35 days</p> <p>with concurrent primary HHV‐6 or HHV‐7 infection</p> <p>(a) all (5 cases)</p> <p>(b) no (4 cases)</p> <p>(c) yes (1 case)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a) 1.34 (0.52 to 3.47)</p> <p>(b) 1.52 (0.52 to 4.41)</p> <p>(c) 0.86 (0.10 to 7.23)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>incidence: cases/PT<br/>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>DTP: diphtheria, tetanus, pertussis vaccine<br/>Hib: Haemophilus influenzae b vaccine<br/>HHV: human herpes virus<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>MenC: meningococcus C vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MRI: magnetic resonance imaging<br/>PT: person‐time<br/>OR: odds ratio<br/>RR: risk ratio (relative risk)<br/>rr = rate ratio (relative incidence; incidence rate ratio) </p> </div> </div> <div class="table" id="CD004407-tbl-0034"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Safety: aseptic meningitis</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a><br/>Matched </p> <p>case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases n = 59<br/>Controls n = 118<br/>(age 12 to 23 months at the time of discharge diagnosis, between 1984 and 1993).<br/>For each ascertained case, 2 controls matched for age, sex, HMO, and HMO membership status were selected. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Potential cases of aseptic meningitis were identified by computerised hospitalisation at 4 HMOs that participated in the Vaccine Safety Datalink project. They were children aged 12 to 23 months with ICD‐9 discharge diagnoses 045.2, 047.*, 048, 072.1, 321.2 or 322.* between 1984 and 1993. Medical records of potential cases were reviewed and included as cases when corresponding to validation criteria (see column on the right). </p> <p>No evidence of prior underlying meningitis or underlying disease caused by toxoplasmosis, syphilis, cytomegalovirus, neonatal herpes simplex, or HIV. (The same exclusion criteria were used for controls.) In addition, bacterial, mycobacterial, and fungal cultures of the cerebrospinal fluid must have been negative, and the patient must have had a cerebrospinal fluid white blood cell count of &gt;= 10 cells/mm<sup>3</sup>. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine: Jeryl Lynn</b> mumps strain. </p> <p><b>Any vaccines</b> includes:<br/><b>Hib:</b> Haemophilus influenzae type b, <b>DPT:</b> diphtheria‐pertussis‐tetanus toxoids, <b>OPV:</b> oral polio vaccine, <b>HDPT:</b> Haemophilus influenzae type b diphtheria pertussis tetanus toxoid vaccine, <b>HepB</b>: hepatitis B vaccine </p> <p><b>Vaccine and time window</b> </p> <p>(a) MMR 0 to 14 days</p> <p>(b) MMR 0 to 30 days</p> <p>(c) MMR 8 to 14 days</p> <p>(d) Any vaccine 0 to 14 days</p> <p>(e) Any vaccine 0 to 30 days</p> <p>(f) Any vaccine 8 to 14 days</p> <p>Vaccination status of both cases and controls was derived from medical record review.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this analysis of hospitalisation caused by AM, there was no increased risk of AM after MMR vaccine containing <b>Jeryl Lynn</b> strain mumps. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) 1/59 versus 4/118</p> <p>(b) 3/59 versus 7/118</p> <p>(c) 1/59 versus 2/118</p> <p>(d) 2/59 versus 8/118</p> <p>(e) 7/59 versus 18/118</p> <p>(f) 2/59 versus 4/118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.50 (0.1 to 4.5)</p> <p>(b) 0.84 (0.2 to 3.5)</p> <p>(c) 1.00 (0.1 to 9.2)</p> <p>(d) 0.44 (0.1 to 2.1)</p> <p>(e) 0.75 (0.3 to 1.9)</p> <p>(f) 1.00 (0.2 to 5.6)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a> </p> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1)</b> n = 39. Children with aseptic meningitis aged 13 to 29 months of both sexes, vaccination date confirmed by vaccination record. </p> <p><b>(2)</b> n = 19. Children with aseptic meningitis aged 12 to 15 months of both sexes, vaccination date confirmed by parents only. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Generically defined as syndrome characterised by acute onset of meningeal symptoms, fever, and cerebrospinal fluid pleocytosis, with bacteriologically sterile cultures. Cases of aseptic meningitis were identified from insurance claims and hospitalisation data during 1998 in Korea. Authors considered cases corresponding to diagnosis criteria occurred in children aged 8 to 36 months who had received MMR vaccine within 1 year before disease onset and for whom vaccination records were available. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b><br/>Strain type not stated (the study was conducted in the same setting of the study <a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a>; both studies were performed in Korea, where <b>MMR vaccine</b> containing <b>Urabe or Hoshino</b> mumps strain was routinely administrated in public health, and <b>MMR vaccines</b> containing the <b>Jeryl Lynn or Rubini</b> in the private sector). </p> <p><b>Risk period (42 days)</b> </p> <p><b>(a)</b> from disease onset date to 42 days after </p> <p><b>Control period (323 days)</b> </p> <p><b>(b)</b> from 42 days up to 365 days after disease onset </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study results showed that risk increased in the third week after vaccination and was elevated until the sixth week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> versus<b>(b)</b> </p> <p><b>(1)</b> 11 versus 28 cases </p> <p><b>(2)</b> 5 versus 14 cases </p> <p><b>Sensitivity analysis</b> </p> <p>n = 58, 16 versus 42 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)(*)</b> </p> <p><b>(1)</b> 3.02 (1.50 to 6.08) </p> <p><b>Sensitivity analysis</b> </p> <p>2.93 (1.65 to 5.22)</p> <p>(*)Mantel‐Haenszel<br/>estimator </p> <p>Under the null hypothesis, this estimator is directly analogous to the Mantel‐Haenszel OR for matched‐pair case‐control study. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a> </p> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 children, mean age 19.1 months (standard deviation = 5.4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Aseptic meningitis is a syndrome characterised by acute onset of meningeal symptoms, fever, and cerebrospinal fluid pleocytosis with bacteriologically sterile cultures. </p> <p>The following criteria were used to define eligible cases of aseptic meningitis for the study: </p> <p>1) Korean insurance claim cases based on the ICD‐10 (codes A87.9, G03.0, G03.9, and G02.0); and </p> <p>2) cerebrospinal fluid pleocytosis (leukocytes ≥ 5) with bacteriologically sterile cultures (if measured); or </p> <p>3) neck stiffness and/or convulsions, or 2 other symptoms (headache or vomiting) in addition to a fever (≥ 38.0 °C, if measured). Patients’ charts were reviewed and their symptoms, laboratory tests, and last diagnoses on the discharge record checked. If patients were diagnosed with aseptic meningitis and were hospitalised in a general hospital, in accordance with these criteria, those who had headache, fever, and vomiting could be included as participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>(1)</b> n = 29 MMR with </p> <p><b>Urabe or Hoshino</b> mumps strain </p> <p><b>(2)</b> n = 38 MMR with </p> <p><b>Jeryl Lynn or Rubini</b> mumps strain </p> <p><b>Risk period (42 days)</b> </p> <p><b>(a)</b> from disease onset date </p> <p>to 42 days after</p> <p><b>Control period (323 days)</b> </p> <p><b>(b)</b> from 42 days up </p> <p>to 365 days after disease onset</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study results showed that no significant risk was associated with the Jeryl Lynn or Rubini strain of the vaccine. For the Urabe or Hoshino strain, the risk increased in the third week after vaccination and was elevated until the sixth week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> versus<b>(b)</b> </p> <p><b>(1)</b> 13 versus 16 cases </p> <p><b>(2)</b> 3 versus 35 cases </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)(*)</b> </p> <p><b>(1)</b> 5.5 (2.6 to 11.8) </p> <p><b>(2)</b> 0.6 (0.18 to 1.97) </p> <p>(*)Mantel‐Haenszel<br/>estimator </p> <p>Under the null hypothesis, this estimator is directly analogous to the Mantel‐Haenszel OR for matched‐pair case‐control study. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children immunised<br/>aged 1 to 7 years old.<br/>Between November 1982<br/>and September 1986 </p> <p>n = 535,544</p> <p>n = 120</p> <p>children<br/>hospitalised<br/>for encephalitis </p> <p>(MMR vaccine was administered before the disease),</p> <p>and only 64 between 0 and 24 months after MMR vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p><b>Inflammation of the meninges.</b> Usually a self‐limiting disease of known or suspected viral cause consisting of fever, headache, signs of meningeal irritation, without evidence of brain parenchymal involvement and a lymphocytic and mononuclear pleocytosis of CSF. The term 'meningoencephalitis' does not differentiate cases with prominent involvement of the brain parenchyma from those with meningeal involvement only. </p> <p>Hospitalisation records (ICD‐8 codes: 045.99, 320.88, 320.99) and review of patients' medical records to assess correspondence to case definition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b> </p> <p>(a) 0 to 3 months after vaccination</p> <p><b>Control period:</b> </p> <p>(b) 4 to 24 months after vaccination</p> <p><b>Observation period:</b> </p> <p>(c) 0 to 24 months after vaccination</p> <p><b>MMR II vaccine</b> (Merck &amp; Co, West Point, PA) </p> <p>Measles: <b>Enders‐Edmonston</b> </p> <p>Mumps: <b>Jeryl Lynn</b> </p> <p>Rubella: <b>Wistar RA 27/3</b> </p> <p>Vaccination data were assessed through vaccination register.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant excess of hospitalisation within 3 months of vaccination (P = 0.57)</p> <p>The incidence of meningitis of undefined causes in 1‐ to 7‐year‐old children decreased from </p> <p>10.17 per 100,000 in 1983 to</p> <p>7.71 per 100,000 in 1985.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 10 cases (3 months)</p> <p>(b) 54 cases (21 months)</p> <p>(c) 64 cases (24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>1.30 (0.66 to 2.55)</p> <p>(*)rate ratio amongst<br/>risk (a) and control (b) period </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a> </p> <p>Self‐controlled case series</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 11 years (from census)</p> <p>n = 452,344</p> <p>n = 129 children aged 1 to 11 years old admitted to the referral hospital with a diagnosis of aseptic meningitis between 10th and 43rd epidemiologic surveillance weeks of 1997 (March to October). </p> <p>n = 87 fulfilled inclusion criteria;</p> <p>n = 29 cases of AM occurred prior to the mass immunisation campaign;</p> <p>n = 58 after the immunisation campaign. Of the 58 children, n = 50 were know to have been vaccinated. (The date of vaccination was available for 43 of these children.) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Data about meningitis were obtained from the state Epidemiology Surveillance System and from the neurologic service of the state referral hospital for infectious disease (Hospital Couto Maia), by reviewing hospital records of children admitted between the 10th and 43rd epidemiological surveillance weeks. Demographic, clinical, and laboratory data were collected on a standardised form. </p> <p><b>Inclusion/exclusion criteria</b> </p> <p>1) Residence in the city of Salvador</p> <p>2) Age 1 to 11 years</p> <p>3) Cerebrospinal fluid with a cell count of &gt; 10 and &lt; 1200 cells per mL (higher counts could be attributed to unconfirmed bacterial meningitis) </p> <p>4) Predominance of lymphocytes in the cerebrospinal fluid of &gt; 50% of the total number of cells </p> <p>5) Exclusion of any bacteriologic or fungal confirmation through the use of Gram stain, latex, immunoelectrophoresis, stain for <i>Cryptococcus neoformans,</i> Ziehl‐Neelsen stain, or culture for bacteria and <i>Mycobacterium tuberculosis</i> </p> <p>6) Exclusion of all cases with a history of prior meningitis or any neurologic disorder and any cases with sepsis, pneumonia, otitis, or any other disease that might be associated with an increased cell count in the cerebrospinal fluid </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Self‐controlled case series</i> </b> </p> <p><b>Exposure risk period:</b> </p> <p>(a) 3 to 5 weeks after vaccination</p> <p>(i.e. 15 to 35 days)</p> <p><b>Control period:</b> </p> <p>(b) 1 to 2 weeks and 6 to 10 weeks after vaccination</p> <p><b>Observation period:</b> </p> <p>(c) 1 to 10 weeks after vaccination</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b><i>Case‐only ecological method</i> </b> </p> <p><b>(a) Reference period (pre‐vaccination):</b> </p> <p>10 to 32 epidemiologic surveillance weeks;<br/>time interval = 23 weeks </p> <p><b>(b) Low‐risk period:</b> </p> <p>34 to 35 epidemiologic surveillance weeks;</p> <p>time interval = 2 weeks</p> <p><b>(c) High‐risk period:</b> </p> <p>36 to 39 epidemiologic surveillance weeks (3 to 6 weeks after vaccination day)<br/>time interval = 4 weeks </p> <p><b>(d) Low‐risk period:</b> </p> <p>40 to 43 epidemiologic surveillance weeks;</p> <p>time interval = 3 weeks</p> <p><b>MMR vaccine</b> </p> <p>Pluserix vaccine (SmithKline Beecham, UK) containing mumps <b>Urabe</b> strain </p> <p><b>Vaccination began</b> on 16 August 1997 (National Immunisation Day, surveillance week 33), 45% coverage of the target population was achieved on that day, high coverage (exact data not reported, but very close to 100%) during the 2 following weeks. </p> <p>Vaccination history was obtained by vaccination cards or visits/phone call.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An elevated risk of aseptic meningitis was observed 3 weeks after Brazil's national vaccination day compared with the risk in the pre‐vaccination period. This result was confirmed by a case series analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 35 cases</p> <p>(b) 3 and 5 cases</p> <p>(c) 43 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Cases/PT (weeks)</b> </p> <p>(a) 29/10,403,912</p> <p>(b) 3/904,688</p> <p>(c) 46/1,809,376</p> <p>(d) 9/1,809,376</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Self‐controlled case series</i> </b> </p> <p><b>rr (95% CI)(*)</b> </p> <p>30.4 (11.5 to 80.8)</p> <p>(*)Poisson regression</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b><i>Case‐only ecological method</i> </b> </p> <p><b>rr (95% CI)(**)</b> </p> <p>(a) reference weeks</p> <p>(b) 1.19 (0.36 to 3.91)<br/>(c) 9.12 (5.73 to 14.52)<br/>(d) 1.78 (0.84 to 3.77) </p> <p>(**)rate ratio amongst<br/>risk periods: (b), (c), (d) </p> <p>and control period (a).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 11 years</p> <p>State of<br/>Mato Grosso do Sul </p> <p><b>(MS)</b> n = 580,587 </p> <p>State of Mato Grosso</p> <p><b>(MT)</b> n = 473,718 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Data on cases of meningitis were obtained from the routine surveillance system in both states. Notification of meningitis is statutory in Brazil, with a standardised form completed for each case. The attending physician or nurse completes the notification form in the health facility where the diagnosis is made. The notification form includes data on patient’s identification, clinical diagnosis, evolution, treatment, results of vaccination status, and laboratory investigations (the last 2 items not always reported). </p> <p>Reported cases of meningitis were classified into aseptic or not based on information from the notification forms, using 2 different criteria, which are independent but non‐exclusive. In both criteria, AM included only cases with absence of a positive bacteriological isolate in culture or stain of CSF and did not have a positive blood culture or mention of other non‐viral aetiology. </p> <p><b>Criterion 1</b>: If the diagnosis in the form was of viral aetiology or unknown aetiology, cases were classified as AM. They were classified as not having AM if they had a suspected or confirmed diagnosis of meningitis by a known (non‐viral) agent through any laboratory or clinical finding. </p> <p><b>Criterion 2 (laboratory)</b>: Cases were considered AM if they had a CSF with the following findings: cell count greater than 10 and less than 1500 and presence of lymphocytes greater that 49%. (Applied for the cases in which laboratory data were present in the notification forms. In their absence, cases were excluded.) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(MS) Unexposed period</b> </p> <p>(a) reference weeks 1 to 31</p> <p><b>(MS) Exposed period</b> </p> <p>(b) low‐risk weeks 32 to 34</p> <p>(c) high‐risk weeks 35 to 37</p> <p>(d) low‐risk weeks 38 to 42</p> <p>(e) all weeks 32 to 42</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) Unexposed period</b> </p> <p>(a) reference weeks 1 to 37</p> <p><b>(MT) Exposed period</b> </p> <p>(b) low‐risk weeks 38 to 40</p> <p>(c) high‐risk weeks 41 to 43</p> <p>(d) low‐risk weeks 44 to 48</p> <p>(e) all weeks 38 to 48</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR vaccine:</b> Serum Institute of India, Ltd, Pune. Contained <b>Leningrad‐Zagreb</b> mumps strain. 3 different lots were used in each state (MS and MT). </p> <p><b>Vaccination began</b> in mid‐August 1998 (week 32) in MS and late September in MT (week 38), and lasted for about 1 month, even if the most part of the doses had been administered during the first 2 campaign weeks. Vaccination was reported for 69.4% and 93.5% of the target population in MT and in MS, respectively. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study shows an increase in number of notified cases of AM in the 2 states studied, 3 to 4 weeks after the MIC using Leningrad‐Zagreb mumps strain MMR vaccine (3 to 4 weeks after the MIC corresponding to incubation period for wild mumps infection, and the increase was restricted to the age group targeted by the campaign and to the aseptic form of meningitis). </p> <p>The use of the vaccine on a large scale over a short period of time made it possible to identify an increase in risk which may be present, but more difficult to measure when vaccination is spread over longer periods. </p> <p>The risk estimates varied depending on the diagnostic criteria used and the state.</p> <p>There was also an increase in the incidence of notified mumps after the campaign in the state where data were available. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>cases/PT (weeks)</b> </p> <p><b>(MS) AM criterion 1</b> </p> <p>(a) 22/14,685,258</p> <p>(b) 7/1,421,154</p> <p>(c) 35/1,421,154</p> <p>(d) 6/2,368,590</p> <p>(e) 48/5,210,898</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 1</b> </p> <p>(a) 71/21,481,719</p> <p>(b) 7/1,741,761</p> <p>(c) 71/1,741,761</p> <p>(d) 25/2,902,935</p> <p>(e) 103/6,386,457</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MS) AM criterion 2</b> </p> <p>(a) 8/14,685,258</p> <p>(b) 4/1,421,154</p> <p>(c) 24/1,421,154</p> <p>(d) 2/2,368,590</p> <p>(e) 30/ 5,210,898</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 2</b> </p> <p>(a) 36/21,481,719</p> <p>(b) 3/1,741,761</p> <p>(c) 54/1,741,761</p> <p>(d) 15/2,902,935</p> <p>(e) 72/6,386,457</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)*</b> </p> <p><b>(MS) AM criterion 1</b> </p> <p>(a) reference weeks</p> <p>(b) 3.3 (1.41 to 7.7)</p> <p>(c) 16.4 (9.65 to 28.0)</p> <p>(d) 1.7 (0.69 to 4.2)</p> <p>(e) 6.2 (3.71 to 10.2)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 1</b> </p> <p>(a) reference weeks</p> <p>(b) 1.2 (0.56 to 2.6)</p> <p>(c) 12.3 (8.88 to 17.1)</p> <p>(d) 2.6 (1.65 to 4.1)</p> <p>(e) 4.9 (3.61 to 6.6)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MS) AM criterion 2</b> </p> <p>(a) reference weeks</p> <p>(b) 5.2 (1.56 to 17.2)</p> <p>(c) 31.0 (13.93 to 69.0)</p> <p>(d) 1.6 (0.33 to 7.3)</p> <p>(e) 10.6 (4.84 to 23.1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 2</b> </p> <p>(a) reference weeks</p> <p>(b) 1.0 (0.32 to 3.3)</p> <p>(c) 18.5 (12.13 to 28.2)</p> <p>(d) 3.1 (1.69 to 5.6)</p> <p>(e) 6.7 (4.51 to 10.0)</p> <p>(*)rate ratio amongst<br/>exposed (risk) periods: (b), (c), (d), (e) </p> <p>and unexposed period (a)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 11 years</p> <p>target population</p> <p>n = 110,629</p> <p>(Rio Grande do Sul)</p> <p>dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> <br/><b>Any‐cause AM</b> was defined as: occurrence of clinically diagnosed meningitis in a person with a CSF pleocytosis (between 5 and 1500 leucocytes/mL) and a negative Gram stain. Viral isolation is not routinely performed in Rio Grande do Sul. </p> <p><b>Mumps‐associated AM</b> was defined as: that occurring in conjunction with or following clinically diagnosed mumps. </p> <p><b>Vaccine‐associated AM</b> was defined as: aseptic meningitis with a pleocytosis of 10 to 1500 leukocytes/mL and occurring within 15 to 35 days after vaccine receipt. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> produced by Serum Institute of India, Lot: 180‐X: measles: <b>Edmonston‐Zagreb</b> ; mumps: <b>Leningrad‐Zagreb</b> ; rubella: <b>Wistar RA 27/3</b>. </p> <p>The campaign was conducted between<br/>8 September and 28 November 1997; </p> <p>weeks 37 to 48.</p> <p><b>(a) unexposed period in 1995/1996</b> </p> <p>39 to 47 weeks</p> <p><b>(b) unexposed period in 1997</b> </p> <p>1 to 38 weeks</p> <p><b>(c) exposed period in 1997:</b> </p> <p><b>High risk:</b> 39 to 47 weeks </p> <p><b>(d) exposed period in 1997:</b> </p> <p><b>Low risk:</b> 48 to 53 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A total of 105,098 doses of Leningrad‐Zagreb were administered to children<br/>aged 1 to 11 years, for an overall coverage of 95%. </p> <p>The risk of vaccine‐associated<br/>aseptic meningitis (31 cases) was 2.9 cases per 10,000 doses of Leningrad‐Zagreb administered (equivalent to 1 case per 3390 doses administered).<br/>Within the 1‐ to 11‐years age group, the risk did not differ significantly by<br/>age group. </p> <p>These findings suggest that Leningrad‐Zagreb is more reactogenic than Urabe and Jeryl‐Lynn strains. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> 2.4 cases per 100,000 person weeks; 4.5 cases in average </p> <p><b>(b)</b> 10 cases (any cause) </p> <p><b>(c)</b> 28.7 per 100,000 person weeks<br/>31 cases vaccine associated (55 any cause, 41 vaccinated) </p> <p><b>(d)</b> 4 cases (any cause) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(c) 12.2 (6.0 to 24.7)(*)</p> <p>(*)rate ratio (c) and (a)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 24 months discharged from hospital in 5 districts in England (Ashford, Leicester, Nottingham, Preston, and Chorley &amp; Ribble) for varying periods between October 1988 and February 1993. Readmissions within 72 h with the same diagnosis were counted as 1 episode. </p> <p>n = 952 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Children discharged from hospital with a diagnosis of: <b>meningitis</b> categorised as mumps, aseptic, or viral (ICD 072.1, 047., 321.) Children aged between 366 and 730 days. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p><b>Urabe</b> mumps strain </p> <p><b>Jeryl Lynn</b> mumps strain </p> <p>Rubella strain not specified.</p> <p><b>Exposure risk period:</b> </p> <p>(a1) 6 to 11 days (1 to 2 weeks after vaccination)</p> <p>(a2) 15 to 35 days (3 to 5 weeks after vaccination) (Urabe strain)</p> <p><b>Control period:</b> </p> <p>(b) for each vaccine was defined as the time not included in a risk period.</p> <p>The analyses were adjusted for age and were grouped in 6 equal intervals of about 2 months. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study shows that there is a true risk of a neurological event attributable to the Urabe strain. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urabe strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 5 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a2) 38.1 (4.3 to 336)(*)</p> <p>(*)Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23 months with discharge diagnosis of febrile convulsion or aseptic meningitis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic menigitis:</b> </p> <p>Viral meningitis (A87), mumps (B26), meningitis in other infections classified elsewhere (G02), and meningitis due to other and unspecified causes (G03) were identified for the period 1 May 1998 to 30 June 2001, and case notes were reviewed by a paediatrician. </p> <p>In addition, computerised hospital records for children aged 12 to 23 months with an ICD‐9 discharge diagnosis of meningitis categorised as mumps, aseptic, or viral (072.1, 047, 321) were identified for the period 1 January 1991 to 30 September 1992, prior to the withdrawal of Urabe‐containing MMR vaccines, and were linked with MMR vaccination histories.<br/>Cases of laboratory‐confirmed mumps meningitis were also ascertained from reports made to the Centre for Infections from laboratories in England and Wales for the period of October 1992 to the end of June 2004. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>(1) MMR with <b>Urabe</b> mumps strain up to September 1992 </p> <p>(2) <b>MMRII</b> (Sanofi Pasteur) <b>Edmonston‐Enders</b> measles strain, <b>Jeryl Lynn</b> mumps strain, between September 1992 and May 1998 </p> <p>(3) <b>MMR Priorix</b> (GlaxoSmithKline) <b>Schwarz</b> measles strain <b>RIT4385</b> (Jeryl Lynn) from May 1998 </p> <p><b>Exposure risk period:</b> </p> <p>(a) 15 to 35 days after vaccination</p> <p>(from May 1998 to June 2001) (Urabe MMR)</p> <p>(b) 15 to 35 days after vaccination</p> <p>(from January 1991 to September 1992) (Jeryl Lynn MMR)</p> <p><b>MMR vaccination</b> histories were independently obtained through linkage with computerised immunisation records in the 2 Thames regions, using either the National Health Service number or sex, date of birth, and post code, a highly specific linking algorithm. Information on batch number was sought for any confirmed aseptic meningitis cases with onset 15 to 35 days after MMR vaccination. The formatting of batch numbers differs substantially between manufacturers in length and alphanumeric coding and is a precise means of distinguishing between vaccines from different manufacturers. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before after between 2 risk periods, re‐analysis of the data presented in <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>This study confirms that the risk of aseptic meningitis with Priorix vaccine, if it exists at all, is significantly lower than with Urabe‐containing mumps vaccine. The study allowed the exclusion of risks as rare as 1 in 437,000 for laboratory‐confirmed mumps meningitis with non‐Urabe‐containing<br/>MMR vaccines. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison between 2 risk periods</p> <p>Aseptic meningitis</p> <p>(a) 4 cases</p> <p>(b) 0 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Laboratory‐confirmed</p> <p>mumps‐positive cerebrospinal fluid</p> <p>(a) 16 cases</p> <p>(b) 0 cases</p> <p>Data from the paper</p> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr(95%CI)</b> </p> <p>25.9 (2.8 to 233)(*)</p> <p>(*) rate ratio (a) versus (b)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For this study, WHO selected 26 sentinel sites (49 hospitals) distributed in 16 countries of the 6 WHO regions. </p> <p>The study population included children ages 9 to 23 months admitted to a network‐participating hospital during January 2010 to March 2014, with a discharge diagnosis of either AM or immune thrombocytopenic purpura. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis probable cases</b> </p> <p>ICD‐9 codes in first discharge diagnosis position:</p> <p>047 (047.0 to 047.9) Meningitis due to enterovirus</p> <p>049.0 to 049.1 Other non‐arthropod‐borne viral meningitis</p> <p>072.1 Mumps meningitis</p> <p>321.2 Meningitis due to viruses not elsewhere classified</p> <p>322.0, 322.1, 322.9 Meningitis</p> <p>of unspecified cause</p> <p>ICD‐10 codes in first discharge diagnosis position:</p> <p>A87.0 Meningitis due to enterovirus</p> <p>A87.1 Adenoviral meningitis</p> <p>A87.2 Lymphocytic choriomeningitis</p> <p>A87.8 Other viral meningitis</p> <p>A87.9 Viral meningitis, unspecified</p> <p>B26.1 Mumps meningitis</p> <p>G02.0 Meningitis due to viruses not elsewhere classified</p> <p>G03.0, G03.8, G03.9 Meningitis of unspecified cause</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> <b>(measles strain) (mumps strain)</b> </p> <p><b>Priorix, GSK</b> (Schwarz) (RIT 4385a)<br/><b>Priorix‐Tetra, GSK</b> (Schwarz) (RIT 4385a)<br/><b>MMR Shanghai Institute</b> (Shanghai‐191) (S79)<br/><b>Measles, Lanzhou Institute</b> (Shanghai‐191) (–)<br/><b>Measles‐Rubella, Beijing Tiantan</b> (Shanghai‐191) (–)<br/><b>M‐M‐R‐II, MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>MMR, Razi Vaccine and Serum Research</b> (AIK‐C) (Hoshino)<br/><b>M‐M‐RVAXPRO, Sanofi Pasteur‐MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>Trimovax, Sanofi Pasteur</b> </p> <p>(Schwarz) (Urabe AM9)<br/><b>Measles, Serum Institute of India Pvt.</b> (Edmonston‐Zagreb) (–)<br/><b>Measles‐Rubella, Serum Institute of India Pvt.</b> (Edmonston‐Zagreb) (–)<br/><b>MMR, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Tresivac, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Rouvax, Sanofi Pasteur</b> (Schwarz) (–) </p> <p><b>Risk period</b> </p> <p>8 to 35 days</p> <p><b>Washout periods</b> </p> <p>1 to 7 days</p> <p>36 to 42 days</p> <p><b>Control period</b> </p> <p>43 to 84 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The elevated risk estimates found for the Leningrad‐Zagreb mumps strain are consistent with previous studies (<a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a>; <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>). Regarding Jeryl‐Lynn‐derived strain vaccines, although the study did not have enough power to confirm the absence of risk for these strains, the finding of zero cases in the risk window was consistent with the hypothesis of no association (<a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>; <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 16 countries n = 84 confirmed aseptic menigitis cases</p> <p><b>(Risk</b> versus<b>control) period</b> </p> <p>(a) Overall risk of AM following mumps‐containing vaccines (35 versus 5)</p> <p>(b) Overall risk of AM following mumps‐containing vaccines (excluding cases from Iran) (22 versus 3) </p> <p>(c) Leningrad‐Zagreb strain (7 versus 1)</p> <p>(d) Vaccines products used Hoshino/Leningrad‐Zagreb/Urabe AM9 (27 versus 2)</p> <p>(e) Vaccines products used Hoshino/Leningrad‐Zagreb/Urabe AM9 (excluded cases from Iran) (14 versus 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) adjusted</b> </p> <p>(a) 10.8 (4.0 to 29.2)</p> <p>(b) 12.4 (3.1 to 49.1)</p> <p>(c) 6.4 (1.3 to 87.4)</p> <p><b>rr (95% CI) unadjusted</b> </p> <p>(d) 20.3 (48 to 85.2)</p> <p>(e) not estimable</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AM: aseptic meningitis<br/>CI: confidence interval<br/>CSO: cerebro‐spinal fluid<br/>HMO: health maintenance organisation<br/>ICD‐10: International Classification of Diseases<br/>incidence: cases/PT<br/>MIC: mass immunisation campaigns<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>n: number of participants<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>WHO: World Health Organization </p> </div> </div> <div class="table" id="CD004407-tbl-0035"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Safety: seizure (febrile/afebrile)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Authors' conclusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a> </p> <p>Retrospective and prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born in</p> <p>Denmark from</p> <p>1 January 1991 to</p> <p>31 December 1998</p> <p>aged 3 months to 5 years</p> <p>n = 537,171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information on febrile seizures and epilepsy was obtained from the National Hospital Register (NHR), which contains information on all patients discharged from Danish hospitals since 1977 (since 1995 information on outpatients (visits to emergency department and hospital clinics)). Diagnostic information was classified according to the Danish version of the ICD as follows: ICD‐8 was used from 1977 to 1993, and ICD‐10 was used from 1994 to the end of 1999. </p> <p><b>Febrile seizure:</b> </p> <p><b>(a) within 2 weeks after vaccination</b> </p> <p><b>(a1) 1 weeks after vaccination</b> </p> <p><b>(a2) 2 weeks after vaccination</b> </p> <p>ICD‐8 code 780.21 or ICD‐10 code R56.0, were aged between 3 and 60 months at the time of discharge, and had no recorded history of non‐febrile seizures, cerebral palsy, severe head traumas, intracranial tumours, meningitis, or encephalitis. The febrile seizures could not be classified as simple or complex because the NHR contains no information on number of febrile seizures occurring within the febrile episode, duration of the febrile seizures, and type of febrile seizures (generalised or focal onset). </p> <p><b>(b) Recurrent febrile seizure</b> </p> <p><b>(b1) within 2 weeks after vaccination</b> </p> <p><b>(b2) &gt; 2 weeks after vaccination</b> </p> <p><b>(c) Epilepsy</b> subsequent to a first febrile seizure episode </p> <p>Children were categorised with epilepsy if they had ICD‐8 code 345 or ICD‐10 code G40. </p> <p><b>(c1) within 2 weeks after vaccination</b> </p> <p><b>(c2) &gt; 2 weeks after vaccination</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccination status of the children was ascertained by using data of the National Board of Health to which vaccination data were transmitted by general practitioners. </p> <p><b>MMR vaccine:</b> </p> <p><b>Moraten</b> measles, <b>Jeryl Lynn</b> mumps, <b>Wistar RA 27/3</b> rubella </p> <p>The national vaccination program recommended during the entire study period that children should be vaccinated twice, at 15 months and at 12 years. </p> <p>Only the first vaccination is relevant to the endpoint under study.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination was associated with a transient increased rate of febrile seizures, but the risk difference was small even in high‐risk children. The long‐term rate of epilepsy was not increased in children who had febrile seizures following vaccination compared with children who had febrile seizures of a different aetiology. </p> <p><b>Febrile seizure:</b> no statistically significant difference in the RR of febrile seizures in the 2 weeks following vaccination between subgroups of children characterised by family history of seizures, sex, birth order, gestational age at birth, birthweight, or socioeconomic factors, compared with non‐vaccinated children within the subgroup under study. </p> <p>The highest rate ratio (2 weeks following vaccination) was found amongst <b>(a1)</b> <b>siblings of children with a history of epilepsy</b> compared with rate of febrile seizures following vaccination in siblings of children with no history of epilepsy. </p> <p><b>Recurrent febrile seizures and epilepsy</b> </p> <p>The authors found that children who experienced febrile seizures within 2 weeks of MMR vaccination had a 19% increased rate of recurrent febrile seizures but no increased rate of epilepsy during up to 105 months of follow‐up. The reference group consisted of children who had not been vaccinated when having their first febrile seizure. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> /<b>PT (years)</b> </p> <p>vaccinated</p> <p>(a) 7445/1,151,661</p> <p>versus</p> <p>unvaccinated</p> <p>10,541/793,568</p> <p>vaccinated</p> <p>(b1) 236/2212</p> <p>(b2) 981/12,675</p> <p>versus</p> <p>unvaccinated</p> <p>2753/23,560</p> <p>vaccinated</p> <p>(c1) 9/3825</p> <p>(c2) 95/21,938</p> <p>versus</p> <p>unvaccinated</p> <p>251/41,310</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)*</b> </p> <p>(a) 2.75 (2.55 to 2.97)</p> <p>(a1) 2.46 (2.22 to 2.73)</p> <p>(a2) 3.17 (2.89 to 3.49)</p> <p>amongst children with a personal history of febrile seizure</p> <p>(a1) 2.75 (2.32 to 3.26)</p> <p>(b1) 1.19 (1.01 to 1.41)</p> <p>(b2) 1.10 (0.96 to 1.26)</p> <p>(c1) 0.70 (0.33 to 1.50)</p> <p>(c2) 0.92 (0.59 to 1.43)</p> <p>(*) Poisson regression adjusted for age, calendar period, age of first febrile seizure, and current vaccination status </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a> </p> <p>Retrospective cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data are collected from 4 HMOs. Children (n = 716) with a confirmed seizure during the study period: </p> <p>from 1 March 1993 to 30 September 1993.</p> <p>n = 679,942 children<br/>n = 137,457 vaccinated MMR </p> <p>n = 340,386 vaccinated DTP</p> <p>n = 202,099 (unvaccinated)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> were identified through the automated data systems of each HMO, on the basis of visits classified according to the ICD‐9‐CM, as code 333.2 (myoclonus), code 345 (epilepsy), code 779.0 (convulsions in a newborn), or code 780.3 (convulsions). </p> <p><b>Simple febrile seizures</b> were defined as short, generalised seizures, accompanied by documented fever or a parental report of fever. </p> <p><b>Complex febrile seizures</b> were defined as febrile seizures that occurred more than once in 24 hours and either lasted for at least 12 minutes or were accompanied by focal signs. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> <br/>strains type not stated </p> <p><b>Exposure period (after vaccination):</b> </p> <p>(a1) 1 to 7 days</p> <p>(a2) 8 to 14 days</p> <p>(a3) 15 to 30 days</p> <p><b>Control period</b> <br/><b>(b)</b> The reference group<br/>at the time of the seizure was composed of children matched for age, calendar time, and HMO but who had not had a vaccination in the preceding 30 days. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study found significantly elevated risks of febrile seizures from 8 to 14 days after the administration of MMR vaccine. The authors did not find a significantly elevated risk of febrile seizures at any other time after vaccination, nor did they find an elevated risk of non‐febrile seizures at any time after vaccination with MMR vaccine. This risk translates into approximately 25 to 34 additional<br/>febrile seizures attributable to MMR vaccine for every 100,000. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 521 febrile seizures in the absence of vaccination</p> <p>Febrile seizures</p> <p>(a1) 8 cases</p> <p>(a2) 13 cases</p> <p>(a3) 11 cases</p> <p>Non‐febrile seizures</p> <p>(a1) 1 case</p> <p>(a2) 1 case</p> <p>(a3) 1 case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>Febrile seizures</p> <p>(a1) 1.73 (0.72 to 4.15)</p> <p>(a2) 2.83 (1.44 to 5.55)</p> <p>(a3) 0.97 (0.49 to 1.95)</p> <p>Non‐febrile seizures</p> <p>(a1) not reported</p> <p>(a2) 1.11 (0.11 to 11.28)</p> <p>(a3) 0.48 (0.05 to 4.64)</p> <p>(*) Cox proportional hazard regression multivariate model estimates adjusted for age, sex, HMO, calendar time, and receipt of DTP vaccine. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 35 months (immunised with MMR; NK) with outcome of interest diagnosed between October 1998 and September 2001 (n = 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case definition of serious neurologic disease: any child 2 to 35 months old with a severe illness with fever and convulsions and/or encephalitis (see <a href="#CD004407-tbl-0033">Table 12</a>) was included. </p> <p><b>Severe illness with fever and convulsions</b> </p> <p> <ul id="CD004407-list-0028"> <li> <p>with a total duration of 30 min; or</p> </li> <li> <p>followed by encephalopathy for 2 to 23 h; or</p> </li> <li> <p>followed by paralysis or other neurologic signs not previously present for 24 h.</p> </li> </ul> </p> <p><b>Exclude:</b> </p> <p>Viral (aseptic) meningitis without encephalopathy</p> <p>The following confirmed causes were</p> <p>excluded: hypoxic/ischaemic; vascular; toxic; metabolic, neoplastic, traumatic, and pyogenic infections; uncomplicated convulsions; or a series of convulsions lasting 30 min in immunocompromised children. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b><br/>6 to 11 days after immunisation </p> <p><b>MMR vaccine type</b>, not reported </p> <p>Immunisation history of cases was obtained by the Immunisation Department of the Health Protection Agency (other than MMR vaccine the study also considers DTP, Hib, and MenC vaccines). Only cases with known vaccination history were included in the analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 11 days after measles, mumps, rubella vaccine there is an increased risk of fever and convulsions lasting 30 minutes. </p> <p>All 6 of the episodes temporally related to immunisation met the criteria for complex febrile convulsions. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within 6 to 11 days</p> <p>With concurrent primary HHV‐6 or HHV‐7 infection</p> <p>(a) all (6 cases)</p> <p>(b) no (4 cases)</p> <p>(c) yes (2 cases)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a) 5.68 (2.31 to 13.97)</p> <p>(b) 5.80 (1.98 to 16.99)</p> <p>(c) 5.55 (1.12 to 27.63)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 24 months discharged from hospital in 5 districts in England (Ashford, Leicester, Nottingham, Preston, and Chorley &amp; Ribble) for varying periods between October 1988 and February 1993. Readmissions within 72 h with the same diagnosis were counted as 1 episode. </p> <p>n = 952 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b> </p> <p>ICD code 780.3 children aged 29 to 730 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p><b>Urabe</b> mumps strain </p> <p><b>Jeryl Lynn</b> mumps strain </p> <p>Rubella strain not specified</p> <p><b>Exposure risk period:</b> </p> <p>(a1) 6 to 11 days (1 to 2 weeks after vaccination)</p> <p>(a2) 15 to 35 days (3 to 5 weeks after vaccination)</p> <p><b>Control period:</b> </p> <p>(b) for each vaccine was defined as the time not included in a risk period</p> <p>The analyses were adjusted for age and were grouped in 6 equal intervals of about 2 months. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study shows that there was an attributable risk of 1 in 2600 doses of a febrile convulsion 15 to 35 days after giving Urabe MMR vaccine. There was no excess of admissions in the same period when Jeryl Lynn vaccine was given. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any strain</b> </p> <p>(a1) 49 cases</p> <p>(a2) 85 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Urabe strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 57 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Jeryl Lynn strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 9 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>Any strain</b> </p> <p>(a1) 3.04 (2.27 to 4.07)</p> <p>(a2) 1.51 (1.21 to 1.90)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Urabe strain</b> </p> <p>(a1) 3.77 (1.95 to 7.30)</p> <p>(a2) 1.66 (1.26 to 2.20)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Jeryl Lynn strain</b> </p> <p>(a1) 2.70 (1.81 to 4.01)</p> <p>(a2) 1.04 (0.56 to 1.93)</p> <p>(*) Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23 months with discharge diagnosis corresponding to the outcome of interest who received MMR n = 894 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b><br/>ICD‐10 code R560 or R568, febrile </p> <p>convulsion or fit, not otherwise specified,</p> <p>who were admitted between</p> <p>1 January 1998 and 30 June 2002</p> <p>were identified and linked with</p> <p>computerised immunisation records</p> <p>to obtain dates of MMR vaccination.</p> <p>Episodes within a same individual were</p> <p>considered as separate when they occurred</p> <p>at least 10 days apart.</p> <p>Case review not performed.</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Febrile convulsion</b> </p> <p>ICD‐10 codes R560 only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>(1) <b>MMRII</b> (Sanofi Pasteur) </p> <p><b>Edmonston‐Enders</b> measles strain, <b>Jeryl Lynn</b> mumps strain, between September 1992 and May 1998 </p> <p>(2) <b>MMR Priorix</b> (GlaxoSmithKline) </p> <p><b>Schwarz</b> measles strain </p> <p><b>RIT4385</b> (Jeryl Lynn) from May 1998 </p> <p>(3) unknown manufacturer</p> <p><b>Exposure risk period:</b> </p> <p><b>(a1)</b> a pre‐vaccination<br/>period of 2 weeks (removed from the background risk by treating it as a separate risk period to allow for delayed vaccination due to convulsion) </p> <p><b>(a2)</b> 6 to 11 days (1 to 2 weeks after vaccination) </p> <p><b>(a3)</b> 15 to 35 days (3 to 5 weeks after vaccination) </p> <p>.</p> <p><b>Control period</b> <br/><b>(b)</b> a pre‐vaccination period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The attributable risk of hospital admission for convulsion following receipt of any MMR vaccine was estimated as 1 in 1150 doses for the 6‐ to 11‐day postvaccination period, based on an estimated relative incidence of 4.09. The excess risk of convulsion in this period was attributable to the measles component of MMR vaccine. </p> <p>The relative incidence of convulsion in the 6‐ to 11‐day period was higher for Priorix than for MMRII, although the difference was not significant. </p> <p>There was no statistically significant evidence that children given MCC vaccine at the same time as MMR vaccine have a somewhat higher risk of convulsion in the 6‐ to 11‐day postvaccination period (rr 7.74, 3.82 to 15.71) than children who receive MMR but not MCC vaccine at the same time (rr 3.81, 2.87 to 5.05). </p> <p>Conclusion: there is no evidence to suggest that the new MMR vaccine used in the UK since mid‐1998 and derived from the Jeryl Lynn‐containing MMR vaccine causes aseptic meningitis attributable to its mumps component. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any MMR</b> vaccine </p> <p>(a1) 13 cases</p> <p>(a2) 66 cases</p> <p>(a3) 65 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMRII</b> vaccine </p> <p><b>Jeryl Lynn</b> </p> <p>(a1) 6 cases</p> <p>(a2) 27 cases</p> <p>(a3) 34 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR Priorix</b> vaccine </p> <p><b>RIT4385</b> </p> <p>(a1) 3 cases</p> <p>(a2) 19 cases</p> <p>(a3) 16 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Unknown manufacturer</b> </p> <p>(a1) 4 cases</p> <p>(a2) 20 cases</p> <p>(a3) 15 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Febrile convulsion (R560 only)</b> </p> <p>(a1) not reported</p> <p>(a2) 52 cases</p> <p>(a3) 57 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>Any MMR</b> vaccine </p> <p>(a1) 0.38 (0.22 to 0.64)</p> <p>(a2) 4.09 (3.14 to 5.33)</p> <p>(a3) 1.13 (0.87 to 1.48)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMRII</b> vaccine </p> <p><b>Jeryl Lynn</b> </p> <p>(a1) 0.39 (0.18 to 0.84)</p> <p>(a2) 3.64 (2.44 to 5.44)</p> <p>(a3) 1.28 (0.89 to 1.84)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR Priorix</b> vaccine </p> <p><b>RIT4385</b> </p> <p>(a1) 0.47 (0.15 to 1.40)</p> <p>(a2) 6.26 (3.85 to 10.18)</p> <p>(a3) 1.48 (0.88 to 2.50)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Unknown manufacturer</b> </p> <p>(a1) 0.32 (0.13 to 0.81)</p> <p>(a2) 3.53 (2.23 to 5.61)</p> <p>(a3) 0.75 (0.44 to 1.26)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Febrile convulsion (R560 only)</b> </p> <p>(a1) not reported</p> <p>(a2) 4.27 (3.17 to 5.76)</p> <p>(a3) 1.33 (1.00 to 1.77)</p> <p>(*) Poisson regression</p> <p>exposure risk period versus control period</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 556,864) were eligible if they had received their first dose of measles‐containing vaccine at age 12 through 23 months from January 2003 through September 2015. </p> <p>Children were excluded if they had a history of seizure or conditions strongly related to seizure prior to 12 months of age. </p> <p>Children born before 37 weeks gestational age were classified as <b>preterm (&lt; 37 weeks)</b> and children born 37 weeks gestational age as <b>full term (≥ 37 weeks).</b> </p> <p>Preterm children were further classified into those born <b>early preterm (&lt; 35 weeks)</b> and <b>late preterm</b> <b>(35 through 36 weeks)</b> gestational age. </p> <p>n = 24,489 were excluded because of documented history of seizures before age 12 months.</p> <p>In analysis n = 532,375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure (febrile/afebrile)</b> </p> <p>A seizure was defined as the first</p> <p>emergency department or inpatient</p> <p>hospital encounter with ICD‐9‐CM</p> <p>diagnostic code of 780.3 (convulsions)</p> <p>during the 42 days following vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR and MMRV vaccines</b> <br/>strains type not stated </p> <p><b>Risk interval</b> </p> <p>7 to 10 days after vaccination</p> <p><b>Control interval</b> </p> <p>15 to 42 days after vaccination</p> <p>n = number of children</p> <p><b>(a) Overall</b> <br/><b>(any measles vaccine)</b> </p> <p>(a1) &lt; 37 weeks n = 45,343</p> <p>(a2) &lt; 35 weeks n = 16,596</p> <p>(a3) 35 to 36 weeks n = 28,757</p> <p>(a4) ≥ 37 weeks n = 487,032</p> <p><b>(b) MMR</b> </p> <p>(b1) &lt; 37 weeks n = 37,262</p> <p>(b2) ≥ 37 weeks n = 403,238</p> <p><b>(c) MMRV</b> </p> <p>(c1) &lt; 37 weeks n = 8081</p> <p>(c2) ≥ 37 weeks n = 83,794</p> <p><b>Age at vaccination</b> <br/><b>(any measles vaccine)</b> </p> <p><b>(d) 12 to 15 months</b> </p> <p>(d1) &lt; 37 weeks n = 41,391</p> <p>(d2) ≥ 37 weeks n = 442,919</p> <p><b>(e) 16 to 23 months</b> </p> <p>(e1) &lt; 37 weeks n = 3952</p> <p>(e2) ≥ 37 weeks n = 4413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>the results support the current</p> <p>ACIP recommendations<br/>to administer the first dose of measles‐containing vaccine<br/>at age 12 through 15 months for all children, including those born<br/>preterm. Delaying vaccination of measles‐containing vaccines<br/>may increase the risk of seizures following vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk versus control interval</b><br/>cases/PT‐years </p> <p><b>(a) Overall</b> <br/><b>(any measles vaccine)</b> </p> <p>(a1) 31/500 versus 56/3500<br/>(a2) 10/182 versus 22/1294<br/>(a3) 21/313 versus 34/2267<br/>(a4) 232/5395 versus 510/36,429 </p> <p><b>(b) MMR</b> </p> <p>(b1) 22/407 versus 48/2824<br/>(b2) 163/434 versus 425/30,357 </p> <p><b>(c) MMRV</b> </p> <p>(c1) 9/90 versus 8/615<br/>(c2) 69/908 versus 85/6538 </p> <p><b>Age at vaccination</b> <br/><b>(any measles vaccine)</b> </p> <p><b>(d) 12 to 15 months</b> </p> <p>(d1) 27/450 versus 51/3188<br/>(d2) 200/4878 versus 477/34,071 </p> <p><b>(e) 16 to 23 months</b> </p> <p>(e1) 4/43 versus 5/294<br/>(e2) 32/485 versus 33/3300 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>(a) Overall</b> <br/><b>(any measles vaccine)</b> </p> <p>(a1) 3.9 (2.5 to 6.0)<br/>(a2) 3.2 (1.5 to 6.7)<br/>(a3) 4.3 (2.5 to 7.4)<br/>(a4) 3.2 (2.7 to 3.7) </p> <p><b>(b) MMR</b> </p> <p>(b1) 3.2 (1.9 to 5.3)<br/>(b2) 2.7 (2.2 to 3.2) </p> <p><b>(c) MMRV</b> </p> <p>(c1) 7.9 (3.0 to 20)<br/>(c2) 5.7 (4.1 to 7.8) </p> <p><b>Age at vaccination</b> <br/><b>(any measles vaccine)</b> </p> <p><b>(d) 12 to 15 months</b> </p> <p>(d1) 3.7 (2.3 to 5.9)<br/>(d2) 2.9 (2.5 to 3.5) </p> <p><b>(e) 16 to 23 months</b> </p> <p>(e1) 5.6 (1.5 to 21)<br/>(e2) 6.8 (4.2 to11) </p> <p>(*) Poisson regression</p> <p>risk interval versus control interval</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0113" title="MacartneyK , GiddingHF , TrinhL , WangH , DeyA , HullB , et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatrics2017;171(10):992-8. ">db‐Macartney 2017</a><br/>Self‐controlled case series </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 11 to 23 months.</p> <p>Analysis was further restricted to include only children who had</p> <p>(1) 1 dose of MMR vaccine followed</p> <p>by 1 dose of MMRV vaccine at least 27</p> <p>days later (consistent with</p> <p>NIP recommendations),</p> <p>(2) 1 dose of MMR vaccine</p> <p>(as some had not yet received</p> <p>MMRV vaccine), or</p> <p>(3) no MMR or MMRV vaccine</p> <p>(unvaccinated children, who contribute</p> <p>to the age‐specific relative incidence).</p> <p>Children who received MMRV</p> <p>vaccine as their first MCV</p> <p>were excluded because this schedule was not consistent with NIP recommendations and occurred rarely. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile seizures</b> </p> <p>in all children younger than 5 years.</p> <p>Periodic review of all ICD‐10‐Australian</p> <p>Modification coded R56.0 was also</p> <p>conducted to capture additional cases.</p> <p>Clinical and demographic data were</p> <p>collected from the medical records</p> <p>and caregiver interviews, and all FS</p> <p>diagnoses were confirmed.</p> <p>The primary analysis included</p> <p>children who had both first<br/>and subsequent FS episodes </p> <p>(considered unique episodes), in<br/>which the subsequent FS was </p> <p>separated by at least 7 days from<br/>a previous episode. </p> <p>2 sensitivity analyses were conducted:<br/>(1) adjustment for age using </p> <p>finer intervals (1‐month age groups);</p> <p>(2) restriction of the analysis</p> <p>to first FS episodes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV Priorix‐Tetra</p> <p>MMR+V</p> <p>Risk period</p> <p>after vaccination</p> <p>(a) 5 to 12 days</p> <p>(b) 13 to 30 days</p> <p>Control period</p> <p>before vaccination</p> <p>excluding interval</p> <p>−13 to −1 days before</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusions:</b> </p> <p><b>"</b>To our knowledge, this is the </p> <p>first study to provide evidence of the absence of an association between</p> <p>use of MMRV vaccine as the</p> <p>second dose of MCV</p> <p>in toddlers and an increased</p> <p>risk of FSs.</p> <p>Incorporation of MMRV vaccine</p> <p>has facilitated improvements</p> <p>in vaccine coverage that will potentially improve disease control.<b>"</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) Primary analysis</b>: children who had both first and subsequent episodes </p> <p><b>(2) Adjustment</b> for age using 1‐month interval </p> <p><b>(3) Restriction</b> of the first FS episode </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>(1) MMR</b> </p> <p>(a) 2.71 (1.71 to 4.29)</p> <p>(b) 0.89 (0.54 to 1.48)</p> <p><b>(1) MMRV</b> </p> <p>(a) 1.08 (0.55 to 2.13)</p> <p>(b) 1.08 (0.67 to 1.74)</p> <p><b>(2) MMR</b> </p> <p>(a) 2.57 (1.56 to 4.43)</p> <p>(b) 0.83 (0.49 to 1.40)</p> <p><b>(2) MMRV</b> </p> <p>(a) 1.17 (0.57 to 2.40)</p> <p>(b) 1.10 (0.66 to 1.83)</p> <p><b>(3) MMR</b> </p> <p>(a) 2.85 (1.78 to 4.56)</p> <p>(b) 0.82 (0.47 to 1.43)</p> <p><b>(3) MMRV</b> </p> <p>(a) 1.06 (0.49 to 2.27)</p> <p>(b) 1.21 (0.73 to 2.01)</p> <p>(*) Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a><br/>Person‐time cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23</p> <p>months who had received</p> <p>either MMRV or<br/>MMR+V in Alberta<br/>between 2006 and 2012. </p> <p>n = 277,774</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure events</b> </p> <p>ascertained from 3 administrative databases:</p> <p>1) the physician claims database;<br/>2) the ambulatory care reporting </p> <p>system, which includes emergency</p> <p>department visits;</p> <p>3) the hospital discharge abstracts</p> <p>database.</p> <p>From the physician claims database</p> <p>(ICD‐9), codes 780.3* for convulsions and</p> <p>the ambulatory care and hospital discharge</p> <p>databases (ICD, 10th revision, Canadian</p> <p>version, codes R56.0* for febrile<br/>convulsions), using coding consistent </p> <p>with other<br/>studies of febrile seizures after vaccination. </p> <p><b>High risk (cohort)</b> </p> <p>Children with a personal history of</p> <p>febrile seizure; seizure disorder;</p> <p>central nervous system injury, infection, or neoplasm; encephalopathy; or a progressive,<br/>evolving, or unstable neurologic </p> <p>condition (as identified from</p> <p>physician claims, emergency department</p> <p>visits, or</p> <p>hospital discharges)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b> </p> <p>vaccine (Priorix‐Tetra)</p> <p>administered to children in Alberta, relative to</p> <p>same‐day</p> <p>administration of separate MMR and varicella<br/>(MMR+V) vaccines. </p> <p><b>Risk period</b> </p> <p>(after vaccination)</p> <p>(a) 0 to 42 days<br/>(b) 7 to 10 days </p> <p><b>Control period</b> </p> <p>(before vaccination)</p> <p>42 days preceding vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>Combining MMR and varicella into a </p> <p>single vaccine decreases</p> <p>pain for children</p> <p>and distress for parents,</p> <p>thus addressing common barriers</p> <p>to vaccine uptake, and may improve</p> <p>vaccine coverage levels and decrease immunisation delivery costs.</p> <p>These potential benefits must be balanced<br/>by the increased risk (albeit small) of febrile<br/>seizures with the combination vaccine. </p> <p>Febrile seizures are typically self‐limiting</p> <p>and rarely have long‐term effects,</p> <p>but they can be extremely distressing</p> <p>for parents, may precipitate acute care</p> <p>visits, and may undermine confidence</p> <p>in immunisation</p> <p>programmes. It is a matter for debate<br/>whether the choice of separate </p> <p>versus combination vaccine is a policy</p> <p>decision or a choice for parents to make in consultation with their vaccination provider.</p> <p>If MMRV continues to be offered for<br/>first‐dose administration, it might be </p> <p>advisable to counsel parents regarding</p> <p>antipyretic use if children</p> <p>experience a fever within the</p> <p>peak risk period.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Full cohort</b> n = 277,774 </p> <p><b>MMRV</b> n = 96,686 </p> <p>(a1) 0 to 41 days</p> <p>(b1) 7 to 10 days</p> <p><b>MMR+V</b> n = 181,088 </p> <p>(a2) 0 to 41 days</p> <p>(b2) 7 to 10 days</p> <p><b>Low risk</b> n = 266,768 </p> <p><b>MMRV</b> n = 92,570 </p> <p>(b3) 7 to 10 days</p> <p><b>MMR+V</b> n = 174,198 </p> <p>(b4) 7 to 10 days</p> <p><b>High risk</b> n = 11,006 </p> <p><b>MMRV</b> n = 4116 </p> <p>(b5) 7 to 10 days</p> <p><b>MMR+V</b> n = 6890 </p> <p>(b5) 7 to 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>MMRV (full‐cohort)</b> </p> <p>(a1) 1.80 (1.43 to 2.27)</p> <p>(b1) 6.57 (4.77 to 9.05)</p> <p><b>MMR+V (full‐cohort)</b> </p> <p>(a2) 1.48 (1.22 to 1.79)</p> <p>(b2) 3.30 (2.40 to 4.52)</p> <p><b>MMRV (low risk)</b> </p> <p>(b3) 6.69 (4.90 to 9.13)</p> <p><b>MMR+V (low risk)</b> </p> <p>(b4) 2.94 (2.13 to 4.07)</p> <p><b>MMRV (high risk)</b> </p> <p>(b5) 4.68 (2.49 to 8.79)</p> <p><b>MMR+V (high risk)</b> </p> <p>(b6) 3.61 (2.20 to 5.93)</p> <p>(*) Poisson regression</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACIP: Advisory Committee on Immunization Practice<br/>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>DTP: diphtheria, tetanus, pertussis vaccine<br/>FS: febrile seizures<br/>HHV: human herpesvirus<br/>Hib: Haemophilus influenzae b vaccine<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>ICD‐9‐CM: International Classification of Diseases, 9th Revision, Clinical Modification<br/>incidence: cases/PT<br/>MCV: measles‐containing vaccines<br/>MenC: meningococcus C vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, plus varicella vaccine<br/>NIP: National Imminization Program<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence; incidence rate ratio)<br/>RR: risk ratio (relative risk) </p> </div> </div> <div class="table" id="CD004407-tbl-0036"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Safety: MMRV versus MMR/MMR+V ‐ febrile seizures</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Authors' conclusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a> </p> <p>Retrospective<br/>cohort study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index cohort</b><br/>(n = 31,298) </p> <p>all children ages 12 to 60 months</p> <p>vaccinated with MMRV at KPSC</p> <p>from February 2006 to June 2007.</p> <p>Children were excluded</p> <p>if they had</p> <p>a history of measles,</p> <p>mumps, rubella,</p> <p>or varicella disease or</p> <p>history of<br/>vaccination for any of </p> <p>these diseases.</p> <p><b>Comparison (matched) cohorts</b> </p> <p>(1) children vaccinated with</p> <p>MMR+V</p> <p>concomitantly before the routine</p> <p>use of MMRV at KPSC</p> <p>(November 2003 to January 2006).</p> <p>Children were optimally</p> <p>matched without</p> <p>replacement to children</p> <p>vaccinated with</p> <p>MMRV, on the basis of age,</p> <p>sex, and</p> <p>vaccination calendar day</p> <p>and month,</p> <p>and had to fulfil the same</p> <p>enrolment criteria.<br/>(2) pre‐vaccination </p> <p>self‐comparison period</p> <p>defined by the period</p> <p>from 60 to 30 days</p> <p>prior to vaccination with MMRV.</p> <p>(3) postvaccination</p> <p>self‐comparison period</p> <p>defined by the period</p> <p>from 60 to 90 days</p> <p>following vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b> </p> <p>Potential convulsions were</p> <p>identified as occurring on any</p> <p>visit with<br/>a diagnosis coded as<br/>779.0 (neonatal seizures), </p> <p>333.2 (myoclonus),<br/>345 (epilepsy), </p> <p>780.39 (other convulsion),</p> <p>780.3 (convulsion),<br/>780.31 (simple febrile convulsion), </p> <p>780.32 (complex febrile convulsion)<br/>regardless of setting (e.g. inpatient, </p> <p>outpatient, emergency<br/>department, or outside facility). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV: ProQuad</p> <p>contains components</p> <p>of 2 Merck vaccines,</p> <p>MMR‐II (MMR) and</p> <p>VARIVAX (V),</p> <p>and was approved in the</p> <p>USA</p> <p>in September 2005.</p> <p>Before MMRV was available,</p> <p>MMR and V were usually given concomitantly</p> <p>as 2 separate injections.</p> <p><b>Risk interval</b> </p> <p>(a) 0 to 4 days</p> <p>(b) 5 to 12 days</p> <p>(c) 13 to 30 days</p> <p>(d) 0 to 30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>"These data suggest that the risk of</p> <p>febrile convulsion is increased in</p> <p>days 5–12</p> <p>following vaccination with MMRV</p> <p>as compared</p> <p>to MMR+V given separately during</p> <p>the same visit,</p> <p>when post‐vaccination fever and</p> <p>rash are also</p> <p>increased in clinical trials.</p> <p>While there was</p> <p>no evidence of an increase in the</p> <p>overall month</p> <p>following vaccination,</p> <p>the elevated</p> <p>risk during</p> <p>this time period should be</p> <p>communicated</p> <p>and needs to be balanced</p> <p>with the</p> <p>potential benefit of a</p> <p>combined vaccine."</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases versus cases</p> <p><b>MMRV</b> versus<b>MMR+V</b><br/>matched n = 31,298 </p> <p>(a) 9 versus 7<br/>(b) 22 versus 10<br/>(c ) 13 versus 23<br/>(d) 44 versus 40<br/><br/><b>MMRV</b> versus<b>Pre‐Vacc</b> </p> <p>matched n = 31,298<br/>(a) 9 versus 4<br/>(b) 22 versus 3<br/>(c ) 13 versus 9<br/>(d) 44 versus 16<br/><br/><b>MMRV</b> versus<b>Post‐Vacc</b> </p> <p>matched n = 31,298<br/>(a) 9 versus 5<br/>(b) 22 versus 5<br/>(c ) 13 versus 13<br/>(d) 44 versus 23 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> <br/><b>MMRV</b> versus<b>MMR+V</b><br/>(a) 1.28 (0.48 to 3.45)<br/>(b) 2.2 (1.04 to 4.65)<br/>(c ) 0.57 (0.29 to 1.12)<br/>(d) 1.1 (0.72 to 1.69) </p> <p><b>MMRV</b> versus<b>Pre‐Vacc</b> <br/>(a) 2.25 (0.69 to 7.31)<br/>(b) 7.33 (2.2 to 24.5)<br/>(c ) 1.44 (0.62 to 3.38)<br/>(d) 2.75 (1.55 to 4.87)<br/><br/><br/><b>MMRV</b> versus<b>Post‐Vacc</b><br/>(a) 1.8 (0.6 to 5.37)<br/>(b) 4.4 (1.67 to 11.62)<br/>(c ) 1 (0.46 to 2.16)<br/>(d) 1.91 (1.16 to 3.17) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> <p>Retrospective<br/>cohort study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index cohort</b> </p> <p>Children aged</p> <p>12 to 23 months</p> <p>who were members of the 7</p> <p>participating versusD sites and</p> <p>had received their first dose of</p> <p>MMRV (n = 83,107)</p> <p><b>Comparison cohorts</b> </p> <p>(1) children vaccinated with<br/>MMR+V between </p> <p>January 2000 and October 2008 (n = 376,354)</p> <p>(2) children vaccinated with<br/>MMR vaccine alone (n = 145,302) </p> <p>(2000 to 2008)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure</b> <b>event</b> </p> <p>The first instance during the 42 days</p> <p>after MMRV vaccination with</p> <p>ICD‐9 codes 345* (epilepsy) or 780.3*<br/>(convulsion) in the emergency department<br/>or hospital. Postvaccination outpatient fever </p> <p>visits were examined by using ICD‐9 code<br/>780.6 for fever or febrile illness at all 7<br/>participating versusD sites from January<br/>2000 through October 2008. Similar to<br/>seizure cases, fever visits were censored<br/>after the first occurrence within<br/>the 42 days. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV (Merck &amp; Co</p> <p>Inc, West Point, PA)</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> <p>(b) 0 to 42 days</p> <p>(c) 0 to 30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>Amongst 12‐ to 23‐month‐olds </p> <p>who had received their first dose of</p> <p>measles‐containing vaccine,</p> <p>fever and seizure were elevated 7<br/>to 10 days after vaccination. </p> <p>Vaccination with MMRV results</p> <p>in 1 additional<br/>febrile seizure for every 2300 </p> <p>doses given instead of separate<br/>MMR varicella vaccines. </p> <p>Providers who recommend</p> <p>MMRV should<br/>communicate to parents that it </p> <p>increases the risk of fever and seizure<br/>over that already associated with measles‐containing vaccines. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures cases from<br/>2000 to 2008 </p> <p><b>MMRV</b> n = 83,107 </p> <p>(a) 77 cases</p> <p>(b) 189 cases</p> <p>(c) not reported</p> <p><b>MMR+V</b> n = 376,354 </p> <p>(a) 174</p> <p>(b) 598</p> <p>(c) not reported</p> <p><b>MMR</b> n = 145,302 </p> <p>(a) 42</p> <p>(b) 151</p> <p>(c) not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p>(a) 1.98 (1.43 to 2.73)</p> <p>(b) 1.42 (1.11 to 1.81)</p> <p>(c) 1.40 (1.06 to 1.85)</p> <p>(*) Poisson regression</p> <p>due to rarity of the event</p> <p>rr (rate ratio)</p> <p>is very close to RR</p> <p><b>RR (95% CI)</b> </p> <p><b>MMRV</b> versus<b>MMR</b> </p> <p>(a) 3.21 (2.2 to 4.67)<br/>(b) 2.19 (1.77 to 2.71)<br/>(c) not reported </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a><br/>Retrospective<br/>cohort study </p> <p>linked to<br/><a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children<br/>aged 48 to 83 months </p> <p>who were<br/>members of the 7 </p> <p>participating versusD<br/>sites between </p> <p>January 2000 and October 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure</b> <b>event</b> </p> <p>Postvaccination seizure event as the first<br/>instance during the 42 days after<br/>a measles‐ or varicella‐containing vaccine<br/>of the ICD‐9 codes<br/>345* (epilepsy) or 780.3* (convulsion) in<br/>the emergency department or hospital.<br/>The authors identified postvaccination medically<br/>attended outpatient fever events by using<br/>ICD‐9 code 780.6 (fever and other physiologic<br/>disturbances of temperature regulation). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) MMRV (Merck &amp; Co)<br/>2) MMR (Merck &amp; Co Inc, </p> <p>West Point, PA) +</p> <p>varicella (Merck &amp; Co)</p> <p>separately administered on the same day</p> <p>3) MMR</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> <p>(b) 0 to 42 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> </p> <p>This study provides</p> <p>reassurance that MMRV</p> <p>and MMR+V were</p> <p>not associated with an increased</p> <p>risk of febrile seizures</p> <p>among 4‐ to 6‐year‐olds.</p> <p>The authors can rule out with 95%</p> <p>confidence a risk greater</p> <p>than 1 febrile seizure</p> <p>per 15,500 MMRV doses</p> <p>and 1 per 18,000</p> <p>MMR+V doses.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases/PT</b> </p> <p><b>MMRV</b> n = <b>86,750</b> <br/>(a) 4/950.1<br/>(b) 19/10,497.2<br/><br/><b>MMR+V</b> n = <b>67,438</b> <br/>(a) 0/739<br/>(b) 10/7874<br/><br/><b>MMR</b> n = <b>479,311</b><br/>(a) 9/5252.7<br/>(b) 99/55,618 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> <br/>(a) 7 (0.38 to 130.02)<br/>(b) 1.48 (0.69 to 3.18)<br/><br/><b>MMRV</b> versus<b>MMR</b><br/>(a) 2.46 (0.76 to 7.99)<br/>(b) 1.06 (0.65 to 1.73) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a> </p> <p>Retrospective<br/>cohort study </p> <p>linked to<br/><a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 840,348 children</p> <p>12 to 23 months of</p> <p>age who had received a measles‐containing</p> <p>vaccine from 2001</p> <p>through 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever events</b> in the o </p> <p>utpatient setting</p> <p>was defined using ICD‐9 code 780.6*.</p> <p><b>Seizure events</b> in the postimmunisation </p> <p>medically</p> <p>attended in the emergency</p> <p>department</p> <p>or hospital</p> <p>setting was defined using</p> <p>ICD‐9 code 780.3* (convulsion) or 345* (epilepsy).</p> <p>The authors do not distinguish</p> <p>between febrile and</p> <p>afebrile seizures.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) MMRV (Merck &amp; Co)<br/>2) MMR (Merck &amp; Co Inc, </p> <p>West Point, PA) +</p> <p>varicella (Merck &amp; Co)</p> <p>separately administered on the same day</p> <p>3) MMR</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> <p>(b) 0 to 42 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> </p> <p>Measles‐containing</p> <p>vaccines are associated</p> <p>with a lower<br/>increased risk of </p> <p>seizures when</p> <p>administered at</p> <p>12 to 15 months of age.</p> <p>Findings of this study<br/>that focused on safety </p> <p>outcomes</p> <p>highlight the importance</p> <p>of timely</p> <p>immunisation of children<br/>with the first dose of </p> <p>measles‐containing vaccines.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 to 15 months</b> <br/><b>Fever cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b> <br/>MMRV n = 105,578 (2191) (864)<br/>MMR+V n = 520,436 (11,300) (3553)<br/>MMR n = 102,537 (2558) (760)<br/><br/><b>16 to 23 months</b> <br/><b>Fever cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b> <br/>MMRV n = 14,799<br/>(300) (116)<br/>MMR+V n = 64,551<br/>(1310) (399)<br/>MMR n = 32,447<br/>(744) (227)<br/><br/><b>12 to 15 months</b> <br/><b>Seizures cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b> <br/>MMRV n = 105,578<br/>(255) (99)<br/>MMR+V n = 520,436<br/>(997) (244)<br/>MMR n = 102,537<br/>(172) (45)<br/><br/><b>16 to 23 months</b> <br/><b>Fever cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b><br/>MMRV n = 14,799<br/>(68) (30)<br/>MMR+V n = 64,551<br/>(231) (70)<br/>MMR n = 32,447<br/>(87) (31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p><b>rr (95% CI)(*)</b> </p> <p><b>Fever</b> </p> <p><b>12 to 15 months</b><br/>(a) 1.4 (1.3 to 1.5) </p> <p><b>16 to 23 months</b> </p> <p>(a) 1.4 (1.1 to 1.7)</p> <p><b>Seizures</b> </p> <p><b>12 to 15 months</b><br/>(a) 2.0 (1.4 to 2.8) </p> <p><b>16 to 23 months</b> </p> <p>(a) 2.1 (1.3 to 3.3)</p> <p>(*)Poisson regression</p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p><b>RR (95% CI)</b> <br/>(a) 2 (1.63 to 2.45)<br/>(b) 1.28 (1.13 to 1.44)<br/><br/><b>MMRV</b> versus<b>MMR</b> <br/><b>RR (95% CI)</b> </p> <p>(a) 1.9 (1.43 to 2.53)<br/>(b) 1.4 (1.19 to 1.65) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a><br/><a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a><br/>Retrospective </p> <p>cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index cohort</b> </p> <p>All participants were</p> <p>aged 10 to 24 months.<br/>(intervention) </p> <p>n = 8344 MMRV<br/>immunised from<br/>1 September 2008 to 31 December 2009 </p> <p><b>Comparison cohorts</b><br/>n = 90,294 MMR<br/>immunised from<br/>1 January 2005 to 31 August 2008 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b><br/>Validation FC cases were retrieved </p> <p>using the<br/>following coded and free‐text </p> <p>diagnoses:<br/>“convulsions in newborn”, </p> <p>“convulsions”,<br/>“febrile convulsions”,<br/>“complex febrile convulsions”,<br/>“other convulsions”.<br/>Children diagnosed with </p> <p>FC differential diagnoses<br/>during the observational period, i.e.<br/>head trauma, epilepsy, or CNS infection,<br/>were excluded from the study.<br/>The exact coded and free‐text </p> <p>diagnoses used<br/>to depict coincidental differential </p> <p>conditions were<br/>“concussion”, “cerebral disease”,<br/>“acquired hydrocephalus”,<br/>“cerebral palsy”, “cerebral cyst”,<br/>“epilepsy”, “meningism”,<br/>types of “bacterial meningitis”, </p> <p>“encephalitis”,<br/>“meningococcal meningitis”,<br/>“aseptic viral meningitis”.<br/>Children were also excluded </p> <p>from the study<br/>if they had a history<br/>of mumps, measles, rubella,<br/>or varicella prior to vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV Priorix‐Tetra</p> <p>MMR (Priorix) GSK<br/>Priorix‐Tetra combines the<br/>components of 2 of GSK's live<br/>attenuated vaccines:<br/>MMR (Priorix) and<br/>varicella vaccine </p> <p>(Varilrix).</p> <p><b>Risk intervals</b> </p> <p><b>Postvaccination</b> </p> <p>(a) 40 days</p> <p>(b) 5 to 12 days</p> <p>(c) 7 to 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>"The risk of FC is elevated<br/>in children immunized with </p> <p>GSK’s MMRV vaccine.<br/>This risk is transient and </p> <p>appears during the<br/>second week<br/>following immunization.<br/>The relative fraction of </p> <p>FC attributable to MMRV<br/>vaccine is very low in the<br/>target population, </p> <p>and is not detectable<br/>in extended follow‐up." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases MMRV/</b> <br/><b>N MMRV</b> <br/>versus<br/><b>N cases MMR/</b> <br/><b>N MMR</b> </p> <p>(a) 19/8344 versus 198/90,294<br/>(b) 8/8344 versus 38/90,294<br/>(c) 7/8344 versus 30/90,294 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>unadjusted estimates<br/>(a) 1.04 (0.65 to 1.66)<br/>(b) 2.28 (1.06 to 4.89)<br/>(c) 2.53 (1.11 to 5.76) </p> <p>adjusted estimate(**)</p> <p>(a) 1.00 (0.6 to 1.67)<br/>(b) 2.16 (1.01 to 4.64)<br/>(c) 2.36 (1.03 to 5.38) </p> <p>(**)</p> <p>2 different types of multivariate<br/>models were used: </p> <p>(a) Cox regression HR</p> <p>(b) logistic‐regression OR</p> <p>(c) logistic‐regression OR</p> <p>Due to rarity of events,<br/>HR and OR are very close. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a><br/>Matched<br/>cohort study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All children born between</p> <p>1 January 2004 and 31 December 2008</p> <p>n = 226,267 received an</p> <p>immunisation</p> <p>with 1 of the index</p> <p>vaccines</p> <p>during the study period</p> <p>(2006 to 2008)</p> <p><b>Index cohort</b> </p> <p>n = 82,656 MMRV</p> <p><b>Comparison cohorts</b> </p> <p>n = 111,241 MMR</p> <p>n = 32,370 MMR+V</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsions</b> </p> <p>Diagnosis of FC, i.e. an ICD‐10‐GM code R56.0</p> <p>in any of the hospital diagnoses.</p> <p>2 outcome definitions, as follows.</p> <p><b>The primary outcome “FC narrow”</b> </p> <p>was defined as hospitalisation where</p> <p>no alternative plausible cause of FC.</p> <p>This endpoint included:</p> <p><b>(i)</b> all hospitalisation with FC as main discharge </p> <p>diagnosis;</p> <p><b>(ii)</b> all hospitalisation with FC as main admission </p> <p>diagnosis</p> <p>and without a main discharge diagnosis of</p> <p>an infectious disease</p> <p>(except measles, mumps, rubella, or</p> <p>chickenpox)</p> <p>or a neurological condition;</p> <p><b>(iii)</b> all hospitalisation with FC as secondary </p> <p>or ancillary diagnosis and a main discharge diagnosis</p> <p>coded as complication following immunisation</p> <p>(ICD‐10 code</p> <p>T88.0 infection following immunization or</p> <p>T88.1 other complications following immunization,</p> <p>not elsewhere classified).</p> <p>Due to exclusion of alternative causes of FC</p> <p>in this outcome definition,</p> <p>it was assumed that it would have higher</p> <p>specificity, but lower sensitivity.<br/><b>The secondary outcome “FC Jacobsen”</b> was defined as follows: </p> <p>only hospitalisations for FC with a neurological condition</p> <p>coded as main discharge diagnosis</p> <p>were excluded (<a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>). </p> <p>Consequently, “FC Jacobsen” included:</p> <p><b>(i)</b> all hospitalisation with FC as main discharge </p> <p>diagnosis;</p> <p><b>(ii)</b> all hospitalisation with FC as main admission </p> <p>diagnosis</p> <p>and without a main discharge diagnosis</p> <p>of a neurological condition; and</p> <p><b>(iii)</b> all hospitalisation with FC as secondary </p> <p>or ancillary diagnosis and with a main discharge</p> <p>diagnosis coded as complication following immunisation.</p> <p><b><i>“FC narrow” cases are a subset of “FC Jacobsen” cases.</i> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b>: Priorix‐Tetra </p> <p>(GSK) compared to</p> <p><b>MMR and V</b> vaccines </p> <p>(MMR+V).</p> <p><b>Risk interval</b> </p> <p><b>postvaccination</b> </p> <p>(a) 0 to 4 days</p> <p>(b) 5 to 12 days</p> <p>(c) 13 to 30 days</p> <p>(d) 0 to 30 days</p> <p>.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>This study suggests a similar<br/>risk of FC after a first dose of<br/>Priorix‐Tetra as has been<br/>observed for a first dose of ProQuad,<br/>pointing to a class effect of these<br/>quadrivalent vaccines. The elevated<br/>risk of FC observed for the quadrivalent<br/>vaccines has to be weighed against<br/>the advantage of only 1 injection<br/>for the child and the potential benefit<br/>of an increased varicella </p> <p>immunisation coverage.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>FC narrow</i> </b> </p> <p><b>MMRV</b> versus<b>MMR</b> </p> <p>matched n = 74,734</p> <p>case versus cases</p> <p>(a) 4 versus 5</p> <p>(b) 14 versus 3</p> <p>(c) 4 versus 9</p> <p>(d) 22 versus 17</p> <p><b><i>FC narrow</i> </b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p>matched n = 32,180</p> <p>case versus cases</p> <p>(a) 2 versus 0</p> <p>(b) 5 versus 1</p> <p>(c) 4 versus 9</p> <p>(d) 22 versus 17</p> <p><b><i>FC narrow</i> </b> </p> <p><b>MMRV</b> versus<b>MMR/MMR+V</b> </p> <p>matched n = 82,561</p> <p>case versus cases</p> <p>(a) 4 versus 4</p> <p>(b) 18 versus 4</p> <p>(c) 4 versus 8</p> <p>(d) 26 versus 16</p> <p><b><i>FC Jacobsen</i> </b> </p> <p><b>MMRV</b> versus<b>MMR</b> </p> <p>matched n = 74,734</p> <p>case versus cases</p> <p>(a) 7 versus 13</p> <p>(b) 45 versus 19</p> <p>(c) 35 versus 31</p> <p>(d) 87 versus 63</p> <p><b><i>FC Jacobsen</i> </b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p>matched n = 32,180</p> <p>case versus cases</p> <p>(a) 5 versus 4</p> <p>(b) 21 versus 14</p> <p>(c) 18 versus 12</p> <p>(d) 44 versus 30</p> <p><b><i>FC Jacobsen</i> </b> </p> <p><b>MMRV</b> versus<b>MMR/MMR+V</b> </p> <p>matched n = 82,561</p> <p>case versus cases</p> <p>(a) 8 versus 15</p> <p>(b) 51 versus 21</p> <p>(c) 40 versus 31</p> <p>(d) 99 versus 67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>FC narrow</b> <br/><b>MMRV</b> versus<b>MMR</b><br/>(a) 0.8 (0.3 to 2.5)<br/>(b) 4.1 (1.3 to 12.7)<br/>(c ) 0.5 (0.2 to 1.4)<br/>(d) 1.3 (0.7 to 2.4) </p> <p><b>FC narrow</b> <br/><b>MMRV</b> versus<b>MMR+V</b><br/>(a) 5.3 (0.4 to 70)<br/>(b) 3.5 (0.76 to 19)<br/>(c ) 1.5 (0.3 to 8.7)<br/>(d) 3.9 (1 to 14.5) </p> <p><b>FC narrow</b> <br/><b>MMRV</b> versus<b>MMR/MMR+V</b><br/>(a) 1 (0.3 to 3.3)<br/>(b) 4.1 (1.5 to 11.1)<br/>(c ) 0.5 (0.2 to 1.6)<br/>(d) 1.6 (0.9 to 3) </p> <p><b>FC Jacobsen</b> <br/><b>MMRV</b> versus<b>MMR</b><br/>(a) 0.5 (0.2 to 1.3)<br/>(b) 2.3 (1.4 to 3.9)<br/>(c ) 1.1 (0.7 to 1.8)<br/>(d) 1.4 (1 to 1.9) </p> <p><b>FC Jacobsen</b> <br/><b>MMRV</b> versus<b>MMR+V</b><br/>(a) 1.1 (0.3 to 3.5)<br/>(b) 1.5 (0.8 to 2.9)<br/>(c ) 1.6 (0.8 to 3.2)<br/>(d) 1.5 (1 to 2.4) </p> <p><b>FC Jacobsen</b> <br/><b>MMRV</b> versus<b>MMR/MMR+V</b><br/>(a) 0.5 (0.2 to 1.2)<br/>(b) 2.4 (1.5 to 3.9)<br/>(c ) 1.3 (0.8 to 2)<br/>(d) 1.5 (1.1 to 2) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0093" title="KleinNP , LewisE , McDonaldJ , FiremanB , NalewayA , GlanzJ , et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. Vaccine2017;35(12):1615-21. ">cb‐Klein 2017</a><br/>Retrospective<br/>cohort study<br/>linked to <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 946,806 children</p> <p>&lt; 36 months</p> <p>of age who had received</p> <p>a first dose of any</p> <p>measles‐containing vaccine</p> <p>from 2000 to 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever visit</b><br/>Fever visits using </p> <p>ICD‐9 code 780.6.</p> <p>Fever due to an MCV was defined as</p> <p>any clinic or emergency department<br/>visit with a fever code 7 to 10 days after </p> <p>a first dose of any MCV<br/>(henceforth known as ‘‘MCV‐associated fever”). </p> <p>This study analysed all fevers during postvaccination days 7 to 10 as if<br/>they were due to MCV. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) MMRV (Merck &amp; Co)<br/>2) MMR (Merck &amp; Co Inc, </p> <p>West Point, PA) +</p> <p>varicella (Merck &amp; Co)</p> <p>separately administered on the same day</p> <p>3) MMR</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>This study identified risk factors</p> <p>associated</p> <p>with developing fever 7 to 10 days after a</p> <p>first dose of measles‐containing vaccines.</p> <p>The study confirmed previous findings</p> <p>that fever was more often associated</p> <p>with receipt of MMRV as compared with</p> <p>MMR vaccine and with older age at time</p> <p>of vaccination during the second</p> <p>year of life, and further found that</p> <p>prior fever and seizure events were</p> <p>associated with fever after</p> <p>measles vaccine and that being fever‐prone</p> <p>in general predicted fever after</p> <p>measles‐containing</p> <p>vaccine. Even after adjusting for</p> <p>general individual</p> <p>and familial susceptibility to fever,</p> <p>fever due to measles vaccine specifically</p> <p>clustered in families. This study suggests an</p> <p>important link between population health</p> <p>(surveillance of a large population for</p> <p>vaccine adverse events) and personalised</p> <p>medicine (possible genetic basis for</p> <p>susceptibility to fever after MCV).</p> <p>Future work is needed to further</p> <p>define this possible relationship of</p> <p>genetics and vaccine‐associated fever.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV versus MMR</p> <p>(a) MCV‐associated fever</p> <p>(b) MCV‐associated fever</p> <p>(older sibling</p> <p>with MCV‐associated fever)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 1.3 (1.2 to 1.5)</p> <p>(b) 1.5 (1.2 to 1.8)</p> <p>(*)logistic regression</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>CNS: central nervous system<br/>FC: febrile convulsion<br/>HR:hazards ratio<br/>ICD: International Classification of Diseases<br/>ICD‐10‐GM: International Classification of Diseases. Tenth Revision, German Modification<br/>incidence: cases/PT<br/>MCV: measles‐containing vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk) </p> </div> </div> <div class="table" id="CD004407-tbl-0037"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Safety: autistic spectrum disorders</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a> </p> <p>Retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danish children born between January 1991 and December 1998 (n = 537,303)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) Autistic disorders</b> ICD‐10 codes<br/>F84.0 or similar DSM‐IV code 299; </p> <p><b>(b) Other autistic spectrum disorders</b><br/>ICD‐10 codes F84.1 through F84.9 </p> <p>and DSM‐IV codes 299.1‐ through 299.80.</p> <p>From medical records<br/>in Danish Psychiatric Central Register </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: </p> <p>Moraten (measles),<br/>Jeryl Lynn (mumps), Wistar RA 27/3 (rubella) </p> <p>Vaccination data reported in the National Board of Health.</p> <p>Vaccinated</p> <p>n = 440,655</p> <p>Unvaccinated</p> <p>n = 96,648</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study provides 3 strong arguments against a causal relation between MMR vaccination and autism. </p> <p> <ol id="CD004407-list-0029"> <li> <p>The risk of autism was similar in vaccinated and unvaccinated children, in both age‐adjusted and fully adjusted analyses. </p> </li> <li> <p>There was no temporal clustering of cases of autism at any time after immunisation.</p> </li> <li> <p>Neither autistic disorder nor other autistic‐spectrum disorders were associated with MMR vaccination. </p> </li> </ol> </p> <p>Furthermore, the results were derived from a nationwide cohort study with nearly complete follow‐up data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) Autistic disorders</b> </p> <p>cases unvaccinated n = 53</p> <p>PT unvaccinated PT(years) = 482,360</p> <p>versus</p> <p>cases vaccinated n = 263</p> <p>PT vaccinated</p> <p>PT(years) = 1,647,504</p> <p><b>(b) Other autistic spectrum disorters</b> </p> <p>cases unvaccinated n = 77</p> <p>PT unvaccinated PT(years) = 482,360</p> <p>versus</p> <p>cases vaccinated n = 345</p> <p>PT vaccinated</p> <p>PT(years) = 1,647,504</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 0.92 (0.68 to 1.24)</p> <p>(b) 0.83 (0.65 to 1.07)</p> <p>(*) adjusted rr. Log‐linear Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a> </p> <p>Retrospective cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 657,461 children born in Denmark from 1999 through 31 December 2010, with follow‐up from 1 year of age and through 31 August 2013. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism spectrum disorders</b> </p> <p>ICD‐10:<br/>F84.0 autistic disorder, </p> <p>F84.1 atypical autism,<br/>F84.5 Asperger syndrome,<br/>F84.8 (other pervasive </p> <p>developmental disorder),<br/>F84.9 (unspecified pervasive </p> <p>developmental disorder).</p> <p><b>Autism risk score:</b> </p> <p>In a preliminary analysis based on</p> <p>autism risk factors (maternal age,</p> <p>paternal age, smoking during pregnancy,</p> <p>method of delivery, preterm birth,</p> <p>5‐minute Apgar score, low birthweight, and head circumference) a</p> <p>Risk Score was estimated for each</p> <p>child in the cohort.</p> <p>(b1) very low risk</p> <p>(b2) low risk</p> <p>(b3) moderate risk</p> <p>(b4) high risk</p> <p><b>Siblings status</b> (at age 1 years): </p> <p>(c1) no siblings with autism</p> <p>(c2) siblings with autism</p> <p>(c3) no siblings</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>Schwarz (measles, 2000 to 2007) or Enders' Edmonston<br/>(measles, 2008 to 2013),<br/>Jeryl Lynn (mumps), and<br/>Wistar RA 27/3 (rubella) </p> <p>Vaccinated</p> <p>n = 625,842</p> <p>Unvaccinated</p> <p>n = 31,619</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>no support for the hypothesis of increased risk for autism after MMR vaccination in a nationwide unselected population of Danish children; </p> <p>no support for the hypothesis of MMR vaccination triggering autism in susceptible subgroups characterised by environmental and familial risk factors; </p> <p>no support for a clustering of autism cases in specific time periods after MMR vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/vaccinated</b> </p> <p>versus</p> <p><b>Cases unvaccinated/ unvaccinated</b> </p> <p><b>All children</b> </p> <p>(a) 5992/625,842 versus 525/31,619</p> <p><b>Autism risk score (*)</b> </p> <p>(b1) 1296 versus 91 cases</p> <p>(b2) 1637 versus 133 cases</p> <p>(b3) 2106 versus 206 cases</p> <p>(b4) 953 versus 95 cases</p> <p><b>Siblings status (*)</b> </p> <p>(c1) 2297 versus 227</p> <p>(c2) 32 versus 5</p> <p>(c3) 3594 versus 283</p> <p>(*) denominator not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)(*)</b> </p> <p><b>All children</b> </p> <p>(a) 0.93 (0.85 to 1.02)</p> <p><b>Autism risk score</b> </p> <p>(b1) 0.93 (0.74 to 1.16</p> <p>(b2) 0.86 (0.71 to 1.04)</p> <p>(b3) 0.91 (0.78 to 1.06)</p> <p>(b4) 1.06 (0.85 to 1.32)</p> <p><b>Siblings status</b> </p> <p>(c1) 0.98 (0.84 to 1.13)</p> <p>(c2) 2.96 (0.58 to 12.43)</p> <p>(c3) 0.89 (0.78 to 1.01)</p> <p>(*) adjusted by birth year, sex, other vaccines received, siblings history of autism, and autism risk score). Cox regression </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a><br/>Retrospective cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children continuously enrolled in the health plan from birth to at least 5 years of age during<br/>2001 to 2012 who also had an older sibling continuously enrolled for at least 6 months between<br/>1997 and 2012. </p> <p>n = 95,727 children in the cohort,</p> <p><b>(a)</b> n = 93,798 older siblings without ASD </p> <p><b>(b)</b> n = 1929 older sibling with ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism spectrum disorders</b> </p> <p>Status in index children and older siblings was determined using a claims‐based algorithm that required 2 or more claims on separate dates of service with an ICD‐9‐CM diagnosis code in any position for autistic disorder, other specified pervasive developmental disorder including: Asperger syndrome, or unspecified PDD (299.0x, 299.8x, and 299.9x). </p> <p>Both index child and older sibling ASD status were determined using their entire enrolment time that fell within the study period. Index children had to have at least 1 older sibling with 2 claims with ASD diagnoses or all older siblings with no ASD diagnoses. Children with an older sibling with only 1 claim with an ASD diagnosis were excluded. Index children with only 1 claim with an ASD diagnosis were also excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> receipt was defined as having a Current Procedural Terminology (CPT) or ICD‐9‐CM procedure code indicating receipt of each component (measles, mumps, and rubella) after 1 year of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>MMR vaccine was not associated with increased risk of ASD, regardless of whether older siblings had ASD. These findings indicate no harmful association between MMR vaccine receipt and ASD even amongst children already at higher risk for ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/vaccinated</b> </p> <p>versus</p> <p><b>Cases unvaccinated/ unvaccinated</b> </p> <p><b>age 2 years ‐ 1 dose</b> </p> <p>(a) 53/77,822 versus 13/15,249</p> <p>(b) 7/1394 versus 6/520</p> <p><b>age 3 years ‐ 1 dose</b> </p> <p>(a) 239/79,666 versus 45/12,853</p> <p>(b) 38/1458 versus 17/438</p> <p><b>age 4 years ‐ 1 dose</b> </p> <p>(a) 395/79,691 versus 65/11,957</p> <p>(b) 64/1491 versus 25/387</p> <p><b>age 5 years ‐ 1 dose</b> </p> <p>(a) 339/40,495 versus 56/7735</p> <p>(b) 51/864 versus 23/269</p> <p><b>age 5 years ‐ 2 doses</b> </p> <p>(a) 244/45,568 versus 56/7735</p> <p>(b) 30/796 versus 23/269</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)(*)</b> </p> <p><b>age 2 years ‐ 1 dose</b> </p> <p>(a) 0.91 (0.68 to 1.20)</p> <p>(b) 0.76 (0.48 to 1.22)</p> <p><b>age 3 years ‐ 1 dose</b> </p> <p>(a) 0.97 (0.77 to 1.21)</p> <p>(b) 0.81 (0.53 to 1.25)</p> <p><b>age 4 years ‐ 1 dose</b> </p> <p>(a) 1.03 (0.81 to 1.31)</p> <p>(b) 0.86 (0.56 to 1.34)</p> <p><b>age 5 years ‐ 1 dose</b> </p> <p>(a) 1.10 (0.79 to 1.53)</p> <p>(b) 0.92 (0.56 to 1.50)</p> <p><b>age 5 years ‐ 2 doses</b> </p> <p>(a) 1.09 (0.76 to 1.54)</p> <p>(b) 0.56 (0.30 to 1.04)</p> <p>(*) Hazard rate ratio from Cox proportional hazards model adjusting for birth year, sex, region, race/ethnicity, maternal or paternal highest education level, household income, mother’s age at birth of index infant, father’s age at birth of index infant, continuous enrolment with mental health carve‐out benefit, Childhood Chronic Conditions score, seizure, allergies, and preterm birth. Cox regression </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a> </p> <p>Retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born between 1976 and 1999 with clinical diagnosis of ASD analysed n = 858</p> <p>(whole sample n = 904; n = 46 cases were excluded due to insufficient information on ASD regression) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Regression in autism spectrum disorders</b> </p> <p>ASD regression defined as “a documented deterioration in any aspect of development or reported loss of skills, however transient” </p> <p>Note: over time 2 different diagnostic processes have been adopted at YPCD: until February 2000, the diagnostic process consisted of the assessment of ASD initially conducted by a child psychiatrist using the DSM‐IV (American Psychiatric Association, 1994), after which a clinical psychologist conducted an intelligence test. After admission a psychiatrist followed the patients once or twice a month. All doctors had been trained in using a common concept of diagnosis. From February 2000 onwards, a child psychiatrist with a clinical psychologist conducted the full assessment in 1 day. Diagnosis of ASD was made by 3 experienced child psychiatrists based on clinical observations, intellectual and developmental tests, and interviews with parents and patients. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>AIK‐C (measles),</p> <p>Urabe AM9 (mumps) To‐336 (rubella) strains.</p> <p>Data concerning MMR vaccination were moreover obtained from records of the Maternal and Child Health Handbook and were referred to the MMR generation group only. </p> <p>Participants were classified according to the chance of having received MMR vaccine (MMR was administered in Japan from April 1989 to April 1993 in children 12 to 36 months of age): </p> <p> <ul id="CD004407-list-0030"> <li> <p><b>pre‐MMR generation (before)</b>: born between January 1976 and December 1984, all ASD cases n = 100; </p> </li> <li> <p><b>MMR generation (MMR‐era)</b>: born between January 1985 and December 1991, all ASD cases n = 275; </p> </li> <li> <p><b>post–MMR generation (after)</b>: aged 1 to 3 years old after 1993 when MMR programme was terminated, all ASD cases n = 483 (regression n = 16); </p> </li> <li> <p>across <b>all generations</b> n = 769. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>within the MMR era, the rate of regression in those who received MMR was not higher than those who did not. Moreover, there was no indication that the rate of regression in ASD was higher during the era when MMR was used, compared to the ‘‘before’’ period and ‘‘after’’ period, and the ‘‘before" and "after’’ periods combined. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N vaccinated</b> <br/>versus<br/><b>N cases unvaccinated/</b> <br/><b>N unvaccinated</b> </p> <p><b>MMR‐generation</b> </p> <p>(a) 15/54 versus 45/132</p> <p><b>All generations (*)</b> </p> <p>(b) 15/54 versus 272/715</p> <p>(*) 98 cases out of 275 (MMR‐generation) were excluded due to unclear vaccination status, analysed n = 186. </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR‐era</b> versus<b>before</b> </p> <p>(c) 98/275 versus 34/100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR‐era</b> versus<b>after</b> </p> <p>(d) 98/275 versus 193/483</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR‐era</b> versus<b>(before + after)</b> </p> <p>(e) 98/275 versus 227/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.744 (0.349 to 1.571)</p> <p>(b) 0.626 (0.323 to 1.200)</p> <p>(c) 1.075 (0.646 to 1.791)</p> <p>(d) 0.832 (0.605 to 1.144)</p> <p>(e) 0.868 (0.638 to 1.182)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with a first diagnosis of a PDD during the study period registered with a GPRD practice. </p> <p>Cases: n = 1294</p> <p>Controls: n = 4469</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pervasive developmental disorder</b> </p> <p>“Those with autistic disorders and similar presentations were classified as having 'autism' and those with other description (such as Asperger’s syndrome) were classified as having 'other PDD'. Patients who had more than one PDD diagnostic code recorded at different times (for example, autism and then Asperger’s syndrome) were classified as having the most specific diagnosis (in this example Asperger’s syndrome)” </p> <p>From diagnosis contained in UK General Practice Research Database (GPRD electronic records). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>No single clinical code was immediately implemented for MMR, then MMR was identified by codes of measles, mumps, and rubella administered on the same day. </p> <p><b>Information on MMR exposure:</b> </p> <p> <ul id="CD004407-list-0031"> <li> <p><b>cases</b>: was abstracted from the GPRD records from their date of birth up until their date of diagnosis with a PDD; </p> </li> <li> <p><b>controls</b>: was abstracted from their date of birth up to their index date, defined as the date when they were the same age (to the nearest month) as their matched case at the time the case was first diagnosed with a PDD. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>MMR vaccination was not associated with an increased risk of subsequently being diagnosed with a PDD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccination</b> </p> <p><b>Before index date</b> </p> <p>(a) at any age</p> <p>(b1) before third birthday</p> <p>(b2) after third birthday</p> <p>(c1) before age 18 months</p> <p>(c2) after age 18 months</p> <p>(d) autism only</p> <p>(e) other PDD only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 0.86 (0.68 to 1.09)</p> <p>(b1) 0.90 (0.70 to 1.15)</p> <p>(b2) 0.77 (0.55 to 1.08)</p> <p>(c1) 0.90 (0.70 to 1.15)</p> <p>(c2) 0.80 (0.61 to 1.05)</p> <p>(d) 0.88 (0.67 to 1.15)</p> <p>(e) 0.75 (0.46 to 1.23)</p> <p>(*)adjusted conditional logistic regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with autism aged 3 to 10 years in 1996.</p> <p><b>All sample</b> </p> <p>Cases: n = 624</p> <p>Controls: n = 1824</p> <p><b>Birth certificate subsample</b> </p> <p>Cases: n = 355</p> <p>Controls: n = 1020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism</b> cases were identified through screening and abstraction of source files at schools, hospitals, clinics, and specialty providers. Clinical psychologists with expertise in the diagnosis of autism reviewed the abstracted records according to a standardised coding scheme to determine the presence of behavioural characteristics consistent with the DSM‐IV criteria for ASDs. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine type: not stated</p> <p>MMR vaccination was abstracted from “standardized state immunization forms”.</p> <p>3 specific years cutoff:</p> <p>(a) <b>18 months of age</b>, as an indicator of “on‐time” vaccination according to the recommended vaccination schedule for MMR vaccine; </p> <p>(b) <b>24 months of age</b>, the age by which atypical development has become apparent in most children with autism; </p> <p>(c) <b>36 months of age</b>, the age by which autistic characteristics must have developed to meet DSM‐IV criteria for autism. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>no significant associations for vaccinated before 18 months or before 24 months of age, including children with some indication of regression or plateau in development, the group of most concern. </p> <p>Vaccination before 36 months of age was more common amongst case children than control children, although only a small proportion of children in either group received their first MMR vaccination after 36 months of age. Rather than representing causal relationships, associations with the 36‐month cutoff would be more likely than associations with earlier age cutoffs to have been influenced by factors related to the evaluation, management, and treatment of the child, e.g. case children might have been more likely than control children to have been vaccinated as a requirement for enrolment in early intervention or preschool special education programs. This possibility is supported by the finding that the difference between case and control children in the proportion vaccinated before 36 months of age was strongest in the 3‐ to 5‐year‐old age group. A majority of case children who were vaccinated after 36 months of age, however, had indications of developmental problems before 36 months of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cases</p> <p>(a1) &lt; 18 months</p> <p>(b1) &lt; 24 months</p> <p>(c1) &lt; 36 months</p> <p>Birth certificate</p> <p>(a2) &lt; 18 months</p> <p>(b2) &lt; 24 months</p> <p>(c2) &lt; 36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>All cases(*)</b> </p> <p>(a1) 1.12 (0.91 to 1.38)</p> <p>(b1) 1.21 (0.93 to 1.57)</p> <p>(c1) 1.49 (1.04 to 2.14)</p> <p><b>Birth certificate (**)</b> </p> <p>(a2) 0.93 (0.66 to 1.30)</p> <p>(b2) 0.99 (0.63 to 1.55)</p> <p>(c2) 1.23 (0.64 to 2.36)</p> <p>(*)partially adjusted estimates: conditional logistic regression model stratified by the matching variables (age, gender, school). </p> <p>(**)adjusted estimates: conditional logistic regression model stratified by the matching variables (age, gender, school) and adjusted for birthweight, multiple gestation, maternal age, and maternal education. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 15 years diagnosed with childhood or atypical autism.</p> <p><b>Cases</b> : n = 96 <b>Controls</b>: n = 192 children matched for birth year, gender, and practice </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Childhood or atypical autism</b> </p> <p>classified according to ICD‐10 criteria as F84.0 or F84.1, respectively. Every diagnosis of autism was made by child psychiatrist. Dates of these diagnoses were recorded in general practitioner files. Cases with uncertain diagnosis of autism, secondary to disease state or trauma, were excluded. </p> <p>Parents were interviewed. Questions for all children included information about prenatal and postnatal development, mental and physical development, chronic diseases, malformations and injuries, history of bowel disturbances, birth order, family size, and parents’ socioeconomic status. </p> <p>Parents of children with autism were additionally asked about the date of onset of symptom, the period when parents first suspected their child’s symptoms might be related to autism, and their knowledge and beliefs regarding the cause of autism. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine type:</b> </p> <p><b>MMR</b> : not described<br/><b>MV:</b> measles vaccine monovalent: not described </p> <p>Information about vaccination history was extracted from physician records.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>MMR vaccination was not significantly associated with an increased risk of autism in children. </p> <p>In a separate analysis, a similar result was achieved for the single‐antigen measles vaccine. An unexpected finding was that odds ratios associated with MMR were lower than with the single measles vaccine. The decreased risk of autism amongst vaccinated children may be due to some other confounding factors in their health status. For example, healthcare workers or parents may have noticed signs of developmental delay or disease before the actual autism diagnosis and for this reason have avoided vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any vaccine</b> versus<b>unvaccinated</b> </p> <p>(a1) vaccinated before symptom onset</p> <p>(a2) vaccinated before diagnosis</p> <p><b>MMR vaccine</b> versus<b>unvaccinated</b> </p> <p>(b1) vaccinated before symptom onset</p> <p>(b2) vaccinated before diagnosis</p> <p><b>MV vaccine</b> versus<b>unvaccinated</b> </p> <p>(c1) vaccinated before symptom onset</p> <p>(c2) vaccinated before diagnosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p><b>any vaccine</b> versus<b>unvaccinated</b> </p> <p>(a1) 0.65 (0.26 to 1.63)</p> <p>(a2) 0.28 (0.01 to 0.76)</p> <p><b>MMR</b> versus<b>unvaccinated</b> </p> <p>(b1) 0.42 (0.15 to 1.16)</p> <p>(b2) 0.17 (0.06 to 0.52)</p> <p><b>MV</b> versus<b>unvaccinated</b> </p> <p>(c1) 0.86 (0.33 to 2.23)</p> <p>(c2) 0.36 (0.13 to 1.00)</p> <p>(*)Adjusted for mother’s age (15 to 35, 36 to 44 years), medication during pregnancy, gestation time (36 to 37, 38 to 43 weeks), perinatal injury, 5‐minute Apgar scale score (3 to 8, 9 to 10). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study analysed case data from patients of YPDC; the cases consisted of<br/>patients who: (1) were diagnosed with ASD, and (2) had been born<br/>between 1 April 1984 and 30 April 1992, the possible time period<br/>for MMR vaccination. </p> <p>Children aged 6 to 36 months</p> <p><b>cases</b>: n = 189 </p> <p><b>control</b>: n = 224 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnosis of ASD:</b> based on the classifications of pervasive developmental disorders in the DSM‐IV and standardised criteria using the Diagnostic Interview for Social and Communication Disorder (DISCO). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>there was no convincing evidence that MMR vaccination and increasing the number of vaccine injections were associated with an increased risk of ASD in a genetically homogeneous population. Consequently, these findings indicate that there is no basis for avoiding vaccination out of concern for ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/N cases</b> </p> <p>versus</p> <p><b>Control vaccinated/N controls</b> </p> <p>47/189 versus 54/224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>1.04 (0.65 to 1.68)</p> <p>(*) matched odds ratio</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 11 years (birth cohorts 1987 to 1998 attending a boarding school in Montreal (n = 27,749, out of whom 180 with PDD) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pervasive developmental disorders</b> </p> <p>Children with a diagnosis of PDD were identified by school personnel and given a study code to preserve the anonymity of the data. Children’s diagnoses were not verified by direct assessments, but it is worth noting that a majority of these children (N = 155; 86.1%) were diagnosed at the Montreal Children’s Hospital. School<br/>personnel further identified the diagnostic subtype using DSM‐IV diagnostic criteria, age, grade, and school the child was attending. When available, place of birth was recorded as well. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR (no description)</p> <p>Identified by vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR and autism: During the 11‐year interval, rates of PDD significantly increased, whereas MMR vaccine uptake showed a slight opposite trend. The opposite directions of both trends make it even less likely that a true association was not detected in the study data. </p> <p>The study shows a lack of association between MMR uptake and PDD rates applied to the period (1987 to 1995) where a single MMR dose was administered at 12 months of age. Rates of PDD were rapidly increasing well before the introduction of the 2‐dose schedule and, during that first phase, the increase of PDD rate bore no relationship with MMR vaccine uptake. </p> <p>The authors tested whether the introduction of a second MMR dose after 1995 accelerated the increase in PDD rates in the following 3 years. No statistically significant difference could be found between the rate of increase in PDD prevalence between the 1‐dosing and the 2‐dosing periods.<br/>In fact, the end point prevalence estimate for 1998 was consistent with the value predicted on the basis of the 1987 to 1995 rate of increase. Consequently, 2‐dosing schedule with MMR before age 2 is not associated with an increased risk of PDD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No association. Significant increase in rates of PDDs from 1987 to 1998 (OR 1.10, 95% CI 1.05 to 1.16; P &lt; 0.001) despite decrease in MMR uptake through birth cohorts from 1988 to 1998 (Chi² for trend = 80.7; df = 1; P &lt; 0.001). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born from 1988 to 1996 (n = 31,426)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism spectrum disorders</b> </p> <p>ASD cases defined as all cases of PDD according to ICD guidelines, but an early detection clinical system called DISCOVERY that included items drawn up by the Public Health Bureau of Yokohama called YACHT (Young Autism and other developmental disorders CHeckup Tool) was active in Kohoku Ward. </p> <p><b>Definite regression</b><br/>Episodes in which caregiver records confirm<br/>loss of skills such as aspects of communication skills, including utterances, social behaviours, play activities, adaptive skills, or motor skills that had appeared<br/>and become established in the child’s daily life. </p> <p><b>Probable regression</b><br/>If there was insufficient evidence to confirm that previous skills had become firmly acquired, or that they had not fully disappeared. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: no description </p> <p><b>Exposed period:</b> </p> <p>1988 to 1992</p> <p>MMR vaccination rates declined from 69.8% in the 1988 birth cohort to 42.9%, 33.6%, 24.0%, and a mere 1.8% in birth cohorts 1989 to 1992. </p> <p><b>Reference period:</b> </p> <p>1993 to 1996</p> <p>In birth cohorts 1993 to 1996, when not a single child was immunised.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination is unlikely to be a main cause of ASD, that it cannot explain the rise over time in the incidence of ASD, and that withdrawal of MMR in countries where it is still being used cannot be expected to lead to a reduction in the incidence of ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk period (cases/population)</p> <p>versus</p> <p>Reference period (cases/population)</p> <p>(a) Childhood autism</p> <p>58/17,704 versus 100/13,722</p> <p>(b) Other ASD</p> <p>50/17,704 versus 70/13,722</p> <p>(c) Definite regression</p> <p>29/17,704 versus 31/13,722</p> <p>(d) Definite + probable regression</p> <p>35/17,704 versus 37/13,722</p> <p>(e) All ASD</p> <p>108/17,704 versus 170/13,722</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a) 0.45 (0.33 to 0.62)<br/>(b) 0.55 (0.39 to 0.80)<br/>(c) 0.73 (0.44 to 1.20)<br/>(d) 0.73 (0.46 to 1.16)<br/>(e) 0.49 (0.39 to 0.63) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children 1 to 7 years old</p> <p>(n = 535,544)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism</b> </p> <p>Autistic disorder: "Severe qualitative impairment in reciprocal social interaction, in verbal and non verbal communication and in imaginative activity and markedly restricted repertoire of activities and interests" (<a href="./references#CD004407-bbs2-0389" title="SteffenburgS , GillbergC , HellgrenL , AnderssonL , GillbergIC , JakobssonG , et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. Journal of Child Psychology and Psychiatry and Allied Disciplines1989;30(3):405-16.">Steffenburg 1989</a>) </p> <p>Data regarding first hospital visits during the study period identified by ICD‐8/9 codes respectively effective from 1969 to 1986 and from1987 through 1995 (299 ‐ Psychoses ex origine infantia; 2990 ‐ Autismus infantilis; 2998 ‐ Developmental disorder; 2999 ‐ Developmental disorder). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR II ‐ vaccine</b> (Merck &amp; Co, West Point, PA) </p> <p>Measles: Enders‐Edmonston</p> <p>Mumps: Jeryl Lynn</p> <p>Rubella: Wistar RA 27/3</p> <p>Vaccination data were assessed through vaccination register.</p> <p>For autism the risk period is open‐ended.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>no distinguishable clustering was detected in the intervals from vaccination to the hospitalisation. The number of hospital admissions remained relatively steady during the first 3 years and then gradually decreased, as was expected because of the increasing age of the vaccinees (Fig 3).<br/>43 children were vaccinated after the first<br/>hospitalisation, and 31 were hospitalised but remained<br/>unvaccinated between November 1982 and June 1986. Of the children hospitalised for autism, none made hospital visits because of inflammatory bowel diseases in 1982 to 1995. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASD cases n = 309</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born since 1979 from 8 health districts (North Thames, UK)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autistic disorder</b> </p> <p>“By use of criteria of the International Classification of Diseases, tenth revision (ICD10), the diagnosis of autism was checked against information in the available records on the child’s present condition and his or her condition between the ages of 18 months and 3 years.” </p> <p>ICD‐10 confirmed and non‐confirmed cases from computerised special needs/disability registers at child development centres and from records in special schools. Information on children with such disorders who were younger than 16 years of age was extracted from clinical records by 1 of 3 experienced paediatric registrars. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination identified by Regional Interactive Child Health Computing System (RICHS)</p> <p><b>Risk period:</b> </p> <p>(a) Autism diagnosis</p> <p>(a1) &lt; 12 months</p> <p>(a2) &lt; 24 months</p> <p>after vaccination</p> <p>(b) Parental concern</p> <p>(b1) &lt; 6 months</p> <p>(b2) &lt; 12 months</p> <p>after vaccination</p> <p>(c) Regression</p> <p>(c1) &lt; 2 months<br/>(c2) &lt; 4 months </p> <p>(c3) &lt; 6 months<br/>after vaccination </p> <p>Where vaccination and the event of interest<br/>occurred in the same month, the authors assumed that vaccination preceded the event. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The case‐series analyses showed no evidence of temporal clustering between MMR or other measles‐containing vaccines and diagnosis of autism. Regression occurred in nearly a third of the cases of core autism; regression was not clustered in the months after vaccination. For age at first parental concern, no significant temporal clustering was seen for cases of core autism or atypical autism, with the exception of a single interval within 6 months of MMR vaccine associated with a peak in reported age at first parental concern at 18 months. This peak is likely to reflect the difficulty experienced by parents in defining the precise age at onset of symptoms in their child, particularly those with atypical autism, and consequent approximation with preference for 18 months. Our results do not support the hypothesis that MMR vaccination is causally related to autism, either its initiation or to the onset of regression. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>(a) Autism diagnosis (n = 357)</p> <p>(b) Parental concern (n = 326)</p> <p>(c) Regression (n = 105)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a1) 0.94 (0.60 to 1.47)</p> <p>(a2) 1.09 (0.79 to 1.52)</p> <p>(b1) 1.48 (1.04 to 2.12)</p> <p>(b2) 0.90 (0.63 to 1.29)</p> <p>(c1) 0.92 (0.38 to 2.21)</p> <p>(c2) 1.00 (0.52 to 1.95)</p> <p>(c3) 0.85 (0.45 to 1.60)</p> <p>(*) relative incidence, Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre‐MMR</b>: Maudsley Family Study (MFS) sample: n = 98 probands who had an ICD‐10 diagnosis of autism PDD. Children born between 1954 and 1979. </p> <p><b>Post‐MMR</b>: Maudsley Hospital Clinical (MHC) sample: n = 68 children born between 1987 and 1996 and had a confirmed diagnosis of PDD. </p> <p><b>Post‐MMR</b>: Stafford sample: n = 96 children born between 1992 and 1995 selected as part of an epidemiologic survey of PDD conducted in Staffordshire (Midlands, UK) </p> <p>total population n = 15,500.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autistic enterocolitis</b> </p> <p><b>(a) Age (in months) at first parental concern:</b> in the 3 samples, item 2 of the ADI (earlier version of the ADI‐R) was used to assess the first onset of autistic symptoms, or the age of the child at which parents first became concerned about their child’s development. The precise wording of the question is, “How old was your child when you first wondered if there might be something not quite right with his/her development?” </p> <p><b>(b) Regression:</b> the assessment of regression in the ADI‐R is covered with items 37 to 41 (for language) and items 95 to 103 (for other domains). The regression is assessed for language skills as follows: “Were you ever concerned that your child might have lost language skills during the first years of his/her life? Was there ever a time when he/she stopped speaking for some months after having learned to talk?” </p> <p><b>Assessment of bowel disorders and symptoms:</b> these data were available only from the epidemiologic sample (Stafford sample). All children were reviewed regularly and are still followed up by the paediatrician, who has records of any additional hospital admissions/medical investigations for bowel disorders in these children. The occurrence of gastrointestinal symptoms was assessed by 2 sources: the parents and the paediatrician. </p> <p><b>ADI‐R</b>: Autism Diagnostic Interview ‐ Revised was administered with the parents by trained staff. Interrater reliability on the ADI‐R interviews was assessed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine type not described</p> <p><b>MFS sample</b> (pre‐MMR): unvaccinated </p> <p><b>MHC sample</b> (post‐MMR): likely vaccinated<br/><b>Stafford sample</b> (post ‐MMR): likely vaccinated </p> <p>The MMR immunisation programme was introduced in 1988 in the UK (with first MMR given between 12 and 15 months of age) with coverage rates above 90%. MMR coverage rates in 2‐year‐olds fell from 92% in 1995 to 88% in 2000. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence was found to support a distinct syndrome of MMR‐induced autism or of “autistic enterocolitis”. </p> <p>No changes in the mean age of parental recognition of first autistic symptoms were found when 2 samples of children, 1 clinical and 1 epidemiologic, all exposed to MMR immunisation, were compared with a pre‐MMR sample. </p> <p>No increase in the rate of regressive autism in recent years. Rates of regression in the development of children with autism were found to be similar in a pre‐ and post‐MMR sample. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐‐‐MFS sample (n = 98)</p> <p>(a) mean = 19.5 (SD = 13.6)</p> <p>(b) n = 18</p> <p>‐‐‐‐MHC sample (n = 68)</p> <p>(a) mean = 19.2 (SD = 8.8)</p> <p>(b) n = 0</p> <p>‐‐‐‐Stafford sample (n = 96)</p> <p>(a) mean = 19.3 (SD = 8.7)</p> <p>(b) n = 15</p> <p>No statistically relevant differences across the 2 samples for the rate of probable or definite regression. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADI‐R: Autism Diagnostic Interview ‐ Revised<br/>ASD: autism spectrum disorders<br/>CI: confidence interval<br/>DSM: Diagnostic and Statistical Manual of Mental Disorders<br/>GPRD: General Practice Research Database<br/>HMO: health maintenance organisation<br/>HR: hazards ratio<br/>ICD: International Classification of Diseases<br/>ICD‐9‐CM: International Classification of Diseases, Ninth Revision, Clinical Modification<br/>incidence: cases/PT<br/>KPSC: Kaiser PermanteSsouth California<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PDD: pervasive developmental disorders<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>SD: standard deviation<br/>YPDC: Yokohama Psycho‐Developmental Clinic </p> <p><b>Definitions:</b> </p> <p><b>Childhood autism:</b> children with symptoms before the age of 3 years that meet the necessary criteria under each section of the diagnostic triad for autism: communication difficulties, problems with social interaction, and behaviour problems such as stereotyped repetitions. </p> <p><b>Atypical autism cases:</b> with many of the features of childhood autism but not quite meeting the required criteria for that diagnosis, or with atypical features such as onset of symptoms after age 3 years (also known as pervasive developmental disorder not otherwise specified). </p> <p><b>Developmental regression:</b> a documented deterioration in any aspect of development or reported loss of skills, however transient (International Classification of Diseases, 10th revision (ICD‐10) and Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV)). </p> </div> </div> <div class="table" id="CD004407-tbl-0038"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Safety: inflammatory bowel disease</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0034" title="DavisRL , KramarzP , BohlkeK , BensonP , ThompsonRS , MulloolyJ , et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine2001;155(3):354-9. ">bb‐Davis 2001</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccine Safety Datalink (versusD) cases were patients born between 1958 and 1989.</p> <p><b>Case IBD</b> n = 142 </p> <p>(n = 75 Crohn's disease and n = 67 ulcerative colitis)</p> <p><b>Controls</b> n = 432 </p> <p>matched for sex, HMO, and birth year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory bowel diseases</b> </p> <p>Review of medical records contained in the Vaccine Safety Datalink database of 4 HMOs and identified by using ICD‐9 codes specific for Crohn's disease, ulcerative colitis and idiopathic proctocolitis (555 and 556). Outpatient, emergency department, urgent care clinic visits were available for 3 out of the 4 HMOs and were also taken into account. </p> <p>After abstraction of medical records, IBD cases were classified as:</p> <p><b>Definite IBD</b>: as individuals diagnosed with IBD by a gastroenterologist at 1 of the HMOs who had at least 1 sign or symptom compatible with IBD (such as bloody stool and/or bloody diarrhoea or severe and/or recurrent abdominal pain) recorded and a diagnostic test result (such as biopsy with pathology specimen, colonoscopy, or sigmoidoscopy) consistent with IBD. </p> <p><b>Probable IBD</b>: the diagnosis of IBD was made by either an HMO non‐gastroenterologist physician or a gastroenterologist outside the HMO; there was at least 1 sign or symptom compatible with IBD; and there was a diagnostic test result consistent with IBD. </p> <p>IBD cases (suspected or questionable) that did not correspond to these criteria were excluded from analysis. IBD (definite and probable) were further classified as Crohn's disease and ulcerative colitis cases. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>not specified </p> <p><b>MCV vaccine</b> </p> <p>not specified</p> <p>MMR administered at any time before index date</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this population‐based study of IBD at 4 large HMOs, the authors found no evidence that vaccination with MMR or other MCV, or that the age of vaccination early in life, was associated with an increased risk for development of IBD. In addition, the authors did not find evidence that MMR or other MCV acutely triggers the onset of either ulcerative colitis/proctitis or Crohn's disease. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p><b>Crohn's disease</b> (n = 75) </p> <p>(a) all age and vaccine type</p> <p>(a1) MMR &lt; 12 months</p> <p>(a2) MMR 12 to 18 months</p> <p>(a3) MMR &gt; 18 months</p> <p><b>Ulcerative colitis</b> (n = 67) </p> <p>(b) all age and vaccine type</p> <p>(b1) MMR &lt; 12 months</p> <p>(b2) MMR 12 to 18 months</p> <p>(b3) MMR &gt; 18 months</p> <p><b>All IBD</b> (n = 142) </p> <p>(c) all age and vaccine type</p> <p>132/142 versus 409/432</p> <p>(c1) MMR &lt; 12 months</p> <p>6/16 versus 25/48</p> <p>(c2) MMR 12 to 18 months</p> <p>84/94 versus 223/246</p> <p>(c3) MMR &gt; 18 months</p> <p>4/14 versus 52/75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p><b>Crohn's disease</b> </p> <p>(a) 0.40 (0.08 to 2.00)</p> <p>(a1) 0.38 (0.05 to 2.86)</p> <p>(a2) 0.54 (0.10 to 3.07)</p> <p>(a3) 0.18 (0.03 to 1.21)</p> <p><b>Ulcerative colitis</b> </p> <p>(b) 0.80 (0.18 to 3.56)</p> <p>(b1) 0.96 (0.12 to 7.57)</p> <p>(b2) 1.14 (0.23 to 5.59)</p> <p>(b3) 0 (0 to 0)</p> <p><b>All IBD</b> </p> <p>(c) 0.59 (0.21 to 1.69)</p> <p>(c1) 0.61 (0.15 to 2.45)</p> <p>(c2) 0.86 (0.28 to 2.59)</p> <p>(c3) 0.16 (0.04 to 0.68)</p> <p>(*)Conditional logistic regression matched on HMO, sex, birth year adjusted for race.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0026" title="BaronS , TurckD , LeplatC , MerleV , Gower-RousseauC , MartiR , et al. Enviromental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut2005;54(3):357-63. [DOI: 10.1136/gut.2004.054353]">bb‐Baron 2005</a> </p> <p>Case‐<b>c</b>ontrol </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases: patients from the registry of inflammatory bowel diseases</p> <p>January 1988 to December 1997</p> <p>aged less than 17 years old.</p> <p><b>Cases</b> n = 222<br/>Crohn's disease </p> <p><b>Cases</b> n = 60 </p> <p>ulcerative colitis</p> <p><b>Controls</b> were randomly selected from telephone<br/>number lists and matched 1:1 to each case by age (2 years), sex, and living area. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Crohn's disease; ulcerative colitis</b> </p> <p>Interviewer practitioners collected data on all patients<br/>diagnosed between 1 January 1988 and 31 December 1997 from all gastroenterologists (including paediatric gastroenterologists) in the entire area. </p> <p>Only patients who had been residents in the defined study areas at the time of diagnosis of their disease were included. </p> <p>A final diagnosis of CD or UC was made by 2 expert gastroenterologists and recorded as definite, probable, or possible, following criteria previously published. For the purpose of this study, only patients with definite or probable CD or UC were considered. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination was negatively associated<br/>with a risk of CD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Crohn's disease</p> <p>(b) ulcerative colitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 0.5 (0.35 to 0.9)</p> <p>(b) no data available</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0042" title="ShawSY , BlanchardJF , BernsteinCN . Early childhood measles vaccinations are not associated with paediatric IBD: a population based analysis. Journal of Crohn's and Colitis2015;9(4):334-8. [DOI: 10.1093/ecco-jcc/jjv029]">bb‐Shaw 2015</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> n = 117 </p> <p>with IBD diagnosis,</p> <p>born after 1989 and diagnosed before 31 March 2008.</p> <p><b>Controls</b> n = 834 </p> <p>matched to cases on the basis of age, sex, and region of residence at time of diagnosis.</p> <p>All with an average age of 11 years.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory bowel diseases</b> </p> <p>The administrative data case definition used to identify patients with IBD was validated with the establishment of the population‐based University of Manitoba IBD Epidemiology Database (UMIBDED) in 1995; the UMIBDED contains extracted administrative data of IBD cases and their controls (at a 1:10 ratio) for those individuals with health coverage between 1 April 1984 and 31 March 2008. Residents of Manitoba who resided in the province for at least 2 years were identified as having IBD if they had at least 5 physician visits or hospitalisations with ICD‐9‐CM codes 555.xx (Crohn’s disease) or 556.xx (UC) recorded as a diagnosis at any time. Since 2004, ICD‐10‐CA codes were used for all inpatient contacts and for IBD included K50.xx and K51.xx. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant association between completed measles‐containing vaccination in the<br/>first 2 years of life and paediatric IBD could be demonstrated in this population‐based study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) IBD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 1.54 (0.54 to 4.36)</p> <p>(*)Conditional logistic regression models were fitted to the data, with models adjusted for physician visits in the first 2 years of life and area‐level socioeconomic status at case date. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0045" title="VcevA , PezerovicD , JovanovicZ , NakicD , VcevI , MajnaricL . A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. Wiener Klinische Wochenschrift2015;127(9-10):345–54. ">bb‐Vcev 2015</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> inflammatory bowel diseases </p> <p>n = 150</p> <p><b>Cases</b> ulcerative colitis n = 119<br/><b>Cases</b> Crohn's disease n = 31 </p> <p><b>Controls</b> n = 150 </p> <p>not having a diagnosis of IBD, age and sex matched, were used as the control group.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory bowel diseases</b> </p> <p>Patients diagnosed with IBD (UC or CD), identified according to the hospital’s patient records. Of a total of 150 patients in the sample, 119 patients were diagnosed with UC and 31 were diagnosed with CD. They were identified according to the hospital’s patient records. Documentation of the regional hospitals in Vukovar and Vinkovci was used for this purpose. Hospitals in the near surroundings such as Clinical Hospital Centre Osijek and General Hospital Slavonski Brod were also contacted, as some patients were directly referred to these hospitals by their primary care physicians without prior registration in the resident hospitals. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> <br/>not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study found an association between exposure to MMR vaccine in the early childhood and later development of CD </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) IBD</p> <p>117/150 versus 101/150</p> <p>(b) UC</p> <p>89/119 versus 101/150</p> <p>(c) CD</p> <p>28/31 versus 101/150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 1.72 (1.03 to 2.88)</p> <p>(b) 1.44 (0.84 to 2.46)</p> <p>(c) 4.53 (1.31 to 15.63)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crohn's Disease emergency admission <b>cases</b> (n = 4463) observed between April 1991 and March 2003 in England population aged below 19 years (about 11.6 million) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Crohn's disease</b><br/>emergency admissions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>not reported</p> <p><b>(a) Reference period:</b> </p> <p>1988 to 1989</p> <p>(7% children completing a primary course)</p> <p><b>(b) Risk period:</b><br/>1990 </p> <p>(68% children completing a primary course)</p> <p><b>(c) Risk period:</b> </p> <p>1991 to 2003</p> <p>(84% children completing a primary course)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study found no increase in Crohn’s disease associated with the introduction of the MMR vaccination programme, providing strong evidence against the hypothesis that MMR vaccine increases the risk of Crohn’s disease. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)(*)</b> </p> <p>0.95 (0.84 to 1.08)</p> <p>(*) Poisson regression.</p> <p>The estimated rate ratio (populations with a vaccination rate of 84% compared with those with a vaccination rate of 7%). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a> </p> <p>Case‐only ecological method</p> <p>linked to <a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with childhood (core autism n = 278) and atypical autism (n = 195) born between 1979 and 1998 from computerised health registers of children with disabilities in the community and from special school and child psychiatry records, using the same methods and classifications as in the authors' earlier study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recorded <b>bowel problems</b> lasting at least 3 months, age of reported regression of the child's development where it was a feature, and relation of these to MMR vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study provides no support for an MMR‐associated “new variant” form of autism with developmental regression and bowel problems, and further evidence against involvement of MMR vaccine in the initiation of autism. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bowel problem</b> </p> <p>all cases n = 78</p> <p>unvaccinated cases n = 9</p> <p>vaccinated before parental concern n = 50</p> <p>vaccinated after parental concern n = 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>0.98 (0.89 to 1.07)</p> <p>(*) logistic regression adjusted for sex, year of birth, district, age at parental concern, and type of autism. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CD: Crohn's disease<br/>CI: confidence interval<br/>DSM: Diagnostic and Statistical Manual of Mental Disorders<br/>HMO: health maintenance organisation<br/>IBD: inflammatory bowel diseases<br/>ICD: International Classification of Diseases<br/>ICD‐10‐CA: <br/>ICD‐9‐CM:<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence; incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>UC: ulcerative colitis </p> <p><b>Definitions:</b> </p> <p><b>Childhood autism:</b> children with symptoms before the age of 3 years that meet the necessary criteria under each section of the diagnostic triad for autism: communication difficulties, problems with social interaction, and behaviour problems such as stereotyped repetitions. </p> <p><b>Atypical autism:</b> with many of the features of childhood autism but not quite meeting the required criteria for that diagnosis, or with atypical features such as onset of symptoms after age 3 years (also known as pervasive developmental disorder not otherwise specified). </p> <p><b>Developmental regression:</b> a documented deterioration in any aspect of development or reported loss of skills, however transient (International Classification of Diseases, 10th revision (ICD‐10) and Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV)). </p> </div> </div> <div class="table" id="CD004407-tbl-0039"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Safety: cognitive delay, developmental delay</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0098" title="Mrozek-BudzynD , KiełtykaA , MajewskaR , AugustyniakM . Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - the results of the Polish prospective cohort study. Vaccine2013;31(22):2551-7. [DOI: 10.1016/j.vaccine.2013.03.057]">cb‐Mrozek‐Budzyn 2013</a> </p> <p>Cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Birth‐cohort) The enrolment (3 November 2000 to 22 August 2003) included only non‐smoking women, aged 18 to 35 years, with singleton pregnancy without illicit drug use and HIV infection, free from chronic diseases such as diabetes or hypertension and residing in Krakow for at least 1 year prior to pregnancy. The infants were followed up to 8th year of life. </p> <p>n = 369 children</p> <p>(n = 307 vaccinated MMR;</p> <p>n = 32 vaccinated monovalent;</p> <p>n = 30 unvaccinated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fagan Test of Infant Intelligence</b> (<b>FTII</b>) at 6th month of life. </p> <p><b>Bayley Scales of Infant Development</b> , second edition (<b>BSID‐II</b>), was administered in the 12th, 24th, and 36th months of life. </p> <p>The Mental Scale of that test includes items that assess memory, habituation, problem solving, early number concepts, generalisation, classification, vocalisation, language, and social skills. Test scores are adjusted to child’s age to obtain the <b>Mental Development Index (MDI)</b>. </p> <p>Test results are in 1 of 4 categories (range: from 50 to 150): <b>(1)</b> accelerated performance (score &gt; 115); <b>(2)</b> within normal limits (score 85 to 114); <b>(3)</b> mildly delayed performance (score 70 to 84), and <b>(4)</b> significantly delayed (score &lt; 69). </p> <p>The<b>test of Raven’s Colored Progressive Matrices</b> (<b>Raven</b>) was administered twice, in 5th and 8th year of life. </p> <p>The <b>Wechsler Intelligence Scale for Children</b> (<b>WISC‐R</b>) was administered in 6th and 7th year of life, and generated verbal, non‐verbal, and total IQ for evaluated children. Category with IQ &lt; 100 was considered as the poorer outcomes. The outcomes range is from 40 to 160. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>not described </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR and cognitive tests outcomes:</b> No significant differences of cognitive and intelligence tests results were observed between children vaccinated with MMR and unvaccinated in univariable analysis. Their outcomes were on similar level. </p> <p><b>Conclusion:</b> The results suggest that there is no relationship between MMR exposure and children’s cognitive development. Furthermore, the safety of triple MMR is the same as the single measles vaccine with respect to cognitive development. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) MDI‐BSID II 24th month</p> <p>(a2) MDI‐BSID II 36th month</p> <p>(b1) Raven (centiles) 5th year</p> <p>(c1) WISC‐R Verbal IQ 6th year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a1) 1.35 (0.15 to 12.0)</p> <p>(a2) 0.37 (0.03 to 4.02)</p> <p>(b1) 1.22 (0.23 to 6.55)</p> <p>(c1) 1.23 (0.09 to 17.03)</p> <p>(*) adjusted for standardised to child’s gender, maternal education, maternal IQ, maternal economical status, birth order (further child versus first one), and exposure to environmental tobacco smoke during pregnancy (yes versus no). </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>incidence: cases/PT<br/>IQ: intelligence quotient<br/>MDI‐BSID II: Mental Development Index of Bayley Scales of Infant Development, second edition<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time </p> </div> </div> <div class="table" id="CD004407-tbl-0040"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a> </p> <p>Nested case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b>: n = 23 children with outcome of interest at 12 to 23 months, between 1988 and 1999, GPRD members. </p> <p><b>Controls</b>: n = 116 participants matching for index date (age), sex, practice. </p> <p>Nested case–control analysis to evaluate whether there was any relationship between recent MMR vaccination and the risk of ITP. Because the data were sparse, the authors grouped case–control sets by 3‐month age bands (13 to 15 months, 16 to 18 months, and so on). In addition, they included boys and girls in sets together because childhood ITP is reported to occur with equal<br/>frequency amongst both sexes, and because preliminary analysis of their data showed no evidence for a predominance of cases amongst either sex. The risk ratio of ITP during the specified time periods after MMR vaccination was estimated as the odds ratio using conditional logistic regression. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idiopathic thrombocytopenic purpura</b> </p> <p>GPRD electronic records with first‐time diagnosis of thrombocytopenia (ICD‐9 code 287.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not reported. </p> <p>Data about MMR vaccination</p> <p>were presumably obtained from</p> <p>GPRD records (type and composition not reported).</p> <p>The authors referred to ITP cases that occurred within 6 weeks after an MMR vaccine as "possible vaccine‐related"; this is a plausible period of risk related to a primary immune response. They also evaluated the risk of ITP during a longer period after MMR vaccination (7 to 26 weeks). </p> <p><b>Risk time</b> following MMR immunisation </p> <p>(a) 0 to 6 weeks</p> <p>(b) 7 to 26 weeks</p> <p>(c) 0 to 26 weeks</p> <p><b>Reference time</b> </p> <p>unexposed MMR or</p> <p>&gt; 26 weeks after MMR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> "Although ITP is one of the most frequently diagnosed haematological disorders amongst young children, it is an uncommon condition. </p> <p>The risk of ITP occurring within the 6 weeks after vaccination with MMR is significantly increased. </p> <p>However, the attributable risk of ITP within 6 weeks after MMR vaccination remains low at 1 in 25,000" (95% CI 21,300 to 89,400) "vaccinated children. </p> <p>Complications or long‐term consequences of ITP in this age group are rare.</p> <p>For the majority of children less than 6 years of age, the illness is self‐limiting."</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>Data reported in the study:</p> <p>(a) 8/17 versus 19/84</p> <p>(b) 6/15 versus 32/97</p> <p>(c) 14/23 versus 51/116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>unadjusted estimates</p> <p>(a) 3.04 (1.03 to 8.96)</p> <p>(b) 1.35 (0.44 to 4.14)</p> <p>(c) 1.98 (0.79 to 4.95)</p> <p>computed from the data reported in the study.</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>adjusted estimates(*)<br/>(a) 6.3 (1.3 to 30.1)<br/>(b) 1.5 (0.4 to 4.8) </p> <p>(*) logistic regresson</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a> </p> <p>Case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases:</b> n = 387 children aged 1 month to 18 years, hospitalised at emergency department with outcome of interest between November 1999 and September 2007, with outcome of interest. </p> <p><b>Controls:</b> n = 1924 children of same age interval hospitalised at emergency department for acute neurological disorders or endoscopically confirmed gastroduodenal lesions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute immune thrombocytopenia</b> </p> <p>Platelets count &lt; 100,000/μL at admission. Participants with following conditions were excluded: cancer, immunodeficiency, chronic renal and hepatic failure, so as acute events related to a reactivation of an underlying chronic disease or a congenital anomaly </p> <p>Hospitalisation (emergency department) records review</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> <p>Exposure to the vaccine (and other drugs) was assessed during hospital admission by means of interview with parents. </p> <p>0 to 6 weeks following MMR immunisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> the study confirms an association between MMR vaccination and ITP. As the risk of ITP after vaccination is smaller than after natural infection with these viruses, it is clear that the benefit of vaccination programmes greatly exceed the significance of this possible adverse effect. Although thrombocytopenia is initially severe, the subsequent course is generally benign and short‐lasting. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>14/387 versus 27/1924</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>2.4 (1.2 to 4.7)</p> <p>(*) adjusted estimates by logistic regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 63) aged 12 to 23 months with ITP identified from versusD database for the years 1991 to 2000, who had been vaccinated with MMR whilst actively enrolled in their respective MCOs. For each child, follow‐up time was limited to the 365 days before and after MMR vaccination. Vaccinated children with ITP that occurred outside this follow‐up window were excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immune thrombocytopenia purpura</b> </p> <p>Participants with 2 platelet counts ≤ 50,000/μL within 6‐week period or with 1 platelets count ≤ 50,000/μL associated with ICD‐9 diagnosis codes 287.0 to 287.9 within 6 weeks, with exclusion of: cases of thrombocytopenia from a known condition (neonatal thrombocytopenia, aplastic anaemia, defibrination syndrome, acquired haemolytic anaemia, chronic liver disease, malignant neoplasm), thrombocytopenia diagnosed within the 30th day of life. By subsequent patient chart reviews, participants who did not have not have ITP, who had drug exposure, with acute illness, or with serendipitous finding during routine care were further excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine: not reported</p> <p>MMR vaccination date assessed by means of separate audit of patient charts.</p> <p><b>Exposed period</b>: 42 days after MMR vaccination </p> <p><b>Unexposed period:</b> defined as the time periods before and after the exposed period. </p> <p>Period of 6 weeks immediately preceding MMR vaccination was excluded from analysis (because this represents a period when a child is most likely to be healthy (the healthy‐vaccinee) and may underestimate the background incidence of ITP) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> since its introduction in the 1960s, the MMR vaccine has reduced the incidence of wild‐type measles by nearly 100% in the USA. Although this vaccine is associated with an increased incidence of ITP, the attributable risk is low (1 case per 40,000 doses of MMR), and the disease associated with MMR vaccination is mild and resolves, on average, within 7 days. Our results, therefore, do not suggest a need to alter current immunisation policies. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age groups</b> </p> <p>(a) 12 to 23 months</p> <p>(b) 12 to 15 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>Self‐controlled case series</b> </p> <p>(a) 5.38 (2.72 to 10.62)</p> <p>(b) 7.06 (1.95 to 25.88)</p> <p>(*) conditional Poisson regression controlled by age in three 4‐month age groupings (12 to 15, 16 to 19, 20 to 23 months) and excluding fixed covariate from the model (gender, MCO, MMR dose number) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Person‐time cohort(**)</b> </p> <p>(a) 3.94 (2.01 to 7.69)</p> <p>(b) 7.10 (2.03 to 25.03)</p> <p>(**) Poisson regression model controlled for age, MMR dose number, MCO site, and gender</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 24 months discharged from hospital in 5 districts in England (Ashford, Leicester, Nottingham, Preston, and Chorley &amp; Ribble) for varying periods between October 1988, and February 1993. Readmissions within 72 h with the same diagnosis were counted as 1 episode. </p> <p>n = 952 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idiopatric thrombocytopenic purpura</b> </p> <p>(ICD 287.3) children aged between 366 and 730 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p><b>Urabe</b> mumps strain </p> <p><b>Jeryl Lynn</b> mumps strain </p> <p>Rubella strain not specified</p> <p><b>Exposure risk period:</b> </p> <p>(a1) 6 to 11 days (1 to 2 weeks after vaccination)</p> <p>(a2) 15 to 35 days (3 to 5 weeks after vaccination)</p> <p><b>Control period:</b> </p> <p>(b) for each vaccine was defined as the time not included in a risk period.</p> <p>The analyses were adjusted for age and were grouped in 6 equal intervals of about 2 months. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> we demonstrated a causal association between ITP and MMR vaccination, with an absolute risk of 1 in 24,000 doses and an attributable risk of 1 in 29,000 doses. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 4 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a2) 6.44 (1.94 to 21.4)</p> <p>(*) Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicountry<br/>collaboration (England and Denmark) study. </p> <p>The chosen study population was children aged 12 to 23 months (365 to 732 days).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenic purpura</b> </p> <p>The case definition for TP was based only on the presence of a relevant ICD‐10 code (D69.3) or ICD‐8 code (287.10) in 1 of the diagnostic discharge fields. First episodes were defined as the earliest record found for an individual, further episodes were initially required to be at least 14 days since a previous episode (to prevent double counting of episodes). </p> <p>In England cases (based on ICD‐10) occurring between 1 April 1996 and 31 March 2007 were linked using NHS number or gender/date of birth/postcode to immunisation records. </p> <p>In Denmark the Central Person Registry (CPR) was used to construct a nationwide cohort consisting of all Danish children born in the period 1 January 1990 to 31 December 2007 (∼1.2 million children). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p><b>Risk periods</b>: (post‐MMR) </p> <p>(a) 0 to 13 days</p> <p>(b) 14 to 27 days</p> <p>(c) 28 to 42 days</p> <p>(d) 0 to 42 days</p> <p><b>Reference period</b> </p> <p>pre‐vaccination</p> <p>(e) −7 to −1 days</p> <p>(to allow for a vaccination being delayed if the child was ill)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> this study gave consistent estimates of the relative incidence of TP following MMR vaccination in 1‐year‐olds. </p> <p>The 95% CI for the attributable risk of TP can be calculated based on the 95% CI for the relative incidence and gives an interval of 1 in 74,000 to 1 in 40,000 doses. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 12 cases</p> <p>(b) 26 cases</p> <p>(c) 17 cases</p> <p>(d) 55 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 1.30 (0.71 to 2.38)</p> <p>(b) 2.87 (1.85 to 4.46)</p> <p>(c) 1.81 (1.07 to 3.05)</p> <p>(d) 1.98 (1.41 to 2.78)</p> <p>(*) adjusting for age, period, country, and country‐age interaction</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children &lt; 18 years old (confirmed ITP cases) who had been vaccinated while actively enrolled in their respective health plans. </p> <p>This investigation was conducted in 5 healthcare systems (Kaiser Permanente: Colorado, Hawaii, Georgia, Northern California, and Harvard Vanguard Medical Associates) by using data from the years 2000 to 2009. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenic purpura</b> </p> <p>Case was defined as a child aged 6 weeks to 18 years with a platelet count of ≤ 50,000/μL, with normal red and white blood cell indices, and the presence of clinical signs and symptoms of ITP, such as petechiae, significant bruising, or spontaneous bleeding. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR, MMRV vaccine:</b> not described </p> <p><b>Follow‐up time:</b> 365 days before and after vaccination. </p> <p><b>Exposed period:</b> 1 to 42 days after vaccination for all vaccines. </p> <p><b>Unexposed period:</b> defined as the time before and after the exposed period within 365 days of follow‐up before or after vaccination.<br/>Day 0 (the day of vaccination) was excluded, because any cases occurring at this time were most likely coincidental. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> none of the routine childhood vaccines given in the first year of life was significantly associated with an increased risk of ITP. For vaccines routinely administered at 12 to 19 months of age, there was a significant association of ITP with MMR. There was no increased risk of ITP (calculated when not given simultaneously with MMR or MMRV). There were 1.9 cases of ITP per 100,000 doses of MMR. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposed cases</b> versus <b>unexposed cases</b> </p> <p><b>(a) 12 to 19 months</b> </p> <p>(a1) MMR: 6 versus 5</p> <p>(a2) MMRV: 4 versus 6</p> <p><b>(b) 4 to 6 years</b> </p> <p>(b1) MMR: 2 versus 7</p> <p>(b2) MMRV: 0 versus 5</p> <p><b>(c) 11 to 17 years</b> </p> <p>(c1) MMR: 0 versus 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a1) 5.48 (1.61 to 18.64)</p> <p>(a2) 2.87 (0.78 to 10.56)</p> <p>(b1) 3.06 (0.42 to 22.30)</p> <p>(b2) not estimable</p> <p>(c1) not estimable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For this study, WHO selected 26 sentinel sites (49 hospitals) distributed in 16 countries of the 6 WHO regions. </p> <p>The study population included children aged 9 to 23 months admitted to a network‐participating hospital during January 2010 to March 2014, with a discharge diagnosis of either aseptic menigitis or immune thrombocytopenic purpura. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immune thrombocytopenia</b> </p> <p>ICD‐9 codes in first discharge diagnosis position:</p> <p>287.30 to 287.39</p> <p>Primary thrombocytopenia</p> <p>287.41 to 287.49</p> <p>Secondary thrombocytopenia</p> <p>287.5</p> <p>Thrombocytopenia, unspecified</p> <p>ICD‐10 codes in first discharge diagnosis position:</p> <p>D69.3, D69.4 (D69.41 to D69.43)</p> <p>Primary thrombocytopenia</p> <p>D69.5 (D69.51, D69.59)</p> <p>Secondary thrombocytopenia</p> <p>D69.6</p> <p>Thrombocytopenia, unspecified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine (measle strain) (mumps strain)</b> </p> <p><b>Priorix, GSK</b> (Schwarz) (RIT 4385a)<br/><b>Priorix Tetra, GSK</b> (Schwarz) (RIT 4385a)<br/><b>MMR Shanghai Institute</b> (Shanghai‐191) (S79)<br/><b>Measles, Lanzhou Institute</b> (Shanghai‐191) (–)<br/><b>Measles‐Rubella, Beijing Tiantan</b> (Shanghai‐191) (–)<br/><b>M‐M‐R‐II, MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>MMR, Razi Vaccine and Serum Research</b> (AIK‐C) (Hoshino)<br/><b>M‐M‐RVAXPRO, Sanofi Pasteur‐MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>Trimovax, Sanofi Pasteur</b> </p> <p>(Schwarz) (Urabe AM9)<br/><b>Measles, Serum Institute of India</b> Pvt. (Edmonston‐Zagreb) (–)<br/><b>Measles‐Rubella, Serum Institute of India</b> Pvt. (Edmonston‐Zagreb) (–)<br/><b>MMR, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Tresivac, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Rouvax, Sanofi Pasteur</b> (Schwarz) (–) </p> <p><b>Risk period</b> </p> <p>8 to 35 days</p> <p><b>Washout periods</b> </p> <p>1 to 7 days</p> <p>36 to 42 days</p> <p><b>Control period</b> </p> <p>43 to 84 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The elevated risk of ITP following measles‐containing vaccination is consistent with the literature (<a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a>: <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a>). Our strain‐specific unadjusted<br/>analysis showed a significantly elevated ITP risk for measles<br/>vaccines containing the Schwarz, Edmonston‐Zagreb, and Enders’ Edmonston strains. No risk of ITP was identified in Iran, which reported the concurrent distribution of 3 vaccine products including the AIK‐C, Edmonston‐Zagreb, and Schwarz strains, without distinguishing between them. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 16 countries n = 183 ITP cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(risk versus control) period</b> </p> <p>(a) overall (36 versus 12)</p> <p>(b) overall (excluding Iran) (36 versus 8)</p> <p>(c) AIK‐C/Edmonston‐Zagreb/Schwarz (2 versus 5)</p> <p>(d) Edmonston‐Zagreb (7 versus 1)</p> <p>(e) Enders' Edmonston (11 versus 3)</p> <p>(f) Schwarz (14 versus 1)</p> <p>(g) Shanghai‐191 (0 versus 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) adjusted</b> </p> <p>(a) 5.6 (2.7 to 11.9)</p> <p>(b) 9.1 (3.7 to 22.3)</p> <p>(c) 0.54 (0.08 to 3.6)</p> <p>(d) 8.4 (0.7 to 100.3)</p> <p>(e) 28.7 (1.9 to 443.5)</p> <p><b>rr (95% CI) unadjusted</b> </p> <p>(f) 20.7 (2.7 to 157.6)</p> <p>(g) not estimable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0126" title="LafaurieM , BaricaultB , Lapeyre-MestreM , SaillerL , MoulisG , SommetA , et al. Risk of vaccine-induced immune thrombocytopenia in children. Nationwide case cross-over and self controlled case series studies in France. Fundamental &amp; Clinical Pharmacology2018;32:86. ">eb‐Lafaurie 2018</a> </p> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population‐based study in France including all children newly diagnosed for primary ITP between July 2009 and June 2015. </p> <p>n = 2549</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immune thrombocytopenia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not described </p> <p><b>Exposed period</b> </p> <p>6‐week interval immediately preceding the event</p> <p>(frequency of exposure to vaccines)</p> <p><b>Control period</b> </p> <p>(1) 6 weeks, 6 months before</p> <p>(2) 6 weeks, 3 months before the case period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> in this nationwide study, no significant risk was observed for vaccines against DTP, pneumococcus, meningococcus, and HBV. The increased risk of MMR‐induced ITP is shown in children (previously demonstrated as lower than after the natural infection with measles). Vaccine‐induced ITP remains an exceptional adverse drug reaction, including for MMR vaccines. </p> <p>The numbers of attributable cases per million MMR doses dispensed were 9.8.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 492 patients included in analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>1.62 (1.21 to 2.16)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a> </p> <p>Case‐only ecological study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacovigilance reports:</p> <p>case observed after vaccine administration between 1984 and 30 June 1992 (n = 60). Estimated number of administered vaccine doses was 9,205,483. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenic purpura</b> Acute haemorrhagic syndrome associated with platelet count of &lt; 100,000/mm³, all cases within 45 days of vaccination, over 8‐year period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: </p> <p>(a) ROR, Trimovax (measles Schwarz strain, mumps Urabe AM9 strain, rubella Wistar RA 27/3 M strain) </p> <p><b>Other measles‐containing vaccines</b>: </p> <p>(b) Rouvax (measles Schwarz strain)</p> <p>(c) Rudi‐Rouvax (measles Schwarz strain, rubella Wistar RA 27/3 M strain)</p> <p><b>Other vaccine:</b> </p> <p>(d) Rudivax (rubella Wistar RA 27/3 M strain) + DTbis (e) Rudivax (rubella Wistar RA 27/3 M strain, diptheria, tetanus) </p> <p>(e) Imovax Oreillons (mumps Urabe AM9 strain)</p> <p>2 to 45 days following immunisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> according to the clinical course and biologic findings, vaccine‐associated TP appears to be similar to that occurring after natural measles or rubella infections and is not distinguishable from acute childhood idiopathic thrombocytopenic purpura not associated with vaccination. Such observation, combined with a clear temporal relationship between MMR vaccination and occurrence of TP, make a causal relationship highly plausible. Nevertheless, the incidence of these events remains relatively low with a favourable immediate outcome. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case/doses</b> </p> <p>(a) 42<b>/</b>4,396,645 </p> <p>‐‐‐</p> <p>(b) 2<b>/</b>860,938 </p> <p>(c) 12<b>/</b>1,480,058 </p> <p>‐‐‐</p> <p>(d) 4<b>/</b>2,295,307 </p> <p>(e) 0<b>/</b>172,535 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence x 100,000 doses (95% CI)(*)</b> </p> <p>(a) 0.96 (0.71 to 1.29)</p> <p>‐‐‐</p> <p>(b) 0.23 (0.06 to 0.85)</p> <p>(c) 0.81 (0.46 to 1.42)</p> <p>‐‐‐</p> <p>(d) 0.17 (0.07 to 0.45)</p> <p>(e) 0.00 (0.00 to 2.23)</p> <p>(*) confidence intervals were recomputed by <a href="./references#CD004407-bbs2-0405" title="WilsonBE . Probable inference the law of succession and statistical inference. Journal of the American Statistical Association1927;22:209-12.">Wilson 1927</a> method. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>DTP: diphtheria, tetanus, and pertussis<br/>GPRD: General Practice Research Database<br/>HMO: health maintenance organisation<br/>HPV: human papillomavirus<br/>ICD: International Classification of Diseases<br/>ITP: idiopathic thrombocytopenic purpura<br/>MCOs: Managed Care Organizations<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>incidence: cases/PT<br/>RR: risk ratio (relative risk)<br/>TP: thrombocytopenic purpura<br/>WHO: World Health Organization </p> </div> </div> <div class="table" id="CD004407-tbl-0041"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0033" title="Da DaltL , ZerbinatiC , StrafellaMS , RennaS , RiceputiL , Di PietroP , et al Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics2016;42(1):60. [DOI: 10.1186/s13052-016-0267-2]">bb‐Da Dalt 2016</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> (n = 288) children (aged &gt; 1 month and ≤ 18 years) hospitalised with a diagnosis of Henoch‐Schönlein purpura through the emergency departments (11 Italian paediatric hospitals/wards spread throughout the country (Treviso, Padua, Naples, Genoa, Turin, Florence, Perugia, Palermo, Messina, and Rome, with 2 centres)). </p> <p><b>Control</b> (n = 617) children hospitalised for gastroduodenal lesions were considered as appropriate controls, since they represent an acute condition admitted through the emergency departments in the same clinical centres in which cases were identified. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Henoch‐Schönlein purpura</b> </p> <p>All children hospitalised with a diagnosis of HSP at admission were included as cases. Discharge diagnosis was retrieved from clinical records and validated by clinicians, according to EULAR/PRINTO/PRES criteria for classification of HSP. Validation was conducted retrieving data from individual patient clinical records, blinded with respect to drug and vaccine exposure. Only validated cases were analysed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccines MMR</b><br/>not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> the association between MMR vaccination and HSP confirms previous published findings and adds a risk estimate. Further studies are needed to increase our understanding of the role of drugs and vaccines in the aetiology of HSP, a disease with important effects on health of children for its potential, though rare, chronic outcomes. </p> <p>This article confirms that HSP is a rare condition (288 children hospitalised in 14 years). Furthermore, the number of vaccinated cases was only 8, suggesting a very low absolute risk of the condition in children vaccinated with MMR vaccine. The benefit/risk profile of MMR vaccine is thus not affected by our results, being that MMR vaccination is an effective and safe tool against serious diseases in childhood. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>8/228 versus 6/617</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>3.4 (1.2 to 10.0)</p> <p>(*) Adjusted by age</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>HSP: Henoch‐Schönlein purpura<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time </p> </div> </div> <div class="table" id="CD004407-tbl-0042"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Safety: type 1 diabetes</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0086" title="HiividAD , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health2004;8(5):286-7. [CRSREF: 2955568]HviidA , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination and type 1 diabetes. New England Journal of Medicine2004;350(14):1398-404. ">cb‐Hviid 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A cohort of children born from 1 January 1990 to 31 December 2000 from the Danish Civil Registration System (n = 739,694) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type 1 diabetes:</b> </p> <p>information on the diagnosis of type 1 diabetes from 1 January 1990 through 31 December 2000 was obtained from the Danish National Hospital Register. </p> <p>From 1990 through 1993, Denmark used a modified version of the ICD‐8.</p> <p>From 1994 through 2001, the ICD‐10 was used. The authors used codes 249 and E10 (the code 249 does not exist in the standard World Health Organization version of the ICD‐8) to identify all cases of type 1 diabetes. </p> <p>Beginning in 1995, visits to the emergency room and outpatient visits were included in the National Hospital Register. </p> <p>(n = 681 cases of type 1 diabetes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>measles Moraten strain,</p> <p>mumps Jeryl Lynn strain,</p> <p>rubella Wistar RA 27/3 strain.</p> <p>Schedule 15 months and 12 years of age; composition:</p> <p>(a1) 1 dose</p> <p>(a2) unknown</p> <p>(b) unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> these results do not support a causal relation between childhood vaccination and type 1<br/>diabetes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All children</b> </p> <p>(a1) 499/293,428</p> <p>(a2) 58/412,830</p> <p>(b) 124/1,373,401</p> <p><b>Children with at least 1 sibling with type 1 diabetes</b> </p> <p>(a1) 20/2795</p> <p>(a2) 0/361</p> <p>(b) 6/1053</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>All children</b> </p> <p>(a1) 1.14 (0.90 to 1.45)</p> <p>(a2) 1.04 (0.71 to 1.52)</p> <p><b>Children with at least 1 sibling with type 1 diabetes</b> </p> <p>(a1) 0.86 (0.34 to 2.14)</p> <p>(a2) ‐ (‐ to ‐)</p> <p>(*) Poisson log linear regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0082" title="BeyerleinA , StroblAN , WinklerC , CarpusM , KnopffA , DonnachieE , et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine2017;35(14):1735-41. ">cb‐Beyerlein 2017</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort of children recruited:</p> <p>between 1989 and 2000, a total of 1650 offspring of patients with T1D were recruited for the BABYDIAB study and were followed for 23,856 patient years. </p> <p>Between 2000 and 2006, 791 additional offspring or siblings of patients with T1D were screened in the context of the BABYDIET study and were followed by using the BABYDIAB protocol for 6358 patient years. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Islet autoimmunity:</b> </p> <p>type 1 diabetes: (T1D) is one of the most common chronic diseases in childhood.</p> <p>The disease is preceded by a preclinical period of <b>islet autoimmunity</b>, which most commonly develops in early infancy. </p> <p>Factors that induce a strong immune response in early life might thus be relevant for the development of T1D‐associated islet autoimmunity. </p> <p>Islet autoantibodies were measured in venous blood samples from scheduled visits. Children in the BABYDIAB study had scheduled visits at birth, at age 9 months, and at 2, 5, 8, 11, 14, 17, and 20 years of age, whereas children in the BABYDIET study had 3‐monthly visits from birth until the age of 3 years, and yearly until the age of 12 years. Measurement of islet autoantibodies in these studies has been described elsewhere. </p> <p>Islet autoimmunity was defined as the development of persistent autoantibodies to 1 or more of the antigens insulin, GAD65, IA‐2 or Zn‐T8, with sample values above the 99th percentile of published population control children classified as positive. </p> <p>In case of single positive antibodies against insulin or GAD65, affinity and epitope reactivity was determined and children with low‐affinity antibodies (&lt; 109 L/mol) were not classified as islet autoantibody positive, as these isolated antibody signals are not T1D specific and are not associated with increased T1D risk. Persistence was defined as positive in at least 2 consecutive samples. Islet autoantibody assays were evaluated according to the Diabetes Autoantibody Standardization Program. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>not described</p> <p>Age</p> <p>(a) 0 to 24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> the authors found no evidence that early vaccinations increase the risk of T1D‐associated islet<br/>autoimmunity development. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> <p>n = 1918</p> <p>n = 1779 children without confirmed islet autoimmunity</p> <p>n = 139 confirmed islet autoimmunity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)(*)</b> </p> <p>(a) 1.08 (0.96 to 1.21)</p> <p>(*) Cox regression</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>HMO: health maintenance organisation<br/>HR:hazards ratio<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>T1D: type 1 diabetes </p> </div> </div> <div class="table" id="CD004407-tbl-0043"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Safety: asthma</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0083" title="DeStefanoF , GuD , KramarzP , TrumanBI , IademarcoMF , MulloolyJP , et al. Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal2002;21(6):498-504. ">cb‐DeStefano 2002</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (0 to 6 years) enrolled in VSD project (4 HMOs) between 1991 and 1997 (n = 167,240) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma:</b> a child had to meet 1 of the following criteria: </p> <p><b>(1)</b> at least 1 diagnosis of asthma ICD‐9 Code 493 and at least 1 prescription for an asthma medication; the first diagnosis and first prescription had to be within a 2‐year period. Asthma medications included oral or inhaled beta‐agonists, theophyllin, oral or inhaled corticosteroids, cromolyn sodium, adrenergic drugs not elsewhere specified, and unclassified asthma medications; </p> <p><b>(2)</b> at least 1 prescription for an inhaled beta‐agonist and at least 1 prescription for cromolyn within a 2 year period; </p> <p><b>(3)</b> at least 5 prescriptions for asthma medications during a 2‐year period. (Total asthma cases n = 18,407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Exposure to MMR vaccine (and other vaccines). Vaccinations were ascertained through computerised immunisation tracking systems, and onset of asthma was identified through computerised data on medical care encounters and medication dispensing. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there is no association between<br/>MMR vaccine and the risk of asthma. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>0.97 (0.91 to 1.04)</p> <p>(*) adjusted rr estimated from a proportional hazard regression model stratified by HMO and month and year of birth, gender, low birthweight status </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 16,470) aged from 20 months to 11 years, accounting for 69,602 person‐years</p> <p>n = 29,238</p> <p>n = 20,845 vaccinated</p> <p>n = 8393 unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma:</b> diagnoses of asthma/wheeze and eczema from the Oxford Medical Information System (which was derived from the ICD‐8) and Read codes (hierarchical codes commonly used in GP practices in England) </p> <p>diagnoses of asthma n = 1753</p> <p>n = 28 (amongst unvaccinated)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Vaccination status extracted from West Midlands General Practice Research Database.</p> <p>Data are presented<br/><b>stratified by consulting</b> <br/><b>frequency in first 18 months</b> </p> <p>(a1) 0 to 6</p> <p>(a2) 7 to 10</p> <p>(a3) 11 to 16</p> <p>(a4) &gt; 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the study data suggest that currently recommended routine vaccinations are not a risk factor for asthma or eczema. In this observational study analysing computerised primary care records, the authors found an association between MMR and DPT vaccination and the incidence of <b>asthma</b> and eczema, but these associations appeared to be limited to the minority of children who rarely seek care from a GP. This limited association is more likely to be the result of bias than a biological effect. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/PT‐years</b> </p> <p>versus</p> <p><b>cases unvaccinated/PT‐years</b> </p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐All‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p>(a) 1725<b>/</b> 65,597 versus 28<b>/</b>4006 </p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p><b>stratified by consulting frequency in first 18 months</b> </p> <p>(a1) 165<b>/</b> 12,462 versus 5<b>/</b>2843 </p> <p>(a2) 351<b>/</b> 17,522 versus 7<b>/</b>425 </p> <p>(a3) 601<b>/</b> 20,693 versus 8<b>/</b>452 </p> <p>(a4) 608 <b>/</b>14,920 versus 8/286 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 2.2 (1.50 to 3.21)</p> <p>(a1) 7.18 (2.95 to 17.49)</p> <p>(a2) 0.95 (0.45 to 2.01)</p> <p>(a3) 1.36 (0.68 to 2.73)</p> <p>(a4) 1.21 (0.60 to 2.43)</p> <p>(*) Adjusted rr estimated from a proportional hazard regression model stratified by consulting frequency, parental smoking, parental allergic disease, maternal age, number of older siblings, use of antibiotics early in life, year of birth, and GP practice. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danish birth cohorts 1991 to 2003 followed up between 1 January 1991 and 31 December 2003, or between 1 and 5 years of age </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma hospitalisation:</b> </p> <p>inpatient hospitalisation with asthma diagnosis (occurred between 1 January 1992 and 31 December 2004) </p> <p> <ul id="CD004407-list-0032"> <li> <p>Asthma diagnosis: 493.xx (ICD‐8) and J45.x, J46.x (ICD‐10)</p> </li> <li> <p>Severe asthma (status asthmaticus) 493.01 (ICD‐8) and J49.9 for severe asthma</p> </li> </ul> </p> <p>n = 871,234 children (vaccine coverage 85%) PT = 2,926,406 (person‐years)</p> <p>n = 26,880 hospitalisations amongst 17,885 children</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Anti‐asthma medication:</b> </p> <p>prescription of the following cases of anti‐asthma medications have been considered:</p> <p> <ul id="CD004407-list-0033"> <li> <p>glucocorticoid inhalants (ACT code R03BA)</p> </li> <li> <p>short‐acting beta2‐agonist inhalants (ACT codes R03AC02, R03AC03, and R03AC04)</p> </li> <li> <p>long‐acting beta2‐agonist inhalants (ACT codes R03AC12 and R03AC13)</p> </li> <li> <p>systemic beta2‐agonists (ACT code R03CC)</p> </li> <li> <p>other types of anti‐asthma medication (all other ACT codes under R03)</p> </li> </ul> </p> <p>n = 600,938 children (vaccine coverage 84%) PT = 1,858,199 (person‐years)</p> <p>n = 833,424 prescriptions anti‐asthma medication amongst 248,907 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: </p> <p>Measles <b>Moraten</b> strain, </p> <p>Mumps <b>Jeryl Lynn</b> strain, </p> <p>Rubella <b>Wistar RA 27/3</b> strain. </p> <p>Dates of MMR vaccination were obtained from the National Board of Health.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> these results are compatible not with an increased risk of asthma following MMR vaccination, but rather with the hypothesis that MMR vaccination is associated with a reduced risk of asthma‐like disease in young children. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Asthma</p> <p>(b) Status asthmaticus</p> <p>(c) Anti‐asthma medication</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 0.75 (0.73 to 0.78)</p> <p>(b) 0.63 (0.49 to 0.82)</p> <p>(c) 0.92 (0.91 to 0.92)</p> <p>(*) Adjusted for age, calendar period, hospitalisations propensity in infancy, birthweight, place of birth, mother’s country of birth, infant vaccine compliance, birth order, maternal age at birth, and child’s sex. Log‐linear Poisson regression. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0081" title="BenkeG , AbramsonM , RavenJ , ThienFC , WaltersEH . Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health2004;28(4):336-8. ">cb‐Benke 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were aged between 22 and 44 years n = 309</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were surveyed by a validated interviewer‐administered questionnaire covering: history of asthma; details of home and occupation environment; smoking history; medications; dietary information; and respiratory symptoms. The respiratory symptoms included wheezing or whistling in the chest, shortness of breath, chest tightness, and cough and phlegm during the previous 12 months. Atopy was assessed by skin prick testing to common aeroallergens. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> <p>Questionnaire included vaccination history questions, which were not included in the questionnaire used by the other study centres. Vaccination history included measles or MMR vaccinations; hepatitis B; Bacille Calmette‐Guérin (BCG); oral polio vaccine (OPV); and diphtheria, tetanus, and whooping cough (DTP). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there was no significant association observed for participants diagnosed with asthma who had received measles or MMR vaccinations compared with those who did not receive measles or MMR vaccinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Asthma</p> <p>(b) Atopy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> <p>(a) 1.33 (0.98 to 1.80)</p> <p>(b) 1.07 (0.88 to 1.30)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 640 children were followed from birth. Follow‐up examinations at ages 5, 7 and 13 years included a physical examination and a maternal questionnaire about the child’s health. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma</b> (and dermatitis eczema) </p> <p>At child's age 5, parents were asked whether the child was suspected to suffer from asthma or had been diagnosed with asthma, hypersensitivity, or allergy. </p> <p>At ages 5, 7, and 13 years, the same paediatrician determined the presence of current wheezing by auscultation. At the same ages, the paediatrician also examined all children for dermatitis/eczema. </p> <p>At age 13, the findings from this examination were graded according to a score for atopic dermatitis (SCORAD). </p> <p>At age 7, a blood sample was drawn and total IgE and grass‐specific IgE were quantified.</p> <p>At age 13, parents were asked whether the child had ever suffered from asthma. In accordance with the International Study of Asthma and Allergies in Childhood (ISAAC), they were also asked to<br/>indicate whether the child had (i) suffered from wheezing in the past 12 months, (ii) suffered from sneezing, running, or blocked‐up nose except for when the child had a cold or was sick in the past 12 months and, if so, whether it had been accompanied by itching running/tearing eyes (current rhinoconjunctivitis symptoms), and (iii) whether the child had ever suffered from an itching rash that comes and goes for at least 6 months (eczema ever). At age 13, the children underwent a skin prick test with extracts of 5 common allergens (birch/grass pollen, dog/cat dander, and house dust mite (<i>Dermatophagoides pteronyssinus</i>)). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p>The Faroe Islands follow the Danish vaccination schedule, in which MMR vaccination, at the time of this study, was administered at age 15 months and 12 years (Fig. 1). There were no specific contraindications. At the 5‐year examination, the child’s vaccination card was inspected and all vaccination dates were registered. At child's age 13, the mothers were asked whether the child had received the MMR vaccination scheduled at 12 years of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the authors' findings support the notion that MMR vaccination may provide beneficial effects in preventing childhood allergy and asthma. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.33 (0.12 to 0.90)(*)</p> <p>(b) 0.22 (0.08 to 0.56)(*)</p> <p>(a) 0.32 (0.10 to 1.05)(*)(**)</p> <p>(b) 0.16 (0.05 to 0.53)(*)(**)</p> <p><b>RR (95% CI)(***)</b> </p> <p>(a) 0.44 (0.18 to 0.93)(*)</p> <p>(b) 0.35 (0.14 to 0.71)(*)</p> <p>(*) Adjusted OR (logistic regression model) for birthweight and family history of chronic bronchitis/asthma. The analyses at age 13 years are additionally adjusted for whether the child had received the second MMR vaccine before the 13‐year examination. </p> <p>(**) Additional adjustment for sex, premature birth, maternal smoking during pregnancy, log (cord blood IgE), breastfeeding, number of older siblings, number of younger siblings, parental smoking in the home, day care, family history of eczema in children/allergic eczema/hay fever, family history of allergy, and age at the examination. </p> <p>(***) OR converted in RR</p> <p>(a) CER = 0.36</p> <p>(b) CER = 0.47</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACT: Asthma Control Test<br/>CER: control event rate<br/>CI: confidence interval<br/>DPT: diphtheria, pertussis, and tetanus vaccine<br/>GP: general practice<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>IgE: Immunoglobulin E<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>VSD: Vaccine Safety Datalink </p> </div> </div> <div class="table" id="CD004407-tbl-0044"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Safety: dermatitis or eczema</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 14,353) aged from 20 months to 11 years, accounting for 59,520 person‐years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eczema:</b> diagnoses of asthma/wheeze and eczema from the Oxford Medical Information System (which was derived from the ICD‐8) and Read codes (hierarchical codes commonly used in GP in England) </p> <p>diagnoses of eczema n = 1884</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Vaccination status extracted from West Midlands General Practice Research Database</p> <p>Data are presented<br/><b>stratified by consulting</b> <br/><b>frequency in first 18 months</b> </p> <p>(a1) 0 to 6</p> <p>(a2) 7 to 10</p> <p>(a3) 11 to 16</p> <p>(a4) &gt; 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the study data suggest that currently recommended routine vaccinations are not a risk factor for asthma or eczema. In this observational study analysing computerised primary care records, the authors found an association between MMR and DPPT vaccination and the incidence of asthma and <b>eczema</b>, but these associations appeared to be limited to the minority of children who rarely seek care from a GP. This limited association is more likely to be the result of bias than a biological effect. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/PT‐years</b> </p> <p>versus</p> <p><b>Cases unvaccinated/PT‐years</b> </p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐All‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p>(a) 1857/55,651 versus 27/3868</p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p><b>Stratified by consulting frequency in first 18 months</b> </p> <p>(a1) 244/10,625 versus 6/2768</p> <p>(a2) 457/14,293 versus 7/402</p> <p>(a3) 601/17,427 versus 9/400</p> <p>(a4) 555/13,306 versus 5/297</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 3.50 (2.38 to 5.15)</p> <p>(a1) 10.4 (4.61 to 23.29)</p> <p>(a2) 1.57 (0.75 to 3.32)</p> <p>(a3) 1.36 (0.71 to 2.64)</p> <p>(a4) 2.21 (0.92 to 5.33)</p> <p>(*) Adjusted rr estimated from a proportional hazard regression model stratified by consulting frequency, parental smoking, parental allergic disease, maternal age, number of older siblings, use of antibiotics early in life, year of birth, and GP practice. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 640 children were followed from birth. Follow‐up examinations at ages 5, 7, and 13 years included a physical examination and a maternal questionnaire about the child’s health. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma and <b>dermatitis eczema</b> </p> <p>At age 5, parents were asked whether the child was suspected to suffer from asthma or had been diagnosed with asthma, hypersensitivity, or allergy. </p> <p>At ages 5, 7, and 13 years, the same paediatrician determined the presence of current wheezing by auscultation. At the same ages, the pediatrician also examined all children for dermatitis/eczema. </p> <p>At age 13, the findings from this examination were graded according to a score for atopic dermatitis (SCORAD). </p> <p>At age 7, a blood sample was drawn and total IgE and grass‐specific IgE were quantified.</p> <p>At child's age 13, parents were asked whether the child had ever suffered from asthma. In accordance with the International Study of Asthma and Allergies in Childhood (ISAAC), they were also asked to indicate whether the child had (i) suffered from wheezing in the past 12 months, (ii) suffered from sneezing, running, or blocked‐up nose except for when the child had a cold or was sick in the past 12 months, and, if so, whether it was accompanied by itching running/tearing eyes (current rhinoconjunctivitis symptoms), and (iii) whether the child had ever suffered from an itching rash that comes and goes for at least 6 months (eczema ever). At age 13, the children underwent a skin prick test with extracts of 5 common allergens (birch/grass pollen, dog/cat dander, and house dust mite (<i>Dermatophagoides pteronyssinus</i>)). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p>The Faroe Islands follow the Danish vaccination schedule, in which MMR vaccination, at the time of this study, was administered at age 15 months and 12 years (Fig. 1). There were no specific contraindications. At the 5‐year examination, the child’s vaccination card was inspected and all vaccination dates were registered. At child's age 13, the mothers were asked whether the child had received the MMR vaccination scheduled at 12 years of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there is no association between<br/>MMR vaccine and the risk of eczema. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eczema</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) no data (*)</p> <p>(b) 0.73 (0.26 to 2.10) (*)</p> <p>(a) no data (*) (**)</p> <p>(b) 0.46 (0.14 to 1.52) (*) (**)</p> <p><b>RR (95% CI) (***)</b> </p> <p>(a) no data (*)</p> <p>(b) 0.75 (0.28 to 1.87) (*)</p> <p>(*) Adjusted OR (logistic regression model) for birthweight and family history of chronic bronchitis/asthma. The analyses at age 13 years are additionally adjusted for whether the child had received the second MMR vaccine before the 13‐year examination. </p> <p>(**) Additional adjustment for sex, premature birth, maternal smoking during pregnancy, log (cord blood IgE), breastfeeding, number of older siblings, number of younger siblings, parental smoking in the home, day care, family history of eczema in children/allergic eczema/hay fever, family history of allergy, and age at the examination. </p> <p>(***) OR converted in RR</p> <p>(a) no data</p> <p>(b) CER = 0.11</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CER: control event rate<br/>CI: confidence interval<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>IgE: immunoglobulin E<br/>GP: general practice<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>VSD: Vaccine Safety Datalink </p> </div> </div> <div class="table" id="CD004407-tbl-0045"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 76,310 children from GPRD born between 1989 and 1993 from 464 general practices, and within a DIN cohort of n = 40,183 children born between 1989 and 1997 from 141 general practices. </p> <p><b>From GPRD</b> </p> <p>cases = 3859</p> <p>controls = 3859</p> <p><b>From DIN</b> </p> <p>cases = 2611</p> <p>controls = 2611</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hay fever</b> </p> <p><b>Case certain (Definition I):</b> a child with hay fever diagnosis before 24 months of age, and a second diagnosis of hay fever or a relevant therapy in a subsequent years and with a third diagnosis or a relevant therapy in a further year. </p> <p><b>Case certain (Definition II):</b> a child without first diagnosis before 24 months of age, but with a second diagnosis of hay fever or a relevant therapy in subsequent year. </p> <p><b>Case less certain (Definition I):</b> a child as a case certain (Definition I) without third diagnosis of hay fever or a relevant therapy in a further year. </p> <p><b>Case less certain (Definition II):</b> a child with at least a hay fever diagnosis, even if there is not a second diagnosis or a relevant therapy in a subsequent year. </p> <p>The <b>cases</b> and <b>controls</b> were children with at least 5 years of follow‐up from birth and registered “within the practice within 3 months of birth”. Only codes synonymous with "allergic rhinitis” and with seasonal variation in recording were permitted. From GPRD and DIN database. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> (first entries) MMR II </p> <p>The time categories for MMR immunisation:</p> <p>(a) 1st to 13th month</p> <p>(b) 14th month</p> <p>(c) 15th month</p> <p>(d) 16th month</p> <p>(e) 17th month</p> <p>(f) 18th to 24th month</p> <p>(g) ≥ 25th month</p> <p>(h) no MMR vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> this study shows that infants vaccinated with MMR are at no greater or lesser risk of developing hay fever than unvaccinated children. </p> <p>This should reassure parents and clinicians, and no opportunity should be missed to immunise. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n</b> = <b>(cases + controls)</b> </p> <p><b>From GPRD</b> </p> <p>(a) n = 1688</p> <p>(b) n = 2311</p> <p>(c) n = 1638</p> <p>(d) n = 1183</p> <p>(e) n = 510</p> <p>(f) n = 618</p> <p>(g) n = 234</p> <p>(h) n = 210</p> <p><b>From DIN</b> </p> <p>(a) n = 1128</p> <p>(b) n = 1769</p> <p>(c) n = 1192</p> <p>(d) n = 772</p> <p>(e) n = 335</p> <p>(f) n = 379</p> <p>(g) n = 119</p> <p>(h) n = 110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>From GPRD(*)</b> </p> <p>(a) 0.97 (0.81 to 1.16)</p> <p>(b) 1.00 (1.00 to 1.00)</p> <p>(c) 0.89 (0.75 to 1.06)</p> <p>(d) 0.93 (0.75 to 1.14)</p> <p>(e) 0.96 (0.73 to 1.25)</p> <p>(f) 0.89 (0.70 to 1.14)</p> <p>(g) 0.83 (0.58 to 1.18)</p> <p>(h) 0.81 (0.53 to 1.24)</p> <p><b>From DIN(**)</b> </p> <p>(a) 0.90 (0.71 to 1.16)</p> <p>(b) 1.00 (1.00 to 1.00)</p> <p>(c) 1.24 (1.00 to 1.53)</p> <p>(d) 0.96 (0.73 to 1.39)</p> <p>(e) 1.00 (0.69 to 1.45)</p> <p>(f) 1.01 (0.73 to 1.28)</p> <p>(g) 0.54 (0.31 to 0.95)</p> <p>(h) 0.82 (0.45 to 1.50)</p> <p><b>From GPRD‐DIN Pooled (fixed‐effect)</b> </p> <p>1.27 (0.93 to 1.72)</p> <p>(*) Adjusted for consultation<br/>frequency and restricted to<br/>pairs with non‐ghost controls,<br/>adjusted for numbers of older<br/>and younger siblings and multiple<br/>births. </p> <p>(**) Adjusted for consultation frequency and restricted to<br/>pairs with non‐ghost controls. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 76,310 children from GPRD born between 1989 and 1993 from 464 practices and within a DIN cohort of n = 40,183 children born between 1989 and 1997 from 141 general practices. </p> <p>case + controls = 13,523</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hay fever</b> risk in the first grass pollen season. </p> <p>Case of hay fever were children with diagnostic codes or treatment for hay fever, or both, after 2 years of age. </p> <p>Control was child that matched for general practice, sex, birth month, and follow‐up of control to at least date of diagnosis case. </p> <p>"Cases of hayfever were those who had diagnostic codes and/or treatment for hayfever, after 2 years of age”. From GPRD and DIN database. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> MMR II </p> <p>exposure by 24 months in a grass pollen season (May, June, July) versus non‐pollen season exposure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> in 2 population‐based birth cohorts, the authors have not<br/>demonstrated any significant relationship between hay fever<br/>and vaccination with MMR. </p> <p>Having MMR vaccine during grass pollen season by age 24 months (compared with MMR outside grass pollen season only) was not associated with an increased OR. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases + control</p> <p>out season = 9690</p> <p>in season = 3833</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>1.05 (0.94 to 1.18)</p> <p>(*) Odds ratios were pooled across databases (GPRD and DIN) using a fixed‐effect model.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> </p> <p>Cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 640 children were followed from birth. Follow‐up examinations at ages 5, 7, and 13 years included a physical examination and a maternal questionnaire about the child’s health. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma (and dermatitis eczema)</p> <p>At child's age 5, parents were asked whether the child was suspected to suffer from asthma or had been diagnosed with asthma, hypersensitivity, or allergy. </p> <p>At ages 5, 7, and 13 years, the same paediatrician determined the presence of current wheezing by auscultation. At the same ages, the paediatrician also examined all children for dermatitis/eczema. </p> <p>At age 13, the findings from this examination were graded according to a score for atopic dermatitis (SCORAD). </p> <p>At age 7, a blood sample was drawn and total IgE and grass‐specific IgE were quantified.</p> <p>At age 13, parents were asked whether the child had ever suffered from asthma. In accordance with the International Study of Asthma and Allergies in Childhood (ISAAC), they were also asked to<br/>indicate whether the child had (i) suffered from wheezing in the past 12 months, (ii) suffered from sneezing, running, or blocked‐up nose except for when the child had a cold or was sick in the past 12 months, and, if so, whether it had been accompanied by itching running/tearing eyes (current <b>rhinoconjunctivitis symptoms</b>), and (iii) whether the child had ever suffered from an itching rash that comes and goes for at least 6 months (eczema ever). At age 13, the children underwent a skin prick test with extracts of 5 common allergens (birch/grass pollen, dog/cat dander, and house dust mite (<i>Dermatophagoides pteronyssinus</i>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described. </p> <p>The Faroe Islands follow the Danish vaccination schedule, in which MMR vaccination, at the time of this study, was administered at age 15 months and 12 years (Fig. 1). There were no specific contraindications. At the 5‐year examination, the child’s vaccination card was inspected and all vaccination dates were registered. At child's age 13, the mothers were asked whether the child had received the MMR vaccination scheduled at 12 years of age. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the authors' findings support the notion that MMR vaccination may<br/>provide beneficial effects in preventing childhood allergy and asthma. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rhinoconjunctivitis</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> <p><b>Hypersensitivity/allergy</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>Rhinoconjunctivitis</b> </p> <p>(a) no data (*)</p> <p>(b) 0.64 (0.19 to 2.07) (*)</p> <p>(a) no data (*)(**)</p> <p>(b) 0.63 (0.14 to 2.71) (*)(**)</p> <p><b>Hypersensitivity/allergy</b> </p> <p>(a) 0.32 (0.11 to 0.88) (*)</p> <p>(b) no data (*)</p> <p>(a) 0.36 (0.11 to 1.21) (*)(**)</p> <p>(b) no data (*)(**)</p> <p>(*) Adjusted for birthweight and family history of chronic bronchitis/asthma. The analyses at age 13 years are additionally adjusted for whether the child had received the second MMR vaccine before the 13‐year examination. </p> <p>(**) Additional adjustment for sex, premature birth, maternal smoking during pregnancy, log (cord blood IgE), breastfeeding, number of older siblings, number of younger siblings, parental smoking in the home, day care, family history of eczema in children/allergic eczema/hay fever, family history of allergy, and age at the examination. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>DIN: doctors' independent network<br/>GPRD: General Practice Research Database<br/>HMO: health maintenance organisation<br/>incidence: cases/PT<br/>IgE: immunoglobulin E<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk) </p> </div> </div> <div class="table" id="CD004407-tbl-0046"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 25.</span> <span class="table-title">Safety: acute leukaemia</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a> </p> <p>case control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases:</b> patients with leukaemia or acute lymphoblastic leukaemia, aged 0 to 14 years identified within the NCCLS between 1995 and 2002. </p> <p><b>Controls:</b> matched to cases for date of birth, gender, Hispanic status (either parent Hispanic), maternal race (white, African‐American, or other), and maternal county of residence, by means of birth certificates. </p> <p>Population coverage initially includes 17 countries in the Greater San Francisco Bay Area, and since 1999 was expanded to a further 18 countries in Northern and Southern California. The present study relies on cases of leukaemia ascertained between 1995 and 2002. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leukaemia</b> </p> <p><b>Acute lymphoblastic leukaemia</b> </p> <p>Within the NCCLS, incident leukaemia cases were ascertained from major paediatric clinical centres within 72 hours after diagnosis. </p> <p>To be eligible, each case or control had to:</p> <p> <ul id="CD004407-list-0034"> <li> <p>reside in the study area at the time of diagnosis;</p> </li> <li> <p>be under 15 years of age at the reference date (date of diagnosis for cases and the corresponding date for matched controls); </p> </li> <li> <p>have at least 1 parent or guardian who speaks English or Spanish;</p> </li> <li> <p>have no previous history of malignancy.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Complete vaccination record was requested to primary caretakers of case or control participants.<br/>Other than MMR, vaccinations against diphtheria, pertussis, and tetanus (DPT), DT, Td, poliomyelitis, hepatitis B, or Hib have been considered in the study. </p> <p>(d1) 1 dose</p> <p>(d2) ≥ 2 doses</p> <p>(d0) unvaccinated</p> <p>(a) Leukaemia</p> <p>(a1) born in or before 1995</p> <p>(a2) born after 1995</p> <p>(b) Acute lymphoblastic leukaemia</p> <p>(b1) born in or before 1995</p> <p>(b2) born after 1995</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>MMR vaccination, measured as the number of doses, was not associated with the risk of overall leukaemia or acute lymphoblastic leukaemia. </p> <p>Each dose of Hib vaccination was associated with a significantly reduced risk of childhood leukaemia, whilst the history of DPT, poliomyelitis, and MMR vaccinations did not differ between cases and controls. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p><b>Leukaemia (0 to 14 years)</b> </p> <p>(d1) 176/323 versus 219/409</p> <p>(d2) 123/323 versus 162/409</p> <p>(d0) 24/323 versus 28/409</p> <p><b>Leukaemia (&gt; 1 years)</b> </p> <p>(d1) 175/308 versus 219/392</p> <p>(d2) 123/308 versus 162/392</p> <p>(d0) 10/308 versus 11/392</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Acute lymphoblastic leukaemia</b> </p> <p>(a) cases = 282; controls = 360</p> <p>(b1) born in or before 1995</p> <p>(b2) born after 1995</p> <p>cases = 270; controls = 346</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>leukaemia (*)</b> </p> <p>(a) 1.06 (0.69 to 1.63)</p> <p>(a1) 0.94 (0.75 to 1.53)</p> <p>(a2) 0.79 (0.35 to 1.78)</p> <p><b>Acute lymphoblastic leukaemia(*)</b> </p> <p>(b) 0.87 (0.55 to 1.37)</p> <p>(b1) 0.95 (0.56 to 1.60)</p> <p>(b2) 0.65 (0.24 to 1.72)</p> <p>(*) Adjusted for maternal education and household income</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0037" title="GrovesFD , GridleyG , WacholderS , ShuXO , RobisonLL , NegliaJP , et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. British Journal of Cancer1999;81(1):175-8. [DOI: 10.1038/sj.bjc.6690668]">bb‐Groves 1999</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases:</b> patients with acute lymphoblastic leukaemia aged 0 to 14, diagnosed between 1989 and 1993. </p> <p>Participants who resided in Illinois, Indiana, Iowa, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, or Wisconsin at the time of diagnosis were eligible for the vaccination component of the study. </p> <p><b>Controls:</b> selected through random‐digit dialling were individually matched to the cases by age (within 25% of the corresponding case's age at diagnosis), the first 8 digits of the telephone number, and race (African‐American/white/other). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute lymphoblastic leukaemia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the MMR vaccine does not alter the risk of subsequent acute lymphoblastic leukaemia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cases = 395; controls = 394</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>1.19 (0.67 to 2.10)</p> <p>(*)conditional logistic regression adjusted for age at censoring, year of birth, sex, race, family income, parental education, and attendance at day care and/or preschool </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0039" title="Mallol-MesnardN , MenegauxF , AuvrignonA , AuclercMF , BertrandY , NelkenB , et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology2007;36(1):110-6. ">bb‐Mallol‐Mesnard 2007</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Each case of acute leukaemia incident in 2003 to 2004 in a child aged &lt; 15 years, residing in France at the time of diagnosis and with no previous history of malignancy, was eligible. </p> <p><b>The</b> <b>leukaemia cases</b> <b>(n = 726)</b> were recruited directly by investigators assigned to each French paediatric oncology hospital department, with the support of the French National Registry of Childhood Haematopoietic Malignancies. </p> <p><b>The controls (n = 1681)</b> were randomly selected from the French population using quotas, a priori determined to make the control group representative of all cancer cases in terms of age and gender. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> <b>Acute leukaemia</b> </p> <p><b>(b)</b> <b>Acute lymphoblastic leukaemia</b> </p> <p><b>(c)</b> <b>Acute myeloblastic leukaemia</b> </p> <p>All the childhood leukaemia cases were confirmed by bone marrow analysis. Children whose mother did not speak French or who had been adopted were not eligible. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p><b>Note:</b> the study shows measle‐mumps‐rubella vaccination separately, probably because for the study each mother was asked to read out each page of the vaccination record, line by line. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> no association between vaccination and the risk of childhood acute leukaemia: acute lymphoblastic leukaemia or acute myeloblastic leukaemia was observed. No relationship between the risk of leukaemia and the type of vaccine, number of doses of each vaccine, total number of injections, total number of vaccine doses, or number of early vaccinations was evidenced. No confounding factor was observed. The study did not show any evidence of a role of vaccination in the aetiology of childhood leukaemia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) 541/618 versus 1110/1258</p> <p>(b) 480/554 versus 1110/1258</p> <p>(c) 50/62 versus 1110/1258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.94 (0.70 to 1.26)</p> <p>(b) 0.86 (0.64 to 1.17)</p> <p>(c) 0.56 (0.29 to 1.07)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0036" title="DockertyJD , SkeggDC , ElwoodJM , HerbisonGP , BecroftDM , LewisME . Infections, vaccinations, and the risk of childhood leukaemia. British Journal of Cancer1999;80(9):1483-9. [DOI: 10.1038/sj.bjc.6690548]">bb‐Dockerty 1999</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The eligible cases were newly diagnosed with childhood leukaemia (aged 0 to 14 years) 1990 to 1993, and born and resident in New Zealand. Controls (matched 1:1 to cases on age and sex) were selected randomly from the New Zealand‐born and resident childhood population, using national birth records. Each control’s birth was registered in the same quarter of the same year as the matched case. Adopted children were not eligible. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute lymphoblastic leukaemia</b> </p> <p>n = 97 matched pairs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described. Vaccination histories were supplemented with information from parent‐held ‘Health and Development’ records. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> for MMR, no association was found with leukaemia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>6/118 versus 15/272</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI) (*)</b> </p> <p>0.8 (0.26 to 2.42)</p> <p>(*)unconditional logistic regression adjusted for age, sex, child’s social class, child’s ethnic group, mother’s marital status, mother’s education, mother’s home ownership, household crowding, delay from reference date to interview, interview year. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>DPT: diphtheria, pertussis, tetanus vaccine<br/>DT: diphtheria, tetanus vaccine<br/>Hib: Haemophilus influenzae b vaccine<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>NCCLS: Northern California Childhood Leukemia Study<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>Td: tetanus, diphtheria vaccine<br/>versusD: Vaccine Safety Datalink </p> </div> </div> <div class="table" id="CD004407-tbl-0047"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 26.</span> <span class="table-title">Safety: demyelinating diseases, multiple sclerosis, acute disseminated encephalomyelitis</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residents in the great Gothenburg area (Sweden) born between 1959 and 1990. The study area was the greater Gothenburg area on the Swedish west coast, with 731,592 residents on 31 December 2000. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple sclerosis (probable or definite) and clinically isolated syndromes.</p> <p>Incidence of <b>multiple sclerosis</b> (4 Poser's criteria) and <b>clinically isolated syndrome</b> with onset between 10 and 39 years of age was assessed in birth cohorts immunised within 4 vaccination programmes. The Gothenburg multiple sclerosis register was established from the 1950s. All records are reviewed with the following MS‐related diagnoses, according to the International Classification of Diseases (ICD) 10, 9, and 8: </p> <p><b>G359; 340; 340.99</b> multiple sclerosis; </p> <p><b>G368; G378; G379; 341W; 341.09</b> demyelinating disorders in the central nervous system; </p> <p><b>G360; 341A; 341.01</b> neuromyelitis optica; </p> <p><b>G369; 341X</b> acute disseminated encephalomyelitis; </p> <p><b>G373</b> acute transverse myelitis: </p> <p><b>H46; 377D; 367.02</b> optic neuritis; </p> <p><b>H48,1; 367.03</b> retrobulbar neuritis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described. </p> <p>Different vaccination programmes carried out from 1971 with different vaccines (single‐component measle, mumps and rubella vaccine so as with MMR vaccine) having as target population children of different ages. 5 population birth cohorts were selected from the total incidence material: </p> <p>(0) born 1959 to 1961: the pre‐vaccine era;</p> <p>(1) born 1962 to 1966: monovalent rubella vaccine;</p> <p>(2) born 1970 to 1973: only received later dose of the MMR vaccine;</p> <p>(3) born 1974 to 1978: monovalent measles;</p> <p>(4) July 1981 to June 1984: combined MMR vaccine.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there was no significant change in the age‐ and gender‐specific incidence of MS in any of the selected cohorts compared with the incidence in the preceding selected birth cohorts. There was thus no significant change in MS incidence related to the implementation of the rubella vaccination programme in the 12‐year‐old female cohort born in 1962 to 1966 compared with the unvaccinated cohort born in 1959 to 1961. The incidence did not significantly change with all preceding selected cohorts as baseline, neither in the MMR‐vaccinated 12‐year‐old cohort born in 1970 to 1973, nor in the cohort born in 1974 to 1978, half of which were measles vaccinated in the preschool age and the majority MMR vaccinated at 12, nor in the cohort born in July 1981 to June 1984, which were MMR vaccinated at both 18 months and 12 years of age. Restricting the analyses to probable and definite MS cases did not change the results. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence per 100,000 person‐years</b> </p> <p><b>(‐) (male female) versus (male female) (*)</b> </p> <p>(1) (14.98; 6.97) versus (17.61; 4.28)<br/>(2) (15.28; 6.61) versus (13.17; 5.27)<br/>(3) (12.29; 3.85) versus (9.48; 4.62)<br/>(4) (4.96; 1.18) versus (3.78; 2.55) </p> <p>(*) including both the unvaccinated cohort 1959 to 1961 and the preceding vaccinated birth cohorts selected for this study, in the corresponding age groups </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a> </p> <p>Case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases (n = 206)</b>: birth years 1959 to 1986, to be resident in the greater Gothenburg area (Sweden), MS onset from age of 10 years onwards, did attend the 6th school grade within study area, availability of CHSH records. </p> <p><b>Controls (n = 888)</b>: matched to cases for year of birth by random selection from the population register. Controls should have attended the 6th school grade within study area, and have available CHSH record. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple sclerosis (probable or definite) and clinically isolated syndromes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p>MMR vaccination (vaccination with single‐component vaccines has also been considered).</p> <p>The second analysis was therefore restricted to the subgroup of the MMR vaccinations.</p> <p>The first analysis was restricted to the subgroup "MMR vaccination". 4 disjointed vaccination categories were defined: </p> <p>(0) no MMR vaccination;</p> <p>(1) early MMR vaccination only; (3) late MMR vaccination only; (4) both an early and a late MMR vaccination. Comparisons were made within the group of MMR vaccinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> no significant association for vaccinated versus unvaccinated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases = 206; controls = 888</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>1.13 (0.62 to 2.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0032" title="ChenY , MaF , XuY , ChuX , ZhangJ . Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine2018;36(26):3733-9. ">bb‐Chen 2018</a> </p> <p>Case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case (n = 272):</b> acute disseminated encephalomyelitis. </p> <p><b>Controls (n = 1096):</b> for each ADEM case, 4 control individuals randomly selected from the same hospital with no history of ADEM were matched to the case according to year of birth (within 1 year), gender, and zip code (a surrogate measure for socioeconomic status) during the same period. The control participants were assigned the same index date as their matched case (symptom onset date). Controls were patients referred for headache (except trigeminal neuralgia), migraine, vascular, or other diseases which were thought not to modify the probability of vaccination. Patients with chronic severe neurological diseases or autoimmune diseases were excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute disseminated encephalomyelitis:</b> </p> <p>immune‐mediated<br/>central nervous system disorder, characterised by an<br/>acute encephalopathy with polyfocal neurological deficits. </p> <p>From the Hospital Information Systems first mention of International Classification of Diseases, Tenth Revision (ICD‐10), diagnostic codes (G04.001, G04.002, G04.051, G04.903, and G04.912) for ADEM from 1 January 2011 to 31 December 2015, for individuals of any age.<br/>Diagnoses were confirmed by neurologists from clinical data, such as clinical manifestations, computed tomography, electroencephalograph, cerebrospinal fluid, and magnetic resonance imaging examinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> findings from the present study do not demonstrate an association of vaccines with an increased risk of ADEM and its recurrence among either paediatric (&lt; 18 years) or adult (≥ 18 years) individuals within the 180 days after vaccinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/272 versus 36/1096</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>adjusted estimate</p> <p>1.03 (0.68 to 3.75)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADEM: acute disseminated encephalomyelitis<br/>CI: confidence interval<br/>CHSH: child health and school health records<br/>CIS: clinically isolated syndromes<br/>HMO: health maintenance organisation<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MS: multiple sclerosis<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>VSD: Vaccine Safety Datalink </p> </div> </div> <div class="table" id="CD004407-tbl-0048"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 27.</span> <span class="table-title">Safety: gait disturbances</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0118" title="MillerE , AndrewsN , GrantA , StoweJ , TaylorB . No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood2005;90(3):292-6. ">db‐Miller 2005</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children <b>hospitalised with gait disturbance</b> between April 1995 and June 2001 (n = 127, age 12 to 24 months). </p> <p>Children with <b>gait disturbance resulting from general practice visit</b> General Practice Research Database. (GPRD archive), born between 1988 and 1997 (n = 1398, age 12 to 24 months) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) Hospitalisation for gait disturbance</b> </p> <p>Review of hospital computerised records</p> <p>(April 1995 to June 2001,</p> <p>children aged 12 to 24 months)</p> <p>with ICD‐10 diagnoses related to acute gait disorder</p> <p>(G111, G112, G25, R26, R27, R29, H55, and F984).</p> <p>Cases were grouped into 5 categories, as follows:</p> <p>(1) presumptive viral/postviral ataxia (clinical history of ataxia and evidence of encephalomyelitis or cerebellitis with lymphocytosis in CSF or encephalographic changes); </p> <p>(2) probable postviral ataxia (history consistent with ataxia but CSF/other investigations inconclusive or not done and no other cause identified); </p> <p>(3) probably not postviral gait disturbance</p> <p>(vague symptoms not suggestive</p> <p>of cerebellar ataxia, e.g. unsteady gait associated</p> <p>with constipation or gastroenteritis);</p> <p>(4) non‐ataxic, non‐viral gait disturbance</p> <p>(including limp after trauma, septic bone or</p> <p>joint disease, unsteadiness following drug ingestion);</p> <p>(5) transient synovitis/‘‘irritable hip’’ (a transient condition described following viral illnesses and with no long‐term sequelae) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(b) GP visits for gait disturbance</b> </p> <p>For the analysis of gait disorders presenting in general practice, information on all children born from 1988 to 1997 with at least 2 years of continuous follow‐up from birth in a GPRD practice deemed as supplying data of research standard was obtained from the Office for National Statistics. Read and OXMIS codes that indicated a consultation for possible gait disturbance in children aged 12 to 24 months were identified by mapping to </p> <p>ICD‐9 codes and by searching on the following keywords: ataxia,</p> <p>gait, co‐ordination, mobility, movement.</p> <p>Read/OXMIS descriptive diagnoses cover a wide range, so were grouped into 6 categories for analysis: </p> <p>(A) ataxia (including cerebellar ataxia and ataxic gait);</p> <p>(B) unsteady/veering/shuffling gait;</p> <p>(C) gait abnormality ‐ unspecified;</p> <p>(D) limp/limping gait;</p> <p>(E) poor mobility;</p> <p>(F) abnormal /involuntary movements.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not reported </p> <p><b>(a) Risk period:</b> </p> <p><b>after immunisation</b> </p> <p>(a1) 0 to 30 days</p> <p>(a2) 31 to 60 days</p> <p>(a3) 0 to 60 days</p> <p><b>(b) Risk period</b> </p> <p><b>after immunisation</b> </p> <p>(b1) 0 to 5 days</p> <p>(b2) 6 to 30 days</p> <p>(b3) 31 to 60 days</p> <p>(b4) 6 to 60 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> this study provides no evidence that MMR vaccine causes acute ataxia or other gait disturbance and suggests that the cases observed were chance occurrences, reflecting background incidence. </p> <p>The increased incidence of consultation for any gait disturbance 0 to 5 days after MMR vaccination was attributable to an excess in categories of gait disturbance (B, unsteady; and C, unspecified) that was caused by a clear excess of consultations on the day that MMR was given. </p> <p>It is biologically implausible that any specific MMR effect would be manifest on the day of vaccination since the viraemia induced by the vaccine, which might produce symptoms, does not start until the end of the first week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation for gait disturbance</b> </p> <p>any (categories 2, 3, 5) n = 62</p> <p>(a1) cases = 3</p> <p>(a2) cases = 1</p> <p>(a3) cases = 4</p> <p><b>GP visits for gait disturbance</b> </p> <p>All cases ((A) to (F))</p> <p>(b1) cases = 31</p> <p>(b2) cases = 69</p> <p>(b3) cases =</p> <p>102</p> <p>(b4) cases = 171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) (*)</b> </p> <p>(a1) 0.83 (0.24 to 2.84)</p> <p>(a2) 0.20 (0.03 to 1.47)</p> <p>(a3) 0.46 (0.16 to 1.35)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b1) 1.88 (1.30 to 2.72)</p> <p>(b2) 0.90 (0.70 to 1.17)</p> <p>(b3) 0.95 (0.77 to 1.19)</p> <p>(b4) 0.93 (0.78 to 1.12)</p> <p>(*) Poisson regression</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>GP: general practitioner<br/>GPRD: General Practice Research Database<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OXMIS: Oxford Medical Information Systems<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio) </p> </div> </div> <div class="table" id="CD004407-tbl-0049"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 28.</span> <span class="table-title">Safety: bacterial or viral infections</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants aged 12 to 23 months hospitalised for viral or bacterial infection between April 1995 and May 2005 identified from hospital admission records (n = 2025 accounting for 2077 admissions) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lobar pneumonia</b> </p> <p>ICD‐9 codes: 481</p> <p>ICD‐10 codes: J18.1</p> <p><b>Invasive bacterial infections</b> </p> <p>ICD‐9 codes: 036, 038, 320, 711.0, 730.0</p> <p>ICD‐10 codes: A39, A40, A41, G00, M00, M86, J13X</p> <p><b>Encephalitis/meningitis</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: A85, A86, A87, A88, A89</p> <p><b>Herpes</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: B00</p> <p><b>Pneumonia</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: J12</p> <p><b>Varicella zoster</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: B01, B02</p> <p><b>Miscellaneous viral infections</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: B08, B09, B15, B17, B25, B27, B34</p> <p>Review of computerised hospital</p> <p>admission records from North, East,</p> <p>and South London, Essex, East Anglia,</p> <p>Sussex, and Kent using ICD‐9 or ICD‐10 codes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p><b>Excluded period</b> from the background </p> <p>from −14 to −1 days before immunisation</p> <p><b>Risk period</b> </p> <p><b>after immunisation</b> </p> <p>(a1) 0 to 30 days</p> <p>(a2) 31 to 60 days</p> <p>(a3) 61 to 90 days</p> <p>(a4) 0 to 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the study confirms that the </p> <p>MMR vaccine does not increase the risk of invasive bacterial or viral infection in</p> <p>the 90 days after the vaccination and</p> <p>does not support the hypothesis</p> <p>that there is an induced immune</p> <p>deficiency due to overload from</p> <p>multi‐antigen vaccines.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cases</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) cases = 57<br/>(a2) cases = 65<br/>(a3) cases = 69<br/>(a4) cases = 191 </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) cases = 30<br/>(a2) cases = 34<br/>(a3) cases = 27<br/>(a4) cases = 91 </p> <p><b>Encephalitis/meningitis</b> </p> <p>(a1) cases = 1<br/>(a2) cases = 1<br/>(a3) cases = 2<br/>(a4) cases = 4 </p> <p><b>Herpes</b> </p> <p>(a1) cases = 16<br/>(a2) cases = 25<br/>(a3) cases = 14<br/>(a4) cases = 55 </p> <p><b>Pneumonia</b> </p> <p>(a1) cases = 0<br/>(a2) cases = 5<br/>(a3) cases = 4<br/>(a4) cases = 9 </p> <p><b>Varicella zoster</b> </p> <p>(a1) cases = 17<br/>(a2) cases = 32<br/>(a3) cases = 24<br/>(a4) cases = 73 </p> <p><b>Miscellaneous viral infections</b> </p> <p>(a1) cases = 12<br/>(a2) cases = 12<br/>(a3) cases = 9<br/>(a4) cases = 33 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) (*)</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) 0.65 (0.48 to 0.86)<br/>(a2) 0.80 (0.61 to 1.05)<br/>(a3) 0.90 (0.69 to 1.18)<br/>(a4) 0.77 (0.64 to 0.93) </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) 0.75 (0.51 to 1.12)<br/>(a2) 1.03 (0.70 to 1.52)<br/>(a3) 0.92 (0.61 to 1.41)<br/>(a4) 0.89 (0.68 to 1.16) </p> <p><b>Encephalitis/meningitis</b> </p> <p>(a1) 0.54 (0.06 to 4.83)<br/>(a2) 0.74 (0.07 to 7.47)<br/>(a3) 1.46 (0.23 to 9.29)<br/>(a4) 0.84 (0.20 to 3.49) </p> <p><b>Herpes</b> </p> <p>(a1) 1.00 (0.57 to 1.74)<br/>(a2) 1.69 (1.06 to 2.70)<br/>(a3) 0.89 (0.50 to 1.59)<br/>(a4) 1.17 (0.56 to 2.47) </p> <p><b>Pneumonia</b> </p> <p>(a1) 0 (‐ to ‐)<br/>(a2) 1.39 (0.49 to 3.90)<br/>(a3) 1.27 (0.41 to 3.94)<br/>(a4) 0.72 (0.33 to 1.62) </p> <p><b>Varicella zoster</b> </p> <p>(a1) 0.58 (0.34 to 0.99)<br/>(a2) 1.23 (0.81 to 1.87)<br/>(a3) 1.05 (0.66 to 1.67)<br/>(a4) 0.93 (0.68 to 1.27) </p> <p><b>Miscellaneous viral infections</b> </p> <p>(a1) 0.71 (0.37 to1.37)<br/>(a2) 0.73 (0.37 to 1.14)<br/>(a3) 0.61 (0.29 to 1.28)<br/>(a4) 0.68 (0.43 to 1.09) </p> <p>(*)Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23 months admitted to hospital between April 1991 and March 1995 in selected districts in the Thames region of southern England. Total of 387 admissions with 1 or more of the bacterial infection codes and with a linked MMR vaccination record were identified; occurred in 387 children (169 in 165 females, and 226 in 222 males); 116 had a diagnosis of invasive bacterial infection and 279 had lobar pneumonia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lobar pneumonia</b> </p> <p><b>Invasive bacterial infections</b> </p> <p>Cases were identified from computerised</p> <p>discharge records using ICD‐9 codes 036 (meningococcal infection),</p> <p>038 (septicaemia), 320 (bacterial meningitis),</p> <p>711.0 (pyogenic arthritis), 730.0 (acute osteomyelitis), and 481 (lobar (pneumococcal) pneumonia). </p> <p>Hospital records were linked with computerised district immunisation records by sex, date of birth, and post code. </p> <p>Cases in children with additional diagnostic codes indicating an underlying disorder predisposing to bacterial infection, such as immunosuppression, malignancy, cystic fibrosis, congenital heart defect, or a cerebrospinal fluid shunt, were excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not described </p> <p><b>Excluded period</b> from the background </p> <p>from −14 to −1 days before immunisation</p> <p><b>Risk period</b> </p> <p><b>after immunisation</b> </p> <p>(a1) 0 to 30 days</p> <p>(a2) 31 to 60 days</p> <p>(a3) 61 to 90 days</p> <p>(a4) 0 to 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> combined measles, mumps, and rubella (MMR) vaccine did not increase the risk of hospitalisation with invasive bacterial infection in the 3 months after vaccination; rather there was a protective effect. These results provide no support for the concept of 'immunological overload' induced by multiple‐antigen vaccinations, nor calls for single‐antigen vaccines. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cases</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) cases = 23<br/>(a2) cases = 24<br/>(a3) cases = 16<br/>(a4) cases = 63 </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) cases = 12<br/>(a2) cases = 14<br/>(a3) cases = 7<br/>(a4) cases = 33 </p> <p><b>Both codes</b> </p> <p>(a1) cases = 35<br/>(a2) cases = 38<br/>(a3) cases = 23<br/>(a4) cases = 96 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) (*)</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) 0.77 (0.48 to 1.23)<br/>(a2) 0.80 (0.50 to 1.28)<br/>(a3) 0.52 (0.30 to 0.90)<br/>(a4) 0.70 (0.50 to 0.97) </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) 1.00 (0.52 to 1.94)<br/>(a2) 1.17 (0.62 to 2.20)<br/>(a3) 0.62 (0.27 to 1.40)<br/>(a4) 0.93 (0.58 to 1.49) </p> <p><b>Both codes</b> </p> <p>(a1) 0.81 (0.56 to 1.19)<br/>(a2) 0.90 (0.62 to 1.31)<br/>(a3) 0.56 (0.36 to 0.89)<br/>(a4) 0.76 (0.58 to 0.99) </p> <p>(*)Poisson regression</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>GP: general practitioner<br/>GPRD: General Practice Research Database<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio) </p> </div> </div> </section> </section> <section id="CD004407-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 27 studies of the 101 papers identified and retrieved for this 2019 update. In addition, of 16 studies awaiting classification (see <a href="./references#CD004407-sec-0167" title="">Characteristics of studies awaiting classification</a>) in the previous update (<a href="./references#CD004407-bbs2-0412" title="DemicheliV , RivettiA , DebaliniMG , Di PietrantojC . Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD004407. [DOI: 10.1002/14651858.CD004407.pub3]">Demicheli 2012</a>), we excluded four studies because they were not comparative; they considered vaccines other than MMR; or they did not present original data (for details see <a href="./references#CD004407-sec-0166" title="">Characteristics of excluded studies</a>). We assessed a further seven studies as awaiting classification and five studies as ongoing because the papers were lacking in some important details (see <a href="./references#CD004407-sec-0167" title="">Characteristics of studies awaiting classification</a> and Characteristics of ongoing studies). </p> </section> </section> <section id="CD004407-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>Of the 138 included studies, we assessed 53 (38%) as at low risk of bias, 55 (40%) as at unclear risk of bias, and 30 (22%) as at high risk of bias (<a href="#CD004407-fig-0003">Figure 3</a>). The quality assessment of each individual study and the description of the quality criteria adopted are shown in <a href="#CD004407-fig-0004">Figure 4</a> and <a href="./appendices#CD004407-sec-0134">Appendix 5</a>, respectively. The risk of bias by study design and by publication year are shown in <a href="#CD004407-tbl-0050">Table 29</a> and <a href="#CD004407-tbl-0051">Table 30</a>, respectively. </p> <div class="figure" id="CD004407-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004407-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004407-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004407-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="table" id="CD004407-tbl-0050"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 29.</span> <span class="table-title">Risk of bias</span></div> <tbody> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <td align="left" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="5" scope="col" valign="top"> <p><b>Effectiveness<br/>studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT/CCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective/retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subtotal</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>15</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>29.4%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>27</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>53.0%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17.6%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>51</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <td align="left" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="7" scope="col" valign="top"> <p><b>Safety<br/>studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT/CCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective/retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐controlled case series/person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subtotal</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>43.7%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>28</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32.2%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>21</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24.1%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total (all studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>53</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38.4%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>55</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>39.9%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>21.7%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>138</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <td align="left" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="6" scope="col" valign="top"> <p><b>Safety studies<br/>(excluding short‐term side effects<br/>studies)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective/retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐controlled case series/person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Total</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>36</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>51%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>26</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>37%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>8</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>70</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/>RCT: randomised controlled trial </p> </div> </div> <div class="table" id="CD004407-tbl-0051"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 30.</span> <span class="table-title">Risk of bias by publication year</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All studies included</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication year</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1971 to 1980</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981 to 1990</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991 to 2000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001 to 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011 to 2019</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>53</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>36%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>54</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>42%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>30</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>22%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>138</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Only safety studies</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication year</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1971 to 1980</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981 to 1990</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991 to 2000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001 to 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011 to 2019</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>38</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>39%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>27</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>37%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>22</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>24%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>87</b> </p> </th> </tr> </tbody> </table> </div> <section id="CD004407-sec-0053"> <h4 class="title">Studies evaluating vaccine effectiveness</h4> <p>Of the 51 studies that assessed the effectiveness of MMR/MMRV vaccines, we assessed 15 (30%) as at low risk of bias, 27 (53%) as at unclear risk of bias, and 9 (17%) as at high risk of bias. These last studies were characterised by poor methodological quality due to poor reporting or missing information about comparability between exposed or non‐exposed groups, and the composition of MMR vaccine is sometimes not reported. See <a href="#CD004407-tbl-0050">Table 29</a>. </p> </section> <section id="CD004407-sec-0054"> <h4 class="title">Studies evaluating vaccine safety</h4> <p>Of 87 included studies, we assessed 38 (44%) as at low risk of bias, 28 (32%) as at unclear risk of bias, and 21 (24%) as at high risk of bias. See <a href="#CD004407-tbl-0050">Table 29</a>. </p> <p> <ol id="CD004407-list-0035"> <li> <p>Short‐term side effects: 17 studies (<a href="#CD004407-tbl-0031">Table 10</a> and <a href="#CD004407-tbl-0032">Table 11</a>): </p> <ol id="CD004407-list-0036"> <li> <p>low risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>); </p> </li> <li> <p>unclear risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>); </p> </li> <li> <p>high risk of bias: 13 studies (<a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; <a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>; <a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a>; <a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>; <a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a>; <a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>; <a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a>; <a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a>; <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>; <a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>; <a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>). </p> </li> </ol> </li> <li> <p>Encephalitis or encephalopathy: 3 studies (<a href="#CD004407-tbl-0033">Table 12</a>): </p> <ol id="CD004407-list-0037"> <li> <p>low risk of bias: 1 study (<a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>); </p> </li> <li> <p>unclear risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0041" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768-73. ">bb‐Ray 2006</a>; <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>). </p> </li> </ol> </li> <li> <p>Aseptic meningitis: 10 studies (<a href="#CD004407-tbl-0034">Table 13</a>): </p> <ol id="CD004407-list-0038"> <li> <p>low risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>; <a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a>); </p> </li> <li> <p>unclear risk of bias: 8 studies (<a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>; <a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a>; <a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a>; <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>). </p> </li> </ol> </li> <li> <p>Seizure ‐ febrile/afebrile: 8 studies (<a href="#CD004407-tbl-0035">Table 14</a>): </p> <ol id="CD004407-list-0039"> <li> <p>low risk of bias: 5 studies (<a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a>; <a href="./references#CD004407-bbs2-0113" title="MacartneyK , GiddingHF , TrinhL , WangH , DeyA , HullB , et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatrics2017;171(10):992-8. ">db‐Macartney 2017</a>; <a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a>; <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a>; <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>); </p> </li> <li> <p>unclear risk of bias: 3 studies (<a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>). </p> </li> </ol> </li> <li> <p>MMRV versus MMR/MMR+V ‐ febrile seizures: 7 studies (<a href="#CD004407-tbl-0036">Table 15</a>): </p> <ol id="CD004407-list-0040"> <li> <p>low risk of bias: 7 studies (<a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a>; <a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a>; <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0093" title="KleinNP , LewisE , McDonaldJ , FiremanB , NalewayA , GlanzJ , et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. Vaccine2017;35(12):1615-21. ">cb‐Klein 2017</a>; <a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a>; <a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a>). </p> </li> </ol> </li> <li> <p>Autism spectrum disorders: 13 studies (<a href="#CD004407-tbl-0037">Table 16</a>): </p> <ol id="CD004407-list-0041"> <li> <p>low risk of bias: 8 studies (<a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a>; <a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a>; <a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a>; <a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a>; <a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a>; <a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a>; <a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a>; <a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a>); </p> </li> <li> <p>unclear risk of bias: 3 studies (<a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a>; <a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a>; <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>); </p> </li> <li> <p>high risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a>; <a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a>). </p> </li> </ol> </li> <li> <p>Inflammatory bowel disease: 6 studies (<a href="#CD004407-tbl-0038">Table 17</a>): </p> <ol id="CD004407-list-0042"> <li> <p>low risk of bias: 1 study (<a href="./references#CD004407-bbs2-0042" title="ShawSY , BlanchardJF , BernsteinCN . Early childhood measles vaccinations are not associated with paediatric IBD: a population based analysis. Journal of Crohn's and Colitis2015;9(4):334-8. [DOI: 10.1093/ecco-jcc/jjv029]">bb‐Shaw 2015</a>); </p> </li> <li> <p>unclear risk of bias: 4 studies (<a href="./references#CD004407-bbs2-0026" title="BaronS , TurckD , LeplatC , MerleV , Gower-RousseauC , MartiR , et al. Enviromental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut2005;54(3):357-63. [DOI: 10.1136/gut.2004.054353]">bb‐Baron 2005</a>; <a href="./references#CD004407-bbs2-0034" title="DavisRL , KramarzP , BohlkeK , BensonP , ThompsonRS , MulloolyJ , et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine2001;155(3):354-9. ">bb‐Davis 2001</a>; <a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a>; <a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a>); </p> </li> <li> <p>high risk of bias: 1 study (<a href="./references#CD004407-bbs2-0045" title="VcevA , PezerovicD , JovanovicZ , NakicD , VcevI , MajnaricL . A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. Wiener Klinische Wochenschrift2015;127(9-10):345–54. ">bb‐Vcev 2015</a>). </p> </li> </ol> </li> <li> <p>Cognitive delay, developmental delay: 1 study (<a href="#CD004407-tbl-0039">Table 18</a>): </p> <ol id="CD004407-list-0043"> <li> <p>unclear risk of bias (<a href="./references#CD004407-bbs2-0098" title="Mrozek-BudzynD , KiełtykaA , MajewskaR , AugustyniakM . Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - the results of the Polish prospective cohort study. Vaccine2013;31(22):2551-7. [DOI: 10.1016/j.vaccine.2013.03.057]">cb‐Mrozek‐Budzyn 2013</a>). </p> </li> </ol> </li> <li> <p>Idiopathic thrombocytopenic purpura: 9 studies (<a href="#CD004407-tbl-0040">Table 19</a>): </p> <ol id="CD004407-list-0044"> <li> <p>low risk of bias: 3 studies (<a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a>; <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a>; <a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a>); </p> </li> <li> <p>unclear risk of bias: 5 studies (<a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a>; <a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>; <a href="./references#CD004407-bbs2-0126" title="LafaurieM , BaricaultB , Lapeyre-MestreM , SaillerL , MoulisG , SommetA , et al. Risk of vaccine-induced immune thrombocytopenia in children. Nationwide case cross-over and self controlled case series studies in France. Fundamental &amp; Clinical Pharmacology2018;32:86. ">eb‐Lafaurie 2018</a>); </p> </li> <li> <p>high risk of bias: 1 study (<a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a>). </p> </li> </ol> </li> <li> <p>Henoch‐Schönlein purpura: 1 study (<a href="#CD004407-tbl-0041">Table 20</a>): </p> <ol id="CD004407-list-0045"> <li> <p>unclear risk of bias (<a href="./references#CD004407-bbs2-0033" title="Da DaltL , ZerbinatiC , StrafellaMS , RennaS , RiceputiL , Di PietroP , et al Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics2016;42(1):60. [DOI: 10.1186/s13052-016-0267-2]">bb‐Da Dalt 2016</a>). </p> </li> </ol> </li> <li> <p>Type 1 diabetes: 2 studies (<a href="#CD004407-tbl-0042">Table 21</a>): </p> <ol id="CD004407-list-0046"> <li> <p>low risk of bias (<a href="./references#CD004407-bbs2-0082" title="BeyerleinA , StroblAN , WinklerC , CarpusM , KnopffA , DonnachieE , et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine2017;35(14):1735-41. ">cb‐Beyerlein 2017</a>; <a href="./references#CD004407-bbs2-0086" title="HiividAD , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health2004;8(5):286-7. [CRSREF: 2955568]HviidA , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination and type 1 diabetes. New England Journal of Medicine2004;350(14):1398-404. ">cb‐Hviid 2004</a>). </p> </li> </ol> </li> <li> <p>Asthma: 5 studies (<a href="#CD004407-tbl-0043">Table 22</a>): </p> <ol id="CD004407-list-0047"> <li> <p>low risk of bias: 1 study (<a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>); </p> </li> <li> <p>unclear risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0083" title="DeStefanoF , GuD , KramarzP , TrumanBI , IademarcoMF , MulloolyJP , et al. Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal2002;21(6):498-504. ">cb‐DeStefano 2002</a>; <a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a>); </p> </li> <li> <p>high risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0081" title="BenkeG , AbramsonM , RavenJ , ThienFC , WaltersEH . Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health2004;28(4):336-8. ">cb‐Benke 2004</a>; <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>). </p> </li> </ol> </li> <li> <p>Dermatitis or eczema: 2 studies (<a href="#CD004407-tbl-0044">Table 23</a>): </p> <ol id="CD004407-list-0048"> <li> <p>low risk of bias: 1 study (<a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>); </p> </li> <li> <p>high risk of bias: 1 study (<a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>). </p> </li> </ol> </li> <li> <p>Hay fever, rhinoconjunctivitis, hypersensitivity/allergy: 3 studies (<a href="#CD004407-tbl-0045">Table 24</a>): </p> <ol id="CD004407-list-0049"> <li> <p>low risk of bias (<a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a>; <a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a>; <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>). </p> </li> </ol> </li> <li> <p>Acute leukaemia: 4 studies (<a href="#CD004407-tbl-0046">Table 25</a>): </p> <ol id="CD004407-list-0050"> <li> <p>low risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a>; <a href="./references#CD004407-bbs2-0039" title="Mallol-MesnardN , MenegauxF , AuvrignonA , AuclercMF , BertrandY , NelkenB , et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology2007;36(1):110-6. ">bb‐Mallol‐Mesnard 2007</a>); </p> </li> <li> <p>unclear risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0036" title="DockertyJD , SkeggDC , ElwoodJM , HerbisonGP , BecroftDM , LewisME . Infections, vaccinations, and the risk of childhood leukaemia. British Journal of Cancer1999;80(9):1483-9. [DOI: 10.1038/sj.bjc.6690548]">bb‐Dockerty 1999</a>; <a href="./references#CD004407-bbs2-0037" title="GrovesFD , GridleyG , WacholderS , ShuXO , RobisonLL , NegliaJP , et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. British Journal of Cancer1999;81(1):175-8. [DOI: 10.1038/sj.bjc.6690668]">bb‐Groves 1999</a>). </p> </li> </ol> </li> <li> <p>Demyelinating diseases, multiple sclerosis, ADEM: 3 studies (<a href="#CD004407-tbl-0047">Table 26</a>): </p> <ol id="CD004407-list-0051"> <li> <p>low risk of bias: 1 study (<a href="./references#CD004407-bbs2-0032" title="ChenY , MaF , XuY , ChuX , ZhangJ . Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine2018;36(26):3733-9. ">bb‐Chen 2018</a>); </p> </li> <li> <p>high risk of bias: 2 studies (<a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a>; <a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a>). </p> </li> </ol> </li> <li> <p>Gait disturbances 1 study (<a href="#CD004407-tbl-0048">Table 27</a>): </p> <ol id="CD004407-list-0052"> <li> <p>low risk of bias (<a href="./references#CD004407-bbs2-0118" title="MillerE , AndrewsN , GrantA , StoweJ , TaylorB . No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood2005;90(3):292-6. ">db‐Miller 2005</a>). </p> </li> </ol> </li> <li> <p>Bacterial or viral infections: 2 studies (<a href="#CD004407-tbl-0049">Table 28</a>): </p> <ol id="CD004407-list-0053"> <li> <p>low risk of bias (<a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a>) </p> </li> <li> <p>unclear risk of bias (<a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a>). </p> </li> </ol> </li> </ol> </p> </section> <section id="CD004407-sec-0055"> <h4 class="title">Allocation</h4> <p>Of 10 RCTs/CCTs, five studies reported adequate concealment (<a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a>; <a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a>; <a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>). See <a href="#CD004407-fig-0004">Figure 4</a>. </p> </section> <section id="CD004407-sec-0056"> <h4 class="title">Blinding</h4> <p>Of 10 RCTs/CCTs assessing effectiveness and/or short‐term side effects, six trials were double‐blind (<a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a>; <a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a>; <a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>); one was single‐blind (<a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>); two were not blinded (<a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>); and in one study blinding was not reported (<a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>). </p> </section> <section id="CD004407-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>In two trials (<a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>), the selection of paediatric practices involved in the recruitment of children was not explained, and the number and assessment of non‐responders were not reported. Similarly in <a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a> there were few details on the refusal and response rate during the recruitment phase, and demographic information from the two UK areas where the trial was conducted was lacking. We considered two trials to be at unclear risk of detection bias affecting the outcomes (<a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; <a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>). </p> </section> <section id="CD004407-sec-0058"> <h4 class="title">Selective reporting</h4> <p>In the two trials we assessed as being at high risk of reporting bias, adverse effects were reported for only 60% and 39% of participants, respectively (<a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>). We evaluated the only included cluster‐RCT as at high risk of reporting bias (<a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>). The number of completed weekly diaries varied over the eight‐week study period, with no indication of whether the losses occurred pre‐ or postvaccination. Furthermore, there was an overall attrition rate of 33%. </p> </section> <section id="CD004407-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <section id="CD004407-sec-0060"> <h5 class="title">Studies evaluating effectiveness</h5> <p>Fifteen (45%) of 33 cohort studies on effectiveness and 8 (57%) of 14 case‐control studies did not report adequate MMR or MMRV vaccine descriptions. </p> </section> <section id="CD004407-sec-0061"> <h5 class="title">Studies evaluating safety ‐ harms</h5> <p>The association between MMR/MMRV and severe harms (excluding short‐term side effects) was investigated in 70 studies (22 cohort studies, 22 CCS, 13 SCCS, 3 PTC, 3 CCO, 8 COEM). Of 70 studies, we assessed 32 (46%) as at low risk of bias; 28 (40%) as at unclear risk of bias; and 10 (14%) as at high risk of bias. See <a href="#CD004407-tbl-0050">Table 29</a>. </p> <p>Several cohort studies used matching procedures to ensure comparability or adopted a multivariate model. When only a few confounders were used to ensure comparability between cohorts, we assigned high risk of bias. </p> <p>The study by <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> was weakened by the loss of 14% of the original birth cohorts and the effects of the rather long‐term follow‐up. The impact of either of these factors in terms of confounders is open to debate. It should be taken into account that autism does not often involve hospitalisation, and data about outpatient visits were not available. Limited errors could have been introduced by using population data from a previous census (as estimation of the denominator) in <a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>. Therefore, the number of doses administered (as opposed to supplied) was used to compute the risk of aseptic meningitis in the mass vaccination programme. In <a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a>, there was an unclear likelihood of selection bias due to missing participants and records (up to 27%). In <a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>, there was an unclear likelihood of selection bias due to missing participants and their records (up to 27%) but the study and its methods were well reported. The exclusive use of discharge diagnoses for identification of cases in <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a> could have introduced a noteworthy selection bias. Estimates from <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> (although significant) were strongly affected by ascertainment bias: children who were not taken to the doctor were less likely to be vaccinated and to have fewer opportunities for diagnoses of allergic diseases to be recorded. Lack of clarity over the vaccine exposure status of the controls made the results of the <a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a> study difficult to interpret. In <a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a>, cases and controls were apparently not matched. In <a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a>, refusal to participate in the study or inability to locate participants and controls could have introduced an unclear risk of selection bias. Exclusion of participants without completed questionnaires and of those who did not attend the sixth grade at school within the study area could have introduced a relevant selection bias in the <a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a> case‐control study. Assessment of pervasive developmental disorders cases in <a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a> was made on the basis of administrative codes only: diagnosis could have been imprecise and did not enable us to consider pervasive developmental disorders subtypes or regression. In <a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a>, the number and possible impact of bias was so high that interpretation of the results was difficult. The cohort study of <a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a> was potentially affected by a different type of bias, considering that the participants were from a private clinic and that definitions of applied autism spectrum disorders diagnosis and methods used for disorders regression ascertainment were not clearly reported. The long follow‐up for autism could be due to the lack of a properly constructed causal hypothesis. The study of <a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a> demonstrated the difficulties of drawing inferences in the absence of a non‐exposed population or a clearly defined causal hypothesis. </p> </section> </section> </section> <section id="CD004407-sec-0062"> <h3 class="title" id="CD004407-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD004407-tbl-0001"><b>Summary of findings 1</b> Effectiveness against measles</a>; <a href="./full#CD004407-tbl-0002"><b>Summary of findings 2</b> Effectiveness against mumps</a>; <a href="./full#CD004407-tbl-0003"><b>Summary of findings 3</b> Effectiveness against rubella</a>; <a href="./full#CD004407-tbl-0004"><b>Summary of findings 4</b> Effectiveness against varicella</a>; <a href="./full#CD004407-tbl-0005"><b>Summary of findings 5</b> Safety: short‐term side effects (local or systemic reactions)</a>; <a href="./full#CD004407-tbl-0006"><b>Summary of findings 6</b> Safety: encephalitis or encephalopathy</a>; <a href="./full#CD004407-tbl-0007"><b>Summary of findings 7</b> Safety: aseptic meningitis</a>; <a href="./full#CD004407-tbl-0008"><b>Summary of findings 8</b> Safety: seizures (febrile/afebrile)</a>; <a href="./full#CD004407-tbl-0009"><b>Summary of findings 9</b> Safety: autistic spectrum disorders</a>; <a href="./full#CD004407-tbl-0010"><b>Summary of findings 10</b> Safety: inflammatory bowel disease</a>; <a href="./full#CD004407-tbl-0011"><b>Summary of findings 11</b> Safety: cognitive delay ‐ developmental delay</a>; <a href="./full#CD004407-tbl-0012"><b>Summary of findings 12</b> Safety: idiopathic thrombocytopenic purpura</a>; <a href="./full#CD004407-tbl-0013"><b>Summary of findings 13</b> Safety: Henoch‐Schönlein purpura</a>; <a href="./full#CD004407-tbl-0014"><b>Summary of findings 14</b> Safety: type 1 diabetes</a>; <a href="./full#CD004407-tbl-0015"><b>Summary of findings 15</b> Safety: asthma</a>; <a href="./full#CD004407-tbl-0016"><b>Summary of findings 16</b> Safety: eczema ‐ dermatitis</a>; <a href="./full#CD004407-tbl-0017"><b>Summary of findings 17</b> Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</a>; <a href="./full#CD004407-tbl-0018"><b>Summary of findings 18</b> Safety: acute leukaemia</a>; <a href="./full#CD004407-tbl-0019"><b>Summary of findings 19</b> Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</a>; <a href="./full#CD004407-tbl-0020"><b>Summary of findings 20</b> Safety: gait disturbances</a>; <a href="./full#CD004407-tbl-0021"><b>Summary of findings 21</b> Safety: bacterial or viral infections, immune overload</a> </p> <section id="CD004407-sec-0063"> <h4 class="title">1. Effectiveness against measles</h4> <p>Seventeen studies included effectiveness data against measles: 14 cohort studies (<a href="./references#CD004407-bbs2-0046" title="ArciuoloRJ , JablonskiRR , ZuckerJR , RosenJB . Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting - New York City, 2013. Clinical Infectious Diseases2017;65(11):1843-7. ">ca‐Arciuolo 2017</a>; <a href="./references#CD004407-bbs2-0047" title="ArenzS , SchmittHJ , TischerA , vonKriesR . Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal2005;24(8):697-9. ">ca‐Arenz 2005</a>; <a href="./references#CD004407-bbs2-0048" title="BarrabeigI , RoviraA , RiusC , MunozP , SoldevilaN , BatallaJ , et al. Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal2011;30(1):78-80. ">ca‐Barrabeig 2011a</a>; <a href="./references#CD004407-bbs2-0049" title="BarrabeigI , RoviraA , MunozP , BatallaJ , RuisC , SanchezJA , et al. MMR vaccine effectiveness in an outbreak that involved day-care and primary schools. Vaccine2011;29(45):8024-31. [DOI: 10.1016/j.vaccine.2011.08.056]">ca‐Barrabeig 2011b</a>; <a href="./references#CD004407-bbs2-0050" title="BhuniyaS , MajiD , MandalD , MondalN . Measles outbreak among Dukpa tribe of Buxa Hills in West Bengal, India: epidemiology and vaccine efficacy. Indian Journal of Public Health2013;57(4):272-5. [DOI: 10.4103/0019-557X.123273]">ca‐Bhuniya 2013</a>; <a href="./references#CD004407-bbs2-0053" title="ChoeYJ , ParkYJ , KimJW , EomHE , ParkO , OhMD , et al. An outbreak of measles in a university in Korea, 2014. Journal of Korean Medical Science2017;32(11):1876-8. ">ca‐Choe 2017</a>; <a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a>; <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0062" title="MarinM , NguyenHQ , LangidrikJR , EdwardsR , BriandK , PapaniaMJ , et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases2006;42(3):315-9. ">ca‐Marin 2006</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0064" title="MusaS , TopalovićB , ĆatićS , SmajlagićZ . Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. Central European Journal of Public Health2018;26(2):79-82. ">ca‐Musa 2018</a>; <a href="./references#CD004407-bbs2-0068" title="OngG , RasidahN , WanS , CutterJ . Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal2007;48(7):656-61. ">ca‐Ong 2007</a>; <a href="./references#CD004407-bbs2-0075" title="WichmannO , HellenbrandW , SagebielD , SantibanezS , AhlemeyerG , VogtG , et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal2007;26(9):782-6. ">ca‐Wichmann 2007</a>; <a href="./references#CD004407-bbs2-0076" title="WoudenbergT , van derMaasNAT , KnolMJ , deMelkerH , vanBinnendijkRS , HahneSJM . Effectiveness of early measles, mumps, and rubella vaccination among 6-14-month-old infants during an epidemic in the Netherlands: an observational cohort study. Journal of Infectious Diseases2017;215(8):1181-7. ">ca‐Woudenberg 2017</a>), and 3 case‐control studies (<a href="./references#CD004407-bbs2-0014" title="DefayF , De SerresG , SkowronskiDM , BoulianneN , OuakkiM , LandryM , et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics2013;132(5):e1126-33. [DOI: 10.1542/peds.2012-3975]">ba‐Defay 2013</a>; <a href="./references#CD004407-bbs2-0019" title="HungerfordD , ClearlyP , GhebrehewetS , KeenanA , VivancosR . Risk factors for transmission of measles during an outbreak: matched case control study. Journal of Hospital Infections2014;86(2):138-43. [DOI: 10.1016/j.jhin.2013.11.008]">ba‐Hungerford 2014</a>; <a href="./references#CD004407-bbs2-0020" title="JickH , HagbergKW . Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine2010;28(29):4588-92. ">ba‐Jick 2010</a>). </p> <p>The studies are described in <a href="#CD004407-tbl-0022">Table 1</a> and <a href="#CD004407-tbl-0023">Table 2</a>, and the summary of findings is presented in <a href="./full#CD004407-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD004407-sec-0064"> <h5 class="title">Evidence from cohort studies</h5> <p><b>Comparison 1.1</b> (<a href="./references#CD004407-fig-0005" title="">Analysis 1.1</a>) reports on vaccine effectiveness (VE) from eight cohort studies (<a href="./references#CD004407-bbs2-0049" title="BarrabeigI , RoviraA , MunozP , BatallaJ , RuisC , SanchezJA , et al. MMR vaccine effectiveness in an outbreak that involved day-care and primary schools. Vaccine2011;29(45):8024-31. [DOI: 10.1016/j.vaccine.2011.08.056]">ca‐Barrabeig 2011b</a>; <a href="./references#CD004407-bbs2-0050" title="BhuniyaS , MajiD , MandalD , MondalN . Measles outbreak among Dukpa tribe of Buxa Hills in West Bengal, India: epidemiology and vaccine efficacy. Indian Journal of Public Health2013;57(4):272-5. [DOI: 10.4103/0019-557X.123273]">ca‐Bhuniya 2013</a>; <a href="./references#CD004407-bbs2-0053" title="ChoeYJ , ParkYJ , KimJW , EomHE , ParkO , OhMD , et al. An outbreak of measles in a university in Korea, 2014. Journal of Korean Medical Science2017;32(11):1876-8. ">ca‐Choe 2017</a>; <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0064" title="MusaS , TopalovićB , ĆatićS , SmajlagićZ . Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. Central European Journal of Public Health2018;26(2):79-82. ">ca‐Musa 2018</a>; <a href="./references#CD004407-bbs2-0068" title="OngG , RasidahN , WanS , CutterJ . Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal2007;48(7):656-61. ">ca‐Ong 2007</a>; <a href="./references#CD004407-bbs2-0075" title="WichmannO , HellenbrandW , SagebielD , SantibanezS , AhlemeyerG , VogtG , et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal2007;26(9):782-6. ">ca‐Wichmann 2007</a>). The VE = (1 − RR) x 100 after one dose is 95% (95% confidence interval (CI) 87% to 98%) and after two doses 96% (95% CI 72% to 99%). Heterogeneity was 88% and 93% for both subgroups, respectively. After exclusion of the two studies at high risk of bias (<a href="./references#CD004407-bbs2-0050" title="BhuniyaS , MajiD , MandalD , MondalN . Measles outbreak among Dukpa tribe of Buxa Hills in West Bengal, India: epidemiology and vaccine efficacy. Indian Journal of Public Health2013;57(4):272-5. [DOI: 10.4103/0019-557X.123273]">ca‐Bhuniya 2013</a><a href="./references#CD004407-bbs2-0053" title="ChoeYJ , ParkYJ , KimJW , EomHE , ParkO , OhMD , et al. An outbreak of measles in a university in Korea, 2014. Journal of Korean Medical Science2017;32(11):1876-8. ">ca‐Choe 2017</a>), heterogeneity was reduced to 32% for the first group and 0% for the second. Overall VE for one dose was 96% (95% CI 93% to 98%) and for two doses 98% (95% CI 96% to 99%). </p> <p>One cohort study evaluated the effectiveness of MMR vaccination in preventing clinical cases of measles in children aged from 18 to 90 months from several local health agencies in Rome, Italy (N = 2745) (<a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>). Vaccination was performed with three different commercial MMR vaccines, two containing both Schwarz strain (Pluserix and Morupar) and one prepared with Edmonston‐Zagreb strain (Triviraten). One other cohort study investigated the effectiveness of MMR immunisation (composition not reported by study authors) in children aged between 8 and 14 years in preventing laboratory‐confirmed measles cases (<a href="./references#CD004407-bbs2-0068" title="OngG , RasidahN , WanS , CutterJ . Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal2007;48(7):656-61. ">ca‐Ong 2007</a>). Two laboratory‐confirmed measles cases occurred amongst the vaccinated children (one dose), whereas seven were observed in the unvaccinated group. </p> <p><b>Comparison 1.2</b> (<a href="./references#CD004407-fig-0006" title="">Analysis 1.2</a>) reports on effectiveness of MMR vaccination in preventing secondary measles cases from three cohort studies (<a href="./references#CD004407-bbs2-0047" title="ArenzS , SchmittHJ , TischerA , vonKriesR . Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal2005;24(8):697-9. ">ca‐Arenz 2005</a>; <a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a>; <a href="./references#CD004407-bbs2-0062" title="MarinM , NguyenHQ , LangidrikJR , EdwardsR , BriandK , PapaniaMJ , et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases2006;42(3):315-9. ">ca‐Marin 2006</a>). 'Household contacts' was defined as a person residing in the household during the primary case's infection period. A contact was considered vaccinated (one dose or two doses) if there was a documented record of measles vaccination before the rash onset of the primary case. In <a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a> and <a href="./references#CD004407-bbs2-0062" title="MarinM , NguyenHQ , LangidrikJR , EdwardsR , BriandK , PapaniaMJ , et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases2006;42(3):315-9. ">ca‐Marin 2006</a>, the VE after one dose was 81% (95% CI 11% to 96%), after two doses 85% (95% CI 25% to 97%), and after three doses 96% (95% CI 77% to 99%). Heterogeneity was 61%, 65%, and 0% for each subgroup, respectively. After excluding one study at high risk of bias (<a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a>), heterogeneity was reduced to less than 30% for each subgroup, and VE after one dose was 91% (95% CI 73% to 97%), after two doses 94% (95% CI 81% to 98%), and after three doses 96% (95% CI 69% to 99%). Vaccination with one or two doses of MMR vaccine (composition unknown) was highly effective in preventing secondary cases amongst contacts. </p> <p><b>Comparison 1.3</b> (<a href="./references#CD004407-fig-0007" title="">Analysis 1.3</a>) reports on effectiveness of MMR vaccination for postexposure prophylaxis from two cohort studies (<a href="./references#CD004407-bbs2-0046" title="ArciuoloRJ , JablonskiRR , ZuckerJR , RosenJB . Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting - New York City, 2013. Clinical Infectious Diseases2017;65(11):1843-7. ">ca‐Arciuolo 2017</a>; <a href="./references#CD004407-bbs2-0048" title="BarrabeigI , RoviraA , RiusC , MunozP , SoldevilaN , BatallaJ , et al. Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal2011;30(1):78-80. ">ca‐Barrabeig 2011a</a>). Where candidates for the intervention were susceptible contacts who had not received either measles‐containing vaccine or had not suffered measles, the VE was 74% (95% CI 50% to 86%). </p> </section> <section id="CD004407-sec-0065"> <h5 class="title">Evidence from case‐control studies</h5> <p><b>Comparison 1.4</b> (<a href="./references#CD004407-fig-0008" title="">Analysis 1.4</a>) reports on vaccine effectiveness from two case‐control studies (<a href="./references#CD004407-bbs2-0019" title="HungerfordD , ClearlyP , GhebrehewetS , KeenanA , VivancosR . Risk factors for transmission of measles during an outbreak: matched case control study. Journal of Hospital Infections2014;86(2):138-43. [DOI: 10.1016/j.jhin.2013.11.008]">ba‐Hungerford 2014</a>; <a href="./references#CD004407-bbs2-0020" title="JickH , HagbergKW . Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine2010;28(29):4588-92. ">ba‐Jick 2010</a>). One study reported insufficient data for quantitative synthesis (<a href="./references#CD004407-bbs2-0014" title="DefayF , De SerresG , SkowronskiDM , BoulianneN , OuakkiM , LandryM , et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics2013;132(5):e1126-33. [DOI: 10.1542/peds.2012-3975]">ba‐Defay 2013</a>). The VE after one dose was 51% (95% CI 42% to 59%) and after two doses 61% (95% CI 42% to 74%) (<a href="./references#CD004407-bbs2-0020" title="JickH , HagbergKW . Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine2010;28(29):4588-92. ">ba‐Jick 2010</a>). One case‐control study was conducted during a measles outbreak amongst children and young previously vaccinated children (<a href="./references#CD004407-bbs2-0019" title="HungerfordD , ClearlyP , GhebrehewetS , KeenanA , VivancosR . Risk factors for transmission of measles during an outbreak: matched case control study. Journal of Hospital Infections2014;86(2):138-43. [DOI: 10.1016/j.jhin.2013.11.008]">ba‐Hungerford 2014</a>). The VE amongst "vaccinate appropriately by age" versus "incomplete or partially vaccinated" was 95% (95% CI 60% to 99%). </p> </section> </section> <section id="CD004407-sec-0066"> <h4 class="title">2. Effectiveness against mumps</h4> <p>Twenty‐one studies reported effectiveness data against mumps: 14 cohort studies, <a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0054" title="Compés-DeaC , Guimbao-BescòsJ , Gaspar-EscayolaJI , Lazaro-BelancheMA , Aznar-BriebaA . An outbreak of mumps in a high school: estimation of vaccine effectiveness. Zaragoza 2011 [Broteescolar de parotiditis: estimacion de la efectividad vacunal Zaragoza 2011]. Enfermedades Infeccionas y Microbiologia Clinical2015;33(6):385-90. [DOI: 10.1016/j.eimc.2014.09.011]">ca‐Compés‐Dea 2014</a>; <a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a>; <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a>; <a href="./references#CD004407-bbs2-0060" title="Lopez HernandezB , Martin VelezRM , Roman GarciaC , Penalver SanchezI , Lopez RosiqueJA . An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion Primaria/Sociedad Española de Medicina de Familia y Comunitaria2000;25(3):148-52. ">ca‐Lopez Hernandez 2000</a>; <a href="./references#CD004407-bbs2-0061" title="MaC , LiuY , TangJ , JiaH , QinW , SuY , et al. Assessment of mumps-containing vaccine effectiveness during an outbreak: importance to introduce the 2-dose schedule for China. Human Vaccines and Immunotherapy2018;14(6):1392-7. ">ca‐Ma 2018</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0065" title="NelsonGE , AguonA , ValenciaE , OlivaR , GuerreroML , ReyesR , et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010. Pediatric Infectious Disease Journal2013;32(4):374-80. [PMID: 23099425]">ca‐Nelson 2013</a>; <a href="./references#CD004407-bbs2-0066" title="OgbuanuIU , KuttyPK , HudsonJM , BlogD , AbediGR , GoodellS , et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics2012;130(6):e1567-74. [PMID: 23129075]">ca‐Ogbuanu 2012</a>; <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>; <a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a>; <a href="./references#CD004407-bbs2-0074" title="TaklaA , BohmerMM , KlincC , KurzN , SchafferA , StichH , et al. Outberak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics2014;10(1):140-5. ">ca‐Takla 2014</a>, and 7 case‐control studies (<a href="./references#CD004407-bbs2-0012" title="CastillaJ , Fernandez AlonsoM , Garcia CenozM , Martinez ArtolaV , Inigo PestanaM , RodrigoI , et al. Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica2009;133(20):777-82. CastillaJ , Garcia CenozM , ArriazuM , Fernandez-AlonsoM , Martinez-ArtolaV , EtxeberriaJ , et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine2009;27(15):2089-93. ">ba‐Castilla 2009</a>; <a href="./references#CD004407-bbs2-0015" title="FuC , XuJ , CaiY , HeQ , ZhangC , ChenJ , et al. Effectiveness of one dose of mumps vaccine against clinically diagnoses mumps in Guangzhou, China, 2006-2012. Human Vaccines and Immunotherapeutics2013;9(12):2524-8. [DOI: 10.4161/hv.26113]">ba‐Fu 2013</a>; <a href="./references#CD004407-bbs2-0016" title="GiovanettiF , LaudaniE , MarinaroL , DoglianiMG , GiachelliV , GiachinoG , et al. Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. Igiene Moderna2002;117(3):201-9. ">ba‐Giovanetti 2002</a>; <a href="./references#CD004407-bbs2-0017" title="GoncalvesG , De AraujoA , Monteiro CardosoML . Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveillance1998;3(12):119-21. ">ba‐Goncalves 1998</a>; <a href="./references#CD004407-bbs2-0018" title="HarlingR , WhiteJM , RamsayME , MacsweenKF , vanden BoschC . The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine2005;23(31):4070-4. ">ba‐Harling 2005</a>; <a href="./references#CD004407-bbs2-0021" title="KimHM , ChoHK , ChoiKM , EunBWY , KimKH . Efficacy of mumps in Korea. International Journal of Infectious Diseases2012;16s:e306. [DOI: 10.1016/j.ijid.2012.05.997]">ba‐Kim 2012</a>; <a href="./references#CD004407-bbs2-0023" title="MackenzieDG , CraigG , HallamNF , MooreJ , StevensonJ . Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice2006;56(528):526-9. ">ba‐Mackenzie 2006</a>). The studies are described <a href="#CD004407-tbl-0024">Table 3</a> and <a href="#CD004407-tbl-0025">Table 4</a>, and the summary of findings are presented in <a href="./full#CD004407-tbl-0002">summary of findings Table 2</a>. </p> <p>All cohort studies present estimates based on binary data as presented in their papers. Only two cohort studies reported binary data and adjusted estimates by multivariate models (<a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a>). The study by <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a> reported a combined (measles‐mumps) adjusted (age and gender) estimate, but binary data were reported separately, and we have included these data in a quantitative synthesis. In <a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a>, VE computed from binary data was 95% for one dose and 96% for two doses, when vaccine effectiveness adjusted estimates were 92% (one dose) and 93% (two doses). We used the method described in <a href="./references#CD004407-bbs2-0339" title="Di PietrantonjC . Four-fold table cell frequencies imputation in meta analysis. Statistics in Medicine2006;25(13):2299-322. [PMID: 16025540]">Di Pietrantonj 2006</a> to convert the adjusted effect estimates to adjusted binary data. </p> <section id="CD004407-sec-0067"> <h5 class="title">Evidence from cohort studies</h5> <p><b>Comparison 2.1</b> (<a href="./references#CD004407-fig-0009" title="">Analysis 2.1</a>) reports vaccine effectiveness containing Jeryl Lynn strain from nine cohort studies (<a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a>; <a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a>; <a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a>; <a href="./references#CD004407-bbs2-0061" title="MaC , LiuY , TangJ , JiaH , QinW , SuY , et al. Assessment of mumps-containing vaccine effectiveness during an outbreak: importance to introduce the 2-dose schedule for China. Human Vaccines and Immunotherapy2018;14(6):1392-7. ">ca‐Ma 2018</a>; <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>; <a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a>; <a href="./references#CD004407-bbs2-0074" title="TaklaA , BohmerMM , KlincC , KurzN , SchafferA , StichH , et al. Outberak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics2014;10(1):140-5. ">ca‐Takla 2014</a>). Occurrence of clinical mumps cases during outbreaks was retrospectively evaluated by comparing the incidence of disease amongst children who had been immunised with MMR vaccines containing Jeryl Lynn strain. Three cohort studies evaluated the effectiveness of MMR vaccination in household contacts during an outbreak (<a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a>; <a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a>). One cohort study was conducted during a mumps outbreak amongst university students previously vaccinated (once or twice) (<a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a>). Four studies did not specify numbers of doses (<a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a>; <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>). The VE after one dose was 72% (95% CI 38% to 87%) and after two doses 86% (95% CI 73% to 93%). The VE from studies that did not specify numbers of doses was 77% (95% CI 65% to 86%). The VE of MMR vaccination in preventing secondary mumps cases (in household contacts) was 74% (95% CI 51% to 87%). </p> <p>We excluded <a href="./references#CD004407-bbs2-0074" title="TaklaA , BohmerMM , KlincC , KurzN , SchafferA , StichH , et al. Outberak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics2014;10(1):140-5. ">ca‐Takla 2014</a> due to its small sample size, which made this study susceptible to bias and low statistical power. We also excluded <a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a> due to its particular population. The VE after one dose was 79% (95% CI 52% to 81%) and after two doses 83% (95% CI 62% to 93%). </p> <p><b>Comparison 2.2</b> (<a href="./references#CD004407-fig-0010" title="">Analysis 2.2</a>) reports vaccine effectiveness containing Urabe strain from four cohort studies (<a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>). In <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>, two different MMR vaccines containing Urabe strain were evaluated (Pluserix and Morupar). To avoid data duplication, half of the control arm (206/646) were assigned to the Morupar arm (28/747 versus 103/323) and half to the Pluserix arm (38/329 versus 103/323). None of the studies specified numbers of doses administered. The cohort study <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a> was carried out in childcare centres and primary schools in Singapore (children aged 5 to 12 years), and the cohort study by <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a> was performed amongst children (aged 5 to 13 years) from a small rural village in Switzerland. The VE (at least one dose) was 77% (95% CI 56% to 88%). The high level of heterogeneity seemed to be due to <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>, which showed a significant difference in vaccine effectiveness amongst Pluserix and Morupar arms, and partially due to the <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a> cohort study. </p> <p><b>Comparison 2.3</b> (<a href="./references#CD004407-fig-0011" title="">Analysis 2.3</a>) reports vaccine effectiveness containing Rubini strain from four cohort studies (<a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a>; <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>). None of the studies specified numbers of doses administered. Overall, the studies did not show statistical evidence of vaccine (containing Rubini strain) effectiveness. Only <a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a> showed statistical evidence in favour of vaccine effectiveness 43% (95% CI 33% to 52%). However, <a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a> showed statistical evidence in favour of the control ‐55% (95% CI ‐122% to ‐9%). The other two studies did not show statistical evidence for vaccine effectiveness (<a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a>; <a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a>). </p> <p><b>Comparison 2.4</b> (<a href="./references#CD004407-fig-0012" title="">Analysis 2.4</a>) reports vaccine effectiveness from two cohort studies where mumps strain is not reported or any strain (when in the same study population different participants are vaccinated with different MMR vaccines, each containing different mumps strain, but results by mumps strain were not reported) (<a href="./references#CD004407-bbs2-0054" title="Compés-DeaC , Guimbao-BescòsJ , Gaspar-EscayolaJI , Lazaro-BelancheMA , Aznar-BriebaA . An outbreak of mumps in a high school: estimation of vaccine effectiveness. Zaragoza 2011 [Broteescolar de parotiditis: estimacion de la efectividad vacunal Zaragoza 2011]. Enfermedades Infeccionas y Microbiologia Clinical2015;33(6):385-90. [DOI: 10.1016/j.eimc.2014.09.011]">ca‐Compés‐Dea 2014</a>; <a href="./references#CD004407-bbs2-0060" title="Lopez HernandezB , Martin VelezRM , Roman GarciaC , Penalver SanchezI , Lopez RosiqueJA . An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion Primaria/Sociedad Española de Medicina de Familia y Comunitaria2000;25(3):148-52. ">ca‐Lopez Hernandez 2000</a>). The cohort study by <a href="./references#CD004407-bbs2-0060" title="Lopez HernandezB , Martin VelezRM , Roman GarciaC , Penalver SanchezI , Lopez RosiqueJA . An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion Primaria/Sociedad Española de Medicina de Familia y Comunitaria2000;25(3):148-52. ">ca‐Lopez Hernandez 2000</a> estimated MMR vaccine effectiveness in preventing clinical mumps in male children aged between 3 and 15 years, attending a scholastic institute in Granada, Spain during an outbreak. Occurrence of clinical mumps cases was compared between children who received at least one dose of MMR vaccine (investigators were not able to determine the vaccine composition), and those who did not receive the MMR vaccine. The cohort study by <a href="./references#CD004407-bbs2-0054" title="Compés-DeaC , Guimbao-BescòsJ , Gaspar-EscayolaJI , Lazaro-BelancheMA , Aznar-BriebaA . An outbreak of mumps in a high school: estimation of vaccine effectiveness. Zaragoza 2011 [Broteescolar de parotiditis: estimacion de la efectividad vacunal Zaragoza 2011]. Enfermedades Infeccionas y Microbiologia Clinical2015;33(6):385-90. [DOI: 10.1016/j.eimc.2014.09.011]">ca‐Compés‐Dea 2014</a> was performed during an outbreak of mumps that occurred in high school students aged 16 to 17 years in December 2011. The study compared occurrence of clinical mumps between students previously vaccinated with at least one dose of MMR vaccine and those who did not receive the MMR vaccine (vaccine containing different mumps strains were used: Jeryl Lynn RIT‐4385 and Rubini). The overall VE was 48% (95% CI 6% to 71%). </p> <p><b>Comparison 2.5</b> (<a href="./references#CD004407-fig-0013" title="">Analysis 2.5</a>) includes two cohort studies that assessed the impact of three doses of MMR vaccine against mumps in children aged 9 to 17 years (<a href="./references#CD004407-bbs2-0065" title="NelsonGE , AguonA , ValenciaE , OlivaR , GuerreroML , ReyesR , et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010. Pediatric Infectious Disease Journal2013;32(4):374-80. [PMID: 23099425]">ca‐Nelson 2013</a>; <a href="./references#CD004407-bbs2-0066" title="OgbuanuIU , KuttyPK , HudsonJM , BlogD , AbediGR , GoodellS , et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics2012;130(6):e1567-74. [PMID: 23129075]">ca‐Ogbuanu 2012</a>). The overall risk ratio (RR) was 0.59 (95% CI 0.33 to 1.05). There was no evidence of effect of the third MMR dose administered in children aged between 9 to 17 years. </p> </section> <section id="CD004407-sec-0068"> <h5 class="title">Evidence from case‐control studies</h5> <p><b>Comparison 2.6</b> (<a href="./references#CD004407-fig-0014" title="">Analysis 2.6</a>) reports vaccine effectiveness containing Jeryl Lynn strain from four case‐control studies (<a href="./references#CD004407-bbs2-0012" title="CastillaJ , Fernandez AlonsoM , Garcia CenozM , Martinez ArtolaV , Inigo PestanaM , RodrigoI , et al. Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica2009;133(20):777-82. CastillaJ , Garcia CenozM , ArriazuM , Fernandez-AlonsoM , Martinez-ArtolaV , EtxeberriaJ , et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine2009;27(15):2089-93. ">ba‐Castilla 2009</a>; <a href="./references#CD004407-bbs2-0015" title="FuC , XuJ , CaiY , HeQ , ZhangC , ChenJ , et al. Effectiveness of one dose of mumps vaccine against clinically diagnoses mumps in Guangzhou, China, 2006-2012. Human Vaccines and Immunotherapeutics2013;9(12):2524-8. [DOI: 10.4161/hv.26113]">ba‐Fu 2013</a>; <a href="./references#CD004407-bbs2-0018" title="HarlingR , WhiteJM , RamsayME , MacsweenKF , vanden BoschC . The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine2005;23(31):4070-4. ">ba‐Harling 2005</a>; <a href="./references#CD004407-bbs2-0021" title="KimHM , ChoHK , ChoiKM , EunBWY , KimKH . Efficacy of mumps in Korea. International Journal of Infectious Diseases2012;16s:e306. [DOI: 10.1016/j.ijid.2012.05.997]">ba‐Kim 2012</a>). The study by <a href="./references#CD004407-bbs2-0021" title="KimHM , ChoHK , ChoiKM , EunBWY , KimKH . Efficacy of mumps in Korea. International Journal of Infectious Diseases2012;16s:e306. [DOI: 10.1016/j.ijid.2012.05.997]">ba‐Kim 2012</a> was available only as a poster presentation and provides very little information. The overall VE after one dose was 57% (95% CI 30% to 73%), after two doses 81% (95% CI 59% to 91%), and the VE irrespective of the number of doses administered was 65% (95% CI 52% to 75%). </p> <p>In <a href="./references#CD004407-bbs2-0012" title="CastillaJ , Fernandez AlonsoM , Garcia CenozM , Martinez ArtolaV , Inigo PestanaM , RodrigoI , et al. Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica2009;133(20):777-82. CastillaJ , Garcia CenozM , ArriazuM , Fernandez-AlonsoM , Martinez-ArtolaV , EtxeberriaJ , et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine2009;27(15):2089-93. ">ba‐Castilla 2009</a>, case definition considers clinical mumps with laboratory or epidemiological confirmation occurring during an outbreak in the Navarre region of northern Spain between August 2006 and June 2008 in children and adolescents (241 cases and 1205 matched controls). The study authors hypothesised a higher risk of having mumps when the first MMR dose was administered after 36 months of age, odds ratio (OR) 3.11 (95% CI 1.15 to 8.43), or when the two MMR doses were administered more than 36 months apart (OR 10.19, 95% CI 1.47 to 70.73). </p> <p><b>Comparison 2.7</b> (<a href="./references#CD004407-fig-0015" title="">Analysis 2.7</a>) reports vaccine effectiveness containing Jeryl Lynn from one case‐control study (<a href="./references#CD004407-bbs2-0018" title="HarlingR , WhiteJM , RamsayME , MacsweenKF , vanden BoschC . The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine2005;23(31):4070-4. ">ba‐Harling 2005</a>), where cases included in the study were laboratory‐confirmed (by immunoglobulin M radioimmunoassay, detection of mumps ribonucleic acid (RNA) by polymerase chain reaction (PCR), or both). The VE after one, two, and any dose was 64% (95% CI 41% to 78%), 88% (95% CI 63% to 96%), and 65% (95% CI 24% to 84%), respectively. </p> <p><b>Comparison 2.8</b> (<a href="./references#CD004407-fig-0016" title="">Analysis 2.8</a>) reports vaccine effectiveness on vaccines containing Urabe strain, and <b>Comparison 2.9</b> (<a href="./references#CD004407-fig-0017" title="">Analysis 2.9</a>) reports on vaccines containing Rubini strain. One case‐control study reported evidence from both strains (<a href="./references#CD004407-bbs2-0017" title="GoncalvesG , De AraujoA , Monteiro CardosoML . Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveillance1998;3(12):119-21. ">ba‐Goncalves 1998</a>), assessing the effectiveness of at least one dose of MMR vaccine in preventing clinical mumps cases during an epidemic in a population of children and adolescents. Significant protection was conferred by the Urabe strain‐containing MMR vaccine (VE 70%, 95% CI 25% to 88%), but not by the Rubini strain‐containing MMR (VE 1%, 95% CI −108% to 53%). </p> <p><b>Comparison 2.10</b> (<a href="./references#CD004407-fig-0018" title="">Analysis 2.10</a>) reports vaccine effectiveness from two case‐control studies where cases and controls were selected from a population where, because of a changing vaccine schedule, different MMR vaccines with different mumps strains were administered (<a href="./references#CD004407-bbs2-0016" title="GiovanettiF , LaudaniE , MarinaroL , DoglianiMG , GiachelliV , GiachinoG , et al. Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. Igiene Moderna2002;117(3):201-9. ">ba‐Giovanetti 2002</a>; <a href="./references#CD004407-bbs2-0023" title="MackenzieDG , CraigG , HallamNF , MooreJ , StevensonJ . Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice2006;56(528):526-9. ">ba‐Mackenzie 2006</a>). <a href="./references#CD004407-bbs2-0016" title="GiovanettiF , LaudaniE , MarinaroL , DoglianiMG , GiachelliV , GiachinoG , et al. Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. Igiene Moderna2002;117(3):201-9. ">ba‐Giovanetti 2002</a> conducted a field study on MMR vaccination effectiveness (at least one dose) in preventing clinical mumps in a population of children and adolescents. <a href="./references#CD004407-bbs2-0023" title="MackenzieDG , CraigG , HallamNF , MooreJ , StevensonJ . Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice2006;56(528):526-9. ">ba‐Mackenzie 2006</a> attempted to estimate the effectiveness of MMR vaccination against virologically confirmed mumps on students aged 13 to 17 years attending a boarding school in Scotland. The study was not large enough to reach statistical evidence of effect. The overall VE (at least one dose) was 50% (95% CI 19% to 69%). </p> </section> </section> <section id="CD004407-sec-0069"> <h4 class="title">3. Effectiveness against rubella</h4> <p><b>Comparison 3.1</b> (<a href="./references#CD004407-fig-0019" title="">Analysis 3.1</a>) reports vaccine effectiveness from one cohort study that attempted to estimate MMR vaccine effectiveness in a population who received two rubella strain‐based MMR vaccines (<a href="./references#CD004407-bbs2-0052" title="ChangC , MoX , HuP , LiangW , MaH , AnZ , et al. Effectiveness of rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014. Vaccine2015;33(28):3223-7. [DOI: 10.1016/j.vaccine.2015.04.083]">ca‐Chang 2015</a>): MMR containing the BRD‐II rubella strain, or MMR containing the RA27/3 rubella strain. The VE was 89% (95% CI 56% to 95%). See <a href="#CD004407-tbl-0026">Table 5</a> and <a href="./full#CD004407-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD004407-sec-0070"> <h4 class="title">4. Effectiveness against varicella (MMR+V or MMRV)</h4> <p>Fourteen studies reported effectiveness data against varicella: 3 RCTs (<a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a>; <a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a>; <a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a>), 4 cohort studies (<a href="./references#CD004407-bbs2-0055" title="GiaquintoC , GabuttiG , BaldoV , VillaM , TramontanL , RaccanelloN , et al. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. BMC Infectious Diseases2018;18(1):103. ">ca‐Giaquinto 2018</a>; <a href="./references#CD004407-bbs2-0069" title="RieckT , FeigM , An der HeidenM , SiedlerA , WichmannO . Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveillance2017;22(17):30521. ">ca‐Rieck 2017</a>; <a href="./references#CD004407-bbs2-0072" title="SpackovaM , Wiese-PosseltM , DehnertM , Matysiak-KloseD , HeiningerU , SiedlerA . Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine2010;28(3):686-91. ">ca‐Spackova 2010</a>; <a href="./references#CD004407-bbs2-0073" title="TafuriS , MartinelliD , PratoR , GerminarioC . Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in region which adopted UMV. Human Vaccines and Immunotherapeutics2013;9(1):184-8. ">ca‐Tafuri 2013</a>), 4 CCS (<a href="./references#CD004407-bbs2-0011" title="AndradeAL , da Silva VieiraMA , MinamisavaR , ToscanoCM , deLima SouzaMB , FiaccadoriF , et al. Single-dose varicella vaccine effectiveness in Brazil: a case-control study. Vaccine2018;36(4):479-83. [PMID: 29249544]">ba‐Andrade 2018</a>; <a href="./references#CD004407-bbs2-0013" title="CenozMG , Martinez-ArtolaV , GuevaraM , EzpeletaC , BarricarteA , CastillaJ . Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Human Vaccines and Immunotherapeutics2013;9(5):1172-6. [DOI: 10.4161/hv.23451]">ba‐Cenoz 2013</a>; <a href="./references#CD004407-bbs2-0022" title="LieseJG , CohenC , RackA , PirzerK , EberS , BlumM , et al. The effectiveness of varicella vaccination in children in Germany. Pediatric Infectious Disease Journal2013;32(9):998-1004. [DOI: 10.1097/INF.0b013e31829ac263]">ba‐Liese 2013</a>; <a href="./references#CD004407-bbs2-0024" title="VazquezM , La RussaPS , GershonAA , StainbergSP , FreudigmanK , ShapiroE . The effectiveness of the varicella vaccine in clinical practice. New England Journal of Medicine2001;344(13):955-60. [DOI: 10.1056/NEJM200103293441302]">ba‐Vazquez 2001</a>), and 3 COEM (<a href="./references#CD004407-bbs2-0128" title="BoccaliniS , BonanniP , BechiniA . Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004–2012. Euro Surveillance2015;21:1-7. [DOI: 10.2807/1560-7917.ES.2016.21.24.30257]">ga‐Boccalini 2015</a>; <a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a>; <a href="./references#CD004407-bbs2-0130" title="TafuriS , FortunatoF , CappelliMG , CozzaV , BechiniA , BonanniP , et al. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012. Human Vaccines and Immunotherapy2015;11(1):214-9. [DOI: 10.4161/hv.36153]">ga‐Tafuri 2015</a>). In <a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a>, data from two independent surveillance systems were reported. The studies are described in <a href="#CD004407-tbl-0027">Table 6</a>, <a href="#CD004407-tbl-0028">Table 7</a>, <a href="#CD004407-tbl-0029">Table 8</a>, and <a href="#CD004407-tbl-0030">Table 9</a>. The summary of findings are presented in <a href="./full#CD004407-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD004407-sec-0071"> <h5 class="title">Evidence from RCTs/CCTs</h5> <p>Three multicentre RCTs evaluated vaccine effectiveness of 2 doses in children aged 11 to 22 months against varicella (any severity) and against varicella (moderate/severe) during 3 follow‐up time periods: up to 5 years, between 5 and 10 years, and 10 years (<a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a>; <a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a>; <a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a>). Each of these studies compared three vaccine types: MMRV (Priorix‐Tetra), MMR (Priorix), and MMR+V (Priorix + Varilrix). </p> <p><b>Comparison 4.1</b> and <b>Comparison 4.2.</b> The overall MMRV vaccine effectiveness against varicella (any severity) after 10 years' follow‐up was 95% (95% CI 94% to 96%) (<a href="./references#CD004407-fig-0020" title="">Analysis 4.1</a>). The vaccine effectiveness against varicella (moderate/severe) was 99% (95% CI 98% to 100%) (<a href="./references#CD004407-fig-0021" title="">Analysis 4.2</a>). </p> <p><b>Comparison 4.3</b> , <b>Comparison 4.4</b> , and <b>Comparison 4.5</b>. The overall MMR+V vaccine effectiveness against varicella (any severity) after 10 years' follow‐up was 67% (95% CI 64% to 70%) (<a href="./references#CD004407-fig-0022" title="">Analysis 4.3</a>); against varicella (moderate/severe) 90% (95% CI 88% to 92%) (<a href="./references#CD004407-fig-0023" title="">Analysis 4.4</a>); and against varicella (severe) 95% (95% CI 53% to 99%) (<a href="./references#CD004407-fig-0024" title="">Analysis 4.5</a>). </p> </section> <section id="CD004407-sec-0072"> <h5 class="title">Evidence from cohort studies</h5> <p><b>Comparison 4.6</b> (<a href="./references#CD004407-fig-0025" title="">Analysis 4.6</a>) reports on MMRV vaccine effectiveness from four cohort studies (<a href="./references#CD004407-bbs2-0055" title="GiaquintoC , GabuttiG , BaldoV , VillaM , TramontanL , RaccanelloN , et al. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. BMC Infectious Diseases2018;18(1):103. ">ca‐Giaquinto 2018</a>; <a href="./references#CD004407-bbs2-0069" title="RieckT , FeigM , An der HeidenM , SiedlerA , WichmannO . Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveillance2017;22(17):30521. ">ca‐Rieck 2017</a>; <a href="./references#CD004407-bbs2-0072" title="SpackovaM , Wiese-PosseltM , DehnertM , Matysiak-KloseD , HeiningerU , SiedlerA . Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine2010;28(3):686-91. ">ca‐Spackova 2010</a>; <a href="./references#CD004407-bbs2-0073" title="TafuriS , MartinelliD , PratoR , GerminarioC . Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in region which adopted UMV. Human Vaccines and Immunotherapeutics2013;9(1):184-8. ">ca‐Tafuri 2013</a>). One study evaluated one dose of the (MMRV ProQuad) vaccine (<a href="./references#CD004407-bbs2-0055" title="GiaquintoC , GabuttiG , BaldoV , VillaM , TramontanL , RaccanelloN , et al. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. BMC Infectious Diseases2018;18(1):103. ">ca‐Giaquinto 2018</a>), whilst the rest of the cohorts evaluated MMRV (Priorix‐Tetra). The one‐dose MMRV (ProQuad) vaccine effectiveness against varicella was 94% (95% CI 92% to 96%). The overall MMRV (Priorix‐Tetra) vaccine effectiveness against varicella was 62% (95% CI 61% to 63%) after one dose and 87% (95% CI 86% to 87%) after two doses. </p> </section> <section id="CD004407-sec-0073"> <h5 class="title">Evidence from case‐control studies</h5> <p><b>Comparison 4.7</b> (<a href="./references#CD004407-fig-0026" title="">Analysis 4.7</a>) includes one case‐control study evaluating the MMRV (GSK) vaccine effectiveness against varicella (any severity) 86% (95% CI 72% to 93%) and against varicella (moderate/severe) 93% (95% CI 83% to 97%) (<a href="./references#CD004407-bbs2-0011" title="AndradeAL , da Silva VieiraMA , MinamisavaR , ToscanoCM , deLima SouzaMB , FiaccadoriF , et al. Single-dose varicella vaccine effectiveness in Brazil: a case-control study. Vaccine2018;36(4):479-83. [PMID: 29249544]">ba‐Andrade 2018</a>). </p> <p><b>Comparison 4.8</b> (<a href="./references#CD004407-fig-0027" title="">Analysis 4.8</a>) includes three studies evaluating MMR+V versus MMR. The overall VE against varicella (any severity) was 86% (95% CI 78% to 92%) after one dose; 95% (95% CI 86% to 99%) after two doses; and 88% (95% CI 82% to 92%) after at least one dose (<a href="./references#CD004407-bbs2-0013" title="CenozMG , Martinez-ArtolaV , GuevaraM , EzpeletaC , BarricarteA , CastillaJ . Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Human Vaccines and Immunotherapeutics2013;9(5):1172-6. [DOI: 10.4161/hv.23451]">ba‐Cenoz 2013</a>; <a href="./references#CD004407-bbs2-0022" title="LieseJG , CohenC , RackA , PirzerK , EberS , BlumM , et al. The effectiveness of varicella vaccination in children in Germany. Pediatric Infectious Disease Journal2013;32(9):998-1004. [DOI: 10.1097/INF.0b013e31829ac263]">ba‐Liese 2013</a>; <a href="./references#CD004407-bbs2-0024" title="VazquezM , La RussaPS , GershonAA , StainbergSP , FreudigmanK , ShapiroE . The effectiveness of the varicella vaccine in clinical practice. New England Journal of Medicine2001;344(13):955-60. [DOI: 10.1056/NEJM200103293441302]">ba‐Vazquez 2001</a>). </p> </section> <section id="CD004407-sec-0074"> <h5 class="title">Evidence from case‐only ecological method studies</h5> <p><b>Comparison 4.9</b> (<a href="./references#CD004407-fig-0028" title="">Analysis 4.9</a>) includes three studies evaluating reduction in the number of hospitalisations before and after introduction of MMRV vaccine in children aged 0 to 14 years (<a href="./references#CD004407-bbs2-0128" title="BoccaliniS , BonanniP , BechiniA . Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004–2012. Euro Surveillance2015;21:1-7. [DOI: 10.2807/1560-7917.ES.2016.21.24.30257]">ga‐Boccalini 2015</a>; <a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a>; <a href="./references#CD004407-bbs2-0130" title="TafuriS , FortunatoF , CappelliMG , CozzaV , BechiniA , BonanniP , et al. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012. Human Vaccines and Immunotherapy2015;11(1):214-9. [DOI: 10.4161/hv.36153]">ga‐Tafuri 2015</a>). The overall vaccine effectiveness (VE = (1 − rate ratio) x 100) in reducing hospitalisation in children aged 0 to 14 years was 57% (95% CI 45% to 66%). </p> <p><b>Comparison 4.10</b> (<a href="./references#CD004407-fig-0029" title="">Analysis 4.10</a>) includes two studies evaluating incidence reduction before and after introduction of MMRV vaccine in children aged 0 to 14 years (<a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a>; <a href="./references#CD004407-bbs2-0130" title="TafuriS , FortunatoF , CappelliMG , CozzaV , BechiniA , BonanniP , et al. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012. Human Vaccines and Immunotherapy2015;11(1):214-9. [DOI: 10.4161/hv.36153]">ga‐Tafuri 2015</a>). The overall vaccine effectiveness (VE = (1 − rate ratio) x 100) in reduced incidence was 76% (95% CI 57% to 86%). </p> <p>However, we note that there was a large difference in efficacy amongst subgroups. The highest efficacy was observed in children aged 1 to 4 years, whilst the smallest efficacy was observed in the subgroup of children aged 0 to 14 years (<a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a>). There was no difference between subgroups aged under 1 year and 5 to 14 years. These differences may be due to different methodological quality amongst studies. </p> </section> </section> <section id="CD004407-sec-0075"> <h4 class="title">5. Safety: short‐term side effects</h4> <p>Seventeen studies reported data on short‐term side effects after MMR vaccination: 7 RCTs/CCTs, <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; <a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>; <a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>, and 10 cohorts (<a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a>; <a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>; <a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a>; <a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>; <a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a>; <a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a>; <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>; <a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>; <a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>). See <a href="#CD004407-tbl-0031">Table 10</a>, <a href="#CD004407-tbl-0032">Table 11</a>, and <a href="./full#CD004407-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD004407-sec-0076"> <h5 class="title">Evidence from RCTs/CCTs and cohort studies</h5> <p><b>From RCTs:</b> MMR vaccines were compared with monovalent measles vaccine (<a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; <a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>), two types of monovalent mumps and rubella vaccines (<a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>), or placebo (<a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>). One trial carried out in twins reported a possible protective effect of the MMR vaccine with a lower incidence of respiratory symptoms, nausea and vomiting, and no difference in the incidence of other unintended side effects compared with placebo, with the exception of irritability (<a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>). Another trial concluded there was no increased clinical reactivity from an MMR vaccine containing two strains of rubella (<a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>). <a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a> concluded there was no significant difference in numbers of children developing symptoms after MMR or measles vaccination. Two studies concluded that the incidences of raised temperature, rash, lymphadenopathy, coryza, rhinitis, cough, local reactions, or limb and joint symptoms were not significantly different from children who received placebo (<a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>). All RCTs and CCTs reported a wide range of outcomes and used different terms, often with no definitions. For example, body temperature higher than 38 °C was measured or reported in 16 ways. When this information was reported, different temperature increments, recording methods, observation periods, and incidence made comparisons amongst trials and pooling of data impossible. In <a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>, conducted by 22 family physicians, the occurrence of common symptoms following MMR immunisation (type not described) was assessed by means of weekly diaries amongst participants immunised at 13 and 15 months of age, comparing incidence during the four weeks before with four weeks after immunisation. The incidence of rash, lymphadenopathy, and nasal discharge was found to be higher after exposure to MMR immunisation. </p> <p><b>From cohort studies:</b> 10 cohort studies assessed the occurrence of short‐term side effects, comparing MMR vaccine with single measles vaccines (<a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a>; <a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>; <a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a>; <a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a>), mumps‐rubella vaccine (<a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>), single mumps vaccines (<a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>), single rubella vaccines (<a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>; <a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>), placebo (<a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a>), or no intervention (<a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>; <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>). <a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a> found that the MMR vaccine was associated with an increased risk of episodes of joint and limb symptoms in girls younger than 5 years of age. There was no difference in the incidence of common outcomes such as fever, rash, lymphadenopathy, cough, arthralgia, myalgia, and anorexia between the MMR vaccine and rubella vaccine (<a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>; <a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>; <a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>), mumps‐rubella vaccine (<a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a>), single mumps vaccine (<a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>), or measles vaccine (<a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a>; <a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a>). Two studies found that symptoms were similar following MMR and measles vaccination (<a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a>; <a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a>), except for a higher incidence of parotitis following MMR vaccination (<a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a>). <a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a> reported a higher incidence of diarrhoea in the MMR vaccines arm compared to the single measles or rubella vaccines arms. Two studies reported no difference in the incidence of rash and lymphadenopathy between MMR vaccination and placebo, <a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a>, or no treatment (<a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>). However, <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a> reported an increase in the incidence of fever in the period Day 5 to Day 12 postvaccination, but <a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a> reported no difference. Considering the cohort of <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a> only within the subgroup of younger children (16 to 24 months of age), fever during the 42 days' postvaccination was reported more frequently amongst children immunised with MMR than in unvaccinated children. This trend appeared to differ when an older population was considered: fever was reported with slightly higher frequency amongst unvaccinated children. </p> <p>We performed quantitative synthesis for the most common adverse effects: temperature, rash, lymphadenopathy, coryza, upper respiratory tract infections, and cough. The analysis includes only studies comparing MMR versus placebo (or no treatment). The measure of association between MMR vaccination and specific adverse effect is the risk ratio (RR) and its 95% confidence interval (CI). Results from RCTs and cohort studies are presented separately. </p> <p><b>Comparison 5.1</b> (<a href="./references#CD004407-fig-0030" title="">Analysis 5.1</a>). Seven studies assessed the association between MMR vaccination and temperature: 3 RCTs, <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>, and 4 cohort studies (<a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a>; <a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>; <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>). From RCT data the overall RR was 1.29 (95% CI 0.77 to 2.17). A close value is shown from cohort data (RR 1.16, 95% CI 0.90 to 1.51). </p> <p><b>Comparison 5.2</b> (<a href="./references#CD004407-fig-0031" title="">Analysis 5.2</a>). Six studies evaluated the association between vaccination and rash: 3 RCTs, <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>, and 3 cohort studies (<a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>; <a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>). From RCT data the overall RR was 2.05 (95% CI 1.21 to 3.48). However, from cohort studies it was RR 1.49 (95% CI 0.73 to 3.04). </p> <p><b>Comparison 5.3</b> (<a href="./references#CD004407-fig-0032" title="">Analysis 5.3</a>). Five studies evaluated the association between vaccination and lymphadenopathy: 3 RCTs, <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>, and 2 cohort studies (<a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a>; <a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>). From RCT data the overall association was RR 1.32 (95% CI 0.52 to 3.33); from cohort studies it was RR 1.98 (95% CI 0.19 to 20.97). </p> <p><b>Comparison 5.4</b> (<a href="./references#CD004407-fig-0033" title="">Analysis 5.4</a>). Three studies assessed the association between vaccination and coryza: 2 RCTs, <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>, and one cohort study (<a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a>); the association was RR 0.45 (95% CI 0.12 to 1.63) and RR 1.13 (95% CI 1.05 to 1.20), respectively. </p> <p><b>Comparison 5.5</b> (<a href="./references#CD004407-fig-0034" title="">Analysis 5.5</a>). Three studies assessed the association between vaccination and coryza: 2 RCTs, <a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>, and one cohort study (<a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a>); the association was RR 0.31 (95% CI 0.06 to 1.56) and RR 1.44 (95% CI 1.26 to 1.64), respectively. </p> <p><b>Comparison 5.6</b> (<a href="./references#CD004407-fig-0035" title="">Analysis 5.6</a>). Two RCTs assessed the association between vaccination and coryza: RR 1.99 (95% CI 0.45 to 8.81) (<a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; <a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>). </p> <p>These results must be interpreted cautiously because different MMR vaccines with different strains were used. However, we found a weak association between MMR vaccination and rash (RCT), coryza (cohort), and upper respiratory tract infections (cohort). We found no evidence of association between MMR vaccine and temperature, lymphadenopathy, and cough. </p> </section> </section> <section id="CD004407-sec-0077"> <h4 class="title">Safety: severe harms</h4> <p>The association between MMR/MMRV and severe harms (excluding short‐term side effects) was investigated in 70 studies (22 cohort studies, 22 CCS, 13 SCCS, 3 PTC, 2 CCO, 8 COEM). The measure of association between MMR vaccination and specific severe harm is the RR for cohort studies, the OR for case‐control studies, and the rate ratio (rr) for cohort studies, self‐controlled case series, and person‐time cohort studies. Each estimate is reported with its 95% CI. </p> </section> <section id="CD004407-sec-0078"> <h4 class="title">6. Safety: encephalitis or encephalopathy</h4> <p>The potential association between MMR immunisation and the occurrence of encephalopathies was investigated in three studies: one case‐control study, <a href="./references#CD004407-bbs2-0041" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768-73. ">bb‐Ray 2006</a>, and two SCCS (<a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>; <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>). See <a href="#CD004407-tbl-0033">Table 12</a> and <a href="./full#CD004407-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD004407-sec-0079"> <h5 class="title">Evidence from case‐control studies</h5> <p><b>Comparison 6.1</b> (<a href="./references#CD004407-fig-0036" title="">Analysis 6.1</a>). <a href="./references#CD004407-bbs2-0041" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768-73. ">bb‐Ray 2006</a> tested if hospitalisations due to encephalopathy, Reye's syndrome, or encephalitis occurring in children aged 0 to 6 years could be linked to MMR vaccine administration (<a href="#CD004407-tbl-0033">Table 12</a>). Different time intervals between MMR exposure and date of hospitalisation were considered: 7 to 14 days, 0 to 14 days, 0 to 30 days, 0 to 60 days, and 0 to 90 days (<a href="./references#CD004407-fig-0036" title="">Analysis 6.1</a>). A total of 452 cases together with their 1280 matched controls were included in the analysis. Exposure to the MMR vaccine did not differ statistically between cases and controls for any of the time intervals considered. </p> </section> <section id="CD004407-sec-0080"> <h5 class="title">Evidence from self‐controlled case series studies</h5> <p><b>Comparison 6.2</b> (<a href="./references#CD004407-fig-0037" title="">Analysis 6.2</a>). <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> was based on a surveillance study by the National Public Health Institute that began after the introduction of MMR vaccination in Finland for children aged 14 to 18 months and 6 years (1982). Participants aged 1 to 7 years (N = 535,544) who received the MMR II vaccine between November 1982 and June 1986 were considered in the study (this population corresponds to 86% of all children scheduled for MMR vaccination in Finland). Risk association was evaluated by comparing the number of hospitalisations for encephalitis or encephalopathy (see <a href="#CD004407-tbl-0033">Table 12</a> for the outcome definition) within three months after vaccination, with those occurring during the subsequent seven three‐month intervals. Of 199 hospitalisations for encephalitis or encephalopathy, 9 occurred within 3 months after MMR vaccination, 110 occurred more than 3 months after vaccination (88 between 3 and 24 months), whereas 80 occurred before the vaccine was administered. The trial authors stated that no hospitalisation excess for encephalitis or encephalopathy was observed during the three months' postimmunisation. In <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>, to evaluate the association between encephalitis and MMR vaccination (see <a href="#CD004407-tbl-0033">Table 12</a> for case definitions), cases (N = 107) diagnosed between the ages of 2 to 35 months were considered (in Britain and Ireland, the MMR vaccine is scheduled at 12 to 15 months of age). The risk period for encephalitis was considered to be the time between 15 and 35 days following MMR immunisation. The incidence of disease within the risk period was compared with the control period. The incidence of encephalitis in the risk period (15 to 35 days) was not statistically different from the control period (rr 1.34, 95% CI 0.52 to 3.47). This estimate did not change in the presence or absence of primary human herpesvirus 6 (HHV‐6) or HHV‐7 infections. The meta‐analysis estimate of the association between MMR immunisation and encephalitis is rr 0.90 (95% CI 0.50 to 1.61; <a href="./references#CD004407-fig-0037" title="">Analysis 6.2</a>). </p> <p>The meta‐analysis did not provide evidence supporting an association between MMR immunisation and encephalitis or encephalopathy. </p> </section> </section> <section id="CD004407-sec-0081"> <h4 class="title">7. Safety: aseptic meningitis</h4> <p>The association between MMR vaccine and aseptic meningitis was evaluated in the following 10 studies: 1 case‐control (<a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>), 2 CCO (<a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a>; <a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a>), 4 SCCS/PTC (<a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>), 1 PTC (<a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>), and 2 COEM (<a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a>; <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>). The qualitative synthesis is presented in <a href="#CD004407-tbl-0034">Table 13</a>. The summary of findings are presented in <a href="./full#CD004407-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD004407-sec-0082"> <h5 class="title">Evidence from case‐control studies ‐ case cross‐over studies</h5> <p><b>Comparison 7.1</b> (<a href="./references#CD004407-fig-0038" title="">Analysis 7.1</a>). In <a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>, MMR vaccination within defined intervals before the index date (0 to 14 days, 0 to 30 days, 8 to 14 days) was assessed in cases and controls to assess its association with aseptic meningitis (see <a href="#CD004407-tbl-0034">Table 13</a> for outcome definitions). Exposure to the MMR vaccine was not statistically different between cases and controls in any of the considered time intervals. The association between MMR vaccination and aseptic meningitis was evaluated in two case cross‐over studies (<a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a>; <a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a>). MMR containing Urabe strain or MMR vaccine containing Hoshino strain was administered to participants of both studies. The overall association between these MMR vaccines and aseptic meningitis is odds ratio (OR) 4.00 (95% CI 2.23 to 7.20; <a href="./references#CD004407-fig-0038" title="">Analysis 7.1</a>). <a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a> presents data from a subgroup for whom only MMR vaccine containing Jeryl Lynn strain was administered. No association between MMR (Jeryl Lynn) vaccine and aseptic meningitis was shown. </p> </section> <section id="CD004407-sec-0083"> <h5 class="title">Evidence from self‐controlled case‐series/person‐time cohort studies</h5> <p><b>Comparison 7.2</b> (<a href="./references#CD004407-fig-0039" title="">Analysis 7.2</a>) includes data from five studies. MMR vaccine containing Urabe strain was used in three studies (<a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>). The overall association between MMR (Urabe) and aseptic meningitis is rr 30.71 (95% CI 13.45 to 70.10). In <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>, no association was shown with MMR II vaccine (Enders‐Edmonston, Jeryl Lynn, Wistar RA 27/3). <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a> was conducted on 26 sentinel sites (49 hospitals) distributed in 16 countries of the 6 World Health Organization (WHO) regions, where different MMR vaccines containing different strains were administered. Data showed no association when MMR containing Lenigrad‐Zagreb was administered. </p> </section> <section id="CD004407-sec-0084"> <h5 class="title">Evidence from case‐only ecological method studies</h5> <p><b>Comparison 7.3</b> (<a href="./references#CD004407-fig-0040" title="">Analysis 7.3</a>) includes data from three studies (<a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>; <a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a>; <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>). MMR with Urabe strain was used in <a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a>. MMR with Leningrad‐Zagreb was used in <a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a> and <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>. The association between MMR and aseptic meningitis was rate ratio (rr) 9.12 (95% CI 5.73 to 14.52) and rr 18.45 (95% CI 13.26 to 25.56), respectively. </p> <p>The association between MMR vaccination and aseptic meningitis was due to the Urabe or Leningrad‐Zagreb strains. The meta‐analysis showed no evidence of an association between MMR containing Jeryl Lynn strain and aseptic meningitis. </p> </section> </section> <section id="CD004407-sec-0085"> <h4 class="title">8. Safety: seizures (febrile/afebrile)</h4> <p>Fifteen studies evaluated the association between MMR/MMR+V/MMRV immunisation and seizure (febrile/afebrile). Eight studies compared MMR/MMR+V/MMRV versus placebo or no treatment: 2 cohorts (<a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a>; <a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a>), 4 SCCS (<a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0113" title="MacartneyK , GiddingHF , TrinhL , WangH , DeyA , HullB , et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatrics2017;171(10):992-8. ">db‐Macartney 2017</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>), and 2 PTC (<a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a>; <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a>) (see <a href="#CD004407-tbl-0035">Table 14</a>). Seven cohort studies compared MMRV versus MMR or MMR+V (<a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a>; <a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a>; <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0093" title="KleinNP , LewisE , McDonaldJ , FiremanB , NalewayA , GlanzJ , et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. Vaccine2017;35(12):1615-21. ">cb‐Klein 2017</a>; <a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a>; <a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a>). See <a href="#CD004407-tbl-0036">Table 15</a> and <a href="./full#CD004407-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD004407-sec-0086"> <h5 class="title">Evidence from cohort studies</h5> <p><b>Comparison 8.1</b> (<a href="./references#CD004407-fig-0041" title="">Analysis 8.1</a>) includes data from two studies (<a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a>; <a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a>). <a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a> is a cohort study assessing the risk of febrile seizure after the introduction of routine MMR vaccination in Denmark in 1987 (<a href="#CD004407-tbl-0035">Table 14</a>). Globally, the risk of febrile seizure was significantly higher amongst vaccinated children (RR 1.10, 95% CI 1.05 to 1.15). When different time frames after vaccination were considered, the RR was at the highest point within two weeks after immunisation (RR 2.75, 95% CI 2.55 to 2.97). The RR did not differ significantly in weeks 3 to 6, and was slightly less than 1 in weeks 7, 8, 9 to 26 and 27 to 52. Amongst children with personal history of febrile seizure, the RR was 2.75 (95% CI 2.32 to 3.26) (adjusted for age, calendar period, age at first febrile seizure) compared with non‐vaccinated children with personal history of febrile seizure. For evaluation of long‐term prognosis, the number of recurrent episodes of febrile seizure and the cases of epilepsy observed in children who received MMR vaccination within 14 days before their first febrile seizure episode, and in those who were vaccinated more than 14 days before their first febrile seizure episode, were compared with those who were not vaccinated at the time of their first febrile seizure episode. A significant risk association was found only for recurrent febrile seizure episodes in children who were immunised with MMR within 14 days before the first episode (RR 1.19, 95% CI 1.10 to 1.41) adjusted for age, calendar period, age at first febrile seizure, and current vaccination status. <a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a> was a cohort study conducted at four large health maintenance organisations. The study showed statistical evidence of association (within two weeks) between MMR immunisation and febrile seizures. However, there was no evidence of an association with afebrile seizures (RR 1.11, 95% CI 0.11 to 11.28). </p> <p>The overall RR of having febrile seizures within two weeks after MMR immunisation was 3.16 (95% CI 2.89 to 3.46). </p> </section> <section id="CD004407-sec-0087"> <h5 class="title">Evidence from self‐controlled case series/person‐time cohort studies</h5> <p><b>Comparison 8.2</b> (<a href="./references#CD004407-fig-0042" title="">Analysis 8.2</a>) includes evidence from six studies (<a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0113" title="MacartneyK , GiddingHF , TrinhL , WangH , DeyA , HullB , et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatrics2017;171(10):992-8. ">db‐Macartney 2017</a>; <a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a>; <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a>; <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>; <a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a>). <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> shows the rr estimates of febrile seizures amongst people vaccinated with the MMR containing Jeryl Lynn strain and people vaccinated with the MMR containing Urabe strain. The seizure risk associate to MMR (Urabe) was rr 3.77 (95% CI 1.95 to 7.30) within 6 to 11 days, and rr 1.04 (95% CI 0.56 to 1.93) within 15 to 35 days. We only included data from MMR (Jeryl Lynn). <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a> shows the rr estimates of febrile seizures for MMR II vaccine (Jeryl Lynn) and MMR Priorix (RIT 4385). Both estimates were included. In <a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>, the risk incidence of febrile convulsion was also analysed considering a more specific definition (<a href="#CD004407-tbl-0037">Table 16</a>). Considering all MMR vaccine types, the risk incidence remained higher in the 6 to 11 days following vaccination (rr 4.27, 95% CI 3.17 to 5.76), whereas at 15 to 35 days following vaccination it remained at borderline significance (rr 1.33, 95% CI 1.00 to 1.77). <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a> reported data for two vaccines (MMR and MMRV) stratified by gestational age (born before 37 weeks, born ≥ 37 weeks). <a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a> analysed the risk of febrile seizure amongst people vaccinated with MMRV and people vaccinated with MMR+V; the rr estimates of febrile seizures for each vaccine (MMRV and MMR+V) were presented stratified in two subcohorts (low risk, high risk). </p> <p>The overall rr of having febrile seizures within two weeks after MMR immunisation was 3.36 (95% CI 2.65 to 4.24; <a href="./references#CD004407-fig-0042" title="">Analysis 8.2</a>). No evidence of association was shown beyond two weeks (rr 1.18, 95% CI 0.93 to 1.50). The rr was 6.08 (95% CI 4.95 to 7.47) within two weeks after MMRV immunisation and 3.13 (95% CI 2.38 to 4.10) after MMR+V immunisation. </p> </section> <section id="CD004407-sec-0088"> <h5 class="title">Evidence from cohort studies ‐ MMRV versus (MMR+V or MMR)</h5> <p>Of seven cohort studies evaluating the risk of having febrile seizures after immunisation with MMRV, four cohort studies evaluated MMRV ProQuad (Merck and Co, USA) (<a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a>; <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a>), and two cohort studies evaluated MMRV Priorix‐Tetra (GSK) (<a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a>; <a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a>). See <a href="#CD004407-tbl-0036">Table 15</a>. </p> <p><b>Comparison 8.3</b> (<a href="./references#CD004407-fig-0043" title="">Analysis 8.3</a>). MMRV versus MMR+V includes evidence from five cohort studies (<a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a>; <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a>; <a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a>). The studies estimated the risk of febrile seizures after MMRV vaccination compared to MMR+V vaccination. The overall estimate was RR 1.31 (95% CI 1.19 to 1.45) within 42 days after vaccination and RR 1.98 (95% CI 1.69 to 2.33) within 7 to 10 days after vaccination. </p> <p><b>Comparison</b> <b>8.4</b> (<a href="./references#CD004407-fig-0044" title="">Analysis 8.4</a>). The RR including only MMRV (Priorix‐Tetra) studies was 1.95 (95% CI 0.85 to 4.48) within 0 to 42 days after vaccination, and RR 1.69 (95% CI 0.93 to 3.07) between 7 and 10 days after vaccination. Including only MMRV (ProQuad) studies, the RR was 1.30 (95% CI 1.17 to 1.44) within 0 to 42 days after vaccination and 2.01 (95% CI 1.70 to 2.38) between 7 and 10 days after vaccination. </p> <p><b>Comparison 8.5</b> (<a href="./references#CD004407-fig-0045" title="">Analysis 8.5</a>). MMRV versus MMR includes evidence from six cohort studies (<a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a>; <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0093" title="KleinNP , LewisE , McDonaldJ , FiremanB , NalewayA , GlanzJ , et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. Vaccine2017;35(12):1615-21. ">cb‐Klein 2017</a>; <a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a>; <a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a>). The studies estimated the risk of febrile seizures after MMRV vaccination compared to MMR vaccination. The overall RR was 1.53 (95% CI 1.37 to 1.71) within 42 days after vaccination and RR 1.50 (95% CI 1.36 to 1.66) within 7 to 10 days after vaccination. </p> <p><b>Comparion 8.6</b> (<a href="./references#CD004407-fig-0046" title="">Analysis 8.6</a>). The RR including only MMRV (Priorix‐Tetra) studies was 1.28 (95% CI 1.00 to 1.64) within 0 to 42 days after vaccination, and 2.49 (95% CI 1.66 to 3.74) between 7 and 10 days after vaccination. However, including only MMRV (ProQuad) studies, the RR was 1.60 (95% CI 1.42 to 1.82) within 0 to 42 days after vaccination, and 1.46 (95% CI 1.32 to 1.61) between 7 and 10 days after vaccination. </p> <p>To correctly interpret the associations between MMR/MMRV/MMRV (containing Jeryl Lynn strain) vaccines and febrile seizures, we must consider that vaccine‐induced febrile seizures is an infrequent event, amongst both non‐vaccinated and vaccinated people. <a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a> reported that febrile seizures normally occur in 2% to 4% of healthy children at least once before the age of five years. <a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a> showed a risk difference (RD) of febrile seizures amongst vaccinated and unvaccinated people equal to 0.16% (95% CI 0.14% to 0.17%), and reported a 0.25% absolute cumulative risk of febrile seizures amongst vaccinated people. <a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a> and <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a> showed a cumulative risk amongst vaccinated people ranging from 0.15% to 0.29%. The attributable risk was estimated to be 1:1700 doses, <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>, and 1:1150 doses (<a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a>). <a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a> found no difference in RR of febrile seizures by gestational age. </p> </section> </section> <section id="CD004407-sec-0089"> <h4 class="title">9. Safety: autism spectrum disorders</h4> <p>Thirteen studies investigated the hypothesised link between MMR vaccination and autism spectrum disorders: 4 cohorts (<a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a>; <a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a>; <a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a>; <a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a>), 4 case‐control (<a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a>; <a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a>; <a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a>; <a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a>), 1 SCCS (<a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a>), 1 PTC (<a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>), and 3 COEM (<a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a>; <a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a>; <a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a>). See <a href="#CD004407-tbl-0037">Table 16</a> and <a href="./full#CD004407-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD004407-sec-0090"> <h5 class="title">Evidence from cohort studies</h5> <p>Four retrospective cohort studies investigated the risk of autism and pervasive developmental disorders following MMR immunisation (<a href="#CD004407-tbl-0037">Table 16</a>) (<a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a>; <a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a>; <a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a>; <a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a>). Two studies were conducted in Denmark and included all Danish children born between January 1991 and December 1998, and 1999 to December 2010, respectively (<a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a>; <a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a>). The study authors linked vaccination data reported by the National Board of Health with a diagnosis of autism (<a href="#CD004407-tbl-0037">Table 16</a>) from the Danish Psychiatric Central Register. <a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a> was conducted in the USA and included children born between 2001 to 2012. Data are presented stratified by age (2‐, 3‐, 4‐year‐olds received first dose, 5‐year‐olds received the first and second dose) and subdivided in two subgroups: low risk of autism (older sibling without autism spectrum disorder) and moderate/high risk of autism (older sibling with autism spectrum disorder). The retrospective cohort study <a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a> assessed the association between exposure to MMR vaccination and regression in autistic spectrum disorders. Participants were children with an autism spectrum disorder diagnosis (<a href="#CD004407-tbl-0037">Table 16</a>) from a private paediatric psychiatric clinic located in Yokohama City, Japan (Yokohama Psycho‐Developmental Clinic, YPCD), which has become recognised as a centre for autism spectrum disorders. Cases of autism spectrum disorders in people born between 1976 and 1999 were considered for study purposes. Regression in autism spectrum could be assessed for 325/904 children who were identified with disorders. Data were analysed in different ways. Within the MMR vaccine generation group, odds ratio (OR) estimates were calculated considering the cases of deterioration observed in children who had received the MMR vaccine from the Mental Child Health Handbook (15/54), and the number of regressions observed amongst participants who did not receive the MMR vaccine (45/132), after exclusion of those with unknown vaccination status (N = 89). Study authors reported a non‐significant OR 0.74 (95% CI 0.35 to 1.52) in people who had received the MMR vaccine versus no MMR vaccination in the MMR period. Furthermore, the OR estimate was calculated considering as the control group (not MMR vaccinated) also both pre‐ and post‐MMR generation groups. Estimates were non‐significant: OR 0.63 (95% CI 0.32 to 1.20). Comparison of regression cases observed within the MMR generation group (independent from documented vaccination status) with that observed in pre‐MMR, post‐MMR, and pre‐ plus post‐MMR groups provided no statistically significant OR estimates. According to the data reported by <a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a>, there was no evidence supporting an association between MMR immunisation and autism spectrum disorders (see <a href="#CD004407-tbl-0037">Table 16</a>). We did not include data in the quantitative synthesis because the study authors did not state which statistical model had been adopted. </p> <p><b>Comparison 9.1</b> (<a href="./references#CD004407-fig-0047" title="">Analysis 9.1</a>) includes evidence from <a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a>, <a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a>, and <a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a>. </p> <p>The meta‐analysis did not provide evidence supporting an association between MMR immunisation and autism spectrum disorder in all children (rr 0.93, 95% CI 0.85 to 1.01). The meta‐analysis did not provide evidence supporting an association between MMR immunisation and autism spectrum disorders amongst low‐risk children (RR 1.00, 95% CI 0.89 to 1.14). </p> <p>The analysis shows statistical evidence of a protective effect of MMR vaccine amongst high‐risk children (rr 0.80, 95% CI 0.64 to 0.98). This result is clearly due to the effect of indication bias. In previous years, children who had an older sibling with an autism spectrum disorder diagnosis were less likely to be vaccinated. Conversely, children who have an older sibling with an autism spectrum disorder diagnosis have a high risk of autism spectrum disorder diagnosis. </p> </section> <section id="CD004407-sec-0091"> <h5 class="title">Evidence from case‐control studies</h5> <p>Four case‐control studies investigated the risk of an association between the MMR vaccine and autism (<a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a>; <a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a>; <a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a>; <a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a>) (<a href="#CD004407-tbl-0037">Table 16</a>). <a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a> assessed the association between exposure to the MMR vaccine and the onset of autism and other pervasive developmental disorders (<a href="#CD004407-tbl-0037">Table 16</a>). The study was based on data from the UK's General Practice Research Database (GPRD), which was established 1 June 1987. <a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a> compared the distribution of ages at first MMR vaccination in children with autism (<a href="#CD004407-tbl-0037">Table 16</a>) cases and controls, divided into three age strata: up to 18, 24, and 36 months. In <a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a>, cases of autism in children aged between 2 and 15 years were identified by means of general practitioners' records from Małopolska Province in southern Poland (<a href="#CD004407-tbl-0037">Table 16</a>). For each case, two controls matching for birth year, gender, and practice were selected. A total of 92 cases with childhood or atypical autism and 192 matched controls were included. Estimate ORs were calculated considering vaccine exposure (MMR or monovalent measles) before autism diagnosis or before onset of symptoms, separately in univariate and multivariate analyses (balanced for mother's age ≥ 35 years, gestation time ≤ 38 weeks, medication during pregnancy, perinatal injuries, and 5‐minute Apgar score). The <a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a> study analysed case data from patients of the Yokohama Psycho‐Developmental Clinic; the cases consisted of children who were diagnosed with autism spectrum disorders born between 1 April 1984 and 30 April 1992, the possible time period for MMR vaccination. </p> <p><b>Comparison 9.2</b> (<a href="./references#CD004407-fig-0048" title="">Analysis 9.2</a>). The meta‐analysis did not provide evidence supporting an association between MMR immunisation and autism spectrum disorders in children vaccinated at any age (18 months to 15 years) (OR 0.62, 95% CI 0.36 to 1.09). </p> <p>The meta‐analysis did not provide evidence supporting an association between MMR immunisation and autism spectrum disorders if the vaccine was administered before 18 months (OR 0.91, 95% CI 0.75 to 1.11) or after 18 months (OR 0.80, 95% CI 0.61 to 1.05). </p> <p>The meta‐analysis did not provide evidence supporting an association between MMR immunisation and autism spectrum disorders if the vaccine was administered before 36 months (OR 0.94, 95% CI 0.74 to 1.18) or after 36 months (OR 0.77, 95% CI 0.55 to 1.08). </p> </section> <section id="CD004407-sec-0092"> <h5 class="title">Evidence from self‐controlled case series/person‐time cohort studies</h5> <p>In <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>, described in the section related to neurological diseases, an attempt to evaluate the association between MMR vaccination and hospitalisation for autism was made (<a href="#CD004407-tbl-0037">Table 16</a>). Unlike for encephalitis and aseptic meningitis, instead of a risk period, changes in the overall number of hospitalisations for autism after MMR vaccination, including only the first hospital visit during the study period, were considered. Times between immunisation and hospitalisation observed amongst the 309 hospitalisations for autism following MMR immunisation were very wide (range 3 days to 12 years and 5 months); their numbers remained relatively steady during the first 3 years and then decreased gradually. No cluster intervals from vaccination could be identified. The study authors concluded that there was no evidence of association, but did not report statistical data supporting this conclusion. Another SCCS assessed clustering of cases of autism by postexposure periods in a cohort of 498 (with 293 confirmed cases) children (<a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a>). The study authors reported a significant increase in onset of parental concern at 6 months postvaccination, but no significant clustering of interval to diagnosis or regression was found within any of the considered time periods (2, 4, 6, 12, 24 months). </p> <p><b>Comparison 9.3</b> (<a href="./references#CD004407-fig-0049" title="">Analysis 9.3</a>) includes data from <a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a>. The results showed no evidence supporting an association between MMR immunisation and autism spectrum disorder diagnosis or regression (autism spectrum disorder diagnosis &lt; 12 months: rr 0.94, 95% CI 0.60 to 1.47; autism spectrum disorder diagnosis &lt; 24 months: rr 1.09, 95% CI 0.79 to 1.52; regression &lt; 2 months: rr 0.92, 95% CI 0.38 to 2.21; regression &lt; 4 months: rr 1.00, 95% CI 0.52 to 1.95; and regression &lt; 6 months: rr 0.85, 95% CI 0.45 to 1.60). </p> </section> <section id="CD004407-sec-0093"> <h5 class="title">Evidence from case‐only ecological method studies</h5> <p><a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a> tested several causal hypotheses and mechanisms of association between exposure to MMR vaccination and pervasive developmental disorders (<a href="#CD004407-tbl-0037">Table 16</a>). The population was made up of three cohorts of participants; one was of older children acting as the control (pre‐MMR vaccination introduction). The study authors concluded that there was no evidence that pervasive developmental disorders had become more frequent; the mean age at parental concern had not moved closer to the date of exposure to MMR vaccination. Furthermore, the study authors concluded that there was no evidence that regression with autism had become more common. The parents of children with autism regression did not become concerned about their child in a different time frame than children without regression; children with regressive autism did not have different profiles or severity to those in the control group. There was no evidence that regressive autism was associated with inflammatory bowel disorders. <a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a> analysed the trend of pervasive developmental disorder prevalence in cohorts born from 1987 to 1998 attending schools in southern and western Montreal (N = 27,749; 1 October 2003). The relationship between pervasive developmental disorder prevalence trends and MMR vaccination coverage through each birth cohort was assessed. Children with pervasive developmental disorders (N = 180) were identified only if their diagnosis was specifically stated as autism and autism spectrum disorder to allow the schools to receive incremental funding. The study authors reported that whilst a significant trend towards a decrease in MMR uptake through birth cohorts from 1988 to 1998 (Chi² for trend = 80.7; df = 1; P &lt; 0.001) could be assessed, a significant increase in rates of pervasive developmental disorders from 1987 to 1998 was found (OR 1.10, 95% CI 1.05 to 1.16; P &lt; 0.001). By comparing the rate of increase in pervasive developmental disorder prevalence between the one‐ and two‐dose period, no statistically significant differences were detected. </p> <p>A Japanese study assessed the autism spectrum disorders incidence trend amongst birth cohorts from 1988 to 1996 in Yokohama City in children aged up to 7 years (<a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a>). <a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a> assessed the incidence trend in relation to decline of MMR vaccination coverage in the same birth cohorts (before and after termination of MMR vaccination programmes in children in 1993). Examination of risk factor analysis with conditional regression detected a significant increase in cumulative incidence of all autism spectrum disorders amongst birth cohorts from 1988 to 1996 (Chi² = 45.17, df = 8, P &lt; 0.001). This trend was different before and after the 1992 birth cohort: considering the 1996 birth cohort as a reference, incidence of all autism spectrum disorders was significantly lower until 1992 and did not differ after 1993. A significantly increased incidence could be assessed when outcomes definition of childhood autism (Chi² = 31.86, df = 8, P &lt; 0.001) or other autism spectrum disorder (Chi² = 19.25, df = 8, P = 0.01) were considered. The study authors concluded that causal hypothesis involving the MMR vaccine as a risk factor was not supported by the evidence because autism spectrum disorder incidence continued to increase even if the MMR vaccination programme was terminated. </p> <p><b>Comparison 9.4</b> (<a href="./references#CD004407-fig-0050" title="">Analysis 9.4</a>) includes data from <a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a>. The analysis showed statistical evidence of a protective effect of MMR vaccine against childhood autism (rr 0.45, 95% CI 0.33 to 0.62); against other autism spectrum disorders (rr 0.55, 95% CI 0.39 to 0.80); and against all autism spectrum disorders (rr 0.49, 95% CI 0.39 to 0.63). These results are surely due to effect of the indication bias. </p> <p>The meta‐analysis did not provide evidence supporting an association between MMR immunisation and autism spectrum disorders. </p> </section> </section> <section id="CD004407-sec-0094"> <h4 class="title">10. Safety: inflammatory bowel disease</h4> <p>Six studies considered the hypothesis of an association between MMR vaccination and inflammatory bowel disease (IBD) or Crohn's disease and ulcerative colitis: 4 case‐control studies, <a href="./references#CD004407-bbs2-0026" title="BaronS , TurckD , LeplatC , MerleV , Gower-RousseauC , MartiR , et al. Enviromental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut2005;54(3):357-63. [DOI: 10.1136/gut.2004.054353]">bb‐Baron 2005</a>; <a href="./references#CD004407-bbs2-0034" title="DavisRL , KramarzP , BohlkeK , BensonP , ThompsonRS , MulloolyJ , et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine2001;155(3):354-9. ">bb‐Davis 2001</a>; <a href="./references#CD004407-bbs2-0042" title="ShawSY , BlanchardJF , BernsteinCN . Early childhood measles vaccinations are not associated with paediatric IBD: a population based analysis. Journal of Crohn's and Colitis2015;9(4):334-8. [DOI: 10.1093/ecco-jcc/jjv029]">bb‐Shaw 2015</a>; <a href="./references#CD004407-bbs2-0045" title="VcevA , PezerovicD , JovanovicZ , NakicD , VcevI , MajnaricL . A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. Wiener Klinische Wochenschrift2015;127(9-10):345–54. ">bb‐Vcev 2015</a>, and 2 COEM (<a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a>; <a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a>). See <a href="#CD004407-tbl-0038">Table 17</a> and <a href="./full#CD004407-tbl-0010">summary of findings Table 10</a>. </p> <section id="CD004407-sec-0095"> <h5 class="title">Evidence from case‐control studies</h5> <p><a href="./references#CD004407-bbs2-0026" title="BaronS , TurckD , LeplatC , MerleV , Gower-RousseauC , MartiR , et al. Enviromental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut2005;54(3):357-63. [DOI: 10.1136/gut.2004.054353]">bb‐Baron 2005</a> was conducted in France between January 1988 and December 1997. Cases were all patients from the EPIMAD (Epidemiology of Inflammatory Bowel Disease) registry who had a diagnosis of either Crohn's disease or ulcerative colitis and were aged under 17 years. <a href="./references#CD004407-bbs2-0034" title="DavisRL , KramarzP , BohlkeK , BensonP , ThompsonRS , MulloolyJ , et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine2001;155(3):354-9. ">bb‐Davis 2001</a> was conducted in the USA using data from the Vaccine Safety Datalink (versusD). Cases were patients born between 1958 and 1989. <a href="./references#CD004407-bbs2-0042" title="ShawSY , BlanchardJF , BernsteinCN . Early childhood measles vaccinations are not associated with paediatric IBD: a population based analysis. Journal of Crohn's and Colitis2015;9(4):334-8. [DOI: 10.1093/ecco-jcc/jjv029]">bb‐Shaw 2015</a> was conducted in Canada University of Manitoba IBD Epidemiology Database (UMIBDED) linked to the Manitoba Immunization Monitoring System. All paediatric IBD cases in Manitoba, born after 1989 and diagnosed before 31 March 2008, were included. <a href="./references#CD004407-bbs2-0045" title="VcevA , PezerovicD , JovanovicZ , NakicD , VcevI , MajnaricL . A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. Wiener Klinische Wochenschrift2015;127(9-10):345–54. ">bb‐Vcev 2015</a> was conducted in Croatia. IBD patients (&gt; 18 years old) were identified according to the hospital’s patient records. This study has different methodological limitations, a small number of cases, and a weak control for confounders. The region where the study was conducted was affected by the war in Croatia between 1991 and 1997, and experienced large demographic changes during the war and long postwar period. </p> <p><b>Comparison 10.1</b> (<a href="./references#CD004407-fig-0051" title="">Analysis 10.1</a>). The meta‐analysis estimates did not provide evidence supporting an association between MMR immunisation and IBD (OR 1.42, 95% CI 0.93 to 2.16) or an association between MMR and ulcerative colitis (OR 1.35, 95% CI 0.81 to 2.23). Crohn's disease data showed a protective effect (OR 0.64, 95% CI 0.42 to 0.98). </p> </section> <section id="CD004407-sec-0096"> <h5 class="title">Evidence from case‐only ecological method studies</h5> <p><a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a> investigated a possible association between the MMR vaccine and Crohn's disease. Using national data on emergency admissions from England, the authors compared admissions for Crohn's disease in populations with a vaccination coverage of ≥ 84% with populations with MMR vaccination coverage of ≥ 7%. Even if age‐specific rates of emergency admission for Crohn's disease increased during the time considered in the study (April 1991 to March 2003), this trend seems not to have been influenced by the introduction of the MMR vaccine. The introduction of the MMR vaccination programme in England did not increase the risk of Crohn's disease. <a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a> is linked to <a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a>, as the study includes children with childhood and atypical autism born between 1979 and 1998, to investigate whether MMR vaccination is associated with bowel problems and developmental regression in children with autism. </p> <p><b>Comparison 10.1</b> (<a href="./references#CD004407-fig-0052" title="">Analysis 10.2</a>) includes data from <a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a>. Results did not show evidence supporting an association between MMR immunisation and Crohn's disease (rr 0.95, 95% CI 0.84 to 1.08). </p> <p><b>Comparison 10.2</b> (<a href="./references#CD004407-fig-0053" title="">Analysis 10.3</a>) includes data from <a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a>. Results did not show evidence supporting an association between MMR immunisation and IBD (in children with autism) (OR 0.98, 95% CI 0.89 to 1.07). </p> </section> </section> <section id="CD004407-sec-0097"> <h4 class="title">11. Safety: cognitive delay/developmental delay</h4> <p>The cohort study <a href="./references#CD004407-bbs2-0098" title="Mrozek-BudzynD , KiełtykaA , MajewskaR , AugustyniakM . Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - the results of the Polish prospective cohort study. Vaccine2013;31(22):2551-7. [DOI: 10.1016/j.vaccine.2013.03.057]">cb‐Mrozek‐Budzyn 2013</a> examined the hypothesis that MMR exposure could have a negative influence on cognitive development in children. The Mental Development Index of Bayley Scales of Infant Development, second edition (MDI‐BSID‐II) was administered in the 24th and 36th months of life. The Raven's Colored Scale was administered in the fifth year of life. The Wechsler Intelligence Scale for Children, Revised Form (WISC‐R) was administered in the sixth year of life. See <a href="#CD004407-tbl-0039">Table 18</a> and <a href="./full#CD004407-tbl-0011">summary of findings Table 11</a>. </p> <p><b>Comparison 11.1</b> (<a href="./references#CD004407-fig-0054" title="">Analysis 11.1</a>). The estimates did not show evidence supporting an association between MMR vaccine and cognitive development in children. </p> </section> <section id="CD004407-sec-0098"> <h4 class="title">12. Safety: idiopathic thrombocytopenic purpura</h4> <p>Nine studies investigated a suspected association between MMR vaccination and idiopathic thrombocytopenic purpura (ITP): 2 case‐control studies (<a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a>; <a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a>), 5 SCCS (<a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a>; <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a>; <a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>), 1 CCO (<a href="./references#CD004407-bbs2-0126" title="LafaurieM , BaricaultB , Lapeyre-MestreM , SaillerL , MoulisG , SommetA , et al. Risk of vaccine-induced immune thrombocytopenia in children. Nationwide case cross-over and self controlled case series studies in France. Fundamental &amp; Clinical Pharmacology2018;32:86. ">eb‐Lafaurie 2018</a>), and 1 COEM (<a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a>). See <a href="#CD004407-tbl-0040">Table 19</a> and <a href="./full#CD004407-tbl-0012">summary of findings Table 12</a>. </p> <section id="CD004407-sec-0099"> <h5 class="title">Evidence from case‐control and case cross‐over studies</h5> <p><a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a> was a matched case‐control study conducted in children aged 12 to 23 months. The cases were patients with a diagnosis of ITP. The controls were selected within data contained in the General Practice Research Database (GPRD). <a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a> tested the association between acute immune thrombocytopenia and MMR vaccination by means of a case‐control design in children and adolescents (aged 1 month to 18 years). <a href="./references#CD004407-bbs2-0126" title="LafaurieM , BaricaultB , Lapeyre-MestreM , SaillerL , MoulisG , SommetA , et al. Risk of vaccine-induced immune thrombocytopenia in children. Nationwide case cross-over and self controlled case series studies in France. Fundamental &amp; Clinical Pharmacology2018;32:86. ">eb‐Lafaurie 2018</a> was a population‐based case cross‐over study. See <a href="#CD004407-tbl-0040">Table 19</a>. </p> <p><b>Comparison 12.1</b> (<a href="./references#CD004407-fig-0055" title="">Analysis 12.1</a>). The overall meta‐analysis estimate from case‐control studies showed statistical evidence of an association between the MMR vaccination and ITP (OR 2.80, 95% CI 1.50 to 5.23). The estimate from the case cross‐over study showed statistical evidence of an association (OR 1.62, 95% CI 1.21 to 2.16). </p> </section> <section id="CD004407-sec-0100"> <h5 class="title">Evidence from self‐controlled case series/person‐time cohort studies</h5> <p>The study by <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a> was based on data contained in the Vaccines Safety Datalink project from 1991 to 2000, covering eight managed care organisations across the USA. By consulting the database, 63 children aged 12 to 23 months who met the definition (<a href="#CD004407-tbl-0040">Table 19</a>) could be identified. The incidence rate ratio between the exposed and unexposed time was calculated using two different analytical methods: the self‐controlled case series and the 'risk interval' (i.e. person‐time cohort) method. For the latter method, the estimate rate ratio was rr 3.94 (95% CI 2.01 to 7.69) in children aged 12 to 23 months, and 7.10 (95% CI 2.03 to 25.03) in children aged 12 to 15 months (the age at which about 80% of MMR vaccinations were administered). To avoid data duplication, we included only data from SCCS designs in the meta‐analysis. <a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a> was a multicountry collaboration (England and Denmark) study. <a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a> involved five healthcare systems. <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a> was conducted on 26 sentinel sites (49 hospitals) in 16 countries of the six WHO regions, that is the Western Pacific region, the South‐East Asia region, the Americas region, the European region, the Eastern Mediterranean region, and the African region. </p> <p><b>Comparison 12.2</b> (<a href="./references#CD004407-fig-0056" title="">Analysis 12.2</a>). The overall meta‐analysis estimate of association between MMR vaccination and ITP in children aged 9 to 23 months was rr 4.21 (95% CI 2.28 to 7.78). There was no statistical evidence in children aged 4 to 6 years (rr 3.06, 95% CI 0.42 to 22.30), and no statistical evidence of association between MMRV vaccination and ITP in children aged 9 to 23 months (rr 2.87, 95% CI 0.78 to 10.56). The latter two results came from one study (<a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a>). </p> </section> <section id="CD004407-sec-0101"> <h5 class="title">Evidence from case‐only ecological method studies</h5> <p>The evidence of association between MMR or any of its component vaccines and the onset of thrombocytopenic purpura was also assessed in one ecological study (<a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a>). The study concluded that the evidence favoured an association, but in all cases thrombocytopenic purpura appeared to be a benign, self‐limiting condition not distinguishable from its idiopathic counterpart or from thrombocytopenic purpura occurring after natural infection with MMR. The study discussed the weakness of relying on the passive reporting system for the identification of cases and acknowledged a possible under‐reporting of cases of thrombocytopenic purpura. </p> <p>The results confirm an association between MMR vaccination and ITP. However, the risk of ITP after vaccination is smaller than the one after natural infection with these viruses (<a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a>; <a href="./references#CD004407-bbs2-0334" title="CecinatiV , PrincipiN , BresciaL , GiordanoP , EspositoS . Vaccine administration and the development of immune thrombocytopenic purpura in children. Human Vaccines and Immunotherapeutics2013;9(5):1158-62. [PMID: 23324619]">Cecinati 2013</a>). <a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a> reported that natural infection of ITP occurs in 5 cases per 100,000 children per year, with a prevalence of 4 to 6 per 100,000. The attributable risk was estimated to be about 1 ITP case per 40,000 administered MMR doses (<a href="./references#CD004407-bbs2-0334" title="CecinatiV , PrincipiN , BresciaL , GiordanoP , EspositoS . Vaccine administration and the development of immune thrombocytopenic purpura in children. Human Vaccines and Immunotherapeutics2013;9(5):1158-62. [PMID: 23324619]">Cecinati 2013</a>; <a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a>; <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a>). <a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a> and <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> estimate the attributable risk of ITP within six weeks after MMR vaccination about 1 case per 25,000 (95% CI 21,300 to 89,400). </p> </section> </section> <section id="CD004407-sec-0102"> <h4 class="title">13. Safety: Henoch‐Schönlein purpura</h4> <p>One case control study estimated the association of Henoch‐Schönlein purpura with drug and vaccine (MMR and diphtheria, tetanus, and pertussis (DTaP) vaccine) administration in a paediatric population (<a href="./references#CD004407-bbs2-0033" title="Da DaltL , ZerbinatiC , StrafellaMS , RennaS , RiceputiL , Di PietroP , et al Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics2016;42(1):60. [DOI: 10.1186/s13052-016-0267-2]">bb‐Da Dalt 2016</a>). See <a href="#CD004407-tbl-0041">Table 20</a> and <a href="./full#CD004407-tbl-0013">summary of findings Table 13</a>. </p> <p><b>Comparison 13.1</b> (<a href="./references#CD004407-fig-0057" title="">Analysis 13.1</a>). The estimate showed statistical evidence of an association between MMR vaccine and Henoch‐Schönlein purpura (OR 3.40, 95% CI 1.18 to 9.81). </p> <p>The result confirmed an association between MMR and Henoch‐Schönlein purpura. However, Henoch‐Schönlein purpura is the most common vasculitis in childhood with an incidence of 10 to 20 cases per 100,000 in children under 17 years, with a peak incidence of 70 cases per 100,000 in the 4‐ to 6‐year age group (<a href="./references#CD004407-bbs2-0033" title="Da DaltL , ZerbinatiC , StrafellaMS , RennaS , RiceputiL , Di PietroP , et al Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics2016;42(1):60. [DOI: 10.1186/s13052-016-0267-2]">bb‐Da Dalt 2016</a>). </p> </section> <section id="CD004407-sec-0103"> <h4 class="title">14. Safety: type 1 diabetes</h4> <p>Two cohort studies reported on type 1 diabetes (<a href="./references#CD004407-bbs2-0082" title="BeyerleinA , StroblAN , WinklerC , CarpusM , KnopffA , DonnachieE , et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine2017;35(14):1735-41. ">cb‐Beyerlein 2017</a>; <a href="./references#CD004407-bbs2-0086" title="HiividAD , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health2004;8(5):286-7. [CRSREF: 2955568]HviidA , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination and type 1 diabetes. New England Journal of Medicine2004;350(14):1398-404. ">cb‐Hviid 2004</a>). See <a href="#CD004407-tbl-0042">Table 21</a> and <a href="./full#CD004407-tbl-0014">summary of findings Table 14</a>. </p> <p><a href="./references#CD004407-bbs2-0082" title="BeyerleinA , StroblAN , WinklerC , CarpusM , KnopffA , DonnachieE , et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine2017;35(14):1735-41. ">cb‐Beyerlein 2017</a> analysed data from two German birth cohorts of healthy neonates with a familial increased risk of type 1 diabetes, the BABYDIAB study and the BABYDIET natural follow‐up study, which were combined for association analyses of vaccination patterns and the development of islet autoimmunity. Between 1989 and 2000, a total of 1650 children of people with type 1 diabetes were recruited. Between 2000 and 2006, 791 additional children or siblings of people with type 1 diabetes were screened and followed up. <a href="./references#CD004407-bbs2-0086" title="HiividAD , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health2004;8(5):286-7. [CRSREF: 2955568]HviidA , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination and type 1 diabetes. New England Journal of Medicine2004;350(14):1398-404. ">cb‐Hviid 2004</a> was a retrospective cohort study carried out in Denmark aiming to evaluate if there was an association between childhood vaccinations and the onset of type 1 diabetes. A cohort of children born between 1 January 1990 and 31 December 2000 from the Danish Civil Registration System was recruited. </p> <p><b>Comparison 14.1</b> (<a href="./references#CD004407-fig-0058" title="">Analysis 14.1</a>). The overall meta‐analysis result did not provide evidence supporting an association between MMR vaccination and type 1 diabetes (rr 1.09, 95% CI 0.98 to 1.21). In addition, restricting the analysis to children with at least one sibling with type 1 diabetes did not show evidence of an association (rr 0.86, 95% CI 0.34 to 2.16). </p> </section> <section id="CD004407-sec-0104"> <h4 class="title">15. Safety: asthma</h4> <p>Five cohort studies reported on asthma (<a href="./references#CD004407-bbs2-0081" title="BenkeG , AbramsonM , RavenJ , ThienFC , WaltersEH . Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health2004;28(4):336-8. ">cb‐Benke 2004</a>; <a href="./references#CD004407-bbs2-0083" title="DeStefanoF , GuD , KramarzP , TrumanBI , IademarcoMF , MulloolyJP , et al. Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal2002;21(6):498-504. ">cb‐DeStefano 2002</a>; <a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a>; <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>; <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>). See <a href="#CD004407-tbl-0043">Table 22</a> and <a href="./full#CD004407-tbl-0015">summary of findings Table 15</a>. </p> <p>As the studies provided insufficient information to enable us to convert rate ratio (hazard ratio) into RR, we performed two meta‐analyses: <a href="./references#CD004407-fig-0059" title="">Analysis 15.1</a> includes <a href="./references#CD004407-bbs2-0083" title="DeStefanoF , GuD , KramarzP , TrumanBI , IademarcoMF , MulloolyJP , et al. Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal2002;21(6):498-504. ">cb‐DeStefano 2002</a>, <a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a>, and <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>, where rate ratio was adopted as the effect measure, and <a href="./references#CD004407-fig-0060" title="">Analysis 15.2</a> includes <a href="./references#CD004407-bbs2-0081" title="BenkeG , AbramsonM , RavenJ , ThienFC , WaltersEH . Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health2004;28(4):336-8. ">cb‐Benke 2004</a> and <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>, where RR was adopted. </p> <p>The cohort study <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> used an historical birth cohort of children (from 1988 to 1999) consisting of 29,238 children of both sexes aged between 0 and 11 years and identified through the West Midlands General Practice Research Database (GPRD), to investigate the association between MMR and diphtheria, polio, pertussis, and tetanus (DPPT) vaccination and asthma or eczema (<a href="#CD004407-tbl-0043">Table 22</a>). Incident diagnoses of asthma/wheeze and eczema (<a href="#CD004407-tbl-0043">Table 22</a>) were identified using the relevant Oxford Medical Information System (OMIS, derived from the International Classification of Diseases, Revision 8 (ICD‐8)) and Read codes (a hierarchical code used in general practitioner (GP) practices in England). Association with MMR vaccine exposure and risk of asthma was assessed by univariate analyses. Adjusted hazard ratios (HR) were 2.20 (95% CI 1.50 to 3.21) for asthma. Stratifying for GP consultation frequency in the first 18 months, HR estimates remained significant only for the subgroup with lower consulting frequency (0 to 6 times in the first 18 months), and not for the other subgroups (7 to 10 times, 11 to 16 times, and more than 16 times): HR 7.18 (95% CI 2.95 to 17.49) for an association between MMR vaccination and asthma. <a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a> shows a protective effect of MMR vaccination against asthma hospitalisation and anti‐asthma medications (<a href="#CD004407-tbl-0043">Table 22</a>). The study was conducted on Danish birth cohorts from 1991 to 2003 using the Danish Civil Registration System. Each participant recorded in the register had an identification number that allowed a link to data contained in other national registers (Danish National Hospital Register, Danish Prescription Drug Database, and National Board of Health). MMR vaccination status was considered as a time‐varying variable, and individuals could contribute to person‐time as both unvaccinated and vaccinated participants. MMR vaccination is protective against all asthma hospitalisations (RR 0.75, 95% CI 0.73 to 0.78); the protective effect of vaccination was greater in younger children (no more significant when the vaccine was administered after 18 months of age), in those with the longest time spent in hospital (18 days to 1 year), in girls, in low‐birthweight children, in children with 1 older sibling, and in those living in rural areas. Vaccination was also protective against hospitalisation for severe asthma (RR 0.63, 95% CI 0.49 to 0.82), even if estimates were not significant within the following stratifications: aged 3 to 4 years; fully immunised children; low hospitalisation propensity; male sex; birthweight below 2499 g or above 4000 g; birth order &gt;/= 3; or born in the capital or in a rural area. Total use of anti‐asthma medications was less frequent amongst participants immunised with MMR (RR 0.92, 95% CI 0.91 to 0.92). No reduction in use of all medications was observed for participants vaccinated between 23 and 26 months old (RR 1.00, 95% CI 0.98 to 1.01) or at 27 months old or later (RR 1.01, 95% CI 0.99 to 1.03). Considering single classes of medication in the unstratified study population, these data were confirmed with the exception for systemic beta2‐agonists, for which reduction in use was not observed (RR 1.02, 95% CI 1.01 to 1.02). Considering only the first use of any anti‐asthma medication in the unstratified population, the RR was 0.93 (95% CI 0.92 to 0.94). Also, <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> showed a protective effect against asthma. The study was conducted on a birth cohort of consecutive, spontaneous births in the Faroe Islands from 1997 to 2000. </p> <p><b>Comparison 15.1</b> (<a href="./references#CD004407-fig-0059" title="">Analysis 15.1</a>). The overall rr estimate did not provide evidence supporting an association between asthma diagnosis and MMR vaccination (rr 1.05, 95% CI 0.80 to 1.39). Excluding a study at high risk of bias, the new estimate did not show evidence of association (rr 0.85, 95% CI 0.66 to 1.10). </p> <p><b>Comparison 15.2</b> (<a href="./references#CD004407-fig-0060" title="">Analysis 15.2</a>). The overall RR estimate did not provide evidence supporting an association between asthma diagnosis and MMR vaccination (RR 0.63, 95% CI 0.24 to 1.63). Excluding a study at high risk of bias, the new estimate based on <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> showed evidence of a protective effect of MMR vaccination against asthma (RR 0.39, 95% CI 0.22 to 0.70). </p> <p>The results did not show evidence supporting an association between MMR vaccination and asthma risk. The association between MMR vaccination and asthma found by <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> appeared to be limited to the minority of children. This limited association is more likely to be the result of bias than a biological effect. </p> </section> <section id="CD004407-sec-0105"> <h4 class="title">16. Safety: eczema ‐ dermatitis</h4> <p>Two cohort studies reported data on dermatitis/eczema (<a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a>; <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>). See <a href="#CD004407-tbl-0044">Table 23</a> and <a href="./full#CD004407-tbl-0016">summary of findings Table 16</a>. </p> <p>The <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> cohort study used an historical birth cohort of children from 1988 to 1999 consisting of 29,238 children of both sexes aged between 0 and 11 years and identified through the West Midlands General Practice Research Database (GPRD) to investigate the association between MMR and DPPT vaccination and asthma or eczema (<a href="#CD004407-tbl-0044">Table 23</a>). Incident diagnoses of asthma/wheeze and eczema (<a href="#CD004407-tbl-0044">Table 23</a>) were identified using the relevant Oxford Medical Information System (OMIS, derived from ICD‐8) and Read codes (a hierarchical code used in GP practices in England). Association with MMR vaccine exposure and the risk of asthma and eczema was assessed by univariate analysis. Correspondent adjusted rate ratio was 3.50 (95% CI 2.38 to 5.15) for eczema (<a href="./references#CD004407-fig-0061" title="">Analysis 16.1</a>). Stratifying for GP consultation frequency in the first 18 months, HR estimates remained significant only for the subgroup with lower consulting frequency (0 to 6 times in the first 18 months) and not for the other subgroups (7 to 10 times, 11 to 16 times, and more than 16 times) for the association between MMR vaccination and asthma (HR 7.18, 95% CI 2.95 to 17.49) and the association between MMR vaccination and eczema (HR 10.4, 95% CI 4.61 to 23.29). Instead, <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> did not show evidence of an association between MMR vaccination and risk of eczema (RR 0.75, 95% CI 0.29 to 1.94; <a href="./references#CD004407-fig-0062" title="">Analysis 16.2</a>). </p> <p>Data suggest that currently MMR vaccinations are not a risk factor for eczema. The association found between MMR vaccination and eczema by <a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> appeared to be limited to a small subset of children. This limited association is more likely to be the result of bias than a biological effect. </p> </section> <section id="CD004407-sec-0106"> <h4 class="title">17. Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</h4> <p>Three studies reported data on hay fever/rhinoconjunctivitis/allergy: 1 cohort study, <a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a>, and 2 case‐control studies (<a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a>; <a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a>). See <a href="#CD004407-tbl-0045">Table 24</a> and <a href="./full#CD004407-tbl-0017">summary of findings Table 17</a>. </p> <section id="CD004407-sec-0107"> <h5 class="title">Evidence from cohort studies</h5> <p><b>Comparison 17.1</b> (<a href="./references#CD004407-fig-0063" title="">Analysis 17.1</a>). The estimate did not provide evidence supporting an association between MMR vaccination and rhinoconjunctivitis (OR 0.64, 95% CI 0.19 to 2.11). </p> <p><b>Comparison 17.2</b> (<a href="./references#CD004407-fig-0064" title="">Analysis 17.2</a>). The estimate did not provide evidence supporting an association between MMR vaccination and hypersensitivity/allergy (OR 0.63, 95% CI 0.14 to 2.77). </p> </section> <section id="CD004407-sec-0108"> <h5 class="title">Evidence from case‐control studies</h5> <p>The two case‐control studies investigated the risk of hay fever in MMR‐vaccinated children in the UK (using the same data source) (<a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a>; <a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a>). The <a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a> study focused particular attention on the timing of MMR vaccination to identify a critical period for MMR immunisation and hay fever risk (see <a href="#CD004407-tbl-0045">Table 24</a> for definitions). The nested case‐control study was conducted within two large databases, the General Practice Research Database (GPRD) and Doctors’ Independent Network (DIN), and involved 7098 hay fever cases and controls. Data were reported by month of life (1st to 13th; 14th, 15th, 16th to 17th, 18th to 24th, and &gt; 25th) by database (GPRD and DIN). <a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a> specifically investigated if exposure to MMR vaccination during the first grass pollen season of life influences the risk of hay fever more than any other time of the year. The study was conducted within GPRD and DIN databases and involved 7098 hay fever cases matched with controls. </p> <p><b>Comparison 17.3</b> (<a href="./references#CD004407-fig-0065" title="">Analysis 17.3</a>). The overall meta‐analysis estimate did not provide evidence supporting an association between MMR vaccination and hay fever (OR 1.16, 95% CI 0.92 to 1.45). The results showed that infants vaccinated with MMR are not at a greater or lesser risk of developing hay fever or rhinoconjunctivitis than unvaccinated children. </p> </section> </section> <section id="CD004407-sec-0109"> <h4 class="title">18. Safety: acute leukaemia</h4> <p>Four case‐control studies reported data on acute leukaemia (<a href="./references#CD004407-bbs2-0036" title="DockertyJD , SkeggDC , ElwoodJM , HerbisonGP , BecroftDM , LewisME . Infections, vaccinations, and the risk of childhood leukaemia. British Journal of Cancer1999;80(9):1483-9. [DOI: 10.1038/sj.bjc.6690548]">bb‐Dockerty 1999</a>; <a href="./references#CD004407-bbs2-0037" title="GrovesFD , GridleyG , WacholderS , ShuXO , RobisonLL , NegliaJP , et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. British Journal of Cancer1999;81(1):175-8. [DOI: 10.1038/sj.bjc.6690668]">bb‐Groves 1999</a>; <a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a>; <a href="./references#CD004407-bbs2-0039" title="Mallol-MesnardN , MenegauxF , AuvrignonA , AuclercMF , BertrandY , NelkenB , et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology2007;36(1):110-6. ">bb‐Mallol‐Mesnard 2007</a>). See <a href="#CD004407-tbl-0046">Table 25</a> and <a href="./full#CD004407-tbl-0018">summary of findings Table 18</a>. </p> <p>Four case‐control studies assessed whether vaccination with MMR (and other vaccines) played a role in the aetiology of leukaemia in children aged between 0 and 14 years (<a href="#CD004407-tbl-0046">Table 25</a>) (<a href="./references#CD004407-bbs2-0036" title="DockertyJD , SkeggDC , ElwoodJM , HerbisonGP , BecroftDM , LewisME . Infections, vaccinations, and the risk of childhood leukaemia. British Journal of Cancer1999;80(9):1483-9. [DOI: 10.1038/sj.bjc.6690548]">bb‐Dockerty 1999</a>; <a href="./references#CD004407-bbs2-0037" title="GrovesFD , GridleyG , WacholderS , ShuXO , RobisonLL , NegliaJP , et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. British Journal of Cancer1999;81(1):175-8. [DOI: 10.1038/sj.bjc.6690668]">bb‐Groves 1999</a>; <a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a>; <a href="./references#CD004407-bbs2-0039" title="Mallol-MesnardN , MenegauxF , AuvrignonA , AuclercMF , BertrandY , NelkenB , et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology2007;36(1):110-6. ">bb‐Mallol‐Mesnard 2007</a>). </p> <p><b>Comparison 18.1</b> (<a href="./references#CD004407-fig-0066" title="">Analysis 18.1</a>). The overall meta‐analysis estimate did not provide evidence supporting an association between MMR vaccination and acute leukaemia (OR 0.97, 95% CI 0.76 to 1.24) or acute lymphoblastic leukaemia (OR 0.91, 95% CI 0.72 to 1.14). Moreover, the overall estimate did not provide evidence supporting an association with acute myeloblastic leukaemia (OR 0.56, 95% CI 0.29 to 1.07). </p> <p>The results showed no evidence of an association between MMR vaccination and the risk of leukaemia. </p> </section> <section id="CD004407-sec-0110"> <h4 class="title">19. Safety: demyelinating diseases, multiple sclerosis, acute disseminated encephalomyelitis</h4> <p>The possible association between the MMR vaccine and demyelinating diseases was assessed in three studies: 1 cohort study, <a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a>, and 2 case‐control studies (<a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a>; <a href="./references#CD004407-bbs2-0032" title="ChenY , MaF , XuY , ChuX , ZhangJ . Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine2018;36(26):3733-9. ">bb‐Chen 2018</a>). See <a href="#CD004407-tbl-0047">Table 26</a> and <a href="./full#CD004407-tbl-0019">summary of findings Table 19</a>. </p> <p>Two studies used the same population data set (<a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a>; <a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a>). <a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a> was a cohort study carried out in the Gothenburg area (Swedish west coast, 731,592 residents on 31 December 2000). Cases of multiple sclerosis and clinically isolated syndrome in participants born between 1959 and 1990 with onset between 10 and 39 years of age before July 1984 amongst Gothenburg residents were considered, corresponding to a total of 5.9 million person‐years of observation (<a href="#CD004407-tbl-0047">Table 26</a>). The incidence of probable or definite multiple sclerosis (Poser criteria) and clinically isolated syndrome (372 and 162 cases, respectively) was analysed in corresponding MMR vaccination programmes, by selecting four birth cohorts corresponding to the first years of a specific vaccination programme. </p> <p> <ol id="CD004407-list-0054"> <li> <p>Birth cohorts 1962 to 1966 (102 multiple sclerosis cases): administration of the monovalent rubella vaccine to 12‐year‐old girls in 1974. </p> </li> <li> <p>Birth cohorts 1970 to 1973 (62 multiple sclerosis cases): administration of the MMR vaccine at 12 years of age (1982). </p> </li> <li> <p>Birth cohorts 1974 to 1978 (37 multiple sclerosis cases): administration of monovalent measles vaccine in preschool children. (It was already introduced in 1971, thus adequate coverage was reached only for those born in 1974 and onwards). About 90% of participants from these birth cohorts received the MMR vaccine at 12 years of age. </p> </li> <li> <p>Born between July 1981 and June 1984 (five multiple sclerosis cases): administration of the MMR vaccine at 18 months and 12 years of age. </p> </li> </ol> </p> <p>The incidence of multiple sclerosis and clinically isolated syndrome within each birth cohort was compared to that calculated for the preceding ones, including that of 1959 to 1961, corresponding to the pre‐vaccine era. No significant changes in age and gender‐specific incidence of multiple sclerosis between selected and preceding selected cohorts was observed. The authors used the same population incidence data in order to assess an association between MMR exposure and multiple sclerosis onset by means of a case‐control design (<a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a>). Similar to the cohort study, case definitions included multiple sclerosis or clinically isolated syndrome according to Poser's criteria, residence in Gothenburg, birth date between 1959 and 1986, and disease onset from the age of 10 years onwards. For analysis of vaccine exposure, only cases and controls who attended the sixth grade in school (12 years) within the study area, for whom child health and school health records were available (206 cases and 888 controls), were included. </p> <section id="CD004407-sec-0111"> <h5 class="title">Evidence from case‐control studies</h5> <p><b>Comparison 19.1</b> (<a href="./references#CD004407-fig-0067" title="">Analysis 19.1</a>). The estimate did not show evidence supporting an association between MMR vaccination and multiple sclerosis (OR 1.13, 95% CI 0.62 to 2.05). The estimate did not show evidence supporting an association between MMR vaccination and acute disseminated encephalomyelitis (OR 1.03, 95% CI 0.44 to 2.42). </p> <p>The results did not show evidence supporting an association between MMR vaccination and the risk of demyelinating diseases. </p> </section> </section> <section id="CD004407-sec-0112"> <h4 class="title">20. Safety: gait disturbance</h4> <p>An association between MMR vaccination and gait disturbance was assessed by means of an SCCS, <a href="./references#CD004407-bbs2-0118" title="MillerE , AndrewsN , GrantA , StoweJ , TaylorB . No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood2005;90(3):292-6. ">db‐Miller 2005</a>, and considered as cases of hospital admissions (<a href="./references#CD004407-fig-0068" title="">Analysis 20.1</a>) or general practice consultations (<a href="./references#CD004407-fig-0069" title="">Analysis 20.2</a>) in children from the Thames regions of England. Hospital admission cases were obtained from hospital computerised records from April 1995 to June 2001 and considered those relative to children aged 12 to 24 months with ICD‐10 diagnoses related to acute gait disorder (G111, G112, G25, R26, R27, R29, H55, and F984). Cases were validated by reviewing hospital case notes and were grouped into five categories. See <a href="#CD004407-tbl-0048">Table 27</a> and <a href="./full#CD004407-tbl-0020">summary of findings Table 20</a>. </p> <p>The vaccination history of cases was obtained from immunisation records. In all, 127 cases with available immunisation status were identified. Of these, 65 belonged to category 4 (i.e. non‐ataxic, non‐viral origin) and were excluded from analysis. No cases corresponding to category 1 definition were found. </p> <section id="CD004407-sec-0113"> <h5 class="title">Evidence from self‐controlled case series</h5> <p><b>Comparison 20.1</b> (<a href="./references#CD004407-fig-0068" title="">Analysis 20.1</a>). The rr within and outside postvaccination time risk (0 to 30 and 31 to 60 days) was calculated after age stratification in one‐month intervals. Rate ratio (rr) estimates for pooled 2, 3, and 5 categories showed no evidence of an association between MMR vaccination and hospitalisations for gait disturbance for 0 to 30 days' risk time (rr 0.83, 95% CI 0.24 to 2.86); 31 to 60 days' risk time (rr 0.20, 95% CI 0.03 to 1.40); and 0 to 60 days' risk time (rr 0.46, 95% CI 0.16 to 1.34). </p> <p>As gait disturbance does not require hospitalisation, the authors carried out a further analysis based on cases observed in general practices using the General Practice Research Database (GPRD) as the source, and considered children aged 12 to 24 months, born between 1988 and 1997. Read and OXMIS codes indicating a possible consult for gait disturbance were identified in the GPRD by mapping ICD‐9 codes and by searching keywords 'ataxia', 'gait', 'co‐ordination', 'mobility', and 'movement'. Diagnoses were grouped into six categories (<a href="#CD004407-tbl-0048">Table 27</a>). Vaccination history was obtained from prescription records. In all, 1398 children with diagnoses A to F and known immunisation history were included. </p> <p><b>Comparison 20.2</b> (<a href="./references#CD004407-fig-0069" title="">Analysis 20.2</a>). The relative incidence (RI) within and outside postvaccination time risk (0 to 5, 6 to 30, 31 to 60 days) was calculated. Rate ratio (rr) estimate for 0 to 5 days' risk time shows evidence of association between MMR vaccination and hospitalisations for gait disturbance (rr 1.88, 95% CI 1.30 to 2.72). However, estimates in any other risk period showed no evidence of association for 6 to 30 days' risk time (rr 0.90, 95% CI 0.70 to 1.16); 31 to 60 days' risk time (rr 0.95, 95% CI 0.76 to 1.18); and 6 to 60 days' risk time (rr 0.93, 95% CI 0.78 to 1.11). Early administration of thiomersal‐containing diphtheria, tetanus, and pertussis (DTP)/ diphtheria tetanus (DT) vaccine did not influence this estimate. </p> <p>The results did not show evidence supporting an association between MMR vaccination and gait disturbance. </p> <p>In the study authors' opinion, a vaccine‐specific effect would appear one week after immunisation. An excess of B and C diagnoses was observed on vaccination day, caused by an excess of consultations on the day that MMR was given. It is biologically implausible that any specific MMR effect would manifest on the day of vaccination since the viraemia induced by the vaccine, which might produce symptoms, does not start until the end of the first week (<a href="./references#CD004407-bbs2-0118" title="MillerE , AndrewsN , GrantA , StoweJ , TaylorB . No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood2005;90(3):292-6. ">db‐Miller 2005</a>). </p> </section> </section> <section id="CD004407-sec-0114"> <h4 class="title">21. Safety: bacterial or viral infections, immune overload</h4> <p>The incidence of viral and bacterial infection following MMR administration was investigated by means of a SCCS design by <a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a> and <a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a>. See <a href="#CD004407-tbl-0049">Table 28</a> and <a href="./full#CD004407-tbl-0021">summary of findings Table 21</a>. </p> <p>Episodes of hospitalisation for bacterial or viral infections occurring in children aged between 12 and 23 months were identified by consulting computerised hospital admission records from southern England using ICD‐9 or ICD‐10 codes between April 1991 and March 1995 (<a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a>); and occurring in children aged between 12 and 23 months were identified by consulting computerised hospital admission records from North, East, and South London, Essex, East Anglia, Sussex, and Kent using ICD‐9 or ICD‐10 codes and covering the time between 1 April 1995 and 1 May 2005 (<a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a>). Bacterial infections were characterised as lobar pneumonia or invasive bacterial infection, whereas those of viral aetiology were encephalitis/meningitis, herpes, pneumonia, varicella zoster, or miscellaneous virus (<a href="#CD004407-tbl-0049">Table 28</a>). Admissions were linked to date of MMR (and meningococcal) immunisation resulting from records held on child health systems. 'At risk' time periods were considered to be the whole risk period (0 to 90) days after immunisation, and subperiods: (0 to 30), (31 to 60), and (61 to 90) days after immunisation. </p> <p><b>Comparison 21.1</b> (<a href="./references#CD004407-fig-0070" title="">Analysis 21.1</a>). The overall meta‐analysis estimate showed that admissions for lobar pneumonia were less frequent in the time between 0 and 90 days after MMR immunisation (protective effect of the MMR vaccine) (rr 0.75, 95% CI 0.64 to 0.89). </p> <p><b>Comparison 21.2</b> (<a href="./references#CD004407-fig-0071" title="">Analysis 21.2</a>). The estimate did not show evidence supporting an association between MMR vaccination and risk of hospitalisations due to invasive bacterial diseases (rr 0.90, 95% CI 0.71 to 1.13) for the whole risk period (0 to 90 days). In addition, no evidence of an association was shown considering the other risk subperiods. </p> <p><b>Comparison 21.3</b> (<a href="./references#CD004407-fig-0072" title="">Analysis 21.3</a>). The estimate did not show evidence supporting an association between MMR vaccination and encephalitis/meningitis (rr 0.84, 95% CI 0.20 to 3.51) for the whole risk period (0 to 90 days) and other risk subperiods. </p> <p><b>Comparison 21.4</b> (<a href="./references#CD004407-fig-0073" title="">Analysis 21.4</a>). The risk of hospitalisation due to herpes infection was higher in the risk time interval between 31 and 60 days after MMR vaccine administration (rr 1.69, 95% CI 1.06 to 2.70), but this risk was not statistically significant. Data showed no evidence of association considering the other risk subperiods and the whole risk period (0 to 90 days) (rr 1.17, 95% CI 0.56 to 2.46). </p> <p><b>Comparison 21.5</b> (<a href="./references#CD004407-fig-0074" title="">Analysis 21.5</a>). The estimate did not show evidence supporting an association between MMR vaccination and hospitalisations due to pneumonia (rr 0.72, 95% CI 0.32 to 1.60) for the whole risk period (0 to 90 days) and the other risk subperiods. </p> <p><b>Comparison 21.6</b> (<a href="./references#CD004407-fig-0075" title="">Analysis 21.6</a>). A significantly lower incidence of varicella zoster was assessed within 30 days after MMR immunisation (protective effect) (rr 0.58, 95% CI 0.34 to 0.99). However, the estimate did not show evidence supporting an association considering the whole risk period (rr 0.93, 95% CI 0.68 to 1.27) and other subperiods. </p> <p><b>Comparison 21.7</b> (<a href="./references#CD004407-fig-0076" title="">Analysis 21.7</a>). The estimate did not show evidence supporting an association between MMR vaccination and hospitalisations due to other viral infections (rr 0.68, 95% CI 0.43 to 1.08) for the whole risk period (0 to 90 days) and the other risk subperiods. No statistically significant risk of both bacterial and viral infection was detected following concomitant administration of MMR and meningococcal C vaccine. </p> <p>The studies confirmed that the MMR vaccine does not increase the risk of invasive bacterial or viral infection in the 90 days after the vaccination and does not support the hypothesis that there is an induced immune deficiency due to overload from multi‐antigen vaccines (<a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a>; <a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004407-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004407-sec-0115"></div> <section id="CD004407-sec-0116"> <h3 class="title" id="CD004407-sec-0116">Summary of main results</h3> <p>MMR vaccination is ≥ 95% effective in preventing clinically confirmed measles in preschool children. Effectiveness is 95% after one dose (7 cohort studies, n = 12,039) and 96% after two doses (5 cohort studies n = 21,604). The estimates were similar for each of the two measles strains with which participants had been immunised (Schwarz or Edmonston‐Zagreb, 1 cohort study, n = 2745). Effectiveness in preventing secondary measles cases amongst household contacts or preventing transmission of measles to people with which the children were in contact was 81% after one dose (3 cohort studies, 151 participants), 85% after two doses (3 cohort studies, 378 participants), and 96% after three doses (2 cohort studies, 151 participants). The effectiveness of MMR vaccination (at least one dose) in preventing measles after postexposure prophylaxis (at least one dose) was 74% (2 cohort studies, 283 participants). The effectiveness of Jeryl Lynn‐containing MMR vaccine in preventing clinical mumps in children and adolescents was 72% after one dose (6 cohort studies, 9915 participants) and 86% after two doses (5 cohort studies, 7792 participants). The effectiveness of Jeryl Lynn‐containing MMR vaccine in preventing mumps being passed on to contacts was 74% (3 cohort studies, 1036 participants). The Urabe strain was also effective at 77% (4 cohort studies, 2721 participants). </p> <p>We found no evidence of effect from administering a third MMR dose to prevent mumps among children aged between 9 and 17 years (2 cohort studies, N = 5417). There is an acceptably high effectiveness of the vaccine prepared only with Urabe or Jeryl Lynn strain, but not for vaccines containing the Rubini strain. MMR vaccination effectiveness against rubella is 89%, (1 cohort study, N = 1621). However, this is based on only one cohort study in China using the BRD2 strain (<a href="./references#CD004407-bbs2-0052" title="ChangC , MoX , HuP , LiangW , MaH , AnZ , et al. Effectiveness of rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014. Vaccine2015;33(28):3223-7. [DOI: 10.1016/j.vaccine.2015.04.083]">ca‐Chang 2015</a>). This strain is not used anywhere else in the world, and higher vaccine effectiveness has been reported with other strains. MMRV vaccination effectiveness against varicella (any severity) after two doses is 95%; effectiveness against varicella (moderate/severe) is 99%. MMR+V vaccination effectiveness is 67% against any severity of varicella. Effectiveness is 90% against moderate/severe varicella, and 95% against severe varicella (1 RCT, N = 2279). </p> <p>Association with aseptic meningitis is confirmed for MMR vaccines containing Urabe and Leningrad‐Zagreb mumps strains on the basis of two very large studies at unclear risk of bias, carried out on about 2 million children aged 1 to 11 years and assessing a significant increased risk in the time between 1 and 10 weeks after immunisation, peaking within the third or fifth week. No evidence of association was found for vaccines prepared with mumps Jeryl Lynn strains in results from one case‐control study and one self‐controlled case series study. </p> <p>We have identified associations between MMR/MMRV/MMRV (containing Jeryl Lynn strain) vaccines and febrile seizures (15 studies, N = 2,166,172). To correctly interpret this association, we must consider that vaccine‐induced febrile seizures is an infrequent event, both amongst non‐vaccinated and vaccinated people. <a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a> reported that febrile seizures normally occur in 2% to 4% of healthy children at least once before the age of 5 years. The risk difference (RD) of febrile seizures amongst vaccinated and unvaccinated was RD 0.16% (95% CI 0.14% to 0.17%). The cumulative risk of having a febrile seizure after vaccination ranges from 0.15% to 0.29%. The attributable risk is estimated to be from 1:1700 to 1:1150 MMR administered doses. </p> <p>The results confirm an association between MMR vaccination and idiopathic thrombocytopenic purpura (ITP). However, the risk of ITP after vaccination is smaller than the risk after natural infection with these viruses. <a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a> reported that natural infection of ITP occurs in 5 cases per 100,000 children per year, with a prevalence of 4 to 6 per 100,000. The attributable risk is estimated to be about 1 ITP case per 40,000 administered MMR doses. The studies estimated the attributable risk of ITP within six weeks after MMR vaccination to be about 1 case/25,000 (95% CI 1/21,300 to 1/89,400) doses. The result confirms an association between MMR and Henoch‐Schönlein purpura. However, Henoch‐Schönlein purpura is the most common vasculitis in childhood with an incidence of 10 to 20 cases per 100,000 in children under 17 years of age, with a peak incidence of 70 cases per 100,000 in the 4‐ to 6‐year age group. Association with acute or idiopathic thrombocytopenic purpura within six weeks of immunisation is assessed in nine studies (n = 6300), but vaccine composition is described in only three studies (<a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a>; <a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a>; <a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a>). </p> <p>Based on the included studies, the meta‐analysis does not provide evidence supporting an association between MMR immunisation and the following conditions: encephalitis or encephalopathy (3 studies, around 500,000 children), autism spectrum disorders (13 studies, around 2 million children), inflammatory bowel disease/Crohn's disease (6 studies, N = 2385 children), cognitive delay (1 study, N = 369 children), type 1 diabetes (2 studies, around 770,000 children), asthma (5 studies, around 1 million children), dermatitis/eczema (2 studies, around 15,000 children), hay fever (3 studies, around 120,000 children), leukaemia (4 studies, N = 4318 children), demyelinating diseases/multiple sclerosis (3 studies, around 730,000 children), gait disturbance (1 study, N = 1525 children), and bacterial or viral infections (2 studies, N = 2412 children). </p> </section> <section id="CD004407-sec-0117"> <h3 class="title" id="CD004407-sec-0117">Overall completeness and applicability of evidence</h3> <p>Internal and external validity of included studies has improved in recent years (<a href="#CD004407-tbl-0051">Table 30</a>). </p> </section> <section id="CD004407-sec-0118"> <h3 class="title" id="CD004407-sec-0118">Quality of the evidence</h3> <p>Of the 138 included studies, we classified 36% as at low risk of bias with reliable results; 42% as at unclear risk of bias due to a problematic aspect of the study (generally selection bias), but the results remain sufficiently reliable; and 22% as at high risk of bias (<a href="#CD004407-fig-0003">Figure 3</a>), for which we found problematic internal validity, and the biases present in the studies (selection, performance, attrition, detection, and reporting) influenced our confidence in their findings. The most common type of bias was selection bias. We analysed reasons presented in the papers to justify missing data. Whilst we accepted as adequate such explanations as 'non‐response to questionnaire' and 'medical records unavailable', not all reports offered adequate explanations for missing data. The overall quality assessment by study design is shown in <a href="#CD004407-tbl-0050">Table 29</a> and by publication year in <a href="#CD004407-tbl-0051">Table 30</a>. </p> <p>Of the 51 studies on MMR effectiveness, 42 were funded by public or government institutions, and only 5 by the pharmaceutical industry. Of the 87 studies on MMR/MMRV safety, 65 were funded by public or government institutions, 9 by the pharmaceutical industry, and 10 studies were funded in part by industry and in part by government or public institutions. </p> </section> <section id="CD004407-sec-0119"> <h3 class="title" id="CD004407-sec-0119">Potential biases in the review process</h3> <p>There are some weaknesses in our review. The age limit of participants, although substantially justified by public health concerns about the effects of vaccination on the developing child, did lead us to exclude some studies on this basis alone. Additionally, the methodological quality tools used to assess the case‐only designs have not, to our knowledge, been empirically tested. We believe this had a minimal impact on our findings, given the size and nature of the biases present in the design and reporting of the included studies. The range of differing study designs used by authors is partly a reflection of the lack of 'control' children not exposed to MMR, due to the population nature of vaccination programmes. As MMR vaccine is universally recommended, recent studies are constrained by the lack of a non‐exposed control group. This is a methodological difficulty that is likely to be encountered in all comparative studies of established childhood vaccines. We were unable to include some of the retrieved studies because a comparable, clearly defined control group or risk period was not available. This exclusion may be a limitation of our review, or may reflect a more fundamental methodological dilemma: how to carry out meaningful studies in the absence of a representative population not exposed to a vaccine that is universally used in public health programmes? Whichever view one takes, we believe that meaningful inferences from individual studies that lack a non‐exposed control group are difficult to make. </p> <p>The hypothesis that secondary vaccine failure (waning immunity) could occur and increase over the years after the last immunisation has been considered in some studies (<a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a>; <a href="./references#CD004407-bbs2-0065" title="NelsonGE , AguonA , ValenciaE , OlivaR , GuerreroML , ReyesR , et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010. Pediatric Infectious Disease Journal2013;32(4):374-80. [PMID: 23099425]">ca‐Nelson 2013</a>; <a href="./references#CD004407-bbs2-0066" title="OgbuanuIU , KuttyPK , HudsonJM , BlogD , AbediGR , GoodellS , et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics2012;130(6):e1567-74. [PMID: 23129075]">ca‐Ogbuanu 2012</a>), but it needs to be better explained. Two studies, <a href="./references#CD004407-bbs2-0330" title="BrissPA , FehrsLJ , ParkerRA , WrightPF , SannellaEC , HutchesonRH , et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. Journal of Infectious Diseases1994;169(1):77-82.">Briss 1994</a>; <a href="./references#CD004407-bbs2-0354" title="HershBS , FinePE , KentWK , CochiSL , KahnLH , ZellER , et al. Mumps outbreak in a highly vaccinated population. Journal of Pediatrics1991;119(2):187-93.">Hersh 1991</a>, carried out in the USA during mumps epidemics on high school students having high vaccination coverage (over 97% received at least one mumps‐containing vaccine dose before the outbreak), showed that the risk of acquiring mumps was higher in participants who were vaccinated at least three, <a href="./references#CD004407-bbs2-0330" title="BrissPA , FehrsLJ , ParkerRA , WrightPF , SannellaEC , HutchesonRH , et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. Journal of Infectious Diseases1994;169(1):77-82.">Briss 1994</a>, or five years, <a href="./references#CD004407-bbs2-0354" title="HershBS , FinePE , KentWK , CochiSL , KahnLH , ZellER , et al. Mumps outbreak in a highly vaccinated population. Journal of Pediatrics1991;119(2):187-93.">Hersh 1991</a>, before the outbreak, than in those who were more recently vaccinated. This estimate was not statistically relevant. Linear regression analysis demonstrated no significant trend for increasing mumps attack rates by years since last vaccination, after either one or two mumps‐containing vaccine doses (<a href="./references#CD004407-bbs2-0280" title="SchaffzinJK , PollockL , SchulteC , HenryK , DayanG , BlogD , et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics2007;120(4):e862-8. ">Schaffzin 2007</a>). A Belgian study carried out on pupils from seven kindergartens and primary schools in Bruges (age range 3 to 12 years) during a mumps epidemic in 1995 and 1996 estimated that the odds of developing mumps increased 27% per one‐year increase, from one year after the last MMR immunisation onwards (<a href="./references#CD004407-bbs2-0391" title="VandermeulenC , RoelantsM , VermoereM , RoseeuwK , GoubauP , HoppenbrouwersK . Outbreak of mumps in a vaccinated child population: a question of vaccine failure?Vaccine2004;22(21-22):2713-6.">Vandermeulen 2004</a>). A case‐cohort study carried out at the University in Kansas, USA, during the 2006 outbreak showed that case patients were more likely than their roommates without mumps to have received the second MMR dose more than 10 years before (OR 2.50, 95% CI 1.28 to 5.00) (<a href="./references#CD004407-bbs2-0335" title="CorteseMM , JordanHT , CurnsAT , QuinlanPA , EnsKA , DenningPM , et al. Mumps vaccine performance among university students during a mumps outbreak. Clinical Infectious Diseases2008;46(8):1172-80.">Cortese 2008</a>). Waning immunity may be secondary to a lack of natural exposure (<a href="./references#CD004407-bbs2-0335" title="CorteseMM , JordanHT , CurnsAT , QuinlanPA , EnsKA , DenningPM , et al. Mumps vaccine performance among university students during a mumps outbreak. Clinical Infectious Diseases2008;46(8):1172-80.">Cortese 2008</a>; <a href="./references#CD004407-bbs2-0194" title="DayanGH , QuinliskMP , ParkerAA , BarskeyAE , HarrisML , SchwartzJM , et al. Recent resurgence of mumps in the United States. New England Journal of Medicine2008;358(15):1580-9. ">Dayan 2008a</a>). The group with the highest mumps incidence during the 2006 outbreak in the USA were college‐age students (18 to 24 years) born during the 1980s, when the spread of mumps was so low that many of them were never exposed to the disease. They probably received a second dose in the early 1990s, when opportunities for booster shots against exposure to wild viruses became increasingly rare (<a href="./references#CD004407-bbs2-0194" title="DayanGH , QuinliskMP , ParkerAA , BarskeyAE , HarrisML , SchwartzJM , et al. Recent resurgence of mumps in the United States. New England Journal of Medicine2008;358(15):1580-9. ">Dayan 2008a</a>). Moreover, the risk of the contracting mumps virus from abroad should be considered, because in several countries, mumps vaccination was not routinely administered (<a href="./references#CD004407-bbs2-0315" title="CohenC , WhiteJM , SavageEJ , GlynnJR , ChoiY , AndrewsN , et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerging Infectious Diseases2007;13(1):12-7. ">Cohen 2007</a>; <a href="./references#CD004407-bbs2-0194" title="DayanGH , QuinliskMP , ParkerAA , BarskeyAE , HarrisML , SchwartzJM , et al. Recent resurgence of mumps in the United States. New England Journal of Medicine2008;358(15):1580-9. ">Dayan 2008a</a>). Apart from waning immunity, it must be considered that mumps strains used in vaccine preparation differed phylogenically from those isolated during recent mumps outbreaks (<a href="./references#CD004407-bbs2-0194" title="DayanGH , QuinliskMP , ParkerAA , BarskeyAE , HarrisML , SchwartzJM , et al. Recent resurgence of mumps in the United States. New England Journal of Medicine2008;358(15):1580-9. ">Dayan 2008a</a>; <a href="./references#CD004407-bbs2-0338" title="DayanGH , RubinS . Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?Clinical Infectious Diseases2008;47(11):1458-67.">Dayan 2008b</a>). These facts could explain, at least in part, the vaccine failure observed during some mumps outbreaks. </p> </section> <section id="CD004407-sec-0120"> <h3 class="title" id="CD004407-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>This is currently the only review covering both effectiveness and safety issues of MMR, MMR+V, and MMRV vaccines. In agreement with results from other studies and reviews, we did not find a significant association between autism and MMR exposure. The <a href="./references#CD004407-bbs2-0303" title="WakefieldAJ , MurchSH , AnthonyA , LinnellJ , CassonDM , MalikM , et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet1998;351(9103):637-41. ">Wakefield 1998</a> study which links MMR vaccination with autism has been fully retracted (<a href="./references#CD004407-bbs2-0340" title="Editors of the Lancet. Retraction - Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet2010;375(9713):445.">Editors of the Lancet 2010</a>), as Wakefield was found guilty of ethical, medical, and scientific misconduct in the publication of the paper. Many other authors have shown that the Wakefield data were fraudulent (<a href="./references#CD004407-bbs2-0344" title="FlahertyDK . The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Annals of Pharmacotherapy2011;45(10):1302-4.">Flaherty 2011</a>). A formal retraction of the interpretation that there was a causal link between MMR vaccine and autism was issued in 2004 by 10 of the 12 original co‐authors (<a href="./references#CD004407-bbs2-0367" title="MurchSH , AnthonyA , CassonDH , MalikM , BerelowitzM , DhillonAP , et al. Retraction of an interpretation. Lancet2004;363(9411):750.">Murch 2004</a>). In 1998, an excessive and unjustified media coverage of this small study had disastrous consequences (<a href="./references#CD004407-bbs2-0344" title="FlahertyDK . The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Annals of Pharmacotherapy2011;45(10):1302-4.">Flaherty 2011</a>; <a href="./references#CD004407-bbs2-0356" title="HiltonS , HuntK , PetticrewM . MMR: marginalised, misrepresented and rejected? Autism: a focus group study. Archives of Disease in Childhood2007;92(4):322-7.">Hilton 2007</a>; <a href="./references#CD004407-bbs2-0370" title="OffitPA , CoffinSE . Communicating science to the public: MMR vaccine and autism. Vaccine2003;22(1):1-6.">Offit 2003</a>; <a href="./references#CD004407-bbs2-0387" title="SmithMJ , EllenbergSS , BellLM , RubinDM . Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics2008;121(4):e836-43.">Smith 2008</a>), such as distrust of public health vaccination programmes and suspicion about vaccine safety. The consequence of this was a significant decrease in MMR vaccine coverage and re‐emergence of measles in the UK. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004407-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram (simplified version)." data-id="CD004407-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram (simplified version).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Flow diagram (complete)." data-id="CD004407-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Flow diagram (complete).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004407-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004407-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effectiveness against measles, Outcome 1: Cohort studies (vaccinated vs unvaccinated)" data-id="CD004407-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Effectiveness against measles, Outcome 1: Cohort studies (vaccinated vs unvaccinated) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effectiveness against measles, Outcome 2: Cohort studies (household contacts: vaccinated vs unvaccinated)" data-id="CD004407-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Effectiveness against measles, Outcome 2: Cohort studies (household contacts: vaccinated vs unvaccinated) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effectiveness against measles, Outcome 3: Cohort studies (postexposure prophylaxis: vaccinated vs unvaccinated)" data-id="CD004407-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Effectiveness against measles, Outcome 3: Cohort studies (postexposure prophylaxis: vaccinated vs unvaccinated) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Effectiveness against measles, Outcome 4: Case‐control studies" data-id="CD004407-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Effectiveness against measles, Outcome 4: Case‐control studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 1: Cohort studies ‐ Jeryl Lynn strain" data-id="CD004407-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 1: Cohort studies ‐ Jeryl Lynn strain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 2: Cohort studies ‐ Urabe strain" data-id="CD004407-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 2: Cohort studies ‐ Urabe strain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 3: Cohort studies ‐ Rubini strain" data-id="CD004407-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 3: Cohort studies ‐ Rubini strain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 4: Cohort studies ‐ mumps strain not reported or mixed" data-id="CD004407-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 4: Cohort studies ‐ mumps strain not reported or mixed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 5: Cohort studies ‐ 3 doses vs 2 doses" data-id="CD004407-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 5: Cohort studies ‐ 3 doses vs 2 doses </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 6: Case‐control studies ‐ Jeryl Lynn strain" data-id="CD004407-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 6: Case‐control studies ‐ Jeryl Lynn strain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 7: Case‐control studies ‐ Jeryl Lynn strain ‐ lab‐confirmed cases" data-id="CD004407-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 7: Case‐control studies ‐ Jeryl Lynn strain ‐ lab‐confirmed cases </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 8: Case‐control studies ‐ Urabe strain" data-id="CD004407-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 8: Case‐control studies ‐ Urabe strain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 9: Case‐control studies ‐ Rubini strain" data-id="CD004407-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 9: Case‐control studies ‐ Rubini strain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Effectiveness against mumps, Outcome 10: Case‐control studies ‐ strain type not reported or any strain" data-id="CD004407-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Effectiveness against mumps, Outcome 10: Case‐control studies ‐ strain type not reported or any strain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Effectiveness against rubella, Outcome 1: Cohort studies secondary cases" data-id="CD004407-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Effectiveness against rubella, Outcome 1: Cohort studies secondary cases</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 1: MMRV randomised clinical trial ‐ any severity" data-id="CD004407-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 1: MMRV randomised clinical trial ‐ any severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 2: MMRV randomised clinical trial ‐ moderate/severe cases" data-id="CD004407-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 2: MMRV randomised clinical trial ‐ moderate/severe cases </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 3: MMR+V randomised clinical trial ‐ any severity" data-id="CD004407-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 3: MMR+V randomised clinical trial ‐ any severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 4: MMR+V randomised clinical trial ‐ moderate/severe cases" data-id="CD004407-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 4: MMR+V randomised clinical trial ‐ moderate/severe cases </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 5: MMR+V randomised clinical trial ‐ severe cases" data-id="CD004407-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 5: MMR+V randomised clinical trial ‐ severe cases </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 6: MMRV cohort study" data-id="CD004407-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 6: MMRV cohort study</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 7: MMRV case‐control" data-id="CD004407-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 7: MMRV case‐control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 8: MMR+V case control" data-id="CD004407-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 8: MMR+V case control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 9: MMRV case only ecological method ‐ hospitalisation" data-id="CD004407-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 9: MMRV case only ecological method ‐ hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Effectiveness against varicella, Outcome 10: MMRV case only ecological method ‐ incidence" data-id="CD004407-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Effectiveness against varicella, Outcome 10: MMRV case only ecological method ‐ incidence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 1: Temperature" data-id="CD004407-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 1: Temperature </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 2: Rash" data-id="CD004407-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 2: Rash </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 3: Lymphadenopathy" data-id="CD004407-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 3: Lymphadenopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 4: Coryza" data-id="CD004407-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 4: Coryza </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 5: URTI (rhinitis, pharyngitis)" data-id="CD004407-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 5: URTI (rhinitis, pharyngitis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 6: Cough" data-id="CD004407-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Safety: short‐term side effects (local or systemic reactions), Outcome 6: Cough </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Safety: encephalitis or encephalopathy, Outcome 1: Case‐control: MMR (risk interval from 0 to 90 days)" data-id="CD004407-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Safety: encephalitis or encephalopathy, Outcome 1: Case‐control: MMR (risk interval from 0 to 90 days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Safety: encephalitis or encephalopathy, Outcome 2: Self‐controlled case series/person‐time cohort" data-id="CD004407-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Safety: encephalitis or encephalopathy, Outcome 2: Self‐controlled case series/person‐time cohort </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Safety: aseptic meningitis, Outcome 1: Case‐control ‐ case cross‐over" data-id="CD004407-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Safety: aseptic meningitis, Outcome 1: Case‐control ‐ case cross‐over</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Safety: aseptic meningitis, Outcome 2: Self‐controlled case series (SCCS)/person‐time cohort (PT)" data-id="CD004407-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Safety: aseptic meningitis, Outcome 2: Self‐controlled case series (SCCS)/person‐time cohort (PT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Safety: aseptic meningitis, Outcome 3: Case only ecological method (COEM)" data-id="CD004407-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Safety: aseptic meningitis, Outcome 3: Case only ecological method (COEM)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Safety: seizures (febrile/afebrile), Outcome 1: Cohort studies" data-id="CD004407-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Safety: seizures (febrile/afebrile), Outcome 1: Cohort studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Safety: seizures (febrile/afebrile), Outcome 2: Self‐controlled case series/person‐time cohort" data-id="CD004407-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Safety: seizures (febrile/afebrile), Outcome 2: Self‐controlled case series/person‐time cohort </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Safety: seizures (febrile/afebrile), Outcome 3: MMRV versus MMR+V" data-id="CD004407-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Safety: seizures (febrile/afebrile), Outcome 3: MMRV versus MMR+V</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Safety: seizures (febrile/afebrile), Outcome 4: MMRV versus MMR+V ‐ by brand" data-id="CD004407-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Safety: seizures (febrile/afebrile), Outcome 4: MMRV versus MMR+V ‐ by brand </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Safety: seizures (febrile/afebrile), Outcome 5: MMRV versus MMR" data-id="CD004407-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Safety: seizures (febrile/afebrile), Outcome 5: MMRV versus MMR</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Safety: seizures (febrile/afebrile), Outcome 6: MMRV versus MMR ‐ by brand" data-id="CD004407-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Safety: seizures (febrile/afebrile), Outcome 6: MMRV versus MMR ‐ by brand </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Safety: autism spectrum disorders, Outcome 1: Cohort studies" data-id="CD004407-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Safety: autism spectrum disorders, Outcome 1: Cohort studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Safety: autism spectrum disorders, Outcome 2: Case‐control" data-id="CD004407-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Safety: autism spectrum disorders, Outcome 2: Case‐control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Safety: autism spectrum disorders, Outcome 3: Self‐controlled case series/person‐time cohort" data-id="CD004407-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Safety: autism spectrum disorders, Outcome 3: Self‐controlled case series/person‐time cohort </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Safety: autism spectrum disorders, Outcome 4: Case only ecological method" data-id="CD004407-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Safety: autism spectrum disorders, Outcome 4: Case only ecological method</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Safety: inflammatory bowel disease (IBD), Outcome 1: Case‐control" data-id="CD004407-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Safety: inflammatory bowel disease (IBD), Outcome 1: Case‐control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Safety: inflammatory bowel disease (IBD), Outcome 2: Case‐only ecological method (rate ratio)" data-id="CD004407-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Safety: inflammatory bowel disease (IBD), Outcome 2: Case‐only ecological method (rate ratio) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Safety: inflammatory bowel disease (IBD), Outcome 3: Case only ecological method (odds ratio)" data-id="CD004407-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Safety: inflammatory bowel disease (IBD), Outcome 3: Case only ecological method (odds ratio) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Safety: cognitive delay ‐ developmental delay, Outcome 1: Cohort study" data-id="CD004407-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Safety: cognitive delay ‐ developmental delay, Outcome 1: Cohort study</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Safety: idiopathic thrombocytopenic purpura, Outcome 1: Case‐control ‐ case cross‐over" data-id="CD004407-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Safety: idiopathic thrombocytopenic purpura, Outcome 1: Case‐control ‐ case cross‐over </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Safety: idiopathic thrombocytopenic purpura, Outcome 2: Self‐controlled case series" data-id="CD004407-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Safety: idiopathic thrombocytopenic purpura, Outcome 2: Self‐controlled case series </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Safety: Henoch‐Schönlein purpura, Outcome 1: Case‐control" data-id="CD004407-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Safety: Henoch‐Schönlein purpura, Outcome 1: Case‐control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Safety: type 1 diabetes, Outcome 1: Cohort study MMR" data-id="CD004407-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Safety: type 1 diabetes, Outcome 1: Cohort study MMR</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Safety: asthma, Outcome 1: Cohort study (rate ratio)" data-id="CD004407-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Safety: asthma, Outcome 1: Cohort study (rate ratio)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Safety: asthma, Outcome 2: Cohort study (risk ratio)" data-id="CD004407-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Safety: asthma, Outcome 2: Cohort study (risk ratio)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Safety: eczema ‐ dermatitis, Outcome 1: Cohort study (rate ratio)" data-id="CD004407-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Safety: eczema ‐ dermatitis, Outcome 1: Cohort study (rate ratio)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Safety: eczema ‐ dermatitis, Outcome 2: Cohort study (risk ratio)" data-id="CD004407-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: Safety: eczema ‐ dermatitis, Outcome 2: Cohort study (risk ratio)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy, Outcome 1: Cohort study ‐ rhinoconjunctivitis" data-id="CD004407-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy, Outcome 1: Cohort study ‐ rhinoconjunctivitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy, Outcome 2: Cohort study ‐ hypersensitivity/allergy" data-id="CD004407-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy, Outcome 2: Cohort study ‐ hypersensitivity/allergy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy, Outcome 3: Case‐control ‐ hay fever" data-id="CD004407-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy, Outcome 3: Case‐control ‐ hay fever </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Safety: acute leukaemia, Outcome 1: Case‐control" data-id="CD004407-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Safety: acute leukaemia, Outcome 1: Case‐control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis, Outcome 1: Case‐control" data-id="CD004407-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis, Outcome 1: Case‐control </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Safety: gait disturbances, Outcome 1: Self‐controlled case series (hospitalisations)" data-id="CD004407-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Safety: gait disturbances, Outcome 1: Self‐controlled case series (hospitalisations)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Safety: gait disturbances, Outcome 2: Self‐controlled case series (GP visits)" data-id="CD004407-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: Safety: gait disturbances, Outcome 2: Self‐controlled case series (GP visits) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 1: Self‐controlled case series ‐ lobar pneumonia" data-id="CD004407-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 1: Self‐controlled case series ‐ lobar pneumonia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 2: Self‐controlled case series ‐ invasive bacterial infections" data-id="CD004407-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 2: Self‐controlled case series ‐ invasive bacterial infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-021.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 3: Self‐controlled case series ‐ encephalitis meningitis" data-id="CD004407-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-021.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 3: Self‐controlled case series ‐ encephalitis meningitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-021.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 4: Self‐controlled case series ‐ herpes" data-id="CD004407-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-021.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.4</div> <div class="figure-caption"> <p>Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 4: Self‐controlled case series ‐ herpes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-021.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 5: Self‐controlled case series ‐ pneumonia" data-id="CD004407-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-021.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.5</div> <div class="figure-caption"> <p>Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 5: Self‐controlled case series ‐ pneumonia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-021.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 6: Self‐controlled case series ‐ varicella zoster" data-id="CD004407-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-021.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.6</div> <div class="figure-caption"> <p>Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 6: Self‐controlled case series ‐ varicella zoster </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004407-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/urn:x-wiley:14651858:media:CD004407:CD004407-CMP-021.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 7: Self‐controlled case series ‐ miscellaneous viral infections" data-id="CD004407-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_t/tCD004407-CMP-021.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.7</div> <div class="figure-caption"> <p>Comparison 21: Safety: bacterial or viral infections, immune overload, Outcome 7: Self‐controlled case series ‐ miscellaneous viral infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/media/CDSR/CD004407/image_n/nCD004407-CMP-021.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Effectiveness against measles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against measles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population or school or day‐care centre or general practitioner or households<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of measles<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of measles<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.05<br/>(0.02 to 0.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12,039<br/>(7 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 9) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.04<br/>(0.01 to 0.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,604<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies household contacts ‐ 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/>(0.04 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/>(20 to 452) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies household contacts ‐ 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.15<br/>(0.03 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>378<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(15 to 381) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies household contacts ‐ 3 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.04<br/>(0.01 to 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(4 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies postexposure prophylaxis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/>(0.14 to 0.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>283<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(44 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Effectiveness against measles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Effectiveness against mumps</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against mumps</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population or school or day‐care centre or general practitioner or households<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of mumps<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of mumps<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/>(0.08 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9915<br/>(6 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(7 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.12<br/>(0.04 to 0.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7792<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(3 to 26) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ unspecified number of doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/>(0.14 to 0.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Jeryl Lynn strain ‐ household contacts</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/>(0.13 to 0.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1036<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>408 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(53 to 200) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Urabe strain ‐ unspecified numbers or at least 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/>(0.12 to 0.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2721<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(24 to 89) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ Rubini strain ‐ unspecified numbers or at least 1 dose</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.55 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4219<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000<br/>(111 to 334) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ mumps strain not reported or any strain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/>(0.29 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>769<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000<br/>(65 to 212) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ third dose versus 2 doses</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.33 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5417<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(2 to 8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies).<br/><sup>2</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Effectiveness against mumps</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Effectiveness against rubella</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against rubella</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> school<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of rubella<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of rubella<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies secondary cases ‐ any strain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.11<br/>(0.03 to 0.42)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1621 (1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Cohort study in China using the BRD2 strain.<br/><sup>2</sup>Upgraded one level for large effect size (non‐critical risk of bias in studies). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Effectiveness against rubella</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Effectiveness against varicella</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Effectiveness against varicella</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMRV or MMR+V vaccine<br/><b>Comparison:</b> MMR vaccine (RCTs), unvaccinated (cohort studies) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of varicella<br/>amongst<br/>unvaccinated<br/>with MMR vaccine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of varicella<br/>amongst<br/>vaccinated<br/>with MMRV vaccine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.05<br/>(0.03 to 0.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3022<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(8 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.05<br/>(0.04 to 0.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>437 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(17 to 26) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 10 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.05<br/>(0.04 to 0.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>473 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(19 to 28) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.00<br/>(0.00 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3022<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.01<br/>(0.00 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.01<br/>(0.00 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3023<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(0 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.35<br/>(0.28 to 0.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3006<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/>(76 to 116) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.33<br/>(0.29 to 0.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>437 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/>(127 to 166) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ any severity ‐ 2 doses ‐ follow‐up at 10 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.33<br/>(0.29 to 0.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>473 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/>(137 to 180) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.09<br/>(0.06 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3006<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(9 to 22) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up between 5 and 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.10<br/>(0.07 to 0.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(17 to 31) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMR+V randomised controlled trial ‐ moderate/severe cases ‐ 2 doses ‐ follow‐up at 10 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.10<br/>(0.08 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3010<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(19 to 33) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>MMRV:</b> measles, mumps, rubella, and varicella vaccine; <b>MMR+V:</b> concurrent administration of MMR vaccine and varicella vaccine; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Effectiveness against varicella</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: short‐term side effects (local or systemic reactions)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term side effects<br/>amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term side effects<br/>amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ RCT/CCT axillary</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.04<br/>(1.09 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(74 to 261) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ RCT/CCT rectal</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/>(0.67 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>170<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>786 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>660 per 1000<br/>(526 to 833) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ RCT/CCT measurement site not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/>(0.83 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>520<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/>(151 to 405) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ cohort studies orally</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/>(1.04 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>334<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>377 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>517 per 1000<br/>(392 to 683) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Temperature ‐ cohort studies measurement site not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.84 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>457,123<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/>(26 to 46) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rash ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.49<br/>(0.73 to 3.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>457,261<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(3 to 13) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lymphadenopathy ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(0.52 to 3.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1156<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(11 to 70) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lymphadenopathy ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.98<br/>(0.19 to 20.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>454,085<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coryza ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/>(0.12 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>831<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(4 to 60) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coryza ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/>(1.05 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3176<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>502 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>567 per 1000<br/>(527 to 602) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>URTI (rhinitis pharyngitis) ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.31<br/>(0.06 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>831<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(16 to 414) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>URTI (rhinitis pharyngitis) ‐ cohort studies</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.44<br/>(1.26 to 1.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>966<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>697 per 1000<br/>(610 to 794) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cough ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.99<br/>(0.45 to 8.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>831<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(4 to 72) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rash ‐ RCT/CCT</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.05<br/>(1.21 to 3.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1156<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1000<br/>(63 to 182) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CCT:</b> controlled clinical trial; <b>MMR</b> : measles, mumps, rubella vaccine; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>URTI:</b> upper respiratory tract infection </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to selective reporting (reporting bias).<br/><sup>2</sup>Downgraded one level due to low comparability amongst groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: encephalitis or encephalopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of encephalitis or encephalopathy<br/>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of encephalitis or encephalopathy<br/>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control: MMR (risk interval from 0 to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.98<br/>(0.64 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>452 cases, 1280 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(22 to 51) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time cohort</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.90<br/>(0.50 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,071,088<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100,000<br/>(11 to 36) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Safety: aseptic meningitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: aseptic meningitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>aseptic meningitis</b><br/>amongst unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>aseptic meningitis</b><br/>amongst vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ Jeryl Lynn ‐ risk interval 0 to 30 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.85<br/>(0.21 to 3.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59 cases, 118 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(13 to 177) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case cross‐over ‐ Urabe or Hoshino</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 4.00<br/>(2.23 to 7.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(2 observational studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case cross‐over ‐ Jeryl Lynn or Rubini</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.60<br/>(0.18 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ any strain</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 12.40<br/>(3.12 to 49.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ Urabe</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 30.71<br/>(13.45 to 70.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>564,635<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 100,000<br/>(214 to 1.117) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self controlled case series ‐ Leningrad‐Zagreb</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 6.40<br/>(0.78 to 52.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 observational study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Person‐time cohort ‐ Jeryl Lynn</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.30<br/>(0.66 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,071,088<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 100,000<br/>(20 to 77) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐only ecological method ‐ Urabe</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 9.12<br/>(5.73 to 14.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,054,305<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 100,000<br/>(51 to 128) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐only ecological method ‐ Leningrad‐Zagreb</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 18.56<br/>(12.09 to 28.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,164,964<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 100,000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR</b> : measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Safety: aseptic meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Safety: seizures (febrile/afebrile)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: seizures (febrile/afebrile)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>seizures </b> <br/><b>(febrile/afebrile)</b><br/>amongst unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>seizures </b> <br/><b>(febrile/afebrile)</b><br/>amongst vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ within 1 week after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 2.45<br/>(2.21 to 2.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,451,990<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000<br/>(238 to 292) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ between 1 and 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.16<br/>(2.89 to 3.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2,147,638<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/>(38 to 46) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ &gt; 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.97<br/>(0.49 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,018,998<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ between 1 and 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.36<br/>(2.65 to 4.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>505,493<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ &gt; 2 weeks after MMR vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.18<br/>(0.93 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>102,099<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ between 1 and 2 weeks after vaccination; MMRV </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 6.08<br/>(4.95 to 7.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180,480<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series/person‐time ‐ between 1 and 2 weeks after MMR+V vaccination</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.13<br/>(2.38 to 4.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>181,088<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.95<br/>(0.85 to 4.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>115,022<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.69<br/>(0.93 to 3.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>114,922<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/>(1.17 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,381,609<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.01<br/>(1.70 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,381,609<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(3 to 4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/>(1.00 to 1.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>292,535<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.49<br/>(1.66 to 3.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>292,535<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(2 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60<br/>(1.42 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,049,831<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 100,000<br/>(61 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/>(1.32 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,989,157<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 100,000<br/>(28 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>MMRV:</b> measles, mumps, rubella, and varicella vaccine; <b>MMR+V:</b> concurrent administration of MMR vaccine and varicella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to large effect size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Safety: seizures (febrile/afebrile)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Safety: autistic spectrum disorders</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Safety: autistic spectrum disorders</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>ASD</b> amongst unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>ASD</b> amongst vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ all children, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.93<br/>(0.85 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,194,764<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>451 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>419 per 100,000<br/>(383 to 455) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ autism risk (low), MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.00<br/>(0.89 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93,071<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 100,000<br/>(76 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies ‐ autism risk (moderate/high), MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.80<br/>(0.64 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1914<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The apparent protective effect is due to indication bias.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(7 to 11) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ASD:</b> autism spectrum disorders; <b>CI:</b> confidence interval; <b>MMR</b>: measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to residual confounding ‐ confounding expected to increase the effect but no effect was observed. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Safety: autistic spectrum disorders</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Safety: inflammatory bowel disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: inflammatory bowel disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>IBD</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>IBD</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ all IBD, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.42<br/>(0.93 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>409 cases, 1416 controls<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ ulcerative colitis, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.35<br/>(0.81 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>292 cases, 582 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ Crohn's disease, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.64<br/>(0.42 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>514 cases, 804 controls<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IBD:</b> inflammatory bowel disease; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to residual confounding ‐ confounding expected to increase the effect but no effect was observed. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Safety: inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Safety: cognitive delay ‐ developmental delay</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: cognitive delay ‐ developmental delay</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>cognitive delay ‐ </b> <br/><b>developmental delay</b> amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>cognitive delay ‐ </b> <br/><b>developmental delay</b> amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ MDI‐BSID II 24th month, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.35<br/>(0.15 to 12.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ MDI‐BSID II 36th month, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.37<br/>(0.03 to 4.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ Raven 5th year, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.22<br/>(0.23 to 6.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ WISC‐R verbal 6th year, MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.23<br/>(0.09 to 16.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>337<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MDI‐BSID II:</b> Mental Development Index of Bayley Scales of Infant Development, second edition; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio; <b>WISC‐R:</b> Wechsler Intelligence Scale for Children, Revised Form </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Safety: cognitive delay ‐ developmental delay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: idiopathic thrombocytopenic purpura</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of ITP </b> <br/><b>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of ITP </b> <br/><b>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ case cross‐over ‐ case controls MMR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.80<br/>(1.50 to 5.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410 cases, 2040 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ MMR vaccine ‐ age from 9 to 23 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 4.21<br/>(2.28 to 7.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3,723,677<br/>(5 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 100,000<br/>(39 to 132) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ITP:</b> idiopathic thrombocytopenic purpura; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to large effect size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: Henoch‐Schönlein purpura</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>HSP </b> <br/><b>amongst</b> <br/><b>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>HSP</b> <br/><b>amongst </b> <br/><b>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ MMR vaccine</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.40<br/>(1.18 to 9.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288 cases, 617 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HSP:</b> Henoch‐Schönlein purpura; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0014"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Safety: type 1 diabetes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: type 1 diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>type 1 diabetes</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>type 1 diabetes</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study MMR ‐ all children</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.09<br/>(0.98 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,666,829<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study MMR ‐ children with at least 1 sibling with type 1 diabetes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.86<br/>(0.34 to 2.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3848<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(2 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Safety: type 1 diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0015"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Safety: asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>asthma </b> <br/><b>amongst </b> <br/><b>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>asthma </b> <br/><b>amongst </b> <br/><b>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study (rate ratio) ‐ all ages</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.05<br/>(0.80 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,067,712<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/>(25 to 44) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort studies (risk ratio) ‐ all ages</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.24 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>886<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000<br/>(99 to 674) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to non‐critical risk of bias in the study and large number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Safety: asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0016"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Safety: eczema ‐ dermatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: eczema ‐ dermatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> vaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>eczema ‐ dermatitis</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>eczema ‐ dermatitis</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study (rate ratio)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 3.50<br/>(2.38 to 5.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,353<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study (risk ratio)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.29 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>555<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to ascertainment bias which seriously weakens confidence in the results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Safety: eczema ‐ dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0017"> <div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>hay fever, rhinoconjunctivitis, hypersensitivity/allergy</b><br/>amongst<br/>unvaccinated </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>hay fever, rhinoconjunctivitis, hypersensitivity/allergy</b><br/>amongst<br/>vaccinated </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ rhinoconjunctivitis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.64<br/>(0.19 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>489<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000<br/>(48 to 360) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cohort study ‐ hypersensitivity/allergy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.63<br/>(0.14 to 2.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>544<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000<br/>(95 to 675) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case control ‐ hay fever</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.16<br/>(0.92 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0 cases, 0 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Upgraded one level due to non‐critical risk of bias in the study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0018"> <div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Safety: acute leukaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: acute leukaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>acute leukaemia </b> <br/><b>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Risk of <b>acute leukaemia </b> <br/><b>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ acute leukaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.97<br/>(0.76 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>941 cases, 1667 controls<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ acute lymphoblastic leukaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.91<br/>(0.72 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1375 cases, 2316 controls<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ acute myeloblastic leukaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.56<br/>(0.29 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>62 cases, 1258 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Safety: acute leukaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0019"> <div class="table-heading"><span class="table-label">Summary of findings 19.</span> <span class="table-title">Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of demyelinating diseases ‐ multiple sclerosis ‐ ADEM<br/>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of demyelinating diseases ‐ multiple sclerosis ‐ ADEM<br/>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ multiple sclerosis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.13<br/>(0.62 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206 cases, 888 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Case‐control ‐ ADEM</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.03<br/>(0.44 to 2.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272 cases, 1096 controls<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ADEM:</b> acute disseminated encephalomyelitis; <b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 19.</span> <span class="table-title">Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0020"> <div class="table-heading"><span class="table-label">Summary of findings 20.</span> <span class="table-title">Safety: gait disturbances</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: gait disturbances</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of gait disturbances<br/>amongst unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of gait disturbances<br/>amongst vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series (hospitalisations) ‐ hospitalisations ‐ risk period: 0 to 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.46<br/>(0.16 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 0 to 5 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.88<br/>(1.30 to 2.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1398<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 6 to 60 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.93<br/>(0.78 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1398<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>GP:</b> general practitioner; <b>MMR:</b> measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 20.</span> <span class="table-title">Safety: gait disturbances</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004407-tbl-0021"> <div class="table-heading"><span class="table-label">Summary of findings 21.</span> <span class="table-title">Safety: bacterial or viral infections, immune overload</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Safety: bacterial or viral infections, immune overload</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> children 9 months to 15 years old<br/><b>Setting:</b> general population<br/><b>Intervention:</b> MMR vaccine<br/><b>Comparison:</b> unvaccinated </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bacterial or viral infections, immune overload amongst<br/>unvaccinated</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk of bacterial or viral infections, immune overload amongst<br/>vaccinated</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ lobar pneumonia ‐ lobar pneumonia risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.75<br/>(0.64 to 0.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2412<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ invasive bacterial infections ‐ invasive bacterial infections risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.90<br/>(0.71 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2412<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ encephalitis meningitis ‐ encephalitis meningitis risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.84<br/>(0.20 to 3.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 1.17<br/>(0.56 to 2.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0 to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.72<br/>(0.32 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ varicella zoster ‐ varicella zoster risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.93<br/>(0.68 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Self‐controlled case series ‐ miscellaneous viral infections ‐ miscellaneous viral infections risk period (0 to 90 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.68<br/>(0.43 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2025<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MMR:</b> measles, mumps, rubella vaccine </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 21.</span> <span class="table-title">Safety: bacterial or viral infections, immune overload</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0022"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Measles: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>N events in exposed/<br/>N total exposed<br/>or person‐time<br/>versus<br/>N events in non‐exposed/<br/>N total non‐exposed<br/>or person‐time</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vaccine effectiveness</b> <br/><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0049" title="BarrabeigI , RoviraA , MunozP , BatallaJ , RuisC , SanchezJA , et al. MMR vaccine effectiveness in an outbreak that involved day-care and primary schools. Vaccine2011;29(45):8024-31. [DOI: 10.1016/j.vaccine.2011.08.056]">ca‐Barrabeig 2011b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children attending day‐care</p> <p>and preschool centres</p> <p>(a) ≥ 15 months (all ages)</p> <p>(b) 15 to 23 months</p> <p>(c) 24 to 35 months</p> <p>(d) ≥ 36 months</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(e) Indirect effectiveness</p> <p>(e1) 12 to 23 months</p> <p>(e2) 24 to 35 months</p> <p>(e3) ≥ 36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed measles</p> <p>was defined as</p> <p>laboratory‐confirmed case or met the WHO clinical case definition</p> <p>and was epidemiologically</p> <p>linked to laboratory‐confirmed case.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Priorix/Schwarz or<br/>MDS/Enders </p> <p>dose 1 at 9 to 12 months</p> <p>dose 2 at 15 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 1027 (any dose)</p> <p>(a1) N = 830 (1 dose)</p> <p>(a2) N = 197 (2 doses)</p> <p>(b) N = 269 (any doses)</p> <p>(c) N = 384 (any doses)</p> <p>(d) N = 374 (any doses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 94</p> <p>(b) n = 57</p> <p>(c) n = 20</p> <p>(d) n = 17</p> <p>unvaccinated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 5/1027 versus 12/94</p> <p>(a1) 5/830 versus 12/94</p> <p>(a2) 0/197 versus 12/94</p> <p>(b) 3/296 versus 6/57</p> <p>(c) 1/384 versus 4/20</p> <p>(d) 1/374 versus 2/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) 96.2% (89.4% to 98.6%)</p> <p>(a1) 95.3% (86.9% to 98.%)</p> <p>(a2) 100% (‐% to ‐%)</p> <p>(b) 89.4% (58.9% to 97.3%)</p> <p>(c) 98.7% (88.9% to 99.8%)</p> <p>(d) 97.7% (76.1% to 99.8%)</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(e1) 71.1% (63.5% to 78.8%)</p> <p>(e2) 80.0% (56.3% to 94.3%)</p> <p>(e3) 88.2% (63.6% to 98.5%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0050" title="BhuniyaS , MajiD , MandalD , MondalN . Measles outbreak among Dukpa tribe of Buxa Hills in West Bengal, India: epidemiology and vaccine efficacy. Indian Journal of Public Health2013;57(4):272-5. [DOI: 10.4103/0019-557X.123273]">ca‐Bhuniya 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 9 to 59 months</p> <p>(at 30 June 2011)</p> <p>(a) 9 to 59 months</p> <p>(b) 9 to 12 months</p> <p>(c) &gt; 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clinical case of measles is</p> <p>defined as fever with maculopapular</p> <p>rash and either conjunctivitis</p> <p>or cough or coryza</p> <p>(catarrhal inflammation of the</p> <p>mucous membrane in the nose).</p> <p>A confirmed case of measles is defined</p> <p>as a clinical case who is positive for</p> <p>anti‐measles virus nucleoprotein</p> <p>immunoglobulin M antibodies</p> <p>in serological tests but has not been</p> <p>vaccinated against measles</p> <p>during last 1 month.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 50 (1 dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 15/50 versus 16/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 66.3% (46.9% to 78.6%)</p> <p>(b) 66.6%(*)</p> <p>(c) 65.4%(*)</p> <p>(*) no statistical evidence</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0053" title="ChoeYJ , ParkYJ , KimJW , EomHE , ParkO , OhMD , et al. An outbreak of measles in a university in Korea, 2014. Journal of Korean Medical Science2017;32(11):1876-8. ">ca‐Choe 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outbreak at a university in 2014</p> <p>Students born between 1984 and 1993.</p> <p>N = 14,465</p> <p>VE &gt; 10 years after vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The definition of suspected measles case was individuals with<br/>following features: fever and rash and at least 1 of cough, coryza,<br/>or conjunctivitis. </p> <p>All suspected cases were quarantined<br/>and were interviewed using standardised questionnaire,<br/>and physical examinations were performed by trained physicians.<br/>Presence of symptoms (fever, rash, cough, coryza, or conjunctivitis),<br/>travel history, and days of illnesses were assessed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/not stated</p> <p>2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 11448</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 3017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/11448 versus 33/3017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60% (38.2% to 74.1%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 11,004</p> <p>children born</p> <p>between 2008 and 2010</p> <p>who underwent vaccination</p> <p>in 2009 to 2011.</p> <p>Follow‐up = 24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for</p> <p>(a) measles</p> <p>(b) mumps (see also <a href="#CD004407-tbl-0024">Table 3</a>) </p> <p>(c) measles and mumps</p> <p>(d) all infectious diseases</p> <p>(e) all respiratory diseases</p> <p>The effectiveness of MMR</p> <p>vaccine in reducing hospitalisations<br/>for any infection was assessed </p> <p>by analysing 2 distinct databases</p> <p>(vaccination record) and</p> <p>(hospital discharge):<br/>Hospital discharge diagnosis which </p> <p>contained the following ICD‐9 codes in primary or secondary diagnosis:</p> <p>001 to 139 for infectious and parasitic diseases;</p> <p>460 to 519 for respiratory diseases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not described</p> <p>the vaccination records of the database of the</p> <p>Roma Local Health Unit from which relevant</p> <p>data were extracted,</p> <p>such as date of birth;</p> <p>MMR vaccination (yes/no);</p> <p>MMR dose (only for vaccinated);</p> <p>personal tax code.</p> <p>The cohort was recomposed</p> <p>through record linkage of the 2<br/>archives, registration and </p> <p>vaccination of hospital discharge<br/>records, using personal </p> <p>tax codes as a common</p> <p>identification<br/>in both archives. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 dose N = 5392</p> <p>(2) 2 doses N = 3310</p> <p>(3) any dose</p> <p>N = 8702</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unvaccinated</p> <p>N = 2302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 3/5392 versus 9/2302</p> <p>(a2) 0/3310 versus 9/2302</p> <p>(a3) 3/8702 versus 9/2302</p> <p>(b1) 1/5392 versus 1/2302</p> <p>(b2) 0/3310 versus 1/2302</p> <p>(b3) 1/8702 versus 1/2302</p> <p>(c1) 4/5392 versus 10/2302</p> <p>(c2) 0/3310 versus 10/2302</p> <p>(c3) 4/8702 versus 10/2302</p> <p>(d1) 82/5392 versus 262/2302</p> <p>(d2) 70/3310 versus 262/2302</p> <p>(d3) 414/8702 versus 262/2302</p> <p>(e1) 202/5392 versus 424/2302</p> <p>(e2) 183/3310 versus 424/2302</p> <p>(e3) 809/8702 versus 424/2302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unadjusted estimates</p> <p>(a1) 85.8% (47.5% to 96.1%)<br/>(a2) 96.3% (37.1% to 99.8%)<br/>(a3) 91.2% (67.5% to 97.6%)<br/>(b1) 57.3% (−582% to 97.3%)*<br/>(b2) 76.8% (−468% to 99.1%)*<br/>(b3) 73.5% (−322% to 98.3%)*<br/>(c1) 82.9% (45.6% to 94.6%)<br/>(c2) 96.7% (43.5% to 99.8%)<br/>(c3) 89.4% (66.3% to 96.7%)<br/>(d1) 86.6% (83% to 89.5%)<br/>(d2) 81.4% (75.9% to 85.6%)<br/>(d3) 84.7% (81.4% to 87.4%)<br/>(e1) 79.7% (76.1% to 82.7%)<br/>(e2) 70% (64.6% to 74.5%)<br/>(e3) 76% (72.6% to 78.9%) </p> <p>(*) no statistical evidence</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Adjusted estimates</p> <p>any doses</p> <p>(a) 91% (68% to 99%)</p> <p>(b) not reported</p> <p>(c) 90% (66% to 97%)</p> <p>(d) 71% (66% to 75%)</p> <p>(e) 82% (52% to 93%)</p> <p>VE = (1 − HR)*100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (19 to 67 months)</p> <p>whose parent required a</p> <p>paediatrician visit during</p> <p>a measles outbreak peak</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis<br/>patient records and<br/>parent interviews </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Pluserix<br/>Schwarz<br/>(b) Morupar<br/>Schwarz </p> <p>(c) Triviraten<br/>Edmonston‐Zagreb </p> <p>vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 329 (1 dose)</p> <p>(b) N = 747 (1 dose)</p> <p>(c) N = 1023 (1dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 646</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0/329 versus 114/646</p> <p>(b) 2/747 versus 114/646</p> <p>(c) 8/1023 versus 114/646</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) 0/ 19,836 PT</p> <p>(b) 2/ 12,906 PT</p> <p>(c) 8/ 31,329 PT</p> <p>(control) 114/22,188 PT = person‐time in months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 100% (‐% to ‐%)</p> <p>(b) 97% (88% to 99%)<br/>(c) 95% (90% to 98%) </p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0064" title="MusaS , TopalovićB , ĆatićS , SmajlagićZ . Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. Central European Journal of Public Health2018;26(2):79-82. ">ca‐Musa 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged up to 14 years.</p> <p>N = 2784</p> <p>(children aged &gt; 14 years, N = 2300).</p> <p>Data were presented by age group.</p> <p>The study included all students in 40</p> <p>classes with 1 or more registered</p> <p>measles cases in the period</p> <p>February 2014 to September 2015.</p> <p>VE</p> <p>≤ 5 years since vaccination</p> <p>6 to 14 years since vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measles diagnosis was confirmed according to WHO guidelines. The clinical criteria<br/>for measles were fever, maculopapular rash (i.e. non‐vesicular<br/>rash), and cough or coryza (i.e. runny nose) or conjunctivitis<br/>(i.e. red eyes). The laboratory criteria for measles surveillance </p> <p>case confirmation were measles IgM antibody detection, or<br/>measles virus isolation, or measles viral RNA detection by<br/>RT‐PCR, or a significant rise in measles IgG antibody in<br/>paired sera.<br/>All suspected cases were investigated and classified based on<br/>clinical, laboratory, and epidemiological data, based on the WHO<br/>case definition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/not stated</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) ≤ 5 years since vaccination</p> <p>(d) 6 to 14 years since vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 100</p> <p>(b) N = 606</p> <p>(c) N = 20</p> <p>(d) N = 76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 3/100 versus 35/95</p> <p>(b) 6/606 versus 35/95</p> <p>(c) 1/20 versus 35/95</p> <p>(d) 2/76 versus 35/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 91.9% (74.4% to 97.4%)<br/>(b) 97.3% (93.8% to 98.8%)<br/>(c) 86.4% (6.6% to 98.0%)<br/>(d) 92.9% (71.2% to 98.2%) </p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0068" title="OngG , RasidahN , WanS , CutterJ . Outbreak of measles in primary school students with high first dose MMR vaccination coverage. Singapore Medical Journal2007;48(7):656-61. ">ca‐Ong 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children from</p> <p>primary school in Singapore</p> <p>(aged 8 to 14 years,</p> <p>&gt; 5 years since vaccination)</p> <p>during</p> <p>a measles outbreak</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical with</p> <p>laboratory confirmation.</p> <p>Active survey and</p> <p>serological confirmation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> <p>Vaccination status was ascertained from health booklet.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 171 (1 dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 13</p> <p>unvaccinated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/171 versus 7 /13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.8% (90.6% to 99.5%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0075" title="WichmannO , HellenbrandW , SagebielD , SantibanezS , AhlemeyerG , VogtG , et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal2007;26(9):782-6. ">ca‐Wichmann 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>School outbreak 2006.</p> <p>Students aged</p> <p>10 to 15 years (N = 875)<br/>16 to 21 years (N = 139) </p> <p>VE</p> <p>&lt; 10 years after vaccination</p> <p>&gt; 10 years after vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or laboratory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/not stated</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) unknown<br/>vaccination status </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>(a) N = 199</p> <p>(b) N = 561</p> <p>(c) N = 218</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years</p> <p>(a) N =196<br/>(b) N = 502<br/>(c) N = 144 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years<br/>(a) N = 3 </p> <p>(b) N = 59</p> <p>(c) N = 74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>N = 36</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years</p> <p>N = 33<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years<br/>N = 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>(a) 2/199 versus 19/36</p> <p>(b) 2/5611 versus 19/36</p> <p>(c) 30/218 versus 19/36</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years</p> <p>(a) 2/196 versus 18/33</p> <p>(b) 2/502 versus 18/33<br/>(c) 25/144 versus 18/33 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years<br/>(a) 0/3 versus 1/3<br/>(b) 0/59 versus 1/3 </p> <p>(c) 5/74 versus 1/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages<br/>(a) 98.1% (92.2% to 99.5%)<br/>(b) 99.3% (97.2% to 99.8%) </p> <p>(c) 73.9% (59.0% to 83.4%)</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>10 to 15 years<br/>(a) 98.1% (92.3% to 99.5%)<br/>(b) 99.3% (97.0% to 99.8%)<br/>(c) 68.2% (48.9% to 80.2%) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>16 to 21 years </p> <p>(a) 66.7% (*)</p> <p>(b) 97.8% (53.7% to 99.9%)</p> <p>(c) 79.7% (*)<br/>VE = (1 − RR) x 100 </p> <p>(*) no evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0076" title="WoudenbergT , van derMaasNAT , KnolMJ , deMelkerH , vanBinnendijkRS , HahneSJM . Effectiveness of early measles, mumps, and rubella vaccination among 6-14-month-old infants during an epidemic in the Netherlands: an observational cohort study. Journal of Infectious Diseases2017;215(8):1181-7. ">ca‐Woudenberg 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants aged 6 to 14 months</p> <p>living in municipalities where coverage</p> <p>with the first dose of MMR vaccine was &lt; 90%.</p> <p>Infants aged 6 to 11 months were</p> <p>offered an extra vaccination</p> <p>(and would thus still be</p> <p>eligible for their second MMR vaccination</p> <p>at the age of 14 months).</p> <p>Infants aged 12 to 14 months were</p> <p>offered an early MMR vaccination</p> <p>as an alternative to the regular</p> <p>time point at 14 months of age.</p> <p>All infants were eligible for another</p> <p>dose of MMR scheduled at 9 years of age.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory‐confirmed measles</p> <p>N = 1080 infants eligible for analysis laboratory‐confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine:</p> <p>(M‐M‐RVAXPRO; Sanofi</p> <p>Pasteur MSD).</p> <p>This vaccine contains measles</p> <p>virus Enders’ Edmonston strain.</p> <p>Vaccination status was checked</p> <p>in the national vaccination register.</p> <p>Parents were asked whether their</p> <p>infant(s) had had measles in the</p> <p>preceding 3 months.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 919</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/106,631 (PT‐days) versus</p> <p>10/23,769 (PT‐days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR (95% CI)(*)</p> <p>0.29 (0.05 to 1.72)</p> <p>(*) adjusted estimates Cox proportional<br/>hazard model </p> <p>VE = 1 − HR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0047" title="ArenzS , SchmittHJ , TischerA , vonKriesR . Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatric Infectious Disease Journal2005;24(8):697-9. ">ca‐Arenz 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Household contacts</b> </p> <p>55 families, 43 children</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR/strain<br/>not stated </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 13</p> <p>(b) N = 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 1/13 versus 19/26</p> <p>(b) 0/4 versus 19/26</p> <p>(c) 1/20 versus 19/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 96.9% (71.8% to 99.7%)</p> <p>(b) 95.7% (10.6% to 99.8%)</p> <p>(c) 97.7% (79.3% to 99.7%)</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) 90% (35% to 97%)</p> <p>(b) not reported</p> <p>(c) 92% (48% to 98%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0057" title="HalesCM , JohnsonE , HelgenbergerL , PapaniaMJ , LarzelereM , GopalaniSV , et al. Measles outbreak associated with low vaccine effectiveness among adults in Pohnpei State, Federated States of Micronesia 2014. Open Forum Infectious Diseases2016;3(2):ofw064. [DOI: 10.1093/ofid/ofw064]">ca‐Hales 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Household contacts</b> </p> <p>adolescents and young</p> <p>adults (10 to 29 years)</p> <p>(a) any dose</p> <p>(b) 1 dose</p> <p>(c) 2 doses</p> <p>(d) 3 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or</p> <p>laboratory confirmation, or both</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 302</p> <p>(b) N = 27</p> <p>(c) N = 205</p> <p>(d) N = 70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐campaign</p> <p>MMR doses</p> <p>(a) 16/302 versus 2/16</p> <p>(b) 3/27 versus 2/16</p> <p>(c) 13/205 versus 2/16</p> <p>(d) 0/70 versus 2/16</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐campaign MMR doses</p> <p>(a) (No data)</p> <p>(b) 23.1% (−425.0% to 87.3%)*</p> <p>(c) 63.4% (−103.0% to 90.6%)*</p> <p>(d) 95.9% (45% to 100%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Campaign MMR doses:</p> <p>78.7% (10.1% to 97.7%)</p> <p>for pre‐exposure doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>50.4% (*)</p> <p>for postexposure doses</p> <p>(*) no statistical evidence</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>VE = (1 − OR) x 100</p> <p>from logistic regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0062" title="MarinM , NguyenHQ , LangidrikJR , EdwardsR , BriandK , PapaniaMJ , et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. Clinical infectious Diseases2006;42(3):315-9. ">ca‐Marin 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Household contacts</b> </p> <p>(6 months to 14 years)</p> <p>of primary measles cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary cases</p> <p>Clinical (WHO definition) or</p> <p>IgM positive antibody of</p> <p>secondary cases</p> <p>Standardised questionnaires</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> <p>Vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) N = 48 (1 dose)</p> <p>(a2) N = 106 (2 doses)</p> <p>(b) N = 44 (&gt; 2 doses)</p> <p>(c) N = 219 any doses</p> <p>contacts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 21</p> <p>unvaccinated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 2/48 versus 11/21</p> <p>(a2) 3/106 versus 11/21</p> <p>(b) 1/44 versus 11/21</p> <p>(c) 17/219 versus 11/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 92.0% (67.2% to 98.1%)</p> <p>(a2) 94.6% (82.3% to 98.4%)</p> <p>(b) 95.7% (68.6% to 99.4%)</p> <p>(c) 85.2% (72.7% to 92.0%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0046" title="ArciuoloRJ , JablonskiRR , ZuckerJR , RosenJB . Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting - New York City, 2013. Clinical Infectious Diseases2017;65(11):1843-7. ">ca‐Arciuolo 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postexposure prophylaxis</b> </p> <p>Childrena aged &lt; 19 years</p> <p>N = 208</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All who subsequently</p> <p>developed measles were</p> <p>considered as contacts.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not described</p> <p>MMR PEP administered within</p> <p>72 hours of initial exposure.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/44 versus 45/164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 83.4% (34.4% to 95.8%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0048" title="BarrabeigI , RoviraA , RiusC , MunozP , SoldevilaN , BatallaJ , et al. Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal2011;30(1):78-80. ">ca‐Barrabeig 2011a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postexposure prophylaxis</b> </p> <p>N = 166 children with</p> <p>median age of 16.5 months</p> <p>(range 6 to 47 months)</p> <p>Candidates for the</p> <p>intervention were</p> <p>susceptible contacts who had</p> <p>not received either measles‐containing vaccine or</p> <p>had not suffered measles.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical and laboratory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not stated</p> <p>(a) at least 1 dose</p> <p>(b) vaccinated ≤ 3 days</p> <p>(c) vaccinated 4 to 5 days</p> <p>(d) vaccinated 6 to 7 days</p> <p>(e) vaccinated 8 to 9 days</p> <p>(f) vaccinated 10 to 12 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 54</p> <p>(b) N = 17</p> <p>(c) N = 14</p> <p>(d) N = 14</p> <p>(e) N = 8</p> <p>(f) N = 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 12/54 versus 13/21</p> <p>(b) 1/17 versus 13/21</p> <p>(c) 4/14 versus 13/21</p> <p>(d) 5/14 versus 13/21</p> <p>(e) 1/8 versus 13/21</p> <p>(f) 1/1 versus 13/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 64.1% (34.5% to 80.3%)</p> <p>(b) 90.5% (34.5% to 98.6%)</p> <p>(c) 53.8% (0.0% to 81.1%)</p> <p>(d) 42.3% (0.0% to 81.1%)</p> <p>(e) 79.8% (0.0% to 73.5%)</p> <p>(f) not reported</p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ARU: attack rate amongst unvaccinated<br/>ARV: attack rate amongst vaccinated<br/>CI: confidence interval<br/>HR: hazard ratio<br/>ICD: International Statistical Classification of Diseases and Related Health Problems<br/>IgG: immunoglobulin G<br/>IgM: immunoglobulin M<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>N: number of participants in intervention and control arm<br/>OR: odds ratio<br/>PEP: postexposure prophylaxis<br/>PT: person‐time in months<br/>rr: rate ratio (relative incidence, incidence rate ratio, hazard ratio)<br/>RR: risk ratio (relative risk)<br/>RNA: ribonucleic acid<br/>RT‐PCR: reverse‐transcription polymerase chain reaction<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Measles: effectiveness ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0023"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Measles: effectiveness ‐ case‐control studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case<br/>definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Controls/<br/>selection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR strain/exposure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N cases vaccinated/N cases<br/>versus<br/>N controls vaccinated/N controls</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OR (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0014" title="DefayF , De SerresG , SkowronskiDM , BoulianneN , OuakkiM , LandryM , et al. Measles in children vaccinated with 2 doses of MMR. Pediatrics2013;132(5):e1126-33. [DOI: 10.1542/peds.2012-3975]">ba‐Defay 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 17 years</p> <p>(a) outside of outbreak school</p> <p>(b) all participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 61</p> <p>(b) N = 102</p> <p>confirmed by laboratory testing</p> <p>or epidemiologic link</p> <p>is notifiables</p> <p>by both physicians and</p> <p>laboratories in Quebec</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 305</p> <p>(b) N = 510</p> <p>Controls were matched</p> <p>for date of birth</p> <p>(± 6 months)</p> <p>and school attended</p> <p>in 2010 to 2011.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR‐II</p> <p>(Merck Canada,</p> <p>Montreal, Quebec)</p> <p>Cases and controls</p> <p>received</p> <p>2 doses of</p> <p>measles‐containing</p> <p>vaccine.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported<br/>amongst unvaccinated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0019" title="HungerfordD , ClearlyP , GhebrehewetS , KeenanA , VivancosR . Risk factors for transmission of measles during an outbreak: matched case control study. Journal of Hospital Infections2014;86(2):138-43. [DOI: 10.1016/j.jhin.2013.11.008]">ba‐Hungerford 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>(median age 16 years,</p> <p>upper quartile age 76 years)</p> <p>living in Merseyside (UK)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 42</p> <p>microbiological confirmation:</p> <p>oral fluid/blood test</p> <p>IgM positive or PCR positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 42</p> <p>Control group participants were</p> <p>selected at random,</p> <p>matched 1:1 by general</p> <p>medical practice and aged</p> <p>within 1 year.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not described</p> <p>(a) vaccinated appropriately for age<br/>(b) under age </p> <p>for vaccination (&lt; 14 months)</p> <p>(c) all ‐ vaccinated</p> <p>Unvaccinated: incompletely or partially vaccinated for age (&gt; 13 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 5/27 versus 23/29</p> <p>(b) 15/37 versus 12/18</p> <p>(c) 20/42 versus 35/42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk factors for</p> <p>measles infection</p> <p>(univariate analysis)</p> <p>age &gt; 13 months and incomplete vaccination</p> <p>6.3 (1.9 to 33.4)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(Multivariate analysis)</p> <p>under age for routine</p> <p>vaccination</p> <p>20.4 (2.0 to 300)</p> <p>incomplete/partial vaccination</p> <p>for age &gt; 13 months</p> <p>22.1 (3.8 to 300)</p> <p>(**) adjusted for confounders</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk factors for</p> <p>measles infection</p> <p>(univariate analysis)</p> <p>age &gt; 13 months and incomplete vaccination</p> <p>84.1% (47.4% to 97.0%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(Multivariate analysis)</p> <p>under age for routine</p> <p>vaccination</p> <p>95.1% (50.0% to 100%)</p> <p>incomplete/partial vaccination</p> <p>for age &gt; 13 months</p> <p>95.5% (73.7% to 100%)</p> <p>(**) adjusted for confounders</p> <p>VE = (1 − OR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0020" title="JickH , HagbergKW . Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. Vaccine2010;28(29):4588-92. ">ba‐Jick 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>aged 1 to 19 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1261</p> <p>clinical definition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 4996</p> <p>randomly selected, matched for year of birth, gender, general practice attended, index date </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR or MR</p> <p>not described</p> <p>(a) 1 dose</p> <p>(b) &gt; 1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 409/1221 versus 2012/4750</p> <p>(b) 40/852 versus 246/2984</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0.49 (0.41 to 0.58)*</p> <p>(b) 0.39 (0.26 to 0.58)*</p> <p>*adjusted estimates, conditional logistic regression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 51.0% (42.0% to 59.0%)<br/>(b) 61.0% (42.0% to 74.0%) </p> <p>VE = (1 − OR) x 100</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>**: multivariate analysis<br/>CCDC: Consultant in Communicable Disease Control<br/>CI: confidence interval<br/>IgM: immunoglobulin M<br/>MR: measles and rubella vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>N: number of participants<br/>OR: odds ratio<br/>PCR: polymerase chain reaction<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Measles: effectiveness ‐ case‐control studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0024"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Mumps: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N events in exposed/<br/>N total exposed<br/>or PT<br/>versus<br/>N events in non‐exposed/<br/>N total non‐exposed<br/>or PT</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0051" title="ChamotE , ToscaniL , EggerP , GermannD , BourquinC . Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Revue d'Epidemiologie et de Sante Publique1998;46(2):100-7. ">ca‐Chamot 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged up to 16 years</p> <p>from Geneva were</p> <p>household contacts<br/>of primary confirmed mumps cases<br/>(clinical or with laboratory confirmation<br/>notified by a paediatrician). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis of</p> <p>secondary cases</p> <p>Phone interview</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) MMR‐II/Jeryl LynnB</p> <p>(b) Pluserix or Trimovax/Urabe AM9</p> <p>(c) Triviraten/Rubini</p> <p>(d) any strain</p> <p>Vaccination records</p> <p>Unspecified</p> <p>number of doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 30</p> <p>(b) N = 75</p> <p>(c) N = 83</p> <p>(d) N = 193</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 72</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 4/30 versus 25/72</p> <p>(b) 7/75 versus 25/72</p> <p>(c) 27/83 versus 25/72</p> <p>(d) 38/193 versus 25/72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 61.6 % (−0.9% to 85.4%)</p> <p>(b) 73.1% (41.8% to 87.6%)</p> <p>(c) 6.3% (−45.9% to 39.8%)</p> <p>(d) 43.0% (12.7% to 62.8%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0054" title="Compés-DeaC , Guimbao-BescòsJ , Gaspar-EscayolaJI , Lazaro-BelancheMA , Aznar-BriebaA . An outbreak of mumps in a high school: estimation of vaccine effectiveness. Zaragoza 2011 [Broteescolar de parotiditis: estimacion de la efectividad vacunal Zaragoza 2011]. Enfermedades Infeccionas y Microbiologia Clinical2015;33(6):385-90. [DOI: 10.1016/j.eimc.2014.09.011]">ca‐Compés‐Dea 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235 students (in Spain)</p> <p>(aged 16 to 17 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine:<br/>Jeryl Lynn RIT4385 or Rubini </p> <p>(a) 1 dose</p> <p>(b) 2 dose</p> <p>(c) 3 dose</p> <p>(d) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 5</p> <p>(b) N = 37</p> <p>(c) N = 2</p> <p>(d) N = 44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 2</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/5 versus 1/2</p> <p>(b) 9/37 versus 1/2</p> <p>(b) 2/2 versus 1/2</p> <p>(d) 13/44 versus 1/2</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Incidence</p> <p>(a) 33 versus 50 x 100 person‐day</p> <p>(≥ 2 doses) 16 versus 50 x 100 person‐day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) not reported<br/>(b) not reported<br/>(c) not reported<br/>(d) not reported </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>VE = (1 − rr) x 100</p> <p>(a) 34% (−44% to 70%)*</p> <p>(≥ 2 doses) 67% (28% to 83%)</p> <p>*no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0056" title="GreenlandK , WhelanJ , FanoyE , BorgertM , HulshofK , YapKB , et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands 2010. Vaccine2012;30(31):4676-80. [DOI: 10.1016/j.vaccine.2012.04083]">ca‐Greenland 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Students from the</p> <p>3 university cities</p> <p>N = 989</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine: Jeryl Lynn</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 29</p> <p>(b) N = 706</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 16</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/29 versus 7/16</p> <p>(b) 92/706 versus 7/16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) not reported</p> <p>(b) 68% (40.6% to 82.2%)</p> <p>adjusted estimate</p> <p>VE = 1 − RR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0058" title="La TorreG , SaulleR , UnimB , MeggiolaroA , BarbatoA , MannocciA , et al. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study. Human Vaccination and Immunotherapy2017;13(8):1879-83. ">ca‐La Torre 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 11,004</p> <p>children born</p> <p>between 2008 and 2010,</p> <p>who underwent vaccination</p> <p>in 2009 to 2011.</p> <p>Follow‐up = 24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for</p> <p>(a) measles (see also <a href="#CD004407-tbl-0022">Table 1</a>) </p> <p>(b) mumps</p> <p>(c) measles and mumps</p> <p>(d) all infectious diseases</p> <p>(e) all respiratory diseases</p> <p>The effectiveness of MMR vaccine in reducing</p> <p>hospitalisations<br/>for any infection </p> <p>was assessed</p> <p>by analysing 2 distinct</p> <p>databases</p> <p>(vaccination record) and</p> <p>(hospital discharge):<br/>hospital discharge </p> <p>diagnosis contained the</p> <p>following ICD‐9 codes</p> <p>in primary or</p> <p>secondary diagnosis:</p> <p> <ul id="CD004407-list-0023"> <li> <p>001 to 139 for infectious and parasitic diseases;</p> </li> <li> <p>from 460 to 519 for respiratory diseases.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR not described (we assume Jeryl Lynn)</p> <p>the vaccination records</p> <p>from the Roma Local Health Unit database</p> <p>from which relevant</p> <p>data were extracted,</p> <p>such as date of birth;</p> <p>MMR vaccination</p> <p>(yes/no);</p> <p>MMR dose (only for vaccinated);</p> <p>personal tax code.</p> <p>The cohort was recomposed</p> <p>through record linkage of the 2<br/>archives, registration and </p> <p>vaccination of hospital discharge<br/>records, using </p> <p>personal tax codes as a common</p> <p>identification<br/>in both archives. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 dose N = 5392</p> <p>(2) 2 doses N = 3310</p> <p>(3) any dose</p> <p>N = 8702</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unvaccinated</p> <p>N = 2302</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 3/5392 versus 9/2302</p> <p>(a2) 0/3310 versus 9/2302</p> <p>(a3) 3/8702 versus 9/2302</p> <p>(b1) 1/5392 versus 1/2302</p> <p>(b2) 0/3310 versus 1/2302</p> <p>(b3) 1/8702 versus 1/2302</p> <p>(c1) 4/5392 versus 10/2302</p> <p>(c2) 0/3310 versus 10/2302</p> <p>(c3) 4/8702 versus 10/2302</p> <p>(d1) 82/5392 versus 262/2302</p> <p>(d2) 70/3310 versus 262/2302</p> <p>(d3) 414/8702 versus 262/2302</p> <p>(e1) 202/5392 versus 424/2302</p> <p>(e2) 183/3310 versus 424/2302</p> <p>(e3) 809/8702 versus 424/2302</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unadjusted estimates</p> <p>(a1) 85.8% (47.5% to 96.1%)<br/>(a2) 96.3% (37.1% to 99.8%)<br/>(a3) 91.2% (67.5% to 97.6%)<br/>(b1) 57.3% (−582% to 97.3%)*<br/>(b2) 76.8% (−468% to 99.1%)*<br/>(b3) 73.5% (−322% to 98.3%)*<br/>(c1) 82.9% (45.6% to 94.6%)<br/>(c2) 96.7% (43.5% to 99.8%)<br/>(c3) 89.4% (66.3% to 96.7%)<br/>(d1) 86.6% (83% to 89.5%)<br/>(d2) 81.4% (75.9% to 85.6%)<br/>(d3) 84.7% (81.4% to 87.4%)<br/>(e1) 79.7% (76.1% to 82.7%)<br/>(e2) 70% (64.6% to 74.5%)<br/>(e3) 76% (72.6% to 78.9%) </p> <p>(*) no statistical evidence</p> <p>VE = (1 − RR) x 100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Adjusted estimates</p> <p>any dose</p> <p>(a) 91% (68% to 99%)</p> <p>(b) not reported</p> <p>(c) 90% (66% to 97%)</p> <p>(d) 71% (66% to 75%)</p> <p>(e) 82% (52% to 93%)</p> <p>VE = 1 − HR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0059" title="LivingstonKA , RosenJB , ZuckerJR , ZimmermanCM . Mumps vaccine effectiveness and risk factors for disease in household during an outbreak in New York City. Vaccine2013;32(3):369-74. [DOI: 10.1016/j.vaccine.2013.11.021]">ca‐Livingston 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 2176 household residents</p> <p>from 2009 to 2010</p> <p>All ages,</p> <p>(age group 1) age ≤ 17 years</p> <p>(age group 2) age ≥ 18 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or<br/>laboratory confirmed, or both </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine: Jeryl Lynn</p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) unknown</p> <p>(d) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age ≤ 17 years</p> <p>(group 1)</p> <p>(1a) 1 dose N = 342</p> <p>(1b) 2 doses N = 361</p> <p>(1c) unknown N = 914</p> <p>(d) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Age ≥ 18 years</p> <p>(2a) 1 dose N = 9</p> <p>(2b) 2 doses N = 97</p> <p>(2c) unknown N = 574</p> <p>(d) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age ≤ 17 years</p> <p>(group 1)</p> <p>N = 126</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Age ≥ 18 years</p> <p>(group 2)</p> <p>N = 6</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages (group 1 + 2)</p> <p>(a) 4/117 versus 4/20</p> <p>(b) 19/691 versus 4/20</p> <p>(c) 17/520 versus 4/20</p> <p>(d) 23/808 versus 4/20</p> <p>Secondary households</p> <p>contacts age ≥ 5 years N = 1348</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages</p> <p>(a) 82.9% (37.1% to 95.4%)</p> <p>(b) 86.3% (63.3% to 94.9%)</p> <p>(c) 83.7% (55.9% to 93.9%)</p> <p>(d) 85.8% (62.7% to 94.6%)</p> <p>VE = (1 − RR) x 100</p> <p>assessed amongst 44</p> <p>secondary cases and</p> <p>1304 non‐sick household contacts</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0060" title="Lopez HernandezB , Martin VelezRM , Roman GarciaC , Penalver SanchezI , Lopez RosiqueJA . An epidemic outbreak of mumps. A study of vaccinal efficacy [Brote epidemico de parotiditis. Estudio de la efectividad vacunal]. Atencion Primaria/Sociedad Española de Medicina de Familia y Comunitaria2000;25(3):148-52. ">ca‐Lopez Hernandez 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male children</p> <p>aged between</p> <p>3 and 15 years</p> <p>attending a scholastic</p> <p>institute in Spain</p> <p>during a mumps outbreak</p> <p>(March to November 1997)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis. Cases notified by the Andalusian survey system.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR strain not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 685</p> <p>vaccination record</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 38</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/685 versus 8/38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (3% to 74%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0061" title="MaC , LiuY , TangJ , JiaH , QinW , SuY , et al. Assessment of mumps-containing vaccine effectiveness during an outbreak: importance to introduce the 2-dose schedule for China. Human Vaccines and Immunotherapy2018;14(6):1392-7. ">ca‐Ma 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conducted between</p> <p>1 December 2014 and</p> <p>20 September 2015.</p> <p>N = 2303 students</p> <p>aged 6 to 15 years.</p> <p>Of these, 114 were excluded</p> <p>because they had history of mumps illness; 281 students were excluded</p> <p>because of unknown immunisation history.</p> <p>N = 1378 vaccinated and</p> <p>unvaccinated</p> <p>N = 530 children included</p> <p>in the analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A mumps case was defined as</p> <p>a student having unilateral or</p> <p>bilateral parotid or other salivary</p> <p>gland swelling and pain, lasting 2 or more days, with onset between</p> <p>1 December 2014 and 20 September 2015.</p> <p>All cases were diagnosed by</p> <p>clinical criteria without laboratory confirmation, and no mumps</p> <p>virus genotype information was obtained during this outbreak investigation.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR:</p> <p>S79 strain of mumps</p> <p>vaccine virus,</p> <p>derived through further attenuation of the Jeryl Lynn strain.</p> <p>Students’ vaccination</p> <p>certificates were obtained during the field investigation.</p> <p>(a) 1 dose</p> <p>(≤ 5 years since vaccination)</p> <p>(b) 1 dose</p> <p>(&gt; 5 years since vaccination)</p> <p>(c) any time since vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 363</p> <p>(b) N = 301</p> <p>(c) N = 664</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unvaccinated</p> <p>N = 530</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 28/363 versus 93/530</p> <p>(b) 21/301 versus 93/530</p> <p>(c) 49/664 versus 93/530</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 56% (34.4% to 70.6%)<br/>(b) 60.2% (37.5% to 74.7%)<br/>(c) 57.9% (41.7% to 69.7%) </p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0063" title="MarollaF , BavieraG , [No Value] Cacciapuoti, CaliaV , CannavavoR , ClementeA , et al. A field study on vaccine efficacy against mumps of three MMR vaccines [Efficacia verso la parotite di tre diversi vaccini a tripla componente: studio sul campo]. Rivista Italiana Di Pediatria1998;24(3):466-72. ">ca‐Marolla 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (19 to 67 months)<br/>whose parent required a<br/>paediatrician visit during a<br/>measles outbreak peak </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>Patient records and</p> <p>parent interviews</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Pluserix/Urabe</p> <p>(b) Morupar/Urabe</p> <p>(c) Triviraten/Rubini</p> <p>Vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 329 (1 dose)</p> <p>(b) N = 747 (1 dose)</p> <p>(c) N = 1023 (1 dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 646</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 38 cases/19433 (PT)</p> <p>(b) 28 cases/12785 (PT)</p> <p>(c) 185 cases/29974 (PT)</p> <p>Control = 206 cases/25,816</p> <p>PT=person‐ time in months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 75% (65% to 83%)</p> <p>(b) 73% (59% to 82%)</p> <p>(c) 23% (6% to 37%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0065" title="NelsonGE , AguonA , ValenciaE , OlivaR , GuerreroML , ReyesR , et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control - Guam 2009 to 2010. Pediatric Infectious Disease Journal2013;32(4):374-80. [PMID: 23099425]">ca‐Nelson 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>During 2009 to 2010 mumps outbreak</b> </p> <p>Children aged 9 to 14 years with a history of 2 MMR vaccine doses,</p> <p>had not previously received</p> <p>a third MMR vaccine dose, and</p> <p>had no history of mumps</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine</p> <p>not described</p> <p>third dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1068</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only 2 doses MMR</b> </p> <p>N = 2171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/1068 versus 5/2171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.3% (−247% to 95.2%)</p> <p><b>VE = (1 − RR) x 100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0066" title="OgbuanuIU , KuttyPK , HudsonJM , BlogD , AbediGR , GoodellS , et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics2012;130(6):e1567-74. [PMID: 23129075]">ca‐Ogbuanu 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>During 2009 to 2010 mumps outbreak</b> </p> <p>Schoolchildren</p> <p>(aged 11 to 17 years) from 3 schools. N = 2665.</p> <p>N = 2178 had validated</p> <p>history of</p> <p>receiving 2 previous</p> <p>doses of MMR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laboratory confirmed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine</p> <p>not described</p> <p>third dose</p> <p>(a) all students with validated 2 doses</p> <p>(b1) postvaccination period 1 to 21 days after third dose</p> <p>(b2) postvaccination period 22 to 41 days after third dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Third dose</p> <p>(a) N = 1755</p> <p>(b1) N = 1751</p> <p>(b2) N = 1723</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Only 2 doses MMR</b> </p> <p>(a) N = 432</p> <p>(b1) N = 420</p> <p>(b2) N = 413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 35/1755 versus 14/432</p> <p>(b1) 28/1751 versus 7/420</p> <p>(b2) 1/1723 versus 2/413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 39.7% (−11.0% to 67.3%)</p> <p>(b1) 4.1% (−118% to 57.8%)</p> <p>(b2) 88% (−31.9% to 98.9%)</p> <p><b>VE = (1 − RR) x 100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0067" title="OngG , GohKT , MaS , ChewSK . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infections2005;51(4):294-8. ">ca‐Ong 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children from childcare centres and<br/>primary schools in Singapore, </p> <p>aged 5 to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis.</p> <p>Standard questionnaire</p> <p>filled by trained public health officer</p> <p>or physician diagnoses.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Jeryl Lynn</p> <p>(b) Urabe</p> <p>(c) Rubini</p> <p>Health booklet</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 711</p> <p>(b) N = 190</p> <p>(c) N = 1694</p> <p>1 or 2 MMR doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 614</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 8/711 versus 35/614</p> <p>(b) 5/190 versus 35/614</p> <p>(c) 150/1694 versus 35/614</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 80.3% (57.8% to 90.8%)</p> <p>(b) 53.8%*</p> <p>(c) −55.3% (−121.8% to −8.8%)</p> <p>VE = (1 − RR) x 100</p> <p>*no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0070" title="SchlegelM , OsterwalderJJ , GaleazziRL , VernazzaPL . Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ1999;319(7206):352. ">ca‐Schlegel 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 13 years<br/>from a small village in Switzerland </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical confirmation</p> <p>after virus isolation</p> <p>or clinical picture observed</p> <p>in sibling of confirmed cases.</p> <p>Parents interview and</p> <p>evaluation by study investigators</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Jeryl Lynn</p> <p>(b) Urabe</p> <p>(c) Rubini</p> <p>Vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 36</p> <p>(b) N = 40</p> <p>(c) N = 79</p> <p>at least 1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 8</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 5/36 versus 5/8</p> <p>(b) 3/40 versus 5/8</p> <p>(c) 53/79 versus 5/8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 78% (64% to 82%)</p> <p>(b) 87% (76% to 94%)</p> <p>(c) −4%</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0071" title="SnijdersBEP , vanLierA , vande KassteeleJ , FanoyEB , RuijsWLM , HulsofF , et al. Mumps vaccine effectiveness in primary schools and household, the Netherlands, 2008. Vaccine2012;30(19):2999-3002. ">ca‐Snijders 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (aged &lt; 19 years)</p> <p>attending</p> <p>(a) primary schools</p> <p>and</p> <p>(b) their household contacts.</p> <p>(c) index case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR Jeryl Lynn</p> <p>or RIT 4385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) (1 dose) N = 484</p> <p>(a2) (2 doses) N = 301</p> <p>(b) (unspecified number of doses) N = 19</p> <p>(c) (any dose) N = 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 351</p> <p>(b) N = 87</p> <p>(c) N = 90</p> <p>unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 13/484 versus 183/351</p> <p>(a2) 7/301 versus 183/351</p> <p>(b) 3/19 versus 44/87</p> <p>(c) 3/16 versus 44/90</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>adjusted data</p> <p>(a1) 9/484 versus 65/351</p> <p>(a2) 7/301 versus 86/351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) 92% (83% to 96%)</p> <p>(a2) 93% (85% to 97%)</p> <p>(b) 67% (65% to 95%)</p> <p>(c) 11% (−4% to 88%)</p> <p>Adjusted for confounders</p> <p>from Poisson regression</p> <p>VE = 1 − incidence rate</p> <p>In order to include "adjusted data", <a href="./references#CD004407-bbs2-0339" title="Di PietrantonjC . Four-fold table cell frequencies imputation in meta analysis. Statistics in Medicine2006;25(13):2299-322. [PMID: 16025540]">Di Pietrantonj 2006</a> method is used to convert adjusted estimates and its 95% CI in "adjusted data". </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0074" title="TaklaA , BohmerMM , KlincC , KurzN , SchafferA , StichH , et al. Outberak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics2014;10(1):140-5. ">ca‐Takla 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary school: 108 students of 5 classes with at least 1 mumps case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical or<br/>laboratory confirmed, or both </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: RIT 4385 or<br/>Jeryl Lynn strain </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) (1 dose) N = 4</p> <p>(b) (2 doses) N = 89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 3/4 versus 5/6</p> <p>(b) 6/89 versus 5/6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 10% (−75% to 53%)</p> <p>(b) 91.9% (81.0% to 96.5%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ARU: attack rate amongst unvaccinated<br/>ARV: attack rate amongst vaccinated<br/>CI: confidence interval<br/>HR: hazard ratio<br/>ICD: International Statistical Classification of Diseases and Related Health Problems<br/>IgM: immunoglobulin M<br/>incidence : cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>N: number of participants<br/>OR: odds ratio<br/>PT: person‐time in months<br/>rr: rate ratio (relative incidence, incidence rate ratio, hazard ratio)<br/>RNA: ribonucleic acid<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Mumps: effectiveness ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0025"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mumps: effectiveness ‐ case‐control studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Controls/selection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR strain/exposure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N cases vaccinated/<br/>N cases<br/>versus<br/>N controls vaccinated/<br/>N controls</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OR (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0012" title="CastillaJ , Fernandez AlonsoM , Garcia CenozM , Martinez ArtolaV , Inigo PestanaM , RodrigoI , et al. Resurgence of mumps in the vaccine era. Factors involved in an outbreak in Navarre, Spain, 2006-2007 [Rebrote de parotiditis en la era vacunal. Factores implicados en un brote en Navarra, 2006-2007]. Medicina Clínica2009;133(20):777-82. CastillaJ , Garcia CenozM , ArriazuM , Fernandez-AlonsoM , Martinez-ArtolaV , EtxeberriaJ , et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine2009;27(15):2089-93. ">ba‐Castilla 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged between 15 months and 10 years from Navarre region</p> <p>(Northern Spain)</p> <p>at the time a mumps outbreak occurred (between August 2006 and June 2008)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 181</p> <p>(b) N = 72</p> <p>(c) N = 241</p> <p>Laboratory or epidemiological<br/>confirmation of clinical cases: </p> <p>swelling of 1 of more salivary glands<br/>for at least 2 days with either laboratory<br/>(PCR or IgM positive) or<br/>epidemiological confirmation<br/>(i.e. epidemiological relation with<br/>other laboratory confirmed or<br/>clinical mumps cases). </p> <p>Obtained from cases notified<br/>to the regional health authority </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 875</p> <p>(b) N = 353</p> <p>(c) N = 1205</p> <p>matched for sex,<br/>municipality,<br/>district of residence, and paediatrician </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) any dose</p> <p>MMR/Jeryl Lynn</p> <p>doses received</p> <p>at least 30 days</p> <p>before symptom</p> <p>disease onset.</p> <p>Blinded review of</p> <p>primary care vaccination</p> <p>registry</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 169/181 versus 852/875</p> <p>(b) 59/72 versus 330/353</p> <p>(c) 228/241 versus 1182/1205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 66% (25% to 85%)</p> <p>(b) 83% (54% to 94%)</p> <p>(c) 72% (39% to 87%)</p> <p>adjusted for confounders</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0015" title="FuC , XuJ , CaiY , HeQ , ZhangC , ChenJ , et al. Effectiveness of one dose of mumps vaccine against clinically diagnoses mumps in Guangzhou, China, 2006-2012. Human Vaccines and Immunotherapeutics2013;9(12):2524-8. [DOI: 10.4161/hv.26113]">ba‐Fu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children in Guangzhou</p> <p>aged 8 months to 12 years</p> <p>during 2006 to 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1983</p> <p>randomly selected clinical definition</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 1983</p> <p>matched 1:1</p> <p>by birth date,</p> <p>gender,</p> <p>residence</p> <p>not reported</p> <p>breakdown</p> <p>by type of vaccine administrated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) MMR/Jeryl Lynn RIT4385</p> <p>(b) measles‐mumps</p> <p>(c) missing (vaccine type)</p> <p>(d) any vaccine</p> <p>1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 112 versus 145</p> <p>(b) 242 versus 261</p> <p>(c) 620 versus 837</p> <p>(d) 974/1983 versus 1243/1983</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) OR extracted from</p> <p>VE reported</p> <p>0.49 (0.26 to 0.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 51.3% (7.2% to 95.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0016" title="GiovanettiF , LaudaniE , MarinaroL , DoglianiMG , GiachelliV , GiachinoG , et al. Evaluation of the effectiveness of mumps immunization during an outbreak [Valutazione dell'efficacia della vaccinazione contro la parotite durante un'epidemia]. Igiene Moderna2002;117(3):201-9. ">ba‐Giovanetti 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents aged 14 months to</p> <p>15 years from urban area of Alba and Bra and 10 rural towns (n = 12,800 residents from 0 to 15 years) </p> <p>during 2000 to 2001 epidemic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>(cases notified by</p> <p>national infectious diseases surveillance system)</p> <p>N = 139</p> <p>notified mumps cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 139 randomly selected from immunisation registry,</p> <p>matched for birth year and address.</p> <p>(controls received<br/>at least 1 MMR dose) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine not specified.</p> <p>Vaccination registry and phone interviews, immunisation</p> <p>should have been received</p> <p>at least 30 days before disease onset.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90/139 versus 111/139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46 (0.27 to 0.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.7% (20.4% to 73.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0017" title="GoncalvesG , De AraujoA , Monteiro CardosoML . Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveillance1998;3(12):119-21. ">ba‐Goncalves 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents</p> <p>(15 months to 16 years)</p> <p>from Oporto (Portugal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>Cases reported by GPs or hospital</p> <p>doctors, occurred during the 1995 to 1996 mumps outbreak</p> <p>(a) N = 73</p> <p>(b) N = 133</p> <p>(c) N = 189</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 consecutive<br/>vaccination records<br/>of the same sex, month and birth year as the case<br/>were selected. </p> <p>(a) N = 169</p> <p>(b) N = 236</p> <p>(c) N = 378</p> <p>Controls received at least 1 MMR dose.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assuming that before 1 November 1992 MMR mumps <b>Urabe</b> strain </p> <p>was administered,</p> <p>subsequently</p> <p>the <b>Rubini</b> strain </p> <p>(a) Urabe</p> <p>(b) Rubini</p> <p>(c) all</p> <p>at least 1 MMR dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 56/73 versus 142/169</p> <p>(b) 116/133 versus 209/236</p> <p>(c) 172/189 versus 351/378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 70% (25% to 88%)</p> <p>(b) 1% (−108% to 53%)</p> <p>adjusted for confounders</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0018" title="HarlingR , WhiteJM , RamsayME , MacsweenKF , vanden BoschC . The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine2005;23(31):4070-4. ">ba‐Harling 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adolescents<br/>aged between 1 and 18 years<br/>from religious community<br/>in Northeast London.<br/>Mumps outbreak </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis</p> <p>N = 156 (GP notification to the local CCDC, mumps diagnoses from electronic practice list, verbal reports by community members) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Laboratory confirmation</p> <p>of clinical diagnosis</p> <p>N = 43</p> <p>GP notification to the local CCDC</p> <p>of notified cases,</p> <p>IgM and mumps RNA</p> <p>testing was offered</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 175<br/>randomly selected<br/>and stratified for<br/>age and sex<br/>from practice list </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Jeryl Lynn</b> 1 or 2 </p> <p>MMR doses</p> <p>received</p> <p>at least 1 month</p> <p>before index date</p> <p>(a) at least 1 dose</p> <p>(b) 1 dose</p> <p>(c) 2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79/156 versus 134/175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0.31 (0.20 to 0.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 69% (50% to 80%) (crude)</p> <p>(a) 69% (41% to 84%)</p> <p>adjusted for age, sex, practice</p> <p>‐‐‐‐‐‐‐‐‐‐</p> <p>Laboratory‐confirmed cases</p> <p>(a) 65% (25% to 84%)</p> <p>(b) 64% (40% to 78%)</p> <p>(c) 88% (62% to 96%)</p> <p>All adjusted for age, sex, practice. Proportion of vaccinated in cases and controls not provided. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0021" title="KimHM , ChoHK , ChoiKM , EunBWY , KimKH . Efficacy of mumps in Korea. International Journal of Infectious Diseases2012;16s:e306. [DOI: 10.1016/j.ijid.2012.05.997]">ba‐Kim 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> <p>(a) prospective</p> <p>case‐control study</p> <p>from March 2010<br/>to October 2011 </p> <p>(b) retrospective</p> <p>case‐control study</p> <p>2008 to 2009 in western Seoul, Incheon, and Goyang</p> <p>(c) total</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 55</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>(a3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b) N = 122</p> <p>(b1) 1 dose</p> <p>(b2) 2 doses</p> <p>(b3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) N = 177</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> <p>(c3) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) N = 165</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>(a3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b) N = 449</p> <p>(b1) 1 dose</p> <p>(b2) 2 doses</p> <p>(b3) any dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) N = 614</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> <p>(c3) any dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described (assumed to be <b>Jeryl Lynn</b> following <a href="./references#CD004407-bbs2-0375" title="ParkSH . Resurgence of mumps in Korea. Infection &amp; Chemotherapy2015;47(1):1-11. [PMID: 25844258]">Park 2015</a>) </p> <p>For (a) and (b):</p> <p>data about demographic characteristics and MMR vaccination status were collected from cases </p> <p>and controls.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐‐‐‐‐‐‐‐‐(a)‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a1) 0.58 (0.05 to 6.90)</p> <p>(a2) 1.1 (0.09 to 13.3)</p> <p>(a3) 0.67 (0.06 to 7.35)</p> <p>‐‐‐‐‐‐‐‐‐‐(b)‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b1) 0.33 (0.02 to 5.33)</p> <p>(b2) 0.11 (0.01 to 2.12)</p> <p>(b3) 0.33 (0.02 to 5.33)</p> <p>‐‐‐‐‐‐‐‐‐(c)‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c1) 0.58 (0.10 to 3.56)</p> <p>(c2) 0.42 (0.06 to 2.81)</p> <p>(c3) 0.50 (0.08 to 2.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐‐‐‐‐‐‐(a)‐‐‐‐‐‐‐‐‐</p> <p>(a1) 42.0%*<br/>(a2) −10.0%*<br/>(a3) 33.0%*<br/>‐‐‐‐‐‐‐‐‐(b)‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(b1) 67.0%*<br/>(b2) 89.0%*<br/>(b3) 67.0%* </p> <p>‐‐‐‐‐‐‐‐‐(c)‐‐‐‐‐‐‐‐‐‐‐<br/>(c1) 42.0%*<br/>(c2) 58.0%*<br/>(c3) 50.0%* </p> <p>*no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0023" title="MackenzieDG , CraigG , HallamNF , MooreJ , StevensonJ . Mumps in a boarding school: description of an outbreak and control measures. British Journal of General Practice2006;56(528):526-9. ">ba‐Mackenzie 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>About 600 pupils attending</p> <p>a boarding school in Scotland</p> <p>during a mumps outbreak that</p> <p>peaked between October and</p> <p>November 2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Virological confirmation<br/>of clinical diagnosis </p> <p>N = 20 (aged 13 to 17 years).</p> <p>Cases notified to consultant<br/>in public health medicine.<br/>Acute cases with virological<br/>positive test </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N = 40<br/>matched for<br/>age, sex,<br/>residential status,<br/>UK or international<br/>students </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> <p>(a) 1 dose</p> <p>(b) 2 doses</p> <p>(c) any dose</p> <p>Not specified. Pre‐outbreak<br/>vaccination status obtained by medical notes held in the school, </p> <p>communication</p> <p>with parents, and</p> <p>from Scottish</p> <p>Immunisation</p> <p>Recall System.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 9/18 versus 20/34</p> <p>(b) 2/11 versus 6/20</p> <p>(c) 11/20 versus 26/40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 0.7 (0.22 to 2.21)</p> <p>(b) 0.52 (0.09 to 3.16)</p> <p>(c) 0.66 (0.22 to 1.97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 30.0%*</p> <p>(b) 48.1%*</p> <p>(c) 32.4%*</p> <p>*no statistical evidence</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CCDC: Consultant in Communicable Disease Control<br/>CI: confidence interval<br/>GP: general practitioner<br/>ICD: International Statistical Classification of Diseases and Related Health Problems<br/>IgM: immunoglobulin M<br/>N: number of participants in intervention and control arm<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PCR: polymerase chain reaction<br/>PT: person‐time<br/>RNA: ribonucleic acid<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mumps: effectiveness ‐ case‐control studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0026"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rubella: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N events in exposed/<br/>N exposed<br/>or person‐months<br/>versus<br/>N events in non‐exposed/<br/>N non‐exposed<br/>or person‐months</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0052" title="ChangC , MoX , HuP , LiangW , MaH , AnZ , et al. Effectiveness of rubella vaccine in a rubella outbreak in Guangzhou city, China, 2014. Vaccine2015;33(28):3223-7. [DOI: 10.1016/j.vaccine.2015.04.083]">ca‐Chang 2015</a> </p> <p>Cohort study</p> <p>Secondary attack rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle school with</p> <p>a total of 1621 students</p> <p>enrolled in the 7th,</p> <p>8th, and 9th grades,</p> <p>with a total of 37 classes (ages 11 to 13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable rubella case: defined as a</p> <p>suspected rubella case with fever &gt; 37.5 °C</p> <p>and at least 1 of the following symptoms:</p> <p>arthralgia, arthritis, lymphadenopathy, or conjunctivitis.</p> <p>Laboratory‐confirmed case: required</p> <p>a positive serologic test for rubella IgM antibody.</p> <p>Epidemiologically linked case: confirmed case</p> <p>was defined as a suspected case or</p> <p>a probable case that was not</p> <p>laboratory confirmed, but that was</p> <p>geographically and temporally</p> <p>related to a laboratory‐confirmed case.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR (BRD‐II or RA27/3)</p> <p>A BRD‐II rubella strain vaccine was</p> <p>developed in the 1980s in China,</p> <p>and has been available in the</p> <p>Chinese private market since1993.</p> <p>All monovalent rubella and measles</p> <p>and rubella combined (MR) vaccines</p> <p>in use in China are based on the BRD‐II rubella</p> <p>strain. A domestic measles, mumps, and rubella</p> <p>combined vaccine (MMR) based on</p> <p>BRD‐II strain has been available in China’s</p> <p>private market since 2003. There is also an imported RA27/3 strain‐based</p> <p>vaccine available in China.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary cases = 2</p> <p>Exposed person = 47</p> <p>RR 0.11 (95% CI 0.03 to 0.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89% (56% to 97%)</p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval<br/>IgM: immunoglobulin M<br/>MMR: measles, mumps, rubella vaccine<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rubella: effectiveness ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0027"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Varicella: effectiveness ‐ RCTs/CCTs</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and<br/>design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>enrolled</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arms<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a> </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study is the first phase</p> <p>(1 September 2005 to 29 June 2009)</p> <p>of an RCT.</p> <p>The study was done in 111</p> <p>study centres in Europe:</p> <p>Czech Republic (22), Greece (11),</p> <p>Italy (9), Lithuania (9), Norway (5),</p> <p>Poland (10), Romania (9), Russia (14),</p> <p>Slovakia (17), and Sweden (5).</p> <p>An eligible participant was a healthy</p> <p>child aged 12 to 22 months at the time of the first vaccination; had a<br/>negative history of varicella, mumps, </p> <p>measles, and rubella diseases and vaccinations; and was one of the following:</p> <p>(1) at home with at least 1 sibling</p> <p>(with negative history</p> <p>of varicella disease and vaccination),</p> <p>(2) attending a child minder</p> <p>(where at least 1 child was without</p> <p>a known positive<br/>history of varicella disease and vaccination), </p> <p>(3) playing for more than 5 min weekly with</p> <p>children without a known positive history of</p> <p>varicella disease and vaccination,<br/>(4) registered to attend </p> <p>a day‐care centre from 24 months of age.</p> <p>An eligible participant’s</p> <p>parents or guardians had direct access</p> <p>to a telephone and were deemed by the<br/>investigator of being capable of </p> <p>complying with the requirements of the trial protocol.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The primary efficacy endpoint was</p> <p>the occurrence of confirmed varicella</p> <p>from 42 days after the second vaccine</p> <p>dose to the end of the first phase of the trial.</p> <p>The secondary efficacy</p> <p>endpoint was</p> <p>the occurrence of confirmed varicella graded by severity</p> <p>over the same time period.</p> <p>Varicella cases</p> <p>(a) All</p> <p>(b) Moderate/severe</p> <p>Follow‐up = 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV group:</p> <p>2 doses of MMRV (Priorix‐Tetra, GSK)</p> <p>N = 2279</p> <p>MMR+V group: 1 dose MMR (Priorix, GSK) and</p> <p>monovalent varicella vaccine</p> <p>(Varilrix, GSK) at dose 2</p> <p>N = 2263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR group (control):</p> <p>2 doses of MMR (Priorix, GSK)</p> <p>N = 743</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV</p> <p>(a) 37/2279</p> <p>(b) 2/2279</p> <p>MMR+V</p> <p>(a) 243/2263</p> <p>(b) 37/2263</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR</p> <p>(a) 201/743</p> <p>(b) 117/743</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV</p> <p>(a) 94.9% (92.4% to 96.6%)</p> <p>(b) 99.5% (97.5% to 99.9%)</p> <p>MMR+V</p> <p>(a) 65.4% (57.2% to 72.1%)</p> <p>(b) 90.7% (85.9% to 93.9%)</p> <p>VE = (1 − HR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0001" title="HenryO , BrzostekJ , CzajkaH , LevinieneG , ReshetkoO , GaspariniR , et al. One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine2018;36(3):381-7. ">aa‐Henry 2018</a> </p> <p>RCT</p> <p>linked to</p> <p><a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy children aged</p> <p>12 to 22 months.</p> <p>n = 5803</p> <p>children enrolled and</p> <p>vaccinated (TVC) in phase A,</p> <p>n = 4580</p> <p>in the TVC in phase B,</p> <p>n = 3829</p> <p>completed the study up to Year 6;</p> <p>n = 5289</p> <p>ATP cohort for efficacy in phase A + B,</p> <p>n = 3791</p> <p>in the ATP cohort for efficacy</p> <p>in phase B</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases</p> <p>(a) All</p> <p>(b) Moderate/severe</p> <p>(c) Severe</p> <p>Follow‐up = 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ATP<br/>cohort for efficacy </p> <p>phase A + B</p> <p>MMRV n = 2279</p> <p>MMR+V n = 2266</p> <p>Phase B</p> <p>MMRV n = 1802</p> <p>MMR+V n = 1593</p> <p>MMRV group</p> <p>2 doses of MMRV</p> <p>(Priorix‐Tetra, GSK) at Day 0 and Day 42</p> <p>MMR+V group</p> <p>1 dose of MMR</p> <p>(Priorix, GSK)</p> <p>at Day 0 and</p> <p>1 dose of monovalent varicella vaccine</p> <p>(Varilrix, GSK)</p> <p>at Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ATP<br/>cohort for efficacy </p> <p>phase A + B<br/>MMR n = 744 </p> <p>Phase B</p> <p>MMR n = 396</p> <p>MMR group</p> <p>2 doses of the MMR</p> <p>(Priorix, GSK) vaccine at Day 0 and Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase A + B</p> <p>MMRV</p> <p>(a) 71/2279</p> <p>(b) 6/2279</p> <p>(c) 0/2270</p> <p>MMR+V</p> <p>(a) 419/2266</p> <p>(b) 58/2266</p> <p>(c) 1/2266</p> <p>Phase B</p> <p>MMRV</p> <p>(a) 33/1800</p> <p>(b) 4/1800</p> <p>(c) 0/1800</p> <p>MMR+V</p> <p>(a) 176/1592</p> <p>(b) 18/1592</p> <p>(c) 0/1592</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phase A + B</p> <p>MMR</p> <p>(a) 325 /744</p> <p>(b) not reported</p> <p>Phase B</p> <p>(a) 125/396</p> <p>(b) not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.0% (93.6% to 96.2%)</p> <p>(b) 99.0% (97.7% to 99.6%)</p> <p>(c) undefined</p> <p><b>MMR+V</b> </p> <p>(a) 67.0% (61.8% to 71.4%)</p> <p>(b) 90.3% (86.9% to 92.8%)</p> <p>(c) 94.6% (55.3% to 99.4%)</p> <p><b>Phase B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.3% (93.1% to 96.8%)</p> <p>(b) 98.4% (95.5% to 99.4%)</p> <p>(c) undefined</p> <p><b>MMR+V</b> </p> <p>(a) 69.5% (61.5% to 75.8%)</p> <p>(b) 91.8% (85.9% to 95.2%)</p> <p>(c) undefined</p> <p>VE = (1 − HR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0002" title="PoveyM , HenryO , Riise BergsakerMA , ChlibekR , EspositoS , FlodmarkCE , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases2019;19(3):287-97. ">aa‐Povey 2019</a> </p> <p>RCT</p> <p>linked to</p> <p><a href="./references#CD004407-bbs2-0003" title="PrymulaR , BergsakerMR , EspositoS , GotheforsL , ManS , SnegovaN , et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet2014;383(9925):1313-24. [PMID: 24485548]">aa‐Prymula 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 22</p> <p>months were eligible</p> <p>for inclusion if: had not received MMR</p> <p>or varicella vaccines, or both, or had measles‐mumps‐rubella</p> <p>or varicella zoster or</p> <p>herpes zoster diseases,</p> <p>or both, and were at home</p> <p>with at least 1 sibling with</p> <p>negative history of varicella</p> <p>disease and vaccination,</p> <p>at a child‐minders where</p> <p>at least 1 child was without</p> <p>a known positive history of</p> <p>varicella disease and vaccination,</p> <p>playing for more than 5 min/week</p> <p>with children without a known positive</p> <p>history of varicella disease</p> <p>and vaccination, or registered</p> <p>to attend day care from 24 months.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases</p> <p>(a) All</p> <p>(b) Moderate/Severe</p> <p>Follow‐up = 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p>MMRV n = 2279</p> <p>MMR+V n = 2266</p> <p><b>Phase B</b> </p> <p>MMRV n = 1800</p> <p>MMR+V n = 1591</p> <p><b>MMRV group</b> </p> <p>2 doses of MMRV</p> <p>(Priorix‐Tetra, GSK)</p> <p>at Day 0 and Day 42</p> <p><b>MMR+V group</b> </p> <p>1 dose of MMR</p> <p>(Priorix, GSK)</p> <p>at Day 0 and</p> <p>1 dose of monovalent</p> <p>varicella vaccine</p> <p>(Varilrix, GSK)</p> <p>at Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b><br/>MMR n = 744 </p> <p><b>Phase B</b> </p> <p>MMR n = 396</p> <p><b>MMR group</b> </p> <p>2 doses of the MMR</p> <p>(Priorix, GSK) vaccine at Day 0 and Day 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMRV</b> </p> <p>(a) 71/2279</p> <p>(b) 6/2279</p> <p><b>MMR+V</b> </p> <p>(a) 469/2266</p> <p>(b) 67/2266</p> <p><b>Phase B</b> </p> <p><b>MMRV</b> </p> <p>(a) 33/1800</p> <p>(b) 4/1800</p> <p><b>MMR+V</b> </p> <p>(a) 176/1592</p> <p>(b) 18/1592</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMR</b> </p> <p>(a) 352/744</p> <p>(b) 176/744</p> <p><b>Phase B</b> </p> <p>(a) 149/396</p> <p>(b) 59/396</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase A + B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.4% (94.0% to 96.4%)</p> <p>(b) 99.1% (97.7% to 99.6%)</p> <p><b>MMR+V</b> </p> <p>(a) 67.2% (62.3% to 71.5%)</p> <p>(b) 89.5% (86.1% to 92.1%)</p> <p><b>Phase B</b> </p> <p><b>MMRV</b> </p> <p>(a) 95.9% (94.1% to 97.1%)</p> <p>(b) 98.7% (96.4% to 99.5%)</p> <p><b>MMR+V</b> </p> <p>(a) 69.8% (62.8% to 75.5%)</p> <p>(b) 90.0% (84.2% to 93.7%)</p> <p><b>VE = (1 − HR) x 100</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ATP: according‐to‐protocol<br/>CI: confidence interval<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>RCT: randomised controlled trial<br/>RR: risk ratio (relative risk)<br/>TVC: total vaccinated cohort<br/>VE: vaccine effectiveness/efficacy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Varicella: effectiveness ‐ RCTs/CCTs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0028"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Varicella: effectiveness ‐ cohort studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine/strain</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N vaccinated<br/>sample size<br/>(dose)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N control</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N events in exposed/<br/>N exposed<br/>or person‐months<br/>versus<br/>N events in non‐exposed/<br/>N non‐exposed<br/>or person‐months</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0055" title="GiaquintoC , GabuttiG , BaldoV , VillaM , TramontanL , RaccanelloN , et al. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy. BMC Infectious Diseases2018;18(1):103. ">ca‐Giaquinto 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 0 to 14 registered with</p> <p>35 Pedianet database physicians</p> <p>across Italy between</p> <p>1 October 1997 and 30 September 1998</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases recorded in the</p> <p>Pedianet databases are based</p> <p>on physician confirmation only</p> <p>(no laboratory tests were performed).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV: vaccine ProQuad</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 2357</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 912 unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43/2357 versus 287/912</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>unadjusted estimate</p> <p>94% (92% to 96%)</p> <p>adjusted estimate</p> <p>94% (91% to 95%)</p> <p><b>VE = (1 −</b> <b>RR) x 100</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0069" title="RieckT , FeigM , An der HeidenM , SiedlerA , WichmannO . Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveillance2017;22(17):30521. ">ca‐Rieck 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Between January 2006</p> <p>and October 2013,</p> <p>n = 1,449,411 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐step algorithm to only select confirmed<br/>and incident varicella cases. </p> <p>Step 1: excluded incompatible or</p> <p>implausible coding combinations for</p> <p>varicella diagnosis reliability;</p> <p>step 2: excluded observations with</p> <p>diagnosis reliability other than confirmed</p> <p>(i.e. suspected, excluded, recovered);</p> <p>step 3: excluded observations</p> <p>with diagnosis</p> <p>type other than incident</p> <p>(i.e. previous state, unknown,</p> <p>not provided);<br/>step 4: limited the data selection </p> <p>to the earliest</p> <p>ICD‐10 code per patient whilst also keeping the information</p> <p>about the most severe</p> <p>ICD‐10 code (within up to one‐quarter</p> <p>following the initial diagnosis) using the</p> <p>following ranking</p> <p>(in descending order of severity):</p> <p>varicella with encephalitis, meningitis,</p> <p>pneumonia, other complications,</p> <p>no complications, no further<br/>details, with the last equalling </p> <p>‘no complications’.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Since 2004, single‐dose</p> <p>varicella vaccination has<br/>been recommended for </p> <p>all children aged 11 to 14 months.</p> <p>2 single‐compound varicella vaccines (VAR; Varivax,<br/>Sanofi Pasteur MSD; Varilrix, GSK) </p> <p>were initially available. In 2006, a combined</p> <p>(MMR)‐varicella vaccine (MMRV;<br/>Priorix‐Tetra, GlaxoSmithKline) </p> <p>was licenced with a 2‐dose schedule.</p> <p>A 2‐dose schedule has been recommended</p> <p>since 2009 targeting children</p> <p>with the second dose at age 15 to 23 months.</p> <p>Since 2011, the first immunisation has been given preferably as 2 separate injections of </p> <p>VAR and MMR due to higher rates of febrile seizures following immunisation with MMRV.</p> <p>(a) 1 dose MMRV</p> <p>(b) 2 doses MMRV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VE = (1 − HR) x 100</b> </p> <p>adjusted estimate</p> <p>(a) 81.7% (81.0% to 82.4%)</p> <p>(b) 94.4% (94.2% to 94.6%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>VE = (1 −</b> <b>RR) x 100</b><br/>RR obtained from HR and attack rate<br/>of varicella in unvaccinated<br/>children, Risk in unvaccinated children = 9% </p> <p>(a) 61.8% (60.6% to 63.0%)<br/>(b) 86.6% (86.1% to 87.0%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0072" title="SpackovaM , Wiese-PosseltM , DehnertM , Matysiak-KloseD , HeiningerU , SiedlerA . Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine2010;28(3):686-91. ">ca‐Spackova 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1084 children attended day‐care centres in Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella was classified clinically as</p> <p>mild (&lt; 50 skin lesions),</p> <p>moderate (≥ 50 skin lesions),</p> <p>severe (any hospitalised case).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV Priorix‐Tetra</p> <p>(a) All‐brand doses</p> <p>(b1) All‐brand 1 dose</p> <p>(b2) All‐brand 2 dose</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) Varivax 1 dose</p> <p>(d) Varilrix 1 dose</p> <p>(e1) Priorix‐Tetra 1 dose</p> <p>(e2) Priorix‐Tetra 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(f1) Mild disease</p> <p>(f2) Moderate disease</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 244</p> <p>(b1) n = 167</p> <p>(b2) n = 77</p> <p>(c) n = 48</p> <p>(d) n = 77</p> <p>(e1) n = 38</p> <p>(e2) n = 56</p> <p>(f1) n = 233</p> <p>(f2) n = 221</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 108</p> <p>(f1) n = 71</p> <p>(f2) n = 93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 33/244 versus 52/108</p> <p>(b1) 31/167 versus 52/108</p> <p>(b2) 2/77 versus 52/108</p> <p>(c) 4/48 versus 52/108</p> <p>(d) 19/77 versus 52/108</p> <p>(e1) 7/38 versus 52/108</p> <p>(e2) 2/56 versus 52/108</p> <p>(f1) 22/233 versus 15/71</p> <p>(f2) 10/221 versus 37/93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 71% (57% to 81%)</p> <p>(b1) 62% (43% to 75%)</p> <p>(b2) 94% (75% to 98%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c) 86% (56% to 96%)</p> <p>(d) 56% (29% to 72%)</p> <p>(e1) 55% (8% to 78%)</p> <p>(e2) 91% (65% to 98%)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(f1) 53% (14% to 75%)</p> <p>(f2) 89% (78% to 95%)</p> <p>adjusted for confounders</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> <p>VE = (1 − RR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0073" title="TafuriS , MartinelliD , PratoR , GerminarioC . Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in region which adopted UMV. Human Vaccines and Immunotherapeutics2013;9(1):184-8. ">ca‐Tafuri 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children at</p> <p>(a) preschool</p> <p>(b) elementary school</p> <p>(c) all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported by<br/>parents </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV</p> <p>(Priorix‐Tetra)</p> <p>Varicella OKA;</p> <p>1 dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 170</p> <p>(b) n = 71</p> <p>(c) n = 241</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) n = 40</p> <p>(b) n = 287</p> <p>(c) n = 327</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 2/170 versus 14/40</p> <p>(b) 2/71 versus 223/287</p> <p>(c) 4/241 versus 237/327</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Not reported</p> <p>(b) 69.2% (50.5% to 88.1%)</p> <p>(c) 59.9% (48.3% to 69.8%)</p> <p>VE = (ARU − ARV)/ARU x 100</p> <p><a href="./references#CD004407-bbs2-0371" title="OrensteinWA , BernierRH , DonderoTJ , HinmanAR , MarksJS , BartKJ , et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization1985;63(6):1055-68.">Orenstein 1985</a> </p> <p>VE = (1 − RR) x 100</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ARU: attack rate amongst unvaccinated<br/>ARV: attack rate amongst vaccinated<br/>CI: confidence interval<br/>ICD‐10: International Classification of Diseases, Tenth Revision<br/>HR: hazards ratio<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>RR: risk ratio (relative risk)<br/>VE: vaccine effectiveness/efficacy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Varicella: effectiveness ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0029"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Varicella: effectiveness ‐ case‐control studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Controls/selection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR strain/exposure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N cases vaccinated/N cases<br/>versus<br/>N controls vaccinated/N controls</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OR (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0011" title="AndradeAL , da Silva VieiraMA , MinamisavaR , ToscanoCM , deLima SouzaMB , FiaccadoriF , et al. Single-dose varicella vaccine effectiveness in Brazil: a case-control study. Vaccine2018;36(4):479-83. [PMID: 29249544]">ba‐Andrade 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From November 2013 to December 2015,<br/>children aged 15 to 32 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases were defined as</p> <p>children aged 15 to 32 months with rash and either suspected</p> <p>as having varicella by an attending physician or being a contact to a confirmed varicella case. Cases were confirmed by either clinical or laboratory criteria. </p> <p><b>Cases:</b> n = 168 </p> <p>Cases were further classified by</p> <p>severity of disease based on number of skin lesions, being:</p> <p>(1) mild – fewer than 50 lesions;</p> <p>(2) mild/moderate – between 50 and 249 lesions;</p> <p>(3) moderate – between 250 and 499 lesions; or</p> <p>(4) severe – 500 lesions or more, having been hospitalised, or having any complication.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Controls matched 1:2 by:</p> <p>age (15 to 32 months).<br/>Controls were defined as<br/>children residing in the </p> <p>neighbourhood of the case,</p> <p>in which no history of varicella or outpatient clinics visits</p> <p>due to skin lesion was reported. To identify controls,</p> <p>houses nearby the cases</p> <p>were visited following a systematic sampling procedure.</p> <p><b>Controls:</b> n = 301 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b> </p> <p>A combined tetravalent vaccine containing measles, mumps, rubella,</p> <p>and varicella antigens (MMRV), manufactured by GlaxoSmithKline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Any severity<br/>(b) Moderate severe cases &gt; 50 lesions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted‐estimates</p> <p>(a) 0.14 (0.07 to 0.28)</p> <p>(b) 0.07 (0.03 to 0.18)</p> <p>adjusted for confounders:<br/>age in months, day‐care attendance, and pulmonary diseases </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 86% (72% to 92%)</p> <p>(b) 93% (82% to 97%)</p> <p>VE = 1 − OR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0013" title="CenozMG , Martinez-ArtolaV , GuevaraM , EzpeletaC , BarricarteA , CastillaJ . Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Human Vaccines and Immunotherapeutics2013;9(5):1172-6. [DOI: 10.4161/hv.23451]">ba‐Cenoz 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children between 15 months and 10 years of age</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR‐confirmed varicella</p> <p>Cases n = 54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matched 1:8 by paediatric practice, district of residence, and date of birth (± 1 year) </p> <p>Controls n = 432</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR+V</b> (Varivax OKA/Merck) </p> <p>not described</p> <p>(a) any doses and age</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>(b) age &lt; 3 years</p> <p>(b1) 1 dose</p> <p>(c) age ≥ 3 years</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 6/54 versus 175/432</p> <p>(a1) 5/54 versus 112/432</p> <p>(a2) 1/54 versus 63/432</p> <p>(b1) 1/6 versus 36/48</p> <p>(c1) 4/48 versus 76/384</p> <p>(c2) 1/48 versus 63/384</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted estimates</p> <p>(a) 92% (77% to 97%)</p> <p>(a1) 87% (60% to 97%)</p> <p>(a2) 97% (79.5% to 99.6%)</p> <p>(b1) 84% (−58% to 100%)(*)</p> <p>(c1) 80% (37% to 95%)</p> <p>(c2) 97% (79% to 100%)</p> <p>VE = (1 −OR) x 100</p> <p>(*) no statistical evidence</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0022" title="LieseJG , CohenC , RackA , PirzerK , EberS , BlumM , et al. The effectiveness of varicella vaccination in children in Germany. Pediatric Infectious Disease Journal2013;32(9):998-1004. [DOI: 10.1097/INF.0b013e31829ac263]">ba‐Liese 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children at least 1 year of age, born on or after 1 July 2003, who resided in Germany</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR‐confirmed varicella</p> <p>n = 432</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children matched by</p> <p>age and paediatric practice,</p> <p>fulfilling the same criteria</p> <p>as cases but without</p> <p>history or present clinical</p> <p>diagnosis of varicella</p> <p>n = 432</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any varicella vaccine</p> <p>(a1) 1 dose</p> <p>(a2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>OKA/GSK</p> <p>(b1) 1 dose</p> <p>(b2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Other than OKA/GSK*</p> <p>(c1) 1 dose</p> <p>(c2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Unknown vaccine</p> <p>(d1) 1 dose</p> <p>(d2) 2 doses</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Any varicella vaccine</p> <p>(after vaccination)</p> <p>(y1) up to 1 year</p> <p>(y2) 1 to 2 year</p> <p>(y3) 4 to 5 year</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(*) includes OKA/Merck<br/>and MMR‐OKA/GSK </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 57/432 versus 195/432</p> <p>(a1) 55/430 versus 153/390</p> <p>(a2) 2/377 versus 42/279</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b1) 35/410 versus 63/300</p> <p>(b2) 0/375 versus 6/243</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(c1) 19/394 versus 87/324</p> <p>(c2) 2/377 versus 25/262</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(d1) 1/376 versus 3/240</p> <p>(d2) 0/375 versus 11/248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted estimates</p> <p>(a1) 86.4% (77.3% to 91.8%)</p> <p>(a2) 94.3% (76.4% to 98.6%)</p> <p>(b1) 71.5% (49.1% to 84.0%)</p> <p>(b2) not reported</p> <p>(c1) not reported</p> <p>(c2) not reported</p> <p>(d1) not reported</p> <p>(d2) not reported</p> <p>(y1) 94.5% (76.9% to 98.7%)</p> <p>(y2) 81.5% (56.8% to 92.1%)</p> <p>(y3) 73.2% (9.1% to 92.1%)</p> <p>VE = (1 − OR) x 100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0024" title="VazquezM , La RussaPS , GershonAA , StainbergSP , FreudigmanK , ShapiroE . The effectiveness of the varicella vaccine in clinical practice. New England Journal of Medicine2001;344(13):955-60. [DOI: 10.1056/NEJM200103293441302]">ba‐Vazquez 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children between 13 months and 16 years of age.</p> <p>(a) &lt; 5 years old</p> <p>(b) 5 to 10 years old</p> <p>(c) &gt; 10 years old</p> <p>(d) all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR‐confirmed varicella</p> <p>n = 202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Matched 1:2 according to date of birth (within 1 month) and paediatric practice</p> <p>n = 389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR+V</b> </p> <p>Vaccine type and<br/>number of doses not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/202 versus 238/389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted estimates</p> <p>(a) 79% (61% to 89%)</p> <p>(b) 89% (80% to 94%)</p> <p>(c) 92% (45% to 99%)</p> <p>(d) 87% (78% to 90%)</p> <p>VE = (1 − OR) x 100</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval<br/>IgM: immunoglobulin M<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, and varicella vaccine<br/>n: number of participants in intervention and control arm<br/>OR: odds ratio<br/>PCR: polymerase chain reaction<br/>VE: vaccine effectiveness/efficacy<br/>WHO: World Health Organization </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Varicella: effectiveness ‐ case‐control studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0030"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Varicella: effectiveness ‐ case‐only ecological method studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population characteristics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Case definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>VE% (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0128" title="BoccaliniS , BonanniP , BechiniA . Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004–2012. Euro Surveillance2015;21:1-7. [DOI: 10.2807/1560-7917.ES.2016.21.24.30257]">ga‐Boccalini 2015</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation between 2004 to 2012 in the Tuscan region.</p> <p>Aged 0 to 14 years</p> <p>(a) age &lt; 1 year</p> <p>(b) age 1 to 4 years</p> <p>(c) age 5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised cases for varicella</p> <p>or its complications, as a primary or secondary discharge diagnosis, with the following ICD‐9‐CM </p> <p>codes (2002 and 2007) were examined:<br/>052.0 (post‐varicella encephalitis),<br/>052.1 (varicella (haemorrhagic) pneumonitis),<br/>052.2 (post‐varicella myelitis),<br/>052.7 (varicella with other specified complications),<br/>052.8 (varicella with unspecified complication),<br/>052.9 (varicella without complication). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV vaccine: not described</p> <p>and monovalent varicella vaccine</p> <p>Reference period</p> <p>2004 to 2007</p> <p>Exposed period</p> <p>2009 to 2012</p> <p>Data from 2008, the transition year<br/>between the 2 periods, were excluded from our analysis in this study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reference period</p> <p>(a) 73/122,483</p> <p>(b) 189/478,481</p> <p>(c) 105/1,141,304</p> <p>Exposed period</p> <p>(a) 42/128,440</p> <p>(b) 99/523,810</p> <p>(c) 55/1,222,222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR (95% CI) (*)</p> <p>(a) 0.55 (0.38 to 0.80)</p> <p>(b) 0.48 (0.38 to 0.61)</p> <p>(c) 0.48 (0.35 to 0.67)</p> <p>(*) Relative risk</p> <p>between exposed and reference period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VE = 1 −</b> RR </p> <p>(a) 45.1% (19.8% to 62.5%)<br/>(b) 52.2% (39% to 62.5%)<br/>(c) 51.1% (32.2% to 64.7%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0129" title="PozzaF , PiovesanC , RussoF , BellaA , PezzottiP , Emberti GialloretiL . Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine2011;29(51):9480-7. [PMID: 22015389]">ga‐Pozza 2011</a><br/>Case‐only ecological method </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation between 2000 to 2008 in the Veneto region.</p> <p>Aged 0 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Varicella cases incidence:</p> <p>(a) from surveillance data retrieved</p> <p>from the RDP</p> <p>(b) sentinel surveillance system</p> <p>based on a sample of paediatricians</p> <p>(SPES).</p> <p>Hospitalised cases for varicella</p> <p>hospital discharges that reported<br/>in the primary and secondary </p> <p>diagnoses codes 052.X.</p> <p>Admissions</p> <p>with coexistent codes</p> <p>for herpes zoster, i.e. 053.X, were excluded.</p> <p>(c) hospitalisations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV vaccine: not described</p> <p>and monovalent varicella vaccine</p> <p>Reference period</p> <p>2000 to 2006</p> <p>Exposed period</p> <p>2007 to 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases/person time</p> <p>(RDP) incidence</p> <p>reference period</p> <p>(a) 81,276/438,3097</p> <p>Exposed period</p> <p>(a) 14,749/1,345,351</p> <p>(SPES) incidence</p> <p>reference period</p> <p>(b) 13,543/196,949</p> <p>Exposed period</p> <p>(b) 1344/26,861</p> <p>Hospitalised</p> <p>reference period</p> <p>(c) 770/4,383,497</p> <p>Exposed period</p> <p>(c) 126/1,348,474</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rr (95% CI)</p> <p>(a) 0.59 (0.58 to 0.6)<br/>(b) 0.73 (0.69 to 0.77)<br/>(c) 0.53 (0.44 to 0.64) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a1) 0.44 (0.43 to 0.45)<br/>(b1) 0.58 (0.53 to 0.64)<br/>(c1) 0.48 (0.37 to 0.63) </p> <p>Sensitivity analysis</p> <p>Data from 2007,<br/>the transition year<br/>between the 2 periods,<br/>were excluded from analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VE = (1 − rr) x 100</p> <p>(a) 40.9% (39.8% to 41.9%)<br/>(b) 27.2% (23% to 31.2%)<br/>(c) 46.8% (35.8% to 55.9%) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a1) 56.2% (54.9% to 57.3%)<br/>(b1) 41.8% (36.2% to 46.8%)<br/>(c1) 52.2% (37.4% to 63.5%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0130" title="TafuriS , FortunatoF , CappelliMG , CozzaV , BechiniA , BonanniP , et al. Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012. Human Vaccines and Immunotherapy2015;11(1):214-9. [DOI: 10.4161/hv.36153]">ga‐Tafuri 2015</a><br/>Case‐only ecological method </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation between 2003 to 2012 in the Puglia region.</p> <p>Aged 0 to 14 years</p> <p>(a) age &lt; 1 year</p> <p>(b) age 1 to 4 years</p> <p>(c) age 5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised cases for varicella</p> <p>Hospitalisation rates, overall and specific by<br/>age, were calculated on data extracted </p> <p>from the regional HDR, selecting</p> <p>all hospital admissions with<br/>a main diagnosis of chickenpox </p> <p>or its complications (ICD9‐CM<br/>codes: 052.x) in the same period. </p> <p>Incidence rates, overall and specific by age,</p> <p>between 2003<br/>and 2012 were calculated by using data </p> <p>collected in the Apulian<br/>computerised surveillance system </p> <p>for communicable diseases.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV vaccine: not described</p> <p>and monovalent varicella vaccine</p> <p>Reference period</p> <p>2003 to 2005</p> <p>Exposed period</p> <p>2009 to 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised</p> <p>reference period</p> <p>(a) 245/39,618</p> <p>(b) 2148/163,321</p> <p>(c) 2201/451,858</p> <p>Exposed period</p> <p>(a) 39/37,356</p> <p>(b) 161/152,607</p> <p>(c) 289/420,058</p> <p>Incidence</p> <p>reference period</p> <p>(a) 14/39,548</p> <p>(b) 57/1,623,931</p> <p>(c) 42/446,809</p> <p>Exposed period</p> <p>(a) 5/39,063</p> <p>(b) 9/160,714</p> <p>(c) 10/434,783</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rr (95% CI)(*)</p> <p>Hospitalised</p> <p>(a) 0.17 (0.12 to 0.24)</p> <p>(b) 0.08 (0.07 to 0.09)</p> <p>(c) 0.14 (0.12 to 0.16)</p> <p>Incidence</p> <p>(a) 0.36 (0.13 to 1.03)</p> <p>(b) 0.16 (0.08 to 0.33)</p> <p>(c) 0.25 (0.12 to.050)</p> <p>(*) Relative risk</p> <p>between exposed and reference period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VE = (1 − rr) x 100</p> <p>Hospitalised</p> <p>(a) 63.8% (−0.4% to 87%)<br/>(b) 84% (67.8% to 92.1%)<br/>(c) 75.5% (51.2% to 87.7%) </p> <p>Incidence</p> <p>(a) 83.1% (76.3% to 88%)<br/>(b) 92% (90.6% to 93.2%)<br/>(c) 85.9% (84% to 87.5%) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>HDR: hospital discharge registry<br/>ICD‐9‐CM<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>n: number of participants in intervention and control arm<br/>RDP: Regional Department of Prevention<br/>SPES: Sorveglianza PEdiatric Sentinella<br/>VE: vaccine effectiveness/efficacy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Varicella: effectiveness ‐ case‐only ecological method studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0031"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions) ‐ RCTs/CCTs</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>enrolled</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR vaccine arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other vaccine arms<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>events/n</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0004" title="BloomJL , SchiffGM , GraubarthH , Lipp RW Jr, JacksonJE , OsbornRL , et al. Evaluation of a trivalent measles, mumps, rubella vaccine in children. Journal of Pediatrics1975;87(1):85-7. ">ab‐Bloom 1975</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>11 months to 4 years</p> <p>Observation period</p> <p>21 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine</p> <p>Measles Schwarz</p> <p>Mumps Jeryl Lynn</p> <p>Rubella Cendehill</p> <p>n = 183</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Temperature<br/>above normal </p> <p>sample size</p> <p>n = 160</p> <p>Normal temperature</p> <p>rectal 99.6 °F (37.5 °C)</p> <p>(163 children)</p> <p>Oral 98.6 °F (37 °C)</p> <p>(6 children)</p> <p>Axillary 97.6 °F<br/>(36.4 °C)<br/>(26 children) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> <p>n = 40</p> <p>‐‐‐‐‐‐‐‐‐‐</p> <p>Temperature</p> <p>sample size</p> <p>n = 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Rash</p> <p>(b) Lymphadenopathy<br/>(c) Coryza </p> <p>(d) Rhinitis</p> <p>(e) Cough</p> <p>(f) Other</p> <p>total</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> <br/><b>above normal</b> </p> <p>(a) 1.5 to 2.4 °F</p> <p>(b) 2.5 to 3.4 °F</p> <p>(c) 3.5 to 4.4 °F</p> <p>(d) 4.5 to 4.9 °F</p> <p>(e) ≥ (normal + 1.5) °F</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>(a) 22/183</p> <p>(b) 2/183</p> <p>(c) 4/183</p> <p>(d) 2/183</p> <p>(e) 5/183</p> <p>(f) 35/183</p> <p>total 70/183</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> </p> <p><b>above norma</b>l </p> <p>(a) 17/160</p> <p>(b) 1/160</p> <p>(c) 5/160</p> <p>(d) 2/160</p> <p>(e) 25/160</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>(a) 2/40</p> <p>(b) 1/40</p> <p>(c) 4/40</p> <p>(d) 4/40</p> <p>(e) 1/40</p> <p>(f) 8/40</p> <p>total 20/40</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> </p> <p><b>above norma</b>l </p> <p>(a) 2/35</p> <p>(b) 2/35</p> <p>(c) 0/35</p> <p>(d) 0/35</p> <p>(e) 4/35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0005" title="CeyhanM , KanraG , ErdemG , KanraB . Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine2001;19(31):4473-8. ">ab‐Ceyhan 2001</a>; </p> <p>CCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants aged</p> <p>38 to 40 months</p> <p>Observation period</p> <p>28 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm A: n = 442</p> <p>(1) MV/Rouvax</p> <p>Measles Schwarz</p> <p>at 9 months;</p> <p>and</p> <p>(2) MMR/Trimovax</p> <p>Measles Schwarz</p> <p>Mumps Urabe AM9</p> <p>Rubella Wistar RA 27/3</p> <p>at 15 months</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Arm B: n = 495</p> <p>(3) MMR/Trimovax</p> <p>Measles Schwarz</p> <p>Mumps Urabe AM9</p> <p>Rubella Wistar RA 27/3</p> <p>at 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No placebo arm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic reactions</b> </p> <p>(a) Fever</p> <p>(b) Runny nose</p> <p>(c) Cough</p> <p>(d) Rash</p> <p>(e) Diarrhoea</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Local</b> </p> <p>(f) Redness</p> <p>(g) Swelling</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Total events</b> </p> <p>(x) Fever</p> <p>(y) Systemic</p> <p>(z) Local</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>(2)15 months; (3)12 months</b> </p> <p>(a) 40/442; 55/495</p> <p>(b) 7/442; 22/495</p> <p>(c) 36/442; 34/495</p> <p>(d) 16/442; 19/495</p> <p>(e) 2/442; 5/495</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Local</b> </p> <p><b>(2)15 months; (3)12 months</b> </p> <p>(f) 14/442; 19/495</p> <p>(g) 2/442; 3/495</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Total events</b> </p> <p><b>(2)15 months; (3)12 months</b> </p> <p>(x) 40/442; 55/495</p> <p>(y) 61/442; 80/495</p> <p>(z) 16/442; 22/495</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MV vaccine</b> </p> <p>(1) 9 months</p> <p>(a) 38/442</p> <p>(b) 19/442</p> <p>(c) 28/442</p> <p>(d) 2/442</p> <p>(e) 5/442</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Local</b> </p> <p>(f) 7/442</p> <p>(g) 2/442</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Total events</b> </p> <p>(x) 38/442</p> <p>(y) 54/442</p> <p>(z) 9/442</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0006" title="EdeesS , PullanCR , HullD . A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health1991;105(2):91-7. ">ab‐Edees 1991</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>12 to 18 months.</p> <p>Observation period</p> <p>21 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arm A:</b> n = 196 </p> <p>MV/Rouvax</p> <p>Measles Schwarz</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Arm B:</b> n = 198 </p> <p>MMR/Trimovax</p> <p>Measles Schwarz</p> <p>Mumps Urabe AM9</p> <p>Rubella Wistar RA 27/3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No placebo arm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local symptoms</b> <br/>(a) Erythema<br/>(b) Induration<br/>(c) Pain </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Specific systemic</b> <br/>(a) Rash<br/>(b) Parotitis<br/>(c) Conjuntivitis<br/>(d) Testicular swelling<br/>(e) Arthralgia<br/>(f) Arthritis<br/>(g) Convulsion </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>N<b>on‐specific systemic</b> <br/>(a) Fever<br/>(b) Adenopathy<br/>(c) Nasopharyngeal disorders<br/>(d) Gastrointestinal disorders<br/>(e) Restlessness </p> <p><b>Restlessness:</b> </p> <p>used to describe a non‐specifically</p> <p>unwell child; it covers terms such as irritable</p> <p>miserable tearful clingy not sleeping.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine (Arm B)</b> </p> <p><b>Local</b> </p> <p>(a) 18/198<br/>(b) 1/198<br/>(c) 9/198 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Specific systemic</b><br/>(a) 87/198<br/>(b) 5/198<br/>(c) 17/198<br/>(d) 0/198<br/>(e) 0/198<br/>(f) 0/198<br/>(g) 0/198 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Non‐specific systemic</b> </p> <p>(a) 76/198<br/>(b) 2/198<br/>(c) 113/198<br/>(d) 83/198<br/>(e) 124/198 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MV vaccine (Arm A)</b> </p> <p><b>Local</b> </p> <p>(a) 16/196</p> <p>(b) 0/196</p> <p>(c) 14/196</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Specific systemic</b> </p> <p>(a) 100/196<br/>(b) 0/196<br/>(c) 21/196<br/>(d) 0/196<br/>(e) 0/196<br/>(f) 0/196<br/>(g) 0/196 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Non‐specific systemic</b> </p> <p>(a) 74/196<br/>(b) 3/196<br/>(c) 115/196<br/>(d) 74/196<br/>(e) 147/196 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0008" title="LermanSJ , BollingerM , BrunkenJM . Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics1981;68(1):18-22. ">ab‐Lerman 1981</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>15 months to 5 years</p> <p>Observation period</p> <p>42 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arm(1): n = 43:<br/>Measles (MSD) </p> <p>Arm(2): n = 41:<br/>Mumps (MSD)<br/>Jeryl Lynn </p> <p>Arm(3): n = 47:<br/>Rubella HPV‐77:CE‐5 </p> <p>Arm(4): n = 142<br/>MMR (MSD)<br/>with Rubella HPV‐77:DE‐5 </p> <p>Arm(5): n = 46:</p> <p>Rubella/Wistar RA27/3</p> <p>Arm(6): n = 141:<br/>MMRII (MSD)<br/>with Rubella Wistar RA27/3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm<br/>n = 42 </p> <p>(vaccine diluent)<br/>1 dose<br/>subcutaneously </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Local reaction</p> <p>(b) Fever<br/>101 to 102.9 °F<br/>(fever 38.3 to 39.4 °C) </p> <p>(c) Fever<br/>103 to 104.9 °F </p> <p>(fever 39.4 to 40.5 °C)</p> <p>(d) Respiratory symptoms</p> <p>(e) Rash</p> <p>(f) Lymphadenopathy</p> <p>(g) Sore eyes</p> <p>(h) Joint symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> <br/><b>Arms: (4); (6)</b><br/>(a) 7/142; 11/141<br/>(b) 31/142; 35/141<br/>(c) 11/142; 16/141<br/>(d) 97/142; 102/141<br/>(e) 24/142; 28/141<br/>(f) 6/142; 11/141<br/>(g) 24/142; 23/141<br/>(h) 1/142; 1/141 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other vaccine arms: (1); (2); (3); (5)</b> </p> <p>(a) 1/43; 6/41; 3/47; 2/46<br/>(b) 12/43; 6/41; 6/47; 11/46<br/>(c) 2/43; 3/41; 3/47; 2/46<br/>(d) 34/43; 26/41; 31/47; 31/46<br/>(e) 5/43; 1/41; 6/47; 5/46<br/>(f) 1/43; 2/41; 2/47; 2/46<br/>(g) 6/43; 8/41; 8/47; 8/46<br/>(h) 0/43; 0/41; 0/47; 0/46 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>(a) 3/42<br/>(b) 10/42<br/>(c) 0/42<br/>(d) 31/42<br/>(e) 4/42<br/>(f) 0/42<br/>(g) 4/42<br/>(h) 0/42 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0009" title="PeltolaH , HeinonenOP . Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1986;1(8487):939-42. ">ab‐Peltola 1986</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pairs of twins aged</p> <p>(a) 14 to 18 months (first dose)</p> <p>(b) 6 years (second dose)</p> <p>Observation period</p> <p>21 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>Vivirac (MSD)</p> <p>2 doses</p> <p>n = 581</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm<br/>n = 581 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for quantitative synthesis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0010" title="EhrenkranzNJ , VenturaAK , MedlerEM , JacksonJE , KennyMT . Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic. Bulletin of the World Health Organization1975;52(1):81-5. Ramos-AlvarezM , BessudoL , KennyMT , JacksonJE , SchwarzAJ . Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella [Administracion simultanea en diferentes dosificaciones de las vacunas de virus vivos atenuados contra el sarampion, parotiditis y rubeola]. Boletín Médico del Hospital Infantil de México1976;33(4):875-86. SchwarzAJ , JacksonJE , EhrenkranzNJ , VenturaA , SchiffGM , WaltersVW . Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. American Journal of Diseases of Children1975;129(12):1408-12. WaltersVW , MillerSA , JacksonJE , KennyMT . A field with a liver measles-mumps-rubella vaccine. Clinical Pediatrics1975;14(10):928-33. ">ab‐Schwarz 1975</a>; </p> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>10 months to 8 years</p> <p>Observation period<br/>21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>Measles Schwarz</p> <p>Mumps Jeryl Lynn</p> <p>Rubella Cendehill</p> <p>n = 403</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm</p> <p>n = 205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Temperature</b> <br/><b>(1) Axillary</b> </p> <p><b>(2) Rectal</b> </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) &lt; 37.0 °C</p> <p>(b) 37.0 to 37.4 °C</p> <p>(c) &lt; 37.5 °C</p> <p>(d) 37.5 to 37.9 °C</p> <p>(e) 38.0 to 38.4 °C</p> <p>(f) 38.5 to 38.9 °C</p> <p>(g) 39.0 to 39.4 °C</p> <p>(h) 39.5 to 39.9 °C</p> <p>(i) 40.0 to 40.4 C°</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Reactions</b> </p> <p>(s1) Rash<br/>(s2) Lymphadenopathy<br/>(s3) Conjunctivitis<br/>(s4) Otitis media<br/>(s5) Coryza<br/>(s6) Rhinitis<br/>(s7) Pharyngitis<br/>(s8) Cough<br/>(s9) Headache<br/>(s10) Parotitis<br/>(s11) Orchitis<br/>(s12) Arthralgia<br/>(s13) Paraesthesia </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>(1) Temperature axillary</b> </p> <p>(a) 56/244</p> <p>(b) 154/244</p> <p>(c) 210/244</p> <p>(d) 21/244</p> <p>(e) 6/244</p> <p>(f) 2/244</p> <p>(g) 3/244</p> <p>(h) 2/244</p> <p>(i) 0/244</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(2) Temperature rectal</b> </p> <p>(a) not reported</p> <p>(b) not reported</p> <p>(c) 48/142</p> <p>(d) 51/142</p> <p>(e) 30/142</p> <p>(f) 8/142</p> <p>(g) 1/142</p> <p>(h) 1/142</p> <p>(i) 3/142</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Reactions</b> </p> <p>(s1) 36/403<br/>(s2) 4/403<br/>(s3) 8/403<br/>(s4) 4/403<br/>(s5) 8/403<br/>(s6) 69/403<br/>(s7) 2/403<br/>(s8) 7/403<br/>(s9) 1/403<br/>(s10) 0/403<br/>(s11) 0/403<br/>(s12) 1/403<br/>(s13) 0/403 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p><b>(1) Axillary temperature</b> </p> <p>(a) 32/176</p> <p>(b) 132/176</p> <p>(c) 164/176</p> <p>(d) 9/176</p> <p>(e) 2/176</p> <p>(f) 1/176</p> <p>(g) 0/176</p> <p>(h) 0/176</p> <p>(i) 0/176</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(2) Rectal temperature</b> </p> <p>(a) Not reported</p> <p>(b) Not reported</p> <p>(c) 6/28</p> <p>(d) 13/28</p> <p>(e) 6/28</p> <p>(f) 1/28</p> <p>(g) 2/28</p> <p>(h) 0/28</p> <p>(i) 0/28</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Reactions</b> </p> <p>(s1) 9/205<br/>(s2) 4/205<br/>(s3) 5/205<br/>(s4) 1/205<br/>(s5) 5/205<br/>(s6) 59/205<br/>(s7) 2/205<br/>(s8) 1/205<br/>(s9) 1/205<br/>(s10) 0/205<br/>(s11) 0/205<br/>(s12) 0/205<br/>(s13) 0/205 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0007" title="FreemanTR , StewartMA , TurnerL . Illness after measles-mumps-rubella vaccination. Canadian Medical Association Journal1993;149(11):1669-74. ">ab‐Freeman 1993</a>; </p> <p>Cluster‐RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>13 to 15 months</p> <p>Observation period</p> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>MMRII</b> (MSD) </p> <p>n = 253</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No placebo arm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Lymphadenopathy</p> <p>(b) Nasal discharge</p> <p>(c) Rash<br/>(d) Otitis media<br/>(e) Conjunctival abnormality<br/>(f) Abnormal tonsils </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) 57/240</p> <p>(b) 15/240</p> <p>(c) 11/240</p> <p>(d) 8/240</p> <p>(e) 8/240</p> <p>(f) 2/240</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>MR: mumps‐rubella vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>RCT: randomised controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions) ‐ RCTs/CCTs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0032"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions) ‐ non‐RCT study designs</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and<br/>design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population<br/>enrolled</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vaccine arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>n = sample size</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MMR vaccine arm<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other vaccine arms<br/>events/n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator arm<br/>events/n</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0079" title="BeckM , Welsz-MalecekR , Mesko-PrejacM , RadmanV , JuzbasicM , Rajninger-MiholicM , et al. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. Journal of Biological Standards1989;17(1):85-90. ">cb‐Beck 1989</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged</p> <p>12 to 14 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> n = 103 </p> <p>containing 4.1 TCID50<br/>mumps strain L‐Zagreb </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> n = 93 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Local reactions(*)</p> <p>(b) Fever &gt; 37.5 °C</p> <p>(c) Catarrhal symptoms</p> <p>(d) Swelling of cheeks</p> <p>(*)Local reactions: redness, swelling, tenderness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b> </p> <p>(a) 2/103</p> <p>(b) 2/103</p> <p>(c) 13/103</p> <p>(d) 3/103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>(a) 1/93</p> <p>(b) 1/93</p> <p>(c) 9/93</p> <p>(d) 4/93</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0080" title="BenjaminCM , ChewGC , SilmanAJ . Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ1992;304(6834):1075-8. ">cb‐Benjamin 1992</a> </p> <p>Retrospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>1 to 5 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> n = 1588 </p> <p>strain not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> <p>Not immunised n = 1242</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All episodes</b> <br/>(a) Arthralgia<br/>(b) Possible or probable arthritis<br/>(c) All specific joint syndromes<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>First‐ever episodes</b><br/>(a1) Arthralgia(*)<br/>(b1) Possible(§)/probable arthritis<br/>(c1) All specific joint syndromes<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>(d) Sore eyes </p> <p>(e) Convulsion</p> <p>(f) Coryza</p> <p>(g) Swollen glands</p> <p>(h) Fever</p> <p>(i) Skin rash<br/>(j) Hospital admission </p> <p>(k) Doctor consultation</p> <p>(*)Arthralgia was defined<br/>as pain experienced in the </p> <p>joint but not accompanied</p> <p>by swelling.</p> <p>(§)Possible arthritis<br/>was defined as swelling of joint<br/>reported by parent<br/>but not corroborated<br/>by a doctor. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b> </p> <p><b>All episodes</b> <br/>(a) 16/1588<br/>(b) 8/1588<br/>(c) 24/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>First‐ever episodes</b><br/>(a1) 16/1588<br/>(b1) 7/1588<br/>(c1) 23/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>(d) 154/1588 </p> <p>(e) 11/1588</p> <p>(f) 897/1588</p> <p>(g) 184/1588</p> <p>(h) 279/1588</p> <p>(i) 260/1588</p> <p>(j) 76/1588</p> <p>(k) 616/1588</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p><b>All episodes</b> <br/>(a) 3/1588<br/>(b) 1/1588<br/>(c) 4/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>First‐ever episodes</b><br/>(a1) 3/1588<br/>(b1) 1/1588<br/>(c1) 4/1588<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/>(d) 150/1588 </p> <p>(e) 5/1588</p> <p>(f) 797/1588</p> <p>(g) 135/1588</p> <p>(h) 262/1588</p> <p>(i) 216/1588</p> <p>(j) 78/1588</p> <p>(k) 554/1588</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0084" title="DunlopJM , Rai ChoudhuryK , RobertsJS , BryettKA . An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health1989;103(5):331-5. ">cb‐Dunlop 1989</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>15 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 319 </p> <p>Trimovax Mérieux,</p> <p>measles Schwarz<br/>1000 TCID50, </p> <p>rubella RA 27/3<br/>1000 TCID50,<br/>mumps Urabe AM/9<br/>5000 TCID50 </p> <p><b>(2) MV vaccine</b> n = 16 </p> <p>Mérieux, containing<br/>measles Schwarz,<br/>1000 TCID50 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local symptoms</b> </p> <p>(a) Injury site bruise</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Systemic symptoms</b> </p> <p>(a) Rash</p> <p>(b) Fever</p> <p>(c) Cough</p> <p>(d) Off‐color</p> <p>(e) Diarrhoea</p> <p>(f) Nappy rash</p> <p>(g) Earache</p> <p>(h) Parotitis</p> <p>(i) Lymphadenopathy</p> <p>(j) Hospital admission<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(a) Asymptomatic/unrelated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p><b>Local symptoms</b> </p> <p>(a) 19/319</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Systemic symptoms</b> </p> <p>(a) 93/319</p> <p>(b) 74/319</p> <p>(c) 71/319</p> <p>(d) 55/319</p> <p>(e) 22/319</p> <p>(f) 29/319</p> <p>(g) 16/319</p> <p>(h) 5/319</p> <p>(i) 4/319</p> <p>(j) 1/319<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(a) 138/319</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) MV vaccine</b> </p> <p><b>Local symptoms</b> </p> <p>(a) 0/16</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Systemic symptoms</b> </p> <p>(a) 4/16</p> <p>(b) 3/16</p> <p>(c) 6/16</p> <p>(d) 8/16</p> <p>(e) 0/16</p> <p>(f) 0/16</p> <p>(g) 0/16</p> <p>(h) 0/16</p> <p>(i) 0/16</p> <p>(j) 0/16<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p>(a) 9/16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0095" title="MakinoS , SasakiK , NakayamaT , OkaS , UranoT , KimuraM , et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. American Journal of Diseases in Children1990;144(8):905-10. ">cb‐Makino 1990</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>8 months to<br/>18 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 893<br/>Kitasato Institute, Japan<br/>containing<br/>measles AIK‐C<br/>5000 TCID50,<br/>mumps Hoshino<br/>15000 TCID50, </p> <p>rubella Takahashi<br/>32000 TCID50<br/><b>(2) Measles vaccine</b> n = 147<br/>Kitasato Institute, containing<br/>measles AIK‐C 25000 TCID50<br/><b>(3) Mumps vaccine</b> n = 122<br/>Kitasato Institute, containing<br/>mumps Hoshino 10000 TCID50 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical reactions</b> </p> <p>(a) Fever (≥ 37.5 °C)<br/>(b) Fever (≥ 39.0 °C)<br/>(c) Rash<br/>(d) Rash (mild)<br/>(e) Rash (moderate)<br/>(f) Rash (severe)<br/>(g) Lymphadenopathy<br/>(h) Parotitis<br/>(i) Cough<br/>(j) Vomiting<br/>(k) Diarrhoea </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p>(a) 139/893<br/>(b) 12/893<br/>(c) 91/893<br/>(d) 81/893<br/>(e) 6/893<br/>(f) 4/893<br/>(g) 12/893<br/>(h) 8/893<br/>(i) 5/893<br/>(j) 2/893<br/>(k) 10/893 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Measles; (3) Mumps</b> </p> <p>(a) 18/147; 0/122<br/>(b) 1/147; 0/122<br/>(c) 24/147; 0/122<br/>(d) 23/147; 0/122<br/>(e) 1/147; 0/122<br/>(f) 0/147; 0/122<br/>(g) 0/147; 0/122<br/>(h) 0/147; 0/122<br/>(i) 0/147; 0/122<br/>(j) 0/147; 0/122<br/>(k) 0/147; 0/122 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0097" title="MillerC , MillerE , RoweK , BowieC , JuddM , WalkerD . Surveillance of symptoms following MMR vaccine in children. Practitioner1989;233(1461):69-73. ">cb‐Miller 1989</a> </p> <p>Prospective<br/>Cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>1 to 2 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 6149 </p> <p>Immrawa or Pluserix,<br/>both containing<br/>measle Schwarz,<br/>rubella RA 27/3,<br/>mumps Urabe 9)<br/><b>(2) Measles vaccine</b> n = 162 </p> <p>(not described)<br/>single dose </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical reactions</b> </p> <p>(a) Symptoms (1 day only)<br/>(b) Fever (&gt; 1 day)<br/>(c) Rash (&gt; 1 day)<br/>(d) Off food (&gt; 1 day)<br/>(e) Convulsion (in 1 to 21 days)<br/>(f) Convulsion (in 1 to 6 days) </p> <p>observation period<br/>21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b><br/>(a) 2319/6149<br/>(b) 976/6149<br/>(c) 1061/6149<br/>(d) 1627/6149<br/>(e) 18/7247<br/>(f) 7/7247 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Measles vaccine</b><br/>(a) 73/162<br/>(b) 23/162<br/>(c) 18/162<br/>(d) 31/162<br/>(e) not reported<br/>(f) not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0099" title="RobertsonCM , BennettVJ , JeffersonN , Mayon-WhiteRT . Serological evaluation of a measles, mumps, and rubella vaccine. Archives of Disease in Childhood1988;63(6):612-6. ">cb‐Robertson 1988</a> </p> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>13 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 236<br/>Mérieux, containing<br/>measles Schwarz,<br/>mumps Urabe AM/9,<br/>rubella Wistar RA 27/3<br/><b>(2) Measles vaccine</b> n = 52<br/>Schwarz strain </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical reactions</b> </p> <p>(a) Irritability<br/>(b) Rash<br/>(c) Coryza<br/>(d) Fever<br/>(e) Cough<br/>(f) Lethargy </p> <p>(g) Diarrhoea<br/>(h) Vomiting<br/>(i) Anorexia<br/>(j) Conjunctivitis<br/>(k) Lymphadenopathy<br/>(l) Parotitis<br/>(m) Local reactions<br/>(n) No symptoms </p> <p>(o) Given paracetamol</p> <p>(p) Seen by a doctor</p> <p>observation period<br/>21 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b><br/>(a) 175/236<br/>(b) 109/236<br/>(c) 104/236<br/>(d) 88/236<br/>(e) 40/236<br/>(f) 65/236 </p> <p>(g) 55/236<br/>(h) 33/236<br/>(i) 48/236<br/>(j) 23/236<br/>(k) 6/236<br/>(l) 3/236<br/>(m) 14/236<br/>(n) 33/236<br/>(o)156/236<br/>(p) 42/236 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Measles vaccine</b><br/>(a) 40/52<br/>(b) 23/52<br/>(c) 27/52<br/>(d) 16/52<br/>(e) 12/52<br/>(f) 13/52 </p> <p>(g) 10/52<br/>(h) 7/52<br/>(i) 14/52<br/>(j) 5/52<br/>(k) 0/52<br/>(l) 0/52<br/>(m) 4/52<br/>(n) 4/52 </p> <p>(o) 29/52<br/>(p) 11/52 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a><br/>Costa Rica; </p> <p>prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Costa Rica</b> </p> <p>children aged<br/>7 months to<br/>7 years old </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>(MSD) containing<br/>measles Moraten<br/>1000 TCID50,<br/>mumps Jeryl Lynn<br/>5000 TCID50,<br/>rubella HPV ‐ 77<br/>1000 TCID50<br/>1 dose subcutaneous </p> <p>n = 457</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> </p> <p>n = 175</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Conjunctivitis<br/>(b) URTI<br/>(c) Lymphadenopathy<br/>(d) Gastroenteritis<br/>(e) Fever<br/>(f) Irritability<br/>(g) Malaise and anorexia<br/>(h) Measles‐like rash<br/>(i) Arthralgia<br/>(j) Unrelated illness* </p> <p>Observation period</p> <p>28 days</p> <p>(*)Otitis, allergy,<br/>fatigue, headache,<br/>viral infection,<br/>chickenpox, flush,<br/>scarlatina,<br/>whooping cough,<br/>abdominal pain,<br/>herniorrhaphy,<br/>heat or diaper rash </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b><br/>(a) 36/457<br/>(b) 312/457<br/>(c) 31/457<br/>(d) 228/457<br/>(e) 217/457<br/>(f) 175/457<br/>(g) 217/457<br/>(h) 10/457<br/>(i) 0/457<br/>(j) 81/457 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b><br/>(a) 0/175<br/>(b) 88/175<br/>(c) 9/175<br/>(d) 77/175<br/>(e) 75/175<br/>(f) 49/175<br/>(g) 64/175<br/>(h) 9/175<br/>(i) 2/175<br/>(j) 29/175 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0103" title="StokesJJ , WeibelRE , VillarejosVM , ArguedasJA , BuynakEB , HillemanMR . Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA1971;218(1):57-61. ">cb‐Stokes 1971</a> </p> <p>USA;</p> <p>prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>USA</b> </p> <p>children aged<br/>10 months to<br/>6 years old </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>(MSD) containing<br/>measles Moraten<br/>1000 TCID50,<br/>mumps Jeryl Lynn<br/>5000 TCID50,<br/>rubella HPV ‐ 77<br/>1000 TCID50<br/>1 dose subcutaneous </p> <p><b>USA</b> n = 228 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b><br/>n = 106 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Conjunctivitis<br/>(b) URTI<br/>(c) Lymphadenopathy<br/>(d) Fever &gt; 37.2 °C (orally)<br/>(e) Gastroenteritis<br/>(f) Irritability<br/>(g) Malaise and anorexia<br/>(h) Measles‐like rash<br/>(i) Unrelated illness*<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>Temperature</b> </p> <p>(a) &lt; 99 °F,<br/>&lt; 37.2 °C<br/>(b) 99 to 100.9 °F,<br/>37.2 to 38.3 °C<br/>(c) 101 to 102.9 °F,<br/>38.3 to 39.4 °C<br/>(d) 103 to 104.9 °F,<br/>39.4 to 40.5 °C<br/>(e) Not taken </p> <p>Observation period</p> <p>28 days</p> <p><b>(*)Unrelated illness:</b><br/>Otitis, allergy, exanthema,<br/>headache, measles,<br/>whooping cough, heat rash,<br/>boils </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> <br/>5 to 12 days after vaccination </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine arm</b><br/>(a) 1/228<br/>(b) 158/228<br/>(c) 3/228<br/>(d) 118/228<br/>(e) 51/228<br/>(f) 43/228<br/>(g) 14/228<br/>(h) 11/228<br/>(i) 89/228 </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>Temperature</b><br/>(a) 105/228<br/>(b) 86/228<br/>(c) 26/228<br/>(d) 6/228<br/>(e) 5/228 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arm</b> <br/>(a) 0/106<br/>(b) 48/106<br/>(c) 1/106<br/>(d) 40/106<br/>(e) 6/106<br/>(f) 2/106<br/>(g) 1/106<br/>(h) 0/106<br/>(i) 13/106<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐<br/><b>Temperature</b><br/>(a) 57/106<br/>(b) 36/106<br/>(c) 3/106<br/>(d) 1/106<br/>(e) 9/106 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0102" title="SharmaHJ , OunSA , BakrSS , KapreSV , JadhavSS , DhereRM , et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clinical Microbiology and Infection2010;16(4):347-52. ">cb‐Sharma 2010</a> </p> <p>cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective<br/>cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged<br/>(1) 16 to 24 months<br/>(2) 5 to 7 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>Tresivac, </p> <p>Serum Institute of India</p> <p>measles Edmonston‐Zagreb, 1000 CCID50<br/>mumps Leningrad‐Zagreb,<br/>5000 CCID50,<br/>rubella Wistar RA 27/3<br/>1000 CCID50,<br/>in each 0.5 mL dose </p> <p><b>Sample sizes vaccine arms</b> </p> <p>(1) n = 65,423</p> <p>(2) n = 329,211</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo arm</p> <p>unvaccinated</p> <p><b>Sample sizes placebo arms</b> </p> <p>(1) n = 12,253</p> <p>(2) n = 46,232</p> <p>observation period<br/>42 days </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local reactions</b><br/>(a) Pain<br/>(b) Redness<br/>(c) Swelling </p> <p><b>Systemic reactions</b><br/>(a) Fever<br/>(b) Rash<br/>(c) Parotitis<br/>(d) Arthralgia<br/>(e) Lymphadenopathy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine arms</b> </p> <p><b>(1) age 16 to 24 months</b> </p> <p><b>Local reactions</b><br/>(a) 1548/65,423<br/>(b) 1157/65,423<br/>(c) 688/65,423 </p> <p><b>Systemic reactions</b><br/>(a) 1640/65,423<br/>(b) 113/65,423<br/>(c) 25/65,423<br/>(d) 11/65,423<br/>(e) 6/65,423<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>(2) age 5 to 7 years</b> </p> <p><b>Local reactions</b><br/>(a) 4350/329,211<br/>(b) 3728/329,211<br/>(c) 2745/329,211 </p> <p><b>Systemic reactions</b><br/>(a) 8184/329,211<br/>(b) 391/329,211<br/>(c) 8208/329,211<br/>(d) 200/329,211<br/>(e) 430/329,211 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo arms</b> </p> <p><b>(1) age 16 to 24 months</b> </p> <p><b>Local reactions</b><br/>(a) 10/12,253<br/>(b) 10/12,253<br/>(c) 12/12,253 </p> <p><b>Systemic reactions</b><br/>(a) 197/12,253<br/>(b) 20/12,253<br/>(c) 21/12,253<br/>(d) 0/12,253<br/>(e) 4/12,253<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>(2) age 5 to 7 years</b> </p> <p><b>Local reactions</b><br/>(a) 0/46,232<br/>(b) 0/46,232<br/>(c) 0/46,232 </p> <p><b>Systemic reactions</b><br/>(a) 1344/46,232<br/>(b) 11/46,232<br/>(c) 433/46,232<br/>(d) 0/46,232<br/>(e) 2/46,232 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0104" title="SwartzTA , KlingbergW , KlingbergMA . Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Infection1974;2(3):115-7. ">cb‐Swartz 1974</a> </p> <p>Prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 children aged<br/>1 to 6 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 22<br/>Merck Institute for<br/>Therapeutic Research<br/><b>(2) Mumps‐rubella vaccine</b> n = 15 </p> <p>Merck Institute<br/>for Therapeutic Research<br/><b>(3) Rubella vaccine</b> n = 22<br/>Merck ‐ Meruvax HPV 77‐DE5 </p> <p><b>Temperature</b> </p> <p>(1) 7 to 11 days</p> <p>(2) 7 to 12 days</p> <p>(3) 7 to 15 days<br/>after vaccination </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Swollen glands<br/>(b) Enanthema </p> <p>(c) Conjunctivitis</p> <p>(d) Rash<br/>(e) No reactions<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b> </p> <p>(a) &lt; 37.2 °C<br/>(b) 37.2 to 38.3 °C<br/>(c) 38.3 to 39.3 °C<br/>(d) ≥ 39.4 °C </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p>(a) 12/22</p> <p>(b) 8/22</p> <p>(c) 7/22</p> <p>(d) 1/22</p> <p>(e) 10/22</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b><br/>(a) 15/22 </p> <p>(b) 4/22</p> <p>(c) 3/22</p> <p>(d) 0/22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) MR; (3) Rubella</b> </p> <p>(a) 9/15: 7/22</p> <p>(b) 8/15; 5/22</p> <p>(c) 7/15; 7/22</p> <p>(d) 3/15; 2/22</p> <p>(e) 6/15; 14/22</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Temperature</b> <br/>(a) 9/15; 16/22 </p> <p>(b) 3/15; 3/22</p> <p>(c) 3/15; 3/22</p> <p>(d) 0/15; 0/22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0108" title="WeibelRE , Carlson AJ Jr, VillarejosVM , BuynakEB , McLeanAA , HillemanMR . Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proceedings of the Society for Experimental Biology and Medicine1980;165(2):323-6. ">cb‐Weibel 1980</a>; </p> <p>Prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> n = 68 </p> <p>(Merck, containing<br/>measles Moraten,<br/>mumps Jeryl Lynn,<br/>rubella RA 27/3)<br/><b>(2) Rubella vaccine</b> n = 67<br/>(strain RA 27/3)<br/>1 dose subcutaneous </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reactions</b> </p> <p>(a) Rash</p> <p>(b) Lymphadenopathy</p> <p>(c) Arthralgia<br/>(d) Myalgia </p> <p>(e) Anorexia<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b> <br/>(a) &lt; 99 °F<br/>&lt; 37.2 °C<br/>(b) 99 to 100.9 °F<br/>37.2 to 38.3 °C<br/>(c) 101 to 102.9 °F<br/>38.3 to 39.4 °C<br/>(d) 103 to 104.9 °F<br/>39.4 to 40.5 °C<br/>(e) &gt; 105 °F, ≥ 40.6 °C </p> <p><b>Temperature</b> <br/>5 to 12 days<br/>after vaccination </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) MMR vaccine</b> </p> <p><b>Reactions</b> </p> <p>(a) 16/68<br/>(b) 8/68<br/>(c ) 3/68<br/>(d) 4/68<br/>(e) 60/68<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b><br/>(a) 39/68<br/>(b) 14/68<br/>(c ) 9/68<br/>(d) 1/68<br/>(e) 0/68 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(2) Rubella vaccine</b> </p> <p><b>Reactions</b> </p> <p>(a) 3/67<br/>(b) 3/67<br/>(c ) 1/67<br/>(d) 3/67<br/>(e) 22/67<br/>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ </p> <p><b>Temperature</b> </p> <p>(a) 37/67<br/>(b) 14/67<br/>(c ) 4/67<br/>(d) 1/67<br/>(e) 0/67 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CCID50: cell culture infectious dose 50%<br/>MR: mumps‐rubella vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>RCT: randomised controlled trial<br/>TCID50: Median Tissue Culture Infectious Dose<br/>URTI: upper respiratory tract infection </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions) ‐ non‐RCT study designs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0033"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and<br/>design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0041" title="RayP , HaywardJ , MichelsonD , LewisE , SchwalbeJ , BlackS , et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatric Infectious Disease Journal2006;25(9):768-73. ">bb‐Ray 2006</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases:<br/>(n = 452) children aged<br/>0 to 6 years<br/>with outcome of interest. </p> <p>Controls: (n = 1280) matching for HMO, location, age within 7 days, sex, and length of enrolment in health plan </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Encephalopathy:</b> acute generalised </p> <p>disturbance of brain function requiring</p> <p>hospitalisation and consisting of coma or</p> <p>stupor that cannot be attributed to medication</p> <p>or postictal state. Such cases must have altered</p> <p>consciousness, delirium, obtundation and/or confusion.</p> <p><b>2. Reyes syndrome:</b> clinical symptoms of </p> <p>acute encephalopathy with altered level of consciousness as well as:</p> <p> <ol id="CD004407-list-0025"> <li> <p>absence of inflammatory changes in cerebrospinal fluid as indicated by 5 white blood cells/mm<sup>3</sup> or brain histology showing cerebral oedema without perivascular or meningeal inflammation, plus </p> </li> <li> <p>evidence of hepatitis or liver failure documented by a 3‐fold or greater elevation in serum glutamic oxaloacetic transaminase, serum glutamate pyruvate transaminase or serum ammonia or fatty changes of hepatocytes on liver biopsy or autopsy, plus </p> </li> <li> <p>absence of other aetiologies for cerebral or hepatic abnormalities.</p> </li> </ol> </p> <p><b>3. Encephalitis/encephalomyelitis:</b> evidence of acute neurologic disease presenting with non‐specific signs such as fever, seizures, altered consciousness, headache, vomiting, meningismus, or anorexia. Multifocal involvement of the central nervous system and evidence of cerebrospinal fluid inflammation (7 white blood cells/mm<sup>3</sup>) were required. </p> <p>Diseases with other known aetiologies were excluded.</p> <p>For data analysis, all cases were stratified on the basis of their aetiology: known, unknown, suspected but unconfirmed (this last when a diagnosis was not confirmed by a diagnostic test). </p> <p>Hospitalisation cases for encephalopathy, Reyes syndrome, or encephalitis (primary or secondary diagnosis) in children aged 0 to 6 years, members of the health plan of 4 HMOs in the USA, and occurred between 1 January 1981 and 31 December 1995, were considered as possible cases.<br/>Hospital charts were reviewed by abstracter (not blind to vaccination status of the cases) who included in first instance encephalitis diagnoses by a neurologist with clear aetiology and excluded all cases with a condition other than encephalopathy. All other neurologic cases were reviewed by a neurologist (blind to vaccination status of the cases) and included as cases if they met case definition (see column on the right). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine exposure</b> <br/>t<b>ime interval</b><br/>relative to onset of<br/>encephalopathy </p> <p>(a) 7 to 14 days<br/>(b) 0 to 14 days<br/>(c) 0 to 30 days<br/>(d) 0 to 60 days<br/>(e) 0 to 90 days </p> <p>MMR type</p> <p>not reported.</p> <p>Vaccination status<br/>of both cases and controls<br/>was ascertained from<br/>medical records. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The findings do not support a conclusion that there is an<br/>increased risk of encephalitis or encephalopathy after MMR vaccination. Although this study is large, encephalopathy is rare and thus it is not possible to exclude completely a small increase in the risk of encephalopathy after MMR vaccination. However, if such an increased risk exists, the absolute risk is extremely small and it is much lower after vaccination than after measles. </p> <p>This corresponds roughly to an all‐cause incidence (not an attributable risk) of 1 in 200,000 after MMR, a rate that is not statistically different from background. </p> <p>Consequently, our results support the continued use of DTP and MMR vaccines.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) 1/452 versus 6/1280<br/>(b) 1/452 versus 7/1280<br/>(c) 4/452 versus 13/1280<br/>(d) 8/452 versus 33/1280<br/>(e) 15/452 versus 44/1280 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(a) 0.40 (0.05 to 3.46)</p> <p>(b) 0.35 (0.04 to 2.95)</p> <p>(c) 0.85 (0.27 to 2.68)</p> <p>(d) 0.64 (0.27 to 1.50)</p> <p>(e) 0.98 (0.47 to 2.01)</p> <p>adjusted estimates</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children immunised aged 1 to 7 years old. Between<br/>November 1982 and September 1986 </p> <p>n = 535,544</p> <p>n = 119</p> <p>children<br/>hospitalised<br/>for encephalitis </p> <p>(MMR vaccine was administered before the disease), and</p> <p>only 97 between 0 and 24 months after MMR vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Encephalitis:</b> acute or subacute onset of neurologic symptoms. Presence of neurologic symptoms or findings (clinical or laboratory, e.g. microbiological, electroencephalographic, computed tomographic) indicative of involvement of the brain parenchyma, such as coma, seizures, focal neurologic findings, or mental function impairment. Absence of evidence of other diagnoses, including non‐inflammatory conditions, and no microbiological or other laboratory findings suggestive of a non‐viral infection. When pleocytosis in CSF is present, the term encephalitis is used, implying an inflammatory response within the brain. The presence of normal CSF findings does not preclude the diagnosis if the other criteria are satisfied. </p> <p><b>Encephalopathy:</b> clinically resembles encephalitis but no inflammatory response is evident. Chronic encephalopathy: persistence of acute findings usually over several months. </p> <p>The National Hospital Discharge Register was consulted by using the following ICD‐8 codes: 065.99, 066.01, 066.02, 072.01, 292.20, 292.38, 292.39, 323.00, 323.01, 323.08, 323.09, 781.70, 999, 999.10. </p> <p>Medical records of hospitalised participants were reviewed (in order to evaluate possible other causes of the event) and their correspondence to diagnostic criteria (see column on the right) examined. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b> </p> <p>(a) 0 to 3 months after vaccination</p> <p><b>Control period:</b> </p> <p>(b) 4 to 24 months</p> <p><b>Observation period:</b> </p> <p>(c) 0 to 24 months</p> <p><b>MMR II vaccine</b> (Merck &amp; Co, West Point, PA) </p> <p>measles: Enders‐Edmonston</p> <p>mumps: Jeryl Lynn</p> <p>rubella: Wistar RA 27/3</p> <p>Vaccination data were assessed through vaccination register.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant excess of hospitalisation within 3 months of vaccination (P = 0.28)</p> <p>Incidence of encephalitis of undefined cause amongst 1‐ to 7‐year‐old children decreased from<br/>19.9 per 100,000 in 1983 to </p> <p>13.0 per 100,000 in 1985.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 9 cases (3 months)</p> <p>(b) 88 cases (21 months)</p> <p>(c) 97 cases (24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)*</b> </p> <p>0.72 (0.36 to 1.42)</p> <p>(*)rate ratio amongst risk period (b) and control period (a)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 35 months (immunised with MMR; NK) with outcome of interest diagnosed between October 1998 and September 2001 (n = 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onset of illness: day of hospital admission Fever: temperature of 37.5 °C; the questionnaire asked whether there was a fever and also for the maximum temperature recorded at any site by any method<br/>Encephalopathy: a depressed or altered level of consciousness<br/>Case definition of serious neurologic disease: any child 2 to 35 months old with a severe illness with fever and convulsions (see <a href="#CD004407-tbl-0035">Table 14</a>)<br/>and/or encephalitis was included </p> <p><b>Encephalitis:</b> </p> <p> <ul id="CD004407-list-0026"> <li> <p>encephalopathy for at least 24 hours and at least 2 of the following: fever, convulsions, focal neurologic findings (≥ 24 h), pleocytosis (&gt; 5 leukocytes per μL CSF), characteristic abnormal results of neuroimaging (computerised tomography or MRI), herpes simplex virus nucleic acid (or nucleic acid of any other virus proven to cause encephalitis) in CSF; or </p> </li> <li> <p>postmortem histologic evidence of encephalitis</p> </li> </ul> </p> <p><b>Exclude:</b> </p> <p> <ul id="CD004407-list-0027"> <li> <p>viral (aseptic) meningitis without encephalopathy</p> </li> <li> <p>the following confirmed causes were excluded: hypoxic/ischaemic; vascular; toxic; metabolic, neoplastic, traumatic and pyogenic infections </p> </li> <li> <p>uncomplicated convulsions or a series of convulsions lasting &lt; 30 min</p> </li> <li> <p>immunocompromised children</p> </li> </ul> </p> <p>Cases of suspected encephalitis and/or severe illness with fever and convulsion occurring in children aged between age 2 and 35 months through Britain and Ireland were identified by consultant paediatricians taking part in a survey (October 1998 to September 2001) and notified to the British Paediatric Surveillance Unit. Details about neurologic illnesses were collected by reporting paediatricians by means of a detailed questionnaire. For diagnostic purposes, saliva, blood, and cerebrospinal samples were also collected. Questionnaires were reviewed by study investigators in order to assess whether reported cases corresponded to an analytical case definition taking into account severe illness with fever and convulsion and encephalitis (see column on the right). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b><br/>15 to 35 days after immunisation, because this is the incubation period for postinfectious encephalitis induced by wild‐type measles and for aseptic meningitis induced by the Urabe vaccine strain mumps </p> <p><b>MMR vaccine type</b>, not reported. </p> <p>Immunisation history of cases was obtained by the Immunisation Department of the Health Protection Agency (other than MMR vaccine, the study also considers DTP, Hib, and MenC vaccines). Only cases with known vaccination history were included in the analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regarding MMR vaccine, there was no evidence of a raised relative incidence of serious neurologic disease 15 to 35 days after immunisation. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within 15 to 35 days</p> <p>with concurrent primary HHV‐6 or HHV‐7 infection</p> <p>(a) all (5 cases)</p> <p>(b) no (4 cases)</p> <p>(c) yes (1 case)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a) 1.34 (0.52 to 3.47)</p> <p>(b) 1.52 (0.52 to 4.41)</p> <p>(c) 0.86 (0.10 to 7.23)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>incidence: cases/PT<br/>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>DTP: diphtheria, tetanus, pertussis vaccine<br/>Hib: Haemophilus influenzae b vaccine<br/>HHV: human herpes virus<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>MenC: meningococcus C vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MRI: magnetic resonance imaging<br/>PT: person‐time<br/>OR: odds ratio<br/>RR: risk ratio (relative risk)<br/>rr = rate ratio (relative incidence; incidence rate ratio) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0034"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Safety: aseptic meningitis</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a><br/>Matched </p> <p>case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases n = 59<br/>Controls n = 118<br/>(age 12 to 23 months at the time of discharge diagnosis, between 1984 and 1993).<br/>For each ascertained case, 2 controls matched for age, sex, HMO, and HMO membership status were selected. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Potential cases of aseptic meningitis were identified by computerised hospitalisation at 4 HMOs that participated in the Vaccine Safety Datalink project. They were children aged 12 to 23 months with ICD‐9 discharge diagnoses 045.2, 047.*, 048, 072.1, 321.2 or 322.* between 1984 and 1993. Medical records of potential cases were reviewed and included as cases when corresponding to validation criteria (see column on the right). </p> <p>No evidence of prior underlying meningitis or underlying disease caused by toxoplasmosis, syphilis, cytomegalovirus, neonatal herpes simplex, or HIV. (The same exclusion criteria were used for controls.) In addition, bacterial, mycobacterial, and fungal cultures of the cerebrospinal fluid must have been negative, and the patient must have had a cerebrospinal fluid white blood cell count of &gt;= 10 cells/mm<sup>3</sup>. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine: Jeryl Lynn</b> mumps strain. </p> <p><b>Any vaccines</b> includes:<br/><b>Hib:</b> Haemophilus influenzae type b, <b>DPT:</b> diphtheria‐pertussis‐tetanus toxoids, <b>OPV:</b> oral polio vaccine, <b>HDPT:</b> Haemophilus influenzae type b diphtheria pertussis tetanus toxoid vaccine, <b>HepB</b>: hepatitis B vaccine </p> <p><b>Vaccine and time window</b> </p> <p>(a) MMR 0 to 14 days</p> <p>(b) MMR 0 to 30 days</p> <p>(c) MMR 8 to 14 days</p> <p>(d) Any vaccine 0 to 14 days</p> <p>(e) Any vaccine 0 to 30 days</p> <p>(f) Any vaccine 8 to 14 days</p> <p>Vaccination status of both cases and controls was derived from medical record review.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this analysis of hospitalisation caused by AM, there was no increased risk of AM after MMR vaccine containing <b>Jeryl Lynn</b> strain mumps. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) 1/59 versus 4/118</p> <p>(b) 3/59 versus 7/118</p> <p>(c) 1/59 versus 2/118</p> <p>(d) 2/59 versus 8/118</p> <p>(e) 7/59 versus 18/118</p> <p>(f) 2/59 versus 4/118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.50 (0.1 to 4.5)</p> <p>(b) 0.84 (0.2 to 3.5)</p> <p>(c) 1.00 (0.1 to 9.2)</p> <p>(d) 0.44 (0.1 to 2.1)</p> <p>(e) 0.75 (0.3 to 1.9)</p> <p>(f) 1.00 (0.2 to 5.6)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0127" title="ParkT , KiM , YiSG . Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statistics in Medicine2004;23(12):1871-83. ">eb‐Park 2004</a> </p> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1)</b> n = 39. Children with aseptic meningitis aged 13 to 29 months of both sexes, vaccination date confirmed by vaccination record. </p> <p><b>(2)</b> n = 19. Children with aseptic meningitis aged 12 to 15 months of both sexes, vaccination date confirmed by parents only. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Generically defined as syndrome characterised by acute onset of meningeal symptoms, fever, and cerebrospinal fluid pleocytosis, with bacteriologically sterile cultures. Cases of aseptic meningitis were identified from insurance claims and hospitalisation data during 1998 in Korea. Authors considered cases corresponding to diagnosis criteria occurred in children aged 8 to 36 months who had received MMR vaccine within 1 year before disease onset and for whom vaccination records were available. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b><br/>Strain type not stated (the study was conducted in the same setting of the study <a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a>; both studies were performed in Korea, where <b>MMR vaccine</b> containing <b>Urabe or Hoshino</b> mumps strain was routinely administrated in public health, and <b>MMR vaccines</b> containing the <b>Jeryl Lynn or Rubini</b> in the private sector). </p> <p><b>Risk period (42 days)</b> </p> <p><b>(a)</b> from disease onset date to 42 days after </p> <p><b>Control period (323 days)</b> </p> <p><b>(b)</b> from 42 days up to 365 days after disease onset </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study results showed that risk increased in the third week after vaccination and was elevated until the sixth week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> versus<b>(b)</b> </p> <p><b>(1)</b> 11 versus 28 cases </p> <p><b>(2)</b> 5 versus 14 cases </p> <p><b>Sensitivity analysis</b> </p> <p>n = 58, 16 versus 42 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)(*)</b> </p> <p><b>(1)</b> 3.02 (1.50 to 6.08) </p> <p><b>Sensitivity analysis</b> </p> <p>2.93 (1.65 to 5.22)</p> <p>(*)Mantel‐Haenszel<br/>estimator </p> <p>Under the null hypothesis, this estimator is directly analogous to the Mantel‐Haenszel OR for matched‐pair case‐control study. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0125" title="KiM , ParkT , YiSG , OhJK , ChoiBY . Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case crossover design. American Journal of Epidemiology2003;157(2):158-65. [DOI: 10.1093/aje/kwf167]">eb‐Ki 2003</a> </p> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 children, mean age 19.1 months (standard deviation = 5.4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Aseptic meningitis is a syndrome characterised by acute onset of meningeal symptoms, fever, and cerebrospinal fluid pleocytosis with bacteriologically sterile cultures. </p> <p>The following criteria were used to define eligible cases of aseptic meningitis for the study: </p> <p>1) Korean insurance claim cases based on the ICD‐10 (codes A87.9, G03.0, G03.9, and G02.0); and </p> <p>2) cerebrospinal fluid pleocytosis (leukocytes ≥ 5) with bacteriologically sterile cultures (if measured); or </p> <p>3) neck stiffness and/or convulsions, or 2 other symptoms (headache or vomiting) in addition to a fever (≥ 38.0 °C, if measured). Patients’ charts were reviewed and their symptoms, laboratory tests, and last diagnoses on the discharge record checked. If patients were diagnosed with aseptic meningitis and were hospitalised in a general hospital, in accordance with these criteria, those who had headache, fever, and vomiting could be included as participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p><b>(1)</b> n = 29 MMR with </p> <p><b>Urabe or Hoshino</b> mumps strain </p> <p><b>(2)</b> n = 38 MMR with </p> <p><b>Jeryl Lynn or Rubini</b> mumps strain </p> <p><b>Risk period (42 days)</b> </p> <p><b>(a)</b> from disease onset date </p> <p>to 42 days after</p> <p><b>Control period (323 days)</b> </p> <p><b>(b)</b> from 42 days up </p> <p>to 365 days after disease onset</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study results showed that no significant risk was associated with the Jeryl Lynn or Rubini strain of the vaccine. For the Urabe or Hoshino strain, the risk increased in the third week after vaccination and was elevated until the sixth week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> versus<b>(b)</b> </p> <p><b>(1)</b> 13 versus 16 cases </p> <p><b>(2)</b> 3 versus 35 cases </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)(*)</b> </p> <p><b>(1)</b> 5.5 (2.6 to 11.8) </p> <p><b>(2)</b> 0.6 (0.18 to 1.97) </p> <p>(*)Mantel‐Haenszel<br/>estimator </p> <p>Under the null hypothesis, this estimator is directly analogous to the Mantel‐Haenszel OR for matched‐pair case‐control study. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children immunised<br/>aged 1 to 7 years old.<br/>Between November 1982<br/>and September 1986 </p> <p>n = 535,544</p> <p>n = 120</p> <p>children<br/>hospitalised<br/>for encephalitis </p> <p>(MMR vaccine was administered before the disease),</p> <p>and only 64 between 0 and 24 months after MMR vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p><b>Inflammation of the meninges.</b> Usually a self‐limiting disease of known or suspected viral cause consisting of fever, headache, signs of meningeal irritation, without evidence of brain parenchymal involvement and a lymphocytic and mononuclear pleocytosis of CSF. The term 'meningoencephalitis' does not differentiate cases with prominent involvement of the brain parenchyma from those with meningeal involvement only. </p> <p>Hospitalisation records (ICD‐8 codes: 045.99, 320.88, 320.99) and review of patients' medical records to assess correspondence to case definition. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b> </p> <p>(a) 0 to 3 months after vaccination</p> <p><b>Control period:</b> </p> <p>(b) 4 to 24 months after vaccination</p> <p><b>Observation period:</b> </p> <p>(c) 0 to 24 months after vaccination</p> <p><b>MMR II vaccine</b> (Merck &amp; Co, West Point, PA) </p> <p>Measles: <b>Enders‐Edmonston</b> </p> <p>Mumps: <b>Jeryl Lynn</b> </p> <p>Rubella: <b>Wistar RA 27/3</b> </p> <p>Vaccination data were assessed through vaccination register.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant excess of hospitalisation within 3 months of vaccination (P = 0.57)</p> <p>The incidence of meningitis of undefined causes in 1‐ to 7‐year‐old children decreased from </p> <p>10.17 per 100,000 in 1983 to</p> <p>7.71 per 100,000 in 1985.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 10 cases (3 months)</p> <p>(b) 54 cases (21 months)</p> <p>(c) 64 cases (24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>1.30 (0.66 to 2.55)</p> <p>(*)rate ratio amongst<br/>risk (a) and control (b) period </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0110" title="DouradoI , CunhaS , TeixeiraMG , FarringtonCP , MeloA , LucenaR , et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. American Journal of Epidemiology2000;151(5):524-30. ">db‐Dourado 2000</a> </p> <p>Self‐controlled case series</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 11 years (from census)</p> <p>n = 452,344</p> <p>n = 129 children aged 1 to 11 years old admitted to the referral hospital with a diagnosis of aseptic meningitis between 10th and 43rd epidemiologic surveillance weeks of 1997 (March to October). </p> <p>n = 87 fulfilled inclusion criteria;</p> <p>n = 29 cases of AM occurred prior to the mass immunisation campaign;</p> <p>n = 58 after the immunisation campaign. Of the 58 children, n = 50 were know to have been vaccinated. (The date of vaccination was available for 43 of these children.) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Data about meningitis were obtained from the state Epidemiology Surveillance System and from the neurologic service of the state referral hospital for infectious disease (Hospital Couto Maia), by reviewing hospital records of children admitted between the 10th and 43rd epidemiological surveillance weeks. Demographic, clinical, and laboratory data were collected on a standardised form. </p> <p><b>Inclusion/exclusion criteria</b> </p> <p>1) Residence in the city of Salvador</p> <p>2) Age 1 to 11 years</p> <p>3) Cerebrospinal fluid with a cell count of &gt; 10 and &lt; 1200 cells per mL (higher counts could be attributed to unconfirmed bacterial meningitis) </p> <p>4) Predominance of lymphocytes in the cerebrospinal fluid of &gt; 50% of the total number of cells </p> <p>5) Exclusion of any bacteriologic or fungal confirmation through the use of Gram stain, latex, immunoelectrophoresis, stain for <i>Cryptococcus neoformans,</i> Ziehl‐Neelsen stain, or culture for bacteria and <i>Mycobacterium tuberculosis</i> </p> <p>6) Exclusion of all cases with a history of prior meningitis or any neurologic disorder and any cases with sepsis, pneumonia, otitis, or any other disease that might be associated with an increased cell count in the cerebrospinal fluid </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Self‐controlled case series</i> </b> </p> <p><b>Exposure risk period:</b> </p> <p>(a) 3 to 5 weeks after vaccination</p> <p>(i.e. 15 to 35 days)</p> <p><b>Control period:</b> </p> <p>(b) 1 to 2 weeks and 6 to 10 weeks after vaccination</p> <p><b>Observation period:</b> </p> <p>(c) 1 to 10 weeks after vaccination</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b><i>Case‐only ecological method</i> </b> </p> <p><b>(a) Reference period (pre‐vaccination):</b> </p> <p>10 to 32 epidemiologic surveillance weeks;<br/>time interval = 23 weeks </p> <p><b>(b) Low‐risk period:</b> </p> <p>34 to 35 epidemiologic surveillance weeks;</p> <p>time interval = 2 weeks</p> <p><b>(c) High‐risk period:</b> </p> <p>36 to 39 epidemiologic surveillance weeks (3 to 6 weeks after vaccination day)<br/>time interval = 4 weeks </p> <p><b>(d) Low‐risk period:</b> </p> <p>40 to 43 epidemiologic surveillance weeks;</p> <p>time interval = 3 weeks</p> <p><b>MMR vaccine</b> </p> <p>Pluserix vaccine (SmithKline Beecham, UK) containing mumps <b>Urabe</b> strain </p> <p><b>Vaccination began</b> on 16 August 1997 (National Immunisation Day, surveillance week 33), 45% coverage of the target population was achieved on that day, high coverage (exact data not reported, but very close to 100%) during the 2 following weeks. </p> <p>Vaccination history was obtained by vaccination cards or visits/phone call.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An elevated risk of aseptic meningitis was observed 3 weeks after Brazil's national vaccination day compared with the risk in the pre‐vaccination period. This result was confirmed by a case series analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 35 cases</p> <p>(b) 3 and 5 cases</p> <p>(c) 43 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Cases/PT (weeks)</b> </p> <p>(a) 29/10,403,912</p> <p>(b) 3/904,688</p> <p>(c) 46/1,809,376</p> <p>(d) 9/1,809,376</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Self‐controlled case series</i> </b> </p> <p><b>rr (95% CI)(*)</b> </p> <p>30.4 (11.5 to 80.8)</p> <p>(*)Poisson regression</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b><i>Case‐only ecological method</i> </b> </p> <p><b>rr (95% CI)(**)</b> </p> <p>(a) reference weeks</p> <p>(b) 1.19 (0.36 to 3.91)<br/>(c) 9.12 (5.73 to 14.52)<br/>(d) 1.78 (0.84 to 3.77) </p> <p>(**)rate ratio amongst<br/>risk periods: (b), (c), (d) </p> <p>and control period (a).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 11 years</p> <p>State of<br/>Mato Grosso do Sul </p> <p><b>(MS)</b> n = 580,587 </p> <p>State of Mato Grosso</p> <p><b>(MT)</b> n = 473,718 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Data on cases of meningitis were obtained from the routine surveillance system in both states. Notification of meningitis is statutory in Brazil, with a standardised form completed for each case. The attending physician or nurse completes the notification form in the health facility where the diagnosis is made. The notification form includes data on patient’s identification, clinical diagnosis, evolution, treatment, results of vaccination status, and laboratory investigations (the last 2 items not always reported). </p> <p>Reported cases of meningitis were classified into aseptic or not based on information from the notification forms, using 2 different criteria, which are independent but non‐exclusive. In both criteria, AM included only cases with absence of a positive bacteriological isolate in culture or stain of CSF and did not have a positive blood culture or mention of other non‐viral aetiology. </p> <p><b>Criterion 1</b>: If the diagnosis in the form was of viral aetiology or unknown aetiology, cases were classified as AM. They were classified as not having AM if they had a suspected or confirmed diagnosis of meningitis by a known (non‐viral) agent through any laboratory or clinical finding. </p> <p><b>Criterion 2 (laboratory)</b>: Cases were considered AM if they had a CSF with the following findings: cell count greater than 10 and less than 1500 and presence of lymphocytes greater that 49%. (Applied for the cases in which laboratory data were present in the notification forms. In their absence, cases were excluded.) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(MS) Unexposed period</b> </p> <p>(a) reference weeks 1 to 31</p> <p><b>(MS) Exposed period</b> </p> <p>(b) low‐risk weeks 32 to 34</p> <p>(c) high‐risk weeks 35 to 37</p> <p>(d) low‐risk weeks 38 to 42</p> <p>(e) all weeks 32 to 42</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) Unexposed period</b> </p> <p>(a) reference weeks 1 to 37</p> <p><b>(MT) Exposed period</b> </p> <p>(b) low‐risk weeks 38 to 40</p> <p>(c) high‐risk weeks 41 to 43</p> <p>(d) low‐risk weeks 44 to 48</p> <p>(e) all weeks 38 to 48</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR vaccine:</b> Serum Institute of India, Ltd, Pune. Contained <b>Leningrad‐Zagreb</b> mumps strain. 3 different lots were used in each state (MS and MT). </p> <p><b>Vaccination began</b> in mid‐August 1998 (week 32) in MS and late September in MT (week 38), and lasted for about 1 month, even if the most part of the doses had been administered during the first 2 campaign weeks. Vaccination was reported for 69.4% and 93.5% of the target population in MT and in MS, respectively. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study shows an increase in number of notified cases of AM in the 2 states studied, 3 to 4 weeks after the MIC using Leningrad‐Zagreb mumps strain MMR vaccine (3 to 4 weeks after the MIC corresponding to incubation period for wild mumps infection, and the increase was restricted to the age group targeted by the campaign and to the aseptic form of meningitis). </p> <p>The use of the vaccine on a large scale over a short period of time made it possible to identify an increase in risk which may be present, but more difficult to measure when vaccination is spread over longer periods. </p> <p>The risk estimates varied depending on the diagnostic criteria used and the state.</p> <p>There was also an increase in the incidence of notified mumps after the campaign in the state where data were available. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>cases/PT (weeks)</b> </p> <p><b>(MS) AM criterion 1</b> </p> <p>(a) 22/14,685,258</p> <p>(b) 7/1,421,154</p> <p>(c) 35/1,421,154</p> <p>(d) 6/2,368,590</p> <p>(e) 48/5,210,898</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 1</b> </p> <p>(a) 71/21,481,719</p> <p>(b) 7/1,741,761</p> <p>(c) 71/1,741,761</p> <p>(d) 25/2,902,935</p> <p>(e) 103/6,386,457</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MS) AM criterion 2</b> </p> <p>(a) 8/14,685,258</p> <p>(b) 4/1,421,154</p> <p>(c) 24/1,421,154</p> <p>(d) 2/2,368,590</p> <p>(e) 30/ 5,210,898</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 2</b> </p> <p>(a) 36/21,481,719</p> <p>(b) 3/1,741,761</p> <p>(c) 54/1,741,761</p> <p>(d) 15/2,902,935</p> <p>(e) 72/6,386,457</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)*</b> </p> <p><b>(MS) AM criterion 1</b> </p> <p>(a) reference weeks</p> <p>(b) 3.3 (1.41 to 7.7)</p> <p>(c) 16.4 (9.65 to 28.0)</p> <p>(d) 1.7 (0.69 to 4.2)</p> <p>(e) 6.2 (3.71 to 10.2)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 1</b> </p> <p>(a) reference weeks</p> <p>(b) 1.2 (0.56 to 2.6)</p> <p>(c) 12.3 (8.88 to 17.1)</p> <p>(d) 2.6 (1.65 to 4.1)</p> <p>(e) 4.9 (3.61 to 6.6)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MS) AM criterion 2</b> </p> <p>(a) reference weeks</p> <p>(b) 5.2 (1.56 to 17.2)</p> <p>(c) 31.0 (13.93 to 69.0)</p> <p>(d) 1.6 (0.33 to 7.3)</p> <p>(e) 10.6 (4.84 to 23.1)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(MT) AM criterion 2</b> </p> <p>(a) reference weeks</p> <p>(b) 1.0 (0.32 to 3.3)</p> <p>(c) 18.5 (12.13 to 28.2)</p> <p>(d) 3.1 (1.69 to 5.6)</p> <p>(e) 6.7 (4.51 to 10.0)</p> <p>(*)rate ratio amongst<br/>exposed (risk) periods: (b), (c), (d), (e) </p> <p>and unexposed period (a)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 11 years</p> <p>target population</p> <p>n = 110,629</p> <p>(Rio Grande do Sul)</p> <p>dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> <br/><b>Any‐cause AM</b> was defined as: occurrence of clinically diagnosed meningitis in a person with a CSF pleocytosis (between 5 and 1500 leucocytes/mL) and a negative Gram stain. Viral isolation is not routinely performed in Rio Grande do Sul. </p> <p><b>Mumps‐associated AM</b> was defined as: that occurring in conjunction with or following clinically diagnosed mumps. </p> <p><b>Vaccine‐associated AM</b> was defined as: aseptic meningitis with a pleocytosis of 10 to 1500 leukocytes/mL and occurring within 15 to 35 days after vaccine receipt. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> produced by Serum Institute of India, Lot: 180‐X: measles: <b>Edmonston‐Zagreb</b> ; mumps: <b>Leningrad‐Zagreb</b> ; rubella: <b>Wistar RA 27/3</b>. </p> <p>The campaign was conducted between<br/>8 September and 28 November 1997; </p> <p>weeks 37 to 48.</p> <p><b>(a) unexposed period in 1995/1996</b> </p> <p>39 to 47 weeks</p> <p><b>(b) unexposed period in 1997</b> </p> <p>1 to 38 weeks</p> <p><b>(c) exposed period in 1997:</b> </p> <p><b>High risk:</b> 39 to 47 weeks </p> <p><b>(d) exposed period in 1997:</b> </p> <p><b>Low risk:</b> 48 to 53 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A total of 105,098 doses of Leningrad‐Zagreb were administered to children<br/>aged 1 to 11 years, for an overall coverage of 95%. </p> <p>The risk of vaccine‐associated<br/>aseptic meningitis (31 cases) was 2.9 cases per 10,000 doses of Leningrad‐Zagreb administered (equivalent to 1 case per 3390 doses administered).<br/>Within the 1‐ to 11‐years age group, the risk did not differ significantly by<br/>age group. </p> <p>These findings suggest that Leningrad‐Zagreb is more reactogenic than Urabe and Jeryl‐Lynn strains. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> 2.4 cases per 100,000 person weeks; 4.5 cases in average </p> <p><b>(b)</b> 10 cases (any cause) </p> <p><b>(c)</b> 28.7 per 100,000 person weeks<br/>31 cases vaccine associated (55 any cause, 41 vaccinated) </p> <p><b>(d)</b> 4 cases (any cause) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(c) 12.2 (6.0 to 24.7)(*)</p> <p>(*)rate ratio (c) and (a)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 24 months discharged from hospital in 5 districts in England (Ashford, Leicester, Nottingham, Preston, and Chorley &amp; Ribble) for varying periods between October 1988 and February 1993. Readmissions within 72 h with the same diagnosis were counted as 1 episode. </p> <p>n = 952 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis</b> </p> <p>Children discharged from hospital with a diagnosis of: <b>meningitis</b> categorised as mumps, aseptic, or viral (ICD 072.1, 047., 321.) Children aged between 366 and 730 days. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p><b>Urabe</b> mumps strain </p> <p><b>Jeryl Lynn</b> mumps strain </p> <p>Rubella strain not specified.</p> <p><b>Exposure risk period:</b> </p> <p>(a1) 6 to 11 days (1 to 2 weeks after vaccination)</p> <p>(a2) 15 to 35 days (3 to 5 weeks after vaccination) (Urabe strain)</p> <p><b>Control period:</b> </p> <p>(b) for each vaccine was defined as the time not included in a risk period.</p> <p>The analyses were adjusted for age and were grouped in 6 equal intervals of about 2 months. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study shows that there is a true risk of a neurological event attributable to the Urabe strain. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urabe strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 5 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a2) 38.1 (4.3 to 336)(*)</p> <p>(*)Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23 months with discharge diagnosis of febrile convulsion or aseptic meningitis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic menigitis:</b> </p> <p>Viral meningitis (A87), mumps (B26), meningitis in other infections classified elsewhere (G02), and meningitis due to other and unspecified causes (G03) were identified for the period 1 May 1998 to 30 June 2001, and case notes were reviewed by a paediatrician. </p> <p>In addition, computerised hospital records for children aged 12 to 23 months with an ICD‐9 discharge diagnosis of meningitis categorised as mumps, aseptic, or viral (072.1, 047, 321) were identified for the period 1 January 1991 to 30 September 1992, prior to the withdrawal of Urabe‐containing MMR vaccines, and were linked with MMR vaccination histories.<br/>Cases of laboratory‐confirmed mumps meningitis were also ascertained from reports made to the Centre for Infections from laboratories in England and Wales for the period of October 1992 to the end of June 2004. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>(1) MMR with <b>Urabe</b> mumps strain up to September 1992 </p> <p>(2) <b>MMRII</b> (Sanofi Pasteur) <b>Edmonston‐Enders</b> measles strain, <b>Jeryl Lynn</b> mumps strain, between September 1992 and May 1998 </p> <p>(3) <b>MMR Priorix</b> (GlaxoSmithKline) <b>Schwarz</b> measles strain <b>RIT4385</b> (Jeryl Lynn) from May 1998 </p> <p><b>Exposure risk period:</b> </p> <p>(a) 15 to 35 days after vaccination</p> <p>(from May 1998 to June 2001) (Urabe MMR)</p> <p>(b) 15 to 35 days after vaccination</p> <p>(from January 1991 to September 1992) (Jeryl Lynn MMR)</p> <p><b>MMR vaccination</b> histories were independently obtained through linkage with computerised immunisation records in the 2 Thames regions, using either the National Health Service number or sex, date of birth, and post code, a highly specific linking algorithm. Information on batch number was sought for any confirmed aseptic meningitis cases with onset 15 to 35 days after MMR vaccination. The formatting of batch numbers differs substantially between manufacturers in length and alphanumeric coding and is a precise means of distinguishing between vaccines from different manufacturers. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before after between 2 risk periods, re‐analysis of the data presented in <a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>This study confirms that the risk of aseptic meningitis with Priorix vaccine, if it exists at all, is significantly lower than with Urabe‐containing mumps vaccine. The study allowed the exclusion of risks as rare as 1 in 437,000 for laboratory‐confirmed mumps meningitis with non‐Urabe‐containing<br/>MMR vaccines. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison between 2 risk periods</p> <p>Aseptic meningitis</p> <p>(a) 4 cases</p> <p>(b) 0 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>Laboratory‐confirmed</p> <p>mumps‐positive cerebrospinal fluid</p> <p>(a) 16 cases</p> <p>(b) 0 cases</p> <p>Data from the paper</p> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr(95%CI)</b> </p> <p>25.9 (2.8 to 233)(*)</p> <p>(*) rate ratio (a) versus (b)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For this study, WHO selected 26 sentinel sites (49 hospitals) distributed in 16 countries of the 6 WHO regions. </p> <p>The study population included children ages 9 to 23 months admitted to a network‐participating hospital during January 2010 to March 2014, with a discharge diagnosis of either AM or immune thrombocytopenic purpura. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aseptic meningitis probable cases</b> </p> <p>ICD‐9 codes in first discharge diagnosis position:</p> <p>047 (047.0 to 047.9) Meningitis due to enterovirus</p> <p>049.0 to 049.1 Other non‐arthropod‐borne viral meningitis</p> <p>072.1 Mumps meningitis</p> <p>321.2 Meningitis due to viruses not elsewhere classified</p> <p>322.0, 322.1, 322.9 Meningitis</p> <p>of unspecified cause</p> <p>ICD‐10 codes in first discharge diagnosis position:</p> <p>A87.0 Meningitis due to enterovirus</p> <p>A87.1 Adenoviral meningitis</p> <p>A87.2 Lymphocytic choriomeningitis</p> <p>A87.8 Other viral meningitis</p> <p>A87.9 Viral meningitis, unspecified</p> <p>B26.1 Mumps meningitis</p> <p>G02.0 Meningitis due to viruses not elsewhere classified</p> <p>G03.0, G03.8, G03.9 Meningitis of unspecified cause</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine</b> <b>(measles strain) (mumps strain)</b> </p> <p><b>Priorix, GSK</b> (Schwarz) (RIT 4385a)<br/><b>Priorix‐Tetra, GSK</b> (Schwarz) (RIT 4385a)<br/><b>MMR Shanghai Institute</b> (Shanghai‐191) (S79)<br/><b>Measles, Lanzhou Institute</b> (Shanghai‐191) (–)<br/><b>Measles‐Rubella, Beijing Tiantan</b> (Shanghai‐191) (–)<br/><b>M‐M‐R‐II, MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>MMR, Razi Vaccine and Serum Research</b> (AIK‐C) (Hoshino)<br/><b>M‐M‐RVAXPRO, Sanofi Pasteur‐MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>Trimovax, Sanofi Pasteur</b> </p> <p>(Schwarz) (Urabe AM9)<br/><b>Measles, Serum Institute of India Pvt.</b> (Edmonston‐Zagreb) (–)<br/><b>Measles‐Rubella, Serum Institute of India Pvt.</b> (Edmonston‐Zagreb) (–)<br/><b>MMR, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Tresivac, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Rouvax, Sanofi Pasteur</b> (Schwarz) (–) </p> <p><b>Risk period</b> </p> <p>8 to 35 days</p> <p><b>Washout periods</b> </p> <p>1 to 7 days</p> <p>36 to 42 days</p> <p><b>Control period</b> </p> <p>43 to 84 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The elevated risk estimates found for the Leningrad‐Zagreb mumps strain are consistent with previous studies (<a href="./references#CD004407-bbs2-0131" title="da CunhaSS , RodriguesLC , BarretoML , DouradoI . Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine2002;20(7-8):1106-12. ">gb‐da Cunha 2002</a>; <a href="./references#CD004407-bbs2-0132" title="da SilveiraCM , KmetzschCI , MohrdieckR , SperbAF , PrevotsDR . The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. International Journal of Epidemiology2002;31(5):978-82. ">gb‐da Silveira 2002</a>). Regarding Jeryl‐Lynn‐derived strain vaccines, although the study did not have enough power to confirm the absence of risk for these strains, the finding of zero cases in the risk window was consistent with the hypothesis of no association (<a href="./references#CD004407-bbs2-0028" title="BlackS , ShinefieldH , RayP , LewisE , ChenR , GlasserJ , et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal1997;16(5):500-3. ">bb‐Black 1997</a>; <a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 16 countries n = 84 confirmed aseptic menigitis cases</p> <p><b>(Risk</b> versus<b>control) period</b> </p> <p>(a) Overall risk of AM following mumps‐containing vaccines (35 versus 5)</p> <p>(b) Overall risk of AM following mumps‐containing vaccines (excluding cases from Iran) (22 versus 3) </p> <p>(c) Leningrad‐Zagreb strain (7 versus 1)</p> <p>(d) Vaccines products used Hoshino/Leningrad‐Zagreb/Urabe AM9 (27 versus 2)</p> <p>(e) Vaccines products used Hoshino/Leningrad‐Zagreb/Urabe AM9 (excluded cases from Iran) (14 versus 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) adjusted</b> </p> <p>(a) 10.8 (4.0 to 29.2)</p> <p>(b) 12.4 (3.1 to 49.1)</p> <p>(c) 6.4 (1.3 to 87.4)</p> <p><b>rr (95% CI) unadjusted</b> </p> <p>(d) 20.3 (48 to 85.2)</p> <p>(e) not estimable</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AM: aseptic meningitis<br/>CI: confidence interval<br/>CSO: cerebro‐spinal fluid<br/>HMO: health maintenance organisation<br/>ICD‐10: International Classification of Diseases<br/>incidence: cases/PT<br/>MIC: mass immunisation campaigns<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>n: number of participants<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>WHO: World Health Organization </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Safety: aseptic meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0035"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Safety: seizure (febrile/afebrile)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Authors' conclusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0107" title="VestergaardM , HviidA , MadsenKM , WohlfahrtJ , ThorsenP , SchendelD , et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA2004;292(3):351-7. ">cb‐Vestergaard 2004</a> </p> <p>Retrospective and prospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born in</p> <p>Denmark from</p> <p>1 January 1991 to</p> <p>31 December 1998</p> <p>aged 3 months to 5 years</p> <p>n = 537,171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information on febrile seizures and epilepsy was obtained from the National Hospital Register (NHR), which contains information on all patients discharged from Danish hospitals since 1977 (since 1995 information on outpatients (visits to emergency department and hospital clinics)). Diagnostic information was classified according to the Danish version of the ICD as follows: ICD‐8 was used from 1977 to 1993, and ICD‐10 was used from 1994 to the end of 1999. </p> <p><b>Febrile seizure:</b> </p> <p><b>(a) within 2 weeks after vaccination</b> </p> <p><b>(a1) 1 weeks after vaccination</b> </p> <p><b>(a2) 2 weeks after vaccination</b> </p> <p>ICD‐8 code 780.21 or ICD‐10 code R56.0, were aged between 3 and 60 months at the time of discharge, and had no recorded history of non‐febrile seizures, cerebral palsy, severe head traumas, intracranial tumours, meningitis, or encephalitis. The febrile seizures could not be classified as simple or complex because the NHR contains no information on number of febrile seizures occurring within the febrile episode, duration of the febrile seizures, and type of febrile seizures (generalised or focal onset). </p> <p><b>(b) Recurrent febrile seizure</b> </p> <p><b>(b1) within 2 weeks after vaccination</b> </p> <p><b>(b2) &gt; 2 weeks after vaccination</b> </p> <p><b>(c) Epilepsy</b> subsequent to a first febrile seizure episode </p> <p>Children were categorised with epilepsy if they had ICD‐8 code 345 or ICD‐10 code G40. </p> <p><b>(c1) within 2 weeks after vaccination</b> </p> <p><b>(c2) &gt; 2 weeks after vaccination</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccination status of the children was ascertained by using data of the National Board of Health to which vaccination data were transmitted by general practitioners. </p> <p><b>MMR vaccine:</b> </p> <p><b>Moraten</b> measles, <b>Jeryl Lynn</b> mumps, <b>Wistar RA 27/3</b> rubella </p> <p>The national vaccination program recommended during the entire study period that children should be vaccinated twice, at 15 months and at 12 years. </p> <p>Only the first vaccination is relevant to the endpoint under study.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination was associated with a transient increased rate of febrile seizures, but the risk difference was small even in high‐risk children. The long‐term rate of epilepsy was not increased in children who had febrile seizures following vaccination compared with children who had febrile seizures of a different aetiology. </p> <p><b>Febrile seizure:</b> no statistically significant difference in the RR of febrile seizures in the 2 weeks following vaccination between subgroups of children characterised by family history of seizures, sex, birth order, gestational age at birth, birthweight, or socioeconomic factors, compared with non‐vaccinated children within the subgroup under study. </p> <p>The highest rate ratio (2 weeks following vaccination) was found amongst <b>(a1)</b> <b>siblings of children with a history of epilepsy</b> compared with rate of febrile seizures following vaccination in siblings of children with no history of epilepsy. </p> <p><b>Recurrent febrile seizures and epilepsy</b> </p> <p>The authors found that children who experienced febrile seizures within 2 weeks of MMR vaccination had a 19% increased rate of recurrent febrile seizures but no increased rate of epilepsy during up to 105 months of follow‐up. The reference group consisted of children who had not been vaccinated when having their first febrile seizure. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> /<b>PT (years)</b> </p> <p>vaccinated</p> <p>(a) 7445/1,151,661</p> <p>versus</p> <p>unvaccinated</p> <p>10,541/793,568</p> <p>vaccinated</p> <p>(b1) 236/2212</p> <p>(b2) 981/12,675</p> <p>versus</p> <p>unvaccinated</p> <p>2753/23,560</p> <p>vaccinated</p> <p>(c1) 9/3825</p> <p>(c2) 95/21,938</p> <p>versus</p> <p>unvaccinated</p> <p>251/41,310</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)*</b> </p> <p>(a) 2.75 (2.55 to 2.97)</p> <p>(a1) 2.46 (2.22 to 2.73)</p> <p>(a2) 3.17 (2.89 to 3.49)</p> <p>amongst children with a personal history of febrile seizure</p> <p>(a1) 2.75 (2.32 to 3.26)</p> <p>(b1) 1.19 (1.01 to 1.41)</p> <p>(b2) 1.10 (0.96 to 1.26)</p> <p>(c1) 0.70 (0.33 to 1.50)</p> <p>(c2) 0.92 (0.59 to 1.43)</p> <p>(*) Poisson regression adjusted for age, calendar period, age of first febrile seizure, and current vaccination status </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0078" title="BarlowWE , DavisRL , GlasserJW , RhodesPH , ThompsonRS , MulloolyJP , et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine2001;345(9):656-61. ">cb‐Barlow 2001</a> </p> <p>Retrospective cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data are collected from 4 HMOs. Children (n = 716) with a confirmed seizure during the study period: </p> <p>from 1 March 1993 to 30 September 1993.</p> <p>n = 679,942 children<br/>n = 137,457 vaccinated MMR </p> <p>n = 340,386 vaccinated DTP</p> <p>n = 202,099 (unvaccinated)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> were identified through the automated data systems of each HMO, on the basis of visits classified according to the ICD‐9‐CM, as code 333.2 (myoclonus), code 345 (epilepsy), code 779.0 (convulsions in a newborn), or code 780.3 (convulsions). </p> <p><b>Simple febrile seizures</b> were defined as short, generalised seizures, accompanied by documented fever or a parental report of fever. </p> <p><b>Complex febrile seizures</b> were defined as febrile seizures that occurred more than once in 24 hours and either lasted for at least 12 minutes or were accompanied by focal signs. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> <br/>strains type not stated </p> <p><b>Exposure period (after vaccination):</b> </p> <p>(a1) 1 to 7 days</p> <p>(a2) 8 to 14 days</p> <p>(a3) 15 to 30 days</p> <p><b>Control period</b> <br/><b>(b)</b> The reference group<br/>at the time of the seizure was composed of children matched for age, calendar time, and HMO but who had not had a vaccination in the preceding 30 days. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study found significantly elevated risks of febrile seizures from 8 to 14 days after the administration of MMR vaccine. The authors did not find a significantly elevated risk of febrile seizures at any other time after vaccination, nor did they find an elevated risk of non‐febrile seizures at any time after vaccination with MMR vaccine. This risk translates into approximately 25 to 34 additional<br/>febrile seizures attributable to MMR vaccine for every 100,000. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 521 febrile seizures in the absence of vaccination</p> <p>Febrile seizures</p> <p>(a1) 8 cases</p> <p>(a2) 13 cases</p> <p>(a3) 11 cases</p> <p>Non‐febrile seizures</p> <p>(a1) 1 case</p> <p>(a2) 1 case</p> <p>(a3) 1 case</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>Febrile seizures</p> <p>(a1) 1.73 (0.72 to 4.15)</p> <p>(a2) 2.83 (1.44 to 5.55)</p> <p>(a3) 0.97 (0.49 to 1.95)</p> <p>Non‐febrile seizures</p> <p>(a1) not reported</p> <p>(a2) 1.11 (0.11 to 11.28)</p> <p>(a3) 0.48 (0.05 to 4.64)</p> <p>(*) Cox proportional hazard regression multivariate model estimates adjusted for age, sex, HMO, calendar time, and receipt of DTP vaccine. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0124" title="WardKN , BryantNJ , AndrewsNJ , BowleyJS , OhrlingA , VerityCM , et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics2007;120(2):314-21. ">db‐Ward 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 35 months (immunised with MMR; NK) with outcome of interest diagnosed between October 1998 and September 2001 (n = 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case definition of serious neurologic disease: any child 2 to 35 months old with a severe illness with fever and convulsions and/or encephalitis (see <a href="#CD004407-tbl-0033">Table 12</a>) was included. </p> <p><b>Severe illness with fever and convulsions</b> </p> <p> <ul id="CD004407-list-0028"> <li> <p>with a total duration of 30 min; or</p> </li> <li> <p>followed by encephalopathy for 2 to 23 h; or</p> </li> <li> <p>followed by paralysis or other neurologic signs not previously present for 24 h.</p> </li> </ul> </p> <p><b>Exclude:</b> </p> <p>Viral (aseptic) meningitis without encephalopathy</p> <p>The following confirmed causes were</p> <p>excluded: hypoxic/ischaemic; vascular; toxic; metabolic, neoplastic, traumatic, and pyogenic infections; uncomplicated convulsions; or a series of convulsions lasting 30 min in immunocompromised children. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure risk period:</b><br/>6 to 11 days after immunisation </p> <p><b>MMR vaccine type</b>, not reported </p> <p>Immunisation history of cases was obtained by the Immunisation Department of the Health Protection Agency (other than MMR vaccine the study also considers DTP, Hib, and MenC vaccines). Only cases with known vaccination history were included in the analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 11 days after measles, mumps, rubella vaccine there is an increased risk of fever and convulsions lasting 30 minutes. </p> <p>All 6 of the episodes temporally related to immunisation met the criteria for complex febrile convulsions. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Within 6 to 11 days</p> <p>With concurrent primary HHV‐6 or HHV‐7 infection</p> <p>(a) all (6 cases)</p> <p>(b) no (4 cases)</p> <p>(c) yes (2 cases)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a) 5.68 (2.31 to 13.97)</p> <p>(b) 5.80 (1.98 to 16.99)</p> <p>(c) 5.55 (1.12 to 27.63)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 24 months discharged from hospital in 5 districts in England (Ashford, Leicester, Nottingham, Preston, and Chorley &amp; Ribble) for varying periods between October 1988 and February 1993. Readmissions within 72 h with the same diagnosis were counted as 1 episode. </p> <p>n = 952 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b> </p> <p>ICD code 780.3 children aged 29 to 730 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p><b>Urabe</b> mumps strain </p> <p><b>Jeryl Lynn</b> mumps strain </p> <p>Rubella strain not specified</p> <p><b>Exposure risk period:</b> </p> <p>(a1) 6 to 11 days (1 to 2 weeks after vaccination)</p> <p>(a2) 15 to 35 days (3 to 5 weeks after vaccination)</p> <p><b>Control period:</b> </p> <p>(b) for each vaccine was defined as the time not included in a risk period</p> <p>The analyses were adjusted for age and were grouped in 6 equal intervals of about 2 months. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study shows that there was an attributable risk of 1 in 2600 doses of a febrile convulsion 15 to 35 days after giving Urabe MMR vaccine. There was no excess of admissions in the same period when Jeryl Lynn vaccine was given. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any strain</b> </p> <p>(a1) 49 cases</p> <p>(a2) 85 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Urabe strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 57 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Jeryl Lynn strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 9 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>Any strain</b> </p> <p>(a1) 3.04 (2.27 to 4.07)</p> <p>(a2) 1.51 (1.21 to 1.90)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Urabe strain</b> </p> <p>(a1) 3.77 (1.95 to 7.30)</p> <p>(a2) 1.66 (1.26 to 2.20)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Jeryl Lynn strain</b> </p> <p>(a1) 2.70 (1.81 to 4.01)</p> <p>(a2) 1.04 (0.56 to 1.93)</p> <p>(*) Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0119" title="MillerE , AndrewsN , StoweJ , GrantA , WaightP , TaylorB . Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology2007;165(6):704-9. ">db‐Miller 2007</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23 months with discharge diagnosis corresponding to the outcome of interest who received MMR n = 894 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b><br/>ICD‐10 code R560 or R568, febrile </p> <p>convulsion or fit, not otherwise specified,</p> <p>who were admitted between</p> <p>1 January 1998 and 30 June 2002</p> <p>were identified and linked with</p> <p>computerised immunisation records</p> <p>to obtain dates of MMR vaccination.</p> <p>Episodes within a same individual were</p> <p>considered as separate when they occurred</p> <p>at least 10 days apart.</p> <p>Case review not performed.</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Febrile convulsion</b> </p> <p>ICD‐10 codes R560 only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>(1) <b>MMRII</b> (Sanofi Pasteur) </p> <p><b>Edmonston‐Enders</b> measles strain, <b>Jeryl Lynn</b> mumps strain, between September 1992 and May 1998 </p> <p>(2) <b>MMR Priorix</b> (GlaxoSmithKline) </p> <p><b>Schwarz</b> measles strain </p> <p><b>RIT4385</b> (Jeryl Lynn) from May 1998 </p> <p>(3) unknown manufacturer</p> <p><b>Exposure risk period:</b> </p> <p><b>(a1)</b> a pre‐vaccination<br/>period of 2 weeks (removed from the background risk by treating it as a separate risk period to allow for delayed vaccination due to convulsion) </p> <p><b>(a2)</b> 6 to 11 days (1 to 2 weeks after vaccination) </p> <p><b>(a3)</b> 15 to 35 days (3 to 5 weeks after vaccination) </p> <p>.</p> <p><b>Control period</b> <br/><b>(b)</b> a pre‐vaccination period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The attributable risk of hospital admission for convulsion following receipt of any MMR vaccine was estimated as 1 in 1150 doses for the 6‐ to 11‐day postvaccination period, based on an estimated relative incidence of 4.09. The excess risk of convulsion in this period was attributable to the measles component of MMR vaccine. </p> <p>The relative incidence of convulsion in the 6‐ to 11‐day period was higher for Priorix than for MMRII, although the difference was not significant. </p> <p>There was no statistically significant evidence that children given MCC vaccine at the same time as MMR vaccine have a somewhat higher risk of convulsion in the 6‐ to 11‐day postvaccination period (rr 7.74, 3.82 to 15.71) than children who receive MMR but not MCC vaccine at the same time (rr 3.81, 2.87 to 5.05). </p> <p>Conclusion: there is no evidence to suggest that the new MMR vaccine used in the UK since mid‐1998 and derived from the Jeryl Lynn‐containing MMR vaccine causes aseptic meningitis attributable to its mumps component. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any MMR</b> vaccine </p> <p>(a1) 13 cases</p> <p>(a2) 66 cases</p> <p>(a3) 65 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMRII</b> vaccine </p> <p><b>Jeryl Lynn</b> </p> <p>(a1) 6 cases</p> <p>(a2) 27 cases</p> <p>(a3) 34 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR Priorix</b> vaccine </p> <p><b>RIT4385</b> </p> <p>(a1) 3 cases</p> <p>(a2) 19 cases</p> <p>(a3) 16 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Unknown manufacturer</b> </p> <p>(a1) 4 cases</p> <p>(a2) 20 cases</p> <p>(a3) 15 cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Febrile convulsion (R560 only)</b> </p> <p>(a1) not reported</p> <p>(a2) 52 cases</p> <p>(a3) 57 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>Any MMR</b> vaccine </p> <p>(a1) 0.38 (0.22 to 0.64)</p> <p>(a2) 4.09 (3.14 to 5.33)</p> <p>(a3) 1.13 (0.87 to 1.48)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMRII</b> vaccine </p> <p><b>Jeryl Lynn</b> </p> <p>(a1) 0.39 (0.18 to 0.84)</p> <p>(a2) 3.64 (2.44 to 5.44)</p> <p>(a3) 1.28 (0.89 to 1.84)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR Priorix</b> vaccine </p> <p><b>RIT4385</b> </p> <p>(a1) 0.47 (0.15 to 1.40)</p> <p>(a2) 6.26 (3.85 to 10.18)</p> <p>(a3) 1.48 (0.88 to 2.50)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Unknown manufacturer</b> </p> <p>(a1) 0.32 (0.13 to 0.81)</p> <p>(a2) 3.53 (2.23 to 5.61)</p> <p>(a3) 0.75 (0.44 to 1.26)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Febrile convulsion (R560 only)</b> </p> <p>(a1) not reported</p> <p>(a2) 4.27 (3.17 to 5.76)</p> <p>(a3) 1.33 (1.00 to 1.77)</p> <p>(*) Poisson regression</p> <p>exposure risk period versus control period</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0116" title="McClureDL , JacobsenSJ , KleinNP , NalewayAL , KharbandaEO , GlanzJM , et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine2019;37(1):76-9. ">db‐McClure 2019</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 556,864) were eligible if they had received their first dose of measles‐containing vaccine at age 12 through 23 months from January 2003 through September 2015. </p> <p>Children were excluded if they had a history of seizure or conditions strongly related to seizure prior to 12 months of age. </p> <p>Children born before 37 weeks gestational age were classified as <b>preterm (&lt; 37 weeks)</b> and children born 37 weeks gestational age as <b>full term (≥ 37 weeks).</b> </p> <p>Preterm children were further classified into those born <b>early preterm (&lt; 35 weeks)</b> and <b>late preterm</b> <b>(35 through 36 weeks)</b> gestational age. </p> <p>n = 24,489 were excluded because of documented history of seizures before age 12 months.</p> <p>In analysis n = 532,375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure (febrile/afebrile)</b> </p> <p>A seizure was defined as the first</p> <p>emergency department or inpatient</p> <p>hospital encounter with ICD‐9‐CM</p> <p>diagnostic code of 780.3 (convulsions)</p> <p>during the 42 days following vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR and MMRV vaccines</b> <br/>strains type not stated </p> <p><b>Risk interval</b> </p> <p>7 to 10 days after vaccination</p> <p><b>Control interval</b> </p> <p>15 to 42 days after vaccination</p> <p>n = number of children</p> <p><b>(a) Overall</b> <br/><b>(any measles vaccine)</b> </p> <p>(a1) &lt; 37 weeks n = 45,343</p> <p>(a2) &lt; 35 weeks n = 16,596</p> <p>(a3) 35 to 36 weeks n = 28,757</p> <p>(a4) ≥ 37 weeks n = 487,032</p> <p><b>(b) MMR</b> </p> <p>(b1) &lt; 37 weeks n = 37,262</p> <p>(b2) ≥ 37 weeks n = 403,238</p> <p><b>(c) MMRV</b> </p> <p>(c1) &lt; 37 weeks n = 8081</p> <p>(c2) ≥ 37 weeks n = 83,794</p> <p><b>Age at vaccination</b> <br/><b>(any measles vaccine)</b> </p> <p><b>(d) 12 to 15 months</b> </p> <p>(d1) &lt; 37 weeks n = 41,391</p> <p>(d2) ≥ 37 weeks n = 442,919</p> <p><b>(e) 16 to 23 months</b> </p> <p>(e1) &lt; 37 weeks n = 3952</p> <p>(e2) ≥ 37 weeks n = 4413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>the results support the current</p> <p>ACIP recommendations<br/>to administer the first dose of measles‐containing vaccine<br/>at age 12 through 15 months for all children, including those born<br/>preterm. Delaying vaccination of measles‐containing vaccines<br/>may increase the risk of seizures following vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk versus control interval</b><br/>cases/PT‐years </p> <p><b>(a) Overall</b> <br/><b>(any measles vaccine)</b> </p> <p>(a1) 31/500 versus 56/3500<br/>(a2) 10/182 versus 22/1294<br/>(a3) 21/313 versus 34/2267<br/>(a4) 232/5395 versus 510/36,429 </p> <p><b>(b) MMR</b> </p> <p>(b1) 22/407 versus 48/2824<br/>(b2) 163/434 versus 425/30,357 </p> <p><b>(c) MMRV</b> </p> <p>(c1) 9/90 versus 8/615<br/>(c2) 69/908 versus 85/6538 </p> <p><b>Age at vaccination</b> <br/><b>(any measles vaccine)</b> </p> <p><b>(d) 12 to 15 months</b> </p> <p>(d1) 27/450 versus 51/3188<br/>(d2) 200/4878 versus 477/34,071 </p> <p><b>(e) 16 to 23 months</b> </p> <p>(e1) 4/43 versus 5/294<br/>(e2) 32/485 versus 33/3300 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>(a) Overall</b> <br/><b>(any measles vaccine)</b> </p> <p>(a1) 3.9 (2.5 to 6.0)<br/>(a2) 3.2 (1.5 to 6.7)<br/>(a3) 4.3 (2.5 to 7.4)<br/>(a4) 3.2 (2.7 to 3.7) </p> <p><b>(b) MMR</b> </p> <p>(b1) 3.2 (1.9 to 5.3)<br/>(b2) 2.7 (2.2 to 3.2) </p> <p><b>(c) MMRV</b> </p> <p>(c1) 7.9 (3.0 to 20)<br/>(c2) 5.7 (4.1 to 7.8) </p> <p><b>Age at vaccination</b> <br/><b>(any measles vaccine)</b> </p> <p><b>(d) 12 to 15 months</b> </p> <p>(d1) 3.7 (2.3 to 5.9)<br/>(d2) 2.9 (2.5 to 3.5) </p> <p><b>(e) 16 to 23 months</b> </p> <p>(e1) 5.6 (1.5 to 21)<br/>(e2) 6.8 (4.2 to11) </p> <p>(*) Poisson regression</p> <p>risk interval versus control interval</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0113" title="MacartneyK , GiddingHF , TrinhL , WangH , DeyA , HullB , et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatrics2017;171(10):992-8. ">db‐Macartney 2017</a><br/>Self‐controlled case series </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 11 to 23 months.</p> <p>Analysis was further restricted to include only children who had</p> <p>(1) 1 dose of MMR vaccine followed</p> <p>by 1 dose of MMRV vaccine at least 27</p> <p>days later (consistent with</p> <p>NIP recommendations),</p> <p>(2) 1 dose of MMR vaccine</p> <p>(as some had not yet received</p> <p>MMRV vaccine), or</p> <p>(3) no MMR or MMRV vaccine</p> <p>(unvaccinated children, who contribute</p> <p>to the age‐specific relative incidence).</p> <p>Children who received MMRV</p> <p>vaccine as their first MCV</p> <p>were excluded because this schedule was not consistent with NIP recommendations and occurred rarely. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile seizures</b> </p> <p>in all children younger than 5 years.</p> <p>Periodic review of all ICD‐10‐Australian</p> <p>Modification coded R56.0 was also</p> <p>conducted to capture additional cases.</p> <p>Clinical and demographic data were</p> <p>collected from the medical records</p> <p>and caregiver interviews, and all FS</p> <p>diagnoses were confirmed.</p> <p>The primary analysis included</p> <p>children who had both first<br/>and subsequent FS episodes </p> <p>(considered unique episodes), in<br/>which the subsequent FS was </p> <p>separated by at least 7 days from<br/>a previous episode. </p> <p>2 sensitivity analyses were conducted:<br/>(1) adjustment for age using </p> <p>finer intervals (1‐month age groups);</p> <p>(2) restriction of the analysis</p> <p>to first FS episodes.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV Priorix‐Tetra</p> <p>MMR+V</p> <p>Risk period</p> <p>after vaccination</p> <p>(a) 5 to 12 days</p> <p>(b) 13 to 30 days</p> <p>Control period</p> <p>before vaccination</p> <p>excluding interval</p> <p>−13 to −1 days before</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusions:</b> </p> <p><b>"</b>To our knowledge, this is the </p> <p>first study to provide evidence of the absence of an association between</p> <p>use of MMRV vaccine as the</p> <p>second dose of MCV</p> <p>in toddlers and an increased</p> <p>risk of FSs.</p> <p>Incorporation of MMRV vaccine</p> <p>has facilitated improvements</p> <p>in vaccine coverage that will potentially improve disease control.<b>"</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) Primary analysis</b>: children who had both first and subsequent episodes </p> <p><b>(2) Adjustment</b> for age using 1‐month interval </p> <p><b>(3) Restriction</b> of the first FS episode </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>(1) MMR</b> </p> <p>(a) 2.71 (1.71 to 4.29)</p> <p>(b) 0.89 (0.54 to 1.48)</p> <p><b>(1) MMRV</b> </p> <p>(a) 1.08 (0.55 to 2.13)</p> <p>(b) 1.08 (0.67 to 1.74)</p> <p><b>(2) MMR</b> </p> <p>(a) 2.57 (1.56 to 4.43)</p> <p>(b) 0.83 (0.49 to 1.40)</p> <p><b>(2) MMRV</b> </p> <p>(a) 1.17 (0.57 to 2.40)</p> <p>(b) 1.10 (0.66 to 1.83)</p> <p><b>(3) MMR</b> </p> <p>(a) 2.85 (1.78 to 4.56)</p> <p>(b) 0.82 (0.47 to 1.43)</p> <p><b>(3) MMRV</b> </p> <p>(a) 1.06 (0.49 to 2.27)</p> <p>(b) 1.21 (0.73 to 2.01)</p> <p>(*) Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0114" title="MacDonaldSE , DoverDC , SimmondsKA , SvensonLW . Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ: Canadian Medical Association Journal2014;186(11):824-9. [PMID: 24914115]">db‐MacDonald 2014</a><br/>Person‐time cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23</p> <p>months who had received</p> <p>either MMRV or<br/>MMR+V in Alberta<br/>between 2006 and 2012. </p> <p>n = 277,774</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure events</b> </p> <p>ascertained from 3 administrative databases:</p> <p>1) the physician claims database;<br/>2) the ambulatory care reporting </p> <p>system, which includes emergency</p> <p>department visits;</p> <p>3) the hospital discharge abstracts</p> <p>database.</p> <p>From the physician claims database</p> <p>(ICD‐9), codes 780.3* for convulsions and</p> <p>the ambulatory care and hospital discharge</p> <p>databases (ICD, 10th revision, Canadian</p> <p>version, codes R56.0* for febrile<br/>convulsions), using coding consistent </p> <p>with other<br/>studies of febrile seizures after vaccination. </p> <p><b>High risk (cohort)</b> </p> <p>Children with a personal history of</p> <p>febrile seizure; seizure disorder;</p> <p>central nervous system injury, infection, or neoplasm; encephalopathy; or a progressive,<br/>evolving, or unstable neurologic </p> <p>condition (as identified from</p> <p>physician claims, emergency department</p> <p>visits, or</p> <p>hospital discharges)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b> </p> <p>vaccine (Priorix‐Tetra)</p> <p>administered to children in Alberta, relative to</p> <p>same‐day</p> <p>administration of separate MMR and varicella<br/>(MMR+V) vaccines. </p> <p><b>Risk period</b> </p> <p>(after vaccination)</p> <p>(a) 0 to 42 days<br/>(b) 7 to 10 days </p> <p><b>Control period</b> </p> <p>(before vaccination)</p> <p>42 days preceding vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>Combining MMR and varicella into a </p> <p>single vaccine decreases</p> <p>pain for children</p> <p>and distress for parents,</p> <p>thus addressing common barriers</p> <p>to vaccine uptake, and may improve</p> <p>vaccine coverage levels and decrease immunisation delivery costs.</p> <p>These potential benefits must be balanced<br/>by the increased risk (albeit small) of febrile<br/>seizures with the combination vaccine. </p> <p>Febrile seizures are typically self‐limiting</p> <p>and rarely have long‐term effects,</p> <p>but they can be extremely distressing</p> <p>for parents, may precipitate acute care</p> <p>visits, and may undermine confidence</p> <p>in immunisation</p> <p>programmes. It is a matter for debate<br/>whether the choice of separate </p> <p>versus combination vaccine is a policy</p> <p>decision or a choice for parents to make in consultation with their vaccination provider.</p> <p>If MMRV continues to be offered for<br/>first‐dose administration, it might be </p> <p>advisable to counsel parents regarding</p> <p>antipyretic use if children</p> <p>experience a fever within the</p> <p>peak risk period.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Full cohort</b> n = 277,774 </p> <p><b>MMRV</b> n = 96,686 </p> <p>(a1) 0 to 41 days</p> <p>(b1) 7 to 10 days</p> <p><b>MMR+V</b> n = 181,088 </p> <p>(a2) 0 to 41 days</p> <p>(b2) 7 to 10 days</p> <p><b>Low risk</b> n = 266,768 </p> <p><b>MMRV</b> n = 92,570 </p> <p>(b3) 7 to 10 days</p> <p><b>MMR+V</b> n = 174,198 </p> <p>(b4) 7 to 10 days</p> <p><b>High risk</b> n = 11,006 </p> <p><b>MMRV</b> n = 4116 </p> <p>(b5) 7 to 10 days</p> <p><b>MMR+V</b> n = 6890 </p> <p>(b5) 7 to 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>MMRV (full‐cohort)</b> </p> <p>(a1) 1.80 (1.43 to 2.27)</p> <p>(b1) 6.57 (4.77 to 9.05)</p> <p><b>MMR+V (full‐cohort)</b> </p> <p>(a2) 1.48 (1.22 to 1.79)</p> <p>(b2) 3.30 (2.40 to 4.52)</p> <p><b>MMRV (low risk)</b> </p> <p>(b3) 6.69 (4.90 to 9.13)</p> <p><b>MMR+V (low risk)</b> </p> <p>(b4) 2.94 (2.13 to 4.07)</p> <p><b>MMRV (high risk)</b> </p> <p>(b5) 4.68 (2.49 to 8.79)</p> <p><b>MMR+V (high risk)</b> </p> <p>(b6) 3.61 (2.20 to 5.93)</p> <p>(*) Poisson regression</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ACIP: Advisory Committee on Immunization Practice<br/>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>DTP: diphtheria, tetanus, pertussis vaccine<br/>FS: febrile seizures<br/>HHV: human herpesvirus<br/>Hib: Haemophilus influenzae b vaccine<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>ICD‐9‐CM: International Classification of Diseases, 9th Revision, Clinical Modification<br/>incidence: cases/PT<br/>MCV: measles‐containing vaccines<br/>MenC: meningococcus C vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, plus varicella vaccine<br/>NIP: National Imminization Program<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence; incidence rate ratio)<br/>RR: risk ratio (relative risk) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Safety: seizure (febrile/afebrile)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0036"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Safety: MMRV versus MMR/MMR+V ‐ febrile seizures</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Authors' conclusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a> </p> <p>Retrospective<br/>cohort study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index cohort</b><br/>(n = 31,298) </p> <p>all children ages 12 to 60 months</p> <p>vaccinated with MMRV at KPSC</p> <p>from February 2006 to June 2007.</p> <p>Children were excluded</p> <p>if they had</p> <p>a history of measles,</p> <p>mumps, rubella,</p> <p>or varicella disease or</p> <p>history of<br/>vaccination for any of </p> <p>these diseases.</p> <p><b>Comparison (matched) cohorts</b> </p> <p>(1) children vaccinated with</p> <p>MMR+V</p> <p>concomitantly before the routine</p> <p>use of MMRV at KPSC</p> <p>(November 2003 to January 2006).</p> <p>Children were optimally</p> <p>matched without</p> <p>replacement to children</p> <p>vaccinated with</p> <p>MMRV, on the basis of age,</p> <p>sex, and</p> <p>vaccination calendar day</p> <p>and month,</p> <p>and had to fulfil the same</p> <p>enrolment criteria.<br/>(2) pre‐vaccination </p> <p>self‐comparison period</p> <p>defined by the period</p> <p>from 60 to 30 days</p> <p>prior to vaccination with MMRV.</p> <p>(3) postvaccination</p> <p>self‐comparison period</p> <p>defined by the period</p> <p>from 60 to 90 days</p> <p>following vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b> </p> <p>Potential convulsions were</p> <p>identified as occurring on any</p> <p>visit with<br/>a diagnosis coded as<br/>779.0 (neonatal seizures), </p> <p>333.2 (myoclonus),<br/>345 (epilepsy), </p> <p>780.39 (other convulsion),</p> <p>780.3 (convulsion),<br/>780.31 (simple febrile convulsion), </p> <p>780.32 (complex febrile convulsion)<br/>regardless of setting (e.g. inpatient, </p> <p>outpatient, emergency<br/>department, or outside facility). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV: ProQuad</p> <p>contains components</p> <p>of 2 Merck vaccines,</p> <p>MMR‐II (MMR) and</p> <p>VARIVAX (V),</p> <p>and was approved in the</p> <p>USA</p> <p>in September 2005.</p> <p>Before MMRV was available,</p> <p>MMR and V were usually given concomitantly</p> <p>as 2 separate injections.</p> <p><b>Risk interval</b> </p> <p>(a) 0 to 4 days</p> <p>(b) 5 to 12 days</p> <p>(c) 13 to 30 days</p> <p>(d) 0 to 30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>"These data suggest that the risk of</p> <p>febrile convulsion is increased in</p> <p>days 5–12</p> <p>following vaccination with MMRV</p> <p>as compared</p> <p>to MMR+V given separately during</p> <p>the same visit,</p> <p>when post‐vaccination fever and</p> <p>rash are also</p> <p>increased in clinical trials.</p> <p>While there was</p> <p>no evidence of an increase in the</p> <p>overall month</p> <p>following vaccination,</p> <p>the elevated</p> <p>risk during</p> <p>this time period should be</p> <p>communicated</p> <p>and needs to be balanced</p> <p>with the</p> <p>potential benefit of a</p> <p>combined vaccine."</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases versus cases</p> <p><b>MMRV</b> versus<b>MMR+V</b><br/>matched n = 31,298 </p> <p>(a) 9 versus 7<br/>(b) 22 versus 10<br/>(c ) 13 versus 23<br/>(d) 44 versus 40<br/><br/><b>MMRV</b> versus<b>Pre‐Vacc</b> </p> <p>matched n = 31,298<br/>(a) 9 versus 4<br/>(b) 22 versus 3<br/>(c ) 13 versus 9<br/>(d) 44 versus 16<br/><br/><b>MMRV</b> versus<b>Post‐Vacc</b> </p> <p>matched n = 31,298<br/>(a) 9 versus 5<br/>(b) 22 versus 5<br/>(c ) 13 versus 13<br/>(d) 44 versus 23 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> <br/><b>MMRV</b> versus<b>MMR+V</b><br/>(a) 1.28 (0.48 to 3.45)<br/>(b) 2.2 (1.04 to 4.65)<br/>(c ) 0.57 (0.29 to 1.12)<br/>(d) 1.1 (0.72 to 1.69) </p> <p><b>MMRV</b> versus<b>Pre‐Vacc</b> <br/>(a) 2.25 (0.69 to 7.31)<br/>(b) 7.33 (2.2 to 24.5)<br/>(c ) 1.44 (0.62 to 3.38)<br/>(d) 2.75 (1.55 to 4.87)<br/><br/><br/><b>MMRV</b> versus<b>Post‐Vacc</b><br/>(a) 1.8 (0.6 to 5.37)<br/>(b) 4.4 (1.67 to 11.62)<br/>(c ) 1 (0.46 to 2.16)<br/>(d) 1.91 (1.16 to 3.17) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> <p>Retrospective<br/>cohort study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index cohort</b> </p> <p>Children aged</p> <p>12 to 23 months</p> <p>who were members of the 7</p> <p>participating versusD sites and</p> <p>had received their first dose of</p> <p>MMRV (n = 83,107)</p> <p><b>Comparison cohorts</b> </p> <p>(1) children vaccinated with<br/>MMR+V between </p> <p>January 2000 and October 2008 (n = 376,354)</p> <p>(2) children vaccinated with<br/>MMR vaccine alone (n = 145,302) </p> <p>(2000 to 2008)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure</b> <b>event</b> </p> <p>The first instance during the 42 days</p> <p>after MMRV vaccination with</p> <p>ICD‐9 codes 345* (epilepsy) or 780.3*<br/>(convulsion) in the emergency department<br/>or hospital. Postvaccination outpatient fever </p> <p>visits were examined by using ICD‐9 code<br/>780.6 for fever or febrile illness at all 7<br/>participating versusD sites from January<br/>2000 through October 2008. Similar to<br/>seizure cases, fever visits were censored<br/>after the first occurrence within<br/>the 42 days. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV (Merck &amp; Co</p> <p>Inc, West Point, PA)</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> <p>(b) 0 to 42 days</p> <p>(c) 0 to 30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>Amongst 12‐ to 23‐month‐olds </p> <p>who had received their first dose of</p> <p>measles‐containing vaccine,</p> <p>fever and seizure were elevated 7<br/>to 10 days after vaccination. </p> <p>Vaccination with MMRV results</p> <p>in 1 additional<br/>febrile seizure for every 2300 </p> <p>doses given instead of separate<br/>MMR varicella vaccines. </p> <p>Providers who recommend</p> <p>MMRV should<br/>communicate to parents that it </p> <p>increases the risk of fever and seizure<br/>over that already associated with measles‐containing vaccines. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures cases from<br/>2000 to 2008 </p> <p><b>MMRV</b> n = 83,107 </p> <p>(a) 77 cases</p> <p>(b) 189 cases</p> <p>(c) not reported</p> <p><b>MMR+V</b> n = 376,354 </p> <p>(a) 174</p> <p>(b) 598</p> <p>(c) not reported</p> <p><b>MMR</b> n = 145,302 </p> <p>(a) 42</p> <p>(b) 151</p> <p>(c) not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p>(a) 1.98 (1.43 to 2.73)</p> <p>(b) 1.42 (1.11 to 1.81)</p> <p>(c) 1.40 (1.06 to 1.85)</p> <p>(*) Poisson regression</p> <p>due to rarity of the event</p> <p>rr (rate ratio)</p> <p>is very close to RR</p> <p><b>RR (95% CI)</b> </p> <p><b>MMRV</b> versus<b>MMR</b> </p> <p>(a) 3.21 (2.2 to 4.67)<br/>(b) 2.19 (1.77 to 2.71)<br/>(c) not reported </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a><br/>Retrospective<br/>cohort study </p> <p>linked to<br/><a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children<br/>aged 48 to 83 months </p> <p>who were<br/>members of the 7 </p> <p>participating versusD<br/>sites between </p> <p>January 2000 and October 2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure</b> <b>event</b> </p> <p>Postvaccination seizure event as the first<br/>instance during the 42 days after<br/>a measles‐ or varicella‐containing vaccine<br/>of the ICD‐9 codes<br/>345* (epilepsy) or 780.3* (convulsion) in<br/>the emergency department or hospital.<br/>The authors identified postvaccination medically<br/>attended outpatient fever events by using<br/>ICD‐9 code 780.6 (fever and other physiologic<br/>disturbances of temperature regulation). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) MMRV (Merck &amp; Co)<br/>2) MMR (Merck &amp; Co Inc, </p> <p>West Point, PA) +</p> <p>varicella (Merck &amp; Co)</p> <p>separately administered on the same day</p> <p>3) MMR</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> <p>(b) 0 to 42 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> </p> <p>This study provides</p> <p>reassurance that MMRV</p> <p>and MMR+V were</p> <p>not associated with an increased</p> <p>risk of febrile seizures</p> <p>among 4‐ to 6‐year‐olds.</p> <p>The authors can rule out with 95%</p> <p>confidence a risk greater</p> <p>than 1 febrile seizure</p> <p>per 15,500 MMRV doses</p> <p>and 1 per 18,000</p> <p>MMR+V doses.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases/PT</b> </p> <p><b>MMRV</b> n = <b>86,750</b> <br/>(a) 4/950.1<br/>(b) 19/10,497.2<br/><br/><b>MMR+V</b> n = <b>67,438</b> <br/>(a) 0/739<br/>(b) 10/7874<br/><br/><b>MMR</b> n = <b>479,311</b><br/>(a) 9/5252.7<br/>(b) 99/55,618 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> <br/>(a) 7 (0.38 to 130.02)<br/>(b) 1.48 (0.69 to 3.18)<br/><br/><b>MMRV</b> versus<b>MMR</b><br/>(a) 2.46 (0.76 to 7.99)<br/>(b) 1.06 (0.65 to 1.73) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0100" title="Rowhani-RahbarA , FiremanB , LewisE , NordinJ , NalewayA , JacobsenSJ , et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatrics2013;167(12):1111-7. [PMID: 24126936]">cb‐Rowhani‐Rahbar 2013</a> </p> <p>Retrospective<br/>cohort study </p> <p>linked to<br/><a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 840,348 children</p> <p>12 to 23 months of</p> <p>age who had received a measles‐containing</p> <p>vaccine from 2001</p> <p>through 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever events</b> in the o </p> <p>utpatient setting</p> <p>was defined using ICD‐9 code 780.6*.</p> <p><b>Seizure events</b> in the postimmunisation </p> <p>medically</p> <p>attended in the emergency</p> <p>department</p> <p>or hospital</p> <p>setting was defined using</p> <p>ICD‐9 code 780.3* (convulsion) or 345* (epilepsy).</p> <p>The authors do not distinguish</p> <p>between febrile and</p> <p>afebrile seizures.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) MMRV (Merck &amp; Co)<br/>2) MMR (Merck &amp; Co Inc, </p> <p>West Point, PA) +</p> <p>varicella (Merck &amp; Co)</p> <p>separately administered on the same day</p> <p>3) MMR</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> <p>(b) 0 to 42 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> </p> <p>Measles‐containing</p> <p>vaccines are associated</p> <p>with a lower<br/>increased risk of </p> <p>seizures when</p> <p>administered at</p> <p>12 to 15 months of age.</p> <p>Findings of this study<br/>that focused on safety </p> <p>outcomes</p> <p>highlight the importance</p> <p>of timely</p> <p>immunisation of children<br/>with the first dose of </p> <p>measles‐containing vaccines.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 to 15 months</b> <br/><b>Fever cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b> <br/>MMRV n = 105,578 (2191) (864)<br/>MMR+V n = 520,436 (11,300) (3553)<br/>MMR n = 102,537 (2558) (760)<br/><br/><b>16 to 23 months</b> <br/><b>Fever cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b> <br/>MMRV n = 14,799<br/>(300) (116)<br/>MMR+V n = 64,551<br/>(1310) (399)<br/>MMR n = 32,447<br/>(744) (227)<br/><br/><b>12 to 15 months</b> <br/><b>Seizures cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b> <br/>MMRV n = 105,578<br/>(255) (99)<br/>MMR+V n = 520,436<br/>(997) (244)<br/>MMR n = 102,537<br/>(172) (45)<br/><br/><b>16 to 23 months</b> <br/><b>Fever cases</b> </p> <p><b>(0 to 42 days) (7 to 10 days)</b><br/>MMRV n = 14,799<br/>(68) (30)<br/>MMR+V n = 64,551<br/>(231) (70)<br/>MMR n = 32,447<br/>(87) (31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p><b>rr (95% CI)(*)</b> </p> <p><b>Fever</b> </p> <p><b>12 to 15 months</b><br/>(a) 1.4 (1.3 to 1.5) </p> <p><b>16 to 23 months</b> </p> <p>(a) 1.4 (1.1 to 1.7)</p> <p><b>Seizures</b> </p> <p><b>12 to 15 months</b><br/>(a) 2.0 (1.4 to 2.8) </p> <p><b>16 to 23 months</b> </p> <p>(a) 2.1 (1.3 to 3.3)</p> <p>(*)Poisson regression</p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p><b>RR (95% CI)</b> <br/>(a) 2 (1.63 to 2.45)<br/>(b) 1.28 (1.13 to 1.44)<br/><br/><b>MMRV</b> versus<b>MMR</b> <br/><b>RR (95% CI)</b> </p> <p>(a) 1.9 (1.43 to 2.53)<br/>(b) 1.4 (1.19 to 1.65) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a><br/><a href="./references#CD004407-bbs2-0085" title="Gavrielov-YusimN , HoshenM , SingerSR , NeumannL , BalicerRD . The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine2014;32(39):4954-9. [PMID: 25075803]">cb‐Gavrielov‐Yusim 2014</a><br/>Retrospective </p> <p>cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index cohort</b> </p> <p>All participants were</p> <p>aged 10 to 24 months.<br/>(intervention) </p> <p>n = 8344 MMRV<br/>immunised from<br/>1 September 2008 to 31 December 2009 </p> <p><b>Comparison cohorts</b><br/>n = 90,294 MMR<br/>immunised from<br/>1 January 2005 to 31 August 2008 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsion</b><br/>Validation FC cases were retrieved </p> <p>using the<br/>following coded and free‐text </p> <p>diagnoses:<br/>“convulsions in newborn”, </p> <p>“convulsions”,<br/>“febrile convulsions”,<br/>“complex febrile convulsions”,<br/>“other convulsions”.<br/>Children diagnosed with </p> <p>FC differential diagnoses<br/>during the observational period, i.e.<br/>head trauma, epilepsy, or CNS infection,<br/>were excluded from the study.<br/>The exact coded and free‐text </p> <p>diagnoses used<br/>to depict coincidental differential </p> <p>conditions were<br/>“concussion”, “cerebral disease”,<br/>“acquired hydrocephalus”,<br/>“cerebral palsy”, “cerebral cyst”,<br/>“epilepsy”, “meningism”,<br/>types of “bacterial meningitis”, </p> <p>“encephalitis”,<br/>“meningococcal meningitis”,<br/>“aseptic viral meningitis”.<br/>Children were also excluded </p> <p>from the study<br/>if they had a history<br/>of mumps, measles, rubella,<br/>or varicella prior to vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV Priorix‐Tetra</p> <p>MMR (Priorix) GSK<br/>Priorix‐Tetra combines the<br/>components of 2 of GSK's live<br/>attenuated vaccines:<br/>MMR (Priorix) and<br/>varicella vaccine </p> <p>(Varilrix).</p> <p><b>Risk intervals</b> </p> <p><b>Postvaccination</b> </p> <p>(a) 40 days</p> <p>(b) 5 to 12 days</p> <p>(c) 7 to 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>"The risk of FC is elevated<br/>in children immunized with </p> <p>GSK’s MMRV vaccine.<br/>This risk is transient and </p> <p>appears during the<br/>second week<br/>following immunization.<br/>The relative fraction of </p> <p>FC attributable to MMRV<br/>vaccine is very low in the<br/>target population, </p> <p>and is not detectable<br/>in extended follow‐up." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases MMRV/</b> <br/><b>N MMRV</b> <br/>versus<br/><b>N cases MMR/</b> <br/><b>N MMR</b> </p> <p>(a) 19/8344 versus 198/90,294<br/>(b) 8/8344 versus 38/90,294<br/>(c) 7/8344 versus 30/90,294 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>unadjusted estimates<br/>(a) 1.04 (0.65 to 1.66)<br/>(b) 2.28 (1.06 to 4.89)<br/>(c) 2.53 (1.11 to 5.76) </p> <p>adjusted estimate(**)</p> <p>(a) 1.00 (0.6 to 1.67)<br/>(b) 2.16 (1.01 to 4.64)<br/>(c) 2.36 (1.03 to 5.38) </p> <p>(**)</p> <p>2 different types of multivariate<br/>models were used: </p> <p>(a) Cox regression HR</p> <p>(b) logistic‐regression OR</p> <p>(c) logistic‐regression OR</p> <p>Due to rarity of events,<br/>HR and OR are very close. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0101" title="GvozdenovicE , VetterV , WillameC , RosillonD . Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine2018;36(39):5803-6. SchinkT , HolstiegeJ , KowalzikF , ZeppF , GarbeE . Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine2014;32(6):645-50. [PMID: 24374498]">cb‐Schink 2014</a><br/>Matched<br/>cohort study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All children born between</p> <p>1 January 2004 and 31 December 2008</p> <p>n = 226,267 received an</p> <p>immunisation</p> <p>with 1 of the index</p> <p>vaccines</p> <p>during the study period</p> <p>(2006 to 2008)</p> <p><b>Index cohort</b> </p> <p>n = 82,656 MMRV</p> <p><b>Comparison cohorts</b> </p> <p>n = 111,241 MMR</p> <p>n = 32,370 MMR+V</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Febrile convulsions</b> </p> <p>Diagnosis of FC, i.e. an ICD‐10‐GM code R56.0</p> <p>in any of the hospital diagnoses.</p> <p>2 outcome definitions, as follows.</p> <p><b>The primary outcome “FC narrow”</b> </p> <p>was defined as hospitalisation where</p> <p>no alternative plausible cause of FC.</p> <p>This endpoint included:</p> <p><b>(i)</b> all hospitalisation with FC as main discharge </p> <p>diagnosis;</p> <p><b>(ii)</b> all hospitalisation with FC as main admission </p> <p>diagnosis</p> <p>and without a main discharge diagnosis of</p> <p>an infectious disease</p> <p>(except measles, mumps, rubella, or</p> <p>chickenpox)</p> <p>or a neurological condition;</p> <p><b>(iii)</b> all hospitalisation with FC as secondary </p> <p>or ancillary diagnosis and a main discharge diagnosis</p> <p>coded as complication following immunisation</p> <p>(ICD‐10 code</p> <p>T88.0 infection following immunization or</p> <p>T88.1 other complications following immunization,</p> <p>not elsewhere classified).</p> <p>Due to exclusion of alternative causes of FC</p> <p>in this outcome definition,</p> <p>it was assumed that it would have higher</p> <p>specificity, but lower sensitivity.<br/><b>The secondary outcome “FC Jacobsen”</b> was defined as follows: </p> <p>only hospitalisations for FC with a neurological condition</p> <p>coded as main discharge diagnosis</p> <p>were excluded (<a href="./references#CD004407-bbs2-0089" title="JacobsenSJ , AckersonBK , SyLS , TranTN , JonesTL , YaoJF , et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine2009;27(34):4656-61. [PMID: 19520201]">cb‐Jacobsen 2009</a>). </p> <p>Consequently, “FC Jacobsen” included:</p> <p><b>(i)</b> all hospitalisation with FC as main discharge </p> <p>diagnosis;</p> <p><b>(ii)</b> all hospitalisation with FC as main admission </p> <p>diagnosis</p> <p>and without a main discharge diagnosis</p> <p>of a neurological condition; and</p> <p><b>(iii)</b> all hospitalisation with FC as secondary </p> <p>or ancillary diagnosis and with a main discharge</p> <p>diagnosis coded as complication following immunisation.</p> <p><b><i>“FC narrow” cases are a subset of “FC Jacobsen” cases.</i> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMRV</b>: Priorix‐Tetra </p> <p>(GSK) compared to</p> <p><b>MMR and V</b> vaccines </p> <p>(MMR+V).</p> <p><b>Risk interval</b> </p> <p><b>postvaccination</b> </p> <p>(a) 0 to 4 days</p> <p>(b) 5 to 12 days</p> <p>(c) 13 to 30 days</p> <p>(d) 0 to 30 days</p> <p>.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>This study suggests a similar<br/>risk of FC after a first dose of<br/>Priorix‐Tetra as has been<br/>observed for a first dose of ProQuad,<br/>pointing to a class effect of these<br/>quadrivalent vaccines. The elevated<br/>risk of FC observed for the quadrivalent<br/>vaccines has to be weighed against<br/>the advantage of only 1 injection<br/>for the child and the potential benefit<br/>of an increased varicella </p> <p>immunisation coverage.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>FC narrow</i> </b> </p> <p><b>MMRV</b> versus<b>MMR</b> </p> <p>matched n = 74,734</p> <p>case versus cases</p> <p>(a) 4 versus 5</p> <p>(b) 14 versus 3</p> <p>(c) 4 versus 9</p> <p>(d) 22 versus 17</p> <p><b><i>FC narrow</i> </b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p>matched n = 32,180</p> <p>case versus cases</p> <p>(a) 2 versus 0</p> <p>(b) 5 versus 1</p> <p>(c) 4 versus 9</p> <p>(d) 22 versus 17</p> <p><b><i>FC narrow</i> </b> </p> <p><b>MMRV</b> versus<b>MMR/MMR+V</b> </p> <p>matched n = 82,561</p> <p>case versus cases</p> <p>(a) 4 versus 4</p> <p>(b) 18 versus 4</p> <p>(c) 4 versus 8</p> <p>(d) 26 versus 16</p> <p><b><i>FC Jacobsen</i> </b> </p> <p><b>MMRV</b> versus<b>MMR</b> </p> <p>matched n = 74,734</p> <p>case versus cases</p> <p>(a) 7 versus 13</p> <p>(b) 45 versus 19</p> <p>(c) 35 versus 31</p> <p>(d) 87 versus 63</p> <p><b><i>FC Jacobsen</i> </b> </p> <p><b>MMRV</b> versus<b>MMR+V</b> </p> <p>matched n = 32,180</p> <p>case versus cases</p> <p>(a) 5 versus 4</p> <p>(b) 21 versus 14</p> <p>(c) 18 versus 12</p> <p>(d) 44 versus 30</p> <p><b><i>FC Jacobsen</i> </b> </p> <p><b>MMRV</b> versus<b>MMR/MMR+V</b> </p> <p>matched n = 82,561</p> <p>case versus cases</p> <p>(a) 8 versus 15</p> <p>(b) 51 versus 21</p> <p>(c) 40 versus 31</p> <p>(d) 99 versus 67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>FC narrow</b> <br/><b>MMRV</b> versus<b>MMR</b><br/>(a) 0.8 (0.3 to 2.5)<br/>(b) 4.1 (1.3 to 12.7)<br/>(c ) 0.5 (0.2 to 1.4)<br/>(d) 1.3 (0.7 to 2.4) </p> <p><b>FC narrow</b> <br/><b>MMRV</b> versus<b>MMR+V</b><br/>(a) 5.3 (0.4 to 70)<br/>(b) 3.5 (0.76 to 19)<br/>(c ) 1.5 (0.3 to 8.7)<br/>(d) 3.9 (1 to 14.5) </p> <p><b>FC narrow</b> <br/><b>MMRV</b> versus<b>MMR/MMR+V</b><br/>(a) 1 (0.3 to 3.3)<br/>(b) 4.1 (1.5 to 11.1)<br/>(c ) 0.5 (0.2 to 1.6)<br/>(d) 1.6 (0.9 to 3) </p> <p><b>FC Jacobsen</b> <br/><b>MMRV</b> versus<b>MMR</b><br/>(a) 0.5 (0.2 to 1.3)<br/>(b) 2.3 (1.4 to 3.9)<br/>(c ) 1.1 (0.7 to 1.8)<br/>(d) 1.4 (1 to 1.9) </p> <p><b>FC Jacobsen</b> <br/><b>MMRV</b> versus<b>MMR+V</b><br/>(a) 1.1 (0.3 to 3.5)<br/>(b) 1.5 (0.8 to 2.9)<br/>(c ) 1.6 (0.8 to 3.2)<br/>(d) 1.5 (1 to 2.4) </p> <p><b>FC Jacobsen</b> <br/><b>MMRV</b> versus<b>MMR/MMR+V</b><br/>(a) 0.5 (0.2 to 1.2)<br/>(b) 2.4 (1.5 to 3.9)<br/>(c ) 1.3 (0.8 to 2)<br/>(d) 1.5 (1.1 to 2) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0093" title="KleinNP , LewisE , McDonaldJ , FiremanB , NalewayA , GlanzJ , et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. Vaccine2017;35(12):1615-21. ">cb‐Klein 2017</a><br/>Retrospective<br/>cohort study<br/>linked to <a href="./references#CD004407-bbs2-0092" title="KleinNP , LewisE , BaxterR , WeintraubE , GlanzJ , NalewayA , et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics2012;129(5):809-14. [PMID: 22473362]">cb‐Klein 2012</a>; <a href="./references#CD004407-bbs2-0091" title="KleinNP . Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. Pediatrics2011;126(1):170. ">cb‐Klein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 946,806 children</p> <p>&lt; 36 months</p> <p>of age who had received</p> <p>a first dose of any</p> <p>measles‐containing vaccine</p> <p>from 2000 to 2012</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever visit</b><br/>Fever visits using </p> <p>ICD‐9 code 780.6.</p> <p>Fever due to an MCV was defined as</p> <p>any clinic or emergency department<br/>visit with a fever code 7 to 10 days after </p> <p>a first dose of any MCV<br/>(henceforth known as ‘‘MCV‐associated fever”). </p> <p>This study analysed all fevers during postvaccination days 7 to 10 as if<br/>they were due to MCV. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) MMRV (Merck &amp; Co)<br/>2) MMR (Merck &amp; Co Inc, </p> <p>West Point, PA) +</p> <p>varicella (Merck &amp; Co)</p> <p>separately administered on the same day</p> <p>3) MMR</p> <p><b>Risk interval</b> </p> <p><b>after vaccination</b> </p> <p>(a) 7 to 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> </p> <p>This study identified risk factors</p> <p>associated</p> <p>with developing fever 7 to 10 days after a</p> <p>first dose of measles‐containing vaccines.</p> <p>The study confirmed previous findings</p> <p>that fever was more often associated</p> <p>with receipt of MMRV as compared with</p> <p>MMR vaccine and with older age at time</p> <p>of vaccination during the second</p> <p>year of life, and further found that</p> <p>prior fever and seizure events were</p> <p>associated with fever after</p> <p>measles vaccine and that being fever‐prone</p> <p>in general predicted fever after</p> <p>measles‐containing</p> <p>vaccine. Even after adjusting for</p> <p>general individual</p> <p>and familial susceptibility to fever,</p> <p>fever due to measles vaccine specifically</p> <p>clustered in families. This study suggests an</p> <p>important link between population health</p> <p>(surveillance of a large population for</p> <p>vaccine adverse events) and personalised</p> <p>medicine (possible genetic basis for</p> <p>susceptibility to fever after MCV).</p> <p>Future work is needed to further</p> <p>define this possible relationship of</p> <p>genetics and vaccine‐associated fever.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMRV versus MMR</p> <p>(a) MCV‐associated fever</p> <p>(b) MCV‐associated fever</p> <p>(older sibling</p> <p>with MCV‐associated fever)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 1.3 (1.2 to 1.5)</p> <p>(b) 1.5 (1.2 to 1.8)</p> <p>(*)logistic regression</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>CNS: central nervous system<br/>FC: febrile convulsion<br/>HR:hazards ratio<br/>ICD: International Classification of Diseases<br/>ICD‐10‐GM: International Classification of Diseases. Tenth Revision, German Modification<br/>incidence: cases/PT<br/>MCV: measles‐containing vaccine<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MMR+V: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Safety: MMRV versus MMR/MMR+V ‐ febrile seizures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0037"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Safety: autistic spectrum disorders</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0094" title="MadsenKM , HviidA , VestergaardM , SchendelD , WohlfahrtJ , ThorsenP , et al. A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2002;347(19):1477-82. NobleKK , MiyasakaK . Measles, mumps, and rubella vaccination and autism. New England Journal of Medicine2003;348(10):951-4; author reply 951-4. ">cb‐Madsen 2002</a> </p> <p>Retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danish children born between January 1991 and December 1998 (n = 537,303)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) Autistic disorders</b> ICD‐10 codes<br/>F84.0 or similar DSM‐IV code 299; </p> <p><b>(b) Other autistic spectrum disorders</b><br/>ICD‐10 codes F84.1 through F84.9 </p> <p>and DSM‐IV codes 299.1‐ through 299.80.</p> <p>From medical records<br/>in Danish Psychiatric Central Register </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: </p> <p>Moraten (measles),<br/>Jeryl Lynn (mumps), Wistar RA 27/3 (rubella) </p> <p>Vaccination data reported in the National Board of Health.</p> <p>Vaccinated</p> <p>n = 440,655</p> <p>Unvaccinated</p> <p>n = 96,648</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study provides 3 strong arguments against a causal relation between MMR vaccination and autism. </p> <p> <ol id="CD004407-list-0029"> <li> <p>The risk of autism was similar in vaccinated and unvaccinated children, in both age‐adjusted and fully adjusted analyses. </p> </li> <li> <p>There was no temporal clustering of cases of autism at any time after immunisation.</p> </li> <li> <p>Neither autistic disorder nor other autistic‐spectrum disorders were associated with MMR vaccination. </p> </li> </ol> </p> <p>Furthermore, the results were derived from a nationwide cohort study with nearly complete follow‐up data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) Autistic disorders</b> </p> <p>cases unvaccinated n = 53</p> <p>PT unvaccinated PT(years) = 482,360</p> <p>versus</p> <p>cases vaccinated n = 263</p> <p>PT vaccinated</p> <p>PT(years) = 1,647,504</p> <p><b>(b) Other autistic spectrum disorters</b> </p> <p>cases unvaccinated n = 77</p> <p>PT unvaccinated PT(years) = 482,360</p> <p>versus</p> <p>cases vaccinated n = 345</p> <p>PT vaccinated</p> <p>PT(years) = 1,647,504</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 0.92 (0.68 to 1.24)</p> <p>(b) 0.83 (0.65 to 1.07)</p> <p>(*) adjusted rr. Log‐linear Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0088" title="HviidA , HansenJV , FrischM , MelbyeM . Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Annals of Internal Medicine2019;170(8):513-20. ">cb‐Hviid 2019</a> </p> <p>Retrospective cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 657,461 children born in Denmark from 1999 through 31 December 2010, with follow‐up from 1 year of age and through 31 August 2013. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism spectrum disorders</b> </p> <p>ICD‐10:<br/>F84.0 autistic disorder, </p> <p>F84.1 atypical autism,<br/>F84.5 Asperger syndrome,<br/>F84.8 (other pervasive </p> <p>developmental disorder),<br/>F84.9 (unspecified pervasive </p> <p>developmental disorder).</p> <p><b>Autism risk score:</b> </p> <p>In a preliminary analysis based on</p> <p>autism risk factors (maternal age,</p> <p>paternal age, smoking during pregnancy,</p> <p>method of delivery, preterm birth,</p> <p>5‐minute Apgar score, low birthweight, and head circumference) a</p> <p>Risk Score was estimated for each</p> <p>child in the cohort.</p> <p>(b1) very low risk</p> <p>(b2) low risk</p> <p>(b3) moderate risk</p> <p>(b4) high risk</p> <p><b>Siblings status</b> (at age 1 years): </p> <p>(c1) no siblings with autism</p> <p>(c2) siblings with autism</p> <p>(c3) no siblings</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>Schwarz (measles, 2000 to 2007) or Enders' Edmonston<br/>(measles, 2008 to 2013),<br/>Jeryl Lynn (mumps), and<br/>Wistar RA 27/3 (rubella) </p> <p>Vaccinated</p> <p>n = 625,842</p> <p>Unvaccinated</p> <p>n = 31,619</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>no support for the hypothesis of increased risk for autism after MMR vaccination in a nationwide unselected population of Danish children; </p> <p>no support for the hypothesis of MMR vaccination triggering autism in susceptible subgroups characterised by environmental and familial risk factors; </p> <p>no support for a clustering of autism cases in specific time periods after MMR vaccination.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/vaccinated</b> </p> <p>versus</p> <p><b>Cases unvaccinated/ unvaccinated</b> </p> <p><b>All children</b> </p> <p>(a) 5992/625,842 versus 525/31,619</p> <p><b>Autism risk score (*)</b> </p> <p>(b1) 1296 versus 91 cases</p> <p>(b2) 1637 versus 133 cases</p> <p>(b3) 2106 versus 206 cases</p> <p>(b4) 953 versus 95 cases</p> <p><b>Siblings status (*)</b> </p> <p>(c1) 2297 versus 227</p> <p>(c2) 32 versus 5</p> <p>(c3) 3594 versus 283</p> <p>(*) denominator not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)(*)</b> </p> <p><b>All children</b> </p> <p>(a) 0.93 (0.85 to 1.02)</p> <p><b>Autism risk score</b> </p> <p>(b1) 0.93 (0.74 to 1.16</p> <p>(b2) 0.86 (0.71 to 1.04)</p> <p>(b3) 0.91 (0.78 to 1.06)</p> <p>(b4) 1.06 (0.85 to 1.32)</p> <p><b>Siblings status</b> </p> <p>(c1) 0.98 (0.84 to 1.13)</p> <p>(c2) 2.96 (0.58 to 12.43)</p> <p>(c3) 0.89 (0.78 to 1.01)</p> <p>(*) adjusted by birth year, sex, other vaccines received, siblings history of autism, and autism risk score). Cox regression </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0090" title="JainA , MarshallJ , BuikemaA , BancroftT , KellyJP , NewschafferCJ . Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA2015;313(15):1534-40. ">cb‐Jain 2015</a><br/>Retrospective cohort </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children continuously enrolled in the health plan from birth to at least 5 years of age during<br/>2001 to 2012 who also had an older sibling continuously enrolled for at least 6 months between<br/>1997 and 2012. </p> <p>n = 95,727 children in the cohort,</p> <p><b>(a)</b> n = 93,798 older siblings without ASD </p> <p><b>(b)</b> n = 1929 older sibling with ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism spectrum disorders</b> </p> <p>Status in index children and older siblings was determined using a claims‐based algorithm that required 2 or more claims on separate dates of service with an ICD‐9‐CM diagnosis code in any position for autistic disorder, other specified pervasive developmental disorder including: Asperger syndrome, or unspecified PDD (299.0x, 299.8x, and 299.9x). </p> <p>Both index child and older sibling ASD status were determined using their entire enrolment time that fell within the study period. Index children had to have at least 1 older sibling with 2 claims with ASD diagnoses or all older siblings with no ASD diagnoses. Children with an older sibling with only 1 claim with an ASD diagnosis were excluded. Index children with only 1 claim with an ASD diagnosis were also excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> receipt was defined as having a Current Procedural Terminology (CPT) or ICD‐9‐CM procedure code indicating receipt of each component (measles, mumps, and rubella) after 1 year of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>MMR vaccine was not associated with increased risk of ASD, regardless of whether older siblings had ASD. These findings indicate no harmful association between MMR vaccine receipt and ASD even amongst children already at higher risk for ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/vaccinated</b> </p> <p>versus</p> <p><b>Cases unvaccinated/ unvaccinated</b> </p> <p><b>age 2 years ‐ 1 dose</b> </p> <p>(a) 53/77,822 versus 13/15,249</p> <p>(b) 7/1394 versus 6/520</p> <p><b>age 3 years ‐ 1 dose</b> </p> <p>(a) 239/79,666 versus 45/12,853</p> <p>(b) 38/1458 versus 17/438</p> <p><b>age 4 years ‐ 1 dose</b> </p> <p>(a) 395/79,691 versus 65/11,957</p> <p>(b) 64/1491 versus 25/387</p> <p><b>age 5 years ‐ 1 dose</b> </p> <p>(a) 339/40,495 versus 56/7735</p> <p>(b) 51/864 versus 23/269</p> <p><b>age 5 years ‐ 2 doses</b> </p> <p>(a) 244/45,568 versus 56/7735</p> <p>(b) 30/796 versus 23/269</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)(*)</b> </p> <p><b>age 2 years ‐ 1 dose</b> </p> <p>(a) 0.91 (0.68 to 1.20)</p> <p>(b) 0.76 (0.48 to 1.22)</p> <p><b>age 3 years ‐ 1 dose</b> </p> <p>(a) 0.97 (0.77 to 1.21)</p> <p>(b) 0.81 (0.53 to 1.25)</p> <p><b>age 4 years ‐ 1 dose</b> </p> <p>(a) 1.03 (0.81 to 1.31)</p> <p>(b) 0.86 (0.56 to 1.34)</p> <p><b>age 5 years ‐ 1 dose</b> </p> <p>(a) 1.10 (0.79 to 1.53)</p> <p>(b) 0.92 (0.56 to 1.50)</p> <p><b>age 5 years ‐ 2 doses</b> </p> <p>(a) 1.09 (0.76 to 1.54)</p> <p>(b) 0.56 (0.30 to 1.04)</p> <p>(*) Hazard rate ratio from Cox proportional hazards model adjusting for birth year, sex, region, race/ethnicity, maternal or paternal highest education level, household income, mother’s age at birth of index infant, father’s age at birth of index infant, continuous enrolment with mental health carve‐out benefit, Childhood Chronic Conditions score, seizure, allergies, and preterm birth. Cox regression </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0106" title="UchiyamaT , KurosawaM , InabaY . MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. Journal of Autism and Developmental Disorders2007;37(2):210-7. ">cb‐Uchiyama 2007</a> </p> <p>Retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born between 1976 and 1999 with clinical diagnosis of ASD analysed n = 858</p> <p>(whole sample n = 904; n = 46 cases were excluded due to insufficient information on ASD regression) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Regression in autism spectrum disorders</b> </p> <p>ASD regression defined as “a documented deterioration in any aspect of development or reported loss of skills, however transient” </p> <p>Note: over time 2 different diagnostic processes have been adopted at YPCD: until February 2000, the diagnostic process consisted of the assessment of ASD initially conducted by a child psychiatrist using the DSM‐IV (American Psychiatric Association, 1994), after which a clinical psychologist conducted an intelligence test. After admission a psychiatrist followed the patients once or twice a month. All doctors had been trained in using a common concept of diagnosis. From February 2000 onwards, a child psychiatrist with a clinical psychologist conducted the full assessment in 1 day. Diagnosis of ASD was made by 3 experienced child psychiatrists based on clinical observations, intellectual and developmental tests, and interviews with parents and patients. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>AIK‐C (measles),</p> <p>Urabe AM9 (mumps) To‐336 (rubella) strains.</p> <p>Data concerning MMR vaccination were moreover obtained from records of the Maternal and Child Health Handbook and were referred to the MMR generation group only. </p> <p>Participants were classified according to the chance of having received MMR vaccine (MMR was administered in Japan from April 1989 to April 1993 in children 12 to 36 months of age): </p> <p> <ul id="CD004407-list-0030"> <li> <p><b>pre‐MMR generation (before)</b>: born between January 1976 and December 1984, all ASD cases n = 100; </p> </li> <li> <p><b>MMR generation (MMR‐era)</b>: born between January 1985 and December 1991, all ASD cases n = 275; </p> </li> <li> <p><b>post–MMR generation (after)</b>: aged 1 to 3 years old after 1993 when MMR programme was terminated, all ASD cases n = 483 (regression n = 16); </p> </li> <li> <p>across <b>all generations</b> n = 769. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>within the MMR era, the rate of regression in those who received MMR was not higher than those who did not. Moreover, there was no indication that the rate of regression in ASD was higher during the era when MMR was used, compared to the ‘‘before’’ period and ‘‘after’’ period, and the ‘‘before" and "after’’ periods combined. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N vaccinated</b> <br/>versus<br/><b>N cases unvaccinated/</b> <br/><b>N unvaccinated</b> </p> <p><b>MMR‐generation</b> </p> <p>(a) 15/54 versus 45/132</p> <p><b>All generations (*)</b> </p> <p>(b) 15/54 versus 272/715</p> <p>(*) 98 cases out of 275 (MMR‐generation) were excluded due to unclear vaccination status, analysed n = 186. </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR‐era</b> versus<b>before</b> </p> <p>(c) 98/275 versus 34/100</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR‐era</b> versus<b>after</b> </p> <p>(d) 98/275 versus 193/483</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>MMR‐era</b> versus<b>(before + after)</b> </p> <p>(e) 98/275 versus 227/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.744 (0.349 to 1.571)</p> <p>(b) 0.626 (0.323 to 1.200)</p> <p>(c) 1.075 (0.646 to 1.791)</p> <p>(d) 0.832 (0.605 to 1.144)</p> <p>(e) 0.868 (0.638 to 1.182)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0043" title="SmeethL , CookC , FombonneE , HeaveyL , RodriguesLC , SmithPG , et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet2004;364(9438):963-9. ">bb‐Smeeth 2004</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with a first diagnosis of a PDD during the study period registered with a GPRD practice. </p> <p>Cases: n = 1294</p> <p>Controls: n = 4469</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pervasive developmental disorder</b> </p> <p>“Those with autistic disorders and similar presentations were classified as having 'autism' and those with other description (such as Asperger’s syndrome) were classified as having 'other PDD'. Patients who had more than one PDD diagnostic code recorded at different times (for example, autism and then Asperger’s syndrome) were classified as having the most specific diagnosis (in this example Asperger’s syndrome)” </p> <p>From diagnosis contained in UK General Practice Research Database (GPRD electronic records). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>No single clinical code was immediately implemented for MMR, then MMR was identified by codes of measles, mumps, and rubella administered on the same day. </p> <p><b>Information on MMR exposure:</b> </p> <p> <ul id="CD004407-list-0031"> <li> <p><b>cases</b>: was abstracted from the GPRD records from their date of birth up until their date of diagnosis with a PDD; </p> </li> <li> <p><b>controls</b>: was abstracted from their date of birth up to their index date, defined as the date when they were the same age (to the nearest month) as their matched case at the time the case was first diagnosed with a PDD. </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>MMR vaccination was not associated with an increased risk of subsequently being diagnosed with a PDD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccination</b> </p> <p><b>Before index date</b> </p> <p>(a) at any age</p> <p>(b1) before third birthday</p> <p>(b2) after third birthday</p> <p>(c1) before age 18 months</p> <p>(c2) after age 18 months</p> <p>(d) autism only</p> <p>(e) other PDD only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 0.86 (0.68 to 1.09)</p> <p>(b1) 0.90 (0.70 to 1.15)</p> <p>(b2) 0.77 (0.55 to 1.08)</p> <p>(c1) 0.90 (0.70 to 1.15)</p> <p>(c2) 0.80 (0.61 to 1.05)</p> <p>(d) 0.88 (0.67 to 1.15)</p> <p>(e) 0.75 (0.46 to 1.23)</p> <p>(*)adjusted conditional logistic regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0035" title="De StefanoF , BhasinTK , ThompsonWW , Yeargin-AllsoppM , BoyleC . Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics2004;113(2):259-66. ">bb‐De Stefano 2004</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with autism aged 3 to 10 years in 1996.</p> <p><b>All sample</b> </p> <p>Cases: n = 624</p> <p>Controls: n = 1824</p> <p><b>Birth certificate subsample</b> </p> <p>Cases: n = 355</p> <p>Controls: n = 1020</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism</b> cases were identified through screening and abstraction of source files at schools, hospitals, clinics, and specialty providers. Clinical psychologists with expertise in the diagnosis of autism reviewed the abstracted records according to a standardised coding scheme to determine the presence of behavioural characteristics consistent with the DSM‐IV criteria for ASDs. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine type: not stated</p> <p>MMR vaccination was abstracted from “standardized state immunization forms”.</p> <p>3 specific years cutoff:</p> <p>(a) <b>18 months of age</b>, as an indicator of “on‐time” vaccination according to the recommended vaccination schedule for MMR vaccine; </p> <p>(b) <b>24 months of age</b>, the age by which atypical development has become apparent in most children with autism; </p> <p>(c) <b>36 months of age</b>, the age by which autistic characteristics must have developed to meet DSM‐IV criteria for autism. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>no significant associations for vaccinated before 18 months or before 24 months of age, including children with some indication of regression or plateau in development, the group of most concern. </p> <p>Vaccination before 36 months of age was more common amongst case children than control children, although only a small proportion of children in either group received their first MMR vaccination after 36 months of age. Rather than representing causal relationships, associations with the 36‐month cutoff would be more likely than associations with earlier age cutoffs to have been influenced by factors related to the evaluation, management, and treatment of the child, e.g. case children might have been more likely than control children to have been vaccinated as a requirement for enrolment in early intervention or preschool special education programs. This possibility is supported by the finding that the difference between case and control children in the proportion vaccinated before 36 months of age was strongest in the 3‐ to 5‐year‐old age group. A majority of case children who were vaccinated after 36 months of age, however, had indications of developmental problems before 36 months of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cases</p> <p>(a1) &lt; 18 months</p> <p>(b1) &lt; 24 months</p> <p>(c1) &lt; 36 months</p> <p>Birth certificate</p> <p>(a2) &lt; 18 months</p> <p>(b2) &lt; 24 months</p> <p>(c2) &lt; 36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>All cases(*)</b> </p> <p>(a1) 1.12 (0.91 to 1.38)</p> <p>(b1) 1.21 (0.93 to 1.57)</p> <p>(c1) 1.49 (1.04 to 2.14)</p> <p><b>Birth certificate (**)</b> </p> <p>(a2) 0.93 (0.66 to 1.30)</p> <p>(b2) 0.99 (0.63 to 1.55)</p> <p>(c2) 1.23 (0.64 to 2.36)</p> <p>(*)partially adjusted estimates: conditional logistic regression model stratified by the matching variables (age, gender, school). </p> <p>(**)adjusted estimates: conditional logistic regression model stratified by the matching variables (age, gender, school) and adjusted for birthweight, multiple gestation, maternal age, and maternal education. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0040" title="Mrozek-BudzynD , KieltykaA , MajewskaR . Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatric Infectious Disease Journal2010;29(5):397-400. ">bb‐Mrozek‐Budzyn 2010</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 2 to 15 years diagnosed with childhood or atypical autism.</p> <p><b>Cases</b> : n = 96 <b>Controls</b>: n = 192 children matched for birth year, gender, and practice </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Childhood or atypical autism</b> </p> <p>classified according to ICD‐10 criteria as F84.0 or F84.1, respectively. Every diagnosis of autism was made by child psychiatrist. Dates of these diagnoses were recorded in general practitioner files. Cases with uncertain diagnosis of autism, secondary to disease state or trauma, were excluded. </p> <p>Parents were interviewed. Questions for all children included information about prenatal and postnatal development, mental and physical development, chronic diseases, malformations and injuries, history of bowel disturbances, birth order, family size, and parents’ socioeconomic status. </p> <p>Parents of children with autism were additionally asked about the date of onset of symptom, the period when parents first suspected their child’s symptoms might be related to autism, and their knowledge and beliefs regarding the cause of autism. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine type:</b> </p> <p><b>MMR</b> : not described<br/><b>MV:</b> measles vaccine monovalent: not described </p> <p>Information about vaccination history was extracted from physician records.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>MMR vaccination was not significantly associated with an increased risk of autism in children. </p> <p>In a separate analysis, a similar result was achieved for the single‐antigen measles vaccine. An unexpected finding was that odds ratios associated with MMR were lower than with the single measles vaccine. The decreased risk of autism amongst vaccinated children may be due to some other confounding factors in their health status. For example, healthcare workers or parents may have noticed signs of developmental delay or disease before the actual autism diagnosis and for this reason have avoided vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any vaccine</b> versus<b>unvaccinated</b> </p> <p>(a1) vaccinated before symptom onset</p> <p>(a2) vaccinated before diagnosis</p> <p><b>MMR vaccine</b> versus<b>unvaccinated</b> </p> <p>(b1) vaccinated before symptom onset</p> <p>(b2) vaccinated before diagnosis</p> <p><b>MV vaccine</b> versus<b>unvaccinated</b> </p> <p>(c1) vaccinated before symptom onset</p> <p>(c2) vaccinated before diagnosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p><b>any vaccine</b> versus<b>unvaccinated</b> </p> <p>(a1) 0.65 (0.26 to 1.63)</p> <p>(a2) 0.28 (0.01 to 0.76)</p> <p><b>MMR</b> versus<b>unvaccinated</b> </p> <p>(b1) 0.42 (0.15 to 1.16)</p> <p>(b2) 0.17 (0.06 to 0.52)</p> <p><b>MV</b> versus<b>unvaccinated</b> </p> <p>(c1) 0.86 (0.33 to 2.23)</p> <p>(c2) 0.36 (0.13 to 1.00)</p> <p>(*)Adjusted for mother’s age (15 to 35, 36 to 44 years), medication during pregnancy, gestation time (36 to 37, 38 to 43 weeks), perinatal injury, 5‐minute Apgar scale score (3 to 8, 9 to 10). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0044" title="UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine2015;33(21):2511-6. UnoY , UchiyamaT , KurosawaM , AleksicB , OzakiN . The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine2012;30(28):4292-8. [DOI: 10.1016/j.vaccine.2012.01.093]">bb‐Uno 2012</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study analysed case data from patients of YPDC; the cases consisted of<br/>patients who: (1) were diagnosed with ASD, and (2) had been born<br/>between 1 April 1984 and 30 April 1992, the possible time period<br/>for MMR vaccination. </p> <p>Children aged 6 to 36 months</p> <p><b>cases</b>: n = 189 </p> <p><b>control</b>: n = 224 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnosis of ASD:</b> based on the classifications of pervasive developmental disorders in the DSM‐IV and standardised criteria using the Diagnostic Interview for Social and Communication Disorder (DISCO). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>there was no convincing evidence that MMR vaccination and increasing the number of vaccine injections were associated with an increased risk of ASD in a genetically homogeneous population. Consequently, these findings indicate that there is no basis for avoiding vaccination out of concern for ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/N cases</b> </p> <p>versus</p> <p><b>Control vaccinated/N controls</b> </p> <p>47/189 versus 54/224</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>1.04 (0.65 to 1.68)</p> <p>(*) matched odds ratio</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0134" title="FombonneE , ZakarianR , BennettA , MengL , McLean-HeywoodD . Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics2006;118(1):e139-50. ">gb‐Fombonne 2006</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 5 to 11 years (birth cohorts 1987 to 1998 attending a boarding school in Montreal (n = 27,749, out of whom 180 with PDD) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pervasive developmental disorders</b> </p> <p>Children with a diagnosis of PDD were identified by school personnel and given a study code to preserve the anonymity of the data. Children’s diagnoses were not verified by direct assessments, but it is worth noting that a majority of these children (N = 155; 86.1%) were diagnosed at the Montreal Children’s Hospital. School<br/>personnel further identified the diagnostic subtype using DSM‐IV diagnostic criteria, age, grade, and school the child was attending. When available, place of birth was recorded as well. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR (no description)</p> <p>Identified by vaccination records</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR and autism: During the 11‐year interval, rates of PDD significantly increased, whereas MMR vaccine uptake showed a slight opposite trend. The opposite directions of both trends make it even less likely that a true association was not detected in the study data. </p> <p>The study shows a lack of association between MMR uptake and PDD rates applied to the period (1987 to 1995) where a single MMR dose was administered at 12 months of age. Rates of PDD were rapidly increasing well before the introduction of the 2‐dose schedule and, during that first phase, the increase of PDD rate bore no relationship with MMR vaccine uptake. </p> <p>The authors tested whether the introduction of a second MMR dose after 1995 accelerated the increase in PDD rates in the following 3 years. No statistically significant difference could be found between the rate of increase in PDD prevalence between the 1‐dosing and the 2‐dosing periods.<br/>In fact, the end point prevalence estimate for 1998 was consistent with the value predicted on the basis of the 1987 to 1995 rate of increase. Consequently, 2‐dosing schedule with MMR before age 2 is not associated with an increased risk of PDD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No association. Significant increase in rates of PDDs from 1987 to 1998 (OR 1.10, 95% CI 1.05 to 1.16; P &lt; 0.001) despite decrease in MMR uptake through birth cohorts from 1988 to 1998 (Chi² for trend = 80.7; df = 1; P &lt; 0.001). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0135" title="HondaH , ShimizuY , RutterM . No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2005;46(6):572-9. ">gb‐Honda 2005</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born from 1988 to 1996 (n = 31,426)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism spectrum disorders</b> </p> <p>ASD cases defined as all cases of PDD according to ICD guidelines, but an early detection clinical system called DISCOVERY that included items drawn up by the Public Health Bureau of Yokohama called YACHT (Young Autism and other developmental disorders CHeckup Tool) was active in Kohoku Ward. </p> <p><b>Definite regression</b><br/>Episodes in which caregiver records confirm<br/>loss of skills such as aspects of communication skills, including utterances, social behaviours, play activities, adaptive skills, or motor skills that had appeared<br/>and become established in the child’s daily life. </p> <p><b>Probable regression</b><br/>If there was insufficient evidence to confirm that previous skills had become firmly acquired, or that they had not fully disappeared. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: no description </p> <p><b>Exposed period:</b> </p> <p>1988 to 1992</p> <p>MMR vaccination rates declined from 69.8% in the 1988 birth cohort to 42.9%, 33.6%, 24.0%, and a mere 1.8% in birth cohorts 1989 to 1992. </p> <p><b>Reference period:</b> </p> <p>1993 to 1996</p> <p>In birth cohorts 1993 to 1996, when not a single child was immunised.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination is unlikely to be a main cause of ASD, that it cannot explain the rise over time in the incidence of ASD, and that withdrawal of MMR in countries where it is still being used cannot be expected to lead to a reduction in the incidence of ASD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk period (cases/population)</p> <p>versus</p> <p>Reference period (cases/population)</p> <p>(a) Childhood autism</p> <p>58/17,704 versus 100/13,722</p> <p>(b) Other ASD</p> <p>50/17,704 versus 70/13,722</p> <p>(c) Definite regression</p> <p>29/17,704 versus 31/13,722</p> <p>(d) Definite + probable regression</p> <p>35/17,704 versus 37/13,722</p> <p>(e) All ASD</p> <p>108/17,704 versus 170/13,722</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a) 0.45 (0.33 to 0.62)<br/>(b) 0.55 (0.39 to 0.80)<br/>(c) 0.73 (0.44 to 1.20)<br/>(d) 0.73 (0.46 to 1.16)<br/>(e) 0.49 (0.39 to 0.63) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0115" title="MakelaA , NuortiJP , PeltolaH . Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics2002;110(5):957-63. ">db‐Makela 2002</a> </p> <p>Person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children 1 to 7 years old</p> <p>(n = 535,544)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autism</b> </p> <p>Autistic disorder: "Severe qualitative impairment in reciprocal social interaction, in verbal and non verbal communication and in imaginative activity and markedly restricted repertoire of activities and interests" (<a href="./references#CD004407-bbs2-0389" title="SteffenburgS , GillbergC , HellgrenL , AnderssonL , GillbergIC , JakobssonG , et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. Journal of Child Psychology and Psychiatry and Allied Disciplines1989;30(3):405-16.">Steffenburg 1989</a>) </p> <p>Data regarding first hospital visits during the study period identified by ICD‐8/9 codes respectively effective from 1969 to 1986 and from1987 through 1995 (299 ‐ Psychoses ex origine infantia; 2990 ‐ Autismus infantilis; 2998 ‐ Developmental disorder; 2999 ‐ Developmental disorder). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR II ‐ vaccine</b> (Merck &amp; Co, West Point, PA) </p> <p>Measles: Enders‐Edmonston</p> <p>Mumps: Jeryl Lynn</p> <p>Rubella: Wistar RA 27/3</p> <p>Vaccination data were assessed through vaccination register.</p> <p>For autism the risk period is open‐ended.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The study found:</b> </p> <p>no distinguishable clustering was detected in the intervals from vaccination to the hospitalisation. The number of hospital admissions remained relatively steady during the first 3 years and then gradually decreased, as was expected because of the increasing age of the vaccinees (Fig 3).<br/>43 children were vaccinated after the first<br/>hospitalisation, and 31 were hospitalised but remained<br/>unvaccinated between November 1982 and June 1986. Of the children hospitalised for autism, none made hospital visits because of inflammatory bowel diseases in 1982 to 1995. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASD cases n = 309</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children born since 1979 from 8 health districts (North Thames, UK)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autistic disorder</b> </p> <p>“By use of criteria of the International Classification of Diseases, tenth revision (ICD10), the diagnosis of autism was checked against information in the available records on the child’s present condition and his or her condition between the ages of 18 months and 3 years.” </p> <p>ICD‐10 confirmed and non‐confirmed cases from computerised special needs/disability registers at child development centres and from records in special schools. Information on children with such disorders who were younger than 16 years of age was extracted from clinical records by 1 of 3 experienced paediatric registrars. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination identified by Regional Interactive Child Health Computing System (RICHS)</p> <p><b>Risk period:</b> </p> <p>(a) Autism diagnosis</p> <p>(a1) &lt; 12 months</p> <p>(a2) &lt; 24 months</p> <p>after vaccination</p> <p>(b) Parental concern</p> <p>(b1) &lt; 6 months</p> <p>(b2) &lt; 12 months</p> <p>after vaccination</p> <p>(c) Regression</p> <p>(c1) &lt; 2 months<br/>(c2) &lt; 4 months </p> <p>(c3) &lt; 6 months<br/>after vaccination </p> <p>Where vaccination and the event of interest<br/>occurred in the same month, the authors assumed that vaccination preceded the event. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The case‐series analyses showed no evidence of temporal clustering between MMR or other measles‐containing vaccines and diagnosis of autism. Regression occurred in nearly a third of the cases of core autism; regression was not clustered in the months after vaccination. For age at first parental concern, no significant temporal clustering was seen for cases of core autism or atypical autism, with the exception of a single interval within 6 months of MMR vaccine associated with a peak in reported age at first parental concern at 18 months. This peak is likely to reflect the difficulty experienced by parents in defining the precise age at onset of symptoms in their child, particularly those with atypical autism, and consequent approximation with preference for 18 months. Our results do not support the hypothesis that MMR vaccination is causally related to autism, either its initiation or to the onset of regression. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>(a) Autism diagnosis (n = 357)</p> <p>(b) Parental concern (n = 326)</p> <p>(c) Regression (n = 105)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a1) 0.94 (0.60 to 1.47)</p> <p>(a2) 1.09 (0.79 to 1.52)</p> <p>(b1) 1.48 (1.04 to 2.12)</p> <p>(b2) 0.90 (0.63 to 1.29)</p> <p>(c1) 0.92 (0.38 to 2.21)</p> <p>(c2) 1.00 (0.52 to 1.95)</p> <p>(c3) 0.85 (0.45 to 1.60)</p> <p>(*) relative incidence, Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0133" title="FombonneE , ChakrabartiS . No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics2001;108(4):E58. ">gb‐Fombonne 2001</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre‐MMR</b>: Maudsley Family Study (MFS) sample: n = 98 probands who had an ICD‐10 diagnosis of autism PDD. Children born between 1954 and 1979. </p> <p><b>Post‐MMR</b>: Maudsley Hospital Clinical (MHC) sample: n = 68 children born between 1987 and 1996 and had a confirmed diagnosis of PDD. </p> <p><b>Post‐MMR</b>: Stafford sample: n = 96 children born between 1992 and 1995 selected as part of an epidemiologic survey of PDD conducted in Staffordshire (Midlands, UK) </p> <p>total population n = 15,500.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Autistic enterocolitis</b> </p> <p><b>(a) Age (in months) at first parental concern:</b> in the 3 samples, item 2 of the ADI (earlier version of the ADI‐R) was used to assess the first onset of autistic symptoms, or the age of the child at which parents first became concerned about their child’s development. The precise wording of the question is, “How old was your child when you first wondered if there might be something not quite right with his/her development?” </p> <p><b>(b) Regression:</b> the assessment of regression in the ADI‐R is covered with items 37 to 41 (for language) and items 95 to 103 (for other domains). The regression is assessed for language skills as follows: “Were you ever concerned that your child might have lost language skills during the first years of his/her life? Was there ever a time when he/she stopped speaking for some months after having learned to talk?” </p> <p><b>Assessment of bowel disorders and symptoms:</b> these data were available only from the epidemiologic sample (Stafford sample). All children were reviewed regularly and are still followed up by the paediatrician, who has records of any additional hospital admissions/medical investigations for bowel disorders in these children. The occurrence of gastrointestinal symptoms was assessed by 2 sources: the parents and the paediatrician. </p> <p><b>ADI‐R</b>: Autism Diagnostic Interview ‐ Revised was administered with the parents by trained staff. Interrater reliability on the ADI‐R interviews was assessed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine type not described</p> <p><b>MFS sample</b> (pre‐MMR): unvaccinated </p> <p><b>MHC sample</b> (post‐MMR): likely vaccinated<br/><b>Stafford sample</b> (post ‐MMR): likely vaccinated </p> <p>The MMR immunisation programme was introduced in 1988 in the UK (with first MMR given between 12 and 15 months of age) with coverage rates above 90%. MMR coverage rates in 2‐year‐olds fell from 92% in 1995 to 88% in 2000. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence was found to support a distinct syndrome of MMR‐induced autism or of “autistic enterocolitis”. </p> <p>No changes in the mean age of parental recognition of first autistic symptoms were found when 2 samples of children, 1 clinical and 1 epidemiologic, all exposed to MMR immunisation, were compared with a pre‐MMR sample. </p> <p>No increase in the rate of regressive autism in recent years. Rates of regression in the development of children with autism were found to be similar in a pre‐ and post‐MMR sample. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐‐‐MFS sample (n = 98)</p> <p>(a) mean = 19.5 (SD = 13.6)</p> <p>(b) n = 18</p> <p>‐‐‐‐MHC sample (n = 68)</p> <p>(a) mean = 19.2 (SD = 8.8)</p> <p>(b) n = 0</p> <p>‐‐‐‐Stafford sample (n = 96)</p> <p>(a) mean = 19.3 (SD = 8.7)</p> <p>(b) n = 15</p> <p>No statistically relevant differences across the 2 samples for the rate of probable or definite regression. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADI‐R: Autism Diagnostic Interview ‐ Revised<br/>ASD: autism spectrum disorders<br/>CI: confidence interval<br/>DSM: Diagnostic and Statistical Manual of Mental Disorders<br/>GPRD: General Practice Research Database<br/>HMO: health maintenance organisation<br/>HR: hazards ratio<br/>ICD: International Classification of Diseases<br/>ICD‐9‐CM: International Classification of Diseases, Ninth Revision, Clinical Modification<br/>incidence: cases/PT<br/>KPSC: Kaiser PermanteSsouth California<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PDD: pervasive developmental disorders<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>SD: standard deviation<br/>YPDC: Yokohama Psycho‐Developmental Clinic </p> <p><b>Definitions:</b> </p> <p><b>Childhood autism:</b> children with symptoms before the age of 3 years that meet the necessary criteria under each section of the diagnostic triad for autism: communication difficulties, problems with social interaction, and behaviour problems such as stereotyped repetitions. </p> <p><b>Atypical autism cases:</b> with many of the features of childhood autism but not quite meeting the required criteria for that diagnosis, or with atypical features such as onset of symptoms after age 3 years (also known as pervasive developmental disorder not otherwise specified). </p> <p><b>Developmental regression:</b> a documented deterioration in any aspect of development or reported loss of skills, however transient (International Classification of Diseases, 10th revision (ICD‐10) and Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV)). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Safety: autistic spectrum disorders</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0038"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Safety: inflammatory bowel disease</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0034" title="DavisRL , KramarzP , BohlkeK , BensonP , ThompsonRS , MulloolyJ , et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatric and Adolescent Medicine2001;155(3):354-9. ">bb‐Davis 2001</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccine Safety Datalink (versusD) cases were patients born between 1958 and 1989.</p> <p><b>Case IBD</b> n = 142 </p> <p>(n = 75 Crohn's disease and n = 67 ulcerative colitis)</p> <p><b>Controls</b> n = 432 </p> <p>matched for sex, HMO, and birth year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory bowel diseases</b> </p> <p>Review of medical records contained in the Vaccine Safety Datalink database of 4 HMOs and identified by using ICD‐9 codes specific for Crohn's disease, ulcerative colitis and idiopathic proctocolitis (555 and 556). Outpatient, emergency department, urgent care clinic visits were available for 3 out of the 4 HMOs and were also taken into account. </p> <p>After abstraction of medical records, IBD cases were classified as:</p> <p><b>Definite IBD</b>: as individuals diagnosed with IBD by a gastroenterologist at 1 of the HMOs who had at least 1 sign or symptom compatible with IBD (such as bloody stool and/or bloody diarrhoea or severe and/or recurrent abdominal pain) recorded and a diagnostic test result (such as biopsy with pathology specimen, colonoscopy, or sigmoidoscopy) consistent with IBD. </p> <p><b>Probable IBD</b>: the diagnosis of IBD was made by either an HMO non‐gastroenterologist physician or a gastroenterologist outside the HMO; there was at least 1 sign or symptom compatible with IBD; and there was a diagnostic test result consistent with IBD. </p> <p>IBD cases (suspected or questionable) that did not correspond to these criteria were excluded from analysis. IBD (definite and probable) were further classified as Crohn's disease and ulcerative colitis cases. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>not specified </p> <p><b>MCV vaccine</b> </p> <p>not specified</p> <p>MMR administered at any time before index date</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this population‐based study of IBD at 4 large HMOs, the authors found no evidence that vaccination with MMR or other MCV, or that the age of vaccination early in life, was associated with an increased risk for development of IBD. In addition, the authors did not find evidence that MMR or other MCV acutely triggers the onset of either ulcerative colitis/proctitis or Crohn's disease. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p><b>Crohn's disease</b> (n = 75) </p> <p>(a) all age and vaccine type</p> <p>(a1) MMR &lt; 12 months</p> <p>(a2) MMR 12 to 18 months</p> <p>(a3) MMR &gt; 18 months</p> <p><b>Ulcerative colitis</b> (n = 67) </p> <p>(b) all age and vaccine type</p> <p>(b1) MMR &lt; 12 months</p> <p>(b2) MMR 12 to 18 months</p> <p>(b3) MMR &gt; 18 months</p> <p><b>All IBD</b> (n = 142) </p> <p>(c) all age and vaccine type</p> <p>132/142 versus 409/432</p> <p>(c1) MMR &lt; 12 months</p> <p>6/16 versus 25/48</p> <p>(c2) MMR 12 to 18 months</p> <p>84/94 versus 223/246</p> <p>(c3) MMR &gt; 18 months</p> <p>4/14 versus 52/75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p><b>Crohn's disease</b> </p> <p>(a) 0.40 (0.08 to 2.00)</p> <p>(a1) 0.38 (0.05 to 2.86)</p> <p>(a2) 0.54 (0.10 to 3.07)</p> <p>(a3) 0.18 (0.03 to 1.21)</p> <p><b>Ulcerative colitis</b> </p> <p>(b) 0.80 (0.18 to 3.56)</p> <p>(b1) 0.96 (0.12 to 7.57)</p> <p>(b2) 1.14 (0.23 to 5.59)</p> <p>(b3) 0 (0 to 0)</p> <p><b>All IBD</b> </p> <p>(c) 0.59 (0.21 to 1.69)</p> <p>(c1) 0.61 (0.15 to 2.45)</p> <p>(c2) 0.86 (0.28 to 2.59)</p> <p>(c3) 0.16 (0.04 to 0.68)</p> <p>(*)Conditional logistic regression matched on HMO, sex, birth year adjusted for race.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0026" title="BaronS , TurckD , LeplatC , MerleV , Gower-RousseauC , MartiR , et al. Enviromental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut2005;54(3):357-63. [DOI: 10.1136/gut.2004.054353]">bb‐Baron 2005</a> </p> <p>Case‐<b>c</b>ontrol </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases: patients from the registry of inflammatory bowel diseases</p> <p>January 1988 to December 1997</p> <p>aged less than 17 years old.</p> <p><b>Cases</b> n = 222<br/>Crohn's disease </p> <p><b>Cases</b> n = 60 </p> <p>ulcerative colitis</p> <p><b>Controls</b> were randomly selected from telephone<br/>number lists and matched 1:1 to each case by age (2 years), sex, and living area. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Crohn's disease; ulcerative colitis</b> </p> <p>Interviewer practitioners collected data on all patients<br/>diagnosed between 1 January 1988 and 31 December 1997 from all gastroenterologists (including paediatric gastroenterologists) in the entire area. </p> <p>Only patients who had been residents in the defined study areas at the time of diagnosis of their disease were included. </p> <p>A final diagnosis of CD or UC was made by 2 expert gastroenterologists and recorded as definite, probable, or possible, following criteria previously published. For the purpose of this study, only patients with definite or probable CD or UC were considered. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccination was negatively associated<br/>with a risk of CD. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Crohn's disease</p> <p>(b) ulcerative colitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 0.5 (0.35 to 0.9)</p> <p>(b) no data available</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0042" title="ShawSY , BlanchardJF , BernsteinCN . Early childhood measles vaccinations are not associated with paediatric IBD: a population based analysis. Journal of Crohn's and Colitis2015;9(4):334-8. [DOI: 10.1093/ecco-jcc/jjv029]">bb‐Shaw 2015</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> n = 117 </p> <p>with IBD diagnosis,</p> <p>born after 1989 and diagnosed before 31 March 2008.</p> <p><b>Controls</b> n = 834 </p> <p>matched to cases on the basis of age, sex, and region of residence at time of diagnosis.</p> <p>All with an average age of 11 years.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory bowel diseases</b> </p> <p>The administrative data case definition used to identify patients with IBD was validated with the establishment of the population‐based University of Manitoba IBD Epidemiology Database (UMIBDED) in 1995; the UMIBDED contains extracted administrative data of IBD cases and their controls (at a 1:10 ratio) for those individuals with health coverage between 1 April 1984 and 31 March 2008. Residents of Manitoba who resided in the province for at least 2 years were identified as having IBD if they had at least 5 physician visits or hospitalisations with ICD‐9‐CM codes 555.xx (Crohn’s disease) or 556.xx (UC) recorded as a diagnosis at any time. Since 2004, ICD‐10‐CA codes were used for all inpatient contacts and for IBD included K50.xx and K51.xx. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant association between completed measles‐containing vaccination in the<br/>first 2 years of life and paediatric IBD could be demonstrated in this population‐based study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) IBD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a) 1.54 (0.54 to 4.36)</p> <p>(*)Conditional logistic regression models were fitted to the data, with models adjusted for physician visits in the first 2 years of life and area‐level socioeconomic status at case date. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0045" title="VcevA , PezerovicD , JovanovicZ , NakicD , VcevI , MajnaricL . A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. Wiener Klinische Wochenschrift2015;127(9-10):345–54. ">bb‐Vcev 2015</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> inflammatory bowel diseases </p> <p>n = 150</p> <p><b>Cases</b> ulcerative colitis n = 119<br/><b>Cases</b> Crohn's disease n = 31 </p> <p><b>Controls</b> n = 150 </p> <p>not having a diagnosis of IBD, age and sex matched, were used as the control group.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory bowel diseases</b> </p> <p>Patients diagnosed with IBD (UC or CD), identified according to the hospital’s patient records. Of a total of 150 patients in the sample, 119 patients were diagnosed with UC and 31 were diagnosed with CD. They were identified according to the hospital’s patient records. Documentation of the regional hospitals in Vukovar and Vinkovci was used for this purpose. Hospitals in the near surroundings such as Clinical Hospital Centre Osijek and General Hospital Slavonski Brod were also contacted, as some patients were directly referred to these hospitals by their primary care physicians without prior registration in the resident hospitals. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> <br/>not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study found an association between exposure to MMR vaccine in the early childhood and later development of CD </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) IBD</p> <p>117/150 versus 101/150</p> <p>(b) UC</p> <p>89/119 versus 101/150</p> <p>(c) CD</p> <p>28/31 versus 101/150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 1.72 (1.03 to 2.88)</p> <p>(b) 1.44 (0.84 to 2.46)</p> <p>(c) 4.53 (1.31 to 15.63)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0137" title="SeagroattV . MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ2005;330(7500):1120-1. ">gb‐Seagroatt 2005</a> </p> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crohn's Disease emergency admission <b>cases</b> (n = 4463) observed between April 1991 and March 2003 in England population aged below 19 years (about 11.6 million) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Crohn's disease</b><br/>emergency admissions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>not reported</p> <p><b>(a) Reference period:</b> </p> <p>1988 to 1989</p> <p>(7% children completing a primary course)</p> <p><b>(b) Risk period:</b><br/>1990 </p> <p>(68% children completing a primary course)</p> <p><b>(c) Risk period:</b> </p> <p>1991 to 2003</p> <p>(84% children completing a primary course)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study found no increase in Crohn’s disease associated with the introduction of the MMR vaccination programme, providing strong evidence against the hypothesis that MMR vaccine increases the risk of Crohn’s disease. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)(*)</b> </p> <p>0.95 (0.84 to 1.08)</p> <p>(*) Poisson regression.</p> <p>The estimated rate ratio (populations with a vaccination rate of 84% compared with those with a vaccination rate of 7%). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0138" title="TaylorB , MillerE , LingamR , AndrewsN , SimmonsA , StoweJ . Measles. mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ2002;321(7334):393-6. [DOI: 10.1136/bmj.324.7334.393]">gb‐Taylor 2002</a> </p> <p>Case‐only ecological method</p> <p>linked to <a href="./references#CD004407-bbs2-0123" title="TaylorB , MillerE , FarringtonCP , PetropoulosMC , Favot-MayaudI , LiJ , et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet1999;353(9169):2026-9. ">db‐Taylor 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with childhood (core autism n = 278) and atypical autism (n = 195) born between 1979 and 1998 from computerised health registers of children with disabilities in the community and from special school and child psychiatry records, using the same methods and classifications as in the authors' earlier study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recorded <b>bowel problems</b> lasting at least 3 months, age of reported regression of the child's development where it was a feature, and relation of these to MMR vaccination. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study provides no support for an MMR‐associated “new variant” form of autism with developmental regression and bowel problems, and further evidence against involvement of MMR vaccine in the initiation of autism. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bowel problem</b> </p> <p>all cases n = 78</p> <p>unvaccinated cases n = 9</p> <p>vaccinated before parental concern n = 50</p> <p>vaccinated after parental concern n = 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>0.98 (0.89 to 1.07)</p> <p>(*) logistic regression adjusted for sex, year of birth, district, age at parental concern, and type of autism. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CD: Crohn's disease<br/>CI: confidence interval<br/>DSM: Diagnostic and Statistical Manual of Mental Disorders<br/>HMO: health maintenance organisation<br/>IBD: inflammatory bowel diseases<br/>ICD: International Classification of Diseases<br/>ICD‐10‐CA: <br/>ICD‐9‐CM:<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence; incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>UC: ulcerative colitis </p> <p><b>Definitions:</b> </p> <p><b>Childhood autism:</b> children with symptoms before the age of 3 years that meet the necessary criteria under each section of the diagnostic triad for autism: communication difficulties, problems with social interaction, and behaviour problems such as stereotyped repetitions. </p> <p><b>Atypical autism:</b> with many of the features of childhood autism but not quite meeting the required criteria for that diagnosis, or with atypical features such as onset of symptoms after age 3 years (also known as pervasive developmental disorder not otherwise specified). </p> <p><b>Developmental regression:</b> a documented deterioration in any aspect of development or reported loss of skills, however transient (International Classification of Diseases, 10th revision (ICD‐10) and Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV)). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Safety: inflammatory bowel disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0039"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Safety: cognitive delay, developmental delay</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0098" title="Mrozek-BudzynD , KiełtykaA , MajewskaR , AugustyniakM . Measles, mumps and rubella (MMR) vaccination has no effect on cognitive development in children - the results of the Polish prospective cohort study. Vaccine2013;31(22):2551-7. [DOI: 10.1016/j.vaccine.2013.03.057]">cb‐Mrozek‐Budzyn 2013</a> </p> <p>Cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Birth‐cohort) The enrolment (3 November 2000 to 22 August 2003) included only non‐smoking women, aged 18 to 35 years, with singleton pregnancy without illicit drug use and HIV infection, free from chronic diseases such as diabetes or hypertension and residing in Krakow for at least 1 year prior to pregnancy. The infants were followed up to 8th year of life. </p> <p>n = 369 children</p> <p>(n = 307 vaccinated MMR;</p> <p>n = 32 vaccinated monovalent;</p> <p>n = 30 unvaccinated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fagan Test of Infant Intelligence</b> (<b>FTII</b>) at 6th month of life. </p> <p><b>Bayley Scales of Infant Development</b> , second edition (<b>BSID‐II</b>), was administered in the 12th, 24th, and 36th months of life. </p> <p>The Mental Scale of that test includes items that assess memory, habituation, problem solving, early number concepts, generalisation, classification, vocalisation, language, and social skills. Test scores are adjusted to child’s age to obtain the <b>Mental Development Index (MDI)</b>. </p> <p>Test results are in 1 of 4 categories (range: from 50 to 150): <b>(1)</b> accelerated performance (score &gt; 115); <b>(2)</b> within normal limits (score 85 to 114); <b>(3)</b> mildly delayed performance (score 70 to 84), and <b>(4)</b> significantly delayed (score &lt; 69). </p> <p>The<b>test of Raven’s Colored Progressive Matrices</b> (<b>Raven</b>) was administered twice, in 5th and 8th year of life. </p> <p>The <b>Wechsler Intelligence Scale for Children</b> (<b>WISC‐R</b>) was administered in 6th and 7th year of life, and generated verbal, non‐verbal, and total IQ for evaluated children. Category with IQ &lt; 100 was considered as the poorer outcomes. The outcomes range is from 40 to 160. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b><br/>not described </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR and cognitive tests outcomes:</b> No significant differences of cognitive and intelligence tests results were observed between children vaccinated with MMR and unvaccinated in univariable analysis. Their outcomes were on similar level. </p> <p><b>Conclusion:</b> The results suggest that there is no relationship between MMR exposure and children’s cognitive development. Furthermore, the safety of triple MMR is the same as the single measles vaccine with respect to cognitive development. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a1) MDI‐BSID II 24th month</p> <p>(a2) MDI‐BSID II 36th month</p> <p>(b1) Raven (centiles) 5th year</p> <p>(c1) WISC‐R Verbal IQ 6th year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>(a1) 1.35 (0.15 to 12.0)</p> <p>(a2) 0.37 (0.03 to 4.02)</p> <p>(b1) 1.22 (0.23 to 6.55)</p> <p>(c1) 1.23 (0.09 to 17.03)</p> <p>(*) adjusted for standardised to child’s gender, maternal education, maternal IQ, maternal economical status, birth order (further child versus first one), and exposure to environmental tobacco smoke during pregnancy (yes versus no). </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>incidence: cases/PT<br/>IQ: intelligence quotient<br/>MDI‐BSID II: Mental Development Index of Bayley Scales of Infant Development, second edition<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Safety: cognitive delay, developmental delay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0040"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0029" title="BlackC , KayeJA , JickH . MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology2003;55(1):107-11. ">bb‐Black 2003</a> </p> <p>Nested case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b>: n = 23 children with outcome of interest at 12 to 23 months, between 1988 and 1999, GPRD members. </p> <p><b>Controls</b>: n = 116 participants matching for index date (age), sex, practice. </p> <p>Nested case–control analysis to evaluate whether there was any relationship between recent MMR vaccination and the risk of ITP. Because the data were sparse, the authors grouped case–control sets by 3‐month age bands (13 to 15 months, 16 to 18 months, and so on). In addition, they included boys and girls in sets together because childhood ITP is reported to occur with equal<br/>frequency amongst both sexes, and because preliminary analysis of their data showed no evidence for a predominance of cases amongst either sex. The risk ratio of ITP during the specified time periods after MMR vaccination was estimated as the odds ratio using conditional logistic regression. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idiopathic thrombocytopenic purpura</b> </p> <p>GPRD electronic records with first‐time diagnosis of thrombocytopenia (ICD‐9 code 287.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not reported. </p> <p>Data about MMR vaccination</p> <p>were presumably obtained from</p> <p>GPRD records (type and composition not reported).</p> <p>The authors referred to ITP cases that occurred within 6 weeks after an MMR vaccine as "possible vaccine‐related"; this is a plausible period of risk related to a primary immune response. They also evaluated the risk of ITP during a longer period after MMR vaccination (7 to 26 weeks). </p> <p><b>Risk time</b> following MMR immunisation </p> <p>(a) 0 to 6 weeks</p> <p>(b) 7 to 26 weeks</p> <p>(c) 0 to 26 weeks</p> <p><b>Reference time</b> </p> <p>unexposed MMR or</p> <p>&gt; 26 weeks after MMR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> "Although ITP is one of the most frequently diagnosed haematological disorders amongst young children, it is an uncommon condition. </p> <p>The risk of ITP occurring within the 6 weeks after vaccination with MMR is significantly increased. </p> <p>However, the attributable risk of ITP within 6 weeks after MMR vaccination remains low at 1 in 25,000" (95% CI 21,300 to 89,400) "vaccinated children. </p> <p>Complications or long‐term consequences of ITP in this age group are rare.</p> <p>For the majority of children less than 6 years of age, the illness is self‐limiting."</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>Data reported in the study:</p> <p>(a) 8/17 versus 19/84</p> <p>(b) 6/15 versus 32/97</p> <p>(c) 14/23 versus 51/116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>unadjusted estimates</p> <p>(a) 3.04 (1.03 to 8.96)</p> <p>(b) 1.35 (0.44 to 4.14)</p> <p>(c) 1.98 (0.79 to 4.95)</p> <p>computed from the data reported in the study.</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>adjusted estimates(*)<br/>(a) 6.3 (1.3 to 30.1)<br/>(b) 1.5 (0.4 to 4.8) </p> <p>(*) logistic regresson</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0027" title="BertuolaF , MorandoC , Menniti-IppolitoF , Da CasR , CapuanoA , PerilongoG , et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Safety2010;33(1):65-72. Menniti-IppolitoF , Da CasR , BolliM , CapuanoA , SagliocaL , TraversaG , et al. A multicenter study on drug safety in children [Studo multicentrico sulla sicurezza dei faraci in pediatria]. Quaderni ACP2007;14(3):98-102. ">bb‐Bertuola 2010</a> </p> <p>Case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases:</b> n = 387 children aged 1 month to 18 years, hospitalised at emergency department with outcome of interest between November 1999 and September 2007, with outcome of interest. </p> <p><b>Controls:</b> n = 1924 children of same age interval hospitalised at emergency department for acute neurological disorders or endoscopically confirmed gastroduodenal lesions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute immune thrombocytopenia</b> </p> <p>Platelets count &lt; 100,000/μL at admission. Participants with following conditions were excluded: cancer, immunodeficiency, chronic renal and hepatic failure, so as acute events related to a reactivation of an underlying chronic disease or a congenital anomaly </p> <p>Hospitalisation (emergency department) records review</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> <p>Exposure to the vaccine (and other drugs) was assessed during hospital admission by means of interview with parents. </p> <p>0 to 6 weeks following MMR immunisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> the study confirms an association between MMR vaccination and ITP. As the risk of ITP after vaccination is smaller than after natural infection with these viruses, it is clear that the benefit of vaccination programmes greatly exceed the significance of this possible adverse effect. Although thrombocytopenia is initially severe, the subsequent course is generally benign and short‐lasting. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>14/387 versus 27/1924</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>2.4 (1.2 to 4.7)</p> <p>(*) adjusted estimates by logistic regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 63) aged 12 to 23 months with ITP identified from versusD database for the years 1991 to 2000, who had been vaccinated with MMR whilst actively enrolled in their respective MCOs. For each child, follow‐up time was limited to the 365 days before and after MMR vaccination. Vaccinated children with ITP that occurred outside this follow‐up window were excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immune thrombocytopenia purpura</b> </p> <p>Participants with 2 platelet counts ≤ 50,000/μL within 6‐week period or with 1 platelets count ≤ 50,000/μL associated with ICD‐9 diagnosis codes 287.0 to 287.9 within 6 weeks, with exclusion of: cases of thrombocytopenia from a known condition (neonatal thrombocytopenia, aplastic anaemia, defibrination syndrome, acquired haemolytic anaemia, chronic liver disease, malignant neoplasm), thrombocytopenia diagnosed within the 30th day of life. By subsequent patient chart reviews, participants who did not have not have ITP, who had drug exposure, with acute illness, or with serendipitous finding during routine care were further excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMR vaccine: not reported</p> <p>MMR vaccination date assessed by means of separate audit of patient charts.</p> <p><b>Exposed period</b>: 42 days after MMR vaccination </p> <p><b>Unexposed period:</b> defined as the time periods before and after the exposed period. </p> <p>Period of 6 weeks immediately preceding MMR vaccination was excluded from analysis (because this represents a period when a child is most likely to be healthy (the healthy‐vaccinee) and may underestimate the background incidence of ITP) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> since its introduction in the 1960s, the MMR vaccine has reduced the incidence of wild‐type measles by nearly 100% in the USA. Although this vaccine is associated with an increased incidence of ITP, the attributable risk is low (1 case per 40,000 doses of MMR), and the disease associated with MMR vaccination is mild and resolves, on average, within 7 days. Our results, therefore, do not suggest a need to alter current immunisation policies. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age groups</b> </p> <p>(a) 12 to 23 months</p> <p>(b) 12 to 15 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>Self‐controlled case series</b> </p> <p>(a) 5.38 (2.72 to 10.62)</p> <p>(b) 7.06 (1.95 to 25.88)</p> <p>(*) conditional Poisson regression controlled by age in three 4‐month age groupings (12 to 15, 16 to 19, 20 to 23 months) and excluding fixed covariate from the model (gender, MCO, MMR dose number) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Person‐time cohort(**)</b> </p> <p>(a) 3.94 (2.01 to 7.69)</p> <p>(b) 7.10 (2.03 to 25.03)</p> <p>(**) Poisson regression model controlled for age, MMR dose number, MCO site, and gender</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0111" title="FarringtonCP , MillerE , TaylorB . MMR and autism: further evidence against a causal association. Vaccine2001;19(27):3632-5. FarringtonCP , NashJ , MillerE . Case series analysis of adverse reactions to vaccines: a comparative evaluation. American Journal of Epidemiology1996;143(11):1165-73. FarringtonP , PughS , ColvilleA , FlowerA , NashJ , Morgan-CapnerP , et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet1995;345(8949):567-9. MillerE , WaightP , FarringtonCP , AndrewsN , StoweJ , TaylorB . Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood2001;84(3):227-9. MillerE . MMR vaccine: review of benefits and risks. Journal of Infection2002;44(1):1-6. ">db‐Farrington 1995</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 24 months discharged from hospital in 5 districts in England (Ashford, Leicester, Nottingham, Preston, and Chorley &amp; Ribble) for varying periods between October 1988, and February 1993. Readmissions within 72 h with the same diagnosis were counted as 1 episode. </p> <p>n = 952 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idiopatric thrombocytopenic purpura</b> </p> <p>(ICD 287.3) children aged between 366 and 730 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p><b>Urabe</b> mumps strain </p> <p><b>Jeryl Lynn</b> mumps strain </p> <p>Rubella strain not specified</p> <p><b>Exposure risk period:</b> </p> <p>(a1) 6 to 11 days (1 to 2 weeks after vaccination)</p> <p>(a2) 15 to 35 days (3 to 5 weeks after vaccination)</p> <p><b>Control period:</b> </p> <p>(b) for each vaccine was defined as the time not included in a risk period.</p> <p>The analyses were adjusted for age and were grouped in 6 equal intervals of about 2 months. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> we demonstrated a causal association between ITP and MMR vaccination, with an absolute risk of 1 in 24,000 doses and an attributable risk of 1 in 29,000 doses. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any strain</b> </p> <p>(a1) 0 cases</p> <p>(a2) 4 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a2) 6.44 (1.94 to 21.4)</p> <p>(*) Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0109" title="AndrewsN , StowebJ , MillerE , SvanströmH , JohansenK , BonhoefferJ , et al, VAESCO consortium. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine2012;30:3042-6. [DOI: 10.1016/j.vaccine.2011.06.009]">db‐Andrews 2012</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicountry<br/>collaboration (England and Denmark) study. </p> <p>The chosen study population was children aged 12 to 23 months (365 to 732 days).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenic purpura</b> </p> <p>The case definition for TP was based only on the presence of a relevant ICD‐10 code (D69.3) or ICD‐8 code (287.10) in 1 of the diagnostic discharge fields. First episodes were defined as the earliest record found for an individual, further episodes were initially required to be at least 14 days since a previous episode (to prevent double counting of episodes). </p> <p>In England cases (based on ICD‐10) occurring between 1 April 1996 and 31 March 2007 were linked using NHS number or gender/date of birth/postcode to immunisation records. </p> <p>In Denmark the Central Person Registry (CPR) was used to construct a nationwide cohort consisting of all Danish children born in the period 1 January 1990 to 31 December 2007 (∼1.2 million children). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p><b>Risk periods</b>: (post‐MMR) </p> <p>(a) 0 to 13 days</p> <p>(b) 14 to 27 days</p> <p>(c) 28 to 42 days</p> <p>(d) 0 to 42 days</p> <p><b>Reference period</b> </p> <p>pre‐vaccination</p> <p>(e) −7 to −1 days</p> <p>(to allow for a vaccination being delayed if the child was ill)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> this study gave consistent estimates of the relative incidence of TP following MMR vaccination in 1‐year‐olds. </p> <p>The 95% CI for the attributable risk of TP can be calculated based on the 95% CI for the relative incidence and gives an interval of 1 in 74,000 to 1 in 40,000 doses. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) 12 cases</p> <p>(b) 26 cases</p> <p>(c) 17 cases</p> <p>(d) 55 cases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 1.30 (0.71 to 2.38)</p> <p>(b) 2.87 (1.85 to 4.46)</p> <p>(c) 1.81 (1.07 to 3.05)</p> <p>(d) 1.98 (1.41 to 2.78)</p> <p>(*) adjusting for age, period, country, and country‐age interaction</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children &lt; 18 years old (confirmed ITP cases) who had been vaccinated while actively enrolled in their respective health plans. </p> <p>This investigation was conducted in 5 healthcare systems (Kaiser Permanente: Colorado, Hawaii, Georgia, Northern California, and Harvard Vanguard Medical Associates) by using data from the years 2000 to 2009. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenic purpura</b> </p> <p>Case was defined as a child aged 6 weeks to 18 years with a platelet count of ≤ 50,000/μL, with normal red and white blood cell indices, and the presence of clinical signs and symptoms of ITP, such as petechiae, significant bruising, or spontaneous bleeding. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR, MMRV vaccine:</b> not described </p> <p><b>Follow‐up time:</b> 365 days before and after vaccination. </p> <p><b>Exposed period:</b> 1 to 42 days after vaccination for all vaccines. </p> <p><b>Unexposed period:</b> defined as the time before and after the exposed period within 365 days of follow‐up before or after vaccination.<br/>Day 0 (the day of vaccination) was excluded, because any cases occurring at this time were most likely coincidental. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> none of the routine childhood vaccines given in the first year of life was significantly associated with an increased risk of ITP. For vaccines routinely administered at 12 to 19 months of age, there was a significant association of ITP with MMR. There was no increased risk of ITP (calculated when not given simultaneously with MMR or MMRV). There were 1.9 cases of ITP per 100,000 doses of MMR. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposed cases</b> versus <b>unexposed cases</b> </p> <p><b>(a) 12 to 19 months</b> </p> <p>(a1) MMR: 6 versus 5</p> <p>(a2) MMRV: 4 versus 6</p> <p><b>(b) 4 to 6 years</b> </p> <p>(b1) MMR: 2 versus 7</p> <p>(b2) MMRV: 0 versus 5</p> <p><b>(c) 11 to 17 years</b> </p> <p>(c1) MMR: 0 versus 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)</b> </p> <p>(a1) 5.48 (1.61 to 18.64)</p> <p>(a2) 2.87 (0.78 to 10.56)</p> <p>(b1) 3.06 (0.42 to 22.30)</p> <p>(b2) not estimable</p> <p>(c1) not estimable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0121" title="Perez-VilarS , WeibelD , SturkenboomM , BlackS , MaureC , CastroJL , et al. Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine2018;36(3):347-54. ">db‐Perez‐Vilar 2018</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For this study, WHO selected 26 sentinel sites (49 hospitals) distributed in 16 countries of the 6 WHO regions. </p> <p>The study population included children aged 9 to 23 months admitted to a network‐participating hospital during January 2010 to March 2014, with a discharge diagnosis of either aseptic menigitis or immune thrombocytopenic purpura. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immune thrombocytopenia</b> </p> <p>ICD‐9 codes in first discharge diagnosis position:</p> <p>287.30 to 287.39</p> <p>Primary thrombocytopenia</p> <p>287.41 to 287.49</p> <p>Secondary thrombocytopenia</p> <p>287.5</p> <p>Thrombocytopenia, unspecified</p> <p>ICD‐10 codes in first discharge diagnosis position:</p> <p>D69.3, D69.4 (D69.41 to D69.43)</p> <p>Primary thrombocytopenia</p> <p>D69.5 (D69.51, D69.59)</p> <p>Secondary thrombocytopenia</p> <p>D69.6</p> <p>Thrombocytopenia, unspecified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine (measle strain) (mumps strain)</b> </p> <p><b>Priorix, GSK</b> (Schwarz) (RIT 4385a)<br/><b>Priorix Tetra, GSK</b> (Schwarz) (RIT 4385a)<br/><b>MMR Shanghai Institute</b> (Shanghai‐191) (S79)<br/><b>Measles, Lanzhou Institute</b> (Shanghai‐191) (–)<br/><b>Measles‐Rubella, Beijing Tiantan</b> (Shanghai‐191) (–)<br/><b>M‐M‐R‐II, MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>MMR, Razi Vaccine and Serum Research</b> (AIK‐C) (Hoshino)<br/><b>M‐M‐RVAXPRO, Sanofi Pasteur‐MSD</b> (Enders’ Edmonston) (Jeryl Lynn (Level B))<br/><b>Trimovax, Sanofi Pasteur</b> </p> <p>(Schwarz) (Urabe AM9)<br/><b>Measles, Serum Institute of India</b> Pvt. (Edmonston‐Zagreb) (–)<br/><b>Measles‐Rubella, Serum Institute of India</b> Pvt. (Edmonston‐Zagreb) (–)<br/><b>MMR, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Tresivac, Serum Institute of India</b> (Edmonston‐Zagreb) (Leningrad‐Zagreb)<br/><b>Rouvax, Sanofi Pasteur</b> (Schwarz) (–) </p> <p><b>Risk period</b> </p> <p>8 to 35 days</p> <p><b>Washout periods</b> </p> <p>1 to 7 days</p> <p>36 to 42 days</p> <p><b>Control period</b> </p> <p>43 to 84 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The elevated risk of ITP following measles‐containing vaccination is consistent with the literature (<a href="./references#CD004407-bbs2-0120" title="O’LearyST , GlanzJM , McClureDL , AkhtarA , DaleyMF , NakasatoC , et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics2012;129:248-55. [DOI: 10.1542/peds.2011-1111]">db‐O'Leary 2012</a>: <a href="./references#CD004407-bbs2-0112" title="FranceEK , GlanzJ , XuS , HambidgeS , YamasakiK , BlackSB , et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics2008;121(3):e687-92. ">db‐France 2008</a>). Our strain‐specific unadjusted<br/>analysis showed a significantly elevated ITP risk for measles<br/>vaccines containing the Schwarz, Edmonston‐Zagreb, and Enders’ Edmonston strains. No risk of ITP was identified in Iran, which reported the concurrent distribution of 3 vaccine products including the AIK‐C, Edmonston‐Zagreb, and Schwarz strains, without distinguishing between them. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 16 countries n = 183 ITP cases</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(risk versus control) period</b> </p> <p>(a) overall (36 versus 12)</p> <p>(b) overall (excluding Iran) (36 versus 8)</p> <p>(c) AIK‐C/Edmonston‐Zagreb/Schwarz (2 versus 5)</p> <p>(d) Edmonston‐Zagreb (7 versus 1)</p> <p>(e) Enders' Edmonston (11 versus 3)</p> <p>(f) Schwarz (14 versus 1)</p> <p>(g) Shanghai‐191 (0 versus 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) adjusted</b> </p> <p>(a) 5.6 (2.7 to 11.9)</p> <p>(b) 9.1 (3.7 to 22.3)</p> <p>(c) 0.54 (0.08 to 3.6)</p> <p>(d) 8.4 (0.7 to 100.3)</p> <p>(e) 28.7 (1.9 to 443.5)</p> <p><b>rr (95% CI) unadjusted</b> </p> <p>(f) 20.7 (2.7 to 157.6)</p> <p>(g) not estimable</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0126" title="LafaurieM , BaricaultB , Lapeyre-MestreM , SaillerL , MoulisG , SommetA , et al. Risk of vaccine-induced immune thrombocytopenia in children. Nationwide case cross-over and self controlled case series studies in France. Fundamental &amp; Clinical Pharmacology2018;32:86. ">eb‐Lafaurie 2018</a> </p> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population‐based study in France including all children newly diagnosed for primary ITP between July 2009 and June 2015. </p> <p>n = 2549</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immune thrombocytopenia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not described </p> <p><b>Exposed period</b> </p> <p>6‐week interval immediately preceding the event</p> <p>(frequency of exposure to vaccines)</p> <p><b>Control period</b> </p> <p>(1) 6 weeks, 6 months before</p> <p>(2) 6 weeks, 3 months before the case period</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> in this nationwide study, no significant risk was observed for vaccines against DTP, pneumococcus, meningococcus, and HBV. The increased risk of MMR‐induced ITP is shown in children (previously demonstrated as lower than after the natural infection with measles). Vaccine‐induced ITP remains an exceptional adverse drug reaction, including for MMR vaccines. </p> <p>The numbers of attributable cases per million MMR doses dispensed were 9.8.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 492 patients included in analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>1.62 (1.21 to 2.16)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0136" title="Jonville-BeraAP , AutretE , Galy-EyraudC , HesselL . Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Mérieux Sérums et Vaccins. Pediatric Infectious Disease Journal1996;15(1):44-8. ">gb‐Jonville‐Bera 1996</a> </p> <p>Case‐only ecological study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacovigilance reports:</p> <p>case observed after vaccine administration between 1984 and 30 June 1992 (n = 60). Estimated number of administered vaccine doses was 9,205,483. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenic purpura</b> Acute haemorrhagic syndrome associated with platelet count of &lt; 100,000/mm³, all cases within 45 days of vaccination, over 8‐year period </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: </p> <p>(a) ROR, Trimovax (measles Schwarz strain, mumps Urabe AM9 strain, rubella Wistar RA 27/3 M strain) </p> <p><b>Other measles‐containing vaccines</b>: </p> <p>(b) Rouvax (measles Schwarz strain)</p> <p>(c) Rudi‐Rouvax (measles Schwarz strain, rubella Wistar RA 27/3 M strain)</p> <p><b>Other vaccine:</b> </p> <p>(d) Rudivax (rubella Wistar RA 27/3 M strain) + DTbis (e) Rudivax (rubella Wistar RA 27/3 M strain, diptheria, tetanus) </p> <p>(e) Imovax Oreillons (mumps Urabe AM9 strain)</p> <p>2 to 45 days following immunisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> according to the clinical course and biologic findings, vaccine‐associated TP appears to be similar to that occurring after natural measles or rubella infections and is not distinguishable from acute childhood idiopathic thrombocytopenic purpura not associated with vaccination. Such observation, combined with a clear temporal relationship between MMR vaccination and occurrence of TP, make a causal relationship highly plausible. Nevertheless, the incidence of these events remains relatively low with a favourable immediate outcome. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case/doses</b> </p> <p>(a) 42<b>/</b>4,396,645 </p> <p>‐‐‐</p> <p>(b) 2<b>/</b>860,938 </p> <p>(c) 12<b>/</b>1,480,058 </p> <p>‐‐‐</p> <p>(d) 4<b>/</b>2,295,307 </p> <p>(e) 0<b>/</b>172,535 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence x 100,000 doses (95% CI)(*)</b> </p> <p>(a) 0.96 (0.71 to 1.29)</p> <p>‐‐‐</p> <p>(b) 0.23 (0.06 to 0.85)</p> <p>(c) 0.81 (0.46 to 1.42)</p> <p>‐‐‐</p> <p>(d) 0.17 (0.07 to 0.45)</p> <p>(e) 0.00 (0.00 to 2.23)</p> <p>(*) confidence intervals were recomputed by <a href="./references#CD004407-bbs2-0405" title="WilsonBE . Probable inference the law of succession and statistical inference. Journal of the American Statistical Association1927;22:209-12.">Wilson 1927</a> method. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>DTP: diphtheria, tetanus, and pertussis<br/>GPRD: General Practice Research Database<br/>HMO: health maintenance organisation<br/>HPV: human papillomavirus<br/>ICD: International Classification of Diseases<br/>ITP: idiopathic thrombocytopenic purpura<br/>MCOs: Managed Care Organizations<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>incidence: cases/PT<br/>RR: risk ratio (relative risk)<br/>TP: thrombocytopenic purpura<br/>WHO: World Health Organization </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0041"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0033" title="Da DaltL , ZerbinatiC , StrafellaMS , RennaS , RiceputiL , Di PietroP , et al Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Italian Journal of Pediatrics2016;42(1):60. [DOI: 10.1186/s13052-016-0267-2]">bb‐Da Dalt 2016</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases</b> (n = 288) children (aged &gt; 1 month and ≤ 18 years) hospitalised with a diagnosis of Henoch‐Schönlein purpura through the emergency departments (11 Italian paediatric hospitals/wards spread throughout the country (Treviso, Padua, Naples, Genoa, Turin, Florence, Perugia, Palermo, Messina, and Rome, with 2 centres)). </p> <p><b>Control</b> (n = 617) children hospitalised for gastroduodenal lesions were considered as appropriate controls, since they represent an acute condition admitted through the emergency departments in the same clinical centres in which cases were identified. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Henoch‐Schönlein purpura</b> </p> <p>All children hospitalised with a diagnosis of HSP at admission were included as cases. Discharge diagnosis was retrieved from clinical records and validated by clinicians, according to EULAR/PRINTO/PRES criteria for classification of HSP. Validation was conducted retrieving data from individual patient clinical records, blinded with respect to drug and vaccine exposure. Only validated cases were analysed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccines MMR</b><br/>not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> the association between MMR vaccination and HSP confirms previous published findings and adds a risk estimate. Further studies are needed to increase our understanding of the role of drugs and vaccines in the aetiology of HSP, a disease with important effects on health of children for its potential, though rare, chronic outcomes. </p> <p>This article confirms that HSP is a rare condition (288 children hospitalised in 14 years). Furthermore, the number of vaccinated cases was only 8, suggesting a very low absolute risk of the condition in children vaccinated with MMR vaccine. The benefit/risk profile of MMR vaccine is thus not affected by our results, being that MMR vaccination is an effective and safe tool against serious diseases in childhood. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>8/228 versus 6/617</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>3.4 (1.2 to 10.0)</p> <p>(*) Adjusted by age</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>HSP: Henoch‐Schönlein purpura<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0042"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Safety: type 1 diabetes</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0086" title="HiividAD , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination does not increase the incidence of type 1 diabetes. Evidence-based Healthcare and Public Health2004;8(5):286-7. [CRSREF: 2955568]HviidA , StellfeldM , WohlfahrtJ , MelbyeM . Childhood vaccination and type 1 diabetes. New England Journal of Medicine2004;350(14):1398-404. ">cb‐Hviid 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A cohort of children born from 1 January 1990 to 31 December 2000 from the Danish Civil Registration System (n = 739,694) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type 1 diabetes:</b> </p> <p>information on the diagnosis of type 1 diabetes from 1 January 1990 through 31 December 2000 was obtained from the Danish National Hospital Register. </p> <p>From 1990 through 1993, Denmark used a modified version of the ICD‐8.</p> <p>From 1994 through 2001, the ICD‐10 was used. The authors used codes 249 and E10 (the code 249 does not exist in the standard World Health Organization version of the ICD‐8) to identify all cases of type 1 diabetes. </p> <p>Beginning in 1995, visits to the emergency room and outpatient visits were included in the National Hospital Register. </p> <p>(n = 681 cases of type 1 diabetes)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> </p> <p>measles Moraten strain,</p> <p>mumps Jeryl Lynn strain,</p> <p>rubella Wistar RA 27/3 strain.</p> <p>Schedule 15 months and 12 years of age; composition:</p> <p>(a1) 1 dose</p> <p>(a2) unknown</p> <p>(b) unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusion:</b> these results do not support a causal relation between childhood vaccination and type 1<br/>diabetes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All children</b> </p> <p>(a1) 499/293,428</p> <p>(a2) 58/412,830</p> <p>(b) 124/1,373,401</p> <p><b>Children with at least 1 sibling with type 1 diabetes</b> </p> <p>(a1) 20/2795</p> <p>(a2) 0/361</p> <p>(b) 6/1053</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p><b>All children</b> </p> <p>(a1) 1.14 (0.90 to 1.45)</p> <p>(a2) 1.04 (0.71 to 1.52)</p> <p><b>Children with at least 1 sibling with type 1 diabetes</b> </p> <p>(a1) 0.86 (0.34 to 2.14)</p> <p>(a2) ‐ (‐ to ‐)</p> <p>(*) Poisson log linear regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0082" title="BeyerleinA , StroblAN , WinklerC , CarpusM , KnopffA , DonnachieE , et al. Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: results from prospective cohort data. Vaccine2017;35(14):1735-41. ">cb‐Beyerlein 2017</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort of children recruited:</p> <p>between 1989 and 2000, a total of 1650 offspring of patients with T1D were recruited for the BABYDIAB study and were followed for 23,856 patient years. </p> <p>Between 2000 and 2006, 791 additional offspring or siblings of patients with T1D were screened in the context of the BABYDIET study and were followed by using the BABYDIAB protocol for 6358 patient years. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Islet autoimmunity:</b> </p> <p>type 1 diabetes: (T1D) is one of the most common chronic diseases in childhood.</p> <p>The disease is preceded by a preclinical period of <b>islet autoimmunity</b>, which most commonly develops in early infancy. </p> <p>Factors that induce a strong immune response in early life might thus be relevant for the development of T1D‐associated islet autoimmunity. </p> <p>Islet autoantibodies were measured in venous blood samples from scheduled visits. Children in the BABYDIAB study had scheduled visits at birth, at age 9 months, and at 2, 5, 8, 11, 14, 17, and 20 years of age, whereas children in the BABYDIET study had 3‐monthly visits from birth until the age of 3 years, and yearly until the age of 12 years. Measurement of islet autoantibodies in these studies has been described elsewhere. </p> <p>Islet autoimmunity was defined as the development of persistent autoantibodies to 1 or more of the antigens insulin, GAD65, IA‐2 or Zn‐T8, with sample values above the 99th percentile of published population control children classified as positive. </p> <p>In case of single positive antibodies against insulin or GAD65, affinity and epitope reactivity was determined and children with low‐affinity antibodies (&lt; 109 L/mol) were not classified as islet autoantibody positive, as these isolated antibody signals are not T1D specific and are not associated with increased T1D risk. Persistence was defined as positive in at least 2 consecutive samples. Islet autoantibody assays were evaluated according to the Diabetes Autoantibody Standardization Program. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> </p> <p>not described</p> <p>Age</p> <p>(a) 0 to 24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> the authors found no evidence that early vaccinations increase the risk of T1D‐associated islet<br/>autoimmunity development. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total</p> <p>n = 1918</p> <p>n = 1779 children without confirmed islet autoimmunity</p> <p>n = 139 confirmed islet autoimmunity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)(*)</b> </p> <p>(a) 1.08 (0.96 to 1.21)</p> <p>(*) Cox regression</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>HMO: health maintenance organisation<br/>HR:hazards ratio<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>T1D: type 1 diabetes </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Safety: type 1 diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0043"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Safety: asthma</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0083" title="DeStefanoF , GuD , KramarzP , TrumanBI , IademarcoMF , MulloolyJP , et al. Childhood vaccinations and risk of asthma. Pediatric Infectious Disease Journal2002;21(6):498-504. ">cb‐DeStefano 2002</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (0 to 6 years) enrolled in VSD project (4 HMOs) between 1991 and 1997 (n = 167,240) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma:</b> a child had to meet 1 of the following criteria: </p> <p><b>(1)</b> at least 1 diagnosis of asthma ICD‐9 Code 493 and at least 1 prescription for an asthma medication; the first diagnosis and first prescription had to be within a 2‐year period. Asthma medications included oral or inhaled beta‐agonists, theophyllin, oral or inhaled corticosteroids, cromolyn sodium, adrenergic drugs not elsewhere specified, and unclassified asthma medications; </p> <p><b>(2)</b> at least 1 prescription for an inhaled beta‐agonist and at least 1 prescription for cromolyn within a 2 year period; </p> <p><b>(3)</b> at least 5 prescriptions for asthma medications during a 2‐year period. (Total asthma cases n = 18,407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Exposure to MMR vaccine (and other vaccines). Vaccinations were ascertained through computerised immunisation tracking systems, and onset of asthma was identified through computerised data on medical care encounters and medication dispensing. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there is no association between<br/>MMR vaccine and the risk of asthma. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>0.97 (0.91 to 1.04)</p> <p>(*) adjusted rr estimated from a proportional hazard regression model stratified by HMO and month and year of birth, gender, low birthweight status </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 16,470) aged from 20 months to 11 years, accounting for 69,602 person‐years</p> <p>n = 29,238</p> <p>n = 20,845 vaccinated</p> <p>n = 8393 unvaccinated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma:</b> diagnoses of asthma/wheeze and eczema from the Oxford Medical Information System (which was derived from the ICD‐8) and Read codes (hierarchical codes commonly used in GP practices in England) </p> <p>diagnoses of asthma n = 1753</p> <p>n = 28 (amongst unvaccinated)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Vaccination status extracted from West Midlands General Practice Research Database.</p> <p>Data are presented<br/><b>stratified by consulting</b> <br/><b>frequency in first 18 months</b> </p> <p>(a1) 0 to 6</p> <p>(a2) 7 to 10</p> <p>(a3) 11 to 16</p> <p>(a4) &gt; 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the study data suggest that currently recommended routine vaccinations are not a risk factor for asthma or eczema. In this observational study analysing computerised primary care records, the authors found an association between MMR and DPT vaccination and the incidence of <b>asthma</b> and eczema, but these associations appeared to be limited to the minority of children who rarely seek care from a GP. This limited association is more likely to be the result of bias than a biological effect. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/PT‐years</b> </p> <p>versus</p> <p><b>cases unvaccinated/PT‐years</b> </p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐All‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p>(a) 1725<b>/</b> 65,597 versus 28<b>/</b>4006 </p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p><b>stratified by consulting frequency in first 18 months</b> </p> <p>(a1) 165<b>/</b> 12,462 versus 5<b>/</b>2843 </p> <p>(a2) 351<b>/</b> 17,522 versus 7<b>/</b>425 </p> <p>(a3) 601<b>/</b> 20,693 versus 8<b>/</b>452 </p> <p>(a4) 608 <b>/</b>14,920 versus 8/286 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 2.2 (1.50 to 3.21)</p> <p>(a1) 7.18 (2.95 to 17.49)</p> <p>(a2) 0.95 (0.45 to 2.01)</p> <p>(a3) 1.36 (0.68 to 2.73)</p> <p>(a4) 1.21 (0.60 to 2.43)</p> <p>(*) Adjusted rr estimated from a proportional hazard regression model stratified by consulting frequency, parental smoking, parental allergic disease, maternal age, number of older siblings, use of antibiotics early in life, year of birth, and GP practice. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0087" title="HviidA , MelbyeM . Measles-mumps-rubella vaccination and asthma-like disease in early childhood. American Journal of Epidemiology2008;168(11):1277-83. ">cb‐Hviid 2008</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Danish birth cohorts 1991 to 2003 followed up between 1 January 1991 and 31 December 2003, or between 1 and 5 years of age </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma hospitalisation:</b> </p> <p>inpatient hospitalisation with asthma diagnosis (occurred between 1 January 1992 and 31 December 2004) </p> <p> <ul id="CD004407-list-0032"> <li> <p>Asthma diagnosis: 493.xx (ICD‐8) and J45.x, J46.x (ICD‐10)</p> </li> <li> <p>Severe asthma (status asthmaticus) 493.01 (ICD‐8) and J49.9 for severe asthma</p> </li> </ul> </p> <p>n = 871,234 children (vaccine coverage 85%) PT = 2,926,406 (person‐years)</p> <p>n = 26,880 hospitalisations amongst 17,885 children</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Anti‐asthma medication:</b> </p> <p>prescription of the following cases of anti‐asthma medications have been considered:</p> <p> <ul id="CD004407-list-0033"> <li> <p>glucocorticoid inhalants (ACT code R03BA)</p> </li> <li> <p>short‐acting beta2‐agonist inhalants (ACT codes R03AC02, R03AC03, and R03AC04)</p> </li> <li> <p>long‐acting beta2‐agonist inhalants (ACT codes R03AC12 and R03AC13)</p> </li> <li> <p>systemic beta2‐agonists (ACT code R03CC)</p> </li> <li> <p>other types of anti‐asthma medication (all other ACT codes under R03)</p> </li> </ul> </p> <p>n = 600,938 children (vaccine coverage 84%) PT = 1,858,199 (person‐years)</p> <p>n = 833,424 prescriptions anti‐asthma medication amongst 248,907 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: </p> <p>Measles <b>Moraten</b> strain, </p> <p>Mumps <b>Jeryl Lynn</b> strain, </p> <p>Rubella <b>Wistar RA 27/3</b> strain. </p> <p>Dates of MMR vaccination were obtained from the National Board of Health.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> these results are compatible not with an increased risk of asthma following MMR vaccination, but rather with the hypothesis that MMR vaccination is associated with a reduced risk of asthma‐like disease in young children. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Asthma</p> <p>(b) Status asthmaticus</p> <p>(c) Anti‐asthma medication</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 0.75 (0.73 to 0.78)</p> <p>(b) 0.63 (0.49 to 0.82)</p> <p>(c) 0.92 (0.91 to 0.92)</p> <p>(*) Adjusted for age, calendar period, hospitalisations propensity in infancy, birthweight, place of birth, mother’s country of birth, infant vaccine compliance, birth order, maternal age at birth, and child’s sex. Log‐linear Poisson regression. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0081" title="BenkeG , AbramsonM , RavenJ , ThienFC , WaltersEH . Asthma and vaccination history in a young adult cohort. Australian and New Zealand Journal of Public Health2004;28(4):336-8. ">cb‐Benke 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were aged between 22 and 44 years n = 309</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were surveyed by a validated interviewer‐administered questionnaire covering: history of asthma; details of home and occupation environment; smoking history; medications; dietary information; and respiratory symptoms. The respiratory symptoms included wheezing or whistling in the chest, shortness of breath, chest tightness, and cough and phlegm during the previous 12 months. Atopy was assessed by skin prick testing to common aeroallergens. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described </p> <p>Questionnaire included vaccination history questions, which were not included in the questionnaire used by the other study centres. Vaccination history included measles or MMR vaccinations; hepatitis B; Bacille Calmette‐Guérin (BCG); oral polio vaccine (OPV); and diphtheria, tetanus, and whooping cough (DTP). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there was no significant association observed for participants diagnosed with asthma who had received measles or MMR vaccinations compared with those who did not receive measles or MMR vaccinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(a) Asthma</p> <p>(b) Atopy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> <p>(a) 1.33 (0.98 to 1.80)</p> <p>(b) 1.07 (0.88 to 1.30)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 640 children were followed from birth. Follow‐up examinations at ages 5, 7 and 13 years included a physical examination and a maternal questionnaire about the child’s health. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma</b> (and dermatitis eczema) </p> <p>At child's age 5, parents were asked whether the child was suspected to suffer from asthma or had been diagnosed with asthma, hypersensitivity, or allergy. </p> <p>At ages 5, 7, and 13 years, the same paediatrician determined the presence of current wheezing by auscultation. At the same ages, the paediatrician also examined all children for dermatitis/eczema. </p> <p>At age 13, the findings from this examination were graded according to a score for atopic dermatitis (SCORAD). </p> <p>At age 7, a blood sample was drawn and total IgE and grass‐specific IgE were quantified.</p> <p>At age 13, parents were asked whether the child had ever suffered from asthma. In accordance with the International Study of Asthma and Allergies in Childhood (ISAAC), they were also asked to<br/>indicate whether the child had (i) suffered from wheezing in the past 12 months, (ii) suffered from sneezing, running, or blocked‐up nose except for when the child had a cold or was sick in the past 12 months and, if so, whether it had been accompanied by itching running/tearing eyes (current rhinoconjunctivitis symptoms), and (iii) whether the child had ever suffered from an itching rash that comes and goes for at least 6 months (eczema ever). At age 13, the children underwent a skin prick test with extracts of 5 common allergens (birch/grass pollen, dog/cat dander, and house dust mite (<i>Dermatophagoides pteronyssinus</i>)). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p>The Faroe Islands follow the Danish vaccination schedule, in which MMR vaccination, at the time of this study, was administered at age 15 months and 12 years (Fig. 1). There were no specific contraindications. At the 5‐year examination, the child’s vaccination card was inspected and all vaccination dates were registered. At child's age 13, the mothers were asked whether the child had received the MMR vaccination scheduled at 12 years of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the authors' findings support the notion that MMR vaccination may provide beneficial effects in preventing childhood allergy and asthma. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.33 (0.12 to 0.90)(*)</p> <p>(b) 0.22 (0.08 to 0.56)(*)</p> <p>(a) 0.32 (0.10 to 1.05)(*)(**)</p> <p>(b) 0.16 (0.05 to 0.53)(*)(**)</p> <p><b>RR (95% CI)(***)</b> </p> <p>(a) 0.44 (0.18 to 0.93)(*)</p> <p>(b) 0.35 (0.14 to 0.71)(*)</p> <p>(*) Adjusted OR (logistic regression model) for birthweight and family history of chronic bronchitis/asthma. The analyses at age 13 years are additionally adjusted for whether the child had received the second MMR vaccine before the 13‐year examination. </p> <p>(**) Additional adjustment for sex, premature birth, maternal smoking during pregnancy, log (cord blood IgE), breastfeeding, number of older siblings, number of younger siblings, parental smoking in the home, day care, family history of eczema in children/allergic eczema/hay fever, family history of allergy, and age at the examination. </p> <p>(***) OR converted in RR</p> <p>(a) CER = 0.36</p> <p>(b) CER = 0.47</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ACT: Asthma Control Test<br/>CER: control event rate<br/>CI: confidence interval<br/>DPT: diphtheria, pertussis, and tetanus vaccine<br/>GP: general practice<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>IgE: Immunoglobulin E<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>VSD: Vaccine Safety Datalink </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Safety: asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0044"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Safety: dermatitis or eczema</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0096" title="McKeeverTM , LewisSA , SmithC , HubbardR . Vaccination and allergic disease: a birth cohort study. American Journal of Public Health2004;94(6):985-9. ">cb‐McKeever 2004</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (n = 14,353) aged from 20 months to 11 years, accounting for 59,520 person‐years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eczema:</b> diagnoses of asthma/wheeze and eczema from the Oxford Medical Information System (which was derived from the ICD‐8) and Read codes (hierarchical codes commonly used in GP in England) </p> <p>diagnoses of eczema n = 1884</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Vaccination status extracted from West Midlands General Practice Research Database</p> <p>Data are presented<br/><b>stratified by consulting</b> <br/><b>frequency in first 18 months</b> </p> <p>(a1) 0 to 6</p> <p>(a2) 7 to 10</p> <p>(a3) 11 to 16</p> <p>(a4) &gt; 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the study data suggest that currently recommended routine vaccinations are not a risk factor for asthma or eczema. In this observational study analysing computerised primary care records, the authors found an association between MMR and DPPT vaccination and the incidence of asthma and <b>eczema</b>, but these associations appeared to be limited to the minority of children who rarely seek care from a GP. This limited association is more likely to be the result of bias than a biological effect. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases vaccinated/PT‐years</b> </p> <p>versus</p> <p><b>Cases unvaccinated/PT‐years</b> </p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐All‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p>(a) 1857/55,651 versus 27/3868</p> <p><b>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</b> </p> <p><b>Stratified by consulting frequency in first 18 months</b> </p> <p>(a1) 244/10,625 versus 6/2768</p> <p>(a2) 457/14,293 versus 7/402</p> <p>(a3) 601/17,427 versus 9/400</p> <p>(a4) 555/13,306 versus 5/297</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI)(*)</b> </p> <p>(a) 3.50 (2.38 to 5.15)</p> <p>(a1) 10.4 (4.61 to 23.29)</p> <p>(a2) 1.57 (0.75 to 3.32)</p> <p>(a3) 1.36 (0.71 to 2.64)</p> <p>(a4) 2.21 (0.92 to 5.33)</p> <p>(*) Adjusted rr estimated from a proportional hazard regression model stratified by consulting frequency, parental smoking, parental allergic disease, maternal age, number of older siblings, use of antibiotics early in life, year of birth, and GP practice. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 640 children were followed from birth. Follow‐up examinations at ages 5, 7, and 13 years included a physical examination and a maternal questionnaire about the child’s health. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma and <b>dermatitis eczema</b> </p> <p>At age 5, parents were asked whether the child was suspected to suffer from asthma or had been diagnosed with asthma, hypersensitivity, or allergy. </p> <p>At ages 5, 7, and 13 years, the same paediatrician determined the presence of current wheezing by auscultation. At the same ages, the pediatrician also examined all children for dermatitis/eczema. </p> <p>At age 13, the findings from this examination were graded according to a score for atopic dermatitis (SCORAD). </p> <p>At age 7, a blood sample was drawn and total IgE and grass‐specific IgE were quantified.</p> <p>At child's age 13, parents were asked whether the child had ever suffered from asthma. In accordance with the International Study of Asthma and Allergies in Childhood (ISAAC), they were also asked to indicate whether the child had (i) suffered from wheezing in the past 12 months, (ii) suffered from sneezing, running, or blocked‐up nose except for when the child had a cold or was sick in the past 12 months, and, if so, whether it was accompanied by itching running/tearing eyes (current rhinoconjunctivitis symptoms), and (iii) whether the child had ever suffered from an itching rash that comes and goes for at least 6 months (eczema ever). At age 13, the children underwent a skin prick test with extracts of 5 common allergens (birch/grass pollen, dog/cat dander, and house dust mite (<i>Dermatophagoides pteronyssinus</i>)). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p>The Faroe Islands follow the Danish vaccination schedule, in which MMR vaccination, at the time of this study, was administered at age 15 months and 12 years (Fig. 1). There were no specific contraindications. At the 5‐year examination, the child’s vaccination card was inspected and all vaccination dates were registered. At child's age 13, the mothers were asked whether the child had received the MMR vaccination scheduled at 12 years of age. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there is no association between<br/>MMR vaccine and the risk of eczema. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eczema</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) no data (*)</p> <p>(b) 0.73 (0.26 to 2.10) (*)</p> <p>(a) no data (*) (**)</p> <p>(b) 0.46 (0.14 to 1.52) (*) (**)</p> <p><b>RR (95% CI) (***)</b> </p> <p>(a) no data (*)</p> <p>(b) 0.75 (0.28 to 1.87) (*)</p> <p>(*) Adjusted OR (logistic regression model) for birthweight and family history of chronic bronchitis/asthma. The analyses at age 13 years are additionally adjusted for whether the child had received the second MMR vaccine before the 13‐year examination. </p> <p>(**) Additional adjustment for sex, premature birth, maternal smoking during pregnancy, log (cord blood IgE), breastfeeding, number of older siblings, number of younger siblings, parental smoking in the home, day care, family history of eczema in children/allergic eczema/hay fever, family history of allergy, and age at the examination. </p> <p>(***) OR converted in RR</p> <p>(a) no data</p> <p>(b) CER = 0.11</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CER: control event rate<br/>CI: confidence interval<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>IgE: immunoglobulin E<br/>GP: general practice<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>VSD: Vaccine Safety Datalink </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Safety: dermatitis or eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0045"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0030" title="BremnerSA , CareyIM , DeWildeS , RichardsN , MaierWC , HiltonSR , et al. Timing of routine immunisations and subsequent hay fever risk. Archives of Disease in Childhood2005;90(6):567-73. ">bb‐Bremner 2005</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 76,310 children from GPRD born between 1989 and 1993 from 464 general practices, and within a DIN cohort of n = 40,183 children born between 1989 and 1997 from 141 general practices. </p> <p><b>From GPRD</b> </p> <p>cases = 3859</p> <p>controls = 3859</p> <p><b>From DIN</b> </p> <p>cases = 2611</p> <p>controls = 2611</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hay fever</b> </p> <p><b>Case certain (Definition I):</b> a child with hay fever diagnosis before 24 months of age, and a second diagnosis of hay fever or a relevant therapy in a subsequent years and with a third diagnosis or a relevant therapy in a further year. </p> <p><b>Case certain (Definition II):</b> a child without first diagnosis before 24 months of age, but with a second diagnosis of hay fever or a relevant therapy in subsequent year. </p> <p><b>Case less certain (Definition I):</b> a child as a case certain (Definition I) without third diagnosis of hay fever or a relevant therapy in a further year. </p> <p><b>Case less certain (Definition II):</b> a child with at least a hay fever diagnosis, even if there is not a second diagnosis or a relevant therapy in a subsequent year. </p> <p>The <b>cases</b> and <b>controls</b> were children with at least 5 years of follow‐up from birth and registered “within the practice within 3 months of birth”. Only codes synonymous with "allergic rhinitis” and with seasonal variation in recording were permitted. From GPRD and DIN database. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> (first entries) MMR II </p> <p>The time categories for MMR immunisation:</p> <p>(a) 1st to 13th month</p> <p>(b) 14th month</p> <p>(c) 15th month</p> <p>(d) 16th month</p> <p>(e) 17th month</p> <p>(f) 18th to 24th month</p> <p>(g) ≥ 25th month</p> <p>(h) no MMR vaccine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> this study shows that infants vaccinated with MMR are at no greater or lesser risk of developing hay fever than unvaccinated children. </p> <p>This should reassure parents and clinicians, and no opportunity should be missed to immunise. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n</b> = <b>(cases + controls)</b> </p> <p><b>From GPRD</b> </p> <p>(a) n = 1688</p> <p>(b) n = 2311</p> <p>(c) n = 1638</p> <p>(d) n = 1183</p> <p>(e) n = 510</p> <p>(f) n = 618</p> <p>(g) n = 234</p> <p>(h) n = 210</p> <p><b>From DIN</b> </p> <p>(a) n = 1128</p> <p>(b) n = 1769</p> <p>(c) n = 1192</p> <p>(d) n = 772</p> <p>(e) n = 335</p> <p>(f) n = 379</p> <p>(g) n = 119</p> <p>(h) n = 110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>From GPRD(*)</b> </p> <p>(a) 0.97 (0.81 to 1.16)</p> <p>(b) 1.00 (1.00 to 1.00)</p> <p>(c) 0.89 (0.75 to 1.06)</p> <p>(d) 0.93 (0.75 to 1.14)</p> <p>(e) 0.96 (0.73 to 1.25)</p> <p>(f) 0.89 (0.70 to 1.14)</p> <p>(g) 0.83 (0.58 to 1.18)</p> <p>(h) 0.81 (0.53 to 1.24)</p> <p><b>From DIN(**)</b> </p> <p>(a) 0.90 (0.71 to 1.16)</p> <p>(b) 1.00 (1.00 to 1.00)</p> <p>(c) 1.24 (1.00 to 1.53)</p> <p>(d) 0.96 (0.73 to 1.39)</p> <p>(e) 1.00 (0.69 to 1.45)</p> <p>(f) 1.01 (0.73 to 1.28)</p> <p>(g) 0.54 (0.31 to 0.95)</p> <p>(h) 0.82 (0.45 to 1.50)</p> <p><b>From GPRD‐DIN Pooled (fixed‐effect)</b> </p> <p>1.27 (0.93 to 1.72)</p> <p>(*) Adjusted for consultation<br/>frequency and restricted to<br/>pairs with non‐ghost controls,<br/>adjusted for numbers of older<br/>and younger siblings and multiple<br/>births. </p> <p>(**) Adjusted for consultation frequency and restricted to<br/>pairs with non‐ghost controls. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0031" title="BremnerSA , CareyIM , De WildeS , RichardsN , MaierWC , HiltonSR , et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. Clinical and Experimental Allergy2007;37(4):512-7. ">bb‐Bremner 2007</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 76,310 children from GPRD born between 1989 and 1993 from 464 practices and within a DIN cohort of n = 40,183 children born between 1989 and 1997 from 141 general practices. </p> <p>case + controls = 13,523</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hay fever</b> risk in the first grass pollen season. </p> <p>Case of hay fever were children with diagnostic codes or treatment for hay fever, or both, after 2 years of age. </p> <p>Control was child that matched for general practice, sex, birth month, and follow‐up of control to at least date of diagnosis case. </p> <p>"Cases of hayfever were those who had diagnostic codes and/or treatment for hayfever, after 2 years of age”. From GPRD and DIN database. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> MMR II </p> <p>exposure by 24 months in a grass pollen season (May, June, July) versus non‐pollen season exposure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> in 2 population‐based birth cohorts, the authors have not<br/>demonstrated any significant relationship between hay fever<br/>and vaccination with MMR. </p> <p>Having MMR vaccine during grass pollen season by age 24 months (compared with MMR outside grass pollen season only) was not associated with an increased OR. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases + control</p> <p>out season = 9690</p> <p>in season = 3833</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>1.05 (0.94 to 1.18)</p> <p>(*) Odds ratios were pooled across databases (GPRD and DIN) using a fixed‐effect model.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0105" title="TimmermannCA , OsunaCE , SteuerwaldU , WeiheP , PoulsenLK , GrandjeanP . Asthma and allergy in children with and without prior measles, mumps, and rubella vaccination. Pediatric Allergy and Immunology2015;26(8):742-9. [DOI: 10.1111/pai.12391]">cb‐Timmermann 2015</a> </p> <p>Cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 640 children were followed from birth. Follow‐up examinations at ages 5, 7, and 13 years included a physical examination and a maternal questionnaire about the child’s health. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma (and dermatitis eczema)</p> <p>At child's age 5, parents were asked whether the child was suspected to suffer from asthma or had been diagnosed with asthma, hypersensitivity, or allergy. </p> <p>At ages 5, 7, and 13 years, the same paediatrician determined the presence of current wheezing by auscultation. At the same ages, the paediatrician also examined all children for dermatitis/eczema. </p> <p>At age 13, the findings from this examination were graded according to a score for atopic dermatitis (SCORAD). </p> <p>At age 7, a blood sample was drawn and total IgE and grass‐specific IgE were quantified.</p> <p>At age 13, parents were asked whether the child had ever suffered from asthma. In accordance with the International Study of Asthma and Allergies in Childhood (ISAAC), they were also asked to<br/>indicate whether the child had (i) suffered from wheezing in the past 12 months, (ii) suffered from sneezing, running, or blocked‐up nose except for when the child had a cold or was sick in the past 12 months, and, if so, whether it had been accompanied by itching running/tearing eyes (current <b>rhinoconjunctivitis symptoms</b>), and (iii) whether the child had ever suffered from an itching rash that comes and goes for at least 6 months (eczema ever). At age 13, the children underwent a skin prick test with extracts of 5 common allergens (birch/grass pollen, dog/cat dander, and house dust mite (<i>Dermatophagoides pteronyssinus</i>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described. </p> <p>The Faroe Islands follow the Danish vaccination schedule, in which MMR vaccination, at the time of this study, was administered at age 15 months and 12 years (Fig. 1). There were no specific contraindications. At the 5‐year examination, the child’s vaccination card was inspected and all vaccination dates were registered. At child's age 13, the mothers were asked whether the child had received the MMR vaccination scheduled at 12 years of age. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the authors' findings support the notion that MMR vaccination may<br/>provide beneficial effects in preventing childhood allergy and asthma. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rhinoconjunctivitis</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> <p><b>Hypersensitivity/allergy</b> </p> <p>(a) 5 years old</p> <p>(b) 13 years old</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>Rhinoconjunctivitis</b> </p> <p>(a) no data (*)</p> <p>(b) 0.64 (0.19 to 2.07) (*)</p> <p>(a) no data (*)(**)</p> <p>(b) 0.63 (0.14 to 2.71) (*)(**)</p> <p><b>Hypersensitivity/allergy</b> </p> <p>(a) 0.32 (0.11 to 0.88) (*)</p> <p>(b) no data (*)</p> <p>(a) 0.36 (0.11 to 1.21) (*)(**)</p> <p>(b) no data (*)(**)</p> <p>(*) Adjusted for birthweight and family history of chronic bronchitis/asthma. The analyses at age 13 years are additionally adjusted for whether the child had received the second MMR vaccine before the 13‐year examination. </p> <p>(**) Additional adjustment for sex, premature birth, maternal smoking during pregnancy, log (cord blood IgE), breastfeeding, number of older siblings, number of younger siblings, parental smoking in the home, day care, family history of eczema in children/allergic eczema/hay fever, family history of allergy, and age at the examination. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>DIN: doctors' independent network<br/>GPRD: General Practice Research Database<br/>HMO: health maintenance organisation<br/>incidence: cases/PT<br/>IgE: immunoglobulin E<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0046"> <div class="table-heading"><span class="table-label">Table 25.</span> <span class="table-title">Safety: acute leukaemia</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0038" title="MaX , DoesMB , MetayerC , RussoC , WongA , BufflerPA . Vaccination history and risk of childhood leukaemia. International Journal of Epidemiology2005;34(5):1100-9. ">bb‐Ma 2005</a> </p> <p>case control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases:</b> patients with leukaemia or acute lymphoblastic leukaemia, aged 0 to 14 years identified within the NCCLS between 1995 and 2002. </p> <p><b>Controls:</b> matched to cases for date of birth, gender, Hispanic status (either parent Hispanic), maternal race (white, African‐American, or other), and maternal county of residence, by means of birth certificates. </p> <p>Population coverage initially includes 17 countries in the Greater San Francisco Bay Area, and since 1999 was expanded to a further 18 countries in Northern and Southern California. The present study relies on cases of leukaemia ascertained between 1995 and 2002. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leukaemia</b> </p> <p><b>Acute lymphoblastic leukaemia</b> </p> <p>Within the NCCLS, incident leukaemia cases were ascertained from major paediatric clinical centres within 72 hours after diagnosis. </p> <p>To be eligible, each case or control had to:</p> <p> <ul id="CD004407-list-0034"> <li> <p>reside in the study area at the time of diagnosis;</p> </li> <li> <p>be under 15 years of age at the reference date (date of diagnosis for cases and the corresponding date for matched controls); </p> </li> <li> <p>have at least 1 parent or guardian who speaks English or Spanish;</p> </li> <li> <p>have no previous history of malignancy.</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p>Complete vaccination record was requested to primary caretakers of case or control participants.<br/>Other than MMR, vaccinations against diphtheria, pertussis, and tetanus (DPT), DT, Td, poliomyelitis, hepatitis B, or Hib have been considered in the study. </p> <p>(d1) 1 dose</p> <p>(d2) ≥ 2 doses</p> <p>(d0) unvaccinated</p> <p>(a) Leukaemia</p> <p>(a1) born in or before 1995</p> <p>(a2) born after 1995</p> <p>(b) Acute lymphoblastic leukaemia</p> <p>(b1) born in or before 1995</p> <p>(b2) born after 1995</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b><br/>MMR vaccination, measured as the number of doses, was not associated with the risk of overall leukaemia or acute lymphoblastic leukaemia. </p> <p>Each dose of Hib vaccination was associated with a significantly reduced risk of childhood leukaemia, whilst the history of DPT, poliomyelitis, and MMR vaccinations did not differ between cases and controls. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p><b>Leukaemia (0 to 14 years)</b> </p> <p>(d1) 176/323 versus 219/409</p> <p>(d2) 123/323 versus 162/409</p> <p>(d0) 24/323 versus 28/409</p> <p><b>Leukaemia (&gt; 1 years)</b> </p> <p>(d1) 175/308 versus 219/392</p> <p>(d2) 123/308 versus 162/392</p> <p>(d0) 10/308 versus 11/392</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>Acute lymphoblastic leukaemia</b> </p> <p>(a) cases = 282; controls = 360</p> <p>(b1) born in or before 1995</p> <p>(b2) born after 1995</p> <p>cases = 270; controls = 346</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p><b>leukaemia (*)</b> </p> <p>(a) 1.06 (0.69 to 1.63)</p> <p>(a1) 0.94 (0.75 to 1.53)</p> <p>(a2) 0.79 (0.35 to 1.78)</p> <p><b>Acute lymphoblastic leukaemia(*)</b> </p> <p>(b) 0.87 (0.55 to 1.37)</p> <p>(b1) 0.95 (0.56 to 1.60)</p> <p>(b2) 0.65 (0.24 to 1.72)</p> <p>(*) Adjusted for maternal education and household income</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0037" title="GrovesFD , GridleyG , WacholderS , ShuXO , RobisonLL , NegliaJP , et al. Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. British Journal of Cancer1999;81(1):175-8. [DOI: 10.1038/sj.bjc.6690668]">bb‐Groves 1999</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases:</b> patients with acute lymphoblastic leukaemia aged 0 to 14, diagnosed between 1989 and 1993. </p> <p>Participants who resided in Illinois, Indiana, Iowa, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, or Wisconsin at the time of diagnosis were eligible for the vaccination component of the study. </p> <p><b>Controls:</b> selected through random‐digit dialling were individually matched to the cases by age (within 25% of the corresponding case's age at diagnosis), the first 8 digits of the telephone number, and race (African‐American/white/other). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute lymphoblastic leukaemia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the MMR vaccine does not alter the risk of subsequent acute lymphoblastic leukaemia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cases = 395; controls = 394</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)(*)</b> </p> <p>1.19 (0.67 to 2.10)</p> <p>(*)conditional logistic regression adjusted for age at censoring, year of birth, sex, race, family income, parental education, and attendance at day care and/or preschool </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0039" title="Mallol-MesnardN , MenegauxF , AuvrignonA , AuclercMF , BertrandY , NelkenB , et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). International Journal of Epidemiology2007;36(1):110-6. ">bb‐Mallol‐Mesnard 2007</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Each case of acute leukaemia incident in 2003 to 2004 in a child aged &lt; 15 years, residing in France at the time of diagnosis and with no previous history of malignancy, was eligible. </p> <p><b>The</b> <b>leukaemia cases</b> <b>(n = 726)</b> were recruited directly by investigators assigned to each French paediatric oncology hospital department, with the support of the French National Registry of Childhood Haematopoietic Malignancies. </p> <p><b>The controls (n = 1681)</b> were randomly selected from the French population using quotas, a priori determined to make the control group representative of all cancer cases in terms of age and gender. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a)</b> <b>Acute leukaemia</b> </p> <p><b>(b)</b> <b>Acute lymphoblastic leukaemia</b> </p> <p><b>(c)</b> <b>Acute myeloblastic leukaemia</b> </p> <p>All the childhood leukaemia cases were confirmed by bone marrow analysis. Children whose mother did not speak French or who had been adopted were not eligible. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p><b>Note:</b> the study shows measle‐mumps‐rubella vaccination separately, probably because for the study each mother was asked to read out each page of the vaccination record, line by line. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> no association between vaccination and the risk of childhood acute leukaemia: acute lymphoblastic leukaemia or acute myeloblastic leukaemia was observed. No relationship between the risk of leukaemia and the type of vaccine, number of doses of each vaccine, total number of injections, total number of vaccine doses, or number of early vaccinations was evidenced. No confounding factor was observed. The study did not show any evidence of a role of vaccination in the aetiology of childhood leukaemia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>(a) 541/618 versus 1110/1258</p> <p>(b) 480/554 versus 1110/1258</p> <p>(c) 50/62 versus 1110/1258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>(a) 0.94 (0.70 to 1.26)</p> <p>(b) 0.86 (0.64 to 1.17)</p> <p>(c) 0.56 (0.29 to 1.07)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0036" title="DockertyJD , SkeggDC , ElwoodJM , HerbisonGP , BecroftDM , LewisME . Infections, vaccinations, and the risk of childhood leukaemia. British Journal of Cancer1999;80(9):1483-9. [DOI: 10.1038/sj.bjc.6690548]">bb‐Dockerty 1999</a> </p> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The eligible cases were newly diagnosed with childhood leukaemia (aged 0 to 14 years) 1990 to 1993, and born and resident in New Zealand. Controls (matched 1:1 to cases on age and sex) were selected randomly from the New Zealand‐born and resident childhood population, using national birth records. Each control’s birth was registered in the same quarter of the same year as the matched case. Adopted children were not eligible. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute lymphoblastic leukaemia</b> </p> <p>n = 97 matched pairs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b> not described. Vaccination histories were supplemented with information from parent‐held ‘Health and Development’ records. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> for MMR, no association was found with leukaemia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N cases vaccinated/</b> <br/><b>N cases</b> <br/>versus<br/><b>N controls vaccinated/</b> <br/><b>N controls</b> </p> <p>6/118 versus 15/272</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI) (*)</b> </p> <p>0.8 (0.26 to 2.42)</p> <p>(*)unconditional logistic regression adjusted for age, sex, child’s social class, child’s ethnic group, mother’s marital status, mother’s education, mother’s home ownership, household crowding, delay from reference date to interview, interview year. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>DPT: diphtheria, pertussis, tetanus vaccine<br/>DT: diphtheria, tetanus vaccine<br/>Hib: Haemophilus influenzae b vaccine<br/>HMO: health maintenance organisation<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>NCCLS: Northern California Childhood Leukemia Study<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>Td: tetanus, diphtheria vaccine<br/>versusD: Vaccine Safety Datalink </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 25.</span> <span class="table-title">Safety: acute leukaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0047"> <div class="table-heading"><span class="table-label">Table 26.</span> <span class="table-title">Safety: demyelinating diseases, multiple sclerosis, acute disseminated encephalomyelitis</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0077" title="AhlgrenC , OdenA , TorenK , AndersenO . Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurologica Scandinavica2009;119(5):313-20. ">cb‐Ahlgren 2009</a> </p> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residents in the great Gothenburg area (Sweden) born between 1959 and 1990. The study area was the greater Gothenburg area on the Swedish west coast, with 731,592 residents on 31 December 2000. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple sclerosis (probable or definite) and clinically isolated syndromes.</p> <p>Incidence of <b>multiple sclerosis</b> (4 Poser's criteria) and <b>clinically isolated syndrome</b> with onset between 10 and 39 years of age was assessed in birth cohorts immunised within 4 vaccination programmes. The Gothenburg multiple sclerosis register was established from the 1950s. All records are reviewed with the following MS‐related diagnoses, according to the International Classification of Diseases (ICD) 10, 9, and 8: </p> <p><b>G359; 340; 340.99</b> multiple sclerosis; </p> <p><b>G368; G378; G379; 341W; 341.09</b> demyelinating disorders in the central nervous system; </p> <p><b>G360; 341A; 341.01</b> neuromyelitis optica; </p> <p><b>G369; 341X</b> acute disseminated encephalomyelitis; </p> <p><b>G373</b> acute transverse myelitis: </p> <p><b>H46; 377D; 367.02</b> optic neuritis; </p> <p><b>H48,1; 367.03</b> retrobulbar neuritis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described. </p> <p>Different vaccination programmes carried out from 1971 with different vaccines (single‐component measle, mumps and rubella vaccine so as with MMR vaccine) having as target population children of different ages. 5 population birth cohorts were selected from the total incidence material: </p> <p>(0) born 1959 to 1961: the pre‐vaccine era;</p> <p>(1) born 1962 to 1966: monovalent rubella vaccine;</p> <p>(2) born 1970 to 1973: only received later dose of the MMR vaccine;</p> <p>(3) born 1974 to 1978: monovalent measles;</p> <p>(4) July 1981 to June 1984: combined MMR vaccine.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> there was no significant change in the age‐ and gender‐specific incidence of MS in any of the selected cohorts compared with the incidence in the preceding selected birth cohorts. There was thus no significant change in MS incidence related to the implementation of the rubella vaccination programme in the 12‐year‐old female cohort born in 1962 to 1966 compared with the unvaccinated cohort born in 1959 to 1961. The incidence did not significantly change with all preceding selected cohorts as baseline, neither in the MMR‐vaccinated 12‐year‐old cohort born in 1970 to 1973, nor in the cohort born in 1974 to 1978, half of which were measles vaccinated in the preschool age and the majority MMR vaccinated at 12, nor in the cohort born in July 1981 to June 1984, which were MMR vaccinated at both 18 months and 12 years of age. Restricting the analyses to probable and definite MS cases did not change the results. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence per 100,000 person‐years</b> </p> <p><b>(‐) (male female) versus (male female) (*)</b> </p> <p>(1) (14.98; 6.97) versus (17.61; 4.28)<br/>(2) (15.28; 6.61) versus (13.17; 5.27)<br/>(3) (12.29; 3.85) versus (9.48; 4.62)<br/>(4) (4.96; 1.18) versus (3.78; 2.55) </p> <p>(*) including both the unvaccinated cohort 1959 to 1961 and the preceding vaccinated birth cohorts selected for this study, in the corresponding age groups </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available for meta‐analysis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0025" title="AhlgrenC , TorenK , OdenA , AndersenO . A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. European Journal of Epidemiology2009;24(9):541-52. ">bb‐Ahlgren 2009</a> </p> <p>Case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases (n = 206)</b>: birth years 1959 to 1986, to be resident in the greater Gothenburg area (Sweden), MS onset from age of 10 years onwards, did attend the 6th school grade within study area, availability of CHSH records. </p> <p><b>Controls (n = 888)</b>: matched to cases for year of birth by random selection from the population register. Controls should have attended the 6th school grade within study area, and have available CHSH record. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple sclerosis (probable or definite) and clinically isolated syndromes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> <p>MMR vaccination (vaccination with single‐component vaccines has also been considered).</p> <p>The second analysis was therefore restricted to the subgroup of the MMR vaccinations.</p> <p>The first analysis was restricted to the subgroup "MMR vaccination". 4 disjointed vaccination categories were defined: </p> <p>(0) no MMR vaccination;</p> <p>(1) early MMR vaccination only; (3) late MMR vaccination only; (4) both an early and a late MMR vaccination. Comparisons were made within the group of MMR vaccinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> no significant association for vaccinated versus unvaccinated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cases = 206; controls = 888</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>1.13 (0.62 to 2.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0032" title="ChenY , MaF , XuY , ChuX , ZhangJ . Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine2018;36(26):3733-9. ">bb‐Chen 2018</a> </p> <p>Case‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case (n = 272):</b> acute disseminated encephalomyelitis. </p> <p><b>Controls (n = 1096):</b> for each ADEM case, 4 control individuals randomly selected from the same hospital with no history of ADEM were matched to the case according to year of birth (within 1 year), gender, and zip code (a surrogate measure for socioeconomic status) during the same period. The control participants were assigned the same index date as their matched case (symptom onset date). Controls were patients referred for headache (except trigeminal neuralgia), migraine, vascular, or other diseases which were thought not to modify the probability of vaccination. Patients with chronic severe neurological diseases or autoimmune diseases were excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute disseminated encephalomyelitis:</b> </p> <p>immune‐mediated<br/>central nervous system disorder, characterised by an<br/>acute encephalopathy with polyfocal neurological deficits. </p> <p>From the Hospital Information Systems first mention of International Classification of Diseases, Tenth Revision (ICD‐10), diagnostic codes (G04.001, G04.002, G04.051, G04.903, and G04.912) for ADEM from 1 January 2011 to 31 December 2015, for individuals of any age.<br/>Diagnoses were confirmed by neurologists from clinical data, such as clinical manifestations, computed tomography, electroencephalograph, cerebrospinal fluid, and magnetic resonance imaging examinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not described </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions:</b> findings from the present study do not demonstrate an association of vaccines with an increased risk of ADEM and its recurrence among either paediatric (&lt; 18 years) or adult (≥ 18 years) individuals within the 180 days after vaccinations. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/272 versus 36/1096</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR (95% CI)</b> </p> <p>adjusted estimate</p> <p>1.03 (0.68 to 3.75)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADEM: acute disseminated encephalomyelitis<br/>CI: confidence interval<br/>CHSH: child health and school health records<br/>CIS: clinically isolated syndromes<br/>HMO: health maintenance organisation<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>MS: multiple sclerosis<br/>OR: odds ratio<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio)<br/>RR: risk ratio (relative risk)<br/>VSD: Vaccine Safety Datalink </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 26.</span> <span class="table-title">Safety: demyelinating diseases, multiple sclerosis, acute disseminated encephalomyelitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0047">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0048"> <div class="table-heading"><span class="table-label">Table 27.</span> <span class="table-title">Safety: gait disturbances</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0118" title="MillerE , AndrewsN , GrantA , StoweJ , TaylorB . No evidence of an association between MMR vaccine and gait disturbance. Archives of Disease in Childhood2005;90(3):292-6. ">db‐Miller 2005</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children <b>hospitalised with gait disturbance</b> between April 1995 and June 2001 (n = 127, age 12 to 24 months). </p> <p>Children with <b>gait disturbance resulting from general practice visit</b> General Practice Research Database. (GPRD archive), born between 1988 and 1997 (n = 1398, age 12 to 24 months) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(a) Hospitalisation for gait disturbance</b> </p> <p>Review of hospital computerised records</p> <p>(April 1995 to June 2001,</p> <p>children aged 12 to 24 months)</p> <p>with ICD‐10 diagnoses related to acute gait disorder</p> <p>(G111, G112, G25, R26, R27, R29, H55, and F984).</p> <p>Cases were grouped into 5 categories, as follows:</p> <p>(1) presumptive viral/postviral ataxia (clinical history of ataxia and evidence of encephalomyelitis or cerebellitis with lymphocytosis in CSF or encephalographic changes); </p> <p>(2) probable postviral ataxia (history consistent with ataxia but CSF/other investigations inconclusive or not done and no other cause identified); </p> <p>(3) probably not postviral gait disturbance</p> <p>(vague symptoms not suggestive</p> <p>of cerebellar ataxia, e.g. unsteady gait associated</p> <p>with constipation or gastroenteritis);</p> <p>(4) non‐ataxic, non‐viral gait disturbance</p> <p>(including limp after trauma, septic bone or</p> <p>joint disease, unsteadiness following drug ingestion);</p> <p>(5) transient synovitis/‘‘irritable hip’’ (a transient condition described following viral illnesses and with no long‐term sequelae) </p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p><b>(b) GP visits for gait disturbance</b> </p> <p>For the analysis of gait disorders presenting in general practice, information on all children born from 1988 to 1997 with at least 2 years of continuous follow‐up from birth in a GPRD practice deemed as supplying data of research standard was obtained from the Office for National Statistics. Read and OXMIS codes that indicated a consultation for possible gait disturbance in children aged 12 to 24 months were identified by mapping to </p> <p>ICD‐9 codes and by searching on the following keywords: ataxia,</p> <p>gait, co‐ordination, mobility, movement.</p> <p>Read/OXMIS descriptive diagnoses cover a wide range, so were grouped into 6 categories for analysis: </p> <p>(A) ataxia (including cerebellar ataxia and ataxic gait);</p> <p>(B) unsteady/veering/shuffling gait;</p> <p>(C) gait abnormality ‐ unspecified;</p> <p>(D) limp/limping gait;</p> <p>(E) poor mobility;</p> <p>(F) abnormal /involuntary movements.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine:</b> not reported </p> <p><b>(a) Risk period:</b> </p> <p><b>after immunisation</b> </p> <p>(a1) 0 to 30 days</p> <p>(a2) 31 to 60 days</p> <p>(a3) 0 to 60 days</p> <p><b>(b) Risk period</b> </p> <p><b>after immunisation</b> </p> <p>(b1) 0 to 5 days</p> <p>(b2) 6 to 30 days</p> <p>(b3) 31 to 60 days</p> <p>(b4) 6 to 60 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> this study provides no evidence that MMR vaccine causes acute ataxia or other gait disturbance and suggests that the cases observed were chance occurrences, reflecting background incidence. </p> <p>The increased incidence of consultation for any gait disturbance 0 to 5 days after MMR vaccination was attributable to an excess in categories of gait disturbance (B, unsteady; and C, unspecified) that was caused by a clear excess of consultations on the day that MMR was given. </p> <p>It is biologically implausible that any specific MMR effect would be manifest on the day of vaccination since the viraemia induced by the vaccine, which might produce symptoms, does not start until the end of the first week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisation for gait disturbance</b> </p> <p>any (categories 2, 3, 5) n = 62</p> <p>(a1) cases = 3</p> <p>(a2) cases = 1</p> <p>(a3) cases = 4</p> <p><b>GP visits for gait disturbance</b> </p> <p>All cases ((A) to (F))</p> <p>(b1) cases = 31</p> <p>(b2) cases = 69</p> <p>(b3) cases =</p> <p>102</p> <p>(b4) cases = 171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) (*)</b> </p> <p>(a1) 0.83 (0.24 to 2.84)</p> <p>(a2) 0.20 (0.03 to 1.47)</p> <p>(a3) 0.46 (0.16 to 1.35)</p> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> <p>(b1) 1.88 (1.30 to 2.72)</p> <p>(b2) 0.90 (0.70 to 1.17)</p> <p>(b3) 0.95 (0.77 to 1.19)</p> <p>(b4) 0.93 (0.78 to 1.12)</p> <p>(*) Poisson regression</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>GP: general practitioner<br/>GPRD: General Practice Research Database<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>OXMIS: Oxford Medical Information Systems<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 27.</span> <span class="table-title">Safety: gait disturbances</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0048">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0049"> <div class="table-heading"><span class="table-label">Table 28.</span> <span class="table-title">Safety: bacterial or viral infections</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID and design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Exposure<br/>MMR/MMRV vaccine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Crude data</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Estimate (95% CI)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0122" title="StoweJ , AndrewsN , TaylorB , MillerE . No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine2009;27(9):1422-5. ">db‐Stowe 2009</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infants aged 12 to 23 months hospitalised for viral or bacterial infection between April 1995 and May 2005 identified from hospital admission records (n = 2025 accounting for 2077 admissions) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lobar pneumonia</b> </p> <p>ICD‐9 codes: 481</p> <p>ICD‐10 codes: J18.1</p> <p><b>Invasive bacterial infections</b> </p> <p>ICD‐9 codes: 036, 038, 320, 711.0, 730.0</p> <p>ICD‐10 codes: A39, A40, A41, G00, M00, M86, J13X</p> <p><b>Encephalitis/meningitis</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: A85, A86, A87, A88, A89</p> <p><b>Herpes</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: B00</p> <p><b>Pneumonia</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: J12</p> <p><b>Varicella zoster</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: B01, B02</p> <p><b>Miscellaneous viral infections</b> </p> <p>ICD‐9 codes: not specified</p> <p>ICD‐10 codes: B08, B09, B15, B17, B25, B27, B34</p> <p>Review of computerised hospital</p> <p>admission records from North, East,</p> <p>and South London, Essex, East Anglia,</p> <p>Sussex, and Kent using ICD‐9 or ICD‐10 codes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not reported </p> <p><b>Excluded period</b> from the background </p> <p>from −14 to −1 days before immunisation</p> <p><b>Risk period</b> </p> <p><b>after immunisation</b> </p> <p>(a1) 0 to 30 days</p> <p>(a2) 31 to 60 days</p> <p>(a3) 61 to 90 days</p> <p>(a4) 0 to 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> the study confirms that the </p> <p>MMR vaccine does not increase the risk of invasive bacterial or viral infection in</p> <p>the 90 days after the vaccination and</p> <p>does not support the hypothesis</p> <p>that there is an induced immune</p> <p>deficiency due to overload from</p> <p>multi‐antigen vaccines.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cases</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) cases = 57<br/>(a2) cases = 65<br/>(a3) cases = 69<br/>(a4) cases = 191 </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) cases = 30<br/>(a2) cases = 34<br/>(a3) cases = 27<br/>(a4) cases = 91 </p> <p><b>Encephalitis/meningitis</b> </p> <p>(a1) cases = 1<br/>(a2) cases = 1<br/>(a3) cases = 2<br/>(a4) cases = 4 </p> <p><b>Herpes</b> </p> <p>(a1) cases = 16<br/>(a2) cases = 25<br/>(a3) cases = 14<br/>(a4) cases = 55 </p> <p><b>Pneumonia</b> </p> <p>(a1) cases = 0<br/>(a2) cases = 5<br/>(a3) cases = 4<br/>(a4) cases = 9 </p> <p><b>Varicella zoster</b> </p> <p>(a1) cases = 17<br/>(a2) cases = 32<br/>(a3) cases = 24<br/>(a4) cases = 73 </p> <p><b>Miscellaneous viral infections</b> </p> <p>(a1) cases = 12<br/>(a2) cases = 12<br/>(a3) cases = 9<br/>(a4) cases = 33 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) (*)</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) 0.65 (0.48 to 0.86)<br/>(a2) 0.80 (0.61 to 1.05)<br/>(a3) 0.90 (0.69 to 1.18)<br/>(a4) 0.77 (0.64 to 0.93) </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) 0.75 (0.51 to 1.12)<br/>(a2) 1.03 (0.70 to 1.52)<br/>(a3) 0.92 (0.61 to 1.41)<br/>(a4) 0.89 (0.68 to 1.16) </p> <p><b>Encephalitis/meningitis</b> </p> <p>(a1) 0.54 (0.06 to 4.83)<br/>(a2) 0.74 (0.07 to 7.47)<br/>(a3) 1.46 (0.23 to 9.29)<br/>(a4) 0.84 (0.20 to 3.49) </p> <p><b>Herpes</b> </p> <p>(a1) 1.00 (0.57 to 1.74)<br/>(a2) 1.69 (1.06 to 2.70)<br/>(a3) 0.89 (0.50 to 1.59)<br/>(a4) 1.17 (0.56 to 2.47) </p> <p><b>Pneumonia</b> </p> <p>(a1) 0 (‐ to ‐)<br/>(a2) 1.39 (0.49 to 3.90)<br/>(a3) 1.27 (0.41 to 3.94)<br/>(a4) 0.72 (0.33 to 1.62) </p> <p><b>Varicella zoster</b> </p> <p>(a1) 0.58 (0.34 to 0.99)<br/>(a2) 1.23 (0.81 to 1.87)<br/>(a3) 1.05 (0.66 to 1.67)<br/>(a4) 0.93 (0.68 to 1.27) </p> <p><b>Miscellaneous viral infections</b> </p> <p>(a1) 0.71 (0.37 to1.37)<br/>(a2) 0.73 (0.37 to 1.14)<br/>(a3) 0.61 (0.29 to 1.28)<br/>(a4) 0.68 (0.43 to 1.09) </p> <p>(*)Poisson regression</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004407-bbs2-0117" title="MillerE , AndrewsN , WaightP , TaylorB . Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood2003;88:222-3. [DOI: 10.1136/adc.88.3.222]">db‐Miller 2003</a> </p> <p>Self‐controlled case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 12 to 23 months admitted to hospital between April 1991 and March 1995 in selected districts in the Thames region of southern England. Total of 387 admissions with 1 or more of the bacterial infection codes and with a linked MMR vaccination record were identified; occurred in 387 children (169 in 165 females, and 226 in 222 males); 116 had a diagnosis of invasive bacterial infection and 279 had lobar pneumonia. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lobar pneumonia</b> </p> <p><b>Invasive bacterial infections</b> </p> <p>Cases were identified from computerised</p> <p>discharge records using ICD‐9 codes 036 (meningococcal infection),</p> <p>038 (septicaemia), 320 (bacterial meningitis),</p> <p>711.0 (pyogenic arthritis), 730.0 (acute osteomyelitis), and 481 (lobar (pneumococcal) pneumonia). </p> <p>Hospital records were linked with computerised district immunisation records by sex, date of birth, and post code. </p> <p>Cases in children with additional diagnostic codes indicating an underlying disorder predisposing to bacterial infection, such as immunosuppression, malignancy, cystic fibrosis, congenital heart defect, or a cerebrospinal fluid shunt, were excluded. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMR vaccine</b>: not described </p> <p><b>Excluded period</b> from the background </p> <p>from −14 to −1 days before immunisation</p> <p><b>Risk period</b> </p> <p><b>after immunisation</b> </p> <p>(a1) 0 to 30 days</p> <p>(a2) 31 to 60 days</p> <p>(a3) 61 to 90 days</p> <p>(a4) 0 to 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusion:</b> combined measles, mumps, and rubella (MMR) vaccine did not increase the risk of hospitalisation with invasive bacterial infection in the 3 months after vaccination; rather there was a protective effect. These results provide no support for the concept of 'immunological overload' induced by multiple‐antigen vaccinations, nor calls for single‐antigen vaccines. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cases</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) cases = 23<br/>(a2) cases = 24<br/>(a3) cases = 16<br/>(a4) cases = 63 </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) cases = 12<br/>(a2) cases = 14<br/>(a3) cases = 7<br/>(a4) cases = 33 </p> <p><b>Both codes</b> </p> <p>(a1) cases = 35<br/>(a2) cases = 38<br/>(a3) cases = 23<br/>(a4) cases = 96 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rr (95% CI) (*)</b> </p> <p><b>Lobar pneumonia</b> </p> <p>(a1) 0.77 (0.48 to 1.23)<br/>(a2) 0.80 (0.50 to 1.28)<br/>(a3) 0.52 (0.30 to 0.90)<br/>(a4) 0.70 (0.50 to 0.97) </p> <p><b>Invasive bacterial infections</b> </p> <p>(a1) 1.00 (0.52 to 1.94)<br/>(a2) 1.17 (0.62 to 2.20)<br/>(a3) 0.62 (0.27 to 1.40)<br/>(a4) 0.93 (0.58 to 1.49) </p> <p><b>Both codes</b> </p> <p>(a1) 0.81 (0.56 to 1.19)<br/>(a2) 0.90 (0.62 to 1.31)<br/>(a3) 0.56 (0.36 to 0.89)<br/>(a4) 0.76 (0.58 to 0.99) </p> <p>(*)Poisson regression</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval<br/>CSF: cerebrospinal fluid<br/>GP: general practitioner<br/>GPRD: General Practice Research Database<br/>ICD: International Classification of Diseases<br/>incidence: cases/PT<br/>MMR: measles, mumps, rubella vaccine<br/>MMRV: measles, mumps, rubella, and varicella vaccine<br/>PT: person‐time<br/>rr: rate ratio (relative incidence, incidence rate ratio) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 28.</span> <span class="table-title">Safety: bacterial or viral infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0049">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0050"> <div class="table-heading"><span class="table-label">Table 29.</span> <span class="table-title">Risk of bias</span></div> <tbody> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <td align="left" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="5" scope="col" valign="top"> <p><b>Effectiveness<br/>studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT/CCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective/retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subtotal</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>15</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>29.4%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>27</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>53.0%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17.6%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>51</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <td align="left" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="7" scope="col" valign="top"> <p><b>Safety<br/>studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT/CCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective/retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐controlled case series/person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subtotal</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>43.7%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>28</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>32.2%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>21</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24.1%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total (all studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>53</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>38.4%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>55</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>39.9%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>30</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>21.7%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>138</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""></td> </tr> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study design</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <td align="left" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="6" scope="col" valign="top"> <p><b>Safety studies<br/>(excluding short‐term side effects<br/>studies)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective/retrospective cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐controlled case series/person‐time cohort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case cross‐over</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐only ecological method</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Total</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>36</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>51%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>26</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>37%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>8</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>11%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>70</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/>RCT: randomised controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 29.</span> <span class="table-title">Risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0050">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004407-tbl-0051"> <div class="table-heading"><span class="table-label">Table 30.</span> <span class="table-title">Risk of bias by publication year</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All studies included</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication year</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1971 to 1980</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981 to 1990</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991 to 2000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001 to 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011 to 2019</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>53</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>36%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>54</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>42%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>30</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>22%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>138</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Only safety studies</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Low risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Unclear risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>High risk of bias</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Total</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication year</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Row %</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1971 to 1980</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981 to 1990</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1991 to 2000</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001 to 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011 to 2019</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>38</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>39%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>27</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>37%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>22</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>24%</b> </p> </th> <th align="right" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>87</b> </p> </th> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 30.</span> <span class="table-title">Risk of bias by publication year</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/full#CD004407-tbl-0051">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0052"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Effectiveness against measles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Cohort studies (vaccinated vs unvaccinated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.02, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Cohort studies (household contacts: vaccinated vs unvaccinated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.04, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.03, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 3 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Cohort studies (postexposure prophylaxis: vaccinated vs unvaccinated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Case‐control studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.41, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.26, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Unspecified number or at least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Effectiveness against measles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0052">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0053"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Effectiveness against mumps</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Cohort studies ‐ Jeryl Lynn strain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.13, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.07, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Unspecified number of doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.14, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Household contacts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.13, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Cohort studies ‐ Urabe strain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Unspecified numbers or at least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.12, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Cohort studies ‐ Rubini strain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Unspecified numbers or at least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.55, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Cohort studies ‐ mumps strain not reported or mixed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.29, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Cohort studies ‐ 3 doses vs 2 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 3 doses vs 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.33, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Case‐control studies ‐ Jeryl Lynn strain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.27, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.09, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 At least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.25, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Case‐control studies ‐ Jeryl Lynn strain ‐ lab‐confirmed cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.22, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.04, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 At least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.16, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Case‐control studies ‐ Urabe strain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 At least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.12, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Case‐control studies ‐ Rubini strain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 At least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.43, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Case‐control studies ‐ strain type not reported or any strain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.22, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.09, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 At least 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Effectiveness against mumps</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0053">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0054"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Effectiveness against rubella</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Cohort studies secondary cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Any strain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Effectiveness against rubella</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0054">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0055"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Effectiveness against varicella</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 MMRV randomised clinical trial ‐ any severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 2 doses ‐ follow up at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.03, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 2 doses ‐ follow up between 5 to 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.04, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 2 doses ‐ follow up at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.04, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 MMRV randomised clinical trial ‐ moderate/severe cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 2 doses ‐ Follow up at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [0.00, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 2 doses ‐ Follow up between 5 to 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 2 doses ‐ Follow up at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 MMR+V randomised clinical trial ‐ any severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.30, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 2 doses ‐ follow up at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.28, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 2 doses ‐ follow up between 5 to 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.29, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 2 doses ‐ follow up at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.29, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 MMR+V randomised clinical trial ‐ moderate/severe cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.08, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 2 doses ‐ Follow up at 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.06, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 2 doses ‐ Follow up between 5 to 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.07, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 2 doses ‐ Follow up at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.08, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 MMR+V randomised clinical trial ‐ severe cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 2 doses ‐ follow up between 5 to 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 MMRV cohort study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 One dose ‐ any severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.11, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Two doses ‐ any severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.13, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 MMRV case‐control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Any dose ‐ any severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.07, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Any dose ‐ moderate/severe cases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.03, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 MMR+V case control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 1 dose ‐ any severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.08, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 2 doses ‐ any severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Any dose ‐ any severity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.08, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 MMRV case only ecological method ‐ hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.34, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Age &lt; 1 year ‐ any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 Age 1 to 4 years ‐ any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.10, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.3 Age 5 to 14 years ‐ any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.19, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.4 Age 0 to 14 years ‐ any doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.44, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 MMRV case only ecological method ‐ incidence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.14, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 Age &lt; 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.12, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.2 Age 1 to 4 years ‐ any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.07, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.3 Age 5 to 14 years ‐ any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.12, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.4 Age 0 to 14 years ‐ any doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.53, 0.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Effectiveness against varicella</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0055">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0056"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Temperature <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 RCT/CCT axillary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.09, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 RCT/CCT rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 RCT/CCT measurement site not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.83, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 Cohort studies orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.04, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.5 Cohort studies measurement site not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.84, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 RCT/CCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.21, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.73, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Lymphadenopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 RCT/CCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.52, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.19, 20.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Coryza <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 RCT/CCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.12, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.05, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 URTI (rhinitis, pharyngitis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 RCT/CCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.06, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Cohort studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.26, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 RCT/CCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.45, 8.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Safety: short‐term side effects (local or systemic reactions)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0056">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0057"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Case‐control: MMR (risk interval from 0 to 90 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Self‐controlled case series/person‐time cohort <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Self‐controlled case series: MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.52, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Person‐time cohort: MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.36, 1.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Safety: encephalitis or encephalopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0057">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0058"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Safety: aseptic meningitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Case‐control ‐ case cross‐over <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Case control ‐ Jeryl Lynn ‐ risk interval 0 to 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.21, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Case crossover ‐ Urabe or Hoshino</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [2.23, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 Case crossover ‐ Jeryl Lynn or Rubini</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.18, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Self‐controlled case series (SCCS)/person‐time cohort (PT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 SCCS ‐ any strain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.40 [3.12, 49.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 SCCS ‐ Urabe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.71 [13.45, 70.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 SCCS ‐ Leningrad‐Zageb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [0.78, 52.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.4 PT ‐ Jeryl Lynn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.66, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Case only ecological method (COEM) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 COEM ‐ Urabe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.12 [5.73, 14.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 COEM ‐ Leningrad‐Zagreb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.56 [12.09, 28.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Safety: aseptic meningitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0058">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0059"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Safety: seizures (febrile/afebrile)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Cohort studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Within 1 week after vaccination MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [2.21, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Between 1 to 2 weeks after vaccination MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [2.89, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 &gt; 2 weeks after vaccination MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.49, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Self‐controlled case series/person‐time cohort <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Between 1 to 2 weeks after vaccination MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [2.65, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 &gt; 2 weeks after vaccination MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.93, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.3 Between 1 to 2 weeks after vaccination; MMRV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.08 [4.95, 7.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.4 between 1 to 2 weeks after vaccination MMR+V</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [2.38, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 MMRV versus MMR+V <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 from 0 to 42 days after vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.19, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 from 7 to 10 days after vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.69, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 MMRV versus MMR+V ‐ by brand <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 From 0 to 42 days after vaccination (Priorix)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.85, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.2 From 7 to 10 days after vaccination (Priorix)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.93, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.3 From 0 to 42 days after vaccination (ProQuad)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.17, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.4 From 7 to 10 days after vaccination (ProQuad)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.70, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 MMRV versus MMR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 From 0 to 42 days after vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.37, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 From 7 to 10 days after vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.36, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 MMRV versus MMR ‐ by brand <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.1 From 0 to 42 days after vaccination (Priorix)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.00, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.2 From 7 to 10 days after vaccination (Priorix)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.66, 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.3 From 0 to 42 days after vaccination (ProQuad)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.42, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.4 From 7 to 10 days after vaccination (ProQuad)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.32, 1.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Safety: seizures (febrile/afebrile)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0059">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0060"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Safety: autism spectrum disorders</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Cohort studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 All children MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.85, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Autism risk (low) MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.3 Autism risk (moderate/high) MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Case‐control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Any age MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.36, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Before age 18 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.75, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.3 After age 18 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.61, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.4 Before age 36 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.5 After age 36 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.55, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Self‐controlled case series/person‐time cohort <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 ASD diagnosis &lt; 12 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.60, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 ASD diagnosis &lt; 24 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.79, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.3 Regression &lt; 2 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.38, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.4 Regression &lt; 4 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.52, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.5 Regression &lt; 6 months MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.45, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Case only ecological method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Childhood autism MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.33, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 Other ASD. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.39, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.3 Definite regression. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.44, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.4 Definite + probable regression. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.5 All ASD. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.39, 0.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Safety: autism spectrum disorders</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0060">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0061"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Safety: inflammatory bowel disease (IBD)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Case‐control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 All IBD. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.93, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Ulcerative colitis. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.81, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.3 Crohn's disease. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.42, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Case‐only ecological method (rate ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Crohn's disease. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Case only ecological method (odds ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 All IBD. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Safety: inflammatory bowel disease (IBD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0061">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0062"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Safety: cognitive delay ‐ developmental delay</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Cohort study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 MDI‐BSID II 24th month. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.15, 12.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 MDI‐BSID II 36th month. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.03, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.3 Raven 5th year. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.23, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.4 WISC‐R verbal 6th year. MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.09, 16.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Safety: cognitive delay ‐ developmental delay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0062">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0063"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Case‐control ‐ case cross‐over <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Case‐controls MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [1.50, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 Case cross‐over MMR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.21, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Self‐controlled case series <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 MMR vaccine ‐ aged from 9 to 23 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.21 [2.28, 7.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 MMR vaccine ‐ aged from 4 to 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.42, 22.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.3 MMRV vaccine ‐ aged from 9 to 23 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.78, 10.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Safety: idiopathic thrombocytopenic purpura</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0063">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0064"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Case‐control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 MMR vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [1.18, 9.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Safety: Henoch‐Schönlein purpura</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0064">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0065"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Safety: type 1 diabetes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Cohort study MMR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 All children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.98, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 Children with at least 1 sibling with type 1 diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.34, 2.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Safety: type 1 diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0065">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0066"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Safety: asthma</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Cohort study (rate ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 All ages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.80, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Cohort study (risk ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 All ages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.98, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.2 Age ≤ 6 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.19, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.3 Age between 11 and 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.16, 0.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Safety: asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0066">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0067"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Safety: eczema ‐ dermatitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Cohort study (rate ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 All ages</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [2.38, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Cohort study (risk ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 Age between 11 and 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.29, 1.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Safety: eczema ‐ dermatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0067">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0068"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Cohort study ‐ rhinoconjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.19, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Cohort study ‐ hypersensitivity/allergy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.14, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 Case‐control ‐ hay fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.92, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Safety: hay fever, rhinoconjunctivitis, hypersensitivity/allergy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0068">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0069"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Safety: acute leukaemia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Case‐control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.1 Acute leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.2 Acute lymphoblastic leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.72, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.3 Acute myeloblastic leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.29, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Safety: acute leukaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0069">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0070"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Case‐control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.1 Multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.62, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.2 Acute disseminated encephalomyelitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.44, 2.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0070">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0071"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Safety: gait disturbances</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Self‐controlled case series (hospitalisations) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.1 Hospitalisation ‐ risk period: (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.24, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.2 Hospitalisations ‐ risk period: (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.3 Hospitalisations ‐ risk period: (0 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.16, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 Self‐controlled case series (GP visits) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.1 GP visit ‐ risk period: (0 to 5 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.30, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.2 GP visit ‐ risk period: (6 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.70, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.3 GP visit ‐ risk period: (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.4 GP visit ‐ risk period: (6 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Safety: gait disturbances</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0071">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004407-tbl-0072"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Safety: bacterial or viral infections, immune overload</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Self‐controlled case series ‐ lobar pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 Lobar pneumonia risk period (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.53, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.2 Lobar pneumonia risk period (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.3 Lobar pneumonia risk period (61 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.64, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.4 Lobar pneumonia risk period (0 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.64, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 Self‐controlled case series ‐ invasive bacterial infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 Invasive bacterial infections risk period (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.58, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.2 Invasive bacterial infections risk period (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.77, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.3 Invasive bacterial infections risk period (61 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.58, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.4 Invasive bacterial infections risk period (0 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.3 Self‐controlled case series ‐ encephalitis meningitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.1 Encephalitis ‐ meningitis risk period (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.06, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.2 Encephalitis ‐ meningitis risk period (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.07, 7.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.3 Encephalitis ‐ meningitis risk period (61 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.23, 9.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.4 Encephalitis ‐ meningitis risk period (0 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.20, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.4 Self‐controlled case series ‐ herpes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4.1 Herpes risk period (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.57, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4.2 Herpes risk period (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.06, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4.3 Herpes risk period (61 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.50, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4.4 Herpes risk period (0 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.56, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.5 Self‐controlled case series ‐ pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.1 Pneumonia risk period (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.2 Pneumonia risk period (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.49, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.3 Pneumonia risk period (61 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.41, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5.4 Pneumonia risk period (0 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.32, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.6 Self‐controlled case series ‐ varicella zoster <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6.1 Varicella zoster risk period (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.34, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6.2 Varicella zoster risk period (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.81, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6.3 Varicella zoster risk period (61 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.66, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6.4 Varicella zoster risk period (0 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.7 Self‐controlled case series ‐ miscellaneous viral infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.1 Miscellaneous viral infections risk period (0 to 30 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.37, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.2 Miscellaneous viral infections risk period (31 to 60 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.42, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.3 Miscellaneous viral infections risk period (61 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.29, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7.4 Miscellaneous viral infections risk period (0 to 90 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Safety: bacterial or viral infections, immune overload</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004407.pub5/references#CD004407-tbl-0072">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004407.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004407-note-0044">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004407-note-0052">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004407-note-0049">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004407-note-0050">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004407-note-0048">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD004407-note-0047">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD004407-note-0051">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD004407-note-0046">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004407-note-0045">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004407\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004407\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004407\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004407\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004407\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004407.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004407.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004407.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004407.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004407.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715462613"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004407.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715462617"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004407.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d87a19f489374',t:'MTc0MDcxNTQ2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 